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Behavioural modification interventions for medically
unexplained symptoms in primary care: systematic
reviews and economic evaluation
Joanna Leavisso ,1* Sarah Daviso ,1 Shijie Reno ,1 Jean Hamiltono ,1
Alison Scope,1 Andrew Bootho ,1 Anthea Suttono ,1 Glenys Parryo ,1
Marta Buszewiczo ,2 Rona Moss-Morriso 3 and Peter Whiteo 4
1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2Department of Primary Care and Population Health, University College London Medical School,
London, UK
3Department of Psychology, King’s College London, London, UK
4Barts and The London School of Medicine and Dentistry, London, UK
*Corresponding author j.leaviss@sheffield.ac.uk
Background: The term ‘medically unexplained symptoms’ is used to cover a wide range of persistent
bodily complaints for which adequate examination and appropriate investigations do not reveal
sufficiently explanatory structural or other specified pathologies. A wide range of interventions may
be delivered to patients presenting with medically unexplained symptoms in primary care. Many of
these therapies aim to change the behaviours of the individual who may have worsening symptoms.
Objectives: An evidence synthesis to determine the clinical effectiveness and cost-effectiveness
of behavioural modification interventions for medically unexplained symptoms delivered in primary
care settings was undertaken. Barriers to and facilitators of the effectiveness and acceptability of
these interventions from the perspective of patients and service providers were evaluated through
qualitative review and realist synthesis.
Data sources: Full search strategies were developed to identify relevant literature. Eleven electronic
sources were searched. Eligibility criteria – for the review of clinical effectiveness, randomised
controlled trials were sought. For the qualitative review, UK studies of any design were included.
For the cost-effectiveness review, papers were restricted to UK studies reporting outcomes as
quality-adjusted life-year gains. Clinical searches were conducted in November 2015 and December
2015, qualitative searches were conducted in July 2016 and economic searches were conducted in
August 2016. The databases searched included MEDLINE, Cumulative Index to Nursing and Allied
Health Literature (CINAHL), PsycINFO and EMBASE. Updated searches were conducted in
February 2019 and March 2019.
Participants: Adult participants meeting the criteria for medically unexplained symptoms, including
somatoform disorders, chronic unexplained pain and functional somatic syndromes.
Interventions: Behavioural interventions were categorised into types. These included psychotherapies,
exercise-based interventions, multimodal therapies (consisting of more than one intervention type),
relaxation/stretching/social support/emotional support, guided self-help and general practitioner
interventions, such as reattribution. Evidence synthesis: a network meta-analysis was conducted to
allow a simultaneous comparison of all evaluated interventions in a single coherent analysis. Separate
network meta-analyses were performed at three time points: end of treatment, short-term follow-up
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(< 6 months since the end of treatment) and long-term follow-up (≥ 6 months after the end of
treatment). Outcomes included physical and psychological symptoms, physical functioning and impact
of the illness on daily activities. Economic evaluation: within-trial estimates of cost-effectiveness were
generated for the subset of studies where utility values (or quality-adjusted life-years) were reported or
where these could be estimated by mapping from Short Form questionnaire-36 items or Short Form
questionnaire-12 items outcomes.
Results: Fifty-nine studies involving 9077 patients were included in the clinical effectiveness review.
There was a large degree of heterogeneity both between and within intervention types, and the
networks were sparse across all outcomes. At the end of treatment, behavioural interventions showed
some beneficial effects when compared with usual care, in particular for improvement of specific
physical symptoms [(1) pain: high-intensity cognitive–behavioural therapy (CBTHI) standardised mean
difference (SMD) 0.54 [95% credible interval (CrI) 0.28 to 0.84], multimodal SMD 0.52 (95% CrI 0.19 to
0.89); and (2) fatigue: low-intensity cognitive–behavioural therapy (CBTLI) SMD 0.72 (95% CrI 0.27 to
1.21), relaxation/stretching/social support/emotional support SMD 0.87 (95% CrI 0.20 to 1.55), graded
activity SMD 0.51 (95% CrI 0.14 to 0.93), multimodal SMD 0.52 (95% CrI 0.14 to 0.92)] and psychological
outcomes [(1) anxiety CBTHI SMD 0.52 (95% CrI 0.06 to 0.96); (2) depression CBTHI SMD 0.80 (95% CrI
0.26 to 1.38); and (3) emotional distress other psychotherapy SMD 0.58 (95% CrI 0.05 to 1.13), relaxation/
stretching/social support/emotional support SMD 0.66 (95% CrI 0.18 to 1.28) and sport/exercise SMD
0.49 (95% CrI 0.03 to 1.01)]. At short-term follow-up, behavioural interventions showed some beneficial
effects for specific physical symptoms [(1) pain: CBTHI SMD 0.73 (95% CrI 0.10 to 1.39); (2) fatigue:
CBTLI SMD 0.62 (95% CrI 0.11 to 1.14), relaxation/stretching/social support/emotional support SMD
0.51 (95% CrI 0.06 to 1.00)] and psychological outcomes [(1) anxiety: CBTHI SMD 0.74 (95% CrI 0.14 to
1.34); (2) depression: CBTHI SMD 0.93 (95% CrI 0.37 to 1.52); and (3) emotional distress: relaxation/
stretching/social support/emotional support SMD 0.82 (95% CrI 0.02 to 1.65), multimodal SMD 0.43
(95% CrI 0.04 to 0.91)]. For physical functioning, only multimodal therapy showed beneficial effects:
end-of-treatment SMD 0.33 (95% CrI 0.09 to 0.59); and short-term follow-up SMD 0.78 (95% CrI 0.23 to
1.40). For impact on daily activities, CBTHI was the only behavioural intervention to show beneficial effects
[end-of-treatment SMD 1.30 (95% CrI 0.59 to 2.00); and short-term follow-up SMD 2.25 (95% CrI 1.34
to 3.16)]. Few effects remained at long-term follow-up. General practitioner interventions showed no
significant beneficial effects for any outcome. No intervention group showed conclusive beneficial effects
for measures of symptom load (somatisation). A large degree of heterogeneity was found across individual
studies in the assessment of cost-effectiveness. Several studies suggested that the interventions produce
fewer quality-adjusted life-years than usual care. For those interventions that generated quality-adjusted
life-year gains, the mid-point incremental cost-effectiveness ratios (ICERs) ranged from £1397 to £129,267,
but, where the mid-point ICER fell below £30,000, the exploratory assessment of uncertainty suggested
that it may be above £30,000.
Limitations: Sparse networks meant that it was not possible to conduct a metaregression to explain
between-study differences in effects. Results were not consistent within intervention type, and there were
considerable differences in characteristics between studies of the same type. There were moderate to high
levels of statistical heterogeneity. Separate analyses were conducted for three time points and, therefore,
analyses are not repeated-measures analyses and do not account for correlations between time points.
Conclusions: Behavioural interventions showed some beneficial effects for specific medically unexplained
symptoms, but no one behavioural intervention was effective across all medically unexplained symptoms.
There was little evidence that these interventions are effective for measures of symptom load (somatisation).
General practitioner-led interventions were not shown to be effective. Considerable heterogeneity in
interventions, populations and sparse networks mean that results should be interpreted with caution.
The relationship between patient and service provider is perceived to play a key role in facilitating a
successful intervention. Future research should focus on testing the therapeutic effects of the general
practitioner–patient relationship within trials of behavioural interventions, and explaining the observed
between-study differences in effects within the same intervention type (e.g. with more detailed reporting
of defined mechanisms of the interventions under study).
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Plain English summary
The term ‘medically unexplained symptoms’ is used in relation to individuals who present totheir general practitioner with persistent symptoms that cannot easily be explained, even after
adequate physical examination and appropriate investigations. Common interventions delivered
in primary care tend to be psychological interventions, behaviour therapies or physical exercise
therapies. These therapies often aim to change the behaviours of the individual that may make
symptoms worse. We conducted systematic reviews of existing evidence to evaluate the effectiveness
and acceptability of behavioural interventions delivered in primary care, and a cost-effectiveness
analysis to see whether or not they offer good value. Studies measured improvement in outcomes,
such as physical or psychological symptoms, or health-related quality of life. There were large
differences in the nature of the behavioural interventions delivered and so we grouped them into
‘types’. These included intervention types involving exercise (e.g. aerobic or strengthening, or graded
activity); different types of psychotherapy, for example cognitive–behavioural therapy; interventions
focused on relaxation or social/emotional support; interventions offering education and information;
and interventions by general practitioners, for example receiving training on how to implement a
behavioural approach to treating medically unexplained symptoms. Statistical analyses were conducted
to investigate which, if any, of the intervention types were effective when compared with usual care.
Results indicated that some of the behavioural intervention types showed beneficial effects at the
end of treatment and at short-term follow-up. In particular, cognitive–behavioural therapy at a higher
intensity, and therapies consisting of components of more than one intervention type (i.e. multimodal
therapies), showed beneficial effects for specific physical symptoms such as pain, fatigue or bowel
symptoms. High-intensity cognitive–behavioural therapy, other types of psychotherapies and interventions
focusing on relaxation and social/emotional support showed some beneficial effects on mood outcomes
such as depression and anxiety. By long-term follow-up, effects had diminished. More complex measures
of symptom load or ‘somatisation’ showed fewer beneficial effects. We found that no one intervention
improved outcomes across all medically unexplained symptoms.
However, the results of the statistical analyses should be interpreted with caution. Not only were there
differences in the types of behavioural interventions trialled in the included studies, but there were
also differences in the characteristics of interventions within the same type. Participants of the studies
had a range of symptoms and syndromes, of varying severity and duration. Interventions of the same
type varied in how they were delivered, for example the qualifications of the therapist and the contact
time spent between therapist and patient. Owing to the limited number of studies in each intervention
type, it has not been possible to identify how these differences influenced the results.
Interventions delivered by general practitioners themselves did not generally show beneficial effects.
However, the relationship between general practitioner and patient was perceived to be important.
Patients valued receiving explanations for their symptoms and learning self-management techniques.
This was facilitated by good relationships with their health-care practitioner. Health-care practitioners
reported a need for training and supervision, but patients reported that the primary care setting was
both appropriate and helpful. A successful behavioural intervention should allow a patient and their
care provider to maintain a relationship where the patient feels supported.
Analyses of the cost-effectiveness of the interventions showed a wide variation in costs. Costs varied
between different intervention types, but also between interventions of the same type. Differences
in the nature of interventions within the same intervention type, for example whether delivery is to
groups or to individuals, make comparisons difficult.
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Future research should focus on identifying how the relationship between the general practitioner
and their patient can influence the effectiveness of a behavioural intervention when it is conducted in
the primary care setting. In addition, more research is needed to explore which aspects of the more
promising interventions are influencing their effectiveness.
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Scientific summary
Background
The term ‘medically unexplained symptoms’ is used to describe a wide range of persistent bodily
complaints for which adequate examination and appropriate investigations do not reveal sufficient
explanatory structural or other specified pathology. Use of the term medically unexplained symptoms
does not require that the physical symptoms have a psychogenic origin, as somatoform disorders
do. The term may be applied to patients presenting with single or multiple symptoms, or clusters of
symptoms specific to a particular organ system or medical specialty, often referred to as functional
somatic syndromes (e.g. fibromyalgia, irritable bowel syndrome or chronic fatigue syndrome). Medically
unexplained symptoms is a controversial term and debate is ongoing regarding its continued use or
a move to alternative terminology. Medically unexplained symptoms is a portfolio term covering a
wide range of presentations. The term ‘medically unexplained’ does not exclude physical pathology.
Medically unexplained symptoms can cause distress to the patient. A range of prevalence rates of
medically unexplained symptoms in primary care are suggested, with UK estimates of around 18%
of consecutive attenders to general practitioners to worldwide estimates of between 25% and 50%
of primary care patients presenting with such symptoms. The financial cost to the UK NHS has been
estimated at > £3B. A wide range of interventions has been implemented in the treatment of medically
unexplained symptoms. These include pharmacological treatments, such as antidepressants; psychological
therapies including psychodynamic therapy; cognitive–behavioural therapy; behaviour therapy, such
as reducing unhelpful coping behaviours (e.g. reassurance seeking); and relaxation therapies, such as
meditation-based stress reduction. Physical therapies have also been implemented, such as graded
exercise therapy, aerobic or strengthening exercises, or alternative therapies, such as acupuncture
or hypnotherapy.
Current evidence for the effectiveness of interventions for medically unexplained symptoms is not
conclusive, with beneficial effects found for psychological interventions conducted in secondary
care but evidence that such therapies are less beneficial when conducted by general practitioners.
Treatment intensity has been proposed as a moderator of effects, with some reviews indicating that
more intense treatments show more beneficial effects. To our knowledge, no review to date has
specifically explored the effectiveness of behavioural modification interventions for a range of
medically unexplained symptoms populations in primary care settings.
Objectives
1. To determine the clinical effectiveness of behavioural modification interventions for medically
unexplained symptoms in primary care and community-based settings, by undertaking a full
systematic review of quantitative literature.
2. To evaluate the barriers to and facilitators of effectiveness and acceptability of behavioural
modification interventions for medically unexplained symptoms from the perspective of both
patients and service providers, by undertaking realist synthesis following a systematic review
of the available qualitative research literature.
3. To undertake meta-analysis of available evidence on clinical effectiveness, including a network
meta-analysis, where appropriate.
4. To identify and synthesise evidence on health economic outcomes such as health-care resource
use (e.g. general practitioner appointments), and health-related quality-of-life data from the studies
included in the clinical effectiveness review.
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5. To provide new evidence on the cost-effectiveness of behavioural modification interventions for
medically unexplained symptoms conducted in a primary care or community setting, by conducting a
systematic review of existing economic analyses and undertaking a de novo model-based evaluation
where there is an absence of high-quality published analyses that are directly applicable to our
research question.
6. To explain which interventions are appropriate for which medically unexplained symptoms patients
under which circumstances (via realist synthesis).
Methods for quantitative review
A systematic review of the literature was undertaken to identify relevant studies to evaluate the clinical
effectiveness of behavioural modification interventions for medically unexplained symptoms in a primary
care or community-based setting. A systematic search strategy using a combination of free-text terms
and thesaurus searching was used. Eleven electronic sources (e.g. MEDLINE, Cumulative Index to
Nursing and Allied Health Literature, PsycINFO and EMBASE) were searched for systematic reviews and
randomised controlled trials, between 20 November 2015 and 7 December 2015. In addition, reference
sections of included studies and existing systematic reviews were scrutinised for potentially relevant
studies. Inclusion criteria are summarised as follows:
l study design – randomised controlled trials with no minimum duration of follow-up
l population – adult participants meeting the inclusion criteria for medically unexplained symptoms,
including ‘medically unexplained symptoms’, somatoform disorders, chronic unexplained pain,
the functional somatic syndromes (e.g. irritable bowel syndrome, fibromyalgia, chronic
fatigue syndrome)
l intervention – behavioural interventions meeting the inclusion criteria including a range of
psychotherapies, exercise-based interventions; multimodal therapies; general practitioner
interventions (e.g. reattribution); promoting a biopsychosocial approach towards the management
of medically unexplained symptoms
l outcomes – improvement in specific physical symptoms; improvement in symptoms of emotional
distress (e.g. depression/anxiety); physical function; impact of illness on daily activities
l setting – primary care or community settings.
Methods for network meta-analysis
A network meta-analysis was used to synthesise the evidence and allow a simultaneous comparison of
all evaluated interventions in a single coherent analysis. Standardised mean differences were computed
for the continuously distributed outcomes to allow the inclusion of studies that evaluated outcomes
using different scales. Separate network meta-analyses were performed for three time points: end
of treatment, short-term follow-up (< 6 months since end of treatment) and long-term follow-up
(≥ 6 months after end of treatment).
Methods for qualitative review
A qualitative evidence synthesis was conducted to provide added value to the quantitative analysis
by exploring patient and service provider issues around the acceptability of behavioural modification
interventions in primary care settings. A systematic search strategy was developed to identify UK-based
qualitative studies, using a combination of free-text terms and thesaurus searching. Searches were
conducted on 4 July 2016. Specifically, thematic synthesis was used to aggregate the findings. The
framework developed for data extraction was used to shape the synthesis of the findings. Themes were
then developed within the framework elements.
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Methods for realist synthesis
The aim of the realist synthesis was to provide an overview and analysis of the evidence for the
contribution of contextual factors associated with the ongoing primary care consultation and the
patient’s interaction with primary care professionals to the success or failure of behaviour modification
interventions (‘behavioural interventions’) for medically unexplained symptoms. A search was conducted
for relevant ‘theories’ in the literature. A list of programme theories was drawn up, which were
subsequently grouped, categorised and synthesised. A theoretically based evaluative framework was
designed, which was then ‘populated’ with evidence.
Methods for cost-effectiveness
A systematic review was conducted to identify published economic evaluations, conducted in the UK,
which measured benefits using quality-adjusted life-years. A systematic search strategy was developed
using a combination of free-text terms and thesaurus searching. Searches were conducted between
15 and 25 August 2016. Economic evaluations that did not report quality-adjusted life-years were
narratively summarised for cost outcomes. Applicability to the National Institute for Health and Care
Excellence’s reference case and methodological quality were assessed using the checklist provided in
the National Institute for Health and Care Excellence’s guidelines manual.
An independent economic assessment was conducted with the aim of generating a within-study
estimate of cost-effectiveness for each trial included in the clinical effectiveness review. Incremental
costs compared with usual care were estimated for each behavioural modification intervention and
for any active comparators. Cost estimates were based on the duration of time spent by health-care
professionals delivering the intervention and the unit cost for the relevant health-care professional.
Our aim was to estimate quality-adjusted life-years based on utilities from the UK version of the
EuroQol-5 Dimensions, but studies reporting utility values using the Short Form questionnaire-6
Dimensions or non-UK valuations of the EuroQol-5 Dimensions were considered acceptable alternatives.
Where these data were not available, we estimated utility values by mapping from the Short Form
questionnaire-12 items or the Short Form questionnaire-36 items to the UK EuroQol-5 Dimensions
whenever possible.
Incremental quality-adjusted life-years were estimated using an area under the curve approach up to
the last time point for which utility data were reported or estimable for each study. Utility values were
adjusted for baseline differences. Uncertainty in the incremental quality-adjusted life-years because
of uncertainty in the Short Form questionnaire-36 items/Short Form questionnaire-12 items study
outcomes was explored through a two-way sensitivity analysis.
Results for quantitative review
In total, 59 randomised controlled trials were included in the quantitative review, providing data on
9077 participants. Studies were rated as being of variable quality, ranging from low to high quality.
Owing to the nature of the interventions and control arms, few studies reported blinding participants.
The number of participants in a single trial ranged from 10 to 524. There was considerable heterogeneity
within the populations and behavioural interventions studied, the outcomes measured and the detail of
the study setting. Data relating to these and other potential sources of heterogeneity were extracted and
a metaregression was planned to investigate the influence of these factors on effects. For population
samples, 29 studies were of participants meeting inclusion criteria for ‘medically unexplained symptoms’
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or somatoform disorders; one trial studied participants with mixed ‘medically unexplained symptoms’
diagnoses; 12 studies were of participants with chronic fatigue; six studies were of participants with
chronic unexplained pain at a single site on the body; seven studies were of participants with chronic
unexplained pain at multiple sites on the body; three studies were of irritable bowel syndrome; and
the remaining study was of a population of women with medically unexplained vaginal discharge.
Within-population variation was identified, with differences in diagnostic/inclusion criteria used for
some of the condition groups, in particular the ‘medically unexplained symptoms’ population.
Behavioural intervention arms were coded into one of 13 behavioural intervention types: high-
intensity cognitive–behavioural therapy; low-intensity cognitive–behavioural therapy; graded activity;
strength/endurance/sport; other psychotherapy; relaxation/stretching/social support/emotional
support; guided self-help; multimodal interventions (interventions consisting of more than one
intervention type); and general practitioner interventions with a behavioural modification basis that
included general practitioner reattribution; general practitioner medically unexplained symptoms
management; general practitioner-delivered cognitive–behavioural therapy; general practitioner-
delivered other psychotherapy; and any other general practitioner-delivered behavioural intervention
not fitting in any other category. Three non-behavioural comparator arms were also identified:
medication; usual care (including treatment as usual and waiting list); and usual care plus (defined
as enhanced usual care but not meeting the criteria for a behavioural intervention). Considerable
heterogeneity was evident within intervention types, with variation in the number and duration of
sessions, treatment duration and differences in treatment provider.
Owing to the heterogeneous populations, a diverse range of outcomes were measured across studies.
Commonalities were sought and 10 key outcomes were identified where it was considered that
sufficient similar data were available to attempt meta-analyses. These were specific physical symptoms
(pain, fatigue, bowel symptoms); emotional distress (depression, anxiety or composite measures,
e.g. mental health); symptom load (somatisation, generic physical symptoms); physical functioning;
and impact of symptoms on daily activities. There was considerable heterogeneity between studies
in the measures used to assess these outcomes.
There was also variation in the detail of setting, with participants in some studies recruited and treated
by their own general practitioner at their own general practitioner practice, whereas in others treatment
involved collaborative care with other health professionals or was co-ordinated by participants’ GP but
involved an external setting such as a fitness facility. In all studies, however, participants were primary
care patients and were not recruited from tertiary care settings.
Results for meta-analysis
For all the results presented in this section, a positive SMD indicates a beneficial effect when compared
with usual care. Cohen’s categories were used to describe the magnitude of the effect size: small
(0.2 ≤ SMD < 0.5), medium (0.5 ≤ SMD < 0.8) and large (0.8 ≤ SMD) (Cohen J. Statistical Power Analysis
for the Behavioral Sciences. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers; 1988).
SMDs < 0.2 were described as ‘not substantial’.
Immediately post treatment
The results were inconclusive for the majority of interventions that were included in the network
meta-analysis but with the following exceptions. High-intensity cognitive–behavioural therapy was
shown to be effective for four outcomes: pain, impact of illness on daily activities, anxiety and depression.
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Relaxation/stretching/social support/emotional support was shown to be effective for two outcomes:
fatigue and emotional distress. Multimodal therapy was shown to be effective for three outcomes: pain,
fatigue and physical functioning. Low-intensity cognitive–behavioural therapy and graded exercise were
shown to be effective for one outcome: fatigue. Other psychotherapy and strength/endurance/sport
were shown to be effective for one outcome: emotional distress. Guided self-help was shown to be not
effective for two outcomes: physical functioning and emotional distress. This result was based on a single
study with an unusually large negative effect size compared with a multimodal intervention. Inconsistency
checking showed this indirect comparison to be inconsistent with the direct comparison.
For physical symptom outcomes, it was found that high-intensity cognitive–behavioural therapy was
the most beneficial intervention for pain when compared with usual care [a medium effect size,
SMD 0.54 with 95% credible interval (CrI) 0.28 to 0.84]. Relaxation/stretching/social support/emotional
support was the most beneficial intervention for fatigue when compared with usual care (a large
effect size, SMD 0.87 with 95% CrI 0.20 to 1.55). High-intensity cognitive–behavioural therapy was
the most beneficial intervention for somatisation when compared with usual care, a small effect size
(SMD 0.32 with 95% CrI –0.12 to 0.75), but the result was inconclusive. Only other psychotherapy
and usual care were included in the network meta-analysis on generic physical symptoms, and usual
care was more effective than other psychotherapy, a small effect size of other psychotherapy versus
usual care (SMD –0.25 with 95% CrI –0.77 to 0.30), but the result was inconclusive.
For physical functioning and impact of symptoms on daily activities, it was found that multimodal
therapy was the most beneficial intervention for physical functioning when compared with usual care,
a small effect size (SMD 0.33 with 95% CrI 0.09 to 0.59). Guided self-help was significantly worse
than usual care (a medium effect size SMD –0.73 with 95% CrI –1.18 to –0.29) for physical functioning.
High-intensity cognitive–behavioural therapy was the most beneficial intervention for impact of
symptoms on daily activities when compared with usual care, a large effect size (SMD 1.30 with 95% CrI
0.59 to 2.00).
For emotional distress outcomes, it was found that high-intensity cognitive–behavioural therapy was
the most beneficial intervention for both anxiety and depression when compared with usual care, with
a medium effect size (SMD 0.52 with 95% CrI 0.06 to 0.96) for anxiety and a large effect size (SMD
0.80 with 95% CrI 0.26 to 1.38) for depression. Relaxation/stretching/social support/emotional support
was the most beneficial intervention for emotional distress when compared with usual care, with a
medium effect size (SMD 0.66 with 95% CrI 0.18 to 1.28). Guided self-help was significantly worse
than usual care (a large effect size SMD –1.03 with 95% CrI –1.95 to –0.10) for emotional distress.
Short-term follow-up
The results were inconclusive for the majority of interventions that were included in the network
meta-analysis but with the following exceptions. High-intensity cognitive–behavioural therapy was
shown to be effective for four outcomes: pain, impact of symptoms on daily activities, anxiety and
depression. Low-intensity cognitive–behavioural therapy was shown to be effective for one outcome:
fatigue. Relaxation/stretching/social support/emotional support was shown to be effective for two
outcomes: fatigue and emotional distress. Multimodal therapy was shown to be effective for two
outcomes: physical functioning and emotional distress. Medication was shown to be effective for
one outcome: impact of symptoms on daily activities.
For physical symptom outcomes, it was found that high-intensity cognitive–behavioural therapy was
the most beneficial intervention for pain when compared with usual care, a medium effect size
(SMD 0.73 with 95% CrI 0.10 to 1.39). Low-intensity cognitive–behavioural therapy was the most
beneficial intervention for fatigue when compared with usual care (with a medium effect size SMD
0.62 with 95% CrI 0.11 to 1.14).
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For physical functioning and impact of symptoms on daily activities outcomes, it was found that
multimodal therapy was the most beneficial intervention for physical functioning when compared
with usual care, with a medium effect size (SMD 0.78 with 95% CrI 0.23 to 1.40). High-intensity
cognitive–behavioural therapy was the most beneficial intervention on impact on daily activities
when compared with usual care, with a large effect size (SMD 2.25 with 95% CrI 1.34 to 3.16).
For emotional distress outcomes, it was found that high-intensity cognitive–behavioural therapy was
the most beneficial intervention for both anxiety and depression when compared with usual care, a
medium effect size (SMD 0.74 with 95% CrI 0.14 to 1.37) for anxiety and a large effect size (SMD 0.93
with 95% CrI 0.37 to 1.52) for depression. Relaxation/stretching/social support/emotional support was
the most beneficial intervention for emotional distress when compared with usual care, with a large
effect size (SMD 0.82 with 95% CrI 0.02 to 1.65).
Long-term follow-up
The results were inconclusive for the majority of interventions that were included in the network
meta-analysis but with the following exceptions. Low-intensity cognitive–behavioural therapy was
shown to be effective for two outcomes: fatigue and bowel symptoms. Guided self-help was shown to
be not effective for four outcomes: pain, physical functioning, impact of symptoms on daily activities
and emotional distress.
For physical symptom outcomes, it was found that medication was the most beneficial intervention for
pain when compared with usual care, with a small effect size (SMD 0.41 with 95% CrI –0.16 to 0.98),
but the result was inconclusive. Guided self-help was significantly worse than usual care (a large effect
size SMD –2.27 with 95% CrI –3.30 to –1.23) for pain. Low-intensity cognitive–behavioural therapy
was the most beneficial intervention for fatigue (with a medium effect size, SMD 0.64 with 95% CrI
0.05 to 1.20) and for bowel symptoms (with a large effect size, SMD 0.84 with 95% CrI 0.17 to 1.52)
when compared with usual care. High-intensity cognitive–behavioural therapy was also the most
beneficial intervention on somatisation when compared with usual care, with a small effect size
(SMD 0.47 with 95% CrI –0.30 to 1.29), but the result was inconclusive.
For physical functioning and impact of symptoms on daily activities outcomes, it was found that high-
intensity cognitive–behavioural therapy was the most beneficial intervention for physical functioning
when compared with usual care, with a small effect size (SMD 0.47 with 95% CrI –0.49 to 1.44), but the
result was inconclusive. Guided self-help was significantly worse than usual care (a large effect size
SMD –2.98 with 95% CrI –4.00 to –1.96) for physical functioning. Low-intensity cognitive–behavioural
therapy was the most beneficial intervention for impact when compared with usual care, with a large
effect size (SMD 0.89 with 95% CrI –0.22 to 1.55), but the result was inconclusive. Guided self-help
was significantly worse than usual care (a large effect size SMD –1.10 with 95% CrI –2.08 to –0.07) for
impact of symptoms on daily activities.
For emotional distress outcomes, it was found that general practitioner ‘other psychotherapy’ was the
most beneficial intervention for anxiety when compared with usual care, a small not substantial effect
size (SMD 0.18 with 95% CrI –0.40 to 0.76), but the result was inconclusive. Multimodal therapy was
the most beneficial intervention on depression when compared with usual care, with a small effect
size (SMD 0.51 with 95% CrI –0.02 to 1.13), but the result was inconclusive. Multimodal was also the
most beneficial intervention on emotional distress when compared with usual care, with a small effect
size (SMD 0.56 with 95% CrI –0.31 to 1.45), but the result was inconclusive. Guided self-help was
significantly worse than usual care (a large effect size SMD –1.44 with 95% CrI –2.60 to –0.30) for
emotional distress.
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Results for the qualitative review
The qualitative systematic review examined patient and health professional perspectives on the
acceptability, relative benefits and potential harms of the interventions. In total, 10 papers reported
evidence from eight studies, providing data from 130 patients and 38 health professionals. Some of the
included studies were only of moderate or low quality and some findings were assessed as being of
moderate or low confidence. The findings of the synthesis across all interventions showed that a major
theme for patients was gaining support. Patients also highly valued receiving an explanation for their
symptoms, together with learning self-management techniques and being provided with support for
learning such techniques. The helpfulness of the intervention appeared to be facilitated by a good
relationship between patients and the health professionals delivering the intervention.
Evidence from health professionals showed that important facilitators were training and supervision
for delivery of the interventions and they found primary care or the community an appropriate and
helpful setting for this. Barriers to intervention participation and success included both patients’
and health professionals’ own attitudes and beliefs, conflicts between health professionals and
patients, health professionals’ lack of confidence in their own skills and abilities to deal with medically
unexplained symptoms, together with resource constraints. Health professionals were also concerned
that the interventions may have inadvertently detrimental consequences for patients, and that they
may be ill-equipped to deal with their own and patients’ emotions. The implications of the findings
suggest that, although a number of patients found interventions helpful, a minority did not find the
intervention helpful or did not want to take part in the intervention at all; therefore, careful matching
of patients to interventions should take place. Further considerations were continuity of care from
the same health professional or team, that interventions do not end suddenly, or without adequate
follow-up. The qualitative synthesis was also able to elucidate and provide potential explanations for
some of the findings of the quantitative review, for example the variation in the number of sessions
patients attended both within and between studies.
Results for realist synthesis
The realist synthesis explored eight programme theory components to explain why interventions for
the target populations are found to be more or less successful, particularly when delivered within
a primary care setting. Key factors contributing to success, across multiple interventions, included
establishing and maintaining belief and trust as a foundation for the relationship between patient and
professional, and negotiation of a shared biopsychosocial disease model. A focus on symptoms was also
believed to be helpful particularly in moving towards an explanation considered sufficient at a specific
point in time, but contingent as further clinical information and patient experience emerges.
Both patients and professionals sought to avoid perpetuation of an unproductive diagnostic cycle
whereby a patient is shifted between referral to different consultants or different diagnostic tests.
More equivocal was the value of a ‘label’ for patients’ symptoms, with perceived differences in the
value of a label such as ‘chronic fatigue syndrome’, which could be considered helpful, compared
with the generic ‘medically unexplained symptoms’, which was considered manifestly unhelpful.
Nevertheless, response to labels could also differ between patients. A particular tension was identified
in whether or not the practitioner should explore psychosocial cues. It surfaced in some interventions
that this was an essential feature of the consultation and subsequent treatment (e.g. reattribution
therapies), whereas others recommended that psychosocial cues should only be initiated by the patient
(e.g. the primary care symptom clinic). There was little evidence considering the inherent advantage of
a primary care setting beyond arguments for continuity of care, which is increasingly being eroded by
team-based delivery of primary care services, although delivery in non-medical settings was suggested
for countering the stigma associated with the psychological framing of symptoms.
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Results for cost-effectiveness
Only two studies were included in our review of UK cost-effectiveness studies. One study found that
neither of the two behavioural modification interventions examined (graded activity; other psychotherapy)
provided more benefits than usual care in patients with chronic fatigue. The other study found that in
patients with chronic unexplained pain, high-intensity cognitive–behavioural therapy was cost-effective
(when valuing a quality-adjusted life-year at £20,000) compared with usual care, and had greater benefit
than strength/endurance/sport and a multimodal intervention combining both strength/endurance/sport
and high-intensity cognitive–behavioural therapy. Five cost–consequences studies were identified, but
again these had heterogeneous results, with only two reporting a statistically significant difference in
costs between study arms.
For the independent assessment of cost-effectiveness, within-trial estimates of cost-effectiveness were
estimated for 18 studies. There is a large degree of heterogeneity in the estimates of cost-effectiveness
across individual studies. Some interventions were found to be dominated by usual care (i.e. they cost
more and produced fewer quality-adjusted life-years) or dominated by other behavioural modification
interventions. For those interventions that generated quality-adjusted life-year gains versus usual care,
the mid-point incremental cost-effectiveness ratios ranged from £1397 to £129,267, but, where the
mid-point incremental cost-effectiveness ratio fell below £30,000, the exploratory assessment of
uncertainty suggested that it may be above £30,000. When comparing studies that had interventions
in the same class, the estimates of cost-effectiveness were often inconsistent across studies. This may
reflect differences between studies within the populations or in the exact delivery of the interventions.
Limitations
Results from the network meta-analysis are limited because of the sparsity of the networks. A lack of
consistency in the point estimates between studies comparing the same type of interventions with usual
care and moderate to high levels of statistical heterogeneity means that the results are not conclusive
and should be interpreted with caution. It was not possible to conduct planned metaregressions to
identify potential moderators because of insufficient replication of each intervention type in the network
and, therefore, it was not possible to explain between-study heterogeneity of effects. In particular, it was
not possible to determine whether or not different medically unexplained symptoms populations respond
differently to similar interventions, although differences in individual point estimates within intervention
types across populations suggest that there are differences, although there were overlapping
confidence intervals.
Results from the cost-effectiveness analyses found considerable heterogeneity between individual
studies, with a lack of consistency in duration/number of treatment sessions and the number of patients
recruited and treated by individual providers. The main limitation of the independent economic evaluation
is that the conclusions that can be drawn are limited to the direct comparisons presented in the subset
of studies for which we were able to estimate quality-adjusted life-year differences.
Discussion and conclusions
Results of the clinical effectiveness review indicate that, when conducted in primary care settings,
behavioural modification interventions, in particular high-intensity cognitive–behavioural therapy and
multimodal therapies, show some beneficial effects for improvement of specific individual physical
symptoms. However, for more complex outcomes, in particular for measures of symptom load (somatisation
and generic physical symptoms), there was little evidence of their effectiveness. There were also some
beneficial effects for improvement of mood, most commonly high-intensity cognitive–behavioural therapy
but also for other psychotherapy, relaxation/stretching/social support/emotional support and strength/
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endurance/sport interventions. Few beneficial effects were found at long-term follow-up. Results of
the network meta-analyses showed no effects for behavioural interventions delivered by general
practitioners themselves. All of these results are limited by a lack of studies for each intervention type
and by considerable heterogeneity within intervention types, and between populations and outcomes,
and should therefore be interpreted with caution. Differences in effects suggest that there is no
specific intervention type that uniformly benefits all ‘medically unexplained symptoms’ populations
included in the review, which might reflect the heterogeneity within medically unexplained symptoms.
Cost-effectiveness also varies considerably depending on a number of factors, such as intensity
of treatment, group size, and the number of patients recruited and treated by each trained
general practitioner.
Patients value receiving an explanation of their symptoms and learning self-management techniques,
with the support provided by a health professional being especially valued. A good relationship between
patient and health professional is perceived to facilitate the effectiveness of behavioural modification
interventions, particularly when based on a common understanding of the illness. Training for general
practitioners in medically unexplained symptoms, although shown to have limited effectiveness as an
intervention in itself, is perceived to be an influential factor in facilitating the doctor/patient relationship
and the effectiveness of behavioural modification interventions. The primary care setting is perceived
as both appropriate and helpful. A collaborative care model of interventions for medically unexplained
symptoms patients may therefore be both acceptable and beneficial.
Potential research priorities
The following research priorities are suggested, based on the findings of the review:
1. Explanation of observed between-study differences in effects within the same intervention type.
This may be addressed by:
i. more detailed reporting of information regarding the defined mechanisms of the behavioural
interventions under study, and how these map onto a theoretical and empirical understanding
of the conditions
ii. more research on potentially influencing factors, such as effective dosage and therapist
competency within the more promising behavioural interventions
iii. within-trial comparisons of interventions targeting specific syndromes with those targeting
general somatic symptoms.
2. Testing the therapeutic effect of the general practitioner–patient relationship. This may be
addressed by:
i. increased awareness of likely general practitioner effects by researchers conducting trials of
behavioural interventions for medically unexplained symptoms, with planned assessment of these
as potential confounders
ii. more research aimed at better understanding the therapeutic elements behind a successful
therapeutic general practitioner–patient alliance, which are key to a successful outcome, and
how these elements can be formalised as general practitioner (and health-care practitioner) skills.
3. Development of standardised measures of adverse effects in trials of behavioural interventions for
medically unexplained symptoms.
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Chapter 1 Background
Definition of medically unexplained symptoms
The term ‘medically unexplained symptoms’ (MUS) is used to describe a wide range of persistent bodily
complaints for which adequate examination does not reveal sufficient explanatory structural or other
specified pathology (reproduced with permission from the Royal College of General Practitioners).1
Henningsen et al.2 describe three main types of MUS: pain in different locations, for example headache,
back pain, non-cardiac chest pain; functional disturbance of organ systems; and complaints of fatigue
or exhaustion. The term MUS may be applied to patients presenting with single symptoms, multiple
symptoms or clusters of symptoms that are related to one another and are specific to a certain organ
system or medical specialty; for example, chronic fatigue syndrome (CFS), irritable bowel syndrome (IBS)
or fibromyalgia. CFS, IBS or fibromyalgia are often referred to as functional somatic syndromes (FSSs).3
For patients reporting multiple symptoms, these may vary in range and type. MUS may also vary in
terms of reported severity (i.e. number/duration of symptoms) and their effects on functional disability
or quality of life.
The term MUS is controversial, and debate regarding its use is ongoing. To many patients with symptoms
that are not readily explainable by disease, a diagnostic label is important, but the label ‘MUS’ can be
regarded as offensive.4 Creed et al.5 suggest that the use of the term ‘MUS’ is a barrier to improved
care and, presented a review of the challenges associated with terminology in this area. They suggested
alternative terms, such as functional or persistent symptoms. ‘MUS’ is a portfolio term covering a wide
range of presentations. The term ‘medically unexplained’ does not exclude physical pathology.
The debate surrounding an appropriate alternative to ‘MUS’ is ongoing and the current review does
not seek to contribute to this, nor to address ‘causes’ of MUS.
Classification and diagnosis of medically unexplained symptoms
Diagnostic criteria for MUS are varied. Most of the FSSs are diagnosed according to published
diagnostic criteria that include specified symptom criteria alongside the exclusion of medical and/or
psychiatric conditions that may mimic similar symptoms [e.g. CFS may be diagnosed by the Fukuda
Diagnostic Criteria,6 functional gastrointestinal disorders may be diagnosed by the Rome 111
Diagnostic Criteria,7 fibromyalgia may be diagnosed by the American College of Rheumatology (ACR)
2010 Diagnostic Criteria8]. Patients visiting their general practitioner (GP) frequently with unexplained
symptoms are not necessarily offered a formal diagnosis. Where diagnosis of MUS is made, this may
be either by use of a validated instrument, such as the Patient Health Questionnaire (PHQ) 15,9
Screening for Somatoform Symptoms (SOMS),10 the Brief Symptom Inventory (BSI),11 or by clinical
judgement, usually by a GP. Hoedeman et al.12 describe a continuum of severity for MUS, ranging
from short term or incidental to persisting and recurrent. Fink et al.13 argue that research into the
FSSs and related disorders and their treatment is restricted by the lack of a valid and reliable
diagnostic classification. There is overlap between the diagnostic categories of functional somatic
disorders and, therefore, patients with similar symptoms and clinical presentations may receive
different diagnostic labels. Fink et al.13 have gone on to describe ‘bodily distress syndrome’ as an
alternative to MUS.
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The presence of MUS is also a key feature of a range of somatoform disorders. These include
somatisation disorder, somatoform pain disorder, undifferentiated somatoform disorder and unspecified
somatisation disorder. Diagnosis of any of the somatoform disorders is made by clinical structured
interview, with patients meeting diagnostic criteria according to the Diagnostic and Statistical Manual
of Mental Disorders (DSM)-IV,14 or V15 or the International Classification of Diseases (ICD)-916 or 10.17
Although the DSM-IV specifically refers to symptoms being medically unexplained, the DSM-V classification
no longer has a requirement that symptoms should lack an explanation. Somatic symptom disorder
in the DSM-V is characterised by ‘the presence of one or more distressing and disabling somatic
symptoms that disrupt daily functioning’.18 Significant, moderate to severe somatic symptoms are
required to be present, accompanied by excessive, illness-related thoughts, feelings or behaviours.
Criticism of the DSM-V definition of somatic symptom disorder centres around the removal of the
requirement for symptoms to be ‘unexplained’, and the focus on ‘excessive responses’. As the DSM-V
classifies mental disorders, it is argued that this extended scope risks mislabelling many people
with physical conditions, such as cancer, heart disease, IBS or fibromyalgia, as mentally ill.19 Frances20
raises concerns that mislabelling a patient with somatic symptom disorder causes harms (e.g. missed
diagnosis of underlying medical causes), subjecting patients to stigma, inappropriate drugs, psychotherapy
and iatrogenic disease, and that it may also cause patients to be disadvantaged with regard to employment,
education and health care. The 2016 Rome IV guidelines suggest removing the term ‘functional’ from
gastrointestinal disorders such as IBS and replacing them with terminology relating to ‘brain–gut
interaction’.21,22 Smith and Dwamena23 propose a clinical spectrum of severity for MUS, from normal/
mild, featuring few, minor transient symptoms and little accompanying depression/anxiety, to very
severe, which includes the somatoform disorders. Other acknowledged somatoform disorders that have
their own diagnostic criteria include bodily distress syndrome, bodily distress disorder and complex
somatic symptom disorder.
The current review uses a broad definition of MUS, which encompasses all of the above definitions,
so that the term MUS will be used to refer to any of the following definitions: (1) the occurrence
of physical symptoms in the absence of clear physical pathology, (2) to FSSs, such as CFS, IBS or
fibromyalgia, (3) the DSM-IV (and more recently V) somatoform disorders and (4) somatoform
disorders that have their own diagnostic criteria (e.g. bodily distress syndrome). The rationale behind
this broad definition is that there is clear overlap between these groups and as yet no consensus
as to the validity of one syndrome (i.e. MUS) versus many (i.e. the various FSSs). Whether patients
are diagnosed with MUS as opposed to a more specific diagnosis can be an artefact of clinician
or researcher preference rather a defining feature of the included patients.3,24 A final point about
classification of MUS is that there is preliminary evidence that several single FSSs are in fact themselves
composed of multiple different conditions, united only by common symptoms, which may complicate our
understanding of whether or not interventions work for MUS.
Clinical guidelines for MUS (Joint Commissioning Panel for Mental Health 201725) encourage a
philosophy of care where physical and mental health are integrated. A recognition that MUS are
‘mind–body problems’ is also encouraged. Some authors have suggested that the biopsychosocial model
itself is responsible for dissatisfaction and harm in patients with CFS,26 arguing that its application is
biased towards the psychological, framing patients as mentally ill. It is argued that this risks distraction
from research into the biological aetiology of symptoms and syndromes, for example Ghoshal and
Gwee,21 de Vega et al.27 and Gur and Oktayoglu.28 Imposing the biopsychosocial model on patients,
it is argued, can lead to ‘disputes over diagnosis, rejection of psychiatric diagnosis, as well as doctors
being dismissive, sceptical and lacking in knowledge about the condition’.29 The alternative view is that
the biopsychosocial model allows the inclusion and integration of biological, psychological and social
factors in understanding and treatment particularly of chronic conditions.30
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Prevalence and costs of medically unexplained symptoms
A range of prevalence rates of MUS have been estimated. Edwards et al.31 report worldwide prevalence
rates of primary care patients presenting with MUS of 25–50%. In the UK, Taylor et al.32 report a MUS
prevalence rate of 18% of consecutive attenders to UK GP practices. It is estimated that this creates
an annual cost to the UK NHS in excess of £3.1B.33,34 Taking into account quality of life and sickness
absence, wider costs to the economy were estimated at over £14B.33 The inappropriate management of
MUS may result in patients undergoing invasive and potentially harmful tests and treatments. Some
patients with MUS have comorbid depression/anxiety.35 Health-care utilisation varies between patients
with MUS due to the wide variability in symptom experience. Collin et al.36 used a case–control study
of nearly 8000 matched pairs to show that GP consultation rates for patients with CFS were 50%
higher in adult cases than in the controls 11–15 years before diagnosis, and 56% higher 6–10 years
after diagnosis, with a peak difference of more than twofold higher in the year of diagnosis. Similarly, a
study of health-care resource use for patients with fibromyalgia37 found that patients had considerably
higher resource use at least 10 years prior to their diagnosis of fibromyalgia. At the time of diagnosis,
patients recorded an average of 25 visits per year compared with 12 visits for the matched controls.
For IBS, health-care visits are considerably lower, with one study estimating one extra visit to primary
care per year compared with controls.38
A systematic review of the course and prognosis of MUS and somatoform disorders39 suggested that
the prognosis for patients with MUS is influenced by the severity of the condition at baseline and by
the number of symptoms. Creed et al.40 showed, in a large epidemiological study, that symptom count
predicted later quality of life. It has been estimated that between 50% and 75% of patients with MUS
will improve, whereas between 10% and 30% will see their condition deteriorate.39
Interventions for medically unexplained symptoms
A wide range of interventions has been implemented in the treatment of MUS. Pharmacological
interventions (e.g. antidepressants) are sometimes used. Reviews of pharmacological interventions have
shown these to produce some improvement in responsive patients in terms of symptom severity and
functioning,12,41,42 but significant heterogeneity of efficacy between different FSSs.
Psychological therapies
Several types of psychological therapies have been implicated. Cognitive–behavioural therapy (CBT)
for treatment of MUS is based on the model of CBT proposed by Beck43 and is one of the most
common interventions used for this group of patients. CBT for MUS focuses on the perpetuating
cycle that maintains symptoms, distress and disability. This type of therapy targets the relationship
between cognitive, behavioural and physiological responses that are proposed to maintain symptoms.44
Reattribution for MUS, although no longer commonly delivered, was designed to be delivered by GPs
and is based on providing a psychological explanation for somatised mental disorders. Patients are
encouraged to reattribute their symptoms and relate them to psychosocial problems. The three stages
of therapy are feeling understood, changing the agenda and making the link.45 Behaviour therapy may
be delivered to MUS patients. In these cases, therapy aims to modify behaviours such as increased vigilance
in detecting physical symptoms, or reducing inappropriate coping behaviours such as reassurance-seeking
or inactivity.46 Relaxation therapies may be used as treatments for MUS – these include biofeedback,47,48
meditation-based stress reduction49 and qigong.49 Third-wave CBTs include mindfulness and acceptance
and commitment therapy (ACT), which focuses on psychological flexibility, self-regulation of attention and
acceptance.50 Other psychological therapies such psychodynamic therapy have also been adopted for the
treatment of MUS.51
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Physical therapies
A further category of interventions for MUS are physical therapies. Such physical therapies include
graded exercise therapy (GET), whereby exercise is started gradually and increased over time, and
may incorporate the psychological component of graded exposure to exercise alongside a range of
aerobic or non-aerobic exercise, such as walking, pool-based exercise or strength training.52–56 More
physiologically based physical activity interventions include aerobic exercises or non-aerobic exercise
(e.g. yoga/qigong), which may also be offered to patients with MUS.57–59 Our review distinguishes
between graded and other physical activity interventions, with the former defined as exercise
with a defined behavioural model and the latter defined as exercise with a physiological rationale.
Physiotherapy-based exercise interventions were considered provided they included an element of
active behavioural participation. Manual therapies were not considered for inclusion if they were
predominantly passive.
Other therapies
Other therapies that have been adopted for the treatment of MUS include alternative therapies such
as hypnotherapy60 or acupuncture.61 These are usually passive therapies and were not included in
the review.
Not all of these treatments are available on the NHS and, therefore, some patients with MUS may pay
to access treatments that they perceive to improve their own symptoms, and where they feel they
have more time to express their concerns without the pressure of a time-limited GP consultation.
Setting
Interventions for MUS may be delivered in primary care settings, or after referral to secondary care
(e.g. to one or more specialists, such as general physicians, immunologists, neurologists, haematologists,
or psychiatrists).62 In primary care, GPs may deliver behavioural modification interventions to MUS
patients as part of enhanced care (encompassing techniques including CBT, reattribution or reframing).
Alternatively, patients with MUS may receive collaborative care, where for example a psychologist may
deliver CBT within the primary care setting. Delivering interventions in a primary care setting may
offer additional benefits, for example patients with MUS may refuse referral to services outside the
primary care setting.63
Evidence for the effectiveness of interventions for medically
unexplained symptoms
To our knowledge, there are currently no published systematic reviews that specifically evaluate
behavioural modification interventions for patients fulfilling the broad definition of MUS patients as
outlined above, within a primary care setting. However, a number of reviews have been conducted for
specific subgroups of interventions or patients. Reviews of evidence for the effectiveness of interventions
for MUS in general are less common than reviews of individual FSS. Reviews of FSSs have shown that,
in the case of CFS, CBT and GET can improve symptom severity and functioning following treatment
and are acceptable to patients.64–67 In the case of fibromyalgia, CBT has been shown to improve physical
symptoms and functioning,68 as have exercise therapies69,70 and multicomponent therapy.71 In the case
of IBS, psychological therapies have been shown to reduce symptoms as effectively as pharmacological
therapies,42 whereas Zijdenbos et al.72 found psychological interventions to be slightly superior to
usual care or waiting list controls. For other conditions, Aggarwal et al.73 found only weak evidence of
effectiveness of psychosocial interventions including CBT and biofeedback for patients with chronic
BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
4
orofacial pain. Champaneria et al.74 found psychological interventions improved pain scores for patients
with chronic pelvic pain compared with no psychological intervention. van Dessel et al.75 conducted a
review of all non-pharmacological interventions for somatoform disorders and MUS but identified only
studies of psychological interventions. The authors found that compared with usual care, treatment
resulted in less severe symptoms at the end of treatment. The evidence for CBTwas similar to
other psychotherapies.
Primary care reviews
The majority of studies included in these reviews were conducted within secondary care. Fewer reviews
addressed the effects of interventions in a primary care setting. A review of psychological interventions
for MUS76 found that short-term psychotherapy demonstrated small effects for the improvement of
physical symptoms in patients with medically unexplained physical symptoms (MUPS), with type and
mode of therapy and profession of the therapist moderating the results (e.g. inpatient therapy was more
effective, as was therapy delivered by mental health professionals). However, GP-delivered interventions
were found to be more effective at reducing health-care utilisation. Rosendal et al.77 reviewed enhanced
care delivered by generalists for patients with functional somatic symptoms and concluded that the
current evidence does not answer the question of whether or not there is an effect for these types of
interventions. Gerger et al.78 reviewed psychological therapies for MUS and compared the effectiveness
of such interventions when delivered by GPs versus psychologists. They found a small effect for
psychological therapies at the end of treatment for physical symptoms, physical functioning and
psychological functioning. This effect was moderated by the provider, with delivery by a psychologist
found to be more effective, but only for physical symptoms. There was no robust evidence for any
long-term effects. Metaregression also showed moderating effects for the number of sessions, with
more sessions being more effective. There was no moderating effect of severity of symptoms, although
exploratory analyses indicated that psychological intervention delivered by a GP was more effective
for more patients with more severe symptoms. Garcia-Campayo et al.79 reported that psychological
interventions may be no less effective in primary care than when conducted in secondary care settings.
Edwards et al.31 provide a narrative review of the literature on the treatment of MUS in primary care,
which outlines some of the issues related to the delivery of interventions in a primary care setting, for
example the importance of the doctor–patient relationship, involving family members in interventions
and the importance of cultural considerations. The authors concluded that no single approach would
effectively treat all MUS patients in primary care, and that care must be taken to investigate which
intervention is appropriate for individual patients. Our qualitative review and realist synthesis will add
to these findings.
Definitions of behavioural modification interventions
As evidenced by the existing literature and described above, interventions for MUS are, in general,
based around pharmacological, psychological or physical therapeutic models. Our review will focus
specifically on interventions that aim to promote behavioural change. Although there are a number
of theoretical models of behavioural change, attempting to assign interventions designed for patients
with MUS to any of these theoretical frameworks presents difficulties. For example, for psychological
therapies, there may be little behaviour modification theory or practice in ‘pure’ cognitive therapies but
it has been shown empirically that in practice not many therapists will practice pure cognitive therapy –
most will incorporate behavioural elements.80 Similarly, for physical therapies, if an intervention is based
around a model of physical fitness rather than behaviour re-engagement, then it could be argued that
this no longer meets the criteria of a behavioural modification intervention. Many physical fitness
methods involve predetermined goals based on a patient’s physiology, which are set by the physiologist
or sport scientist and may not be considered as ‘therapy’, although they still constitute an intervention.
We will therefore adopt a liberal definition of ‘behavioural modification interventions’ as ‘interventions
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aimed to achieve behavioural change’. Interventions will include ‘named’ behavioural interventions
such as CBT, behavioural therapy and GET (GET incorporates principles of systematic desensitisation
and behaviour modification with the aim of gradually increasing physical activity, see, for example,
Bagnall et al.62). However, we will also include any intervention that meets the criteria described above.
Owing to wide variation in these interventions, we will categorise them by subtype rather than attempt
to treat them as one homogeneous intervention type.
Modifying effects
Results of existing reviews suggest that the effectiveness of treatments for MUS may be modified by
a number of factors and that treatment may depend on how MUS is defined. There is currently no
consensus on whether or not to use a generic intervention protocol, where all patients with MUS
receive the same treatment protocol regardless of key presenting symptoms and/or level of disability
versus the use of a very specific protocol, developed for patients with a defined functional somatic or
DSM syndrome. There is some suggestion from previous reviews that more specific protocols may
have larger treatment effects but this has yet to be investigated systematically.76
Furthermore, the type of control condition used in randomised controlled trials (RCTs) may influence an
intervention’s effectiveness. Some studies have shown that patients with IBS respond well to placebo,72
whereas patients with CFS do not respond well.81 This highlights the importance of recognising differences
in the design and conduct of control conditions.Where the control condition is inactive (e.g. waiting list or
treatment as usual), good effect sizes for the experimental intervention have been found, whereas trials
with active control interventions have shown small effect sizes.82 Our review will take account of these
issues by extracting information from individual studies for a number of potential modifiers, including
mode of delivery of the intervention, MUS population (e.g. diagnosed FSSs), multiple MUS, and chronic
unexplained pain as described in Chapter 3, Description of the evidence. Potential modifying effects for
intervention type will be explored by categorising by broad type of behavioural modification intervention
(e.g. CBT, GET, behaviour therapy). Details of all types of controls will be synthesised for all included trials.
Acceptability of primary care interventions for medically
unexplained symptoms
Several authors suggest that the relationship between service users and service providers is key to
the success of primary care interventions.83–85 Poor communication between the GP and the patient
as well as lack of emotional and practical support are suggested as barriers to effective treatment of
MUS. Creating a safe, therapeutic environment, and the importance of offering effective reassurance,
are highlighted as important enabling factors for effective treatment of MUS.84 Therefore, the current
review aims to add greater depth to the clinical effectiveness data by retrieving qualitative data relating
to potential barriers to and facilitators of effectiveness and conducting realist synthesis of these data.
This is of particular importance as a good proportion of these patients hold strong views about the
biological nature of their condition and view the suggestion of a more psychosocial approach to
treatment as invalidating their symptoms.86 Understanding ways in which to make behavioural
approaches more acceptable may increase their uptake.
BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
Chapter 2 Definition of the decision problem
Decision problem
The assessment addressed the question: what is the clinical effectiveness, cost-effectiveness
and acceptability of behavioural modification interventions for MUS in primary care or
community-based settings?
Intervention
Interventions that aimed to modify behaviour were sought. These included explicit behavioural
interventions such as CBT, behaviour therapy and GET. Where the intervention was not explicitly
named as a behavioural modification intervention (i.e. one of the above), a broad definition of
behavioural change interventions was adopted. Interventions therefore included but were not
exclusive to a range of psychotherapies, for example CBT, behavioural therapy, psychodynamic
therapy, mindfulness and reattribution. Interventions also included other physical therapies, such as
aerobic exercise and strengthening or stretching exercises. Interventions with multiple components
were included where one of the components was considered a behavioural modification technique as
defined by the above criteria. Individual and group interventions were noted as separate interventions;
however, because of the limited number of studies per intervention type, both group and individual
interventions of the same type were considered together for the purposes of the network meta-analyses,
and sensitivity analyses conducted where possible. Interventions were also considered where primary
care practitioners were trained to communicate a ‘behavioural’ message to patients during their
consultations. In these cases, interventions required a stated explicit aim to train GPs to adopt
a behavioural or biopsychosocial approach towards consultations with patients with MUS.
Population and relevant subgroups
Studies of populations meeting the criteria for MUS, MUPS, and somatoform disorders were included.
Populations with defined FSSs were also included. Diagnostic/inclusion criteria used are discussed in
more detail in Chapter 5, Scope the primary literature.
Relevant comparators
Any comparator was considered. Comparators are described in greater detail in Chapter 5, Scope the
primary literature.
Overall aims and objectives of assessment
Research aim
This project evaluated the clinical effectiveness, cost-effectiveness and acceptability of behavioural
modification interventions for MUS in primary care or community-based settings. The purpose of the
project was to provide a comprehensive systematic review of both quantitative and qualitative studies,
using rigorous methods for reviewing, evidence synthesis and cost-effectiveness modelling to evaluate
the clinical effectiveness and cost-effectiveness of these interventions.
Research objectives
1. To determine the clinical effectiveness of behavioural modification interventions for MUS in primary
care and community-based settings, by undertaking a full systematic review of quantitative literature.
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2. To evaluate the barriers to and facilitators of effectiveness and acceptability of behavioural modification
interventions for MUS from the perspective of both patients and service providers, by undertaking a
realist synthesis following a systematic review of the available qualitative research literature.
3. To undertake a meta-analysis of the available evidence on clinical effectiveness, including a
network meta-analysis (NMA) to allow simultaneous comparison of all identified intervention types
where appropriate.
4. To identify and synthesise evidence on health economic outcomes such as health-care resource use
(e.g. GP appointments), and health-related quality-of-life (HRQoL) data from the studies included in
the clinical effectiveness review.
5. To provide new evidence on the cost-effectiveness of behavioural modification interventions for
MUS conducted in a primary care or community setting, by conducting a systematic review of
existing economic analyses and undertaking a de novo model-based evaluation where there is an
absence of high-quality published analyses which are directly applicable to our research question.
6. To explain which circumstances influence the effects of behavioural interventions for MUS patients
(via realist synthesis).
Patient and public involvement
Patients were involved throughout the review process. Two members of the public with a history of
MUS contributed to the writing of the review protocol. They, along with a person with experience of
fibromyalgia, went on to be active members of our Expert Advisory Group. The Expert Advisory Group
was made up of subject experts, clinicians and our patient and public involvement (PPI) representatives
(experts by experience). There were two whole-group meetings: the project team and one of the Expert
Advisory Group, held at the School of Health and Related Research (ScHARR) but with an independent
chairperson. These were at the beginning of the review to discuss plans and potential issues before
the review got started, and at the end of the review to report the results of the review. Between these
meetings, the Expert Advisory Group were e-mailed at key stages in the project to receive updates on
progress and to be invited to contribute any feedback.
In addition to the two whole-group meetings, a meeting with JL, AS and MB was held in London solely
for the PPI representatives. The purpose of this meeting was to allow a more informal discussion of the
project, in particular the qualitative and quantitative reviews, with a focus on a patient point of view.
The PPI representatives were also given a booklet containing plain English information on the
systematic review process.
All of the PPI representatives made substantial and valuable contributions to the project. Providing a
patient perspective at each stage of the review enabled the project team to gain a deeper understanding
of the issues arising from the literature, and kept the importance of patient perceptions of their symptoms
and health-care provision in focus.
One patient with MUS wrote:
Being involved with this review has opened up my understanding of how important it is when one
has ‘unexplained symptoms’ to take part in one’s own recovery and health and how difficult it must be
for doctors to have patients who look to them as saviours, not to be able to diagnose and then treat.
I thoroughly enjoyed having an insight into both doctors’ and patients’ point of view into the frustrating
world of MUS! It also gave me hope seeing the differing and varied interventions available. It was
encouraging to see that nearly all symptoms under the various headings seemed to respond to CBT.
It has been a great pleasure to be involved with this study and review. The team were brilliant in
making a very complex subject accessible and interesting to a lay person.
DEFINITION OF THE DECISION PROBLEM
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The other patient with MUS wrote:
It has been a fascinating experience being a small part of a very carefully thought out and thorough
review. Credit should go to the team that managed to filter through all of the studies and create a
model that allowed for some conclusions to be made. While the review didn’t perhaps reach the clear
conclusions it aimed for, there were a lot of interesting observations: From a patient-perspective, the fact
that there were few significant effects for any GP intervention, i.e. reattribution, GP led CBT, or GP MUS
management, is quite worrying. It is useful knowledge that multimodal and CBT interventions have an
impact on the majority of MUS. These findings are something that should be embraced and addressed by
the NHS (although it’s interesting to see that there is little evidence supporting the impact on long-term
health). It seems that patient caution and stigma can still be attached to CBT and similar therapies
so I would be interested to find how this problem could be tackled in the future. It’s also a pity that
little could be found that would benefit patients with ‘somatisation and generic physical symptoms’.
I’ve really enjoyed working on this project and would be happy to contribute to any further studies.
The person with experience of fibromyalgia wrote:
My experience of being part of the stakeholder group: It was an enormous piece of research that was
undertaken and I observed that it was done with great care. I always felt that my opinions, written and
oral, were taken seriously and followed-up. I am not sure how valuable my contributions were. I do know
that I tried my best to look at all the information and paid attention to the details as much as I tried
to look at the bigger picture. I do think that having patient representatives helps to keep the research
grounded in the real world. I was astounded by some of the outcomes, as they seemed counter to
generally held beliefs. This only shows how important it was to collate this evidence. I do hope that the
report will help many people with pain and other unexplained symptoms to reach relief that they have
not yet achieved.
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Chapter 3 Assessment of clinical
effectiveness
Methods for reviewing effectiveness
A systematic review of the literature and (network) meta-analysis (where appropriate) was undertaken
to evaluate the clinical effectiveness of behavioural modification interventions for MUS, in a primary
care or community setting. The review of the clinical evidence was undertaken in accordance with
the general principles recommended in the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement.
Identification of studies
Searches were undertaken to identify relevant studies regarding clinical effectiveness, cost-
effectiveness and acceptability (qualitative studies). The search strategies are reported separately
for each below. Methods of searching for studies included in the realist synthesis are described in
Chapter 7.
Screening and eligibility
A two-stage sifting process for inclusion of studies (title/abstract then full-paper sift) was undertaken.
Titles and abstracts were scrutinised by one systematic reviewer (JL) according to the inclusion and
exclusion criteria. There was no exclusion on the basis of quality. All studies identified for inclusion
using the abstract alone, plus any study in which a decision on inclusion was not possible only from
the abstract, were retrieved for more detailed appraisal. Agreement on inclusion at title/abstract sift
was checked by a second systematic reviewer (CGC) for 20% of the total electronic search results.
Further sifting processes were developed as it became apparent that there were many studies where
inclusion/exclusion was unclear. A sifting meeting was held with all subject experts present to discuss
general sifting issues and specific individual cases. A common issue was whether or not interventions
met the primary care/community-based criteria. To address this issue, operational sifting criteria were
developed in order to aid decision-making. Data were extracted regarding where diagnosis, recruitment
and referral (to the study) took place and where the intervention took place, and outcomes were
assessed. Inclusion was decided based on a combination of these factors and, where there was doubt,
judgements were made via discussion among the review team. Inclusion of studies on setting was kept
broad. Appendix 2, Table 40, shows the sifting criteria considered for setting for each included study.
Another common issue was the nature of the symptoms meeting the ‘unexplained’ criteria. Studies were
included if symptoms were explicitly described as ‘medically unexplained’, as were studies that explicitly
stated that they included patients with ‘MUS’. Studies of populations with FSSs were included without
a need for further reference to medical explanation. Inclusion issues became apparent in studies of
patients with chronic pain but no description of whether or not the pain had a known organic cause.
To address this issue, a sample of study authors of these papers were contacted to request further
information about their populations. None of the studies of those who responded had lack of ‘medical
explanation’ as a criterion for inclusion. Therefore, it would be impossible to determine whether the
populations contained a mix of patients with chronic pain with known cause, for example arthritis,
and patients with pain without known cause. Specifically, an explanation of the cause of pain was not
deemed necessary in these studies, nor was it necessary for pain to be a target for the interventions.
It was therefore decided to keep this inclusion criterion narrow, and to include only studies of patients
with chronic pain that deliberately targeted pain of unknown or ‘unexplained’ origin.
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Clinical effectiveness searches
A systematic search strategy was developed in consultation with the review team, to identify systematic
reviews and RCTs relating to the defined population. The focus was on identifying studies in primary
care or community-based settings; therefore, population terms were combined with terms to define the
setting. A combination of free-text terms and thesaurus searching was used. Published methodological
search filters to limit the study type (systematic review or RCT) were used where available. No other
search limits were applied. Reference sections of included studies were scrutinised for additional
potential studies to include, as were reference lists from relevant reviews.
Searches were conducted in the following sources:
l MEDLINE via OvidSP (1946–20 November 2015)
l MEDLINE In-Process & Other Non-Indexed Citations & Epub Ahead of Print & MEDLINE® without
Revisions via OvidSP (2013–20 November 2015)
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCOhost
(1981–3 December 2015)
l PsycINFO via OvidSP (1967–3 December 2015)
l EMBASE via Ovid SP (1974–4 December 2015)
l Cochrane Database of Systematic Reviews (CDSR) via the Cochrane Library (2005–4 December 2015)
l Database of Abstracts of Reviews of Effects (DARE) via the Cochrane Library (1994–April 2015 –
no longer updated, archive only searched 4 December 2015)
l Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Library
(1898–4 December 2015)
l Health Technology Assessment (HTA) Database via the Cochrane Library (1989–4 December 2015)
l Science Citation Index via Web of Science (1900–7 December 2015)
l Social Sciences Citation Index via Web of Science (1956–7 December 2015).
Searches for systematic reviews and RCTs were conducted between 20 November and 7 December
2015. Detailed search strategies are provided in Appendix 1.
Qualitative searches
A systematic search strategy was developed in consultation with the review team to identify qualitative
research relating to the defined population. The focus was on identifying studies in primary care or
community-based settings; therefore, population terms were combined with terms to define the setting.
A combination of free-text terms and thesaurus searching was used. Published methodological search
filters to limit to study type (qualitative) were used where available. The qualitative research filter was
combined with a geographic filter to identify UK studies only. No other search limits were applied.
Searches were conducted in the following sources:
l MEDLINE via OvidSP (1946–4 July 2016)
l MEDLINE In-Process & Other Non-Indexed Citations & Epub Ahead of Print & MEDLINE without
Revisions via OvidSP (2013–4 July 2016)
l EMBASE via Ovid SP (1974–4 July 2016)
l CINAHL via EBSCOhost (1981–4 July 2016)
l PsycINFO via OvidSP (1967–4 July 2016)
l Science Citation Index via Web of Science (1900–4 July 2016)
l Social Sciences Citation Index via Web of Science (1956–4 July 2016).
Searches for qualitative research were conducted on 4 July 2016. Detailed search strategies are
provided in Appendix 1.
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Economic searches
A systematic search strategy was developed in consultation with the review team to identify economic
evaluations relating to the defined population. The focus was on identifying studies in primary care
or community-based settings; therefore, population terms were combined with terms to define the
setting. A combination of free-text terms and thesaurus searching was used. Published methodological
search filters to limit to study type (economic evaluation) were used where available. No other search
limits were applied.
Searches were conducted in the following sources:
l MEDLINE via OvidSP (1946–15 August 2016)
l MEDLINE In-Process & Other Non-Indexed Citations & Epub Ahead of Print & MEDLINE without
Revisions via OvidSP (2013–15 August 2016)
l EMBASE via Ovid SP (1974–25 August 2016)
l CINAHL via EBSCOhost (1981–25 August 2016)
l PsycINFO via OvidSP (1967–25 August 2016)
l NHS Economic Evaluation Database (NHS EED) via the Cochrane Library (1968–April 2015 – no
longer updated, archive only searched 25 August 2015)
l Science Citation Index via Web of Science (1900–25 August 2015)
l Social Sciences Citation Index via Web of Science (1956–25 August 2015).
Searches for economic evaluations were conducted between 15 and 25 August 2016. The search
results were imported into EndNote [Clarivate Analytics (formerly Thomson Reuters), Philadelphia, PA,
USA] and subsequently filtered to identify UK studies, using terms from line 29 of the EU economies
search filter to search the EndNote library for potentially relevant references. Detailed search
strategies are provided in Appendix 1.
Clinical effectiveness review
Details of the qualitative and cost-effectiveness review methods are detailed in Chapters 4–6.
Inclusion and exclusion criteria
Study design
Only RCTs were included as these represent the optimal study design for assessing intervention
effectiveness. Scoping of the review indicated the availability of a substantial number of published RCTs.
No minimum duration of follow-up was applied.
Intervention
A diverse range of interventions that met with our definition of behavioural interventions were identified.
Interventions were subsequently ‘grouped’ by type. Definitions of intervention groups were created
following review team discussions. These are presented in Table 1. Two reviewers initially grouped each
included intervention into these groups. Where there were difficulties or disagreements, subject experts
were consulted.
Appendix 2, Table 28, describes the interventions at a study level, with a brief description, with their
designated intervention groupings.
Population
Adults aged ≥ 18 years with MUS, MUPS or somatoform disorders were included. Diagnosis of MUS
or MUPS could be either by validated instrument (e.g. PHQ-15, SOMS, BSI) or by clinician judgement.
Diagnosis was not restricted by duration (except in the case of chronic pain the duration of which should
be > 3 months) or severity (e.g. number of symptoms). Patients with single symptoms were included.
Populations with FSSs were included (e.g. IBS, CFS, fibromyalgia). For somatoform disorders, diagnosis
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should have been made by formal clinical interview and should meet DSM-IV or DSM-V, or ICD-9
or ICD-10 criteria. Somatoform disorders included somatisation disorder, somatoform disorders,
somatoform pain disorders, persistent physical symptoms, bodily distress syndrome, bodily distress
disorder, FSS, medically unexplained syndrome.
Appendix 2, Tables 29–36, shows diagnostic/inclusion criteria used by condition for individual studies.
Comparator
Studies where ‘usual care’ was the comparator were included. Owing to variation in terminology,
studies where the comparator is ‘treatment as usual’ or ‘waiting list’ ’were also included as usual care’.
A ‘medication’ control group was included for studies where a comparator arm consisted of a specific
medication regimen. Trials with a ‘placebo’ control (e.g. which control for time and attention) were also
included. As a number of high-quality head-to-head trials of two or more experimental interventions
were identified during scoping searches, head-to-head trials were also included where at least one
intervention arm met the definitions outlined above.
TABLE 1 Intervention groupings
Intervention group Description
CBT – high intensity CBT, delivered by a trained clinical specialist, ≥ 6 hours’ contact
CBT – low intensity CBT, either delivered by a trained clinical specialist but < 6 hours’
contact time, or delivered by a non-specialist (may be > 6 contact hours)
Other psychotherapy Any other psychotherapy (e.g. expressive, psychoanalytic)
Graded activity or exercise therapy Exercise with a defined behavioural model
Strength, endurance, sport Exercise with a physiological model (e.g. aerobic, strengthening)
Relaxation, stretching, social support/
emotional support
Interventions designed to encourage relaxation or stress relief,
general MUS-focused support, stretching
Guided self-help Educational support, including information or self-management
materials; visual presentations
Multimodal An intervention that incorporates components from more than one
category or was conceptualised as ‘multimodal’ by the study authors
GP interventions
GP – reattribution GP trained in reattribution according to Goldberg principles45 or
modified reattribution
GP – CBT GP trained in and delivered CBT
GP – other psychotherapy GP trained in and delivered any other type of psychotherapy as
described in general ‘other psychotherapy’ category
GP – MUS management GP trained in the management of MUS. Must be focused on
management using behavioural/biopsychosocial principles
GP – other GP intervention consisting of multiple components, does not fit with any
other category
Non-behavioural comparator interventions
Medication Any medication prescribed specifically as a comparator intervention
(i.e. above patients’ usual regimen)
Usual care Care as usual, also incorporates waiting list or treatment as usual
Usual care plus Enhanced usual care or usual care with minor addition (e.g. a leaflet)
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Outcomes
Appendix 2, Table 37, presents information on primary and secondary outcomes measured in each
study, with an indication of the scale used.
Primary outcomes
Patient level: improvement in symptoms, functioning and/or health-related quality of life (HRQoL).
Measures of symptom improvement could be through assessment of severity or frequency and must
have been assessed using a generic or symptom-specific validated instrument, for example EuroQol-5
Dimensions (EQ-5D)/Short Form questionnaire-36 items (SF-36) for HRQoL, symptom checklist for
symptom severity and PHQ-15.
Health-care level: use of health-care resources (e.g. frequency of GP visits, diagnostic outpatient
procedures, hospital admissions, emergency department attendances). Costs are reviewed in detail in
the cost-effectiveness review Chapter 6.
Secondary outcomes
Emotional distress, including depression and anxiety as diagnosed by a validated instrument [e.g. Beck
Depression Inventory (BDI) or Beck Anxiety Inventory (BAI)] or a composite measure, such as the
mental health component from the SF-36; satisfaction with care; attrition (persistence and adherence).
Studies were diverse and, because of the differences in populations, types of symptoms measured were
varied. Scales used to measure similar constructs (e.g. depression, quality of life) differed between studies.
Appendix 2, Table 37, lists all the primary and secondary outcomes measured, with scales used, for all
included studies. Outcome data for individual studies were extracted and commonalities were sought.
Ten key outcomes were considered to have sufficiently similar data to be included in meta-analyses.
These were individual physical symptoms: pain, fatigue and bowel symptoms; somatisation; composite
measures of emotional distress; physical functioning; depression; anxiety; impact of symptoms on daily
activities (including disability); and generic physical symptoms (e.g. severity of ‘main’ symptom, where no
particular symptom is specified). In addition, data were extracted regarding satisfaction/adherence,
adverse events and health-care utilisation. These outcomes were considered too heterogeneous to
consider meta-analysis and are reported as a narrative synthesis only.
Outcome measurement time points
Studies measured outcomes at a range of time points. As well as variation in follow-up times (e.g. 3 months,
6 months, 1 year), there was variation in the definitions of these time points. As an example, Figure 1 shows
three different ways of defining ‘6 months’ follow-up’.
Follow-up
Intervention begins Intervention ends
6 months
6 months
6 months
Intervention ends
One-session
intervention/training
Intervention begins
Follow-up
Follow-up
FIGURE 1 Variation in definitions of follow-up.
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Although all of these variations may be described in individual studies as ‘6 months’ follow-up’,
6 months may refer to the time since one-off treatment, to the time since the end of treatment,
to the time since the GP received training, or to the time since baseline (pre-treatment). As previous
studies have shown that intervention effects can diminish once treatment has ended, time since end
of treatment was considered important. Time points used in the meta-analyses were extracted as
baseline, end of treatment (i.e. corresponding to duration of treatment), short-term follow-up (time
since end of treatment < 6 months) or long-term follow-up (time since end of treatment ≥ 6 months).
The longest follow-up time point within these categories was chosen where possible. Where studies did
not explicitly report end-of-treatment time, this was calculated by subtracting duration from follow-up
since baseline. Weeks were converted to months using a conversion of 1 week = 0.230137 months.
Assessment time points as reported in individual studies are reported in the table of basic study design
characteristics in Appendix 2, Table 42. Converted or calculated time points are reported for individual
studies in Appendix 2, Table 39.
Settings
Studies in primary care or community-based settings were included. To be considered a primary care
setting, interventions must have been conducted within a primary care or community-based setting, but
they could have been delivered by any health-care discipline within that setting. Interventions could be
face to face or delivered at a distance (e.g. via the internet or telephone), and may include computer-
assisted interventions. However, to be considered primary care, a degree of involvement with primary
health professionals (HPs) was necessary. Therefore studies of e-health, telephone interventions or self-
help that were conducted by university research teams with no primary care practitioner involvement
were excluded. For interventions delivered by a therapist (e.g. a psychologist or physiotherapist – not
by the GP or primary care practice staff), these could have been delivered by the therapist while the
patient was still regarded as a ‘primary care patient’, but not once the patient had been referred to
secondary or tertiary care. Improving Access to Psychological Therapies (IAPT) interventions were
included if delivered in a primary care or community-based setting.
Data extraction strategy
Data extraction was performed by one reviewer into a standardised data extraction form and
independently checked for accuracy by a second. The extraction form was designed using the Template
for Intervention Description and Replication (TIDieR) Checklist as a guide. Intervention information
regarding setting, duration, provider (e.g. qualifications and training) and number of sessions, etc.,
was extracted. Basic demographic information for participants was also extracted. Discrepancies
were resolved by discussion between the two reviewers and, if agreement could not be reached,
then a third reviewer was consulted.
Critical appraisal strategy
The quality assessment of included RCTs was performed by one reviewer (JL) using Higgins’ risk-of-bias
tool87 for RCTs, and 20% of completed checklists were independently checked for accuracy by a second
reviewer (AS). Discrepancies were resolved by discussion between the two reviewers and, if agreement
could not be reached, then a third reviewer was consulted.
Methods of data synthesis
Comparative effectiveness was evaluated using a NMA to allow a comprehensive synthesis of all
evidence on all relevant interventions. NMA is an extension of pairwise meta-analysis and it can be
used to combine direct and indirect evidence about treatment effects across studies to provide an
internally consistent set of intervention effects while respecting the randomisation used in individual
studies.88 The NMAs were conducted using a Bayesian Markov chain Monte Carlo approach88 on the
following outcomes: pain, fatigue, bowel symptoms, somatisation, generic physical symptoms, physical
functioning, impact of illness on daily activities, anxiety, depression and emotional distress. This
assumed a random-effects model to allow for heterogeneity in treatment effects across studies.
Separate NMAs were performed for the three time points: immediately post treatment, short term
(up to 6 months post treatment) and long term (> 6 months post treatment).
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Definition of treatment effect (continuous outcome measures)
For each outcome of interest, the individual studies may have used one of several different (continuous)
measurement scales (see Appendix 2, Table 38). To allow studies using different measurement scales to
be included in a single NMA, standardised mean differences (SMDs) were computed for each study. The
use of SMDs stems from the concept that the different reported measures are essentially quantifying
the same effect and can be placed on a common scale by dividing the mean difference between the
intervention and control arms in each study by the standard deviation (SD). Raw reported data, in the
form of mean/median, SD/standard error (SE)/confidence interval (CI)/interquartile range (IQR), were
used to calculate the SMD for each study using Hedges’ (corrected) g.87 The SMD was computed based
on absolute values at the end of follow-up rather than mean difference from baseline, as the within-study
correlation would be needed for the latter and was not reported. All of the scales were transferred to be
consistent across the scales used in the included studies so that a positive SMD indicates beneficial effect
of a treatment in the intervention group when compared with the treatment in the control group.
Synthesis population
The synthesis population was defined following the inclusion criteria as all MUS. Condition groupings
within MUS have been defined as chronic fatigue, chronic pain single site, chronic pain multiple sites,
IBS or MUS/somatoform disorders. All condition groupings were synthesised in a single integrated
analysis. Ideally, differential responses within each condition grouping would be explored through
metaregression; however, the networks were too sparse to allow this.
Statistical model for the network meta-analysis
Let yik denote the observed SMD of arm k of trial i (i = 1 . . . ns, k = 1 . . . na), with variance Vik. We
assume that the treatment effects are normally distributed such that:
y ik ∼N(θik ,V ik). (1)
The parameters of interest, θik, are modelled using the identity link function:
θik = δi, 1k. (2)
A random-effects model was assumed, so that the trial-specific treatment effects, δi,1k, are assumed to
arise from a common population distribution with mean treatment effect relative to the reference
treatment such that:
δi, 1k ∼N(dti1tik , τ
2), (3)
where dti1tik represents the mean effect of the treatment in arm k of study i (tik) compared with the
treatment in arm 1 of study i (ti1) and τ2 represents the between-study variance in treatment effects
(heterogeneity), which is assumed to be the same for all treatments.
Parameters were estimated in a Bayesian framework. Where there was sufficient sample data,
conventional reference prior distributions were used:
l between-study SD of treatment effects, τ ∼ U(0,1.1)
l mean of treatment effects dti1tik ∼N(0, 100
2).
In the case of there being relatively few studies, an informative prior distribution was assumed for the
between-study SD. Rhodes et al.89 proposed a t-distribution for log of the heterogeneity parameter
for the SMD scale. The prior proposed by Rhodes et al.89 still has probabilities of extremely high
heterogeneity, which is implausible in the context that we are working on. For example, this prior
represents the belief that the heterogeneity will be low, moderate, high or extremely high with
probabilities of 22%, 41%, 16% or 20%, respectively. It has about 20% of the odds ratio in one study
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would be > 50 times greater than in another. Hence, the prior prosed by Ren et al.90 is used, which is a
truncated Turner et al.91 prior [a log-normal (–2.56, 1.742)]. The truncation is based on the judgement
that the odds ratio in one study would not be ≥ 50 times greater than in another. The resulting prior
represents the belief that the heterogeneity will be low, moderate, high or extremely high with
probabilities of 15%, 66%, 19% or 0%, respectively.
Inconsistency checking was performed by comparing the standard NMA consistency model with an
inconsistency model.92 In the inconsistency model, no consistency is assumed; that is, each of the
pairwise comparisons represents an unrelated parameter to be estimated. The deviance information
criteria (DIC) for both models are compared, as are the contributions to the deviance for both models,
to determine if there is evidence to suggest inconsistency in the network.
All analyses were conducted in the freely available software packages WinBUGS93 (MRC Biostatistics
Unit, Cambridge, UK) and R (The R Foundation for Statistical Computing, Vienna, Austria) using the
R2Winbugs interface package.94 Convergence to the target posterior distributions was assessed using
the Gelman–Rubin statistic.95 The chains converged within 18,000 iterations so a burn-in of 18,000
iterations was used. We retained a further 20,000 iterations of the Markov chain to estimate parameters
using one chain. The absolute goodness of fit was checked by comparing the total residual deviance with
the total number of data points included in an analysis.
Results are presented using the posterior median treatment effects, 95% credible intervals (CrIs) and 95%
prediction interval (PrI). The 95% PrI indicates the extent of between-study heterogeneity by illustrating
the range of SMDs that might be expected in a future study. The PrI is calculated based on the predictive
distribution of the mean treatment effect. In a Bayesian Markov chain Monte Carlo setting, the predictive
distribution is obtained by sampling from the distribution of effects N(d,τ2). Probabilities of treatment
rankings were computed by counting the proportion of iterations of the Markov chain in which each
intervention had each rank. Median treatment rankings and the probabilities of being the best treatment
are presented.
Results
Quantity of research available
Characteristics of included studies
The searches identified 8925 citations for RCTs and 2929 citations for reviews. After deduplication,
there were 5909 unique citations for RCTs and 2464 for reviews. For the RCTs, 281 full papers were
retrieved as being potentially relevant. A total of 220 of these papers were excluded for at least one
of the following reasons: pain was acute or subacute; symptoms did not meet the pre-defined review
criteria for ‘unexplained’ as described above; pain was mixed explained/unexplained but populations
could not be distinguished from one another in the results; setting was not primary care or insufficient
primary care involvement; outcomes were not relevant; conference abstracts or dissertations; or not
RCTs. Figure 2 shows the PRISMA flow chart. Studies excluded at full-paper stage are presented with
reasons in Appendix 4.
Sixty-two papers provided data from 59 trials. There were a total of 9077 participants across all trials
that randomised numbers in each arm. The number of participants in a single trial ranged from 1096 to
524.97 Owing to the nature of some of the interventions (i.e. where GPs received training to deliver
treatment of MUS), some studies were cluster randomised, whereas the rest were randomised at
patient level. Basic study characteristics are presented in Appendix 2, Table 42.
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Description of the evidence
Study characteristics
Population
Appendix 2, Tables 29–36, shows the population inclusion criteria for individual studies by condition
grouping. Condition groupings were MUS/somatoform disorder (including single MUS or mixed MUS),
chronic fatigue (including but not exclusive to CFS), chronic pain (single site), chronic pain (multisite,
including fibromyalgia) and IBS.
Of 59 studies that met the inclusion criteria, 29 studied either ‘MUS’ or ‘somatoform disorder’.
Approximately half of these studies required participants to meet the diagnostic criteria for either
somatoform disorder (DSM-III-R, DSM-IV, ICD-9, or ICD-10) or abridged somatisation disorder.98
The remaining studies included populations of patients with ‘MUS’. Criteria for inclusion were varied,
from number of unexplained symptoms within a set time (e.g. two or more within the past 6 months,99
lifetime history of 6–12 unexplained symptoms,100 five or more symptoms meeting the definition of
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FIGURE 2 The PRISMA flow diagram.
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unexplained during past 6 months101) to more general criteria (e.g. ‘multiple unexplained symptoms’,102
‘symptoms rated by the GP as psychosomatic in origin’,103 ‘GP confirmed medically unexplained nature
of symptoms’104 or ‘primary care providers had recognised that emotional status may have been related
to their patient’s symptoms’105). The remaining studies set duration of unexplained symptoms as their
inclusion criteria (e.g. duration of unexplained complaints of at least 12 months,106 no documented
organic disease to explain symptoms of at least 6 months’ duration107 and ≥ 3 months’ physical
symptoms not explained by physical pathology108).
One of the 59 studies109 had a population of mixed diagnoses that included any functional disorders, and
one further study included participants with a single MUS: medically unexplained vaginal discharge.110
Twelve of the 59 studies were of participants with chronic fatigue, and 7 of these 12 included
populations meeting diagnostic criteria for CFS. Most of these used the US Centers for Disease
Control and Prevention (CDC) criteria for CFS,6 but one study used the Oxford criteria.111 Two of
the 12 studies included participants who either met US CDC criteria for CFS or scored ≥ 4 on the
Chalder Fatigue Scale.112,113 The remaining three studies did not include participants with CFS, with two
requiring a score of ≥ 4 on the Chalder Fatigue Scale,114,115 and one requiring a score of ≥ 35 on the
fatigue subscale of the Dutch Checklist of Individual Strength.116,117
Six of the 59 studies were of chronic pain at a single site on the body. Four of these were of back pain,118–121
one was of headache122 and one was of neck pain.123 All required the duration of pain to be ≥ 3 months,
apart from Loew et al.,122 in which the requirement was for ≥ 12 months’ duration.
Seven of the 59 studies were of chronic pain at multiple sites of the body. Four of these studies were
of participants with fibromyalgia, and these used the 1990 ACR diagnostic criteria as their inclusion
criteria.124 The remaining three studies were of chronic widespread pain125,126 or mixed chronic multisite
pain, for example chronic generalised or regional pain where organic explanation had been ruled out.127,128
The remaining three studies were of IBS. Inclusion criteria were that patients met the Rome I
diagnostic criteria129 or Rome I and II diagnostic criteria.130 The third IBS study required a diagnosis
of functional gastrointestinal symptoms diagnosed as IBS, but participants did not necessarily have to
meet Rome criteria.131
Setting
Fifty-six of the included studies were defined as ‘primary care’, with the remaining three studies defined
as ‘community based’. Appendix 2, Table 40, shows that there was considerable heterogeneity in the
details of the setting of the studies. Studies varied in the primary care involvement, although all were
designed for primary care patients rather than patients already in tertiary care or who self-referred to a
university-based study without co-ordination with a primary care practitioner. Variation in setting detail
included study designs where:
l Patients were recruited and treated by their own GP at their own GP practice.
l Patients were recruited by their GP, but treated by another health-care professional at their own
GP practice.
l Patients were recruited and assessed by their GP, but treated by another health-care professional
at an outside facility; for example a gymnasium or park.
l Patients were recruited and co-ordinated by their GP, but treatment was self-directed
(e.g. home-based exercises).
l Non-UK studies where the organisation of primary care may differ from the UK health-care system
(e.g. ‘primary care physiotherapy clinic’). These clinics are described as working in close co-operation
with ordinary primary health systems.
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Studies where the intervention itself was not delivered within the primary care practice tended to be
sport- or exercise-based interventions, or use of self-help materials. Community-based interventions
were included only if the study was explicit in its description and aim of the intervention as being
community based. Appendix 2, Table 40, shows setting details for individual studies.
Interventions
Intervention arms were coded into one of the 13 pre-defined intervention groupings. Appendix 2,
Table 28, reports the detail of the intervention arms for each study, as described by the authors, and
the intervention grouping that the arm has been coded into. Control arms that were active rather
than passive were coded into one of the intervention groupings, therefore the numbers reported below
for each intervention group add up to greater than the number of studies. Passive control arms were
coded either as medication or as usual care/usual care plus. There were a total of 127 intervention
arms. Of these, 80 were active intervention arms (or were categorised as such by the review team;
for example, where an education booklet/presentation was called usual care by the authors, this was
categorised as guided self-help and, therefore, an active intervention) and 47 were passive control
arms. There was considerable heterogeneity both between and within groupings. Numbers for types
of intervention groups are listed below. Appendix 2, Table 41, presents a summary of intervention
groupings for each study arm.
Active intervention arms:
l GP reattribution (including modified), n = 5
l GP MUS management, n = 6
l GP-CBT, n = 1
l GP other psychotherapy, n = 1
l GP other, n = 1
l CBT high intensity, n = 8
l CBT low intensity, n = 7
l other psychotherapy, n = 11
l graded activity (GA), n = 7
l strength/endurance/sport (SES), n = 7
l relaxation, stretching, social support, emotional support (RSSE), n = 8
l guided self-help, n = 6
l multimodal, n = 12.
Passive control arms:
l medication, n = 3
l usual care, n = 39
l usual care plus, n = 5.
The most common active intervention was multimodal therapy. There was wide variation in the nature
of the multimodal interventions, with various combinations of the individual interventions represented.
These may be specifically defined in the paper as ‘multimodal’ (e.g. Smith et al.107) or may consist of
components from different groups (e.g. van der Roer et al.120 sport/exercise + education + behavioural
programme; McBeth et al.125 CBT + sport/exercise). Not only did the RSSE group encompass a wide
range of different types of intervention, but these types of intervention were also commonly used
as active controls (or were classed as active controls by the review team), as were guided self-help
interventions, which were often a self-management information/education booklet. There was an
element of overlap between some of the guided self-help interventions and low-intensity CBT (CBTLI),
with the latter providing more structure and support than the guided self-help interventions. Other
psychotherapy was the next most common intervention, with high-intensity CBT (CBTHI) and CBTLI
being the third and fourth most common. Graded activity and sport/exercise interventions were equally
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represented, with seven arms each. Some interventions were conducted in groups and some were
conducted individually. Some were conducted face to face whereas others were conducted at a distance,
either by telephone or by e-mail. Appendix 2, Table 41, presents these details by arm for each study.
For most interventions, treatment was directed at patients, in a set number of sessions, for a
recommended duration. However, some interventions were directed primarily at the GP. GPs would
receive training in methods of treating patients with MUS. This training aimed to enable the GP to
communicate a behavioural/biopsychosocial approach to unexplained symptoms to their patients.
In these cases, a set study period was usually specified, during which time the GP would conduct
consultations with patients in their usual distribution of surgeries rather than at a set number of
GP/patient sessions. This study period could last up to 2 years.97
There was also heterogeneity within intervention groups. Appendix 2, Tables 43 and 44, presents
details of planned duration of treatment sessions for each arm, and Table 44 presents details of
planned duration of the treatment period. Greater detail by intervention arm for actual mean sessions/
duration for each arm is reported in the cost analysis in Chapter 6. There was no typical treatment
duration, either between or within intervention groups. Treatment sessions ranged from 1 × 10- to
15-minute session with a HP followed by self-management114 to 10 × 90-minute sessions of treatment
plus booster sessions.132 The shortest treatment periods were around 6–8 weeks (e.g. McCleod et al.,105
LeFort128 – 6 weeks; Macedo et al.,119 Moss-Morris et al.130 – 8 weeks), with a mid-range of 12 weeks
(e.g. Marques et al.133 and Ridsdale et al.112). Longer-term treatment periods ranged up to 1 year
(e.g. Kocken et al.103 and Smith et al.107).
Differences in intervention provider and the contact time spent with patients are shown in Appendix 2,
Table 45. Interventions were delivered by a range of health-care professionals (e.g. GPs, psychologists,
practice nurses, physiotherapists, psychiatrists, psychiatric nurses and health educators). There was
little consistency in contact time between provider and patient across the studies.
Most usual-care arms were not specific in their descriptions of care received – this probably varies
between individual patients in response to their particular needs, but may consist of giving information
leaflets/medication. Some controls defined as ‘usual care’ by the study authors were categorised into
active intervention groups. For example, an active study intervention ‘self-help’ consisting of a self-
management booklet and minimal contact with a HP114 is categorised as guided self-help. The same
booklet is used as a part of a ‘usual-care’ control arm in another study115 but, for the purposes of the
review, has been categorised as guided self-help.
Outcomes
All primary and secondary outcomes assessed in each study, together with the scales used for
assessment, are reported in Appendix 2, Table 37. Owing to differences in populations, outcomes varied
between studies. Key outcomes across studies were identified and are presented in Appendix 2, Table 38.
Condition-specific symptoms were measured, for example bowel symptoms for IBS studies, fatigue for
chronic fatigue studies, and pain for chronic pain studies. Some of these condition-specific symptoms
were also recorded for studies of ‘MUS’ patients, most commonly for pain, but never for bowel
symptoms. Pain was most frequently measured using a visual analogue scale (VAS) or numerical rating
scale (NRS) in studies of chronic pain populations, whereas, for studies of MUS patients, the SF-36 bodily
pain subscale was more frequently used. Fatigue was almost always assessed using the Chalder Fatigue
Scale. Psychological symptoms, most commonly anxiety and depression, were measured across all
condition groups. For depression, the Hospital Anxiety and Depression Scale – Depression (HADS-D),
BDI, Hamilton Rating Scale for Depression (HAM-D) and Symptom Checklist-90 – Depression (SCL-90-D)
were the most frequently used scales. For anxiety, the Hospital Anxiety and Depression Scale – Anxiety
(HADS-A), Hamilton Anxiety Rating Scale (HAM-A) and Symptom Checklist-90 – Anxiety (SCL-90-A) were
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
the most frequently used scales. Composite measures of emotional distress were also reported, most
commonly using the SF-36 mental health subscale, but also HADS total scores, or the General Health
Questionnaire (GHQ-30). For ‘MUS/somatoform’ studies, ‘somatisation’ was commonly measured to assess
symptom load, using a number of scales but most commonly the SOMS or PHQ-15 or Brief Symptom
Inventory (BSI). Severity of main symptoms or number of symptoms was also measured (generic
physical symptoms) in a minority of studies, with severity VAS or number of symptoms used as
methods of assessment. Physical function was measured in studies of all conditions, almost always
using the Short Form questionnaire-12 items (SF-12) or SF-36 physical functioning subscale. Finally,
illness impact on daily activities was measured across conditions, using disability scales such as the
Roland–Morris Disability Questionnaire (RMDQ), the Neck Disability Index or Oswestry Disability
Index (ODI), or, for fibromyalgia, the Fibromyalgia Impact Questionnaire (FIQ) total.
Quality of the evidence
Individual risk-of-bias extractions and summary tables can be found in Appendix 3. The quality of
individual studies ranged from low to high. Most commonly, studies were found to be at high risk of
performance bias, with patients and intervention providers frequently not blinded because of the
nature of the interventions and comparators. Over 25% of studies were at high risk of attrition bias,
but over 50% of studies were found to be at low risk of attrition bias using the 20% cut-off point.134
Reporting bias was assessed by reference to study protocols. Study protocols were sought using a
number of methods and these are described, with success rates, in a separate paper.135 Figure 3 shows
the summary table for risk-of-bias assessments.
Study results
Raw data extracted from individual studies (means, SD/SE by outcome) can be found in Appendix 4.
For the following reasons, studies do not contribute data to all outcomes in the NMA:
l as is seen in Appendix 2, Table 38, key outcomes vary by study
l as is seen in Appendix 2, Table 39, follow-up time points are not consistent between studies
l studies could not be included in the NMA where both intervention arms were grouped into the
same intervention category; for example, Aiarzeguena et al.136 where both arms were grouped as
GP reattribution (one arm being modified reattribution) or where both arms were GA (one arm
being symptom contingent and one arm being time contingent)
l data could not be included where no variance was given
l data could not be included when only provided in graphical format
l studies could not be included where no raw data were provided for non-significant outcomes.
For these reasons, results of the NMA should be interpreted with caution, and considered within the
context of the narrative summaries of results from individual studies. Appendix 2, Tables 46–76, presents
narrative summaries of results for key outcomes for individual studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
0% 25% 50% 75% 100%
Low
Unclear
High
Risk of bias
FIGURE 3 Summary table of risk-of-bias assessments.
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Narrative overviews for key outcomes are presented below, complementing the summaries in Appendix 2,
Tables 46–80. Studies varied in the manner in which they reported their results. Some presented
information on significance of effects both within and between groups, whereas others reported only
between-group differences. Some studies report significance controlling for baseline variables, or before
and after controlling for multiple comparisons. Owing to these differences in reporting, it was considered
inappropriate to present ‘counts’ or ‘percentages’ of significant effects for each outcome by time point.
However, a summary of main effects by outcomes as reported in individual studies is presented in
Appendix 2, Tables 46–80, along with key information regarding the patient population studied and the
interventions being compared. Therefore, this indicates whether the trials had active or ‘do nothing’
(usual care/treatment as usual/waiting list) controls.
Physical symptoms
Pain
Twenty-three studies reported pain as an outcome. Thirteen of these were studies of the chronic
pain population: six of single-site chronic pain118–123 and seven of chronic pain at multiple sites on
the body.125,127,128,137–140 The remaining 10 studies were in the MUS/somatoform disorder population
(see Appendix 2, Table 46).103,106,136,141–148 A number of intervention types were reported to show an
improvement in pain intensity. These include CBTHI, SES, RSSE and multimodal (exercise+ education).
No other psychotherapy or any GP intervention showed a positive effect. There were no CBTLI studies.
Narrative summaries for each individual study for pain results are presented in Appendix 2, Table 46.
Fatigue
Fourteen studies reported fatigue as an outcome. Most studies measured fatigue using the Chalder
Fatigue Scale, although the Checklist of Individual Strength (CIS) fatigue severity subscale and the
FIQ fatigue subscale were also used in a minority of studies. Twelve studies were undertaken in
participants with chronic fatigue111–115,133,149–155 and two studies in a chronic multisite pain population.125,139
Intervention types that were reported to show a positive improvement in fatigue included CBTLI, GA
and RSSE. No GP interventions were found to be effective. There were no studies of CBTHI. Narrative
summaries for each individual study for fatigue results are presented in Appendix 2, Table 47.
Bowel symptoms
Three studies reported bowel symptoms as an outcome and these were all in populations with IBS.
Two studies used the IBS Symptom Severity Scale129,130 and one used the Clinical Global Impression
Scale (CGIS) – Severity of Symptoms.131 Two studies reported significant improvements in bowel
symptoms after behavioural interventions. These were both CBTLI, with one also including medication,
but CBT was reported to have a beneficial summary effect over medication alone, although the effect
was lost by 12 months. The one study131 that found no significant effect for behavioural interventions
compared an RSSE intervention with a multimodal intervention and a third arm of usual care. Narrative
summaries for bowel symptoms results are presented in Appendix 2, Table 48.
Somatisation
Twenty-one studies reported somatisation as an outcome. Of these, 19 were of populations of patients
in the MUS/somatoform disorder condition group,97,99,102,104–107,116,117,141–144,146–148,156–159 one study was
of unexplained vaginal discharge110 and the remaining study was of patients with chronic fatigue.133
Studies measured somatisation using the Symptom Checklist-90 – Somatisation (SCL-90-S), the
BSI-somatic complaints, the PHQ-15 somatic complaints, the SOMS-7 and the Scale for Assessment
of Somatic Symptoms (SASS)-somatisation. Intervention types that were reported to show positive
improvement in somatic complaints after behavioural modification interventions included both CBTLI
and CBTHI, other psychotherapy, multimodal therapy and GP reattribution, although this significant
effect was lost after controlling for confounding factors. Narrative summaries for somatisation results
are presented in Appendix 2, Table 49.
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Generic physical symptoms
Five studies reported this outcome, which represents ‘symptom load’ or severity of unspecified symptoms
where not measured by a validated scale (see ‘somatisation’ outcome for these).96,104,109,156,160 This outcome
includes measures such as ‘N unexplained symptoms’ or severity of ‘main’ symptom’ (where the symptom
is not specified and not specific to a particular condition, e.g. IBS or fibromyalgia). All studies were of the
MUS/somatoform disorder condition group. Intervention types that were reported to show positive
improvement in symptom load included CBTLI, CBTHI and multimodal therapy.
Physical functioning and impact
Physical function
Thirty-two studies reported physical function as an outcome (see Table 38 for condition groups and
scales used in individual studies).97,100,106,107,111,114,118,119,125,127,128,131,133,136,139–153,155–158,161 Most of these studies
used either the SF-12 or SF-36, either the physical functioning subscale or less commonly the physical
component summary only. One study used the FIQ physical functioning subscale. Of the 32 studies,
eight were in the chronic fatigue condition group, 16 were in the MUS/somatoform condition group,
one was in the IBS group, and seven were in chronic pain populations (two single site and five multisite).
A number of different intervention types showed significant positive improvement in physical function.
These included RSSE, SES, CBTHI, GP reattribution and multimodal interventions. Narrative summaries
for physical function results are presented in Appendix 2, Table 53.
Impact of illness on daily activities
Twenty-two studies reported measures of impact as an outcome (see Table 38 for conditions and scales
used in individual studies).103,112,113,115,118–121,123,127–130,137–141,146,154,159,160 These mostly used disability scales: the
RMDQ, ODI, London Handicap Scale, NDI, or the SCL-90 – Global Wellness (SCL-90-G), the FIQ-total,
or the Work and Social Adjustment Scale (WASA)162 impact subscale. Four studies were of populations
in the chronic fatigue condition group, 11 in the chronic pain condition group (five single site and six
multisite), two in IBS populations and five in the MUS/somatoform disorder condition group. A number of
different intervention types showed significant improvements in ‘impact’ after behavioural interventions.
These were both CBTLI and CBTHI, RSSE, SES and multimodal interventions.
Emotional distress
Anxiety
Thirty studies reported anxiety as an outcome.102,104–108,110–113,115,127–130,133,137–139,141,142,144,145,148,149,151,154,156–159
A range of measures was used, most commonly the HADS-A and the HAM-A, but also the BAI, SCL-90-A,
the BSI-anxiety and the FIQ anxiety subscale. Fifteen studies were in populations in the MUS/somatoform
condition group, two were in populations of patients with IBS, eight studies were in populations in the
chronic fatigue condition group, and four were in populations with chronic multisite pain. The remaining
study was of unexplained vaginal discharge (see Table 38 for conditions and measures used for individual
studies). A number of different intervention groups showed positive effects: CBTLI and CBTHI, RSSE, GP
MUS management and GP reattribution, although the GP reattribution effect was lost when controlling
for confounders. Narrative summaries for anxiety results are presented in Appendix 2, Table 51.
Depression
Depression, along with physical functioning, was the most commonly reported outcome, with 32 studies
representing populations in four condition groups: seven for chronic fatigue, six for pain – multisite, one
for IBS and 17 for the MUS/somatoform condition group, and one for unexplained vaginal discharge
(see Table 38 for conditions and measures used for individual studies).99,102,105–108,111–113,115,127–130,133,137–145,147,
148,151,156–159 A range of measures were used, the most common being HADS-D, HAM-D and BDI, with other
studies using CES-D, SCL-90-D and the PHQ-9. Studies reporting positive improvement in depression were
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found across a number of intervention types, including CBTHI, GA, SES and GP reattribution, although this
effect was lost after controlling for confounders. Narrative summaries for depression are presented in
Appendix 2, Table 52.
Emotional distress
Thirty studies reported composite measures of emotional distress.97,100,103,106,107,114,116–119,125,128,129,131,133,136,
140–148,150,153,155,157,158,160,161 All condition groups were represented, with five chronic pain studies (two
single site, three multisite), four chronic fatigue studies, two IBS studies and 19 MUS/somatoform
studies) (see Table 38 for conditions and measures used for individual studies). The majority of these
studies used the SF-12 or SF-36 mental health subscale or mental component summary. HADS total,
GHQ-30 psychological morbidity and sickness impact profile (SIP) psychological subscales were also
used. Positive effects were found across a number of different intervention types: CBTLI and CBTHI,
other psychotherapy, RSSE, GA, SES, GP reattribution and multimodal. Narrative summaries for
emotional distress results are presented in Appendix 2, Table 50.
Satisfaction, acceptability and adherence
Satisfaction, acceptability and adherence were not measured or reported in a consistent way across
studies and, therefore, no attempt was made to conduct a meta-analysis of the data. For GP interventions,
‘attendance’ (by patients to their treatment sessions) or by GPs (to their training) gave an indication of
acceptability where no formal measure was taken. GPs were also asked for their confidence in dealing
with patients with MUS, or their satisfaction with their training and its relevance to their practice. Patients
were also asked about satisfaction with their care. For other interventions, satisfaction was rarely formally
measured. Uptake, attendance and attrition data were presented for many studies, giving an indication of
acceptability of the treatment offered. Appendix 2, Tables 54–62, presents a narrative synthesis of data
relating to these outcomes for individual studies by intervention type. Narrative summaries of results for
satisfaction, acceptability or adherence by intervention type are also presented in Appendix 2, Tables 54–62.
Health-care utilisation
The review of health economic literature in Chapter 6 presents data relating to costs associated with
health-care utilisation. Owing to sparse reporting of health-care utilisation and heterogeneity of
reported data, this is not included as an outcome in the NMA. Appendix 2, Tables 63–71, presents a
narrative synthesis of data relating to this outcome, by intervention type. As most studies did not
provide these data, only those that did are reported.
Adverse events
Very few studies reported adverse events in detail. It is unclear whether this is because of a lack of
events or a lack of recording of events. Where data were reported, the most frequent adverse events
were increase in pain with exercise interventions, increase in nausea and dry mouth for pharmaceutical
interventions, and an increase in rumination for CBT in one study. One patient was found to have an
incorrect diagnosis of CFS. Although other studies did report numbers of reported adverse events,
the specific nature of these events was not reported. Appendix 2, Tables 72–76, presents a narrative
summary of data relating to this outcome. As the majority of studies did not record/report adverse
events, only those that did so are presented in the tables, by intervention type, where available.
Results for network meta-analysis
For all the results presented in this section, a positive SMD indicates a beneficial effect when compared
with usual care. Cohen’s categories were used to describe the magnitude of the effect size, with SMD
≥ 0.2 to 0.5 being a small effect size, SMD ≥ 0.5 to 0.8 being a medium effect size, and SMD ≥ 0.8 being
a large effect size.163 SMD < 0.2 was labelled ‘not substantial’ effect size.
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Physical symptom outcome measures immediately post treatment
Pain (post treatment)
Data were available from 10 studies presenting the pain score immediately post treatment. A NMA
was used to compare the effects of usual care plus, medication, CBTHI, other psychotherapy, RSSE,
guided self-help, SES and multimodal relative to usual care on pain score. Figure 4 presents the
network of evidence.
Figure 5 presents the SMD of each intervention relative to usual care, the median of treatment rankings
and the probability of being the best treatment. For all interventions with the exception of guided
self-help, the estimated SMD was greater than zero, suggesting a beneficial effect compared with usual
care. However, only the effect of CBTHI (a medium effect size, SMD 0.54, with 95% CrI 0.28 to 0.84)
and multimodal (a small effect size, SMD 0.52, with 95% CrI 0.19 to 0.89) were statistically significant
at a conventional 5% level. CBTHI was also statistically significant compared with usual care, based
on the 95% prediction intervals (which illustrate the range of SMDs that might be expected in a future
study) (see Figure 5). The interventions with the highest probabilities of being the best were CBTHI and
multimodal (probability 0.31 and 0.30, respectively). The between-study SD was estimated to be 0.19
(95% CrI 0.04 to 0.44), which implies moderate heterogeneity of intervention effects between studies.
Fatigue (post treatment)
Data were available from nine studies presenting the fatigue score immediately post treatment.
A NMA was used to compare the effects of GP-CBT, CBTLI, CBTHI, other psychotherapy, RSSE,
guided self-help, GA, SES and multimodal relative to usual care on fatigue score. Figure 6 presents
the network of evidence.
Figure 7 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception of
guided self-help, the estimated SMD was greater than zero, suggesting a beneficial effect compared
with usual care. However, only the effect of RSSE (a large effect size, SMD 0.87, with 95% CrI 0.20
to 1.55), CBTLI (a medium effect size, SMD 0.72, with 95% CrI 0.27 to 1.21), multimodal (a medium
effect size, SMD 0.52, with 95% CrI 0.14 to 0.92) and GA (a medium effect size, SMD 0.51, with
95% CrI 0.14 to 0.93) were statistically significant at a conventional 5% level. Only the effects of
RSSE and CBTLI were statistically significant compared with usual care based on the 95% prediction
intervals (which illustrate the range of effect size that might be expected in a future study) (see
Figure 7). The intervention with the highest probability of being the best was RSSE (probability 0.60).
SES
MM
UC
CBTHI
ME
GSH
RSSE
OP
UC+
Comparisons
1
2
4
FIGURE 4 Pain score immediately post treatment: network of evidence. GSH, guided self-help; ME, medication;
MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
DOI: 10.3310/hta24460 Health Technology Assessment 2020 Vol. 24 No. 46
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Leaviss et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
27
UC
UC+
Treatment SMD
0
ME
CBTHI
OP
RSSE
GSH
SES
MM
95% CrI 95% PrI Rank (%)a
8 (0)
0.33
0.28
0.54
0.09
0.36
–0.44
0.30
0.52
4 (11)
5 (3)
2 (31)
7 (6)
–0.29 to 0.98
–0.12 to 0.66
–0.75 to 0.96
–0.34 to 1.05
–1.21 to 0.36
–0.14 to 0.74
0.19 to 0.89
0.28 to 0.84
–0.44 to 1.15
–0.33 to 0.90
–0.87 to 1.10
–0.47 to 1.19
–1.34 to 0.49
–0.36 to 0.95
–0.04 to 1.12
0.01 to1.12
4 (18)
9 (0)
5 (2)
2 (30)
Favours control Favours intervention (scale: SMD)
–2 –1 0 1 2
Heterogeneity: between-study SD is 0.19 (95% CrI 0.04 to 0.44)
FIGURE 5 Pain score immediately post treatment: SMD for all interventions relative to usual care. a, Probability of being
the best treatment. GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care;
UC+, usual care plus.
Comparisons
1
2
CBTLI GP-CBT
MM
OP
RSSE
GA SES
GSH
UC
CBTHI
FIGURE 6 Fatigue score immediately post treatment: network of evidence. GSH, guided self-help; ME, medication;
MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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The between-study SD was estimated to be 0.18 (95% CrI 0.04 to 0.48), which implies moderate
heterogeneity of intervention effects between studies.
Bowel symptoms (post treatment)
Two studies (Kennedy et al.129 compared multimodal with medication and Moss-Morris et al.130 compared
usual care vs. CBTLI) were available on the bowel symptoms outcome immediately post treatment. No
NMA was performed because of the disconnect network. The estimated SMD of multimodal compared
with medication was a small effect size, 0.45 (95% CI 0.13 to 0.77), from Kennedy et al.129 The estimated
SMD of CBTLI compared with usual care was a small effect size, 0.44 (95% CI –0.03 to 0.95), from
Moss-Morris et al.130
Somatisation (post treatment)
Data were available from 11 studies presenting the somatisation score immediately post treatment.
A NMA was used to compare the effects of usual care plus, GP reattribution, CBTLI, CBTHI, other
psychotherapy, RSSE and SES relative to usual care on somatisation score. Figure 8 presents the network
of evidence.
Treatment SMD 95% Crl 95% Prl Rank (%)a
UC
GP-CBT
GA
CBTHI
OP
RSSE
GSH
SES
MM
CBTLI
Favours control
Heterogeneity: between-study SD is 0.18 (95% CrI 0.04 to 0.48)
Favours intervention (scale: SMD)
0.52
0.34
0.51
–0.10
0.87
0.00
0.24
0.72
0.12
0
–0.45 to 0.70 –0.65 to 0.87
0.06 to 1.43
–0.48 to 0.99
–0.70 to 0.76
–0.96 to 0.84
–0.08 to 1.20
–0.38 to 1.05
–0.11 to 1.17
0.05 to 1.73
0.27 to 1.21
0.14 to 0.93
0.14 to 0.92
0.20 to 1.55
–0.28 to 0.79
–0.50 to 0.55
–0.80 to 0.68
–0.17 to 0.86
–2 –1 0 1 2
8 (0)
7 (1)
2 (28)
6 (1)
8 (0)
1 (60)
9 (0)
4 (3)
5 (2)
3 (5)
FIGURE 7 Fatigue score immediately post treatment: SMD for all interventions relative to usual care. a, Probability of
being the best treatment. GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual
care; UC+, usual care plus.
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Figure 9 presents the SMD of each intervention relative to usual care, the median of treatment rankings
and the probability of being the best treatment. For all interventions with the exception of usual care
plus, the estimated SMD was greater than zero, suggesting a beneficial effect compared with usual care.
However, none of the results was statistically significant at a conventional 5% level and the largest
beneficial effect was associated with CBTHI with a small effect size (SMD 0.32, with 95% CrI –0.12
to 0.75). None of the results was statistically significant based on the prediction interval (PrI) (see
Figure 9). The intervention with the highest probability of being the best was CBTHI (probability 0.39).
The between-study SD was estimated to be 0.16 (95% CrI 0.03 to 0.43), which implies moderate
heterogeneity of intervention effects between studies.
Generic physical symptoms (post treatment)
Data were available from two studies presenting the generic physical symptoms score immediately
post treatment. A NMA was used to compare the effects of other psychotherapy relative to usual care
on generic physical symptoms score. Figure 10 presents the network of evidence.
Figure 11 presents the SMD of each intervention relative to usual care, the median of treatment rankings
and the probability of being the best treatment. The estimated SMD of other psychotherapy was less
effective than usual care (a small effect size, SMD –0.25, with 95% CrI –0.77 to 0.30). This effect was
not statistically significant at a conventional 5% level, and it was also not statistically significant based
on the PrI (see Figure 11). The intervention with the highest probability of being the best was usual care
(probability 0.83). The between-study SD was estimated to be 0.13 (95% CrI 0.03 to 0.45), which implies
moderate heterogeneity of intervention effects between studies.
Physical functioning and impact outcome measures immediately post treatment
Physical functioning (post treatment)
Data were available from 14 studies presenting the physical functioning score immediately post
treatment. A NMA was used to compare the effects of usual care plus, GP reattribution, GP-CBT,
CBTLI, CBTHI, other psychotherapy, RSSE, guided self-help and GA, SES and multimodal relative to
usual care on physical functioning score. Figure 12 presents the network of evidence.
Figure 13 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception of
usual care plus, GP-CBT, other psychotherapy and guided self-help, the estimated SMD was greater
than zero, suggesting a beneficial effect compared with usual care. However, only the effect of
multimodal (a small effect size, SMD 0.33, with 95% CrI 0.09 to 0.59) was statistically significant at
SES
GPRE
UC
CBTHI
RSSE
CBTLI
OP
UC+
Comparisons
1
2
FIGURE 8 Somatisation score immediately post treatment: network of evidence. GPRE, general practitioner-delivered
reattribution; GSH, guided self-help; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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Treatment SMD 95% Crl 95% Prl Rank (%)a
UC
UC+
GPRE
CBTLI
CBTHI
OP
RSSE
SES
Favours control Favours intervention (scale: SMD)
0.05
0.04
0.24
0.32
0.08
0.20
–0.18
0
–0.65 to 0.29)
–0.33 to 0.73
–0.32 to 0.50
–0.12 to 0.75
–0.14 to 0.62
–0.42 to 0.53
–0.62 to 0.75
–0.82 to 0.46
–0.50 to 0.89
–0.49 to 0.70
–0.30 to 0.92
–0.33 to 0.81
–0.60 to 0.69
–0.73 to 0.87
6 (0)
8 (0)
3 (23)
5 (7)
2 (39)
3 (18)
5 (3)
5 (11)
0–1–2 1 2
Heterogeneity: between-study SD is 0.16 (95% CrI 0.03 to 0.43)
FIGURE 9 Somatisation score immediately post treatment: SMD for all interventions relative to usual care. a, Probability
of being the best treatment. GPRE, general practitioner-delivered reattribution; GSH, guided self-help; OP, other
psychotherapy; UC, usual care; UC+, usual care plus.
Comparisons
2
UC
OP
FIGURE 10 Generic physical symptoms score immediately post treatment: network of evidence. OP, other psychotherapy;
UC, usual care.
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Treatment SMD 95% CrI 95% PrI Rank (%)a
OP
UC
Favours control Favours intervention (scale: SMD)
0 1 (83)
–0.25 –0.77 to 0.30 –0.91 to 0.44 2 (17)
–2 –1 0 1 2
Heterogeneity: between-study SD is 0.13 (95% CrI 0.03 to  0.45)
FIGURE 11 Generic physical symptoms score immediately post treatment: SMD for all interventions relative to usual
care. a, Probability of being the best treatment. OP, other psychotherapy; UC, usual care.
Comparisons
1
2
SES
GA
UC
GSH
UC+
RSSE
OP
CBTHI
CBTLI
GP-CBT
GPRE
MM
FIGURE 12 Physical functioning score immediately post treatment: network of evidence. GPRE, general practitioner-
delivered reattribution; GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual
care; UC+, usual care plus.
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a conventional 5% level, but none of the beneficial effects was statistically significant based on the PrI
(see Figure 13). Guided self-help was significantly worse than usual care (a medium effect size, SMD –0.73,
with 95% CrI –1.18 to –0.29), and this effect was also statistically significant on the PrI (see Figure 13).
The intervention with the highest probability of being the best was multimodal (probability 0.35).
The between-study SD was estimated to be 0.10 (95% CrI 0.03 to 0.29), which implies moderate
heterogeneity of intervention effects between studies.
Impact of illness on daily activities (post treatment)
Data were available from nine studies presenting the impact score immediately post treatment.
A NMA was used to compare the effects of medication, CBTLI, CBTHI, other psychotherapy, guided
self-help, SES and multimodal relative to usual care on impact score. Figure 14 presents the network
of evidence.
Figure 15 presents the SMD of each intervention relative to usual care, the median of treatment rankings
and the probability of being the best treatment. For all interventions with the exception of guided
self-help, SES and multimodal, the estimated SMD was greater than zero, suggesting a beneficial effect
Treatment SMD 95% CrI 95% PrI Rank (%)a
Favours control Favours intervention (scale: SMD)
–2 –1 0 1 2
0.33
0.05
0.13
0.23
0.25
–0.32
0.22
–0.11 –0.44 to 0.21
0
–0.73
–0.26
–0.02
7 (0)
9 (0)
3 (22)
11 (0)
3 (26)
–0.24 to 0.66
–0.20 to 0.69
–0.02 to 0.48
–0.59 to 0.05
–0.23 to 0.50
–0.18 to 0.29
–0.34 to 0.32
–0.24 to 0.35
0.09 to 0.59 –0.03 to 0.71
–0.36 to 0.46
–0.44 to 0.42
–1.25 to –0.23
–0.32 to 0.59
–0.70 to 0.15
–0.14 to 0.60
–0.27 to 0.76
–0.82 to 0.18
–0.31 to 0.74
–0.55 to 0.31
–0.74 to 0.10
3 (9)
10 (0)
5 (6)
12 (0)
7 (1)
6 (1)
2 (35)MM
SES
GA
GSH
RSSE
OP
CBTHI
CBTLI
GPRE
GP-CBT
UC+
UC
Heterogeneity: between-study SD is 0.10 (95% CrI 0.03 to 0.29)
FIGURE 13 Physical functioning score immediately post treatment: SMD for all interventions relative to usual care.
a, Probability of being the best treatment. GPRE, general practitioner-delivered reattribution; GSH, guided self-help;
ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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Comparisons
1
2
OP UC
CBTHI
CBTLI
ME
SES
MM
GSH
FIGURE 14 Impact score immediately post treatment: network of evidence. GSH, guided self-help; ME, medication;
MM, multimodal; OP, other psychotherapy; UC, usual care.
Treatment SMD 95% CrI 95% PrI Rank (%)a
Favours control Favours intervention (scale: SMD)
–2 –1 0 1 2
0
0.19
0.78
1.30
0.54
–0.79
–0.10
–0.01 –0.70 to 0.66 –1.18 to 1.11
–1.32 to 1.14
–2.38 to 0.77
–0.83 to 1.92
0.15 to 2.47
–0.64 to 2.17
–0.93 to 1.31
–0.93 to 0.75
–2.07 to 0.46
–0.47 to 1.55
0.59 to 2.00
–0.27 to 1.83
–0.44 to 0.81
6 (0)
4 (0)
2 (19)
1 (72)
3 (8)
8 (0)
6 (0)
6 (0)
UC
ME
CBTLI
CBTHI
OP
GSH
SES
MM
Heterogeneity: between-study SD is 0.48 (95% Crl 0.31 to 0.55)
FIGURE 15 Impact score immediately post treatment: SMD for all interventions relative to usual care. a, Probability of
being the best treatment. GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy.
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compared with usual care. However, only the effect of CBTHI (a large effect size, SMD 1.30, with
95% CrI 0.59 to 2.00) was statistically significant at a conventional 5% level, and it was also statistically
significant based on the PrI (see Figure 15). The intervention with the highest probability of being the
best was CBTHI (probability 0.72). The between-study SD was estimated to be 0.48 (95% CrI 0.31 to
0.55), which implies high heterogeneity of intervention effects between studies.
Emotional distress outcome measures immediately post treatment
Anxiety (post treatment)
Data were available from 14 studies presenting the anxiety score immediately post treatment.
NMA was used to compare the effects of usual care plus, medication, GP reattribution, CBTLI,
CBTHI, other psychotherapy, guided self-help, GA and multimodal relative to usual care on anxiety
score. Figure 16 presents the network of evidence.
Figure 17 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception
of GP reattribution, guided self-help and GA, the estimated SMD was greater than zero, suggesting a
beneficial effect compared with usual care. However, only the effect of CBTHI with a medium effect
size (SMD 0.52, with 95% CrI 0.06 to 0.96) was statistically significant at a conventional 5% level,
but this effect was not statistically significant based on the PrI (see Figure 17). The intervention with
the highest probability of being the best was CBTHI (probability 0.48). The between-study SD was
estimated to be 0.22 (95% CrI 0.05 to 0.45), which implies moderate heterogeneity of intervention
effects between studies.
Depression (post treatment)
Data were available from 13 studies presenting the depression score immediately post treatment.
A NMA was used to compare the effects of usual care plus, medication, GP reattribution, CBTLI,
CBTHI, other psychotherapy, GA and multimodal relative to usual care on depression score.
Figure 18 presents the network of evidence.
Comparisons
1
2
4
ME
UC
GSH
MM
GPRE
CBTLI
CBTHI
OP
GA UC+
FIGURE 16 Anxiety score immediately post treatment: network of evidence. GPRE, general practitioner-delivered
reattribution; GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care;
UC+, usual care plus.
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Treatment SMD 95% CrI 95% PrI Rank (%)a
Favours control Favours intervention (scale: SMD)
–2 –1 0 1 2
UC
UC+
ME
GPRE
CBTLI
CBTHI
OP
GSH
GA
MM
0
0.15
0.42
–0.05
0.01
0.52
0.02
–0.35
–0.10
0.36 –0.20 to 0.95
–0.55 to 0.32
–1.12 to 0.41
–0.30 to 0.37
–0.41 to 0.39
–0.66 to 0.56
–0.03 to 0.87
–0.47 to 0.77 –0.66 to 0.94
–0.27 to 1.10
–0.84 to 0.76
–0.66 to 0.64
–0.16 to 1.21
–0.58 to 0.65
–1.29 to 0.58
–0.77 to 0.58
–0.39 to 1.14
0.06 to 0.96
3 (25)
8 (0)
10 (1)
6 (1)
2 (48)
6 (1)
7 (3)
2 (20)
4 (2)
6 (0)
Heterogeneity: between-study SD is 0.22 (95% CrI 0.05 to 0.45)
FIGURE 17 Anxiety score immediately post treatment: SMD for all interventions relative to usual care. a, Probability of
being the best treatment. GPRE, general practitioner-delivered reattribution; GSH, guided self-help; ME, medication;
MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
Comparisons
1
2
3
ME
GPRE
UC
UC+
MM
GA
OP
CBTHI
CBTLI
FIGURE 18 Depression score immediately post treatment: network of evidence. GPRE, general practitioner-delivered
reattribution; GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care;
UC+, usual care plus.
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Figure 19 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions, the estimated SMD was
greater than zero, suggesting a beneficial effect compared with usual care. However, only the effect of
CBTHI, with a large effect size (SMD 0.80, with 95% CrI 0.26 to 1.38), was statistically significant at a
conventional 5% level, but the result was not statistically significant based on the PrI (see Figure 19).
The intervention with the highest probability of being the best was CBTHI (probability 0.66). The
between-study SD was estimated to be 0.40 (95% CrI 0.24 to 0.54), which implies high heterogeneity
of intervention effects between studies.
Emotional distress (post treatment)
Data were available from 14 studies presenting the emotional distress score immediately post
treatment. A NMA was used to compare the effects of usual care plus, medication, GP reattribution,
GP-CBT, GP MUS management, CBTLI, CBTHI, other psychotherapy, RSSE, guided self-help, GA,
SES and multimodal relative to usual care on emotional distress score. Figure 20 presents the network
of evidence.
Treatment SMD 95% CrI 95% PrI Rank (%)a
–2
Favours control Favours intervention (scale: SMD)
–1 0 1 2
MM
GA
OP
CBTHI
CBTLI
GPRE
ME
UC+
UC 0
0.41
0.34
0.02
0.08
0.08
0.17
0.19
0.36
–0.45 to 0.82
–0.31 to 0.64
0.26 to 1.38
–0.49 to 0.63
–0.85 to 0.90
–0.27 to 0.96
–0.24 to 1.08 –0.64 to 1.46
–0.49 to 1.20 –0.81 to 1.54
–0.84 to 1.21
–0.75 to 1.12
–0.16 to 1.81
–0.90 to 1.06
–1.17 to 1.22
–0.67 to 1.38
7 (0)
3 (5)
4 (4)
7 (4)
7 (1)
1 (66)
6 (1)
5 (4)
4 (15)
Heterogeneity: between-study SD is 0.40 (95% CrI 0.24 to 0.54)
FIGURE 19 Depression score immediately post treatment: SMD for all interventions relative to usual care. a, Probability
of being the best treatment. GPRE, general practitioner-delivered reattribution; GSH, guided self-help; ME, medication;
MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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Figure 21 presents the SMD of each intervention relative to usual care, the median of treatment rankings
and the probability of being the best treatment. For all interventions with the exception of GP reattribution,
guided self-help and GA, the estimated SMD was greater than zero, suggesting a beneficial effect compared
with usual care. However, only the effect of other psychotherapy (a medium effect size, SMD 0.58, with
95% CrI 0.05 to 1.13), RSSE (a medium effect size, SMD 0.66, with 95% CrI 0.18 to 1.28) and SES (a small
effect size, SMD 0.49, with 95% CrI 0.03 to 1.01) were statistically significant at a conventional 5% level,
but none of the effects was statistically significant based on the PrI (see Figure 21). Guided self-help was
significantly worse than usual care (a large effect size, SMD –1.03, with 95% CrI –1.95 to –0.10), but the
result was not statistically significant based on the PrI. The interventions with the highest probabilities of
being the best were RSSE and CBTLI (probability 0.32 and 0.32, respectively), but the effect of CBTLI was
inconclusive. The between-study SD was estimated to be 0.20 (95% CrI 0.04 to 0.49), which implies high
heterogeneity of intervention effects between studies.
Physical symptom outcome measures at short term
Pain (short term)
Data were available from six studies presenting the pain score at short term. A NMA was used to
compare the effects of medication, GP MUS management, CBTHI, guided self-help, SES and multimodal
relative to usual care on pain score. Figure 22 presents the network of evidence.
Figure 23 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception of
guided self-help, the estimated SMD was greater than zero, suggesting a beneficial effect compared
with usual care. However, only the effect of CBTHI with a medium effect size (SMD 0.73, with 95% CrI
0.10 to 1.39) was statistically significant at a conventional 5% level, but this effect was not statistically
significant based on the PrI (see Figure 23). The intervention with the highest probability of being the best
was CBTHI (probability 0.41). The between-study SD was estimated to be 0.45 (95% CrI 0.27 to 0.55),
which implies high heterogeneity of intervention effects between studies.
MMGPRE
GP-CBT SES
CBTLI
CBTHI
RSSE
UC
ME
GP-MM
GA
GSH
OP
UC+
Comparisons
1
FIGURE 20 Emotional distress score immediately post treatment: network of evidence. GPRE, general practitioner-
delivered reattribution; GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual
care; UC+, usual care plus.
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Treatment SMD 95% Crl 95% Prl Rank (%)a
UC
UC+
ME
GP-MM
GPRE
GP-CBT
CBTLI
CBTHI
OP
RSSE
GSH
GA
SES
MM 0.32
0.49
–0.53
–1.03
0.66
0.58
0.33
0.63
0.14
0.25
0.31
–0.15
–0.12
0
–0.28 to 0.91 –0.48 to 1.11
–1.08 to 0.87–0.92 to 0.73
–0.77 to 0.48
–0.55 to 1.06
–0.47 to 0.75
–0.09 to 1.32
–0.16 to 0.85
–1.95 to 0.10
–1.64 to 0.61
0.05 to 1.13
0.18 to 1.28
0.03 to 1.01
–0.21 to 0.88
10 (0)
6 (2)
11 (1)
–0.98 to 0.66
–0.70 to 1.21
–0.65 to 0.96
–0.24 to 1.48
–0.37 to 1.09
–0.16 to 1.36
–0.02 to 1.50
–2.10 to 0.04
–1.76 to 0.75
–0.19 to 1.25
–0.43 to 1.10
11 (1)
7 (5)
9 (1)
3 (32)
6 (1)
3 (20)
2 (32)
14 (0)
13 (1)
4 (4)
6 (1)
–2 –1 0 1 3
Favours control Favours intervention (scale: SMD)
Heterogeneity: between-study SD is 0.20 (95% CrI 0.04 to 0.49)
FIGURE 21 Emotional distress score immediately post treatment: SMD for all interventions relative to usual care.
a, Probability of being the best treatment. GPRE, general practitioner-delivered reattribution; GSH, guided self-help;
ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
Comparisons
1
2UC
ME
GP-MM
CBTHI
GSH
SES
MM
FIGURE 22 Pain score at short term: network of evidence. GSH, guided self-help; ME, medication; MM, multimodal;
OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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Fatigue (short term)
Data were available from seven studies presenting the fatigue score at short term. A NMA was used
to compare the effects of usual care plus, CBTLI, CBTHI, other psychotherapy, RSSE, GA, SES and
multimodal relative to usual care on fatigue score. Figure 24 presents the network of evidence.
Figure 25 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions, the estimated SMD was
greater than zero, suggesting a beneficial effect compared with usual care. However, only the effect of
CBTLI with a medium effect size (SMD 0.62 with 95% CrI 0.11 to 1.14) and RSSE with a medium effect
size (SMD 0.51 with 95% CrI 0.06 to 1.00) were statistically significant at a conventional 5% level, but
none of the results was statistically significant based on the PrI (see Figure 25). The interventions with
the highest probability of being the best were CBTLI (probability 0.34). The between-study SD was
estimated to be 0.18 (95% CrI 0.03 to 0.49), which implies moderate heterogeneity of intervention
effects between studies.
Treatment SMD 95% Crl (95% Prl) Rank (%)a
UC
ME
GP-MM
CBTHI
GSH
SES
MM
Favours control Favours intervention (scale: SMD)
–2 –1 0 1 2
0
0.42
0.22
0.73
–0.17
0.49
0.62 2 (24)
3 (16)
7 (0)
2 (41)
5 (4)
4 (15)
6 (0)
–0.47 to 1.33
–0.48 to 0.95
0.10 to 1.39
–0.96 to 0.59
–0.33 to 1.34
–0.01 to 1.28 –0.45 to 1.73
–0.72 to 1.70
–1.36 to 0.99
–1.37 to 1.84
–0.89 to 1.38
–0.83 to 1.70
Heterogeneity: between-study SD is 0.45 (95% CrI 0.27 to 0.55)
FIGURE 23 Pain score at short term: SMD for all interventions relative to usual care. a, Probability of being the best
treatment. GSH, guided self-help; ME, medication; MM, multimodal; UC, usual care.
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Comparisons
1
2
RSSE
CBTHI
UC
CBTLI
GA
SES
GSH
MM
OP
FIGURE 24 Fatigue score at short term: network of evidence. GSH, guided self-help; ME, medication; MM, multimodal;
OP, other psychotherapy; UC, usual care; UC+, usual care plus.
Treatment SMD 95% Crl 95% Prl Rank (%)a
UC
OP
CBTLI
CBTHI
RSSE
GSH
GA
SES
MM 0.50
0.40
0.52
0.41
0.51
0.37
0.62
0.30
0
–0.23 to 0.84
0.11 to 1.14
–0.11 to 0.87
0.06 to 1.00
–0.06 to 0.89
–0.04 to 1.07 –0.24 to 1.26
–0.30 to 1.12
–0.16 to 1.23
–0.32 to 1.06
–0.10 to 1.35
–0.43 to 1.06
–0.14 to 0.96 –0.32 to 1.17
–0.04 to 1.06 –0.25 to 1.27 4 (17)
5 (7)
3 (14)
5 (5)
9 (0)
7 (2)
2 (34)
6 (3)
4 (18)
Favours control Favours intervention (scale: SMD)
1 20–1–2
Heterogeneity: between-study SD is 0.18 (95% CrI 0.03 to 0.49)
FIGURE 25 Fatigue score at short term: SMD for all interventions relative to usual care. a, Probability of being the best
treatment. GSH, guided self-help; MM, multimodal; OP, other psychotherapy; UC, usual care.
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Bowel symptoms (short term)
Two studies (Kennedy et al.129 compared multimodal vs. medication and Moss-Morris et al.130 compared
usual care vs. CBTLI) were available on the bowel symptoms outcome immediately post treatment.
No NMA was performed because of the disconnect network. The estimated SMD of multimodal compared
with medication was a small effect size, 0.42 (95% CI 0.10 to 0.74), from Kennedy et al.129 The estimated
SMD of CBTLI compared with usual care was a medium effect size, 0.66 (95% CI 0.16 to 1.16), from
Moss-Morris et al.130
Somatisation (short term)
Data were available from six studies presenting the somatisation score at short term. A NMA was used
to compare the effects of GP MUS management, GP reattribution and multimodal relative to usual
care on somatisation score. Figure 26 presents the network of evidence.
Figure 27 presents the SMD of each intervention relative to usual care, the median of treatment rankings
and the probability of being the best treatment. Only the estimated SMD of multimodal was greater than
zero, suggesting a beneficial effect compared with usual care. However, this is a not substantial effect
size (SMD 0.18, with 95% CrI –0.28 to 0.61) and it was not statistically significant at a conventional 5%
level. None of the results was statistically significant based on the PrI (see Figure 27). The intervention
with the highest probability of being the best was multimodal (probability 0.74), but the result of
treatment effect was inconclusive. The between-study SD was estimated to be 0.15 (95% CrI 0.03 to
0.42), which implies moderate heterogeneity of intervention effects between studies.
Generic physical symptoms (short term)
Only one study,160 which compared multimodal versus GP reattribution, was available on the generic
physical symptoms at short term. No NMA was performed because of the disconnect network. The
estimated SMD of multimodal compared with GP reattribution was a large effect size, 1.13 (95% CI
0.62 to 1.64), from van der Feltz-Cornelis et al.160
Physical functioning and impact outcome measures at short term
Physical functioning (short term)
Data were available from 10 studies presenting the physical functioning score at short term. A
NMA was used to compare the effects of GP reattribution, GP MUS management, CBTLI, CBTHI,
RSSE, guided self-help, SES and multimodal relative to usual care on physical functioning score.
Figure 28 presents the network of evidence.
Comparisons
1
2
3
UC
GP-MM
MM
GPRE
FIGURE 26 Somatisation score at short term: network of evidence. GPRE, general practitioner-delivered reattribution;
MM, multimodal; UC, usual care.
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Treatment SMD (95% CrI) (95% PrI) Rank (%)a
0UC
GP-MM
GPRE
MM 0.18
–0.13
–0.06 –0.34 to 0.23
–0.65 to 0.40
–0.28 to 0.61
–0.56 to 0.44
–0.80 to 0.52
–0.43 to 0.78
2 (12)
3 (2)
4 (13)
1 (74)
–2 –1 0 1 2
Favours control Favours intervention (scale: SMD)
Heterogeneity: between-study SD is 0.15 (95% CrI 0.03 to 0.42)
FIGURE 27 Somatisation score at short term: SMD for all interventions relative to usual care. a, Probability of being the
best treatment. GPRE, general practitioner-delivered reattribution; MM, multimodal; UC, usual care.
Comparisons
1
2
GPRE
UC
GP-MM
CBTLI
CBTHI
RSSE
GSH
SES
MM
FIGURE 28 Physical functioning score at short term: network of evidence. GPRE, general practitioner-delivered
reattribution; GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care.
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Figure 29 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception of
GP reattribution, the estimated SMD was greater than zero, suggesting a beneficial effect compared
with usual care. However, only the effect of multimodal, with a medium effect size (SMD 0.78, with
95% CrI 0.23 to 1.40), was statistically significant at a conventional 5% level, but none of the results
was statistically significant based on the PrI (see Figure 29). The intervention with the highest probability
of being the best was multimodal (probability 0.50). The between-study SD was estimated to be 0.40
(95% CrI 0.21 to 0.54), which implies high heterogeneity of intervention effects between studies.
Impact (short term)
Data were available from seven studies presenting the impact score at short term. A NMA was used
to compare the effects of medication, CBTLI, CBTHI, other psychotherapy, guided self-help, GA and
multimodal relative to usual care on impact score. Figure 30 presents the network of evidence.
Figure 31 presents the SMD of each intervention relative to usual care, the median of treatment rankings
and the probability of being the best treatment. For all interventions, the estimated SMD was greater
Treatment SMD 95% Crl 95% Prl Rank (%)a
0
–0.01
0.34
0.49
0.34
0.22
–0.10
0.46
0.78
–2 –1 0 1 2
0.23 to 1.40 –0.17 to 1.82
–0.64 to 1.60
–1.08 to 0.85
–0.82 to 1.27
–0.32 to 1.28
–0.67 to 0.44
–0.43 to 0.87
–0.44 to 1.16 –0.77 to 1.50
–0.71 to 1.69
–0.63 to 1.37
–1.23 to 1.19
–0.38 to 1.33
–0.19 to 0.92
–0.89 to 0.86
7 (0)
7 (3)
4 (3)
3 (22)
4 (7)
5 (3)
8 (0)
3 (13)
2 (50)
UC
GPRE
GP-MM
CBTLI
CBTHI
RSSE
GSH
SES
MM
Favours control Favours intervention (scale: SMD)
Heterogeneity: between-study SD is 0.40 (95% CrI 0.21 to 0.54)
FIGURE 29 Physical functioning score at short term: SMD for all interventions relative to usual care. a, Probability of
being the best treatment. GPRE, general practitioner-delivered reattribution; GSH, guided self-help; MM, multimodal;
UC, usual care.
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GA
MM
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FIGURE 30 Impact score at short term: network of evidence. GSH, guided self-help; ME, medication; MM, multimodal;
OP, other psychotherapy.
Treatment SMD 95% CrI 95% PrI Rank (%)a
MM
GA
GSH
OP
CBTHI
CBTLI
ME
UC
Favours control Favours intervention (scale: SMD)
0.83
0.45
0.34
0.21
2.25
0.63
0.79
0
0.02 to 1.56
–0.17 to 1.45
1.34 to 3.16
–0.82 to 1.25
–0.37 to 1.04
–0.44 to 1.34
–0.04 to 1.75 –0.35 to 2.06
–0.76 to 1.66
–0.74 to 1.44
–1.10 to 1.57
1.02 to 3.49
–0.53 to 1.80
–0.34 to 1.94
8 (0)
3 (0)
4 (0)
1 (98)
7 (0)
6 (0)
5 (0)
3 (1)
–4 –2 0 2 4
Heterogeneity: between-study SD is 0.41 (95% CrI 0.20 to 0.54)
FIGURE 31 Impact score at short term: SMD for all interventions relative to usual care. a, Probability of being the best
treatment. GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care.
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than zero, suggesting a beneficial effect compared with usual care. However, only the effect of CBTHI,
with a large effect size (SMD 2.25, with 95% CrI 1.34 to 3.16), and the effect of medication with a
medium effect size (SMD 0.79 with 95% CrI 0.02 to 1.56) were statistically significant at a conventional
5% level. The effect of CBTHI was also statistically significant based on the PrI (see Figure 31). The
intervention with the highest probability of being the best was CBTHI (probability 0.98). The between-
study SD was estimated to be 0.41 (95% CrI 0.20 to 0.54), which implies high heterogeneity of
intervention effects between studies.
Emotional distress outcome measures at short term
Anxiety (short term)
Data were available from nine studies presenting the anxiety score at short term. A NMA was used
to compare the effects of medication, GP reattribution, GP MUS management, CBTLI, CBTHI, other
psychotherapy, RSSE, guided self-help and GA relative to usual care on anxiety score. Figure 32 presents
the network of evidence.
Figure 33 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception of GP
reattribution, GP MUS management and RSSE, the estimated SMD was greater than zero, suggesting a
beneficial effect compared with usual care. However, only the effect of CBTHI with a medium effect
size (SMD 0.74 with 95% CrI 0.14 to 1.37) was statistically significant at a conventional 5% level,
but this effect was not statistically significant based on the PrI (see Figure 33). The intervention with
the highest probability of being the best was CBTHI (probability 0.59). The between-study SD was
estimated to be 0.25 (95% CrI 0.06 to 0.51), which implies moderate heterogeneity of intervention
effects between studies.
Depression (short term)
Data were available from 12 studies presenting the depression score at short term. A NMA was used
to compare the effects of medication, GP reattribution, GP MUS management, CBTLI, CBTHI, other
psychotherapy, RSSE, guided self-help, GA and multimodal relative to usual care on depression score.
Figure 34 presents the network of evidence.
Comparisons
1
2
RSSE
GA OP
GSH
UC
ME
GPREGP-MM
CBTLI
CBTHI
FIGURE 32 Anxiety score at short term: network of evidence. GPRE, general practitioner-delivered reattribution;
GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care.
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Treatment SMD (95% Crl) (95% Prl) Rank (%)a
GA
GSH
CBTLI
CBTHI
GP-MM
GPRE
ME
UC
RSSE
OP
210–1–2
Favours control Favours intervention (scale: SMD)
0.30
0.11
–0.01
0.28
0.74
0.32
–0.27
–0.21
0.59
0
–0.09 to 1.27
–0.90 to 0.47
–0.76 to 0.29
–0.19 to 0.79
0.14 to 1.37
–0.44 to 1.01
–0.69 to 0.66
–0.74 to 0.97
–0.41 to 0.98  –0.62 to 1.20
–0.93 to 1.15
–0.93 to 0.88
–0.64 to 1.22
–0.09 to 1.62
–0.47 to 1.06
–1.03 to 0.57
–1.13 to 0.69
–0.31 to 1.48
7 (0)
2 (27)
9 (1)
9 (0)
4 (4)
1 (59)
5 (2)
7 (1)
6 (3)
4 (4)
Heterogeneity: between-study SD is 0.25 (95% CrI 0.06 to 0.51)
FIGURE 33 Anxiety score at short term: SMD for all interventions relative to usual care. a, Probability of being the best
treatment. GPRE, general practitioner-delivered reattribution; GSH, guided self-help; ME, medication; MM, multimodal;
OP, other psychotherapy; UC, usual care.
Comparisons
1
2
ME
UC
OP
GA
MM
GSH
RSSE
CBTHI
CBTLI
GP-MM
GPRE
FIGURE 34 Depression score at short term: network of evidence. GPRE, general practitioner-delivered reattribution;
GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care.
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Figure 35 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions, with the exception of
GP reattribution and GP MUS management, the estimated SMD was greater than zero, suggesting
a beneficial effect compared with usual care. However, only the effect of CBTHI, with a large effect
size (SMD 0.93, with 95% CrI 0.37 to 1.52), was statistically significant at a conventional 5% level,
and this effect was also statistically significant based on the PrI (see Figure 35). The intervention with
the highest probability of being the best was CBTHI (probability 0.64). The between-study SD was
estimated to be 0.24 (95% CrI 0.07 to 0.49), which implies moderate heterogeneity of intervention
effects between studies.
Emotional distress (short term)
Data were available from 12 studies presenting the emotional distress score at short term. A NMA
was used to compare the effects of medication, GP reattribution, GP MUS management, CBTHI,
RSSE, guided self-help, SES relative and multimodal relative to usual care on emotional distress score.
Figure 36 presents the network of evidence.
Treatment SMD 95% Crl 95% Prl Rank (%)a
MM
GA
GSH
RSSE
CBTHI
CBTLI
GP-MM
GPRE
ME
UC
OP
0
0.39
–0.28
–0.15
0.37
0.93
0.59
0.07
0.44
0.45
0.14 –0.66 to 0.92
–0.13 to 1.01
–0.08 to 0.96
–0.38 to 0.52
–0.01 to 1.21
0.37 to 1.52
–0.08 to 0.81
–0.66 to 0.34
–0.95 to 0.37
–0.26 to 1.06 –0.46 to 1.26
–1.16 to 0.58
–0.92 to 0.61
–0.36 to 1.10
0.14 to 1.76
–0.22 to 1.42
–0.65 to 0.80
–0.32 to 1.23
–0.35 to 1.25
–0.83 to 1.10 7 (3)
4 (3)
4 (3)
8 (0)
3 (6)
1 (78)
5 (2)
10 (0)
11 (0)
5 (4)
9 (0)
–2 –1 0 1 2
Favours control Favours intervention (scale: SMD)
Heterogeneity: between-study SD is 0.24 (95% CrI 0.07 to 0.49)
FIGURE 35 Depression score at short term: SMD for all interventions relative to usual care. a, Probability of being the
best treatment. GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care.
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Figure 37 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception of
GP reattribution, medication and GP MUS management, the estimated SMD was greater than zero,
suggesting a beneficial effect compared with usual care. However, only the effect of RSSE (a large
effect size, SMD 0.82, with 95% CrI 0.02, 1.65) and multimodal (a small effect size, SMD 0.43, with
95% CrI 0.04 to 0.91) were statistically significant at a conventional 5% level, but none of the results
was statistically significant based on the PrI (see Figure 37). The intervention with the highest probability
of being the best was RSSE (probability 0.68). The between-study SD was estimated to be 0.32 (95% CrI
0.11 to 0.52), which implies high heterogeneity of intervention effects between studies.
Physical symptom outcome measures at long term
Pain (long term)
Data were available from seven studies presenting the pain score at long term. A NMA was used to
compare the effects of usual care plus, medication, GP MUS management, GP other, CBTHI, other
psychotherapy, guided self-help and multimodal relative to usual care on pain score. Figure 38 presents
the network of evidence.
Figure 39 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception of
guided self-help, GP MUS management, other psychotherapy, multimodal and usual care plus, the
estimated SMD was greater than zero, suggesting a beneficial effect compared with usual care. The
largest beneficial effects were associated with medication (a small effect size, SMD 0.41, with 95% CrI
–0.16 to 0.98) and CBTHI (a small effect size, SMD 0.36, with 95% CrI –0.21 to 0.94). However,
none of the beneficial effects was statistically significant at a conventional 5% level, and none of the
beneficial effects was statistically significant based on the PrI (see Figure 39). Guided self-help was
significantly worse than usual care (a large effect size, SMD –2.27, with 95% CrI –3.30 to –1.23). The
intervention with the highest probabilities of being the best was medication and CBTHI (a probability
of 0.49 and 0.28, respectively), but the results of treatment effects were inconclusive. The between-
study SD was estimated to be 0.14 (95% CrI 0.03 to 0.48), which implies moderate heterogeneity of
intervention effects between studies.
Comparisons
1
2
CBTHI
GP-MM
GPRE
UC
ME
MM
SES
GSH
RSSE
FIGURE 36 Emotional distress score at short term: network of evidence. GPRE, general practitioner-delivered
reattribution; GSH, guided self-help; ME, medication; MM, multimodal; UC, usual care.
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Treatment SMD 95% CrI 95% PrI Rank (%)
a
MM
SES
GSH
RSSE
CBTHI
GP-MM
GPRE
ME
UC
–2 –1 0 21
Favours control Favours intervention (scale: SMD)
0.43
0.35
0.01
0.82
0.46
–0.02
–0.21
–0.05 –0.89 to 0.84
–0.80 to 0.39 –1.12 to 0.71
–0.80 to 0.82
–0.50 to 1.44
–0.23 to 1.89
–0.86 to 0.81
–0.58 to 1.33
–0.34 to 1.30
–1.12 to 1.09
0 6 (0)
7 (2)
8 (0)
7 (0)
3 (15)
1 (68)
6 (0)
4 (8)
3 (8)0.04 to 0.91
–0.29 to 1.04
–0.50 to 0.46
0.02 to 1.65
–0.21 to 1.14
–0.42 to 0.42
Heterogeneity: between-study SD is 0.32 (95% CrI 0.11 to 0.52)
FIGURE 37 Emotional distress score at short term: SMD for all interventions relative to usual care. a, Probability of
being the best treatment. GPRE, general practitioner-delivered reattribution; GSH, guided self-help; ME, medication;
MM, multimodal; OP, other psychotherapy; UC, usual care.
GP-MM
Comparisons
1
ME
UC
GSH
UC+
GP-O
OP
MM
CBTHI
FIGURE 38 Pain score at long term: network of evidence. GP-O, GP – other; GSH, guided self-help; ME, medication;
MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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Fatigue (long term)
Data were available from five studies presenting the fatigue score at long term. A NMA was used to
compare the effects of GP-CBT, CBTLI, CBTHI, other psychotherapy, RSSE, guided self-help, GA, SES
and multimodal relative to usual care on fatigue score. Figure 40 presents the network of evidence.
Figure 41 presents the SMD of each intervention relative to usual care, the median of treatment rankings
and the probability of being the best treatment. For all interventions, with the exception of GP-CBT,
the estimated SMD was greater than zero, suggesting a beneficial effect compared with usual care.
However, only the effect of CBTLI, with a medium effect size (SMD 0.64, with 95% CrI 0.05 to 1.20),
was statistically significant at a conventional 5% level, but none of the results was statistically significant
based on the PrI (see Figure 41). The intervention with the highest probability of being the best was
CBTLI (probability 0.73). The between-study SD was estimated to be 0.11 (95% CrI 0.03 to 0.42),
which implies moderate heterogeneity of intervention effects between studies.
Treatment SMD 95% CrI 95% PrI Rank (%)a
Favours control Favours intervention (scale: SMD)
MM
GSH
OP
CBTHI
GP-O
GP-MM
ME
UC+
UC
–4 –1 0 1 2
0 5 (1)
5 (1)
2 (49)
6 (1)
4 (13)
2 (28)
6 (3)
9 (0)
6 (4)–0.99 to 0.70
–3.38 to –1.14
–1.24 to 0.95
–0.37 to 1.09
–0.96 to 1.20
–0.82 to 0.54
–0.31 to 1.14
–0.94 to 0.94–0.81 to 0.82–0.02
–0.15
0.10
0.36
–0.15
–2.27
–0.15
0.41
–0.84 to 0.57
–3.30 to –1.23
–1.12 to 0.85
–0.21 to 0.94
–0.87 to 1.09
–0.62 to 0.34
–0.16 to 0.98
Heterogeneity: between-study SD is 0.14 (95% CrI 0.03 to 0.48)
FIGURE 39 Pain score at long term: SMD for all interventions relative to usual care. a, Probability of being the best
treatment. GP-O, GP – other; GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy;
UC, usual care; UC+, usual care plus.
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Treatment SMD 95% Crl 95% Prl Rank (%)a
UC
GP-CBT
CBTLI
CBTHI
OP
RSSE
GSH
GA
SES
MM 0.22
0.21
0.21
0.26
0.10
0.05
0.19
0.64
–0.11
0
–2 –1 0 1 2
Favours control Favours intervention (scale: SMD)
–0.58 to 0.35
0.05 to 1.20
–0.25 to 0.62
–0.35 to 0.47
–0.46 to 0.65
–0.29 to 0.81
–0.20 to 0.61
–0.24 to 0.63
–0.23 to 0.65 –0.34 to 0.77
–0.35 to 0.77
–0.32 to 0.74
–0.39 to 0.92
–0.56 to 0.74
–0.49 to 0.62
–0.38 to 0.74
–0.03 to 1.30
–0.70 to 1.47
8 (0)
9 (1)
1 (73)
5 (3)
7 (0)
6 (1)
4 (11)
5 (3)
5 (4)
4 (5)
Heterogeneity: between-study SD is 0.11 (95% CrI 0.03 to 0.42)
FIGURE 41 Fatigue score at long term: SMD for all interventions relative to usual care. a, Probability of being the best
treatment. GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care.
Comparisons
1
2
RSSE
OP
CBTHI
CBTLI GP-CBT
MM
UC
GSH
SESGA
FIGURE 40 Fatigue score at long term: network of evidence. GSH, guided self-help; ME, medication; MM, multimodal;
OP, other psychotherapy; UC, usual care.
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Bowel symptoms (long term)
Data were available from two studies presenting bowel symptoms at long term. A NMA was used
to compare the effects of usual care plus, CBTLI and guided self-help relative to usual care on bowel
symptoms. Figure 42 presents the network of evidence.
Figure 43 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. The estimated SMDs of both CBTLI and
guided self-help were greater than zero, suggesting a beneficial effect compared with usual care.
However, only the effect of CBTLI, with a large effect size (SMD 0.84, with 95% CrI 0.17 to 1.52),
was statistically significant at a conventional 5% level, and also statistically significant based on
the PrI (see Figure 43). The intervention with the highest probability of being the best was CBTLI
(probability 0.95). The between-study SD was estimated to be 0.15 (95% CrI 0.03 to 0.49), which
implies moderate heterogeneity of intervention effects between studies.
Somatisation (long term)
Data were available from 11 studies presenting the somatisation score at long term. A NMA was
used to compare the effects of usual care plus, GP MUS management, GP reattribution, GP other,
CBTLI, CBTHI, other psychotherapy and multimodal relative to usual care on somatisation score.
Figure 44 presents the network of evidence.
Figure 45 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception
of GP MUS management, GP reattribution, CBTLI and GP other, the estimated SMD was greater
than zero, suggesting a beneficial effect compared with usual care. The largest beneficial effect was
associated with CBTHI (a small effect size, SMD 0.47 with 95% CrI –0.30 to 1.29), but this effect was
not statistically significant at a conventional 5% level, and it was also not statistically significant based
on the PrI (see Figure 45). The intervention with the highest probability of being the best was CBTHI
(probability 0.71), but the result of treatment effect was inconclusive. The between-study SD was
estimated to be 0.11 (95% CrI 0.02 to 0.35), which implies moderate heterogeneity of intervention
effects between studies.
Comparisons
1UC
CBTLI
GSH
FIGURE 42 Bowel symptoms at long term: network of evidence. GSH, guided self-help; UC, usual care.
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Treatment SMD 95% Crl 95% Prl Rank (%)
a
GSH
CBTLI
UC 0
0.84
0.16
3 (0)
1 (95)
Favours control Favours intervention (scale: SMD)
–2 –1 1 20
0.17 to 1.52 0.05 to 1.66
–0.36 to 0.68 –0.55 to 0.87 2 (5)
Heterogeneity: between-study SD is 0.15 (95% CrI 0.03 to 0.49)
FIGURE 43 Bowel symptoms at long term: SMD for all interventions relative to usual care. a, Probability of being the
best treatment. GSH, guided self-help; UC, usual care.
Comparisons
1
2
MM
UC
GP-MM
GPRE
GP-O
CBTLI
OP
UC+
CBTHI
FIGURE 44 Somatisation score at long term: network of evidence. GP-O, GP – other; GPRE, general practitioner-delivered
reattribution; MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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Generic physical symptoms (long term)
Only one study,104 which compared other psychotherapy and usual care, was available on the generic
physical symptoms at short term. No NMA was performed because of the disconnect network. The
estimated SMD of other psychotherapy compared with usual care was a small effect size, –0.30 (95% CI
–0.76 to 0.16), from Kolk et al.104
Physical functioning and impact outcome measures at long term
Physical functioning (long term)
Data were available from 13 studies presenting the physical functioning score at long term. A NMA
was used to compare the effects of usual care plus, GP reattribution, GP MUS management, GP-CBT,
CBTLI, CBTHI, other psychotherapy, RSSE, guided self-help, GA, SES and multimodal relative to usual
care on physical functioning score. Figure 46 presents the network of evidence.
Figure 47 presents the SMD of each intervention relative to usual care, the median of treatment rankings
and the probability of being the best treatment. For all interventions with the exception of GP-CBT,
other psychotherapy and guided self-help, the estimated SMD was greater than zero, suggesting a
Treatment SMD 95% CrI 95% PrI Rank (%)a
UC
UC+
GP-MM
GPRE
GP-O
CBTHI
CBTLI
OP
MM
Favours control Favours intervention (scale: SMD)
0 5 (1)
5 (0)
6 (0)
6 (6)
5 (7)
1 (71)
8 (1)
3 (5)
4 (8)
0.00
–0.06
–0.02
0.00
0.47
–0.22
0.16
0.06 –0.36 to 0.43 –0.46 to 0.53
–0.48 to 0.79
–0.77 to 0.31
–0.37 to 1.33
–0.54 to 0.54
–0.56 to 0.53
–0.49 to 0.34
–0.78 to 0.81
–0.40 to 0.72
–0.68 to 0.22
–0.30 to 1.29
–0.45 to 0.44
–0.33 to 0.19
–0.48 to 0.43
–0.73 to 0.75
0 1 2–1–2
Heterogeneity: between-study SD is 0.11 (95% CrI 0.02 to 0.35)
FIGURE 45 Somatisation score at long term: SMD for all interventions relative to usual care. a, Probability of being
the best treatment. GP-O, GP – other; GPRE, general practitioner-delivered reattribution; GSH, guided self-help;
MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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beneficial effect compared with usual care. The largest beneficial effect was associated with CBTHI
(a small effect size, SMD 0.47, with 95% CrI 0.19 to 1.44), but this effect was not statistically significant
at a conventional 5% level, and none of the results was statistically significant based on the PrI (see
Figure 47). Guided self-help was significantly worse than usual care (a large effect size, SMD –2.98, with
95% CrI –4.00 to –1.96), and the result was statistically significant based on the PrI. The intervention
with the highest probability of being the best was CBTHI (probability 0.38). The between-study SD was
estimated to be 0.21 (95% CrI 0.05 to 0.49), which implies moderate heterogeneity of intervention
effects between studies.
Impact (long term)
Data were available from four studies presenting the impact score at long term. A NMA was used to
compare the effects of medication, CBTLI, CBTHI, guided self-help and multimodal relative to usual
care on impact score. Figure 48 presents the network of evidence.
Figure 49 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception of
guided self-help and multimodal, the estimated SMD was greater than zero, suggesting a beneficial
effect compared with usual care. The largest beneficial effect was associated with CBTLI (a large effect
size, SMD 0.89, with 95% CrI 0.22 to 1.55), and it was also statistically significant at a conventional
5% level. Guided self-help was significantly worse than usual care (and a large effect size, SMD –1.10,
with 95% CrI –2.08 to –0.07 for guided self-help). However, this result was statistically significant
based on the PrI (see Figure 49). The intervention with the highest probability of being the best was
CBTLI (probability 0.92), but the result of treatment effect was inconclusive. The between-study SD
was estimated to be 0.15 (95% CrI 0.03 to 0.48), which implies moderate heterogeneity of intervention
effects between studies.
Emotional distress outcome measures at long term
Anxiety (long term)
Data were available from 11 studies presenting the anxiety score at long term. A NMA was used to
compare the effects of usual care plus, medication, GP reattribution, GP MUS management, GP other,
GP other psychotherapy, CBTLI, CBTHI, other psychotherapy, RSSE and GA relative to usual care on
anxiety score. Figure 50 presents the network of evidence.
Comparisons
1
2
GP-MM
GPRE
MM
GA
UC
CBTLI
OP
SES
RSSE
CBTHI
UC+
GSH
GP-CBT
FIGURE 46 Physical functioning score at long term: network of evidence. GPRE, general practitioner-delivered
reattribution; GSH, guided self-help; MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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Treatment SMD 95% CrI 95% PrI Rank (%)a
UC
UC+
GPRE
GP-MM
GP-CBT
CBTLI
CBTHI
OP
RSSE
GSH
GA
SES
MM
Favours control Favours intervention (scale: SMD)
–5 –1 0 1 3
0.28
0.27
0.13
–2.98
–0.15
–0.32
0.06
0.16
0.02
0
0.36
0.47
0.35
8 (0)
8 (0)
6 (7)
7 (1)
12 (0)
4 (16)
2 (38)
10 (0)
3 (13)
13 (0)
6 (3)
5 (13)
4 (9)–0.36 to 0.99
–0.76 to 1.30
–0.67 to 0.90
–4.11 to –1.85
–0.50 to 1.20
–0.93 to 0.63
–0.62 to 1.57
–0.52 to 1.19
–1.12 to 0.48
–0.60 to 0.78
–0.66 to 0.97
–0.96 to 1.04–0.84 to 0.88
–0.46 to 0.79
–0.35 to 0.53
–0.91 to 0.28
–0.33 to 1.02
–0.49 to 1.44
–0.74 to 0.44
–0.32 to 1.01
–4.00 to –1.96
–0.46 to 0.70
–0.63 to 1.15
–0.09 to 0.72
Heterogeneity: between-study SD is 0.21 (95% CrI 0.05 to 0.49)
FIGURE 47 Physical functioning score at long term: SMD for all interventions relative to usual care. a, Probability of
being the best treatment. GPRE, general practitioner-delivered reattribution; GSH, guided self-help; ME, medication;
MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
Comparisons
1
UC
MECBTLI
CBTHI
MM GSH
FIGURE 48 Impact score at long term: network of evidence. GSH, guided self-help; ME, medication; MM, multimodal;
UC, usual care.
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Treatment SMD 95% Crl 95% Prl Rank (%)a
UC
ME
CBTLI
CBTHI
GSH
MM
0
0.07
0.89
0.54
–0.10
–0.17
Favours control Favours intervention (scale: SMD)
–3 –1 0 1 3
4 (0)
3 (0)
1 (79)
2 (20)
6 (0)
5 (1)–0.95 to 0.60
–2.08 to –0.07
–0.04 to 1.12
0.22 to 1.55
–0.50 to 0.64 –0.65 to 0.80
0.07 to 1.69
–0.21 to 1.27
–2.18 to 0.03
–1.07 to 0.74
Heterogeneity: between-study SD is 0.15 (95% CrI 0.03 to 0.48)
FIGURE 49 Impact score at long term: SMD for all interventions relative to usual care. a, Probability of being the best
treatment. GSH, guided self-help; ME, medication; MM, multimodal; UC, usual care.
Comparisons
1
2
UC
OP
RSSE
GA
ME
GPRE
GP-MM
GP-OP
CBTLI
CBTHI
UC+
GP-O
FIGURE 50 Anxiety score at long term: network of evidence. GP-O, GP – other; GPRE, general practitioner-delivered
reattribution; ME, medication; MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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Figure 51 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception
of medication, GP other psychotherapy and CBTHI, the estimated SMD was smaller than zero,
suggesting a negative effect compared with usual care. None of the effects was statistically significant
at a conventional 5% level and based on the PrI (see Figure 51). The largest beneficial effect was
associated with GP other psychotherapy (a not substantial effect size, SMD 0.18, with 95% CrI –0.40
to 0.76). The intervention with the highest probability of being the best was GP other psychotherapy
(probability 0.32). The between-study SD was estimated to be 0.19 (95% CrI 0.04 to 0.46), which
implies moderate heterogeneity of intervention effects between studies.
Depression (long term)
Data were available from 14 studies presenting the depression score at long term. A NMA was used to
compare the effects of usual care plus, medication, GP reattribution, GP MUS management, GP other,
GP other psychotherapy, CBTLI, CBTHI, other psychotherapy, RSSE, GA and multimodal relative to
usual care on depression score. Figure 52 presents the network of evidence.
Treatment SMD 95% CrI 95% PrI Rank (%)a
UC
UC+
ME
GPRE
GP-MM
GP-O
GP-OP
CBTLI
CBTHI
OP
RSSE
GA
Favours control Favours intervention (scale: SMD)
–2 –1 0 1 2
0
–0.44
–0.23
–0.03
–0.55
–0.03
–0.21
–0.08
–0.16 –0.70 to 0.37
–0.69 to 0.54
–0.65 to 0.20
–0.47 to 0.74
–0.50 to 0.44
–0.40 to 0.76
–1.48 to 0.36
–0.58 to 0.53
–0.82 to 0.37
–0.52 to 0.70
–1.19 to 0.27 –1.35 to 0.43
–0.70 to 0.87
–1.01 to 0.56
–0.77 to 0.73
–1.61 to 0.49
–0.58 to 0.93
–0.71 to 0.65
–0.63 to 0.93
–0.88 to 0.43
–0.85 to 0.74
–0.90 to 0.55
0.13
0.18
0.09
5 (0)
11 (0)
4 (16)
9 (3)
6 (8)
11 (1)
2 (32)
6 (6)
3 (22)
8 (1)
6 (7)
8 (3)
Heterogeneity: between-study SD is 0.19 (95% CrI 0.04 to 0.46)
FIGURE 51 Anxiety score at long term: SMD for all interventions relative to usual care. a, Probability of being the best
treatment. GP-O, GP – other; GPRE, general practitioner-delivered reattribution; ME, medication; MM, multimodal;
OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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Figure 53 presents the SMD of each intervention relative to usual care, the median of treatment
rankings and the probability of being the best treatment. For all interventions with the exception of
usual care plus, GP reattribution, GP other, GP other psychotherapy, CBTLI, other psychotherapy, RSSE
and GA, the estimated SMD was greater than zero, suggesting a beneficial effect compared with usual
care. The largest beneficial effect was associated with multimodal (a small effect size, SMD 0.51, with
95% CrI –0.02 to 1.13), but this effect was not statistically significant at a conventional 5% level. None
of the results was statistically significant based on the PrI (see Figure 53). The intervention with the
highest probability of being the best was multimodal (probability 0.66). The between-study SD was
estimated to be 0.20 (95% CrI 0.05 to 0.46), which implies moderate heterogeneity of intervention
effects between studies.
Emotional distress (long term)
Data were available from nine studies presenting the emotional distress score at long term. There were
two separate networks for the emotional distress score at long term due to disconnect networks.
A NMA was used to compare the effects of medication, GP reattribution, GP MUS management,
GP-CBT, guided self-help and multimodal to usual care on emotional distress score. A separate NMA
was used to compare the effect of CBTHI, other psychotherapy relative to usual case plus. Figure 54
presents the network of evidence.
Figure 55 presents the SMD from network 1, the median of treatment rankings and the probability of
being the best treatment. For all interventions with the exception of GP reattribution, guided self-help,
the estimated SMD was greater than zero, suggesting a beneficial effect compared with usual care.
However, none of the beneficial effects was statistically significant at a conventional 5% level and
based on the PrIs. The largest beneficial effect was associated with multimodel (a small effect size,
SMD 0.56, with 95% CrI –0.31 to 1.45). Guided self-help was significantly worse than usual care
(a large effect size, SMD –1.44, with 95% CrI –2.60 to –0.30), and this effect was also statistically
significant based on the PrI (see Figure 55). The intervention with the highest probability of being
the best was multimodal (probability 0.73), but the result of treatment effect was inconclusive.
The between-study SD was estimated to be 0.15 (95% CrI 0.03 to 0.47), which implies moderate
heterogeneity of intervention effects between studies.
Comparisons
1
2
3
RSSE
UC
CBTHI
GP-O
UC+
OP
CBTLI
GP-OP
GP-MM
GPRE
MM
GA
FIGURE 52 Depression score at long term: network of evidence. GP-O, GP – other; GSH, guided self-help; ME, medication;
MM, multimodal; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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Treatment SMD 95% CrI 95% PrI Rank (%)a
UC
UC+
GPRE
GP-MM
GP-O
GP-OP
CBTLI
CBTHI
OP
RSSE
GA
MM
0
–2 –1 0 1 2
Favours control Favours intervention (scale: SMD)
0.51
0.00
–0.03
–0.20
0.17
–0.04
–0.03
–0.30
0.09
–0.23
–0.29 –1.00 to 0.42
–0.85 to 0.36
–0.38 to 0.59
–1.21 to 0.61
–0.61 to 0.54
–0.39 to 0.33
–0.63 to 1.00
–0.63 to 0.21
–0.61 to 0.57
–0.54 to 0.52
–0.02 to 1.13 –0.19 to 1.31
–0.72 to 0.71
–0.80 to 0.74
–0.85 to 0.42
–0.78 to 1.12
–0.63 to 0.58
–0.78 to 0.72
–1.33 to 0.73
–0.59 to 0.80
–1.03 to 0.55
–1.16 to 0.57
6 (0)
10 (0)
9 (1)
4 (1)
10 (1)
6 (4)
7 (1)
3 (19)
9 (0)
6 (4)
6 (3)
1 (66)
Heterogeneity: between-study SD is 0.20 (95% CrI 0.05 to 0.46)
FIGURE 53 Depression score at long term: SMD for all interventions relative to usual care. a, Probability of being the
best treatment. GP-O, GP – other; GPRE, general practitioner-delivered reattribution; MM, multimodal; OP, other
psychotherapy; UC, usual care; UC+, usual care plus.
Comparisons
1
2
ME
UC
(a)
GPRE
GP-CBT
GSH
MM
GP-MM
Comparisons
1UC+
(b)
CBTHI
OP
FIGURE 54 Emotional distress score at long term: network of evidence – (a) network 1; and (b) network 2. GPRE, general
practitioner-delivered reattribution; GSH, guided self-help; ME, medication; MM, multimodal; OP, other psychotherapy;
UC, usual care; UC+, usual care plus.
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Figure 56 presents the SMD from network 2, the median of treatment rankings and the probability
of being the best treatment. The estimated SMDs of CBTHI and other psychotherapy were both
greater than zero, suggesting a beneficial effect compared with usual care. However, only the effect
of CBTHI with a median effect size (SMD 0.61, with 95% CrI 0.05 to 1.18) was statistically significant
at a conventional 5% level, but none of the results was statistically significant based on the PrI (see
Figure 56). The intervention with the highest probability of being the best was CBTHI (probability 0.94).
The between-study SD was estimated to be 0.19 (95% CrI 0.03 to 0.49), which implies moderate
heterogeneity of intervention effects between studies.
Model checking
The goodness of model fit is presented in Table 2. For all the analyses, the models fitted the data
well, with the total residual deviance close to the total number of data points. Inconsistency checking
was performed using the inconsistency model approach.92 The DICs for both the consistency model
and the inconsistency model are presented in Appendix 13, Figures 75–84. Plots of the posterior mean
deviance of the individual data points in both the consistency model and the inconsistency model for
each of the outcomes are presented in Appendix 11.
For all the outcomes, the consistency model provides a similar DIC as the inconsistency model, with
the exception of physical functioning at post treatment and short term, and emotional distress at
short term. The contributions to the deviance are very similar in the two models for all the outcomes,
with the exception of pain short term (the comparison between guided self-help and multimodal,
Treatment SMD 95% Crl 95% Prl Rank (%)a
UC
ME
GPRE
GP-MM
GP-CBT
GSH
MM
0
0.15
–0.39
0.38
0.01
–1.44
0.56
Favours control Favours intervention (scale: SMD)
–3 –1 0 1 2
–0.31 to 1.45
–2.60 to –0.30
–0.52 to 0.55
–0.55 to 1.34
–0.94 to 0.17
–0.86 to 1.18 –0.95 to 1.26
–1.09 to 0.32
–0.64 to 1.44
–0.68 to 0.68
–2.67 to –0.22
–0.39 to 1.56 1 (73)
7 (0)
4 (10)
2 (9)
6 (0)
3 (4)
4 (4)
Heterogeneity: between-study SD is 0.15 (95% CrI 0.03 to 0.47)
FIGURE 55 Emotional distress score at long term: SMD for all interventions relative to usual care (network 1).
a, Probability of being the best treatment. GPRE, general practitioner-delivered reattribution; GSH, guided self-help;
ME, medication; MM, multimodal; UC, usual care.
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Treatment SMD 95% CrI 95% PrI Rank (%)a
UC+ 0
0.61
0.02
CBTHI
OP
Favours control Favours intervention (scale: SMD)
–2 –1 0 1 2
3 (1)
1 (94)0.05 to 1.18
–0.55 to 0.59
–0.12 to 1.35
–0.74 to 0.77 2 (6)
Heterogeneity: between-study SD is 0.15 (95% CrI 0.03 to 0.49)
FIGURE 56 Emotional distress score at long term: SMD for all interventions relative to usual care plus (network 2).
a, Probability of being the best treatment. OP, other psychotherapy; UC+, usual care plus.
TABLE 2 Goodness of model fit and inconsistency check
Outcome Time point
Total number of
data points
Total residual
deviance
Inconsistency check
Consistency
model DIC
Inconsistency
model DIC
Pain Post treatment 14 16.21 4.27 6.19
Short term 9 10.38 0.96 1.25
Long term 8 8.05 1.00 0.97
Fatigue Post treatment 12 13.38 2.95 3.79
Short term 11 13.54 3.96 4.60
Long term 10 9.51 –0.75 0.38
Bowel symptoms Long term 2 2.03 0.91 0.98
Somatisation Post treatment 11 12.04 2.96 3.75
Short term 6 6.80 –0.16 –0.20
Long term 11 10.99 –0.90 –0.74
Generic physical symptoms Post treatment 2 1.32 2.30 2.19
Physical functioning Post treatment 17 16.32 –1.44 2.74
Short term 13 15.16 4.57 1.39
Long term 15 16.24 4.40 4.49
continued
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the comparison between usual care and medication, and the comparison between usual care and
CBTHI), fatigue at short term (the comparison between usual care and RSSE), physical functioning
at short term (the comparison between guided self-help and multimodal, and the comparison between
usual care and GP MUS management), emotional distress at post treatment (the comparison between
usual care and RSSE) and short term (the comparison between guided self-help and multimodal), and
depression at short term (the comparison between usual care and medication, and the comparison
between usual care and CBTHI). However, there are overlaps in the 95% CrIs for the estimates between
the two models (see Appendix 11). Hence, overall there is no evidence to suggest inconsistency in the
networks for all the outcomes.
All NMAs had moderate to high heterogeneity in treatment effects between studies. For most of the
outcomes, there were only one or two studies to inform each of the pairwise comparisons/contrasts,
with the exception for pain and anxiety both at post treatment, where one contrast was informed by
four studies, somatisation at short term and depression at both post treatment and long term, where
one contrast was informed by three studies. Hence, there were not enough data to update the prior
for the heterogeneity parameter in most analyses. However, the use of plausible informative prior
distribution for the heterogeneity ensures that the posterior distribution of the heterogeneity and
treatment effects were in also in the plausible range.
It was not possible to perform a metaregression to explain the heterogeneity because there was
insufficient replication of each treatment effect across studies. Hence, we compared the point estimate
and CIs across condition groupings.
The outcome measures of pain, fatigue, physical functioning, anxiety, depression and emotional distress
have been assessed in different condition groupings. For all of these outcomes, the point estimates
of the pooled SMDs differed over condition groups, when they were estimated separately in each of
these groups. The exceptions to this were for physical functioning score (guided self-help vs. usual care)
at short term between the chronic fatigue group and the pain multiple sites group, and for depression
score (CBTLI vs. usual care) at short term between the IBS group and the chronic fatigue group.
In both of these cases, the SMDs for the individual condition groups were similar.
TABLE 2 Goodness of model fit and inconsistency check (continued )
Outcome Time point
Total number of
data points
Total residual
deviance
Inconsistency check
Consistency
model DIC
Inconsistency
model DIC
Impact Post treatment 11 11.51 9.34 10.15
Short term 9 10.43 9.34 10.15
Long term 5 4.95 3.42 3.56
Emotional distress Post treatment 15 16.24 3.42 3.57
Short term 14 17.03 4.30 0.21
Long term for NMA1 7 7.23 3.21 3.15
Long term for NMA2 2 2.03 0.92 No indirect
evidence
Anxiety Post treatment 17 19.05 7.78 8.70
Short term 12 13.35 6.95 5.45
Long term 14 15.09 4.66 4.80
Depression Post treatment 16 17.39 6.20 7.33
Short term 15 16.11 5.69 2.04
Long term 16 17.29 5.30 6.11
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In all the cases, the CIs of the point estimates generally overlapped indicating that the difference in SMD
between condition groups was not statistically significant. Overall, the evidence suggested that the
relative treatment effects for the interventions listed in Table 3 were not significantly different across
condition groupings.
TABLE 3 Comparison of treatment effects in condition groupings
Time point
Outcome
measure
Treatment
(vs. usual
care)
Condition grouping (first author
and year of publication) SMD (95% CI) Comments
Immediately
post treatment
Pain CBTHI MUS/somatoform (Zonneveld,
2012141)
0.51 (0.20 to 0.82) Different point
estimates, but
overlapping CIs
Pain multiple sites (Alda, 2011137) 0.23 (–0.14 to 0.59)
Pain multiple sites (Luciano,
2014138)
1.20 (0.78 to 1.61)
Pain multiple sites (McBeth,
2012125/Beasley 2015126)
0.35 (0.08 to 0.61)
Physical
functioning
CBTHI MUS/somatoform (Zonneveld,
2012141)
0.39 (0.08 to 0.70) Different point
estimates, but
overlapping CIs
Pain multiple sites (McBeth,
2012125)
0.15 (–0.11 to 0.41)
Anxiety CBTLI Chronic fatigue (Tummers, 2012)149 0.14 (–0.21 to 0.50) Different point
estimates, but
overlapping CIsIBS (Moss-Morris, 2010
130) –0.46 (–0.95 to 0.04)
OP MUS/somatoform (Kolk, 2004104) –0.01 (–0.47 to 0.45) Different point
estimates, but
overlapping CIsMUS/somatoform (McLeod,
1997105)
0.32 (–0.08 to 0.72)
MUS/somatoform (Posse, 200496) 0.46 (–0.67 to 1.59)
Chronic fatigue (Wearden, 2010111) –0.18 (–0.45 to 0.10)
Depression CBTLI IBS (Moss-Morris, 2010130) –0.03 (–0.51 to 0.45) Different point
estimates, but
overlapping CIsMUS/somatoform (Martin, 2007
99) –0.14 (–0.47 to 0.19)
OP MUS/somatoform (Kolk, 2004104) –0.10 (–0.55 to 0.36) Different point
estimates, but
overlapping CIsMUS/somatoform (McLeod,
1997105)
0.57 (0.16 to 0.97)
Chronic fatigue (Wearden, 2010111) –0.09 (–0.36 to 0.19)
Short term Physical
functioning
GSH Pain multiple sites (LeFort, 1998128) 0.27 (–0.10 to 0.64) Similar point
estimates, and
overlapping CIsChronic fatigue (Chalder, 1997
114) 0.26 (–0.06 to 0.58)
Anxiety CBTLI IBS (Moss-Morris, 2010130) –0.08 (–0.56 to 0.41) Different point
estimates, but
overlapping CIsChronic fatigue (Friedberg,
2013151)
0.35 (–0.10 to 0.80)
Depression CBTLI IBS (Moss-Morris, 2010130) 0.29 (–0.20 to 0.78) Similar point
estimates, and
overlapping CIsChronic fatigue (Friedberg,
2013151)
0.25 (–0.20 to 0.70)
RSSE MUVD (Kobeissi, 2012110) 0.10 (–0.14 to 0.34) Different point
estimates, but
overlapping CIsChronic fatigue (Friedberg,
2013151)
–0.02 (–0.48 to 0.42)
Emotional
distress
GSH Pain multiple sites (LeFort, 1998128) 0.38 (0 to 0.75) Different point
estimates, but
overlapping CIsChronic fatigue (Chalder, 1997
114) 0.28 (–0.37 to 0.60)
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Discussion of clinical effectiveness review
The review identified 59 studies that met the inclusion criteria. A broad approach to inclusion was taken,
and this is reflected in the considerable heterogeneity found. Owing to the considerable differences in
types of interventions, it was not appropriate to treat all interventions as one behavioural intervention
group and, therefore, study arms were categorised into 13 types. Even within intervention types, there
was variation in treatment duration and intensity, mode of delivery and intervention provider, and
differences in the specifics of the primary care setting – from interventions delivered by the patient’s
own GP within their own GP practice to those involving collaborative care with health-care professionals
from outside the practice or primary care patients travelling to a gym or fitness facility. Studies included
a range of populations, and this resulted in further heterogeneity, with, for example, several studies of
CBTHI but these being in different populations. Ideally, these differences would have been explored
through metaregression, but there was insufficient replication of each intervention type within the
networks to allow this. These issues have resulted in limitations when drawing conclusions regarding
clinical effectiveness. Further to this, studies did not measure the same outcomes at the same time
points (i.e. end of treatment, short- and long-term follow-up) and, therefore, different studies inform the
network at these different time points; these analyses are not repeated measures and do not account for
correlations between time points.
The evaluation of clinical effectiveness necessitated making judgements regarding intervention groups, and
inclusion judgements such as participants meeting ‘medically unexplained’ criteria (where populations did
not meet the criteria for FSSs or other pre-defined diagnostic classifications) and primary care setting
criteria. Although efforts were made to ensure that these judgements were made using objective criteria,
and with consultation between project team members when borderline decisions were required, it is
acknowledged that judgements could arguably have been made differently. A narrower scope may have
reduced this possibility but using broad inclusion criteria has allowed a broader evaluation of the topic. With
regard to setting, the review did not include studies of home-based or self-help behavioural interventions,
such as e-health, where these had insufficient or no involvement of primary care practitioners (i.e. were
conducted solely by university research teams). These interventions may well be feasible and effective in a
primary care setting and when co-ordinated by primary care teams. However, as was evidenced by the wide
variation in recruitment by GPs seen in the current review, it was considered inappropriate to include these
interventions until they have been conducted in the ‘real world’ of primary care.
TABLE 3 Comparison of treatment effects in condition groupings (continued )
Time point
Outcome
measure
Treatment
(vs. usual
care)
Condition grouping (first author
and year of publication) SMD (95% CI) Comments
Long term Anxiety OP MUS/somatoform (Kolk, 2004104) –0.34 (–0.80 to 0.13) Different point
estimates, but
overlapping CIsChronic fatigue (Wearden, 2010
111) –0.15 (–0.42 to 0.13)
CBTLI IBS (Moss-Morris, 2010130) –0.27 (–0.76 to 0.21) Different point
estimates, but
overlapping CIsChronic fatigue (Friedberg, 2013
151) 0.18 (–0.26 to 0.63)
Depression OP MUS/somatoform (Kolk, 2004104) –0.31 (–0.77 to 0.15) Different point
estimates, but
overlapping CIsChronic fatigue (Wearden, 2010
111) –0.13 (–0.41 to 0.14)
CBTLI IBS (Moss-Morris, 2010130) 0.35 (–0.14 to 0.83) Different point
estimates, but
overlapping CIsMUS/somatoform (Martin, 2007
99) –0.26 (–0.60 to 0.06)
Chronic fatigue (Friedberg, 2013151) –0.07 (–0.52 to 0.37)
GSH, guided self-help; MUVD, medically unexplained vaginal discharge; OP, other psychotherapy.
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Appendix 12, Table 97, summarises the significant results identified in the NMAs, showing the SMDs for
the significant intervention groups for each outcome and time point. Although the NMAs do not identify
individual significant trials, SMDs for all individual trials are presented by outcomes in Appendix 12,
Tables 98–107. For those intervention groups that were shown to have significant beneficial effects, a
brief description of the key characteristics of the trials in those groups is presented below by outcome.
Pain
At the end of treatment, CBTHI and multimodal interventions were shown to be significantly more
effective than usual care at reducing pain. CBTHI was the only intervention to be significantly more
effective than usual care at short-term follow-up. No interventions were more effective than usual care
at long-term follow-up.
High-intensity cognitive–behavioural therapy
There were four studies that informed the pain networks for CBTHI interventions. These were
Zonneveld et al.,141 Alda et al.,137 Luciano et al.138 and McBeth et al.125 One of these studies141 was of a
population of patients with unexplained physical symptoms, referred to the study by the GPs if their
symptoms were considered to be unexplained by a physical condition. Patients were then included if
they fulfilled the DSM-IV criteria for undifferentiated somatoform disorder or a chronic pain disorder.
The CBT intervention was based on the consequences model, tailored for MUS in primary care, and
delivered over 13 weeks by an outreaching mental health service. Patients in the control group were
put on a waiting list. At the end of treatment, small to moderate SMDs were found in favour of the
intervention for pain, physical functioning, emotional distress and somatisation.
The remaining three studies that informed this network were of populations of patients with chronic
widespread pain. McBeth et al.125 report results from the MUSICIAN trial [Managing Unexplained
Symptoms (chronic widespread pain) In primary Care: Involving traditional and Accessible New
approaches].125 Patients meeting the criteria were recruited from primary care practices in the UK
and were allocated to one of four arms: (1) telephone CBT, consisting of seven weekly sessions of
45–60 minutes plus two further follow-up sessions. Patients were given a self-management CBT
manual and offered some choice in the type of CBT they preferred, including behavioural activation,
cognitive restructuring and lifestyle changes; (2) exercise, consisting of a leisure facility- and gym-based
exercise programme, with recommended exercise duration of 20 to 60 minutes, at least twice per week;
(3) combined, consisting of both the telephone CBT and exercise interventions; and (4) treatment as
usual, consisting of usual care by their family physician. Small SMDs were found in favour of all three
active intervention groups, with the SMDs for CBTHI and combined groups marginally larger.
Luciano et al.138 studied a population of patients fulfilling the ACR 1990 criteria for fibromyalgia,
recruited by GPs from primary health-care centres in Spain. The intervention arm received group ACT,
adapted to fibromyalgia patients, consisting of sessions on mindfulness, cognitive defusion, committed
action and observation of the self. Sessions were delivered by a therapist over eight 2.5-hour sessions,
with daily homework exercises. A second intervention group received recommended pharmacological
treatment, prescribed by the GP after a 2-hour training session. A third, control, group were put on a
waiting list. At the end of treatment, large SMDs were found for patients in the CBTHI group, and
moderate effects for those in the medication group, when compared with those on the waiting list.
Alda et al.137 also included patients with fibromyalgia recruited by primary care doctors from primary
health-care centres in Spain. The intervention arm received CBT based on Thorn’s model of pain
catastrophising, adapted to people with fibromyalgia. The main components of the CBT were cognitive
restructuring and coping. Ten 90-minute group CBT sessions were delivered over 10–12 weeks by
trained therapists. A second intervention group received recommended pharmacological treatment,
administered by a psychiatrist. A third, control, group received treatment as usual. At the end of
treatment, SMDs showed no substantial effects on pain for CBT compared with usual care, although
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a small effect was found at long-term follow-up. There was a small effect for the medication group
both at the end of treatment and in the long term.
Only the McBeth et al.125 and Luciano et al.138 studies informed the network for CBTHI at short-term
follow-up, with the CBTHI group in Luciano et al.138 continuing to show a large effect size, and McBeth
et al.125 showing a small effect size for CBTHI compared with usual care. By long-term follow-up, the
NMA found no significant effects for CBTHI compared with usual care, with data from only one study
remaining to inform the network (Alda et al.137).
Multimodal interventions
Five studies informed the pain networks for multimodal (MM) interventions. These were Cuesta-Vargas
et al.,118 Schaefert et al.,132 Walti et al.,121 Luciano et al.139 and McBeth et al.125 McBeth et al.125 had
multiple arms and has been previously described under CBTHI. Cuesta-Vargas et al.118 is described
under guided self-help.
Schaefert et al.132 reports results from the speciAL trial (specific collaborative group intervention for
MUS patients in general practice). This was a cluster randomised trial including patients meeting the
criteria of > 6 months’ bodily complaints without sufficient explanatory peripheral organ pathology,
and with MUS as the main treatment issue. The multimodal group consisted of GP MUS management
training, plus a syndrome-oriented psychosomatic group intervention for MUS patients conducted by
GPs together with a psychosomatic specialist, in 10 weekly sessions of 90 minutes plus two booster
sessions. The GP training consisted of a guideline-based curriculum in the diagnosis and management
of patients with MUS. At follow-up, SMDs showed that there were no substantial differences between
the two groups for pain scores.
Walti et al.121 conducted a pilot RCT with a population of patients with non-specific lower back pain
recruited and treated in a primary care physiotherapy centre in Switzerland. Patients had moderate to
severe disability. The multimodal intervention group received patient education, sensory retraining and
motor retraining. Sessions were delivered in 16 sessions over 8–12 weeks. The control group received
usual physiotherapy care, which consisted primarily of active treatment, such as muscle-strengthening
exercises and mobilisation or stretching exercises.
Luciano et al.139 conducted a trial of 216 patients with fibromyalgia. The intervention was set in three
general practices in Spain. GPs previously referred patients suspected of fibromyalgia for diagnosis at a
rheumatology unit. A database of these patients is kept at the GP practice for monitoring. These patients
were included in the trial, which was conducted by a multidisciplinary team within the three general
practices. The multimodal intervention consisted of five 2-hour group sessions of education and four
2-hour sessions of autogenic training. The education element included information on symptoms, course
of the condition, comorbidities and causes. The programme outlined the influence of psychosocial factors
on pain, the benefits of exercise and behavioural change. The autogenic training focused on physical and
mental relaxation, pain relief and stress reduction. The group sessions encouraged emotive exchange
with other patients. The control group received usual care. The multimodal intervention group reported
a greater reduction in pain than the control group. SMDs showed this to be a moderate effect.
Guided self-help
Guided self-help was shown to be less effective than usual care at long-term follow-up. Only one study
of guided self-help informed the network. Cuesta-Vargas et al.118 studied a population of 58 primary care
patients with > 3 months of non-specific chronic lower back pain, who had been referred to the study
by their GP. The intervention arm was deep-water running three times per week for 4 months plus an
education intervention. This consisted of a 25-page educational booklet and verbal presentation on
basic anatomy and physiology of the spine, principles of ergonomics for low back pain patients, and
instructions for coping strategies. The booklet encouraged the patients to treat themselves instead of
undergoing passive treatments. This was presented alongside usual care from their GP. Patients in the
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
control arm received the education booklet and presentation alongside usual care from their GP. Both
groups showed improvement over time, but the deep-water running/education group showed more
improvement with large SMDs for pain, physical functioning, impact and emotional distress at all time
points. The effect sizes for this study were particularly large, and inconsistency checking of the NMA
showed that the direct evidence of this effect was not consistent with the indirect evidence.
Fatigue
At the end of treatment, RSSE, CBTLI, multimodal interventions and GA were shown to be significantly
more effective than usual care at reducing fatigue. RSSE and CBTLI were significantly more effective
than usual care at short-term follow-up. CBTLI was the only intervention more effective than usual
care at long-term follow-up.
Relaxation/stretching/social support/emotional support interventions
Two RSSE interventions informed the fatigue network at the end of treatment. The first of these was
Ho et al.,150 a Hong Kong study of people with CFS who were recruited from the community. Participants
were recruited following screening via a web-based questionnaire and were required to meet the US
CDC criteria for CFS; however, diagnosis was not confirmed by medical examination. The intervention
group received 2-hour group qigong training for 5 weeks. The group sessions included basic theories
of Chinese medicine and physiology of mind–body connections, mindful meditation for relaxation and
gentle movement or body stretching in standing postures. A final session in qigong exercise training was
delivered by a Daoist qigong master. Participants were also expected to continue to practise qigong
exercise at home for the remaining 12 weeks of the study period. Participants in the control group
received qigong training at the end of the study. SMDs showed a large beneficial effect on reduction
in self-perceived fatigue at the end of the 5-week group training for the qigong group. At the 4-month
follow-up, this beneficial effect remained, although it should be noted that it was expected that
participants continued to practise qigong at home during this follow-up period.
A further RSSE intervention arm informed the network at short- and long-term follow-up (Friedberg
et al.151), which also included a CBTLI arm and is described below.
Low-intensity cognitive–behavioural therapy interventions
Two CBTLI interventions informed the fatigue network at the end of treatment,113,149 with a further
study informing the network at short- and long-term follow-up.151
Ridsdale et al.113 studied a UK population of 123 patients presenting to their GPs with unexplained
fatigue of > 3 months. The study compared two active interventions: CBT and graded exercise. Both
treatments were delivered on the GP premises by CBT therapists and physiotherapists, in six 45-minute
sessions over 12 weeks. The CBT treatment was manualised, based on a model of precipitating and
perpetuating factors. It involved activity planning, establishing a sleep routine and other cognitive
interventions, and addressed negative beliefs, self-expectations and self-esteem. The GA intervention
(i.e. GET) was based on each individual patient’s physical capacity, and aimed to achieve a gradual
but progressive increase in aerobic activity. A third, non-randomised cohort of patients received an
educational booklet. Both groups saw a significant reduction in fatigue from baseline. SMDs showed a
small beneficial effect for the CBT group compared with the GET group at the end of treatment, but
showed no substantial difference between groups at follow-up. A total of 3% of patients in the CBT
group showed an increase in fatigue after treatment, compared with 12% of patients in the GET group.
Tummers et al.149 studied a population of 123 patients in Holland diagnosed with CFS (US CDC criteria)
by either their GP or a consultant. The active intervention was a minimal intervention based on CBT,
previously shown by the authors to be effective in a tertiary treatment setting. The intervention was
applied in a community-based mental health centre, with no previous experience of treating patients
with CFS. Psychiatric nurses were trained to deliver the intervention, which was based on a protocol
for CBT for CFS, and was in the form of a guided self-instruction booklet delivered over 20 weeks.
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The programme focused on precipitating and perpetuating factors, challenging fatigue-related cognitions,
reducing the focus of fatigue, establishing a sleep routine, assessing activity patterns and gradually
increasing physical activity. The control group was put on a waiting list. A total of 12 out of the 123
randomised patients were found to have a misdiagnosis of CFS during the course of the trial but were
not excluded from the analyses. Patients in the intervention group showed a significantly greater
reduction in fatigue severity than those in the waiting list group at the end of treatment. SMDs showed
this effect to be moderate.
Friedberg et al.151 studied a population of 111 primary care patients with chronic fatigue, recruited
from a family medicine/primary care practice in the USA. A total of 39% of the included sample
met the US CDC criteria for CFS, and the remaining 61% did not meet the full criteria but had
at least 6 months’ persistent fatigue not clearly attributable to identifiable medical conditions, with
associated impairment in functioning. The study had three arms. The CBTLI intervention was ‘fatigue
self-management’. This consisted of two nurse-led sessions based on a CBT treatment programme for
CFS, with a self-help booklet for a period of home-based self-management. The nurse-led sessions
covered diagnosis and possible causes, stress and sleep disturbance, balance between mental and
physical exertion, unhelpful behaviours or illness beliefs, and development of more useful cognitive
and behavioural strategies. The second arm was an attention control RSSE intervention. It included
emotional support and self-monitoring of symptoms, affect and stress. The intervention also consisted
of two sessions and a period of home-based activities. The third arm was usual medical care/no
treatment. The results showed significantly greater reduction in fatigue in the CBTLI group than in
both the RSSE attention control group and the usual-care group. SMDs showed moderate effects
for the CBTLI group compared with usual care, and showed no substantial effects for the RSSE
intervention compared with usual care.
Multimodal interventions
Two multimodal interventions informed the fatigue network, McBeth et al.125 and Luciano et al.139
For both of these studies, the populations were patients with chronic widespread pain/fibromyalgia.
The studies are outlined above under Pain. For fatigue, SMDs showed a small effect for the intervention
on reduction in fatigue at the end of treatment in Luciano et al.139 compared with usual care, and a large
effect at the end of treatment in McBeth et al.,125 reducing to a small effect at long-term follow-up
compared with usual care.
Graded activity
Four studies with GA arms informed the fatigue network: Ridsdale et al.113 (described in Low-intensity
cognitive–behavioural therapy interventions), Marques et al.,133 Wearden et al.111 and Ridsdale et al.115
Marques et al.133 included a study population of 99 patients meeting the CDC criteria for idiopathic
chronic fatigue, recruited to the study by their medical doctor. The trial took place in four public primary
care centres and one private practice, and in a patient association. The active intervention arm was the
4-STEPS programme, which was delivered by a health psychologist over a 12-week intervention period.
The intervention was based on the use of self-regulation theory to promote physical activity. Features of
the intervention were the use of motivational interviewing to increase motivation and confidence, and
the formation of action plans with specific personal physical activity goals. The control condition (guided
self-help) comprised an educational booklet containing information about the benefits of physical
activity and physical activity guidelines for adults, and participants in this group were set a personal
activity goal. At the end of the intervention, a significant beneficial effect for the GA intervention was
found compared with the control of guided self-help. SMDs showed this to be a moderate effect.
Ridsdale et al.115 included a study population of 222 primary care patients consulting with their GPs
for fatigue of > 3 months’ duration as the main problem, but with no known physical condition that
could explain the fatigue. The study had three arms. The graded exercise intervention was delivered by
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physiotherapists over eight 30-minute sessions at 2-weekly intervals in the patient’s own primary care
practice. Patients were guided through supervised exercise (walking), tailored to their individual current
physical capacity, and gradually building in intensity. A second arm was a psychotherapy intervention.
This consisted of Rogerian client-centred non-directive counselling. The counselling was delivered by
trained therapists in eight 50-minute sessions at 2-weekly intervals. The third arm was usual care with
the addition of a booklet of self-help techniques based on CBT principles, and including information on
the causes of fatigue (guided self-help). No significant differences in reduction in fatigue were found
between the three intervention groups at either the 6- or the 12-month follow-up. SMDs showed no
substantial effect for either guided self-help or GA when compared with other psychotherapy at either
time point. The authors reported a high level of dissatisfaction with care, but less dissatisfaction in the
GA group.
Wearden et al.111 included a study population of 296 patients who met the Oxford criteria for CFS/
myalgic encephalomyelitis, and who scored < 70% on the SF-36 physical functioning scale, and > 4 on
the Chalder Fatigue Scale. Patients meeting these criteria were referred by their GP. The study had
three intervention arms. The GA intervention (‘pragmatic rehabilitation’) consisted of a programme of
graded return to activity, and a focus on regularising sleep patterns, addressing somatic symptoms of
anxiety and addressing concentration and memory problems. The counselling intervention (‘other
psychotherapy’) was a non-directive listening therapy, allowing the patient to discuss their concerns
and problems. Both the GA and the counselling interventions were delivered over a 10-week period by
general nurses with experience of working in primary care, but not of CFS/myalgic encephalomyelitis,
in the patients’ own homes, with additional telephone sessions. Home visits were of 1 hour’s duration,
and telephone sessions were of 30 minutes’ duration. The third arm was GP usual care. At the end of
treatment, patients in the GA group had significantly reduced fatigue compared with patients in the
usual-care group. This effect was no longer significant at long-term follow-up; however, at 70 weeks,
GA was significantly better than usual care when the Chalder Scale was used with Likert scoring. There
was no significant beneficial effect on fatigue of other psychotherapy compared with usual care at
the end of treatment or follow-up. SMDs show small effects at the end of treatment and long-term
follow-up for GA compared with usual care, but show no substantial effects for other psychotherapy
compared with usual care at either time point.
Bowel symptoms
There were insufficient studies to form networks for bowel symptoms for end of treatment and
short-term follow-up. Only two studies informed the network for long-term follow-up. Of these,
only CBTLI was shown to have a significantly beneficial effect compared with usual care.
Low-intensity cognitive–behavioural therapy intervention
Moss-Morris et al.130 reported results from a pilot study of a population of 64 patients meeting the
Rome II criteria for IBS. Patients were recruited either from a database of known patients with IBS
who had taken part in a previous primary care study or from patients presenting to the study GP with
IBS symptoms. The study GP screened interested participants for eligibility. The intervention arm was
a 7-week home-based manualised self-management programme. The programme included one 1-hour
face-to-face session and two 1-hour telephone sessions with a health psychologist. The programme
focused on assessment of symptoms and self-monitoring behaviours, behavioural management of
symptoms and goal-setting, managing unhelpful thoughts, personal expectations and activity patterns,
and relaxation and stress management. The control arm received treatment as usual, which included a
sheet explaining that a range of tests had been conducted and had ruled out structural causes for their
IBS. Results showed a significant reduction in bowel symptoms severity at the end of treatment and at
long-term follow-up. SMDs showed this to be a moderate to large effect.
Somatisation
Data from 11 studies were available to inform the network for somatisation. Despite this, no interventions
were found to have any significant beneficial effects on somatisation compared with usual care. Trials of a
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range of intervention types were identified. SMDs for individual trials show that, although a small number
of trials found small beneficial effects at the end of treatment, these effects are mostly lost by long-term
follow-up. One trial of CBTHI144,148 produced moderate beneficial effects both at end of treatment and at
long-term follow-up. This was a study of patients meeting the criteria for Escobar’s Abridged Somatisation
Disorder, recruited by GPs from 21 primary care centres in Spain. The CBT intervention was based on a
protocol by Escobar et al.,156 delivered over 10 weekly sessions. The programme included muscle relaxation,
emotional mindfulness, cognitive restructuring and social skills.
Generic physical symptoms
Data from two studies were available to inform the network for generic physical symptoms at the end
of treatment; however, no interventions showed significant beneficial effects. There were insufficient
data to form networks for short- or long-term follow-ups.
Physical functioning
At the end of treatment and short-term follow-up, multimodal interventions were the only interventions
that showed significant beneficial effects. No interventions showed significant beneficial effects at
long-term follow-up. Studies that contributed data to the network for multimodal studies have been
described previously.107,118,125,132,139,142 SMDs for these studies showed that, in Cuesta Vargas et al.,118
large effects were found for multimodal compared with guided self-help at the end of both short-
and long-term treatment; in Schaefert et al.,132 a small effect was found at short-term follow-up for
multimodal compared with GP MUS management, but no substantial effect was found at long-term
follow-up; in Luciano et al.,139 a small effect was found for multimodal compared with usual care at the
end of treatment; and in McBeth et al.,125 a small effect was found in favour of multimodal compared
with usual care at the end of treatment and at short-term follow-up.
Smith et al.107 report results from a study of 206 high-utilising MUS patients recruited from a health
maintenance organisation in the USA. MUS patients were identified through patient records, with
eligibility assessed in patients who had more than eight visits per year. MUS was identified if symptoms
of > 6 months’ duration were present that had no documented disease. Nurse practitioners with no
prior experience in mental health received a 10-week training programme to deliver the intervention.
The intervention consisted of patient-centred management to improve communication and establish
positive patient–provider relationships, antidepressants, exercise, relaxation training, physical therapy
and comorbid organic disease management. It was delivered in 12 20-minute visits with patients over
a 1-year period. The control group received usual care. Patients in the intervention group were more
likely to improve than those in the control group.
Smith et al.142 report results from a pilot study of 30 high-utilising patients with MUS. Patients were
identified from the Henry Ford Health System using ICD-9 codes to identify MUS. The intervention group
received a multimodal intervention delivered by primary care physicians (PCPs) who had received training
for the study. The intervention was similar to that of Smith et al.,107 with the exception that the prior study
used nurse practitioners to deliver the intervention. It consisted of antidepressant medication (where
PHQ-9 identified depression), structured CBT and patient-centred management aimed at maximising
communication and the patient–provider relationship. The intervention was delivered over 1 year, with
seven visits with the PCP, and three visits with a case manager. The intervention produced a significant
beneficial effect on somatisation compared with the control group, which was usual care. SMDs show a
moderate effect for the multimodal intervention compared with usual care at long-term follow-up.
Impact
At the end of treatment and at short-term follow-up, only the CBTHI interventions were shown to
have a significant beneficial effect on impact of the illness on daily life. Two studies of CBTHI informed
the network at the end of treatment.137,138 Only data from Luciano et al.138 informed the network at
short-term follow-up. Both of these studies have been previously described.
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Anxiety
At the end of treatment and at short-term follow-up, only the CBTHI interventions were shown to have
a significant beneficial effect on anxiety compared with usual care. Four studies of CBTHI informed the
network at the end of treatment. These were Escobar et al.,156 Gili/Moreno,144,148 Alda et al.137 and Luciano
et al.138 At short-term follow-up, only data from Luciano et al.138 informed the network. Gili/Moreno,144,148
Alda et al.,137 and Luciano et al.138 have been previously described. No interventions showed significant
beneficial effects on anxiety at long-term follow-up.
Escobar et al.156 studied a population of patients meeting the criteria for Escobar’s abridged somatisation,
recruited from primary care clinics in the USA. PCPs and nurses referred consecutive adult patients
who had repeatedly sought care for MUS and for whom the symptoms were a source of distress.
The intervention group received a CBT-type intervention delivered by therapists trained for the study.
The intervention was delivered in 10 sessions of 45–60 minutes over 10–20 weeks. The control group
received usual clinical care from their PCP, which included a consultation letter. SMDs showed a small
beneficial effect on anxiety for the intervention group versus the control at the end of treatment.
In Gili/Moreno,144,148 a moderate beneficial effect was found for the CBTHI group compared with usual
care. For Alda et al.,137 no substantial effect was found compared with usual care. In Luciano et al.,138
a large beneficial effect was found for the CBTHI group compared with usual care.
Depression
At the end of treatment and at short-term follow-up, only the CBTHI interventions were shown to have
significant beneficial effects. Four studies on CBTHI informed the network at the end of treatment.
These were the same studies as for anxiety, and all have been described previously.137,138,144,148,156 No
interventions had significant beneficial effects at long-term follow-up. SMDs showed small beneficial
effects in Escobar 2007156 and Gili/Moreno.144,148 No substantial effects on depression were found in
Alda et al.,137 but a large beneficial effect on depression was found in Luciano et al.138 Only Luciano et al.138
showed a beneficial effect at short-term follow-up.
DOI: 10.3310/hta24460 Health Technology Assessment 2020 Vol. 24 No. 46
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Leaviss et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
73
Chapter 4 The acceptability of primary care
or community-based behaviour modification
interventions for medically unexplained
symptoms: qualitative systematic review
This chapter aims to provide an overview of the evidence for patients’ and HPs’ perspectives on theacceptability, relative benefits and potential harms of primary care or community-based behaviour
modification interventions for MUS.
Review methods
Screening and eligibility
A two-stage sifting process for inclusion of studies (title/abstract then full-paper sift) was undertaken.
Titles and abstracts were scrutinised by one systematic reviewer (AS) according to the inclusion and
exclusion criteria. There was no exclusion on the basis of quality. All studies identified for inclusion
using the abstract, together with any in which a decision on inclusion was not possible from these brief
details, was obtained for more detailed appraisal. Agreement on inclusion at title/abstract sift was
checked by a second systematic reviewer (AB) for 20% of the total electronic search results; therefore,
345 records were sifted by both AS and AB. Agreement was calculated using the kappa statistic. Based
on these data, the kappa statistic was 0.765. As the kappa statistic was above acceptable levels (i.e.
0.7), double-sifting was not deemed necessary. Where the reviewers disagreed on inclusion/exclusion
at title/abstract sift, these records were retrieved to check at full text. In the event of disagreement
regarding the inclusion of a study, the opinion of the MUS experts in the project team was sought.
The inclusion and exclusion criteria for the qualitative review are reported in Table 4. The inclusion and
exclusion criteria for the project as a whole are presented in detail in Chapter 3. Any inclusion and
exclusion criteria that are specific to the qualitative review are documented in more detail here.
TABLE 4 Inclusion and exclusion criteria for the qualitative review
Inclusion
criteria Included Excluded
P – population Patients meeting the criteria for MUS, MUPS
and somatoform disorders. Populations with
FSSs were included (e.g. IBS, CFS, fibromyalgia).
Health-care providers who had delivered
behavioural modification interventions designed
for these patients were also included
Subacute patients. Patients with intermittent pain
(where current episode was < 3 months – or this
information was not available from the paper/or
they cannot be disentangled from the rest of the
sample)
I – intervention Behavioural modification interventions Studies of management of MUS where evidence
relating to a treatment of interest was not
separately identifiable
C – comparator N/A N/A
O – outcomes Qualitative data N/A
S – study design Qualitative research, mixed-methods research,
qualitative data embedded in trial reports or
process evaluations
Quantitative reports without qualitative evidence
N/A, not applicable.
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Evidence from health-care providers who delivered the behavioural interventions for included patients
was sought, in addition to patients’ views. Studies were included only if they contained data related
specifically to an intervention that met the review’s inclusion criteria, as the review was specifically
aimed at evaluating perceptions of behavioural interventions delivered in a primary care setting.
Studies containing qualitative data relating to general management of MUS and not to a specific
included intervention were therefore excluded (e.g. Ax et al.,164 Bayliss et al.,165 Wallace et al.,166
Deale and Wessely,167 Raine et al.168).
Study types: (1) studies reporting qualitative research or qualitative data elicited via a survey or a
mixed-methods study to include qualitative data on the perspectives and attitudes of patients who
had received behaviour modification interventions in a primary care or community-based setting;
(2) qualitative data, embedded in trial reports or in accompanying process evaluations, which can inform
an understanding of how issues of acceptability are likely to affect the clinical effectiveness of eligible
interventions; (3) qualitative data, either from separately conceived research or embedded within
quantitative study reports, reporting the acceptability of interventions to health-care practitioners.
Quality assessment strategy
Assessment of confidence in the review findings:
The Confidence in the Evidence from Reviews of Qualitative (CERQual)169 research approach was used to
summarise our confidence in the findings across the studies included in the review. CERQual is currently
under development and draws on the principles used to develop the GRADE approach. An earlier version
of this approach has been used in two Cochrane reviews169,170 and three non-Cochrane reviews.171–173
CERQual assesses confidence in the evidence based on four key components:
1. The methodological limitations of included studies. Methodological quality of individual studies was
appraised using an abbreviated version of the Critical Appraisal Skills Programme (CASP) quality
assessment tool for qualitative studies.174 Two reviewers (AS and AB) independently applied the set
of quality criteria to each included study. In the event of a disagreement, a third reviewer (JL) was
consulted. Studies were included in the review regardless of study quality.
2. The relevance of the included studies to the review question, which is the extent to which the review
finding is applicable to the context (perspective or population, setting) specified in the review question.
3. The coherence of the review finding, which is the extent to which the pattern across the data that
constitutes a review finding, is based on evidence that is consistent across multiple individual
studies and/or incorporates convincing explanations for the patterns of evidence in the underlying
studies, including explanations for variations across individual studies. The coherence of each review
finding was assessed by looking at the extent to which a clear pattern across the data was identified
and was contributed to by each individual study, and whether or not this was consistent across
multiple contexts.
4. The adequacy of the data contributing to a review finding that refers to an overall determination of
the degree of richness and quantity of data supporting a review finding.
Confidence in a finding will be weakened when:
l the included studies have important methodological limitations
l the contexts of the primary studies underlying a review finding are substantively different from the
context of the review question (relevance)
l variation is found across data from individual studies and there is no convincing explanation for this
variation (coherence)
l a review finding is supported by data from only one or few primary studies, settings or relevant
groups, or the data supporting a finding are very thin (adequacy).
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After assessing each of the four components, a judgement was made about the overall confidence in
each review finding. Confidence was judged as high, moderate, low or very low. The starting point of
‘high confidence’ reflects a view that each review finding should be seen as a reasonable representation
of the phenomenon of interest unless there are factors that would weaken this assumption.
Data extraction strategy
Data extraction from included qualitative studies was undertaken by one reviewer (AS) using a data
extraction tool adapted and tailored for the purpose of this qualitative review. All data extractions
were checked by a second reviewer (AB), with any discrepancies being discussed by both reviewers.
Where data for included studies were missing, reviewers attempted to contact the authors at their last
known e-mail addresses. For the purpose of data extraction, two principal approaches to decide what
counts as qualitative evidence have been proposed.175 In the first, only data from primary studies that
are illustrated by a direct quotation from the respondent are extracted, whereas, in the second, all
qualitative data identified in the primary studies and relevant to the review question are extracted.
Given the anticipated paucity of relevant evidence (i.e. evidence relating specifically to behavioural
modification interventions in primary care rather than perceptions and attitudes towards general
management of MUS), the latter, more inclusive, approach to data type was adopted, together with
a selective approach to extract data relevant to the specific research question. A framework for
extraction was developed which focused specifically on data relating to the review question. This
framework allowed the data to be extracted into broad themes relating to the research question,
as illustrated in Table 5. Within these broad themes, more specific subthemes were then generated
by coding the data. Although in a number of papers the authors had coded the data and had arranged
it in themes, these themes were not always used in this review; in some cases, these themes were
adapted and in other cases data were subsumed into other, different, themes.
Data synthesis strategy
Qualitative evidence synthesis was undertaken to provide added value to the quantitative analysis by
indicating patient and service provider issues around the acceptability of interventions. Specifically,
thematic synthesis was used to aggregate the findings.176 The framework developed for data
extraction was used to shape the synthesis of the findings. Themes were then developed within the
framework elements.
TABLE 5 Framework for data extraction
Source of data Theme
Data from patients Positive factors relating to behavioural modification interventions as reported by patients/what
did you gain from being referred to a behavioural modification intervention?
Factors reported as important, wanted or expected in behavioural modification interventions
What patients did not like about (being referred to) behavioural interventions
Barriers – why patients did not want behavioural interventions/or could not engage with them
Neutral effects (neither benefits or harms)
Data from HPs Positive factors relating to behavioural modification interventions as reported by HPs/what did
you gain from being trained to deliver and/or delivering a behavioural modification intervention?
Factors reported as important, wanted or expected for training in and delivery of behavioural
modification interventions
What did not help or was detrimental to the patients or delivery of the intervention
Barriers – from the perspective of HPs as to why patients did not want behavioural
interventions/or could not engage with them, or barriers to delivery of the intervention
Neutral effects (neither benefits or harms)
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Combining the quantitative and qualitative data
Methodological work to date has been unable to establish the superiority of conducting the qualitative
and quantitative synthesis in parallel or of conducting quantitative followed by qualitative, qualitative
followed by quantitative or some more iterative approach. Our choice of method of combining data
was determined by the needs of this particular review, in which the quantitative data were the
main focus and the qualitative data were used for their explanatory potential. We, therefore, employ
methods similar to those described by Noyes et al.177 to explore the effectiveness review in the light of
supporting qualitative research data.
Results of the qualitative review
Included studies: qualitative review
From the 1735 citations identified from the initial searches, 42 remained after title and abstract sift
and these citations were considered at full-paper sift for the qualitative review. Figure 57 shows the
flow chart of studies included in the qualitative review. The sifting process resulted in the inclusion of
10 studies at full paper. These 10 papers reported evidence from eight studies. Two papers reported
evidence from the same study but from some of the same participants; of these one reported evidence
from both the patients and HPs178 and the other reported evidence only from patients.179 A further two
papers reported on the same study, with one paper reporting evidence from patients180 and the other
reporting evidence from HPs.181 Details of studies excluded at full-paper sift together with reasons are
shown in Appendix 5. All included full papers were published between 2007 and 2016. A summary of
the included studies and their sample and study characteristics can be found in Table 6.
• Does not include qualitative
   data, n = 13
• Population did not fit the
   inclusion criteria, n = 11
• Does not include data about
   a specific intervention, n = 4
• Non-UK study, n = 2
• Opinion piece, n = 1
Records identified through
database searching
(n = 1730 and 293 duplicates)
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Additional records identified
through other sources
Citation searching
(n = 5)
Records after duplicates removed
(n = 1735)
Records screened by
title and abstract
(n = 1735)
Records excluded at title
and abstract sift
(n = 1693)
Full-text articles
assessed for eligibility
(n = 42 citations;
41 studies)
Full-text articles excluded,
with reasons
(n = 32 citations; 31 studies)
Studies included in
qualitative synthesis
(n = 10)
FIGURE 57 The PRISMA flow diagram for the MUS qualitative review.
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Study respondents
Eight studies assessed patients’ attitudes and three studies assessed HPs’ attitudes to the intervention
(of these, two studies178,181 reported data from both patients and the HPs who had been involved in
delivering the intervention). Altogether, the studies contained qualitative data from 130 patients and
from 38 HPs. In terms of HPs, the data were specifically from 24 GPs, eight CBT therapists, three nurse
therapists and three nurse therapist supervisors. A summary of HPs’ characteristics is shown in Table 7.
Respondent characteristics
Six studies focused on interventions for MUS/MUPS, one focused on interventions for CFS/myalgic
encephalomyelitis and one focused on interventions for somatisation. The majority of patient participants
met the criteria for MUS or MUPS (n = 78) as reported in the studies, with 46 patients diagnosed with
CFS/myalgic encephalomyelitis and six who met the criteria for somatisation as reported in the studies.
Reporting of patient characteristics was limited and incomplete in a number of studies. Details, where
reported, are shown in Table 8. The general trend was that more women than men contributed data for
the studies, and age varied widely, ranging from 19 to 84 years.
For HP details, reporting of participant characteristics was also limited across the included primary
studies. Again, more of the HPs who contributed data were women and the age of the participants
ranged from 30 to 60 years, where reported.
TABLE 6 Summary of the included studies and their sample and study characteristics
First author and year
of publication
Sample
(contributing
qualitative data)
Population
being treated
as described
in the study Data collection Intervention
Burton, 2012157 11 patients MUS Interview GP with special interest
‘symptoms’ clinic
Chew-Graham, 2011179
Peters, 2011178
3 nurse therapists,
3 supervisors,
46 patients
CFS/myalgic
encephalomyelitis
Semistructured interviews Pragmatic rehabilitation
and supportive listening
Dowrick, 2008181
Peters, 2009180 (report
different data from
the study above)
24 GPs
23 patients
MUS Semistructured interviews Reattribution (by trained
GPs)
Gerskowitch, 2015182 11 patients MUPS Semistructured interviews CBT and mindfulness-
based stress reduction
Graham, 2007183 6 patients Somatisation Self-reports – a series of
open questions put to
each patient in writing
Group counselling
(humanistic)
Lewis, 2013184 8 CBT therapists MUS Semistructured interviews Individual CBT
Morton, 2016185 17 patients MUS Semistructured interviews GP with special interest
‘symptoms’ clinic
Payne, 2015186 16 patients MUS Case studies; qualitative
data from a survey
The BodyMind Approach™
(Pathways2Wellbeing,
University of Hertfordshire,
Hatfield, UK) group
intervention
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Study setting
All interventions took place in primary care or in the community. One study reported on interventions
that were delivered in patients’ homes,178,179 one in a primary care mental health trust,184 one in a primary
care psychological therapies service,182 four in GP practices157,180,183,185,187 and one in a community setting.186
Intervention description and facilitators
Three of the interventions described here were GP delivered; these included reattribution180,187 and
special interest ‘symptoms’ clinic.157,185 These interventions were delivered individually to patients
and involved a series of structured consultations. Nurse-delivered interventions were reported in
one study; these interventions were pragmatic rehabilitation, a therapist-facilitated self-management
intervention178,179 and supportive listening,178 which were delivered individually to patients in their
own home. Trained CBT therapists delivered one of the interventions investigated in two studies.182,184
In one of these studies, the intervention that was delivered by a trained CBT therapist was described
as high intensity182 and simply described as CBT in the other study.184 A psychological well-being
practitioner delivered a CBTLI intervention and a trained mindfulness-based stress reduction (MBSR)
facilitator delivered a MBSR intervention in one of these studies.182 All CBT interventions were
delivered to patients individually, whereas the MBSR intervention was delivered in a group setting.
The final two interventions included were also delivered in a group setting.183,186 Group counselling
TABLE 7 Summary of HP characteristics
First author
and year of
publication Sample
Population being
treated as described
in the study Sex Age (years)
Peters, 2011178 3 nurse therapists,
3 supervisors
CFS/myalgic
encephalomyelitis
Nurses = 3 women;
NR for supervisors
NR for nurses and
supervisors
Dowrick, 2008181 24 GPs MUS 16 female; 8 male Three aged < 35;
14 between 35 and
50 and 7 > 50
Lewis, 2013184 8 CBT therapists MUS Five female; three male Mean 43.5 (SD = 9.04)
(range 30–60)
NR, not reported.
TABLE 8 Summary of patient characteristics
First author and year
of publication
Sample (contributing
qualitative evidence)
Population being
treated as described
in the study Sex Age (years)
Burton, 2012157 11 patients MUS NR NR
Chew-Graham, 2011179
Peters, 2011178
46 patients CFS/myalgic
encephalomyelitis
33 female; 13 male Patients =mean 46.11
(range 20–73)
Gerskowitch, 2015182 11 patients MUPS 8 female; 3 male Median age 50
(range 19–60)
Graham, 2007183 6 patients Somatisation NR NR
Morton, 2016185 17 patients MUS NR NR
Payne, 2015186 16 patients MUS 10 female; 6 male Range 19–80
Peters, 2009180 23 patients MUS 20 female; 3 male Mean = 53
(range 32–84)
NR, not reported.
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(humanistic) was delivered by a facilitator described as a ‘group counsellor’ in one study,183 and the
BodyMind Approach intervention was delivered by clinical psychologists together with facilitators who
were psychotherapists or art therapists in the final study.186
The reattribution intervention delivered by GPs180,187 was linked to the MUST trial,108 and the pragmatic
rehabilitation and supportive listening interventions delivered by nurse therapists reported by Peters
et al.178 and Chew-Graham et al.179 were linked to the Fatigue Intervention by Nurses Evaluation (FINE)
trial.111 Both of these trials are included in the quantitative review. A description of the interventions
delivered in the included studies can be found in Table 9.
Quality of the included studies
The inclusion criteria for study design for the qualitative review were broad, in that any study presenting
qualitative evidence was eligible. Therefore, it was evident at the outset that the majority of the included
studies would not meet the quality criteria for qualitative research. Nevertheless, these data are important
to assess the perceptions of patients and HPs who are receiving or delivering behavioural modification
interventions for MUS. To this end, it is acknowledged that a number of the included studies did not have
qualitative research aims as their primary aims. Furthermore, owing to journal word count limits, it may
not have been possible to provide the level of detail relating to qualitative methods and analysis in the
published papers that would be expected for qualitative research. Therefore, we have used an adaptation
of the CASP assessment of study quality for qualitative studies to assess the included studies. This sought
to provide some leeway in terms of reporting of the findings in order to account for studies with primary
research designs that were not qualitative in nature. Studies were assessed in terms of the extent to
which they met each of the seven CASP requirements. If the study met all seven requirements it was
assessed as high quality, if it met six of the criteria it was assessed as moderate quality, and it was
assessed as low quality if it met only five or fewer criteria. Results are presented in Table 10.
Certainty of the review findings: CERQual assessment
The CERQual assessment relied on the assessment of the methodological quality of each study
contributing to the review finding, as assessed by CASP. The relevance of the individual studies
contributing to the review finding was assessed by considering both the format of the intervention
(whether it was individual or group based) and the facilitator who delivered the intervention (whether
a GP, nurse therapist or psychological therapist). As the review inclusion criteria specified that the
setting was primary care or community based, this criterion was not considered in the CERQual
analysis of relevance. The coherence of each review finding was assessed by considering if all the data
contributing to that finding supported the finding and whether or not there were any ambiguities or
any plausible alternative explanations. Finally, the adequacy of the data was assessed by considering
the richness and number of data supporting each review finding. The synthesis of evidence from
patients yielded 22 findings overall. Only one finding was assessed as high confidence, six findings
were assessed as moderate confidence, 13 were assessed as low confidence and two were assessed as
very low confidence. The evidence from HPs yielded 16 findings overall. Four findings were assessed as
high confidence, eight as moderate confidence and four as low confidence. The results of the CERQual
assessment are set out alongside each review finding in Tables 11 and 12.
Synthesis of patient and health professional evidence
Findings were synthesised across all intervention types and organised in accordance with the questions
outlined in the data extraction framework items as detailed in the methods section. The findings of
the synthesis have been summarised and are presented in Figure 58 to demonstrate the expectations,
perceived barriers and facilitators, and potential outcomes of the interventions. Thus, the figure
represents the experience of having received the interventions rather than the anticipation of them.
Within these, a number of important themes emerged. Each metatheme, together with subthemes
where applicable, with examples and an estimate of the strength of the evidence, is presented
in Tables 11 and 12. The themes are synthesised further within the following narrative synthesis.
As illustrated in Table 11, the synthesis of evidence from patients yielded 22 findings overall.
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TABLE 9 Description of the interventions delivered in the included studies
First author and year
of publication
Population
being treated
as described
in the study Intervention Intervention provider Intervention setting Intervention duration
Individual
or group
Burton, 2012157 MUS GP with special interest ‘symptoms’
clinic. The consultations were structured
to first hear the patient’s experience of
illness then to propose and negotiate
constructive explanations of physical
symptoms. These explanations were
used as the basis for simple cognitive
and behavioural actions to modify
symptoms and their impact
GP GP practice Four appointments; the first
was of 1-hour duration and
the subsequent three lasted
20 minutes
Individual
Chew-Graham, 2011179
Peters, 2011178
CFS/ME 1. Pragmatic rehabilitation – a therapist
facilitated self-management
intervention, which shares features in
common with CBT and GET, but
which does not require a specialist
CBT or physiotherapist to deliver it
2. Supportive listening
Primary care nurses trained
to deliver the interventions
Patients’ homes 90-minute session followed by
1-hour sessions on weeks 2,
4, 10 and 18. 30-minute
telephone calls on weeks 3, 6,
8, 12 and 15
Individual
Dowrick, 2008181
Peters, 2009180
MUS Reattribution – a structured
intervention, designed to provide a
simple explanation of the mechanism of
a patient’s MUS, through negotiation
and other features of patient-centred
communication, and to be delivered
during routine consultations
GP GP practice The time since the index
consultation ranged from
8 to 55 weeks (mean 32 weeks)
Individual
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First author and year
of publication
Population
being treated
as described
in the study Intervention Intervention provider Intervention setting Intervention duration
Individual
or group
Gerskowitch, 2015182
Gerskowitch, 2015182
MUPS CBT high intensity HI-CBT therapist Primary care
psychological
therapies service
Weekly 1-hour appointments.
The median number of sessions
attended was 17 (range 4–25)
Individual
CBT low intensity Psychological well-being
practitioner
Fortnightly with homework set
between meetings
Individual
MBSR Trained MBSR facilitator An 8-week programme for
2 hours per week
Group
Graham, 2007183 Somatisation Group counselling (humanistic) Group counsellor GP practice 1.5-hour weekly sessions for
half a year
Group
Lewis, 2013184 MUS CBT CBT therapists with a
postgraduate diploma in
CBT
Primary care mental
health-care trust
Not specified Individual
Morton, 2016185 MUS SCI – a structured series of
consultations. The SCI comprises four
key elements: recognition, explanation,
action and learning
GP GP practice 3 or 4 consultations over a
period of 6–8 weeks. The
first lasts 50 minutes and
subsequent consultations are
shorter (15–20 minutes)
Individual
Payne, 2015186 MUS The BodyMind Approach, based on a
biopsychosocial model derived from
dance movement psychotherapy
Clinical psychologist/
facilitators (psychotherapists
or art therapists)
Community setting 2 hours for 12 sessions
over 8 weeks and other
communication over a
12-month period. Total face-to-
face contact is 27 hours
Group
SCI, Symptoms Clinic Intervention.
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Only one finding, ‘support’, was assessed as high confidence and was derived from six studies, in which
the quality was judged to be moderate, and the finding was seen across most of the studies in the
synthesis and across different intervention formats and facilitators. Six findings were assessed as
moderate confidence, with these each including evidence from more than one study, with some thick
data. In addition, the overall quality was at least moderate, with coherence across different studies.
Thirteen findings were assessed as low confidence and two as very low confidence, with evidence
coming from only one study for each finding and, therefore, this paucity of evidence should be taken
into account when interpreting the synthesis findings. The evidence from HPs yielded 16 findings overall.
Four findings were assessed as high confidence, with evidence emerging from two or more studies,
including some thick data. They were of moderate quality, and had coherence across studies. Eight were
assessed as moderate confidence, with evidence coming from at least two studies (of moderate quality),
including thick data and with coherence across studies. Finally, four studies were assessed as low
confidence, with evidence only coming from one study for each finding and, again, the paucity of the
evidence for these findings should be taken into account during interpretation.
Factors identified as important in primary care-delivered behavioural modification
interventions for medically unexplained symptoms from the perspective of patients
who had received the interventions
Support
Support was defined by patients as being accepted and validated by HPs and fellow intervention
participants, receiving empathy and being listened to. This was found across an array of intervention
types and there was high confidence in this finding.178,180,182,183,185,186 This type of support was described
as the most positive part of the pragmatic rehabilitation intervention in one study, with ‘being believed
and feeling understood by the therapist’ as a key part of the intervention.179 Patients across various
intervention types reported valuing a feeling of being understood and validated by the HP.179,182 This
was sometimes as a result of the knowledge that the HP had about the patient’s symptoms, which
gave them a sense of having someone ‘on their side’.180,182,185 In some instances, it appeared that no
one else in their lives was able to provide such support, ‘It was just an understanding from her that
I didn’t, haven’t had from anybody else’ (patient).179 One patient reporting that the empathetic nature
of the nurse delivering the supportive listening intervention was their most valued attribute.178 This
feeling of being understood also came from fellow participants with similar symptoms, as part of group
interventions.182,183,186 These factors were reported as key to patient engagement and contributed to
whether or not the interventions were reported as acceptable to the participants.179 Some participants
thought that the ‘extra time’ afforded by the interventions allowed these aspects of support to
be accessed.185
TABLE 10 Critical Appraisal Skills Programme results
Question
Yes/somewhat
(N= 9 studies),
% (n)
1 Is the study qualitative research or does it provide qualitative data? 100 (9)
2 Are the study context and aims clearly described? 100 (9)
3 Is there evidence of research reflexivity? 33 (3)
4 Are the sampling methods clearly described and appropriate for the research question? 89 (8)
5 Are the methods of data collection clearly described and appropriate to the research
question?
89 (8)
6 Is the method of analysis clearly described and appropriate to the research question? 67 (6)
7 Are the claims made supported by sufficient evidence (i.e. Did the data provide sufficient
depth detail and richness)?
56 (5)
PRIMARY CARE OR COMMUNITY-BASED BEHAVIOUR MODIFICATION INTERVENTIONS FOR MUS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
TABLE 11 Thematic synthesis of evidence from patients
Meta theme Theme
Studies (first author)
contributing to the finding
CERQual
assessment of
confidence in the
evidence Explanation CERQual assessment
Positive factors relating to behavioural modification interventions as reported by patients/what did you gain from being referred to a behavioural modification intervention.
Support Acceptance Gerskowitch;182 Chew-Graham;179
Graham;183 Morton;185 Peters;180
Peters;178 Payne186
High confidence 6 studies, in general the studies were moderately
well done. The finding was seen across most of
the studies in the synthesis and across different
intervention formats and facilitators. Included
studies with thick data. Coherent data across
the studies
Validation
Empathy
Being listened to
Explanation leading to
understanding
Accepting the treatment model Gerskowitch;182 Chew-Graham179 Moderate confidence 2 studies, both of moderate quality, and including
thick data. Evidence came from different
intervention types, and different facilitators.
Coherent data across the studies
Understanding the treatment model Gerskowitch182
Learning achieved/gains
from the interventions
Self-management techniques Gerskowitch;182 Graham;183
Morton;185 Payne186
Moderate confidence 4 studies of moderate to low quality. Evidence
came from different settings. However, there
were limited rich data. The data appeared to be
coherent across the studiesImproved confidence Graham;
183 Payne186
Improved communication with family
and friends
Graham183
Benefits from being part
of a group (specific to
group interventions)
Sharing experiences with other patients Gerskowitch182 Low confidence 2 studies: one moderate quality with rich data and
one low quality with thin data. Data were specific
to group interventions. Coherent data across
the studies
Learning from other patients Gerskowitch;182 Graham183
Factors reported as important, wanted or expected in behavioural modification interventions
Balance between psychological and physical elements Burton157 Very low confidence 1 one study of low quality with thin dataa
Flexibility Gerskowitch182 Low confidence 1 study of moderate quality with thick dataa
Other factors such as diet/nutrition advice, the role of faith Gerskowitch182 Low confidence 1 study of moderate quality with thick dataa
Group-based treatment Gerskowitch182 Low confidence 1 study of moderate quality with thick dataa
More consultation time Burton157 Very low confidence 1 one study of low quality with thin dataa
More investigations Peters180 Low confidence 1 study of moderate quality with thick dataa
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TABLE 11 Thematic synthesis of evidence from patients (continued )
Meta theme Theme
Studies (first author)
contributing to the finding
CERQual
assessment of
confidence in the
evidence Explanation CERQual assessment
Explanation Specialist knowledge of the symptoms Gerskowitch;182 Peters180 Moderate confidence 2 studies, both of moderate quality with thick
data. Data evident across different formats, and
different facilitators. Coherent data across
the studies
Explanation of the symptoms
HPs’ understanding of
the patient and
symptoms
Reassurance Peters180 Low confidence 1 study of moderate quality with thick dataa
Relationship with the GP Peters180
Learning skills to deal
with the symptoms
Self-management techniques Gerskowitch;182 Peters180 Moderate confidence 2 studies, both of moderate quality with thick
data. Data evident across different formats, and
different facilitators. Coherent data across
the studies
Support for learning
What patients did not like about (being referred to) behavioural interventions
It made things worse/did
not make any difference
(adverse effects)
Frustration – things are not getting any
better
Gerskowitch182 Low confidence 3 studies of moderate quality. Coherence is
unclear as findings within the theme are diverse,
thick data, consistent across different formats and
facilitatorsNegativity of the intervention Gerskowitch
182
Made symptoms worse Gerskowitch182
Inflexibility of the model/not workable
in everyday life
Chew-Graham;179 Peters180
HPs’ lack of understanding HP does not understand Peters180 Low confidence 2 studies, both moderate quality, only one with
thick data. Specific to, GP-delivered, individual
interventions. Coherent data across the studiesFeeling of being blamed by the GP Morton
185
It ended A feeling of loss when the intervention
ends/lost a friend
Peters;178 Chew-Graham179 Low confidence 1 study of moderate quality with thick dataa
This finding was only seen in the one included
study of patients with CFS and may only be
specific to this group
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Meta theme Theme
Studies (first author)
contributing to the finding
CERQual
assessment of
confidence in the
evidence Explanation CERQual assessment
Conflicts between HPs
and patients
Intervention asserted as the only
right answer
Chew-Graham179 Low confidence 1 study of moderate quality with thick dataa
This finding was only seen in the one included
study of patients with CFS and may only be
specific to this group
Patients felt the intervention did not
address their symptoms
Peters178
A belief exercise is damaging despite
HP advice
Chew-Graham179
Barriers – why patients did not want behavioural interventions/or could not engage with them
Lack of choice Lack of information/choice given
by referrers
Gerskowitch182 Low confidence 1 study of moderate quality with thick dataa
Sceptical of HPs GPs aim is to assert problems are
psychological
Burton157 Moderate confidence 4 studies, three of moderate quality, one low
quality, three with thick data, across different
intervention formats and facilitators. Coherent
data across the studiesMention of psychosocial problems
diverts GPs attention from other
problems (so should not mention them)
Peters180
Simplistic explanations Gerskowitch;182 Peters180
Disagreements with HPs that illness
is physical
Peters178
Physical limitations Cannot physically undertake the
intervention
Gerskowitch182 Low confidence 1 study of moderate quality with thick dataa
HPs’ lack of knowledge/
skill at treating the
symptoms
GPs are unskilled Peters180 Moderate confidence 2 studies, both moderate quality and with thick
data, across different intervention formats and
facilitators. Coherent data across the studiesNurse therapists are novices Peters
178
Patients beliefs that you
should deal with it
yourself
Patients should self-manage Peters180 Low confidence 1 study of moderate quality with thick dataa
Specific to a GP-delivered intervention
Inappropriate to discuss psychosocial
problems (with GP)
Peters180
Stigma related to psychosocial problems Peters180
a Where only one study relates to a finding, it is not possible to assess whether the finding would remain across other settings or assesses the coherence of the finding.
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TABLE 12 Thematic synthesis of evidence from HPs delivering the intervention
Meta theme Theme
Studies (first author)
contributing to the finding
CERQual assessment
of confidence in the
evidence Explanation CERQual assessment
Positive factors relating to behavioural modification interventions as reported by HPs/what did you gain from being trained to and/or delivering a behavioural modification intervention?
Training and supervision was
useful
Supervision in managing tensions Peters178
Peters178
Dowrick181
Dowrick181
Moderate confidence 2 studies, both of moderate quality, both including
thick data. Evidence came from different
intervention types with different facilitators.
Coherent data across the studies
Therapist peer support
Increased GPs’ awareness and altered
perceptions
Addressed professional and/or training
needs
Extended knowledge and
skill of the HP
Learning and applying boundaries of
their role
Peters178 High confidence 3 studies: one high quality and two of moderate
quality. All three including thick data. Evidence
came from different intervention types with
different facilitators. Coherent data across
the studies
Flexibility of the therapist Peters;178 Lewis184
Increasing confidence in discussing MUS Dowrick181
Helped structure MUS consultations Dowrick181
The primary care/community
setting was helpful
Secondary care may support a belief in a
physical cause
Dowrick181 Moderate confidence 2 studies, both of moderate quality, both including
thick data. Evidence came from different
intervention types with different facilitators.
Coherent data across the studiesTool to protect patients (from secondary
care)
Dowrick181
Primary care allowed a more tailored
approach
Peters178
Being in patients’ homes was helpful in
building a therapeutic relationship
Peters178
Rewarding experience Rewarding when patients engaged Peters;178 Lewis184 High confidence 2 studies, one high quality, one of moderate
quality, both including thick data. Evidence came
from different intervention types with different
facilitators. Coherent data across the studies
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Meta theme Theme
Studies (first author)
contributing to the finding
CERQual assessment
of confidence in the
evidence Explanation CERQual assessment
What did not help or were detrimental to the patients or delivery of the intervention?
When HPs felt that they
were a novice or did not
have the required skill levels
Being a novice therapist/lack of
experience
Peters;178 Lewis184 High confidence 2 studies, one high quality, one of moderate
quality, both including thick data. Evidence came
from different intervention types with different
facilitators. Coherent data across the studiesAnxiety because of a lack of training/
knowledge
Lewis184
Unfamiliarity with MUS Lewis184
No specific MUS model to work with Lewis184
Not as comfortable with mental health
aspects of the interventions (as physical
health)
Peters178
When HPs struggled to deal
with their own or patient
emotions
Not dealing well with failure Peters178 Moderate confidence 2 studies, both of moderate quality, both including
thick data. Evidence came from different
intervention types with different facilitators.
Coherent data across the studies
Pessimism (from HP) about dealing
with MUS
Lewis184
Angry patients Peters178
HPs’ anxieties that the
intervention may have
detrimental consequences
for the patients
Nurse therapists worries about the
interventions consequences
Peters178 Moderate confidence 2 studies, both of moderate quality, both including
thick data. Evidence came from different
intervention types with different facilitators.
Coherent data across the studiesCould increase patient dependency Dowrick
181
Too much complexity Difficulty of applying when the patients
have multiple symptoms/complaints
Dowrick181 Low confidence 1 study of moderate quality with thick dataa
The community setting was
unhelpful
Difficulties of being in the patients’ home Peters178 Low confidence 1 study of moderate quality with thick dataa
It’s nothing new (neutral effects) Ride it out (when the intervention is not
addressing needs and both parties know it)
Peters178 Moderate confidence 2 studies, both of moderate quality, both including
thick data. Evidence came from different
intervention types with different facilitators.
Coherent data across the studiesNothing new (HPs felt that they were
already doing it)
Dowrick181
continued
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TABLE 12 Thematic synthesis of evidence from HPs delivering the intervention (continued )
Meta theme Theme
Studies (first author)
contributing to the finding
CERQual assessment
of confidence in the
evidence Explanation CERQual assessment
Barriers – from the perspective of HPs why patients did not want behavioural interventions/or could not engage with them, or barriers to delivery of the intervention
Resource constraints Not enough time Peters;178 Dowrick181 Moderate confidence 3 studies, all of moderate quality, both including
thick data. Evidence came from different
intervention types with different facilitators.
Coherent data across the studies
Other time constraints/competing
pressures
Dowrick181
Other pressures go against applying
reattribution (medicolegal)
Dowrick181
Lack of clarity on service provision
for MUS
Lewis184
Patient beliefs Patients’ belief in a physical cause Dowrick181 High confidence 3 studies: one high quality and two of moderate
quality. All three including thick data. Evidence
came from different intervention types with
different facilitators. Coherent data across
the studies
Patients benefit from their symptoms
(an agenda – secondary gain)
Dowrick181
Patients have an agenda (e.g. target the
locum)/patients’ pre-existing beliefs/
an agenda
Dowrick;181 Lewis184
Patients’ beliefs about not being able to
do physical activity
Lewis184
Patients’ resistance to intervention/
patients did not want to engage with
the model
Peters;178 Lewis184
HP skill, beliefs and attitudes Some GPs more skilled than others Dowrick181 Low confidence 1 study of moderate quality with thick dataa
GPs’ prior expectations of patients Dowrick181
GPs’ mood Dowrick181
Personality clash (between HPs and
patients)
Dowrick181
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Meta theme Theme
Studies (first author)
contributing to the finding
CERQual assessment
of confidence in the
evidence Explanation CERQual assessment
Patient barriers Patients not able/willing to share Dowrick181 Moderate confidence 2 studies: one of high quality and one of moderate
quality. Both including thick data. Evidence came
from different intervention types with different
facilitators. Coherent data across the studies
Patients’ physical difficulties were
barriers to attendance and adherence
Lewis184
Other factors Not knowing if it is actually MUS Dowrick181 Low confidence 1 study of moderate quality with thick dataa
Factors reported as important, wanted or expected for training in and delivery of behavioural modification interventions
More training and
supervision required
Supervision Dowrick;181 Lewis184 Moderate confidence 2 studies: one of high quality and one of moderate
quality. Both including thick data. Evidence came
from different intervention types with different
facilitators. Coherent data across the studies
More training Lewis184
a Where only one study relates to a finding, it is not possible to assess whether the finding would remain across other settings or assesses the coherence of the finding.
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1
Patients’ ideal intervention Facilitators as reported by HPs
Barriers/unwanted effects as reported by patients 
and HPs 
Outcomes for patients
(to be fed back in, to improve
future interventions) 
Training and supervision
The extended knowledge and
skill of the HPs
The primary care/community setting
Rewarding experience
Future
training and
supervision
HPs
Resource constraints
Patient beliefs and patient barriers
HPs’ skill, beliefs and attitudes and
HPs not dealing with their own or patients’ emotions
Too much symptom complexity
The community setting was unhelpful
It is nothing new (neutral effects)
Other factors (not knowing if it is actually MUS) 
Explanation from specialists with
knowledge of the symptoms
HPs’ understanding through
reassurance and a good
relationship
Learning skills to deal with the
symptoms
More time
More investigations
Balance between psychological
and physical components
Flexibility
Complementary advice such as
diet, nutrition and faith
Option of group-based
intervention 
Support in terms of acceptance,
validation, empathy and being
listened to
An explanation of their
symptoms and treatment model
leading to an understanding
of both
Ability to apply
self-management techniques,
improved confidence and
improved communication
with others
Sharing experiences and
learning from others within
a group intervention 
The intervention does not work for
some patients
When HPs lack understanding
Patients feel a sense of loss when an
intervention ends
Conflicts between patients and HPs  
.
Patients
Lack of choice
Sceptical of HPs
Physical limitations
HPs’ lack of knowledge and skill
Patient beliefs about not seeking help
Should result in
HPs’ anxieties that the intervention may have
detrimental consequences for the patients
FIGURE 58 Patients’ and HPs’ perceptions of behavioural interventions for MUS in primary care settings. Model to show expectations, perceived barriers and facilitators, and potential
outcomes, based on evidence from included studies.
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Explanation
Patients also clearly valued explanations that they had been provided with as part of the interventions,
and reported that this led to accepting and understanding the treatment model,179,182 with moderate
confidence assessed in this finding. Patients felt that the pragmatic rehabilitation intervention helped
them to come to terms with and accept a diagnosis (of CFS) and that having an explanation and
understanding of their symptoms was key to this. ‘She explained all about CFS and the physiology of it
really, which was the first time really that I understood why my energy was so low, so that made a lot
of sense’ (patient).179 Gaining new knowledge about their symptoms was reported to be reassuring to
patients, enabling them to accept the idea that the pragmatic rehabilitation intervention might be
appropriate for them and, therefore, facilitated the progress made with the intervention.179 Similar
factors were also identified in the data about what patients wanted from an intervention. Patients
reported that they consulted their GP to seek an explanation for their symptoms180 and took part in
interventions to see someone who had specialist knowledge and information about their symptoms.182
Important intervention elements for the delivery and success of primary
care-delivered behavioural modification interventions for MUS from the
perspective of patients and health professionals
Intervention elements
An important feature of the evidence from patients was the reported benefit that they had gained from
the behavioural self-management techniques that they had learned. This was evident across four of
the studies that included the following interventions, with participants commenting on their improved
confidence and improved communication with significant others: CBT, mindfulness, group counselling,
GP interventions and the BodyMind Approach intervention.182,183,185,186 This also emerged in the evidence
around what was wanted or needed as part of any future intervention, with patients saying they needed
to learn skills such as self-management techniques to deal with the symptoms and to have the support for
learning such techniques.180,182 Specific to group interventions, patients found sharing their experiences
with other patients182 and learning skills from other patients182,183 valuable as part of the intervention.
A number of additional elements were suggested by patients in single studies as potentially important as
part of any intervention for MUS. These elements included having a balance between the psychological
and physical elements of an intervention in one GP-delivered intervention study,157 and incorporating
other factors, such as diet and nutrition advice and the role of faith, in the management of symptoms in
another study.182 Patients also reported that flexibility in accessing the therapy was important to them
in one study,182 as was the availability of group-based treatment.182 Specific to a GP-delivered study,
patients wanted more consultation time,157 which, in comparison with standard care, most of the
behavioural interventions detailed here provided. Again specific to a GP-delivered intervention, some
patients simply wanted to have further investigations.180
Health professional training and supervision
From the point of view of the HPs, training and supervision in applying behaviour modification
interventions was reported as helpful in two studies178,187 and was also recommended as useful for
future training in two studies.184,187 Supervision was reported as ‘fundamental’ and as key to resolving
difficulties that might arise between the deliverer of the intervention and the patient receiving the
intervention in a nurse therapist-delivered intervention.178 Having the support of peers who were
delivering the same intervention was also valued, ‘If we were having a really difficult time with a
certain patient, then we would sort of pool ideas, and ask advice how they would cope with it, the
other nurse therapists or what do they think is going on’ (nurse).178 GPs delivering a reattribution
intervention found the training useful in that it increased their awareness of MUS and suggested
it ‘altered my perception a bit, it’s easy to get stale and view that group of patients as difficult or
troublesome or irksome at times because we’re not always at our best every time (GP).187 GPs
also reported that it addressed their training needs and allowed them the opportunity it compare
consultation skills with colleagues.187
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Primary care and community setting
The primary care or community setting was reported to be a helpful factor by the HPs in two studies.
In one study, the reasons for this were that the primary care setting provided a tailored approach, and
the setting (e.g. being in patients’ homes) was useful when trying to develop a therapeutic relationship.178
In another case, this contrasted with the perceived failing of the secondary care setting.187 ‘You see these
people getting referred to the hospital with back pain and the next thing you know some bright spark is
going to operate on them and you think ‘What!’ . . . Maybe we’re here in a way as a gateway to try and
prevent harm as well as anything else’ (GP).187 This appears to indicate that primary care practitioners
see part of their role as protecting their patient from entering secondary care when they believe
this is unnecessary. Although the evidence pointed towards favourable views regarding the primary
care and community setting, it should be considered that the home setting could also be a source of
difficulties (e.g. issues with privacy and interference from family members), but this finding was specific
to the intervention for CFS/myalgic encephalomyelitis.178
Important facilitating factors for intervention success by patients and
health professionals
Good relationships
It was important that the HPs delivering an intervention had an understanding of the patients and
their symptoms. Specifically, the patients in one study reported needing reassurance and a good
relationship with the person delivering the intervention.180 Patients liked the fact that they had
a longstanding relationship with the HP. In a reattribution intervention, this gave them a feeling
that they knew what type of treatment, if any, would be suitable for them: ‘He knows I like to keep
myself to myself, knows I believe in self-help . . . knows I’m somebody that likes to work it out for
myself’ (patient).180 Others simply appreciated the understanding and reassurance they received
from the HP and just wanted an opportunity to share their difficulties.180
Health professional knowledge and skill
Health professionals across three different interventions reported that they found being involved in
delivering behaviour modification interventions helped them to develop their knowledge and skills in
the area of MUS.178,184,187 This training helped them learn about the boundaries of their own role178 and
to be flexible when delivering interventions.178,184 GPs reported being able to structure consultations in
an appropriate way for MUS and that the intervention, in this case reattribution, provided this structure
and increased their confidence in discussing MUS with patients.187 Although acknowledging that there
can be difficulties in delivering MUS interventions, CBT therapists184 and nurse therapists178 both reported
that it can be rewarding when it is evident that patients have gained benefit from the intervention.
Factors identified as barriers to intervention success by patients and
health professionals
Difficult relationships
At the same time as good relationships facilitating intervention success, difficult relationships between
patients and HPs appeared to undermine progress, and this was reported across five studies. Some
patients, taking part in a reattribution intervention, felt that there was a lack of understanding on
the part of the HP, with simplistic causes and resolutions to problems being proffered.180 Sometimes,
reported specifically in one GP-delivered intervention study, this extended to patients feeling that
they were being blamed by the GP.185 Specific to the intervention study for patients with CFS/myalgic
encephalomyelitis, the relationship between HPs and patients also sometimes led to conflict, in some
cases patients felt the HPs were asserting the intervention (in this case pragmatic rehabilitation) as
the only right answer, and patients disagreed with this point of view, ‘I think my main reason is the
fundamental theory behind it [the treatment model offered] just disregards it as illness’ (patient).179
There was also a feeling from patients that some heath professionals were unskilled or lacked the
knowledge to deal with their symptoms or provide appropriate intervention.178,180
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Patients in a GP-delivered intervention study also reported being sceptical of HPs, believing that
the aim was to assert that their problems were psychological,157 and some patients reported having
disagreements with their HP regarding the physical nature of their symptoms in an intervention for
patients with CFS.178 Patients were also sceptical that they would only be provided with simplistic
explanations for their symptoms,182 and that if they were to mention any psychosocial problems this
would divert the HP’s attention away from other problems associated with their symptoms.180 Specific to
a GP-delivered intervention, GPs reported that there might be a personality clash between them and their
patients, meaning that insufficient rapport is built for reattribution to be successfully delivered.187 Other
factors reported by HPs included patients not being able or willing to communicate with their GP.187
Attitudes and beliefs
In one study, some patients simply felt that the intervention did not address their symptoms and that
they could not believe in the intervention,178 contrary to the HP view. It was also reported that several
patients held a belief that an activity (as part of the pragmatic rehabilitation intervention) could be
damaging to them, despite the fact that it was described in the intervention manual and recommended
by the HP delivering the intervention.179 Patients reported that the lack of information given to them
by those who referred them meant that they did not know the remit of the intervention, and it was
also reported that patients felt that the referring GP did not know what the intervention entailed.
Patients were therefore surprised about the content of the intervention and found it difficult to see
why they had been referred to a psychological therapy-based intervention when their problems were
physical.182 Furthermore, evidence suggested that some patients may hold the belief that they should
deal with the symptoms themselves, and that they should self-manage without the input of HPs.180
Patients had their own ideas around what they should be doing to self-manage: ‘I’ve started knitting –
gets my mind occupied’ (patient).180 Further barriers came from an opinion that it is inappropriate to
discuss psychosocial problems (with the GP)180 and the idea of there being a stigma related to
reporting psychosocial problems.180 In addition to these beliefs, patients also reported physical
limitations that represented barriers to physically undertaking the intervention.182
Health professionals also reported that they felt patient beliefs could be significant barriers to
engagement with behavioural modification interventions.178,184,187 HPs described, and some appeared
to expect, patients to have a belief in a physical cause.187 HPs were reported in one reattribution study
to suggest that this belief was a learned behaviour to deal with unhappiness.187 HPs also reported in
two studies that patients could be resistant to the intervention or the treatment model itself.178,184
Furthermore, CBT therapists reported that patients sometimes held a belief that they were not
able to take part in aspects of interventions that required physical activity, despite HPs’ reassurances
otherwise.184 Finally, it was suggested by HPs that patients might be benefiting materially from their
MUS symptoms, in terms of family support and state benefits, which might have an impact on their
willingness to engage with an intervention.187
Health professionals’ lack of experience and skills
Nurse therapists and CBT therapists who had been trained to deliver MUS-specific interventions
felt that they were novices and lacked the experience to deliver the interventions in two separate
studies.178,184 It was reported that they did not have a specific MUS model to work with, and they
were unfamiliar with the symptoms.184 Furthermore, they experienced anxiety because of this lack of
training and experience in MUS184 and were not comfortable dealing with the mental health aspects
as compared with the physical health aspects of the interventions they were delivering.178 This also
emerged as a barrier to service provision, with GPs acknowledging that the successful application of
reattribution may be dependent on variations in the communication skills of the practitioner delivering
the intervention.187
Difficulty of dealing with emotions
Patient and HP emotions emerged as a source of difficulty in delivering MUS interventions in two
studies.178,184 Nurse therapists found at times that they did not deal well with failure, ‘One common
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theme I think with has come up is the difficult of accepting that you can’t get it right all the time’
(supervisor).178 Sometimes patients became angry when an intervention could not address their needs,
and this was also a source of difficulty for nurse therapists.178 Conversely, some CBT therapists
reported a level of pessimism when faced with patients with MUS.184
Constraining factors
Health professionals reported that resource constraints, such as time constraints, and impositions about
what data needed to be collected during a consultation presented barriers to delivering interventions
in two studies.178,187 The concerns regarding time constraints were associated with each consultation187
and also with the length of the course of therapy, with concerns expressed that too few sessions were
available to deal with deep-seated issues.178 Other constraining factors reported by HPs included
physical difficulties preventing patients attending and adhering to interventions.184
Problems of diagnosis
The GPs were also concerned about medicolegal issues in one study, such as overdiagnosing and
overtreating patients.187 It was also reported that a lack of information about service provision may
have lowered the referral rate in another study.184 Other constraining factors included situations in
which HPs were unsure that the symptoms were actually medically unexplained,187 or in which there
was too much symptom complexity.187
Potential unwanted or adverse effects on patients as reported by patients and
health professionals
The HPs in two studies reported that they had concerns that the intervention might be detrimental to
patients.184,187 These worries took the form in one case with a reattribution intervention that patients
might form a dependent relationship with the GP and become reliant on them.187 In another case,
these worries took the form of the impact of the intervention (pragmatic rehabilitation and supportive
listening) possibly being negatively felt in wider aspects of the patients’ lives.184
Some patients considered that the psychological interventions made things worse, or were not making
things any better in one study.182 This manifested itself in the form of frustration in some cases,182
whereas, in others, patients found the intervention model negative in nature.182 Some patients with
CFS found the pragmatic rehabilitation intervention model inflexible and, therefore, were unable to
make it work in everyday life.179,180
Where good relationships were established between the two parties, as in a study of an intervention
for CFS/myalgic encephalomyelitis, patients reported finding it difficult when the intervention came to
an end, experiencing a feeling of loss when support was withdrawn.178,179
In some cases, it was felt that the intervention was not suited to the patient and that both the HP
delivering the intervention and the patient receiving the intervention had come to this realisation
but both parties followed through with it despite this.178 In another case, HPs felt that the
intervention training on reattribution offered them nothing new and that they were already
providing it in their consultations.187
Table 13 shows a summary of the key findings.
Discussion of the qualitative review
This review presents patients’ and HPs’ perspectives on the acceptability, relative benefits and potential
harms of primary care or community-based behaviour modification interventions for MUS. The findings
offer insight into what aspects of the interventions patients and HPs found helpful, what was unhelpful
and what were the barriers to participation or intervention success, which could all contribute towards
an understanding of what might make a more successful intervention.
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Although the quality of the study reports included in the review was not universally high, studies were
in general suitable for the purpose of the review. Although the quality of the studies would have been
increased by limiting our review to studies that could be identified as qualitative research (i.e. using
both accepted methods of qualitative data collection and data analysis), important data may have been
missed had this criterion been applied.
The findings of the synthesis showed that, across all interventions, what patients thought was helpful
was gaining support. Patients found being accepted and validated by the HP (and also other intervention
participants, in the case of group interventions), together with receiving empathy and being listened to,
helpful as part of an intervention. Patients also valued receiving an explanation for their symptoms and
appeared to find interventions that offered this to be helpful. In terms of practical intervention elements,
an important feature was the gains made from the self-management techniques they had learned, and
patients reported that support for learning such techniques was important. The progress and perceived
helpfulness of the intervention appeared to be facilitated by a good relationship between patients
and the HPs delivering the intervention. In terms of findings relating exclusively to GP-delivered
interventions, patients reported that helpful elements of an intervention included having a balance
between psychological and physical elements,157 more consultation time157 and, in one study, further
investigations.180
Patients’ own attitudes and beliefs appeared to be potential barriers to their participation in the
intervention and its success, with some patients reporting that they did not believe in the treatment
model or found it unworkable, or had a belief in dealing with problems themselves. It also appeared
that conflicts between HPs and patients could impede success. A small number of findings related
exclusively to the intervention study for patients with CFS/ME. Patients reported finding it difficult when
the intervention came to an end, experiencing a feeling of loss when support was withdrawn.178,179 They
also reported that the relationship between HPs and patients could sometimes lead to conflict – in some
cases patients felt that the HPs were asserting the intervention (in this case pragmatic rehabilitation) as
the only right answer and disregarded the patient’s point of view.179 Specifically relating to GP-delivered
interventions, patients reported that they felt that there was a lack of understanding from the GP,180 and
they also reported a feeling of being blamed by the GP.185 Again relating to GP-delivered interventions,
TABLE 13 Summary of the key findings
Patients HPs
Valuable results from
intervention participation or
training
Gaining support being validated Developing knowledge and skills
around MUS
Explanation
Support for self-management Rewarding when patients engaged
Facilitators Good relationships between patients
and HPs
Training and supervision
Primary care or community setting
Barriers Patient attitudes and beliefs Lack of confidence in their own skills
and abilities to deal with MUS
Poor relationship with HPs Patient attitudes and beliefs
HP attitudes and beliefs
Resources constraints
Adverse effects It ended Detrimental intervention consequences
for patients
Conflicts between HPs and patients,
and HPs’ lack of understanding
Patient and HP emotions
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the evidence suggested that some patients may hold a belief that you should deal with the symptoms
yourself and that they should self-manage without the input of HPs.180
Evidence from HPs described how they found being trained or delivering the interventions helped
to develop their own knowledge and skills around MUS, and they reported that the experience was
rewarding when patients engaged with them. They found important facilitators were training and
supervision for the interventions and found primary care or the community an appropriate and helpful
setting for the delivery of the intervention. Barriers to successful delivery of the intervention(s) were
reported to include a lack of confidence in their own skills and abilities to deal with MUS, patient attitudes
and beliefs that went against the intervention, their own attitudes and beliefs and resource constraints.
HPs were also worried that the interventions might have inadvertent detrimental consequences for
patients, and that they might be ill-equipped to deal with their own and the patient’s emotions. Although
the evidence indicated favourable views regarding the primary care and community setting, it should be
considered that the home setting could also be a source of difficulties (e.g. issues with privacy and
interference from family members), but this finding was specific to the intervention for CFS/myalgic
encephalomyelitis.178
Barriers reported specifically from GP-delivered interventions included GPs feeling that there was too
much condition complexity,187 GPs’ skills, beliefs and attitudes sometimes not helping,187 and GPs, on
some occasions, not knowing if it was actually MUS did not help in the delivery of the intervention.187
The implications of the findings suggest that, although a number of patients found the interventions
helpful, with a number of key helpful factors that could inform the development of a future intervention,
a minority did not find the intervention helpful or did not want to take part in the intervention at all.
This links to one of the barriers to taking part in or engaging with interventions, which was reported
as a lack of information and choice given by referrers. If patients do not have the information that
they need to make an informed choice, it is less likely that the intervention will be suitable for them.
Therefore, this requires consideration of the matching of intervention type to patients where possible.
Other barriers that would need to be addressed in any future intervention include patients’ scepticism
of HPs, with patients reporting disagreements with HPs regarding the nature of their symptoms, and an
expectation that simplistic explanations will be provided. Patients also reported in some cases that they
were not convinced that the HPs delivering the intervention had an appropriate level of knowledge and
skill. Further barriers included physical limitations, problems of stigma around asking for help and a
belief in dealing with problems oneself. A further consideration for all interventions, but specifically
evidenced here from the patient evidence on the intervention for CFS/myalgic encephalomyelitis,178,179 is
continuity of care from the same HP or team and that interventions should not end suddenly or without
adequate follow-up.
Limitations
Limitations include the fact that some of the included studies were of moderate or low quality, as
assessed using CASP,174 and that confidence in some of the findings was assessed as moderate or low
using the CERQual assessment.169 Word limits imposed by journals may have contributed to this. Such
limitations may result in a lack of rich data consistently across all studies, limiting (to some degree) the
interpretations that can be made, particularly for some of the minor themes identified. Although the
metathemes identified were supported by a number of studies and were supported by the CERQual
assessment, a number of other findings reported here did not offer the same strength of evidence.
In addition, although the validity of these findings should not be understated, it may be the case that
further research is required to ascertain their generalisability and importance in the development
of future interventions. A further limitation concerns the inclusion criteria for the qualitative review.
The scope of the qualitative review was to present evidence about the experience of the interventions
rather than the anticipation of them; therefore, the data included were in the main from patients who
had agreed to take part in an intervention. Evidence about the general management of MUS was not
included in the qualitative review but these data did meet the inclusion criteria for the realist synthesis.
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Summary of the findings of the qualitative review
l Both patients and HPs reported positive gains from taking part or delivering interventions.
l A number of reported barriers appeared to be underpinned by the relationship between the
patients and HPs delivering the intervention, and by beliefs and attitudes held by both parties.
l Both positive and negative experiences of the primary care setting were reported.
l Detrimental effects of the intervention were associated with an abrupt end to the intervention and
frustration attributable to symptoms not improving.
l Some patients and HPs did not feel it could add anything for them.
Combining the quantitative and qualitative findings
The quantitative review did not consistently reveal one intervention as more successful than any
other across the various outcomes, with the exception of GP-delivered interventions, which were rarely
successful. Therefore, as suggested in the qualitative evidence, considered matching of intervention type
to patients, taking into account patient preferences, should take place. Further to this, the qualitative
evidence showed that patients’ own attitudes and beliefs may be barriers to intervention participation,
with some patients reporting that they did not believe in the treatment model, found it unworkable
or had a belief in dealing with problems themselves, again giving support for careful matching of
intervention to patient. Although not frequently reported in the trials of clinical effectiveness, this
theme was sometimes reflected in the numbers of eligible participants declining to take part, with
reasons including beliefs that the interventions would not work, or would exacerbate symptoms.
Although the quantitative findings did not show that the GP-delivered interventions were generally
effective, the qualitative review demonstrated that patients found that the GPs’ understanding of
them and their symptoms and a good relationship with them was an important part of a successful
intervention. However, the qualitative review also demonstrated that a key barrier for patients taking
part in interventions, including those that were GP delivered, was a scepticism regarding the deliverer.
Specifically, some patients reported disagreements with GPs regarding the physical or psychological
nature of their symptoms and also that sometimes simplistic explanations were proffered by GPs.
Evidence outlined in the review of cost-effectiveness demonstrated a large variation in the number of
patients recruited by GPs between studies. Evidence from the qualitative review showed that some HPs
found delivering the interventions to be a rewarding experience, and it might therefore be assumed that
such HPs would be more likely to recruit patients. Others had a contrasting view, that the training they
were given for MUS interventions was nothing new, and some reported that they found it difficult to deal
with failure and were ill-equipped to deal with angry patients. Some HPs worried that it could increase
dependency and that it would be difficult to apply when symptoms were complex. Other factors that may
prevent HPs from recruiting to interventions include resource constraints, medicolegal concerns and a
lack of clarity around service provision. HPs were also concerned that it was not always clear that it was
actually MUS that the patients had, and they wanted more training and supervision.
Findings from the cost-effectiveness review also demonstrated a large variation in the number of
sessions the patients attended both within and between studies. Evidence from the qualitative review
may provide explanations for this; for example, there were a number of things that patients felt that
they did not like about the intervention or were barriers to them taking part or continuing with it.
These factors included frustration that things were not getting any better after attending and finding
the rationale of the intervention negative and that they could not work it into their everyday life.
They also reported feeling that the HP did not understand, or that the HP was blaming them. There
were also conflicts reported between HPs and patients, and a reported lack of understanding from the
HP. This may include patients losing faith in the intervention when it was asserted as the only right
answer to their problems and that their needs were not addressed.
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Chapter 5 The contribution of contextual
factors to the success or failure of behaviour
modification interventions for medically
unexplained symptoms: realist synthesis
This chapter aims to provide an overview and analysis of the evidence for the contribution ofcontextual factors associated with the ongoing primary care consultation and the patient’s
interaction with primary care professionals to the success or failure of behaviour modification
interventions (‘behavioural interventions’) for MUS. Given the complexity of the phenomenon and
the interaction between HPs for a variety of purposes and at multiple levels, the review team has
undertaken a review utilising realist principles. Realist reviews particularly offer a lens or strategy
by which complex interventions can be examined and analysed.
This realist synthesis on behaviour modification interventions for MUS draws on three main sources:
1. study ‘clusters’ of primary studies, linking UK quantitative and qualitative reports, identified from
the effectiveness review and from the qualitative synthesis, to all other published accounts that
share a study context
2. the qualitative synthesis conducted for this HTA, which focused on UK intervention studies only
3. published narrative and systematic reviews, particularly qualitative evidence syntheses, covering
the entire primary care pathway from making an appointment through to potential referral to
secondary care.
In addition, further systematic reviews, qualitative research and conceptual papers were examined as
referenced by any of the above, offering productive ‘forays’ into the relevant literature.
Evidence identification
Study ‘clusters’ of primary studies
When exploring complex interventions, a review team must seek to gain as full an understanding as
possible of the essential characteristics of the context and the intervention. One possible way of acquiring
such an understanding is by examining papers and additional studies that have been conducted alongside
an effectiveness study, either as part of an integrated mixed-methods study or as a ‘sibling study’. Sibling
studies may include qualitative research studies, economic evaluations or process evaluations associated
with specific RCTs, whereas additional papers may offer commentaries on the programme theory or
contextual issues. Sibling and associated studies are particularly valuable because they offer additional
insights beyond the reporting limitations of the key index paper ‘in explaining contextual factors that
influence implementation and/or outcomes’.58 The systematic searches reported in Chapter 3 identified
59 RCTs, of which 15 were UK-based trials and 10 were UK-based qualitative intervention studies.
From this initial yield of 24 citations, including one mixed-methods paper that featured in both sets,
19 ‘clusters’ were formed to reflect a proportion of overlap of three RCTs (five papers) with qualitative
papers. Each of the 24 citations was searched using the ‘cited by’ facility on Google Scholar (Google Inc.,
Mountain View, CA, USA) via Publish or Perish software (Harzing.com, London, UK)188 to retrieve a total
of 1182 citations. These were manually checked to identify associated study reports. Other methods of
identification included author searching, checking of websites, and trial name and number searching.
A total of 80 additional papers were identified to augment the original 24 papers, making a total of
104 papers spread across 19 different clusters (see Appendix 2, Table 69).
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Qualitative synthesis
Findings from the qualitative synthesis conducted for this HTA (see Chapter 4), which focused on UK
intervention studies only, were examined in addition to details of the interventions and contexts with
additional data being extracted to templates for reporting interventions (see Appendix 6).
Review-level evidence
Qualitative syntheses on MUS and associated conditions were identified from the study register of
the Cochrane Qualitative and Implementation Methods Group together with systematic reviews
and narrative reviews (see Appendix 2, Table 68) identified from the PubMed Reviews subset.
Formulate review question
The realist review was framed within the overall study objectives for the HTA as a whole. However,
within this broader aim it sought to address the following specific question:
To what extent do contextual factors associated with the ongoing primary care consultation between
the PCP (GP) and the patient, or the patient’s interaction with other primary care professionals,
collectively contribute to the success or failure of behavioural interventions for MUS?
Scope the primary literature
The team started by using a large number of narrative reviews and qualitative syntheses (see Appendix 2,
Table 68) as key documents to be harvested as a source of potential programme theory. Once a generic
pathway had been developed to map the patient’s journey, and challenging junctures throughout this
process had been identified, the team moved on to interrogate ‘clusters’ of primary studies. According to
previously published work, clusters represent multiple related outputs associated with a single project or,
at the very least, with investigation within the same context.58 These documents, labelled ‘sibling studies’,
are considered particularly important because they remove variation in context among the set of studies
while contributing collective detail and interpretation. By extension, a further group of related studies,
identified as ‘kinship studies’, relate to the original cluster at a more conceptual level, not sharing the
same context but sharing conceptual links. For example, kinship papers may share an underpinning
theory of change or may seek to replicate, or indeed may have preceded the intervention or study
design that are the focus of the index study.
Previous research, by ourselves and others, has found that these sets of cluster documents are often
thickly populated; expenditure on a trial and the range of individual collaborators on a project act as
catalysts for substantive collateral research activity.135,189,190 Given the large number of trials identified,
and anticipating multiple related reports per trial, the review team took a decision to focus on trials
and/or qualitative intervention studies conducted in a UK context. To this extent our focus was more
co-terminous with the qualitative synthesis for this project, rather than the review of effectiveness.
Nevertheless, a major difference was that the realist synthesis extended its purview, not only by
covering the entire primary care pathway, and not just the intervention itself, but by accessing
non-intervention-based qualitative sibling studies and metasyntheses, narrative reviews and
systematic reviews recording experiences from a diverse range of countries and settings.
The review team identified six UK-based potential clusters (Table 14).157,182,184,185,191 However, ultimately
only three of these represented viable clusters with at least one trial report and one qualitative study
from within the same study context. The remaining interventions were centred on qualitative intervention
studies already covered by the qualitative synthesis. Two independent studies examined the IAPT Long-
Term Condition/MUPS intervention and were therefore linked to broaden their explanatory power.
Similarly, studies by Burton et al.,157 Morton et al.185 and Morton et al.191 related to the same intervention
in the same context, but were not formally linked to the same project. For included studies, see Chapter 4.
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Decide on the scope of the review
In contrast to the qualitative systematic review, which focused on the direct treatment context
(see Chapter 4), the realist review adopted a broad pathway-based perspective. Essentially this
followed an input–processes–output logic, with input being the decision of the patient to present
with symptoms to their GP, the processes covering all interactions with primary health-care services,
including initial and repeat consultations and the treatment itself, and output occurring at the
resolution of the initial situation through relief, recovery, resignation to the situation or referral
(Table 15). McGowan et al.227 describe a typical pathway in connection with chronic pelvic pain:
The process of seeking medical advice followed a typical cycle of events: consultation with GP (initial
investigations and treatment) – diagnosis – no resolution of symptoms – referral (further investigations
and treatment) – diagnosis – back to the GP – diagnosis – (treatment and management).227
Table 15 necessarily presents a simplified primary care pathway; the pathway to see a HP other than the
GP for treatment involves various significant additional steps that have been omitted from the pathway
as described.
TABLE 14 Included study clusters (by first author)
Cluster identifier RCT
Other
quantitative Qualitative Economic Other evidence
The BodyMind
Approach
Payne192,193 Payne194–197 Payne186 Payne192,198 Payne199–201
Lin202
Payne203,204
Samaritter205
FINE (2010) Wearden111 Wearden111,206–208 Chew-Graham209–211 [NI]
Chew-Graham179 [I];
Peters178 [I]
Hannon214
Bayliss215
Brooks216,217 [NI]
Wearden212 (C);
Band213 (SR)
Bayliss165 (QES)
Humanistic group
counselling for
somatisation84
Graham183 [I]
IAPT long-term
condition/MUPS85
Gerskowitch182 [I]
Lewis184 [I]
MUST reattribution
training (2007)
Morriss63,108 Salmon218,219
Morriss223
Morriss220 [NI]
Dowrick181 [I]
Peters180 [I]
Salmon226 [NI]
Morriss221 Salmon222
Morriss224,225
Salmon226 [C]
Gask85 [NR]
(Primary) SCI
(2012/16)
Burton157 [I]
Morton185,191 [I]
SCI, Symptoms Clinic Intervention.
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TABLE 15 Simplified primary care pathway
Why will
patients be
more or
less likely
to present
to their GP
with MUS?
What will
make the
initial
consultation
more or less
successful
from the
patient’s
viewpoint?
What will
make a
patient
more or
less likely to
benefit
from being
assigned
the MUS
label?
What will
make a
patient
more or less
likely to
benefit
from being
assigned a
diagnostic
label?
How do
patients/
doctors
benefit
from
more
having a
disease
model?
What will
make the
initial
consultation
more or less
successful
from the
GP’s
viewpoint?
What will
make the
ongoing
relationship
between
patient
and GP/HP
more or less
successful?
What
will
make a
patient
likely
to
attend?
What will
make a
patient
more or
less likely
to receive/
accept
behavioural
treatment?
What will
make a
patient
more or
less likely
to continue
behavioural
treatment?
What will
make a
patient
more or
less likely
to respond
to
behavioural
treatment?
What will
make a
patient more
or less likely
to be able to
cope with
unsuccessful
behavioural
treatment?
What will
make a
patient
more or
less likely
to use/be
referred to
another
service?
What will
make the
patient more
or less likely
to view the
overall
therapeutic
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Despite this broad perspective, which extends beyond that of the accompanying syntheses, this model
might still be considered simplistic, in that therapeutic scenarios can include diagnosis and treatment
in primary care, diagnosis in primary care and treatment within secondary or tertiary services, and
referral to secondary care and subsequent treatment in primary care. The other observation to help
unravel this complexity is that important issues such as trust and the continuity of the therapeutic
relationship inform the context even prior to presentation to the GP (e.g. past experiences of the GP,
practice or health services in general by either the patient or their friends and family).103,104 Indeed,
the decision as to whether or not to attend a GP appointment depends on the patient’s anticipation
of the reception from the GP and practice to their particular presentation.
Mapping the programme theory/theories
Initially, seven programme theory statements were developed for testing from engagement with
conceptual and qualitative literature. Such theory-driven evaluation aims to offer plausible explanations,
not probabilistic statements:228
l Belief (in the patient, doctor and symptoms) is key.
l Focus on symptom management not labels.
l A healthy professional–patient relationship is fundamental.
l Congruity between disease models facilitates treatment.
l Working together, professional and patient can exit the diagnostic cycle.
l Psychosocial talk only to be cued by the patient.
l Honesty helps more than certainty.
Following discussion within the team, and advice from a clinical expert, one of these statements was
modified and another was added. The initial programme theory on ‘honesty’ was felt to imply some
absolute value; in fact, what the patient responds to is a belief that the professional is offering an
explanation for their symptoms that they (the professional) believe is congruent with the facts and
uncertainties at that particular point in time, while acknowledging that this may change as new data
or experience become available. This ‘explanation’ may include not being able to offer an explanation
at all, and openly acknowledging this. The more relative statement ‘a useful explanation can be good
enough’ was felt within the team to more accurately reflect the data in capturing the dynamic context
within which the explanation is negotiated between GP and patient, therefore requiring that the
prevalent explanation be more contingent, flexible and modifiable as new clinically relevant information
or additional patient experience becomes apparent.
In addition, it was felt important to try to surface the specific impact of setting, given the exclusive
focus of this project on primary care interventions. The team therefore explored the proposition that
‘a contextually sensitive therapeutic response (i.e. a setting within which a patient feels that their concerns
are being addressed) facilitates resolution’. Three of the programme theory statements were prioritised
for a fuller exploration [indicated below with a double asterisk (**)]. See the finalised list of exploratory
programme statements in Box 1.
Finally, at a relatively late stage of the review, the wording of programme theory 2 was amended to
read ‘focus on symptom management versus labels’. This was in direct response to the equivocation
within the literature, and surfaced among stakeholders, regarding the utility of a label. In some contexts,
a label was seen to offer validation to a patient or entry on a pathway, and there was some evidence
of perceived differences in the value between two labels (e.g. CFS and myalgic encephalomyelitis).
The revised wording offered a choice rather than a dogmatic course of action.
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Propositional statements
A series of propositional statements were devised linking characteristics with key outcomes in the
form of ‘if–then’ statements.
Programme theory 1: belief (in the patient, doctor and symptoms) is key
How might this work?
IF HPs show that they take the patient and their concerns seriously, THEN the patient will engage
with treatment.1
A consistent response from patients within qualitative studies, qualitative syntheses and the intervention
clusters is that patients want their concerns to be taken seriously. Patients are more likely to feel that
they are being taken seriously when the GP:
l pays empathic attention to them as individuals, meaning that the GP knows their personal
circumstances and has an open and empathic approach105–107
l ensures a good conversation by treating the patient as an equal partner105,108
l is attentive to their symptoms by exploring these symptoms in depth and by acting on them.108,109
These findings cross-cut the foci of other programme theories, especially programme theory 2
(focus on symptom management vs. labels) and programme theory 3 (a healthy professional–patient
relationship is fundamental). Furthermore, within a healthy climate for communication, there is increased
likelihood that a further programme theory will be accessed [i.e. that doctor and patient will negotiate
and reach a congruent understanding of the disease (programme theory 5)]. Locating or co-ordinating
treatment within primary care is also described as being likely to activate a further programme theory,
not as a location but in recognition of the GP role, namely that of better knowledge of personal
circumstances, which is achieved through continuity of care.
BOX 1 Finalised list of exploratory programme statements
PT1: belief (in the patient, doctor and symptoms) is key.
PT2: focus on symptom management versus labels.
PT3: a healthy professional–patient relationship is fundamental.
PT4: a contextually sensitive therapeutic response facilitates resolution (**).
PT5: congruity between disease models facilitates treatment.
PT6: working together, professional and patient can exit the diagnostic cycle.
PT7: psychosocial talk only to be cued by the patient (**).
PT8: a useful explanation can be good enough (**).
Prioritised statements are indicated with a double asterisk (**). A fuller explanation of each programme
statement follows below (see programme therories 1–8). PT, programme theory.
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Two further observations can be made. First, the trend away from the personal GP to more of a team-
based approach, with the associated difficulties in making an appointment with the same GP, is likely to
fragment this knowledge. Paradoxically, it may heighten the likelihood of meeting at least one GP with
whom one has a rapport. Larger practices also extend the prospect of more flexible appointments and
individual therapists.110 Second, the need to be believed is often highlighted as key at the beginning of
the consultation episode. However, patients also express a need for the GP to keep believing in them,
even when negative test results or other modifiers challenge this therapeutic relationship. In group
interventions, this feeling of being understood could alternatively derive from fellow participants with
similar problems (see Chapter 465,84,85).
Conversely, not being believed may have a significant impact on individuals with myalgic encephalomyelitis/
CFS. These patients have reported feelings of shame associated with invalidation of their symptoms,111
with patients sometimes attributing their feelings of shame to the attitudes encountered from medical
professionals and others expressing the idea that they were made to feel that myalgic encephalomyelitis/
CFS was ‘all in their heads’.112
Contextually, there is reason to believe that the impact of non-belief by the HP may differ according to
the amount of social support being received from friends and family by the individual. Kendrick229 cites
the mechanism of the Stress Buffering Model in achieving an ameliorative role of social support so
that any potentially shaming effects of illness invalidation are diminished. However, ‘illness invalidation’
must not only be considered in the context of the direct relationship between HP and patient; the GP
is also a source of diagnosis that offers social identity, removing the patient from perceived isolation.113
Such labels may be accessible for fibromyalgia or CFS, but are typically lacking for MUS/somatoform
disorders, which are, in fact, characterised by an absence of diagnostic labels. In this context, ‘diagnosis’
lacks the precise use favoured by the biomedical model, instead referring to a number of unexplained
symptoms making it challenging to pass these on to the patient. Recent commentators have remarked
on the risk that the new somatic symptom disorder in DSM-5 may mislabel many people as mentally
ill.20 The absence of a label or diagnosis does not necessarily throw into question the GP’s belief in the
validity of the patient’s symptoms. However, were this to translate into an expression of non-belief,
verbal or non-verbal, by the HP this could indirectly undermine the patient’s credibility should the
patient decide to disclose this non-belief to family members or significant others.111
How the disease label is viewed within the medical profession and within society more generally is
another source of potential variation. Doctors may be more likely to maintain their belief if they are
able to map the patient’s symptoms to a disorder that they recognise or understand. Labels may also
offer patients a communicative mechanism by which they can validate their experience with their
family members, serving as a form of ‘shorthand’. The corollary is that where the label is perceived
negatively, being associated with ‘skivers’73 or those who are ‘hysterical’,114,115 the label operates in a
negative way, causing frustration, stigma and shame. Patients with unexplained neurological symptoms
are reported to prefer the term ‘functional’ to MUS as it appears to offer a diagnostic category with
which they can identify.114 As Jutel230 observes, diagnosis, as a form of classification, valorises some
points of view, and silences others.
How might this be explained?
Many studies confirm the need for a patient to feel heard, believed, accepted,118 and this aligns well
with the Health Belief Model,119 which emphasises the importance of the patient feeling that the GP
is gaining a true understanding of where they are coming from. According to the Health Belief Model,
three factors explain whether or not a patient will decide to consult their GP:
1. the extent to which a person perceives a threat to his or her health
2. the degree to which a person believes that consultation with the GP will help to reduce that threat
3. ‘cues to action’, prompting a person to consult the GP, either internal (symptoms) or external
(e.g. mass media communications or interpersonal interactions).231
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When a patient feels that their GP understands them, this may pave the way for a healthy relationship
between patient and professional that helps when subsequent challenges need to be ‘smoothed out’.
As a corollary, the literature also reveals the unhelpfulness of the patient not being listened to and the
psychological impact that this may have.120 For example, Horton-Salway232 describes how a member
of a myalgic encephalomyelitis support group attributed much of the associated depression with the
challenge of trying to convince doctors that there is something wrong with them.
Therefore, a major role of the initial conversation may be in serving to validate the patient’s
experience.122,123 Numerous studies describe how this is critical to the receptivity and subsequent
engagement of the patient within the treatment pathway. Hoedeman et al.233 describe the contents
of a ‘consultation letter’, which states that patients are best helped by having their symptoms taken
seriously. Other content of this consultation letter implicitly confirms that the GP symbolises their
belief by not telling the patient that their symptoms are ‘all in your head’; conducting a physical
examination at each visit; and arranging to see the patient at regular intervals. However, this study
does not address whether or not repeated examinations might have unintended consequences in
contributing to patient concern that the doctor had previously missed significant physical pathology.
Potentially, a pattern where further physical examination is directly triggered either by new symptoms
or by exacerbation of existing symptoms may be more acceptable and more feasible within existing
time and resource constraints.
What are the implications?
A key factor in whether or not a patient will engage with, and ultimately benefit from, a treatment is
whether or not they believe that their concerns are being taken seriously and that their feelings are
being respected. It is important that a GP works continuously on maintaining this belief beyond the
initial consultation, making sure that any referrals and tests are justified123 and explained so that they
are not misconstrued. However, the reality of demands of GP workload must understandably recognise
instances where GP and patient negotiate an agreed explanation for and understanding of the patient’s
symptoms (e.g. programme theory 8). Given the absence of a link between the patient’s symptoms and
a serious pathology, both may agree that there is no need for ongoing review by the GP. In other more
complex cases, regular review every few weeks by the same GP with whom the patient maintains a
good relationship may be helpful in managing the patient’s concerns and may help to avoid superfluous
investigations and referrals.126 However, such complex cases probably constitute only a minority of
patients presenting with MUS, and so such regular reviews need not place a substantial burden
on already-pressed services. Some evidence suggests that preparing the patient for a negative or
inconclusive outcome, in cases where the tests and investigations are predominantly for the purpose
of ‘reassurance’, can be considered helpful.127–129
Programme theory 2: focus on symptom management versus labels
How might this work?
IF HPs focus on the patient’s symptoms and how to manage them, THEN the patient feels that something
is being done about their symptoms and that their symptoms are not being dismissed as all in the mind.130
Several commentators have explored the importance of the label assigned to the patient’s
symptoms.113,114,125,131 Stone et al.4 has reported on the potential of particular diagnostic labels to offend
patients, particularly ‘when they imply a psychological rather than a physical explanation’. He observes
that ‘Although “medically unexplained” is scientifically neutral, it had surprisingly negative connotations
for patients’4 and proposes use of a preferred term ‘functional’. Jutel proposes reorientation from
clinical diagnosis to clinical interpretation as a route to ‘reconcile medicine and the individual, the
unexplained symptom and the patient distress’.230 The objective becomes not accurate diagnosis but
satisfactory interpretation (e.g. programme theory 8). More recently, Sharpe et al.234 highlights the
erosion of the uncertain boundaries between medically explained and MUS, with the latter having
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previously been seen as the traditional domain of the psychiatrist.131 In doing so, he advocates a
closer working relationship between psychiatrist and clinician consonant with the current professional
movement towards a more integrated approach to physical and mental symptoms in primary care.130
How might this be explained?
Medical diagnosis explains, legitimises and normalises.113 The absence of diagnosis denies the patient
an immediate explanatory framework, a treatment, access to the sick role and legitimisation of the
complaint.113 This factor surfaced during the project’s public involvement consultations (for details see
Chapter 2, Patient and public involvement). Diagnosis of MUS is recognised as particularly challenging,
with HPs demonstrating considerable uncertainty, particularly where symptoms are seen as particularly
complex (see the qualitative review in Chapter 491). Jutel230 sees this as inevitable given that both
practice and the literature have sought to reduce a diversity of symptoms into a single unitary term:
‘MUS’. In this context we can identify a demonstrable difference between IBS, fibromyalgia and CFS,
where the clinician is able to pass on a definition in their transaction with the patient, and ‘MUS’,
where a clinician seeks to explain that the patient has one or more symptoms for which the clinician
does not have an explanation.
Jutel230 highlights circumstances where, when a patient presents with multiple unexplained causes,
their doctor may translate these into ‘a unitary condition under an informal diagnostic category linked
to psychiatric dysfunction’. Whether the new DSM-5 classification114 is practically useful or whether
the label simply operates as a ‘secret’ label that facilitates coding of patients on administrative systems
or for academic research purposes requires further exploration. However, this technical consideration
should not be allowed to subvert recognition of overall resistance to the use of labels. Labels may be
perceived as consigning patients to a metaphorical ‘scrapheap’132 and so it has been suggested that
metaphors, models, informal terms or stories could productively be used as an alternative to labels.132
Stone235 also describes how taking physical symptoms seriously helps to establish trust between the
patient and the professional.132 Some clinicians report not giving the patient a formal ‘label’, suggesting
that there are circumstances when either patient or clinician, or even both, do not feel it productive to
‘trigger’ a label.
What are the implications?
Given that evidence on the value of either condition-specific labels or of the general MUS label is
equivocal, GPs should seek to focus the consultation and subsequent treatment on symptoms. Use of
labels is located firmly within a biomedical disease model which is not generally helpful within the
context of MUS. If it becomes clear that the patient would value assignation of a label, then a GP can
consider this possibility. In some cases, diagnostic labels will be required in order to access a particular
treatment pathway.
Programme theory 3: a healthy professional–patient relationship
is fundamental
How might this work?
IF HPs maintain a positive relationship with the patient, THEN professional and patient develop a
shared understanding of the patient’s experience.
Many papers identify the importance of initiating and maintaining a healthy relationship between
professional and patient as a key factor in successful resolution of MUS. Deale and Wessely29 confirmed
this programme theory via a questionnaire survey of 68 patients with CFS. They found that dissatisfied
patients were more likely to describe delay, dispute or confusion over diagnosis; to have received and
rejected a psychiatric diagnosis; and to perceive doctors as dismissive, sceptical or lacking knowledge
about CFS. Dissatisfied patients were also more likely to feel that the advice given was inadequate or
conflicting. In contrast, satisfied patients were more likely to perceive doctors as caring, supportive and
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interested in their illness; to state that they did not expect their doctors to cure CFS; and to perceive
their GP or hospital doctor as the source of greatest help during their illness. These findings support
the view that medical care is evaluated less on the ability of doctors to treat CFS, and more on the
interpersonal and informational skills of those delivering care. One apparent mechanism for improved
satisfaction with care is ‘engagement’.133 Such engagement uses a ‘five areas approach’ that ‘allows
patient and therapist to develop a deeper understanding of the patient’s physical symptoms by
integrating the full range of the patient’s experiences in areas of (1) situation, relationships, resources,
and practical problems; (2) symptoms; (3) behaviour; (4) thinking; and (5) feeling’.131 Extra time spent on
such engagement is seen as critical.86 However, this provides particular challenges within the pressured
time and resource context of primary care.
How might this be explained?
Substantial numbers of studies have identified the importance of trust to the success of the primary
care consultation. Although trust is key to most medical contexts, it becomes even more important
within a context where epistemological incongruence and communication challenges are likely to occur.
In this context, trust has both a supportive function and an enabling function, and it affects not only
what is said but how it is said and interpreted.
Continuity of care is also related to the formation of trust. GPs feel that trust makes patients more
likely to disclose problems and, in return, GPs feel more able to openly challenge patients.160 In contrast,
referral to other types of HP may subvert the trusting doctor–patient relationship; for example, referral
to an orthopaedic surgeon for neck pain was seen to act contrary to a provisional psychosomatic cause.141
Under other circumstances, however, referral to an orthopaedic surgeon offered reassurance and backup
to the GP diagnosis. Collectively, this emphasises the importance of preparing the ground with clear
communication of expectations of both GP and patient from the consultation.
Central to trust is empathy; this may be challenging if patients are felt to be ‘heartsink’132 or demanding
of time and resources.131 Wileman et al.236 report how GPs, when interviewed, felt that showing an
empathy with the patient, and taking an interest in them, enabled the patients to gain personal trust
in the doctor.
Another sign of a healthy relationship is avoidance of destructive and unhealthy relationship behaviours.
Commentators have highlighted the risk of what they have labelled the ‘duet of escalating antagonism’.138
A similar challenge is posed by ‘looping effects’ (vicious cycles where the emotion of one person causes
escalation within the relationship).149
A contrary type of dysfunctional relationship is the ‘dependency relationship’. Salmon et al.218 highlight the
importance of ‘getting the balance right’ between meeting the patient’s support needs and encouraging
dependency. It should also not be assumed that all patients experience an ongoing relationship with their
GP72 or that they may not be simultaneously managed by multiple practitioners.91,92
What are the implications?
The state of the professional–patient relationship is critical to the success of the primary care model, both
in initiating a consultation and in maintaining engagement. Where a patient’s interaction persists beyond
initial consultation and investigation, a GP must utilise communication behaviours that allow continual
renegotiation of the patient’s understanding of their symptoms in the light of that patient’s ongoing
experience and as new information becomes available.98 A patient will be more likely to volunteer useful
information within a climate of mutual trust. Increasingly, the general public appears to be becoming
aware of the potentially debilitating effects of stress-related symptoms that do not have a clear organic
basis.237 At the same time, a GP must work hard to prevent the creation of a model of dependency.
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Programme theory 4: a contextually sensitive therapeutic response
facilitates resolution
How might this work?
IF diagnosis, management and treatment takes place within a primary care setting, THEN the patient
experiences continuity of care that may lead to progress and resolution.
A key issue in assessing the value of primary care-based behavioural approaches relates to the perceived
relative advantage of delivering treatment within a primary care setting. Within the literature the discourse
revolves around two types of potential advantage, namely the operational and the conceptual.139 It is
noteworthy that many operational issues, relating to the logistics and practicality of a primary care setting,
are stated explicitly, whereas perceived inherent advantages of the setting from a therapeutic perspective
tend to be understated or even implicit.
Operational benefits of a primary care setting
Commentators express many potential benefits in favour of treating MUS in primary care. For example,
Kroenke and Swindle238 suggest that primary care may be considered an appropriate care setting,
highlighting how patients who do not wish to explore psychological attributions for their symptoms,
and are therefore unwilling to accept psychological/psychiatric referral elsewhere, may find primary
care more acceptable.86 However, such a conclusion fails to acknowledge that a large proportion of
MUS patients do not have underlying psychological causes or associations.83 Foremost among identified
benefits is the opportunity to understand the patient’s circumstances and context and to bring this
understanding to bear when interpreting their symptoms. Personalised care is a fundamental value for
general practice. Knowledge of the patient and his/her history and context is considered to facilitate
recognition of MUS early in the consultation.142,151,160 Other clues used by GPs to aid recognition of MUS
in familiar patients include frequent and often prolonged consultations, with many frequent requests for
referrals, and engendering subjective feelings such as irritability and frustration.
Huibers156 advances several reasons why GPs may be particularly suited to performing psychosocial
interventions in primary care. First, GPs are able to exercise the ‘stepped-care’ principle so that all
appropriate options are explored prior to referral to specialist care. Second, many GPs already provide
general support to patients with stress, anxiety or depression. Offering GPs a behavioural toolkit to
manage patients with MUS as well as those with more generalised complaints may simply be making
better use of their time with a stronger likelihood of benefit or resolution. However, introducing
additional demands on an already pressurised frontline service, with the associated demands on time,
skills and motivation that such an approach might bring, may not be considered feasible. One alternative
may lie with the availability of psychological practitioners based in primary care (e.g. through IAPT
workers based in primary care), which is becoming an increasingly common model. These interventions
offer an opportunity to build on an existing relationship of trust as an alternative to an unfamiliar
provider in secondary care. Finally, provision in general practice could potentially disrupt the strongly
entrenched split between psychological and physical forms of primary care.
Conceptual benefits of a primary care setting
Continuity of care is frequently cited as a benefit of locating treatments in a primary care setting239
and is particularly endorsed by the Royal Colleges (Psychiatrists, GPs and Physicians) which espouse
the value of co-locating physical and mental health services.240 It is frequently assumed in the literature
that being seen repeatedly by the same professional is advantageous. Although this may be true from
a service perspective (e.g. in perpetuating stable expectations and a consistent standard of care), there
may also be negative consequences that become particularly important during the breakdown of the
therapeutic relationship. Different personnel may be able to offer an alternative perspective, establish
a different type of relationship or draw on a different set of intellectual and emotional ‘resources’
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in seeking to address the symptoms. By way of a contrast, Peters et al.180 report how patients may
gravitate towards the doctor with whom they have had a longstanding relationship in the knowledge
that they would ‘avoid challenging their current ways of managing their problem’. The long-term nature
of the relationship, ‘time is on our side’, was seen as an opportunity to work together on resolving
patient symptoms.
Although it is difficult to draw robust conclusions about continuity of care, given such variation within
the professional–patient relationships, it is certainly worth recording that developments within UK
general practice (e.g. larger practices, practice teamworking rather than personal GP provision,
increasing front-line nurse roles, etc., to support improved access and out-of-hours coverage) may
subvert this as a claimed advantage.160
Contrary evidence
This realist review found some evidence that patients believed that primary care is an inappropriate
setting for exploration of psychosocial issues. Murray et al.241 offer multiple reasons why this might
be the case, citing patient beliefs concerning the superiority of self-management of symptoms and
assumptions that limited treatment options would be available. Past experiences of primary care may
also be influential.104 Patients may feel that their primary care provider does not have the ability to
resolve such health problems.92,137,228 Advocates of the BodyMind Approach, one suggested therapeutic
intervention for disrupting the expression of MUS, attributed benefit from delivering the intervention
in a setting that does not hold the negative connotations of health premises.65
Murray et al.241 further highlights other, practical, constraints that may negatively impact on diagnosis in
primary care. Of particular resonance are the short consultation time available and a correspondingly
heavy patient caseload. Patients may ‘second guess’ the receptivity of the primary care professional,
based on prior familiarity with the practice context. Other considerations may relate to financial factors
and a lack of local mental health resources.
How might this be explained?
Many factors used to endorse location of services in primary care are generic and seem determined by
current models of service delivery, not by the specific requirements of these treatments. This ongoing
discourse is currently taking place against a backdrop of service reconfiguration, new models of care
and migration of services from secondary to primary care. A further argument relates to integration
of physical and mental health services, for which MUS seems to have a particular case.
What are the implications?
A GP must seek to establish a role not as an expert on the patient’s symptoms, but as a co-ordinator
and facilitator of the patient’s overall care, regardless of setting. Referral must not be used simply for
respite, possibly signalling that the doctor has run out of ideas or patience. Conversely, demand for
referral may be initiated by the patient, who requires some sort of ‘reassurance’ that nothing more
sinister underlies their symptoms. Care therefore needs to be taken that referral is being initiated in
response to need and that entry into the referral pathway will benefit the individual patient in the
long run.
The main strength of a primary care setting appears to be the opportunity to offer continuity of care,
contextualised within an understanding of a patient’s individual circumstances. However, recourse to
external expertise or resources may help in exiting unproductive loops and in advancing the negotiation.
Such a finding fits well with the collective body of effectiveness studies that cover a wide variety of
primary care-based service models from those that deliver services on primary care premises through
to those where the GP acts as initiator and co-ordinator of care but where the services are actually
delivered by another professional.
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Programme theory 5: congruity between disease models
facilitates treatment
How might this work?
IF the disease model advanced by the HP matches, or is compatible with, that of the patient, THEN the
patient will accept treatment.20
Qualitative research has revealed that a dissonance frequently exists between the mental conception, or
models, of disease held by the patient and those held by the GP.242 In a qualitative study that accompanied
a trial of training family practitioners in reattribution to manage patients with MUS (the MUST trial),
Peters et al.180 describe how patient explanatory models were ‘multifaceted, simultaneously incorporating
disease and non-disease causes and the interaction between them’. This complexity was portrayed in
fragmented and chaotic narratives ‘presenting multiple, seemingly unconnected and incoherent problems
with no clear beginning or end’. In contrast, some patients viewed GPs as holding ‘more unidimensional,
dualistic and hence simplistic models about cause and resolution of problems than their own’.180
Other studies note how patients remark on the insufficiency of doctor’s illness models.243 In their
metasynthesis of 32 quantitative and qualitative studies of CFS/myalgic encephalomyelitis, Bayliss
et al.165 report that working within the biomedical model has led some GPs to be sceptical about the
existence of CFS/myalgic encephalomyelitis. In contrast, GPs who provide a diagnosis were likely to
hold a broader, multifactorial biopsychosocial model of CFS/myalgic encephalomyelitis and also to
possess more positive attitudes to its symptoms.
Achieving greater congruity between disease models,244 reached through a process of negotiation as
modelled by medical reattribution interventions, may thus contribute to improved communication
and, potentially, to a healthier patient–professional relationship.98 However, some evidence suggests
that these improvements are not as far-reaching as intended, contributing only to improved patient
satisfaction but not to more effective treatment.
van Ravenzwaaij et al.245 identified nine different potential explanatory models for MUS. This examination
concluded by identifying the superiority of a cognitive–behavioural metamodel, principally because
it was the only model to include all four domains (i.e. somatic causes, perception, illness behaviour and
predisposition) inhabited by the alternative models.11 This metamodel proposes that the cause of MUS
is a self-perpetuating multifactorial cycle, with interaction of different factors across the four domains.
This model provides a framework to incorporate patients’ own personal perpetuating factors as well as
predisposing and precipitating factors. These three categories offer a framework for understanding
individual variation in MUS. Predisposing factors are individual characteristics that make people more
vulnerable to distress, physiological arousal and bothersome physical symptoms. Precipitating factors
are events or factors that initiate physically symptomatic episodes within vulnerable asymptomatic
individuals or that increase disability or distress among those who are already symptomatic. Perpetuating
factors maintain symptoms, distress and disability, and extend their period of duration.246 Each factor can
result in physical symptoms and/or distress. The doctor and patient collaborate to identify those elements
of a patient’s personal circumstances that might contribute to the patient’s distress. The metamodel
incorporates at least five different theories: sensitivity, sensitisation, somatosensory amplification,
endocrine dysregulation and the illness behaviour model. The authors conclude that these explanatory
models should be ‘integrated in the educational programs of all medical doctors in order to improve the
quality of care for patients with persistent MUS’.247
How might this be explained?
The conceptualisation of the ‘unexplained symptom’ has been seen ‘to shift responsibility for the
inability to explain the symptom from the doctor to the patient’. Hadler248 describes a ‘contest of
diagnosis’, with medicine ‘not [being] likely to accept blame for subjecting the patient to months of an
exercise that turn[s] out to be flawed in design and iatrogenic in execution’.248 Johansen and Risor242
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identify what they term ‘epistemological incongruence’ between dominant disease models and the
realities of encountering patients with persistent symptoms. When facing cognitive incongruence,
GPs should strive to achieve relational or emotional congruence, through the establishment of good
relations, alliances and partnerships with patients.242 This is seen to contribute to positive experiences
of mutual trust and validation.
Achieving congruity of models is also a key factor in treatment success. If a patient feels that a proposed
treatment is compatible with their illness model and with their preferences/lifestyle (e.g. dance classes
vs. exercise) then they are more likely to initiate the treatment and to persist with it.249
What are the implications?
Successful resolution of, not necessarily recovery from, challenging MUS is largely dependent on a
shared understanding of the problem.250 There is clear evidence that the different mental models used
by GPs and patients to understand the symptoms may contribute to communication difficulties. Ideally,
professional and patient should arrive at a negotiated and necessarily contingent understanding; a
biopsychosocial model, as proposed by Engel > 40 years ago,251 may offer a meeting point between
initially conflicting or incompatible models.
Programme theory 6: working together, professional and patient can
exit the diagnostic cycle99,102
How might this work?
IF patient and professional can avoid perpetuating extensive and unproductive diagnostic tests,
THEN patient and professional achieve a sense of progress.252
Patients appear to attach great importance to gaining a diagnosis, which was reported in one study
of CFS patients as the single most helpful event.253 However, the same study reveals this as another
example of dissonance between patients and GPs, with GPs seeing a definitive diagnosis for CFS as
disabling, potentially becoming a self-fulfilling prophecy.253 Patients also find it frustrating if they have to
wait for years before receiving a diagnosis. Diagnostic tests are viewed as a way of securing a diagnosis,
but at the risk of increased frustration if a definitive diagnosis is not actually realised. Frustrations
also accompany receiving the ‘wrong’ diagnosis, with some patients expressing a preference of myalgic
encephalomyelitis over CFS.253 Misdiagnosis also carries frustrations and risks. GPs therefore find
themselves in a paradoxical situation where the ordering of diagnostic tests may be variously seen as a
response to patient demand, a signal to the patient that they are unable to resolve the situation within
their more immediate resources, an abdication of interest or commitment to the therapeutic relationship
and a potential cause of additional frustration when faced with a subsequent negative result. Such
frustration can be mediated if the GP or secondary care clinician has created clear expectations, with
the patient being advised of the potential implications of a negative test. Avoidance of unnecessary
tests carries further benefits for the patient and health-care system; it reduces costs, patient anxiety
and the possibility of identifying ‘incidentalomas’, which then need further investigation but may not be
of serious significance.254,255
How might this be explained?
Several authors use the concept of the ‘diagnostic cycle’ in connection with MUS. Figure 59 shows a pictorial
representation of diagnostic loops potentially leading to an unproductive diagnostic cycle.257 This concept
figures in the title of a study of chronic pelvic pain.102 The authors describe the underpinning biomedical
programme theory that diagnosis will, in turn, lead to a ‘suitable resolution of the problem’. However,
the reality as revealed by the women’s narratives is that ‘many women do not complete this cycle, they
become stuck at a certain point, or re-enter the cycle repeatedly.Women can only opt out of the cycle if
the problem is resolved, or by choosing to disengage with medical care’.227 Women enter the diagnostic
cycle actively seeking an explanation for their pain and are consequently frustrated if this is not attained.
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In a subsequent study, McGowan et al.258 revisit this phenomenon, again in the context of chronic
pelvic pain, describing how failure to receive a ‘medical explanation’ for their pain can lead women
to enter ‘a cycle of re-investigation and re-referral’. Burton et al.157 extend this concept to a wider
group of symptoms to be addressed by a primary symptom clinic. The Symptom Clinic model ‘aims
to negotiate a “medical” explanation for symptoms involving physiological processes’.157 The Serene
health organisation in Plymouth uses a diagram of the unproductive diagnostic cycle to illustrate the
need to ensure that patients progress along the pathway and to not become becalmed within a cycle of
successive tests and/or referrals.257
Stone235 extends this analogy, using the words of a GP informant, to that of a spiral or cascade effect,
where ‘someone sees a specialist, and because the thing is not within the specialty for which they are
trained [they] don’t feel able to exclude organic pathology, and will therefore either make a referral or
intimate that a referral would be required . . .’.
The consultation letter intervention described by Hoedeman et al.259 specifically seeks to avoid
unproductive tests, with the psychiatrist providing detailed recommendations to the GP concerning
management, that is, to avoid unnecessary diagnostic procedures and hospitalisation.
Embarking on such a diagnostic cascade, where the clinician feels out of control of the decision-making
process, has previously been identified as a source of particular stress and anxiety, both for the GP
and for those experiencing the symptoms.260 This further explains why non-resolution of MUS can be
perceived as threatening to the professional–patient relationship. However, a counterargument relates
to the persistent ‘niggling biomedical doubt’ that may be held by a GP, or a prevalent fear of litigation,
requiring them to rule out symptoms related to such conditions as cancer, thus precipitating further
tests or referral.132
The literature reflects an ambiguous attitude towards referral to a specialist and/or for further tests.
Use of referral appears to differ according to whether the GP seeks resolution, reassurance or respite.
In the first context, the GP may genuinely feel, operating within a culture of ‘medical certainty’, that
the patient simply needs a label to attach to their symptoms and then this will serve as a passport
to their legitimate entry into a treatment pathway. If they communicate this prospect to the patient,
then the result of a negative test can prove frustrating to patient and professional alike. On the other
hand, it may be valuable to forewarn, and thereby prepare, the patient when a negative result from
SpecialistInvestigationPrimary care
Onward
referral
Symptom and
experience/examination
Recognition
FIGURE 59 Pictorial representation of diagnostic loops potentially leading to unproductive diagnostic cycle.256 A pictorial
representation of the loop that people with MUS can pass around. Reproduced with permission from Byng (Plymouth
University, personal communication, 2018).257
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investigations may be expected.261 In the second context, the GP is seeking a second opinion, either
to confirm or to disconfirm a putative diagnosis or to offer an additional ‘resource’ that they would
otherwise not be able to access. Confirmation or negation of a GP’s diagnosis may reassure the GP
that they are not missing or overlooking something, but may not necessarily advance the patient’s
agenda.129 In the final context, the GP feels unable to sustain their interaction with the patient in a
healthy manner and so looks for respite during which they are able to reorganise their resources
and plan a future strategy. Shattock et al.262 describes circumstances under which frustration and
hopelessness may precipitate referral.
The verdict resulting from the external referral either to a specialist or for diagnostic tests may or
may not provide useful additional information, but in a way that is only a secondary objective. Being
referred to a specialist or for further diagnostic tests holds considerable potential for frustration –
from a negative test result, from a narrowing down of possibilities or from being assigned a label that
is either unhelpful or unwelcome.
If the patient seeks a referral, in the quest to receive a clear and ambiguous diagnosis, they may find
any persistent medical uncertainty unfulfilling and unrewarding.263 From the patient’s perspective,
there are potential unintended consequences. Referral from the GP to an external source may
undermine the GP’s credibility, creating the impression that the GP is unable to address the patient’s
symptoms within their own expertise or resources. Alternatively, the patient may perceive that the GP
is trying to obviate responsibility, whether or not this is actually the case, or is beginning to find the
professional–patient relationship too demanding and thus requires respite.
What are the implications?
Being tied into the diagnostic cycle can prove frustrating for GP and patient alike and can result in
unwarranted utilisation of referral and/or tests. Ongoing referral from an inconclusive consultation
with a first specialist to subsequent additional specialists may perpetuate and exacerbate this problem.
When tests or referral are being ordered, GP and patient should share an understanding of how they
will potentially advance the patient’s circumstances.123 Tests should not be used in a symbolic way,
nor as a manifestation of GP, or even patient, power.
Programme theory 7: psychosocial talk only to be cued by the patient
How might this work?
IF HPs introduce psychosocial explanations, THEN the patient feels that they are being problematised.
If GPs conduct a physical examination for any new symptoms at each consultation, this may signal to
the patient that the GP is resisting a tendency for early closure by offering an expeditious psychosocial
explanation.264 Some GP trainees describe how they try to initiate discussion as early as possible
about underlying psychological factors.265 This opens the way for future consultations to be able to
legitimately return to these possibilities without appearing a course of last recourse. This illustrates an
important contextual determinant in how programme theory 7 is seen to operate.141
Doctors have also described how CFS/myalgic encephalomyelitis patients resisted any attempt to
attribute their disorder to psychological factors. Patients may feel that a physical explanation for a
symptom does not imply that the doctor is attributing personal responsibility for its onset. Conversely,
patients may feel that, when a doctor provides a psychological explanation, they are implying that the
patient might be able to control, or even reverse, the physical symptoms.113 Given that the patient has
sought help for their distress in the first place, such an interpretation may seem impossible to the
sufferer, and several commentators85,158 observe that this may precipitate stigma and shame. Recent
literature on the causes of CFS reveals a vigorous and ongoing debate about the extent to which the
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condition may be explained by physiological findings. The extent to which physiological explanations
might offer a challenge to the stigma associated with specific labels is not yet clear and may, in fact,
vary across the conditions associated with MUS.
In particular, patients may show themselves as reluctant to engage with follow-up that attributes a
psychological explanation to their symptoms.266 Lewis184 describes how patients were less likely to
engage with CBT if they had strong ideas about what was causing their symptoms, perceiving that
their problem was purely a physical one. The literature contrasts this response to that for other
applications of CBT where patients accept that there is a psychological element to their symptoms.184
Murray et al.241 describe how some GPs are reluctant to suggest a significant influence of psychosocial
factors fearing that this will have adverse consequences. For example, patients may feel that a
psychosocial-oriented discussion will deflect attention away from some serious underlying pathology.180
Indeed, some patients may avoid discussing psychosocial factors for this reason.
Evidence suggests that patients often actively resist reattribution.267 Even when they experience
anxiety and depression, patients with MUS may see these as associated with, rather than causal to,
their physical symptoms.268 Patients’ reasons for not wanting to share psychosocial information may
be sensitive to context; for example, some patients may want to protect their GP from burden.92
However, such caveats do not, in themselves, represent sufficient reason for not asking the patients
about possible anxiety or depression symptoms when taking a medical history.
The GPs may be reluctant to hand the onus of initiating discussion of psychosocial cues to patients,
feeling that the patient is unlikely to volunteer such information within the time-limited constraints of
a brief consultation.269 However, qualitative analysis of audiotaped consultations between patients and
GPs revealed that in > 95% of the consultations with patients with MUS, patients presented signals or
cues of one or more psychosocial problems.270 Many patients with MUS presented psychosocial cues
that their GPs tended to ignore until they encountered a physical symptom that offered a rationale
for exploring or investigating. Salmon et al.271 found that patients with MUS appeared to be seeking
emotional reassurance more than patients with clear organic problems.
Thus, GPs have cause to reflect on their own communication skills with such patients.272
How might this be explained?
Traditionally, GPs have sought to rule out an organic illness before exploring a possible psychological
origin. This focus on organic illness has been suggested as a potential reason for low detection rates
for mental health problems in primary care generally.273 It has also been suggested that this approach
can reinforce the patient’s view that the cause is physical, which could exacerbate the symptoms –
especially if the doctor and patient have not previously discussed the possibility of something other
than an organic cause.274,275 By contrast, current GP training places emphasis on taking a proper
biopsychosocial history, acknowledging that even when a patient appears to have a physical problem
this may be associated with accompanying psychological symptoms or exacerbating social difficulties.130
This approach is further underpinned by the philosophy of ‘parity of esteem’ between physical and
mental health problems currently endorsed by the same Royal Colleges.276
Promising initial results in reattribution training from poorly designed studies have probably been
unduly influential in supporting the hypothesis that patients will achieve better outcomes if the GP
and patient are able to establish a clear link between psychological distress and physical symptoms.277
This remains an area where the literature and the theoretical base underpinning particular interventions
demonstrate largely unresolved dissonance. Rosendal77 highlights potential explanations for these
conflicting results, citing the heterogeneity of both patients and their disorders and the differential
effects that psychosocial interpretations and interventions may have in the short term.278
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What are the implications?
Most patients presenting to HPs with MUS believe that they have a physical health problem, rather than
a mental health problem. They therefore feel more able to trust a physician to respond appropriately
to their ‘physical’ health problems.279 In a sizeable proportion of cases, patients with MUS may in fact
have an underlying psychological cause for their physical symptoms. What is less clear is the extent to
which psychological problems are the consequences of a patient having unexplained physical symptoms.
In the light of this, doctors may choose to respond to patient cues of emotional distress rather than
directly asking patients about their feelings, unless doing so in the context of understanding how their
symptoms have affected their mood. The increased risk of suicide reported among patients with MUS
suggests that elucidation of mood and associated risks, by one means or another, is important in any
assessment of such patients. However, GPs need to ensure that the approaches that they typically use in
consultation and diagnosis do not in themselves generate or maintain MUS.132,280
Programme theory 8: a useful explanation can be good enough
How might this work?
IF HPs offer an explanation that they believe is congruent with current facts and uncertainties AND
this explanation makes sense to, and is accepted by, the patient, THEN the patient believes that it is
possible to maintain the therapeutic relationship.274
Patients frequently express dissatisfaction with explanations that are provided for their symptoms.20,129
However, where explanations are effective and empowering, making sense to both patient and clinician,
patients feel a corresponding sense of satisfaction.20 Salmon et al.281 describe how empowering
explanations are tangible, exculpating and involving.20 Conversely, primary care providers sometimes feel
unable to explain symptoms.272,282 Numerous reasons are advanced to seek to explain this inability.139
These include feeling unsure or inadequate. Doctors frequently resort to the use of multiple tests in the
pursuit of certainty or may refer to a specialist to compensate for their own perceived uncertainties
or inadequacies in relation to this complex range of symptoms and explanations. Kirmayer et al.283
observe that lack of explanation reflects ‘the limits of medical knowledge, available technology and
the epistemological difficulties of assigning a clear cause to subjective complaints like pain and fatigue,
which may have no objectively measurable correlates and may change rapidly over time in quality and
intensity’. Additionally, clinicians, including GPs, are unlikely to have received any training in providing
effective explanations for MUS.159,265
This uncertainty is seen to persist to subsequent stages of the pathway, namely to access to treatment
or referral.139 In the intervention studies, patients clearly valued explanations that helped them to
come to terms with and accept a diagnosis (see Chapter 4). Where this explanation is not forthcoming
within a primary care setting, patients valued being able to access specialist knowledge and information
on their symptoms and what they might mean.85
The converse is that if the GP and patient feel able to accommodate uncertain or ‘good enough’ explanation
at the stage of diagnosis, they may jointly feel able to carry this forward, given their ongoing relationship,
to the subsequent stage of action, making that equally contingent and pragmatic.20 For example, Lewis184
describes how therapists were prepared for ‘having a go’ rather than feeling sure about their approach,
acknowledging, however, that working in such an ad hoc way can feel uncomfortable. Under such
contingency, patients may modify their expectations and may seek to self-manage their symptoms rather
than necessarily resolve them. In a trial of self-management for chronic fatigue in primary care, Friedberg
et al.151 contrast the theory of illness with a more common physical deconditioning and avoidance model,
particularly emphasising that their model makes no assumptions about recovery or cure.
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How might this be explained?
Although GPs may feel a compulsion to seek a definitive diagnosis and thus achieve ‘closure’ of
the consultation, several commentators describe the unhelpfulness of this ‘myth of certainty’.284,285
Howman286 characterises the prevailing need for GP trainees to want to ‘fix things’ as evidenced
in contemporary medical training. Where distrust is initially present, either of doctors or of HPs
more generally, providing a frank and bounded explanation, even if acknowledged as contingent or
incomplete, may be seen as a form of propitiation.
Some commentators have located that doctors, including GPs, experience difficulty with admitting
uncertainty within a prevalent discourse of power.236 Medical training and the role of the GP assert the
importance of the GP appearing competent and knowledgeable168,287 as a way of ensuring their medical
authority.241 Jutel230 highlights that, specifically, diagnosis is the foundation of that social authority.
MUS, and their associated uncertainty, can pose a direct challenge to this authority.181,288
Furthermore, some commentators describe how truthfulness about the limitations of medical options
can enable patients to discard the likelihood of medical resolution of their symptoms. This can serve to
reduce their dependence on their GP and encourage self-reliance.288 In this way, patients are facilitated
in building up their resilience, adaptability and defiance.187 However, it may also have the unintended
consequence of steering the patient to seek resolution from complementary therapies, often at great
personal expense and with limited evidence of effectiveness.289
The value of a contingent ‘good enough’ explanation, rather than a more definite conclusive verdict, is
that it keeps open the possibility of medical options. Clinicians may be concerned about the possibility
of missing a serious diagnosis, and this risk-averse culture may influence their test-ordering behaviour.
Lines of communication between GP and patient remain open without offering a solid prospect of
immediate resolution by medical means.
Caution must be expressed, however, against the presumption that it is simply the apparent agreement
of doctor and patient with a ‘shared’ explanation that underpins satisfactory resolution. In a qualitative
analysis, Stanley et al.290 demonstrated that agreement between patients and their doctors in assigning
symptoms to broadly defined ‘syndromes’ appears to reflect collaboration that is largely expedient,
implying that something more pervasive than superficial compromise is required.
What are the implications?
While the evidence relating to the value of the GP’s explanation for the patient’s symptoms is broad and
diverse, it offers a strong theme relating to providing a contingent and sincere explanation. This explanation
needs to be seen, by both GP and patient, to be compatible with available facts and experiences but to
remain flexible to future adaptation and modification as further information and experience becomes
available. Above all, the explanation must keep open possible physical explanations as a potentially viable
line of inquiry. The explanation should be jointly owned and the product of ongoing negotiation between
GP and patient.98
Specific evidence exists for the value of specific management techniques in improving clinician
communication skills for patients with MUS with the aim of reducing investigations and health-care
costs.152 For example, in a multicentre RCT, Weiland et al.291 describe how medical specialists received
a 14-hour training programme based around experiential learning and feedback. Using techniques
from CBT, those in the intervention group were stimulated to ‘seek interrelating factors (symptoms,
cognitions, emotions, behaviour, and social environment) that reinforced a patient’s symptoms’.291
The specialists were taught to explain MUPS understandably, reassure patients effectively and avoid
unnecessary diagnostic testing.
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Rief et al.102 describe a training package entitled ‘How to Manage Patients With Unexplained Physical
Symptoms’, which utilises guidelines that embody much of the programme theory elicited by this
realist review (Table 16 maps programme theory components to the guidelines). This 1-day workshop
included how to communicate with MUPS patients, when to start and stop medical examinations, and
treatment options. GPs valued this workshop as highly relevant to their daily practice. Patients in the
study reported a small reduction in general psychopathology between the index visit and the 6-month
follow-up. Data suggesting better outcomes for the patients of trained GPs were inconclusive, given
that the attribution of this improvement to the GP training is less clear and could potentially be
confounded by time effects as GPs become more experienced or attuned to patients with unexplained
physical symptoms.29
Programme components
Generically speaking, behavioural intervention programmes follow a similar process:
1. sensitisation of the HP to the patient’s symptoms and circumstances
2. selection of resources or strategies
3. initiation of the treatment
4. review and evaluation of the treatment
5. continuation or discontinuation of the treatment.
A previous meta-analysis found that psychological interventions can be effective for patients with
MUS, but the effects were modest and of probable short duration.78 Analysis demonstrated that
psychotherapists achieved larger effects on unexplained physical symptoms than GPs. However,
TABLE 16 Management guidelines from GP training mapped to programme theories (adapted from and annotated
from Rief et al.102)
Stage Approach
General aspects Show empathy and understanding for the complaints and frustrating experiences the patient has had
so far (PT1)
Develop a good patient–physician relationship (PT3)
Diagnosis Explore not only history of complaints and former treatments, but impairment, (health) anxiety,
psychosocial issues
Use symptom diaries to assess course and influencing factors on symptoms (PT7)
When patient presents with a new symptom, examine the relevant organ system (PT2)
Show results of investigations to explain absence of pathology and to give clear reassurance that
there is no serious physical disease (PT8)
Avoid unnecessary diagnostic tests or surgical procedures (PT6)
Treatment Provide regularly scheduled visits (e.g. every 4–6 weeks), especially in cases of very frequent
health-care utilisation (PT1)
Explain that treatment is coping, not curing (when pathology cannot be found or does not explain
degree of complaints) (PT8)
Suggest coping strategies (e.g. regular physical activity, relaxation, distraction)
Referral If referral is necessary to start psychotherapy or psychopharmacotherapy, prepare the patient for
the treatment. Reassure him/her that you will continue to be his/her ‘doctor’ (PT3)
PT, programme theory.
CONTEXTUAL FACTORS AND BEHAVIOUR MODIFICATION INTERVENTIONS FOR MUS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
120
it was unclear whether or not this advantage is attributable to a larger number of psychotherapist-led
sessions. Evidence for the effectiveness of teaching GPs skills in brief CBT for depression suggests
that CBT training has little effect on GPs’ knowledge and attitudes or on overall treatment outcomes
at 6 months.292 This may equally be the case for MUS. The authors conclude that GPs may require
more training and support than a basic educational package on brief CBT to acquire requisite skills.292
Current training does not equip junior doctors with the necessary knowledge and skills to effectively
and confidently manage patients with MUS.293
Providing patients with a convincing explanation for their symptoms (programme theory 8) is seen as
a key component of the FINE Supportive Listening Intervention.206 This initial session also involves
indicating how symptoms may be targeted for treatment (programme theory 2).
Interventions may differ in the extent to which stages 1 and 2 of the behavioural components listed
occur within or outside a typical primary care consultation. Furthermore, where treatment is being
delivered by a HP other than the patient’s GP, it seems inevitable that there will be some overlap
or repetition of these two stages across both HPs. In other cases, the gatekeeper role of the GP is
simply to channel the patient towards a particular pathway and then the selection of resources is
fundamental to the actual treatment. This personalised tailoring of resources could contribute to a
feeling of individualised care and of being taken seriously. This element of personalisation is commonly
believed to be more likely to be achieved if the HP is able to gain an understanding of the patient’s
individualised personal circumstances.
What is absent from this generic five-stage model for behavioural intervention programmes is a formal
stage of ‘labelling’ to achieve matching of strategy to label in stage 2. As itemised above, Burton et al.157
point out the shared limitation of approaches that ‘concentrate on making the link between physical
symptoms and underlying psychological cause’ (cp. Hubley et al.277). Instead, professionals are encouraged
to base the selection of resources and strategies on the patient’s symptoms (see Programme theory 2).
Burton suggests that there is value in initially providing conventional biomedical (i.e. contingent ‘good
enough’) explanations for MUS (see Programme theory 8).157 However, it remains unclear if such a
biomedical model offers advantages over a biopsychosocial model as endorsed by other commentators.
Similarly, the suggestion to embark on psychosocial talk only when cued by the patient (see Programme
theory 7)157 receives an equivocal response from the literature and from practitioners. For example,
initiating psychosocial talk only when cued by the patient contrasts with reattribution approaches that
specifically aim to ‘encourage people to reattribute their MUS to physiological or psychosocial causes
rather than to somatic causes’.294
Another CBT-based approach to MUS is problem-solving treatment. The aim is to reduce complaints
associated with unresolved problems in daily life by enhancing a person’s problem-solving capacities
in a step-by-step manner. This approach is not explicitly addressed by any of our focal programme
theories. Nevertheless, it is firmly grounded implicitly in several of these programme theory assumptions.
For example, maintenance of a healthy professional–patient relationship (programme theory 3) is
essential in creating a climate in which the patient is prepared to share their problems. Similarly, being
provided with a ‘good enough’ explanation may allow a patient to metaphorically draw a line under a
potentially futile quest for a definitive explanation and to move on to adopt self-management and
problem-solving strategies.
Neither does this staged approach acknowledge a recursive and unproductive loop, with the patient
requiring legitimation of their symptoms through a definitive result from a diagnostic test in order to
be admitted to the treatment pathway (see programme theory 6, below). Where the diagnosis cycle
is repeated, particularly with non-productive results, then not only does the patient feel frustrated,
but concerns about the professional–patient relationship (programme theory 3) may be exacerbated.
The patient may start to question the skills, abilities and resources possessed by their GP or may feel
that they are becoming a ‘guinea pig’295 for diagnostic testing or that they are being ‘fobbed off’.296
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The ‘consultation letter’ intervention259 includes three specific provisions that can be seen as tackling
some of these concerns. Unnecessary tests are to be avoided (programme theory 6), the patient is
to be monitored regularly and a physical examination is to be conducted at each consultation. This last
provision may help to confirm that the professional is still taking physical symptoms seriously (programme
theory 1).297 However, it is recognised that regular physical examination, outside the specific context of
new symptoms, may be prohibitive in terms of time and may add little additional useful information.
Collectively, avoidance of unnecessary tests and physical examination for new symptoms may serve
to maintain a healthy relationship between GP and patient (programme theory 3) although, in this
particular study, intervention by an external specialist (i.e. a psychiatrist) precipitated this series of
measures. Focusing entry into the treatment pathway on symptoms, not on labels or test results,
appears to be key to making progress.
The consultation letter approach259 includes three components that may contribute to the effect of the
intervention and that could explain how the intervention might work:
l confirmation of the persistent diagnosis MUPS
l management rules for communication
l management rules for case management.
It should be emphasised that it is the mechanisms that underpin this intervention that may be
generalisable to primary care and not the exact intervention that was targeted at secondary care and
delivered by psychiatrists. Hoedeman et al.259 conclude that it is not known which of these components
is effective or whether a synergistic effect exists.
Burton et al.157 claim several advantages for components of his symptom clinic approach. Unlike the
consultation letter approach, the symptom clinic model aims to negotiate a ‘medical’ explanation for
symptoms involving physiological processes (programme theory 8), thus reducing uncertainty and
permitting an exit from the diagnostic cycle (programme theory 6). They describe how this explanation is
followed up over a series of shorter consultations, offering the prospect of the professional demonstrating
belief in the patient (programme theory 1), of maintaining a healthy professional–patient relationship
(programme theory 3) and, above all, of negotiating a shared mental model (programme theory 5).
However, as demonstrated throughout this chapter, avoidance of psychosocial cues unless initiated by the
patient is more equivocal and does not receive substantive support from within the literature as a whole.
In addition, Burton et al.’s157 underlying epidemiological approach, identifying patients from a combination
of their symptoms and health-care resource use, may be felt to negate recognition of the individualised
experience of MUS. Individual symptoms may be common but may present in an almost infinite variety of
combinations. Patients may therefore resist any attempt to pigeonhole their experience through strictly
epidemiological means.
Another group of therapies offered to people with MUS, and examined in a Cochrane review,77 relates
to ‘enhanced care’. Usual care, typically delivered by GPs, is enhanced by the addition of ‘participant
education, structured counselling moments, a psychiatric interview, or a reattribution training of the
doctor’.77 These therapies offer no specific treatment agenda or structure. Instead, they aim to offer
the person tools to assist them in the recovery process, stimulating self-management (programme
theory 8).
Although validation of patient symptoms is primarily invoked within the context of the patient–professional
consultation,298 other types of treatment offer alternative forms of validation.179,182 Group-based sessions
can lead to the discovery of a shared experience thereby legitimating patients’ symptoms. Such findings
have been reported for fibromyalgia,299 low back pain,300 CFS,301 pelvic pain227 and MUS.302 However, group
sessions do not privilege a particular worldview and, therefore, dissonant explanations and disease
models across a group of patients may prove threatening or divisive. As with other treatments, the
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patient often requires some form of ‘label’ to access a pathway leading to group treatment, again
emphasising the potential value of employing a symptom-based approach (programme theory 2)
rather than assigning patients by label or test result. Notably, the BodyMind Approach focuses only on
symptoms and does not utilise labels.186 In doing so it acknowledges the personalised and individualised
nature of the patient experience, harnessing an almost exclusively somatic frame of reference when
offering potential physical explanations (negating programme theory 7). Searches of the literature
identified no RCTs of this intervention.
Summary statements
Programme theory 1: take concerns seriously
There is consistent evidence across multiple studies and intervention packages that it is necessary
for the GP to take patients’ concerns seriously both at the time of initial consultation and at
subsequent visits.
Programme theory 2: focus on symptom management
Many interventions focus on symptoms rather than labels. Evidence for the effect of patients being
given a label in general, or a specific diagnostic label, is equivocal and dependent on the needs of the
patient, public perceptions of particular labels and the link with subsequent action/inaction.
Programme theory 3: maintain positive relationship
Irrespective of outcome, a GP must seek to maintain a positive relationship characterised by the
presence of empathy, trust and good communication.
Programme theory 4: provide a context-sensitive response
Claimed benefits for treating MUS in a primary care setting include enhanced knowledge of the patient
and their particular circumstances. However, evidence for these advantages of the primary care setting
is equivocal, with some patients feeling that a GP does not have the skills, expertise or resources to
manage their symptoms. In turn, doctors may feel that the practical constraints of the consultation,
against a backdrop of moves to extended opening and a consequent reduction in access to a personal
GP, may run counter to such a direction of travel. Access to psychological practitioners in primary care,
as under the IAPT programme, may help to ameliorate such concerns.
Programme theory 5: share congruent disease models
The literature is consistent in highlighting the shortcomings of the biomedical model for MUS. A
cognitive–behavioural metamodel136 offers an alternative way of explaining what is happening that may
be useful in bridging the incompatibility of professional and patient models.
Programme theory 6: avoid futile diagnostic cycle
There is widespread agreement in the literature, and incorporated within the components of particular
interventions, that the HP should seek to avoid perpetuating an unhelpful cycle of tests. However,
professional and patient attitudes towards tests or referral are complex and may be construed
positively or negatively. In some cases, a diagnostic label can function as a pass key to a particular
treatment pathway.
Programme theory 7: consider the appropriateness of initiating psychosocial cues
We were unable to identify definitive evidence in support of this initial programme theory. The literature
is equivocal regarding the value of the GP making a connection between the physical symptoms and
psychosocial factors. Some treatments are predicated on this connection whereas others purposefully
circumvent it. It is likely that this factor is very dependent on the context in which these cues operate.
It can be helpful not to exclude this possibility too prematurely. Patient-initiated psychosocial cues have
been shown to be more prevalent than doctors think. Further research is required to explore those
contexts in which initiation of psychosocial cues by the GP is helpful and those where it might be more
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appropriate to have such issues raised by the patient. At present, recommendations for each approach
in the literature appear determined by the prevailing philosophy of the intervention and not by more
salient contextual characteristics of the doctor–patient consultation and ongoing interaction.
Programme theory 8: offer useful explanations
A GP must seek a balance between their expected role of medical authority and the considerable
uncertainty that accompanies MUS. Plausible and believable explanations, constructed through
negotiation between GP and patient, can offer a contingent way forward, particularly in encouraging
an expectation of coping rather than curing.
Discussion of the realist review
The therapeutic relationship is key to a satisfactory interaction between patient and HP and to
successful engagement with the treatment. Establishing trust, believing and valuing the patient and
developing an empathetic style of communication may all contribute to a positive experience,
irrespective of treatment outcome.
Patient and professionals must feel that they are not entering into a destructive diagnostic cycle that
may lead to unnecessary or uninformative tests or to referral to secondary care. Such a cycle may lead
to excess health-care costs, unnecessary anxiety and frustration and, ultimately, may threaten the
therapeutic relationship.
It is challenging to try to extricate the differential effects of a productive consultation, interaction
according to behavioural principles and a manualised approach to behavioural modification. Attention
must be directed to all three if one is to optimise clinician–patient interaction.
A CBT metamodel136 may offer a useful frame for analysis of an individual presentation and a tool
for communication and a constructive dialogue. This may challenge existing mental models, relieve
epistemological incongruence and acknowledge individual differences in MUPS.
Limitations
The realist review served a subsidiary, explanatory function for the overall intervention-focused
HTA. It focused on a UK context and accessed large bodies of qualitative data through existing rich
metasyntheses (Table 17), including the tailored qualitative systematic review reported in Chapter 4.
It was not possible to engage with all available primary qualitative studies (Table 18) and the focus was
necessarily limited to interventions trialled within a UK setting. Descriptions of interventions were
variable, making it challenging to identify intervention components and putative mechanisms of effect.
Lewis184 describes how many published RCTs give only brief descriptions of the techniques used, with
treatment manuals being rarely published.
Nevertheless, the realist review has expanded the analytical lens beyond the UK intervention studies
included in the qualitative systematic review and extends beyond delivery of the intervention to include
the entire pathway from initiation of the consultation through to resolution or referral. In particular, the
realist review has engaged at a higher level of theorising with a view to helping to highlight promising
candidate interventions or components. A valuable contribution of the realist review is the completion
of the TIDieR templates for each of the focal interventions150 (see Appendix 6). The TIDieR checklist
and guide was developed to improve the completeness of reporting, and ultimately the replicability,
of interventions and can be used by reviewers to assess completeness of intervention descriptions
and by readers who want to access more detailed information on the focal interventions.
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TABLE 17 Narrative and qualitative systematic reviews
Study (first author
and year of
publication) Patient group
Number of included
studies/references Principal themes
Anderson, 2012303 Myalgic
encephalomyelitis/
CFS
34 qualitative
studies
Three substantive thematic areas:
1. experiences of people with myalgic
encephalomyelitis/CFS
2. experiences of physicians
3. themes intersecting both groups.
For patients, illness development influenced
identity, reductions in functioning and coping.
Physician-specific themes described lack of
awareness about myalgic encephalomyelitis/CFS
and recommended improvement in educational
resources. Intersecting themes expressed issues
with diagnosis creating tensions and fuelling
stigmatisation of myalgic encephalomyelitis/CFS.
Findings indicate multilayered, context-specific
experiences and ways in which people with myalgic
encephalomyelitis/CFS, as well as family or the
medical community, interpret this illness. Future
qualitative studies should recognise diverse facets
of myalgic encephalomyelitis/CFS experience,
the network members of people with myalgic
encephalomyelitis/CFS and the sociocultural
environment through which illness is understood
Bayliss, 2014165 CFS/myalgic
encephalomyelitis
21 studies HPs report a limited understanding of CFS/myalgic
encephalomyelitis. Working within the biomedical
model has led some GPs to be sceptical about
the existence of CFS/myalgic encephalomyelitis.
GPs who provide a diagnosis tend to have a broader,
multifactorial, model of CFS/myalgic encephalomyelitis
and more positive attitudes towards CFS/myalgic
encephalomyelitis. GPs collaborate with patients to
reach agreement on symptom management, and use
their therapeutic skills to promote self-care
Burton, 2003304 MUPS 77 references Neither somatised mental distress nor somatisation
disorders, based on symptom counts, account for
most MUPS patients. With substantial overlap
between symptoms/syndromes, suggesting much
commonality, patients with MUPS may best be
viewed as having complex adaptive systems in
which cognitive and physiological processes interact
with each other and with their environment. CBT
and antidepressant drugs can be effective. Their
effects may be greatest when the patient feels
empowered by their doctor to tackle their problem
Drachler, 2009305 CFS/myalgic
encephalomyelitis
32 quantitative and
qualitative studies
Identified support needs:
1. to make sense of symptoms and gain diagnosis
2. for respect and empathy from service providers
3. for positive attitudes and support from family
and friends
4. for information on CFS/myalgic encephalomyelitis
5. to adjust views and priorities
6. to develop strategies to manage impairments
and activity limitations
7. to develop strategies to maintain/regain
social participation
continued
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TABLE 17 Narrative and qualitative systematic reviews (continued )
Study (first author
and year of
publication) Patient group
Number of included
studies/references Principal themes
Edwards, 201031 MUS 109 references No single approach will be effective in all patients.
Chronic, high-utilising patients with MUS need
care that is patient centred and attentive to their
biopsychosocial needs. Requires careful assessment
of the following: psychological concerns, family
and cultural issues, a history of a dysfunctional
childhood and symptoms of depression, anxiety
and post-traumatic stress disorder. To be followed
with confirmation that symptoms are real even
when linked to psychosocial stress. GPs should
clarify appropriate options for individual patients
[e.g. reattribution, progressive muscle relaxation/
related techniques, CBT (group/individual, by GP/
mental health clinician) or medication]. Clinicians
require patience and empathic communication.
Multiple methods available but territory is
unfamiliar/uncharted. Time taken to develop one’s
clinical approach can contribute to welfare of
patients and their family and to GPs’ personal
and professional growth
Gask, 201185 MUS 25 publications from
13 studies
The reattribution model is too simplistic in its
current form to address the needs of many people
presenting with MUS in primary care. Reattribution
of physical symptoms to psychological causes is
often unnecessary. Further research is required
into the effectiveness of stepped and collaborative
care models that include the education of primary
care practitioners. The consultation process is best
seen as a conversation and ongoing negotiation
between doctor and patient in which there are no
certainties about the presence/absence of organic
pathology
Hubley, 2016277 MUS 62 references Challenges include complex symptom presentations,
strained patient–physician relationships and
treatment-resistant symptoms that challenge clinician
competency. Emphasises importance of co-creating
plausible explanations for MUS, understanding
the pitfalls of consultations involving MUS and
developing multimodal treatment plans
Johansen, 2017242 MUS 13 studies Epistemological incongruence between dominant
disease models and reality of meeting patients
suffering from persistent illness. GPs have used
flexible approaches to manage the situation, yet
patients and doctors have parallel negative
experiences of being stuck, untrustworthy and
helpless. When facing cognitive incongruence, GPs
strive to achieve relational congruence with patients.
This has led to parallel positive experiences of mutual
trust and validation.With more experience, some
GPs overcome incongruences; later studies point
towards reframing of problem
Larun, 2007301 CFS 20 studies Symptom experiences and responses from
significant others could jeopardise the patient’s
sense of identity; feeling severely ill, yet blamed
and dismissed. Patients’ beliefs and causal
attributions oppose the doctor’s understanding
of CFS. For the patient, getting a diagnosis and
knowing more was necessary for recovery. Doctors
were reluctant towards the diagnosis, and struggle
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TABLE 17 Narrative and qualitative systematic reviews (continued )
Study (first author
and year of
publication) Patient group
Number of included
studies/references Principal themes
to maintain professional authority. For patients,
experience of discreditation could lead to
withdrawal and behavioural disengagement
MacNeela, 2013187 Chronic low back
pain
38 studies Proposes four themes:
1. the undermining influence of pain
2. its disempowering impact on all levels
3. unsatisfying relationships with health-care
professionals and
4. learning to live with the pain.
Findings dominated by wide-ranging distress and
loss but acknowledge self-determination and
resilience. Identifies need to study facets of
subjective experience (e.g. illness trajectory and
social identity)
Murray, 2016241 Somatoform
disorders
42 studies Identified 379 barriers within 77 barrier-level
codes, 16 thematic categories and five overarching
themes (i.e. patient-related, primary care
practitioner-related, doctor–patient interactional,
situational, and conceptual and operational barriers
Pinxsterhuis, 2015306 CFS 15 studies Coping strategies, including activity management
and the use of cognitive and emotional strategies,
and psychological processes, such as acceptance
and the rebuilding of identities and lives, may
promote coping with CFS. Use of adequate
coping strategies facilitated by progress in these
psychological processes. Coping facilitated mainly
by self-management, occasionally complemented by
treatments and social support
Toye, 2013307–309 Chronic non-
malignant
musculoskeletal
pain; fibromyalgia
77 studies of
musculoskeletal pain
including 28 on
fibromyalgia
Concept of adversarial struggle (includes struggle
to affirm self and construct self over time; find an
explanation for pain; negotiate the health-care
system while feeling compelled to stay in it; be
valued and believed; and find the right balance
between sick/well and hiding/showing pain). Some
people move forward by listening to their body
rather than fighting it, letting go of old self and
finding a new self, becoming part of a community
and not feeling like the only one, telling others
about pain and redefining relationships, realising
that pain is here to stay rather than focusing on
diagnosis and cure, and becoming the expert and
making choices
van Ravenzwaaij,
2011247
MUS 24 papers Identified nine specific explanatory models of
MUS: somatosensory amplification, sensitisation,
sensitivity, immune system sensitisation, endocrine
dysregulation, signal filter model, illness behaviour
model, autonomous nervous system dysfunction and
abnormal proprioception. Explanatory models focus
on four domains: somatic causes, perception, illness
behaviour and predisposition. One metamodel,
incorporates all four domains: the CBT model.
May help GPs in providing explanations to patients
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TABLE 18 Follow-up references and conceptual papers
Study (first author and year of publication) Publication type Contribution
Aiarzaguena, 2007136 RCT Primary care-based intervention
Aiarzaguena, 2009310 RCT Primary care-based intervention
Arnold, 2009311 Controlled trial Primary care-based intervention
Blane, 2014312
Chew-Graham, 2017313 Editorial
Corbett, 2007300
Deary, 200744 Conceptual model
den Boeft, 2017314 Doctor–patient communication
den Boeft, 2016315
den Boeft, 2017316
Dimsdale, 201319 Diagnostic background
Finset, 2009317 Doctor–patient communication
Gerger, 201578 Meta-analysis
Graugaard, 2003318 Doctor–patient communication
Hoedeman, 2010259 Systematic review Cochrane review
Howman, 2016286 GP trainee perspectives
Huibers, 2007319 Systematic review Cochrane review
Jutel, 2010230 Literature review Effects of ‘labelling’
Kromme, 2016320 Doctor perspective
Layard, 2006321 Editorial Trends in psychological treatment centres
Malins, 2016322
McDermott, 2011323 Qualitative research Patient perspective
Picariello, 2017324 Qualitative research Patient perspective
Rask, 2014325 Mixed methods GP perspective
Reid, 2001261
Rosendal, 201377 Systematic review Cochrane review
Schweickhardt, 2005326
Shattock, 2013262 Qualitative research Trainee perspective
Sirri, 2017327 Qualitative research Doctor perspective
Stone, 2014235 Qualitative research Trainers’ and trainees’ perspective
van Dessel, 2014294 Systematic review Cochrane review
Weiland, 2015291 RCT Doctor training programme
Ziadni, 2018328 RCT
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Conclusions
This realist review was able to identify eight key programme theories (Table 19) that underpin the likely
success of current UK-based interventions as explored in clinical trials (see Table 70). Confirmatory
evidence was found for the majority of these programme theories, primarily in qualitative research and
expert commentary. Few of these component theories have been explored empirically and, indeed, many
of them would challenge current trial design. The two remaining programme theories, regarding the
role of labels (programme theory 2) and avoidance of psychosocial cues unless initiated by the patient
(programme theory 7), present more equivocal evidence – with the literature and our clinical experts
equally being split on both the theoretical underpinnings and the practical usefulness of such theories.
Although it seems that the value of such strategies would ultimately be determined by the characteristics
of the patient, the nature of their symptoms and the context of the clinician–patient interaction, it
remains unclear how these strategies might be differentially selected according to patient need. Reasons
for this include the fact that these strategies are inextricably tied up with particular types of intervention
(e.g. reattribution or the primary care symptom clinic) and not to some underlying theory-informed
differentiation. Nevertheless, this chapter has been able to identify where and to what extent current
intervention components seem to engage with our prioritised programme theories (Table 20). In doing
this, we extend the usefulness of the realist review beyond existing UK trials to include all interventions
covered by the effectiveness review and inform possible future intervention design.
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TABLE 19 Presence of programme theory elements in focal UK interventions
Cluster
identifier PT1 PT2 PT3 PT4 PT5 PT6 PT7 PT8
IF HPs show that
they take the patient
and their concerns
seriously, THEN the
patient will engage
with treatment
IF HPs focus on
patient’s symptoms
and how to manage
them, THEN patient
feels something is
being done about their
symptoms and that
their symptoms are
not being dismissed as
all in the mind
IF HPs maintain
a positive
relationship with
the patient, THEN
professional and
patient develop
a shared
understanding of
the patient’s
experience
IF diagnosis,
management and
treatment takes
place within a
primary care setting,
THEN the patient
experiences
continuity of care
that may lead to
progress and
resolution
IF the disease model
advanced by the
HP matches, or is
compatible with, that
of the patient, THEN
the patient will accept
treatment
IF patient and
professional can
avoid perpetuating
extensive and
unproductive
diagnostic tests,
THEN patient and
professional achieve a
sense of progress
IF HPs introduce
psychosocial
explanations, THEN
the patient feels
that they are being
problematised
IF HPs offer an
explanation that they
believe is congruent
with current facts
and uncertainties
THEN the patient,
believes that it is
possible to maintain
the therapeutic
relationship
The BodyMind
Approach
By validating the
symptom helps
patients to feel
believed. Utilises
patient’s strengths
and resources rather
than focusing on
remediation and
deficits (cp. other
mental health
approaches)
Validates the symptom
[cp. other approaches
that invalidate and/or
negate symptoms
(e.g. terms such
as psychological
therapies/
psychosomatic
conditions that result in
patients not feeling
believed)]. By starting
where patient is,
sensory, physical,
bodily symptom is
acknowledged and
worked with as an ally,
promoting positive
reassociation with the
body, which is often
viewed as the ‘enemy’
Alternative:
relationship with
other members of
the group is
important in
combating
isolation
Group sessions
conducted in a
non-stigmatising,
non-medical venue
in the community,
designed to be more
anonymous than GP
setting or a room
within psychological
services setting
Frames sessions as
social rather than
medical model,
promoting inclusion
Case study states that
frequent referrals for
tests and scans
increase patient’s
belief that there would
be a physical, medical
explanation
Negating:
biopsychosocial model
is fundamental. Relies
on somatic awareness,
a normal part of
consciousness, to
resolve body–mind
dualism inherent in
conventional
multidisciplinary
approaches
Works on principle
of recovery, giving
hope to people to
live well with their
symptom rather
than promising a
cure or having to
learn to live with it.
Empowers patient to
self-manage their
symptoms
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Cluster
identifier PT1 PT2 PT3 PT4 PT5 PT6 PT7 PT8
FINE (2010)
(pragmatic
rehabilitation)
No details Nurses give patients
detailed physiological
explanation of
symptom patterns,
followed by treatment
programme focusing on
graded exercise, sleep
and relaxation
No details No details No details No details Patients keep a diary of
their progress on the
exercise programme,
together with a note of
their daily activities, rest
and sleep, and any
problems encountered
and how they were
dealt with. Diaries are
reviewed at each
contact with the nurse
Initial session, which
provides patients
with convincing
explanations for their
symptoms and also
indicates how they
can be targeted in
treatment, is crucial
to the success of the
intervention
FINE (2010)
(supportive
listening)
Patients may
improve if they feel
that the therapist
empathises with
them and takes their
concerns seriously.
Aims to provide
emotional support
and validation for
the patient
No details Aims to develop
a collaborative
relationship
in which the
patient is held in
unconditional
positive regard,
and encouraged
to talk about his
or her experience
of CFS/myalgic
encephalomyelitis
and problems
which he or she
has in dealing
with it
No details No details No details No details Patients encouraged
to find their own
approach to
addressing their
symptoms
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TABLE 19 Presence of programme theory elements in focal UK interventions (continued )
Cluster
identifier PT1 PT2 PT3 PT4 PT5 PT6 PT7 PT8
IAPT long-term
condition/
MUPS85
No details Seeks to elicit patient
beliefs and concerns
about symptoms,
provide positive
diagnosis if possible,
biopsychosocial
explanation of
symptoms
No details Describes
importance of
centring on setting
and integration with
existing services.
Physical and mental
health-care provision
should be co-located
to address:
1. patient preference
for receiving
physical and
mental health
care in the
same setting;
2. availability of
expertise for
provision of
physical and
mental health
care and symptom
management in the
medical setting;
3. continuity of care;
4. multidisciplinary
teamworking
and sharing
5. removing stigma
and;
6. improving access
No details Proposes that MUPS
are caused by a
self-perpetuating
multifactorial cycle,
based on interaction of
different factors in
several domains,
including somatic
(physical) aspects,
cognitions (thoughts),
behaviour, emotions
and environment.
Important not to
continue to look for
possible disease once
rigorous diagnostic
workup has been
completed. Ongoing
referral and testing
increases patient
anxiety and can be
iatrogenic preventing
patients from moving
forward into
appropriate treatment
GPs have an important
role in ensuring people
experiencing FSS
engage with IAPT
services. GPs are
usually first point of
contact for people with
FSS. They may need to
prepare patients who
present with FSS for
psychological therapies
by explaining the
biopsychosocial
model of FSS
No details
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Cluster
identifier PT1 PT2 PT3 PT4 PT5 PT6 PT7 PT8
MUST
reattribution
training (2007)
No details No details No details No details Aims to generate
information to provide
a simple three-stage
psychological
explanation (symptom,
psychosocial problem,
physiological or
temporal mechanism
linking symptom to
psychosocial problem)
for the patient’s MUS
through negotiation
between the GP and
patient
No details Explores social and
family factors. explores
possibility that physical
symptoms might be
linked to psychosocial
factors. Links physical
symptom to an
underlying psychosocial
or lifestyle issue
using normalising
physiological, temporal
or social link
Three elements to
explanation: the
symptom (e.g.
backache), the
psychosocial issue
(e.g. stress at home)
and mechanism (e.g.
muscles held tight by
stress for long time
start to ache)
(Primary)
symptoms clinic
intervention
(2012/16)
No details No specific attempt is
made to screen for
common mental
disorders; however,
patients are
encouraged to
describe their
emotional responses
to symptoms and
other events, and
diagnostic labels
such as depression
were discussed
collaboratively with
the patient rather than
imposed by the doctor
No details No details Consultations are
structured to first
hear the patient’s
experience of illness
then to propose and
negotiate constructive
explanations of
physical symptoms.
Aims to negotiate a
‘medical’ explanation
for symptoms involving
physiological processes
Aims to reduce
uncertainty and
thereby permit an exit
from the diagnostic
cycle
Focuses on biological
(including neurological
and cognitive)
mechanisms rather
than psychological
cause
GP explores
acceptable
explanations for
symptoms in terms
of biological
(including
neurological and
cognitive)
mechanisms rather
than psychological
cause
PT, programme theory.
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TABLE 20 Summary of relationship between interventions (identified from UK trials and UK qualitative intervention
studies) and programme theory components
Intervention PT1 PT2 PT3 PT4 PT5 PT6 PT7 PT8
The BodyMind Approach ✓✓ ✓✓ ✓ ✓✓ ✓ ✓ ✗✗ ✗
FINE (pragmatic rehabilitation) ? ✓ ? ? ✓ ? ✓ ✓✓
FINE (supportive listening) ✓✓ ? ✓✓ ? ? ? ? ✓
IAPT ✓✓ ✓✓ ✓ ✓ ? ✓✓ ✗✗ ✓
MUST ✓✓ ✓✓ ✓ ✓ ✓ ? ✗✗ ✓
Symptom clinic intervention ✓✓ ✓✓ ✓✓ ? ✓✓ ✓✓ ✓✓ ✓✓
✓✓, integral; ✓, referenced; ✗, overlooked; ✗✗, contrary; ?, insufficient detail.
PT, programme theory.
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Chapter 6 Assessment of cost-effectiveness
Systematic review of existing cost-effectiveness evidence
Objective
A systematic review was conducted to identify published economic evaluations examining the
cost-effectiveness of behavioural modification interventions in patients with MUS.
Inclusion/exclusion criteria
Populations, interventions and comparators were defined as per the clinical effectiveness review (see
Chapter 3) with the additional requirement that the study population was restricted to patients treated
in the UK NHS as estimates of resource use, and costs may not be transferable between different
health-care settings. In terms of study design, we restricted the review to cost-effectiveness studies.
In terms of outcomes, we restricted the review to studies that measured benefits using quality-adjusted
life-years (QALYs), as the QALY has been defined by the National Institute for Health and Care Excellence
(NICE) as the reference case measure for benefit for UK cost-effectiveness studies and the NICE methods
guide provides guidance on the range of cost per QALY values that can be considered to represent good
value for money within the UK NHS.244 Cost–consequences studies that reported incremental costs but
did not report benefits as QALYs were excluded from the cost-effectiveness review, but are narratively
summarised in Narrative summary of cost-consequences studies as these studies provide evidence on whether
behavioural modification interventions have a negative or positive impact on net health-care costs.
Search strategy
A systematic search strategy was developed in consultation with the review team, to identify economic
evaluations relating to the defined population. The focus was on identifying studies in primary care
or community-based settings; therefore, population terms were combined with terms to define the
setting. A combination of free-text terms and thesaurus searching was used. Published methodological
search filters329 to limit to study type (economic evaluation) were used where available. No other search
limits were applied.
Searches were conducted in the following sources:
l MEDLINE via OvidSP (1946–15 August 2016)
l MEDLINE In-Process & Other Non-Indexed Citations and Epub Ahead of Print & MEDLINE®
without Revisions via OvidSP (2013–15 August 2016)
l EMBASE via Ovid SP (1974–25 August 2016)
l CINAHL via EBSCOhost (1981–25 August 2016)
l PsycINFO via OvidSP (1967–25 August 2016)
l NHS EED via the Cochrane Library (1968–April 2015 – no longer updated, archive only searched
25 August 2015)
l Science Citation Index via Web of Science (1900–25 August 2015)
l Social Sciences Citation Index via Web of Science (1956–25 August 2015).
Searches for economic evaluations were conducted between 15 and 25 August 2016. The search
results were imported into EndNote [Clarivate Analytics (formerly Thomson Reuters), Philadelphia, PA,
USA] and subsequently filtered to identify UK studies, using terms from line 29 of the EU economies
search filter,249 to search the EndNote library for potentially relevant references. Detailed search
strategies are provided in Appendix 1.
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Methods
The citations were sifted by a single reviewer. Full-text articles were examined for those studies that
could not be excluded based on the title or the abstract and the reason for exclusion was recorded for
all articles for which the full text was examined. Those studies that were also identified in the search for
relevant RCTs were cross-checked to ensure that the population, intervention and comparator inclusion
criteria were being consistently applied across the clinical effectiveness and cost-effectiveness reviews.
The applicability of the studies to the NICE reference case and their methodological quality was
addressed using the checklist provided in the NICE guidelines manual.250
Results
The search identified 1606 unique citations, of which 1541 were excluded at either the title or the
abstract searching stage. The exclusion of papers at each stage is summarised in Figure 60. One paper
reported clinical outcomes for a study that reported the economic analysis in a separate paper.112
Three papers were excluded because they reported a population not recruited from primary care.252,330
Six papers were excluded because they reported a population that did not meet the requirements
to be classified as MUS253–256,331,332 and 14 papers were excluded because they reported non-UK
populations.109,138,260,263,265–270,272,273,333,334 One study was excluded because it was not considered to
be a behavioural modification intervention.274 Six papers were classified as cost–consequence
studies131,275,276,278–280 and 30 papers were classified as providing only costing or resource use data.
Reasons for exclusion for each paper examined at full text are provided in Appendix 7.
• Cost/resource use
   outcomes only, n = 30
• Non-UK, n = 14
• Not MUS, n = 6
• Cost–consequence, n = 6
• Not primary care, n = 3
• Intervention not
   appropriate, n = 1
• Clinical outcomes only,
    n = 1
Records identified through
database searching
(n = 1608)
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Additional records identified
through other sources
(n = 0)
Records after duplicates removed
(n = 1606)
Records screened
(n = 1606)
Records excluded
(n = 1541)
Full-text articles
assessed for eligibility
(n = 65)
Full-text articles excluded,
with reasons
(n = 61)
Included articles
(n = 4)
articles describing
two unique
cost-effectiveness
studies
FIGURE 60 The PRISMA flow diagram for identification of cost-effectiveness studies.
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Four papers met the criteria for inclusion in the review.125,126,282,335 Two papers125,126 described results
from the MUSICIAN trial at different periods of follow-up, and one paper335 was a conference abstract
for the FINE study that was reported in full in another included paper.282 Clinical outcomes for the
FINE study were reported by Wearden et al.111 and clinical outcomes for the MUSICIAN trial were
reported in the same two papers that reported the economic evaluation. Therefore, our review
identified two unique cost-effectiveness studies (referred to in this review as Beasley et al.126 and
Richardson et al.282). The characteristics of the two included studies are summarised in Table 21.
Each of the included analyses examined a different population, with Richardson et al.282 examining
patients with chronic fatigue and Beasley et al.126 examining patients with chronic pain. Both of the
studies included treatment as usual as a comparator and both evaluated more than one behavioural
modification intervention. In terms of the interventions examined, there were some common elements,
with both studies including a psychological intervention and both including an intervention that involved
some form of activity or exercise. However, the interventions examined by Richardson et al.282 have been
categorised in the clinical review as GA and other psychotherapy, whereas the interventions examined
by Beasley et al.126 have been categorised as CBTHI and SES. In addition, Beasley et al.126 examined
a multimodal intervention combining both CBTHI and exercise, whereas Richardson et al.282 did not
examine any multimodal interventions. The two studies were not judged to be sufficiently similar in
their population, interventions and comparators to allow a direct comparison of outcomes but similar
issues were identified when assessing the applicability and quality of the studies. Therefore, a narrative
summary of methodological quality across both studies is provided followed by a summary of results
from each individual study.
There were significant similarities in the studies in terms of the methods employed. Both were
within-trial economic analyses. The duration of the analysis period was 70 weeks for Richardson et al.282
and 2 years for Beasley et al.,126 which are both relatively short time horizons for a population with
chronic symptoms. Both studies applied the discount rate recommended in the NICE methods guide
(3.5% per annum).244 Owing to the inclusion criteria of the review, both were conducted in the UK
and valued outcomes using QALYs. Both measured HRQoL using the EQ-5D and restricted benefits to
those accrued by patients. Both studies used patient self-report to assess resource use, which may be
subject to recall bias.
Richardson et al.282 stated that they took an NHS and PSS perspective. The approach taken by Beasley
et al.126 is consistent with an NHS perspective. In terms of the assessment of broader costs falling
outside the stated perspective, Richardson et al.282 examined the costs to patients and families,
including lost working days, but excluded these from the cost-effectiveness analysis. Both studies
evaluated the uncertainty surrounding the cost-effectiveness estimates by using bootstrapping to
generate a cost-effectiveness acceptability curve (CEAC), which shows the probability that the
intervention is cost-effective for various willingness-to-pay thresholds. Both studies used multiple
imputation to handle missing data either in their base-case analysis or in a sensitivity analysis, but no
other sensitivity analyses were reported. Overall, both of the studies were assessed to be directly
applicable and to have minor limitations.
The MUSICIAN trial compared CBTHI alone, SES alone and CBTHI combined with SES against treatment
as usual in patients with chronic widespread pain. This study was originally reported by McBeth et al.125
using data from a 9-month follow-up, but here we focus on the results at 24 months post intervention,
which were reported by Beasley et al.126 When using the complete-case analysis, all three active
strategies (i.e. CBTHI alone, SES alone and CBTHI with SES) provided more benefits than usual care
but at an additional cost. However, SES alone and CBTHI with SES were both dominated by CBTHI
alone, which had an incremental cost-effectiveness ratio (ICER) of £5917 compared with treatment as
usual and approximately a 75% chance of being optimal at £20,000 per QALY. Sensitivity analysis using
multiple imputations to handle missing data resulted in qualitatively similar results but with an ICER
of £3957 for CBTHI compared with treatment as usual. These results were more favourable than the
DOI: 10.3310/hta24460 Health Technology Assessment 2020 Vol. 24 No. 46
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Leaviss et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
137
TABLE 21 Summary of included cost-effectiveness studies
First author and
year of publication Population
Interventions and
comparators Study design
Incremental costs
(£) (mean, 95% CI)
Incremental
QALYs (mean,
95% CI) Cost-effectiveness Uncertainty
Applicability and
limitationsa
Richardson, 2013282 CFS/ME 1. Pragmatic
rehabilitation (GA)
2. Supportive listening
(other psychotherapy)
3. Treatment as usual
Within-trial
analysis
1 vs. 3= 218
(–474 to 911)
2 vs. 3= 460
(–250 to 1169)
1 vs. 3= –0.012
(–0.09 to 0.07)
2 vs. 3= –0.042
(–0.12 to 0.04)
1 and 2 were
dominated by 3
Probability that 3 was
cost-effective was 0.645
at £20,000 per QALY and
0.626 at £30,000 per
QALY
1 not dominated by 3 for
sensitivity analysis using
complete cases
(ICER for 1 vs.
3= £39,583), but 2
remained dominated
Directly applicable.
Minor limitations
Beasley, 2015126
(short-term
outcomes in
McBeth, 2012125)
Chronic
pain
1. CBTHI
2. Exercise (SES)
3. CBTHI with
exercise (SES)
4. Treatment as usual
Within-trial
analysisb
1 vs. 4= 574
(–441 to 1554)
2 vs. 4= 1924
(782 to 3295)
3 vs. 4= 1778
(690 to 3009)
1 vs. 4= 0.097
(–0.05 to 0.24)
2 vs. 4= 0.025
(–0.10 to 0.15)
3 vs. 4= 0.047
(–0.09 to 0.18)
1 vs. 4= £5917
2 dominated by 1
3 dominated by 1
1 had approximately a
75% chance of being
optimal at £20,000
per QALY
Sensitivity analysis using
multiple imputation to
handle missing data gave
similar results with 1 vs. 4
having an ICER of £3957
and 2 and 3 remaining
dominated by 1
Directly applicable.
Minor limitations
ME myalgic encephalomyelitis/encephalitis.
a Tables detailing the assessment of applicability and limitations for each study are provided in Appendix 7.
b Results are those presented by Beasley et al.126 for 24 months using complete-case analysis.
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short-term results reported by McBeth et al.,125 suggesting that the cost-effectiveness is improved by
considering a longer time frame.
The FINE study282 compared pragmatic rehabilitation (GA), supportive listening (other psychotherapy)
and treatment as usual in patients with CFS or myalgic encephalomyelitis/encephalitis. Richardson
et al.282 reported that both pragmatic rehabilitation (GA) and supportive listening (other psychotherapy)
provided less benefit than treatment as usual but at an additional cost and, therefore, both strategies
were dominated by treatment as usual, which had a 65.5% probability of being cost-effective at
£20,000 per QALY. In the complete-case analysis, pragmatic rehabilitation (GA) was no longer
dominated by treatment as usual but the ICER versus treatment as usual was £39,583. Supportive
listening (other psychotherapy) remained dominated in the complete-case analysis.
Conclusions
The review found relatively few UK-based cost-effectiveness analyses in comparison with the number of
RCTs included in the clinical effectiveness review. The studies that were identified both used a within-
trial analysis to examine the short-term cost-effectiveness of behavioural modification interventions.
Although both studies assessed the cost-effectiveness of behavioural modification interventions in
patients with MUS, the two studies examined different behavioural modification interventions in
different populations. Richardson et al.282 found that neither GA nor other psychotherapy provided
more benefit than usual care in patients with CFS/myalgic encephalomyelitis. Beasley et al.126 found that
CBTHI was cost-effective compared with usual care when valuing a QALY at £20,000 in patients with
chronic pain. In addition Beasley et al.126 found that CBTHI provided more benefit than both SES and a
multimodal intervention combining both CBTHI and SES. The studies were all generally applicable to the
stated aims of this review and were mostly of reasonable quality, although their short-term nature is a
potential limitation.
Narrative summary of cost–consequences studies
Six of the papers131,275,276,278–280 excluded from the review of cost-effectiveness were classified as
cost–consequence studies, as they reported the impact of behavioural modification interventions on
both costs and benefits but did not measure benefits using QALYs and, therefore, did not meet the
inclusion criteria for the review of cost-effectiveness studies. However, these studies do provide
evidence regarding whether behavioural modification interventions result in an overall reduction
or increase in health-care costs. Two of these papers276,278 reported results from the same study.
This resulted in a total of five unique cost–consequence studies being included.
We applied relevant aspects of the applicability and quality criteria used in the cost-effectiveness
review250 to the cost element of these studies. The findings for each study are provided in Appendix 8
and are narratively summarised below. The incremental costs reported by each study are summarised in
Table 22 and discussed in turn for each study.
All of the studies had a UK setting as this was one of the inclusion criteria. All five were economic
evaluations conducted alongside a RCT, although one paper279 reported a non-randomised comparison
against usual care in addition to the randomised comparison of two behavioural modification interventions.
All five studies had a time horizon of ≤ 1 year and, therefore, costs were not discounted. The perspectives
were often not reported explicitly. Robinson et al.131 included only NHS costs, but the remaining four
studies275,276,279,280 included costs for alternative/complementary therapies within health service costs.
Three papers reported the broader costs falling on patients or their carers including lost employment275,276
or informal care-giving275,279 and one paper275 did not report health service costs separately from these
societal costs. Four papers relied on patient self-report for resource using some form of the Client Service
Receipt Inventory275,276,279,280 Robinson et al.131 used GP records for primary care resource use but relied on
patient self-report for secondary care consultations. Kennedy et al.129 reported the intervention costs
separately from the costs for other resource use. All five used bootstrapping to estimate the uncertainty
around the difference in costs between trial arms. Four papers131,276,279,280 used regression analysis to
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TABLE 22 Summary of cost–consequence studies
First author and year
of publication Population
Interventions and
comparators Study design
Incremental costs (£) (mean,
95% CI) Applicability and limitationsa
Chisholm, 2001275 Chronic fatigue 1. Other psychotherapy
(counselling)
2. CBTHI
Within-trial analysis 1 vs. 2= –63 (–258 to 42)
(health care only)
Directly applicable for health service
cost outcomes. Minor limitations
Kennedy, 2005129 IBS (not responded
to drug therapy)
1. CBT low intensity
plus medication
2. Medication
Within-trial analysis 1 vs. 2= –64b (–201 to 83) at
12 months [does not include
intervention costs, which were
308 (SD 202)]
Directly applicable for health service
cost outcomes. Minor limitations
McCrone, 2004279
(clinical paper is
Ridsdale, 2004113)
Chronic fatigue 1. GA
2. CBTLI
3. Usual care plus (self-help
booklet)c
Within-trial analysis 1 vs. 2= 193 (–946 to 458),
0.589 probability of 2 being
cost-saving vs. 1
Therapy (1 or 2) vs. 3= 149
(–708 to 1001)c
Partly applicable. Potentially serious
limitations for the comparison against
3. Minor limitations for 1 vs. 2
Robinson, 2006131 IBS 1. Self-help guidebook (GSH)
2. Self-help guidebook
and self-help group
[MM (GSH + RSSE)]
3. Usual care
Within-trial analysis Effect of guidebook = –72.74
(–102.63 to –42.84); p = 0.000d
Effect of self-help group
(over and above effect of
guidebook) = 7.53 (–20.41 to
35.48); p = 0.591
Directly applicable for health service
cost outcomes. Potentially serious
limitations
Sabes-Figuera, 2012280
(clinical paper is
Ridsdale, 2012115)
Chronic fatigue 1. GA
2. Other psychotherapy
(counselling)
3. Guided self-help
(usual care with self-help
booklet)
Within-trial analysis 1 vs. 3= 261 (141 to 382)
2 vs. 3= 423 (288 to 559)
1 vs. 2= –202 (–362 to –43)
Directly applicable for health service
cost outcomes. Minor limitations
GHS, guided self-help; MM, multimodal.
a Applicability issues and limitations for each study are reported in detail in Appendix 8.
b Mean difference estimated for means reported for each arm (262 for drug and 198 for CBTLI plus medication), p-value for difference is 0.487 in Kennedy et al.129,276 95% CI is
reported as –£221 to £104 in McCrone et al.278
c Comparison of therapy against usual care with self-help booklet in McCrone et al.279 is a non-randomised comparison, whereas GA vs. CBT is a randomised comparison.
d Described as statistically significant result.
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estimate differences in costs and three papers131,279,280 adjusted for baseline costs or resource use in their
regression analysis. All five studies reported using standard sources for unit costs, such as NHS Reference
Costs336 or Personal Social Services Research Unit (PSSRU)337 costs, but two papers279,280 reporting using a
nominal cost for the self-help booklet provided alongside usual care.
One study279 was considered to be partly applicable because, although it did report informal care
separately for each treatment arm, it did not report incremental costs falling on the health service
separately from total incremental costs, which included costs of informal care. This study was also
considered to have potentially serious limitations, but only for the comparison against usual care with
self-help booklet as this comparison was non-randomised. However, the randomised comparison of two
behavioural modification interventions was considered to have only minor limitations. The other four
studies131,275,276,280 were considered to be directly applicable because they reported health service costs
separately from broader societal costs. Three of these four papers were considered to have minor
limitations.275,276,280 The remaining paper, by Robinsons et al.,131 was found to have potentially serious
limitations because it did not appear to include the costs of the intervention in the analysis.
Chisholm et al.275 report results from a RCT that compared CBTHI with counselling (classified as other
psychotherapy) for patients with chronic fatigue. The clinical results are reported by Ridsdale et al.112
and have been included in the clinical effectiveness review. Costs at baseline are compared with costs at
6 months to estimate the change in costs for each therapy and the difference between arms is calculated
for change from baseline. CBTHI resulted in a statistically significant increase in health-care costs
from baseline (mean change in cost from baseline £129, 95% CI £23 to £242). Other psychotherapy
(counselling) resulted in a non-significant increase from baseline (mean change in cost from baseline
£65, 95% CI –£6 to £146). The difference in change from baseline for health-care costs was not
statistically significantly different between the two active interventions (mean change in cost from
baseline –£63, 95% CI –£258 to £42).
Kennedy et al.129 reported the results of a RCT that compared CBTLI with mebeverine to mebeverine
alone in patients who continue to report moderate to severe IBS symptoms after 4 weeks of drug
therapy with mebeverine. Mean costs for resource use (other than that associated with CBT) were
lower in the CBTLI with mebeverine arm at 12 months than in the mebeverine-alone arm, but the
difference was not statistically significant. The cost of CBT was reported to be £308 (SD £202), but
these costs do not appear to have been combined with the costs of other resource use to estimate
the overall incremental cost for CBT with mebeverine versus mebeverine alone.
McCrone et al.279 report results from a RCT that compared GA with CBTLI. A non-randomised comparison
against usual care plus (self-help booklet) is also reported but was considered to have potentially serious
limitations. The clinical results are reported by Ridsdale et al.113 and the results from the randomised
comparison have been included in the clinical effectiveness review. GA was found to have a lower mean
cost than CBTLI but the difference was not statistically significant. Behavioural modification interventions
(CBTLI or GA) were found to have higher costs than usual care plus (self-help booklet) when results from
the two therapies were combined but the comparison against usual care plus was non-randomised.
Robinson et al.131 reported a comparison of a self-help guidebook (guided self-help) and a self-help group
in addition to a guidebook (multimodal combining guided self-help and RSSE) with usual care in patients
with IBS. In addition to reporting the mean costs across each of the arms, regression was also used to
estimate the individual impact on costs of the guidebook and the self-help group. The guidebook was
found to have statistically significantly lower costs by £72.74 (a 40% reduction) but the addition of the
self-help group was found not to have a statistically significant impact on costs. The results were not
sensitive to whether or not the patients met the Rome criteria for IBS.
Sabes-Figuera et al.280 report results from a RCT that compared two behavioural modification
interventions [i.e. GA and counselling (classified as other psychotherapy)] against usual care plus
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self-help booklet (classified as guided self-help) for patients with chronic fatigue. The clinical results are
reported by Ridsdale et al.115 and have been included in the clinical effectiveness review. Both GA and
other psychotherapy (counselling) resulted in additional costs relative to guided self-help. GA resulted
in significantly lower costs than other psychotherapy (counselling). The authors conclude that GA
dominates (has lower cost and better outcomes) other psychotherapy (counselling), but this conclusion
is made on the basis of a single clinical effectiveness outcome measure and, therefore, should be
interpreted with caution.
Overall, the impact of behavioural modification interventions on net health-care costs was found to
vary between studies. Only two studies131,280 reported a statistically significant difference in health-care
costs between trial arms. From the study by Robinson et al.,131 we can conclude that the self-help
guidebook used in this study is likely to be cost-saving for patients with IBS provided that it has a
low cost per patient (i.e. < £72). From the study by Sabes-Figuera et al.,280 we can conclude that the
choice of behavioural modification intervention is important as some interventions may achieve similar
effectiveness results while having a lower impact on overall costs than other interventions. However,
two other studies275,279 were unable to show a statistically significant difference in overall health-care
costs when comparing one behavioural modification against another. From the study by Kennedy et al.,129
we can conclude that CBT does not lead to a statistically significant increase in health service costs over
and above those associated with the intervention.
Independent economic assessment
The general approach taken in our independent economic assessment was to generate a within-study
estimate of cost-effectiveness for individual trials included in the clinical effectiveness review. The four
main steps required were to:
1. estimate the incremental costs relative to usual care of delivering the behavioural modification
interventions (and any active comparator interventions) reported in the individual studies
2. estimate health-utility outcomes from the clinical outcomes reported in the individual studies
3. estimate the difference in benefits between trial arms in terms of the incremental QALYs gained
4. combine these to estimate the cost-effectiveness.
The methods for each of these steps are described in Inclusion/exclusion criteria to Methods, respectively,
and the results are described in sections Results: intervention and comparator costs to Results: cost-
effectiveness analysis. Information on the impact of interventions on other NHS resource use (i.e.
resource not directly related to the delivery of the intervention) has also been incorporated in the
estimates of cost-effectiveness described in Results: cost-effectiveness analysis, where this was identified
within the economic studies described in Systematic review of existing cost-effectiveness evidence.
Our decision to focus on within-trial estimates of cost-effectiveness rather than using the outcomes of
the NMA to conduct a single incremental analysis covering all of the different categories of behavioural
modification interventions is discussed further in Chapter 7, Cost-effectiveness.
Methods used to estimate intervention costs
Each of the included studies was examined to determine the resources required to deliver the intervention
and any active comparators (i.e. comparators that were not usual care/treatment as usual or waiting list
control).We have assumed that usual care (or treatment as usual/waiting list control) has zero cost so
that any intervention or active comparator is costed relative to usual care. Six studies100,113,118,151,159,160
had comparator arms that were categorised as ‘usual care plus’, and these have been costed where
possible. Information was extracted on the number of sessions, duration of sessions and the health-care
professionals involved in delivering or facilitating the intervention. For interventions delivered to groups,
information was also extracted on the number of individuals who started the intervention and either the
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group size or the number of groups to allow an estimation of the average cost per patient. Unit costs were
taken from the most recent edition of the PSSRU Unit Costs of Health and Social Care 2016338 with three
exceptions: the unit costs for clinical psychologists, counsellors and mindfulness trainers were reported in
the 2014 edition of PSSRU unit costs (Unit Costs of Health and Social Care 2014339) but not in the 2016
edition, so the costs from the 2014 edition have been uplifted to 2016 prices using the Hospital and
Community Health Service Pay and Prices index.338 We have used unit costs including qualification costs
where these are reported. The ratio of direct to indirect time is the ratio of time spent in direct contact
with patients relative to time spent on other activities. As the resource use in our studies is based on
face-to-face time with patients, we have used the cost per minute of face-to-face time where this has been
reported.Where this has not been reported we have used the ratio of direct to indirect time to estimate
the cost per minute of face-to-face time. For example, the ratio of direct to indirect time for a nurse in
general practice is 1 : 0.20, so for each hour spent in contact with a patient an additional 12 minutes is
spent on other activities. Therefore, if the cost per working hour is £43 then the cost per minute of
face-to-face time is £0.86 (= 1.2 × £43/60). An exception was made for the time that GPs spent training
in the GP interventions, which included a training element. For these interventions, the training time was
based on the cost per minute across all GP activity, but the time spent with patients was still based on the
cost per minute of face-to-face time with patients. Unit costs are summarised in Table 23.
TABLE 23 Unit costs applied in the costing of interventions
Health-care staff Unit cost
Ratio of direct
to indirect time
Cost per
minute (£)a Source
CBT £97 per 55 minutes of contact
time
NAb 1.76 Unit Costs of Health and
Social Care 2016338
Clinical psychologist £138 per hour of client contact NAb 2.35c Unit Costs of Health and
Social Care 2014339
Counsellor £50 per hour Not reported 0.85c Unit Costs of Health and
Social Care 2014339
Consultant, medicine £135 per working hour 1 : 0.61d 3.62 Unit Costs of Health and
Social Care 2016338
Consultant, psychiatry £138 per working hour 1 : 0.61d 3.70 Unit Costs of Health and
Social Care 2016338
GP (training) £147 per hour of GMS activity NA 2.45 Unit Costs of Health and
Social Care 2016338
GP (treating) £3.90 per minute of patient
contact time
1 : 0.61 3.90 Unit Costs of Health and
Social Care 2016338
Mindfulness-based
cognitive therapy
£172 per 2-hour session NAb 1.47c Unit Costs of Health and
Social Care 2014339
Nurse practitioners £61 per hour 1 : 0.33 1.35 Unit Costs of Health and
Social Care 2016338
Physiotherapist £45 per hour 1 : 0.37 1.03 Unit Costs of Health and
Social Care 2016338
Primary care nurse £43 per hour 1 : 0.20 0.86 Unit Costs of Health and
Social Care 2016338
Social worker adult services £98 per hour of
client-related work
NAb 1.63 Unit Costs of Health and
Social Care 2016338
HCHS, Hospital and Community Health Service; NA, not applicable.
a After adjusting for ratio of direct to indirect time (except for GP training time).
b Not applicable as unit cost already adjusted for ratio of direct to indirect time.
c Inflated from 2014 to 2016 using HCHS Pay and Prices Index338 (inflation rate= 297.0/290.5).
d Ratio for GP assumed to apply.
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Interventions delivered to groups and interventions delivered to individuals have been split into
separate categories as interventions delivered to groups are usually cheaper on a cost per patient
basis. A list of the detailed assumptions used in the costing analysis is provided in Appendix 9.
Methods used to estimate utility values from study outcomes
The method for estimating treatment benefit recommended by NICE is to estimate the difference in
QALYs between groups receiving different interventions.244 Health utility is a measure of HRQoL on a
scale of zero to one; one represents full health and zero represents a state equivalent to death. When
calculating QALYs, the patient’s estimated survival is adjusted to reflect their health utility during that
period of survival. Therefore, an estimate of health utility is needed to estimate treatment benefit
using QALYs. Some generic measures of HRQoL, such as the EQ-5D, come with a tariff that allows
utility to be estimated from an individual’s response to the EQ-5D using preferences obtained from a
UK general population sample. The EQ-5D is NICE’s preferred measure of health utility for estimating
QALYs.244 When health-utility values based on the EQ-5D are not available, NICE recommends that
these are estimated by using mapping functions that estimate EQ-5D utility values from the other
HRQoL measure or health-related benefits observed in the trials.244
It was our aim to measure health benefits using QALYs based on EQ-5D outcomes valued with UK
preferences whenever this was feasible from the data collected, as this is consistent both with the
NICE methods guide and with the data reported in those studies included in our systematic review of
published cost-effectiveness studies. We examined the generic preference and non-preference-based
measures of HRQoL reported in the included studies. For studies that did not report EQ-5D directly,
we looked to identify mapping algorithms that would allow us to estimate EQ-5D utility values from
the other measures of HRQoL reported. Studies that reported EQ-5D utility values obtained with a
non-UK preference set were considered acceptable where it was not possible to obtain EQ-5D values
obtained using the UK preference set. Estimates obtained from alternative generic quality-of-life
instruments were also considered acceptable if they met NICE’s requirement that health-utility values
should be based on a valuation of public preferences from a representative sample of the UK
population using a choice-based method.
Summary of generic preference and non-preference-based measures reported
Both of the published cost-effectiveness analyses identified in our systematic review126,282 measured
QALYs using the EQ-5D with UK preferences. A further six studies108,115,137,138,143,340 reported EQ-5D
outcomes in their clinical or economic papers but did not meet the inclusion criteria for our systematic
review of published cost-effectiveness analyses. Morriss et al.108 reported both the EQ-5D utility index
and resource use but did not conduct a full economic evaluation. Furthermore, the scale on which the
EQ-5D score is reported does not appear to be the standard zero to one scale and, therefore, it is
unclear if the value reported is based on the UK tariff or some other method for scoring the EQ-5D.
Luciano et al.138 (the economic paper for Alda et al.)137 present a full economic evaluation, but the
setting was the USA rather than the UK. In addition, Luciano et al.138 used a Spanish tariff rather than
the UK tariff to calculate utility values from the EQ-5D. van Ravesteijn et al.143 reported only the VAS
part of the EQ-5D, which is not a preference-based measure of health utility and, therefore, cannot be
used to calculate QALYs. The related economic paper341 reported QALY gains, but these were obtained
using a different measure of health utility rather than the EQ-5D. A second study by Luciano et al.138
also reported only the VAS part of the EQ-5D. van der Roer et al.340 reported QALY gains calculated
using the EQ-5D in their within-trial economic evaluation,340 but the utility values were estimated using
the Dutch rather than the UK tariff. Ridsdale et al.115 reported EQ-5D values at baseline only within the
related economic paper,280 stating that there was an ‘unexpected unavailability of EQ-5D questionnaire
data for the six-month follow-up’. Therefore, although eight studies reported some aspect of the
EQ-5D, only the two studies included in the systematic review of cost-effectiveness analyses126,282
reported EQ-5D values that can be used to calculate QALYs based on UK preferences, although a
further two studies reported EQ-5D utility values based on non-UK preferences.137,340
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
144
Twenty-five of the studies included in the systematic review of clinical effectiveness reported some
aspect of the Medical Outcomes Survey (MOS) Short Form questionnaire-36 items (SF-36).97,103,106,107,111,
112,114,119,125,131,136,140,141,143–147,149,151–153,156,342,343 This is a generic measure of HRQoL that is usually reported
as either eight domain scores (i.e. physical functioning, role physical, role emotional, vitality, mental
health, social functioning, bodily pain and general health) or a pair of higher-level summary scores
described as the mental component summary (MCS) score and the physical component summary
(PCS) score. An additional five studies reported outcomes from the MOS SF-12.118,133,150,157,158 This is a
shortened version of the SF-36 that is able to produce MCS and PCS scores similar to those reported
by the SF-36 with less respondent burden.344 The Short Form questionnaire-6 Dimensions (SF-6D) is a
shortened version of the SF-36 that contains only six items.345 A preference-based measure of utility
exists for the SF-6D, which was derived using preferences expressed by a sample representative of
the UK general population. Although this is not NICE’s preferred method for estimating utility, it has
similarities with the EQ-5D in that it provides a measure of HRQoL that is based on public preferences
from a representative sample of the UK population using a choice-based method. The study by van
Ravesteijn et al.143 used the SF-6D to estimate QALYs for the within-trial economic analysis, and one
further study by Aiarzaguena et al.136 reported outcomes using the SF-6D (although the utility values
appear to have been reported on a 0 to 100 scale rather than a 0 to 1 scale).
Identification and selection of mapping algorithms
‘Mapping’ or ‘cross-walking’ algorithms exist that allow the expected outcomes from the EQ-5D
instrument to be calculated from other generic or disease-specific HRQoL instruments. These have
been systematically reviewed by Dakin et al.346,347 and a database of instruments that map to the
EQ-5D is provided on the website of the Health Economic Research Centre (HERC) at the University
of Oxford (version 5.0, last updated 16 May 2016). We examined this database to identify algorithms
that would allow us to map trial outcomes measured using the SF-36 to utility values measured using
the EQ-5D with the UK tariff. We also examined the list of titles identified during a systematic review
of mapping studies that was ongoing at ScHARR at the time to find any studies not picked up in the
HERC database.
Six studies that mapped from the SF-36 to the EQ-5D were identified from the HERC database and
no additional studies were identified from the list of titles taken from the ongoing ScHARR systematic
review. One of these studies was discounted because it used preferences from a Korean population
rather than a UK population.348 Three others were discounted because they used a data set for a
specific condition, which may limit the generalisability of the results to patients with a more diverse
range of health conditions.349–351 Of the two remaining papers, the paper by Ara and Brazier352 was
selected in preference to the paper by Rowen et al.353 because it specifically validated the algorithm for
use in predicting mean EQ-5D scores from mean SF-36 domain scores in situations where the patient-
level data are not available. It was also noted that the data sets used by Ara and Brazier352 covered a
range of conditions, including some conditions, such as IBS, which would be managed in primary care,
whereas the data set used by Rowen et al.353 was limited to secondary care inpatients and outpatients
and, therefore, it might be less generalisable to our target primary care population. Ara and Brazier352
examined seven different ordinary least squares (OLS) models and concluded the simplest model
(referred to as eq1) was the preferred model for estimating group EQ-5D scores from group domain
scores, whereas the model referred to as eq4, which contained second-order terms, was preferred for
estimating between-group differences and changes over time. However, after discussion with the
corresponding author, we decided that as there was little difference between the performances of these
two models, it was best to use the simplest model, which contained only linear functions of the domain
scores, as this allowed us to calculate changes from baseline and differences between groups where the
absolute scores were not reported.
Eight studies that mapped from SF-12 to EQ-5D were identified from the HERC database and two
additional studies were identified from the list of titles taken from the ongoing ScHARR systematic
review. Of these 10 studies, five354–358 used US preferences for the EQ-5D and three359–361 mapped to
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the actual EQ-5D responses rather than to the preference-based EQ-5D index. The remaining three
papers362–364 used US samples to derive the mapping algorithm, but they used UK preferences for the
EQ-5D index as they were developed before the US preference set was published. All three studies
used a similar methodology of OLS regression to map from the MCS and PCS scores of the SF-12 to
the UK preference-based index for EQ-5D. One study used a sample (n = 240) from a single health
centre to examine the validity of the EQ-5D in a low-income minority population.364 The other two
papers362,363 used larger general population samples and these were considered more generalisable
to our target population. The algorithm reported by Lawrence and Fleishman362 was selected in
preference to the one reported by Franks et al.363 because Lawrence and Fleishman362 explicitly
validated whether or not the algorithm could predict the mean EQ-5D score across a group from
the mean PCS and MCS score for that group. This was carried out for groups of patients stratified
by age and for groups stratified according to the presence of six different conditions.362 Although the
algorithm developed by Franks et al.363 was validated using an external data set, the validation did not
explicitly examine whether or not the algorithm could predict group mean EQ-5D scores for different
groups of patients.363 Lawrence and Fleishman362 examined two-, three- and six-variable algorithms but
found that two- and three-variable models performed better than the six-variable model and there
was not much difference in performance between the two- and three-variable models.362 We therefore
decided to use the two-variable model, which predicted the EQ-5D score as a linear function of MCS
and PCS. This had the added advantage that differences in EQ-5D scores (over time or between groups)
could be calculated from the differences in MCS and PCS when the absolute scores are not reported.
Twelve of the included studies reported outcomes on only one or two domains of the SF-36.97,103,107,111,
112,114,149,151–153,156,343 We considered whether or not it was feasible to use these outcomes to estimate
changes in EQ-5D based on changes in a single SF-36 domain by using the linear algorithm presented
by Ara and Brazier352 and assuming no changes on any other domains. The study by Wearden et al.111
provided an opportunity to validate if this approach provided reasonable estimates as it reported only
a single domain of the SF-36 in the clinical paper, but also reported EQ-5D scores in the accompanying
economic analysis by Richardson et al.282 We found that the changes in utility from baseline based on
changes in the single domain of SF-36 (physical functioning in this case) were a factor of 10 smaller
than the changes in utility measured on the EQ-5D. This discrepancy may be due to the intervention
having an effect on multiple aspects of HRQoL and these effects not being constrained to the single
domain reported, as changes in other domains may influence the overall EQ-5D score. For these
reasons, the approach of mapping EQ-5D changes from changes in a single domain of the SF-36
was not considered to be valid and we did not explore applying this mapping approach any further.
Three studies reported SF-36 MCS and PCS scores but did not report the scores for all eight domains.
A study by Maund et al.351 used OLS regression to estimate a mapping algorithm for SF-36 MCS and PCS
to EQ-5D in a population with shoulder pain. The median duration of shoulder pain in the population
used to derive the algorithm was < 12 weeks, with population being acute pain and, therefore, this
population would not have been categorised as having chronic pain according to the definition used in
our clinical effectiveness review. Although other studies were chosen in preference to the study by
Maund et al.351 for mapping between eight domains of SF-36 to EQ-5D, no alternatives were found in
the HERC database that mapped SF-36 MCS and PCS to EQ-5D. We used the data from McBeth et al.125
to validate whether or not using the algorithm presented by Maund et al.351 generated QALY gains
similar to those estimated directly using the EQ-5D in the McBeth et al.125 study. We found that the
utility values estimated indirectly from the SF-36 MCS and PCS scores varied from those estimated
directly by up to 20% with lower absolute utility values predicted. The QALY gains between active
intervention and the treatment-as-usual arm were up to 70% smaller than those estimated directly and
the ordering of interventions in terms of the QALY gain was not consistent, with combined CBTHI and
GA having the largest QALY gain when measuring utility indirectly from SF-36 MCS and PCS scores
and CBTHI alone having the largest QALY gain based on direct EQ-5D scores. For these reasons,
we did not explore applying this mapping approach any further.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
146
The paper by Franks et al.363 suggested that algorithms that map MCS and PCS scores from the
SF-12 to the EQ-5D may be suitable for use with summary scores from the SF-36, but Franks et al.363
recommended that this approach be validated further. Given that the algorithm by Lawrence and
Fleishman362 for mapping between SF-12 MCS and PCS scores and EQ-5D has been developed and
validated in a data set covering a more diverse population than the algorithm reported by Maund
et al.,351 we decided to explore the validity of using the SF-36 MCS and PCS scores in the algorithm
intended for SF-12 MCS and PCS scores developed by Lawrence and Fleishman.362 Again, we validated
this approach using the data from McBeth et al.,125 which reported both EQ-5D and SF-36 MCS and
PCS scores. We found that the utility values calculated from the SF-36 MCS and PCS scores using the
algorithm published by Lawrence and Fleishman362 were not similar to those measured directly using
the EQ-5D with differences of 34% to 38% in the absolute utility values predicted. Furthermore, the
incremental QALY gains differed by up to 80%, and again the ordering of interventions in terms of the
greatest QALY gain versus treatment as usual was not consistent with the directly measured EQ-5D
values. Therefore, this mapping approach was not considered to be valid and was not explored further.
Overall, there were 19 studies that reported either EQ-5D (four studies reported utility using UK or
non-UK preferences),111,125,137,340 the SF-6D (two studies),136,143 all eight domains of the SF-36 (eight
studies)106,131,141,144–147,342 or both the MCS and PCS of the SF-12 (five studies).118,133,150,157,158 There
were 41 studies remaining either that did not report any generic measures of HRQoL or for which
we were unable to estimate preference-based utilities from the generic measures of HRQoL reported
using a mapping algorithm. We considered if it was feasible to estimate QALY gains for these remaining
studies by mapping from a single key symptom measure, such as fatigue, pain or disability. However,
this was considered to potentially have limitations similar to mapping from a single domain of the
SF-36; an improvement in one symptom may underestimate the overall benefit if other symptoms
improve but the opposite could be true if an intervention improved one symptom but caused others to
worsen. We therefore decided that this was not a valid approach as it could provide misleading results.
In summary, utility values over time have been extracted for those studies reporting utility values
directly from the EQ-5D (using either UK preferences or non-UK preferences and the SF-6D (using
UK preferences). For those studies reporting all eight domains of the SF-36 or the MCS and PCS of the
SF-12, utility values have been estimated using algorithms provided by Ara and Brazier352 and Lawrence
and Fleishman,362 respectively.
For studies that reported both SF-6D outcomes and all eight domains of the SF-36, we have conducted
a sensitivity analysis to determine whether or not the estimates of utilities differed substantially when
using utility values based on mapping to the EQ-5D from the SF-36 rather than those obtained directly
from the SF-6D.
Methods used to estimate quality-adjusted life-years from utility values
The QALY gains have been estimated by assuming a linear change in utility values between each
reported value and using an area under the curve approach to estimate QALYs for each arm. Where
the absolute utility values were not reported, we have used data on the change in utility values from
baseline or data on the difference in utilities between arms to estimate the QALY gains relative to
usual care (or the lowest cost comparator arm if no usual-care arm was included).
We calculated the QALY gains using both the raw utility values and the utility values adjusted for
baseline differences. We adjusted for utility differences at baseline using one of the following methods.
Where the difference between arms has been reported after adjustment for differences in baseline
characteristics, these have been used in preference to the raw values. Where these data are not
available, the baseline value in all arms has been set to that observed in the comparator arm and then
values thereafter have been determined using the difference from baseline for each study arm.
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The time frame for estimating QALYs has been restricted to the last time point with comparative utility
data for each study. Given the differences in populations and interventions across the studies being
considered, it did not seem reasonable to use data from studies with a longer follow-up period to
make predictions about the long-term persistence of treatment effects beyond the study period for
studies with shorter follow-up times. Only two studies reported utility values beyond 12 months.
Both of these were within-trial economic evaluations that reported QALY gains after discounting at
3.5% per annum.111,125,126,282 Therefore, no further adjustments for discounting were required.
A full probabilistic assessment of the uncertainty around the estimates of QALY gains has not been
conducted. This is because to do so for those studies where utility values have been estimated by
applying a mapping algorithm to the mean SF-36 or SF-12 scores would have required the covariance
matrix for the regression coefficients, which we did not have. Instead, we have used the estimates
of variance for the SF-36 and SF-12 scores to derive the IQR for each score used in the mapping
algorithm. We have then estimated the output of the mapping algorithm when all of the SF-36 (or
both SF-12) scores are at their lower IQR and the output when they are all at their upper IQR. These
utility values have been used as the upper and lower IQR for the utility values. The utility values in
the comparator arm were kept fixed at their mean values and the lower and upper IQR for the QALY
gain versus the comparator were calculated by setting the utility values in the intervention arm to
their upper and lower IQR. (Note: if the lower IQR for both intervention and comparator are compared
then the incremental QALY gains remain broadly similar as both the intervention and the comparator
move a similar amount in a similar direction.) The IQR was used instead of the 95% CI because our
method assumes that all eight domains of the SF-36 (or both summary component scores of the SF-12)
are perfectly correlated (i.e. change in the same direction all of the time), which is unlikely to be true.
So while the variability in the QALY gains is presented as an IQR, it is possible that the variance for the
QALY gains is overestimated. Using the broader 95% CI as inputs to the mapping algorithm would have
further exacerbated this potential overestimation of variance. Where studies have reported the 95% CI
for QALYs directly, these have been used in preference to our IQR estimate.
Methods used to estimate cost-effectiveness
We sought to obtain a within-trial estimate of cost-effectiveness for each of those studies for which we
were able to obtain an estimate of incremental QALYs, either from utilities/QALYs reported directly in the
study or from mapping from SF-36/SF-12 outcomes to utility values (described previously in this chapter).
The estimates of incremental QALYs described in Results: estimates of quality-adjusted life-year gains have
been combined with the estimates of intervention costs described in Results: comparator costs. Where
there were data from the published cost-effectiveness studies and cost–consequence studies, described
in Systematic review of existing cost-effectiveness evidence, to indicate that an intervention increased or
decreased other NHS resource use (e.g. GP consultations, hospital visits, etc. not related directly to
delivery of the intervention), these have also been incorporated in the incremental cost used to calculate
the ICER. However, the estimates of intervention costs from earlier in this chapter have been used, rather
than any estimates of intervention costs reported in the studies themselves, for two reasons: first, it
allowed a consistent costing methodology to be employed across all studies and, second, it allowed us
to apply up-to-date unit costs. A fully probabilistic assessment of uncertainty was not feasible as the
QALY estimates were based on a mapping algorithm and no information was available on the correlation
between different quality-of-life domains used as inputs to the mapping algorithm (see Results: estimates of
health utility). Instead, the lower and upper IQR range for the incremental QALYs, estimated as described
in Results: estimates of quality-adjusted life-year gains, were used to calculate an IQR for the ICERs. For
studies involving more than two treatment options, the IQR for the ICER was calculated only versus
the lowest cost treatment option (usual care or lowest cost active comparator if no usual-care arm).
Results: intervention and comparator costs
Tables of costs estimated for each behavioural modification intervention (or active comparator,
e.g. medication) by intervention types are provided in Tables 77–96 of Appendix 11. Costs could not be
estimated for three studies105,146,149 because no information was provided in the publications on the
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duration of sessions with health-care providers. In addition, costs for the training element of two
GP interventions101,159,365 could not be estimated because of a lack of information on the nature of
the training, so costs for these interventions exclude training costs and total costs are therefore
underestimated. For three studies that were classified as guided self-help,115,131,133 one of the study
arms consisted of providing materials to patients without any sessions with health-care providers.
One of these studies reported a nominal cost for a CBT booklet of £5 in its economic analysis.115
No costs were reported for the materials provided in the other two studies.131,133 In the study by
Smith et al.,100 GPs were provided with a consultation letter that gave advice on how to manage
patients with somatisation disorder, but no cost was provided for this consultation letter. Consultation
letters were also provided to GPs as part of ‘usual care plus’ in four other studies but the associated
costs were not provided and could not be estimated from the papers.143,144,156,161 Two studies137,138 had
active comparator arms that consisted of recommended pharmacological management, which was
costed as £217.60 and £214.03 respectively for the 6-month trial period (see Appendix 11, Table 96,
for details). In Kennedy et al.,129 both the intervention and the comparator arms received medication,
but this was not costed as the medication was considered to form part of usual care. Overall, a cost
was estimated for at least one arm of 55 studies that included a total of 77 intervention or active
comparator arms. The median costs according to intervention type are summarised in Table 24. For GP
interventions, the costs are summarised both by the type of intervention (e.g. CBT, reattribution) and by
the mode of delivery (e.g. whether or not there was GP training and whether the intervention involved
any interventions delivered to individual patients or groups of patients). We have summarised the other
interventions according to whether they are delivered to a group of patients or to individuals.
The costs for interventions are summarised in Figures 61–64 as box-and-whisker plots. The green box for
each intervention type shows the IQR, with the line dividing it indicating the median value. The upper
and lower whiskers show the maximum and minimum values for interventions of that type. Means are
shown on the plot as individual points sitting on the line between the maximum and minimum values.
TABLE 24 Median costs by intervention typea
Intervention type
Group or individual
intervention for patients Number of study armsb Median cost (£)
CBT low intensity Group 1 123
Individual 5 317
CBT high intensity Group 4 216
Individual 4 794
Other psychotherapy Group 2 228
Individual 8 462
GA Individual 7 564
SES Group 1 128
Individual 6 740
RSSE Group 7 62
Individual 1 212
Guided self-help Group 1 143
Individual 2 240
Multimodal Group 3 193
Individual 5 892
Pharmacological Individual 2 216
continued
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TABLE 24 Median costs by intervention typea (continued )
Intervention type
Group or individual
intervention for patients Number of study armsb Median cost (£)
GP interventions summarised by delivery mode
GP training NA 7 337
GP training with group intervention
for patients
Group 1 1299
GP interventions for individuals Individual 2 505
GP training with individual GP
intervention
Individual 8 871
GP interventions summarised by intervention type
CBT One individual 1 939
Reattribution (including modified) Individual 5 793
Multimodal Three individual and one group 4 1288
MUS management Individual 7 337
Other psychotherapy Individual 1 802
All GP interventions NA 18 546
NA, not applicable.
a Results for individual studies are reported in Tables 77–96 of Appendix 11.
b Excluding those studies where costs were not estimable.
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The costs for interventions delivered to individuals are summarised in Figure 61. It can be seen that
within each intervention type there is typically a broad range of costs, with the greatest range being
for other psychotherapy because of one very high-cost outlier.96 There was also a wide IQR for the SES
intervention type because of the results from two of the six interventions, which came from the same
study,140 having a very high cost. However, the median values were less variable and ranged from £212
for RSSE to £892 for multimodal interventions.
A similar picture is seen for interventions delivered to groups in Figure 62. The median costs for group
interventions range from £62 for RSSE to £227 for other (i.e. not CBT) psychotherapy interventions. The
multimodal group intervention had a broad range of costs because of the results from one study, which
had a very high cost (£2088), possibly because it combined both group and individual sessions. In
general, the mean and median costs per patient for each intervention type are lower for interventions
delivered to groups than for interventions delivered to individuals.
The costs for GP interventions by delivery mode are presented in Figure 63. The most common mode
of delivery was one that involved training for GPs followed by a specific intervention for individual
patients (eight study arms),101,136,153,154,159,160,311,343 which had a median cost £871 but a wide range of
costs (£500–2561). It should be noted that training costs were not estimable for two of the studies
included so the costs of this delivery model may have been underestimated. The next most common
delivery mode was GP training with no specific intervention for patients (seven study arms),97,102,108,146,147,
158,160 which had a median cost of £337 (range £160–821). The highest median cost was for GP training
followed by a group intervention for patients, but the estimate was based on a single study.147,365
When summarising the GP interventions according to the type of intervention (see Figure 64) rather
than the mode of delivery, the most common intervention type was MUS management with a median
cost of £337 and a range of £160–550. The other intervention types generally had higher costs and a
greater spread of cost estimates, ranging from approximately £450 to £2500.
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When considering all GP interventions (18 study arms), the median cost was £546 and the range was
£160–2561. Part of the reason for the large variation in cost per patient is due to significant variation
in the number of patients treated by each GP who was trained. In the studies that included a training
element, the cost per patient is based on the number of patients treated by the GP within the study.
However, this may overestimate the long-term cost per patient if GPs continue to use the training to
improve their management of additional patients who were not recruited to the trial. Variation in the
number of patients treated per GP trained is an important factor driving variation in the cost per
patient. For example, van der Feltz-Cornelis et al.160 included 18 GPs in the arm that received GP
training but only 23 patients were enrolled in this arm. This was partly explained by a fall-off in
recruitment once GPs discovered that they had been allocated to the control arm. For this reason, we
used the number recruited in the intervention arm (n = 58) to estimate the cost per patient. However,
even when using this latter figure, the cost per patient was very high in the control arm (i.e. £821).
Conversely, Rosendal et al.146 had a slightly higher duration of training but 506 patients were treated
by 22 GPs, resulting in a much lower cost per patient (i.e. £160).
Results: estimates of health utility
Figures 65–72 show the profile of utility values over time for the 14 studies for which we were able
to estimate absolute utility values either directly from the studies or via mapping from the SF-36 or
the SF-12 outcomes reported. It can be seen from these figures that the utility at baseline is not
always equal between arms taken from the same study, with clear baseline differences in 8 out of
the 14 studies.111,118,125,133,144,147,157,158
In general, those interventions that achieved a difference in utility at short-term follow-up were able to
maintain that utility gain in the long term.118,125,147,150 However, given that the populations and interventions
varied considerably across the studies, it was not considered reasonable to assume that a similar
maintenance of treatment effects would be seen across other behavioural modification interventions
where long-term data were lacking.
We were unable to estimate absolute utility values for 5 of the 19 studies identified as including
EQ-5D, SF-6D, SF-12 or SF-36 data, so these studies are not included in Figures 65–72.106,131,145,146,340
Three of these studies131,145,146 provided data that allowed us to estimate the utility difference between
trial arms, by assuming a common utility at baseline. Pols and Battersby145 reported the difference from
baseline for each study arm. Robinson et al.131 reported the difference between trial arms at 12 months,
and Rosendal et al.146 reported the difference from baseline for each arm and the adjusted difference
between trial arms, with the adjusted difference between trial arms being used in the analysis. For one
study,106 which reported SF-36 outcomes, we were unable to apply the utility mapping algorithm from
SF-36 to EQ-5D as a mixture of mean and median SF-36 domain scores. Therefore, no utility values or
QALYs could be estimated for this one study. The remaining study reported incremental QALYs directly,
in the accompanying economic paper,340 so it was not necessary to calculate absolute or incremental
utility values.
A sensitivity analysis was conducted to explore whether or not the utility values differed substantially
when using EQ-5D-based utility values obtained via mapping from the SF-36 compared with using
utility values based directly on the SF-6D. The results for the studies by Aiarzaguena et al.136 and
van Ravesteijn et al.143 are shown in Figures 73 and 74, respectively.
In the study by Aiarzaguena et al.,136 the utility values obtained by mapping from the SF-36 to the
EQ-5D and those obtained directly from the SF-6D are similar in the reattribution arm. In the modified
reattribution arm, the values at baseline are lower when obtained by mapping from the SF-36 and the
gain in utility values is slightly larger.
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FIGURE 65 Utility values for studies comparing CBTHI with usual care.
A
SSE
SSM
E
N
T
O
F
C
O
ST
-E
F
F
E
C
T
IV
E
N
E
SS
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
a
lslib
ra
ry
.n
ih
r.a
c.u
k
1
5
4
Utility
0
.8
0
.7
0
.6
0
.5
0
.4
0
.3
0
.2
0
.1 0
T
im
e
 (
w
e
e
k
s)
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
G
ra
d
e
d
 e
xe
rc
is
e
1
3
3
G
S
H
1
3
3
G
ra
d
e
d
 e
xe
rc
is
e
1
1
1
U
su
a
l c
a
re
1
1
1
F
IG
U
R
E
6
6
U
ti
lit
y
va
lu
es
fo
r
st
u
d
ie
s
co
m
p
ar
in
g
G
A
w
it
h
u
su
al
ca
re
o
r
gu
id
ed
se
lf
-h
el
p
.
DOI: 10.3310/hta24460 Health Technology Assessment 2020 Vol. 24 No. 46
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Leaviss et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
155
Time (weeks)
0 10 20 30 40 50 60 70 80
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
U
ti
li
ty
Other psychotherapy143
Usual care plus143
Other psychotherapy111
Usual care111
FIGURE 67 Utility values for studies comparing other psychotherapy with usual care.
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FIGURE 69 Utility values for studies comparing guided self-help with usual care.
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FIGURE 71 Utility values for studies comparing multimodal treatments with single modality treatments.
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FIGURE 73 Sensitivity analysis comparing utility values mapped from SF-36 to EQ-5D with those obtained directly from SF-6D for Aiarzaguena et al.136
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In the study by van Ravesteijn et al.,143 the absolute utility values are higher in both arms when using
the values obtained by mapping from the SF-36 to the EQ-5D. The ordering of the intervention and
comparator arms in terms of absolute utility is different at final follow-up between the two methods
for estimating health utility, with other psychotherapy having greater utility at final follow-up when
using the values obtained directly from the SF-6D and usual care having greater utility at final follow-up
when using the values mapped from SF-36 to EQ-5D. However, in both cases the differences between
trial arms are small and the utility profiles cross during the duration of the study.
Results: estimates of quality-adjusted life-year gains
The QALY gains estimated for each study are provided in Table 25. It can be seen that the mean
estimates of QALY gains are generally small and are consistently under 0.1 QALYs. In the five studies
that directly reported the QALY gains and their 95% CI,111,125,126,137,143,282,340 it was found that there was
no statistically significant difference in QALYs between trial arms. In the studies where the IQRs for
the QALY gains were estimated from the IQRs for the SF-36/SF-12 outcomes, we found that the lower
IQR was above zero for all but three comparisons.144,146,147
A sensitivity analyses was conducted in which the utility values obtained by mapping from the SF-36 to
the EQ-5D were used to calculate QALY gains for the two studies that reported SF-6D utility values.136,143
For Aiarzaguena et al.136 the QALY using the utility value obtained by mapping from SF-36 to EQ-5D was
0.028, after adjusting for baseline differences, whereas the equivalent estimate when using the SF-6D
utility values reported directly in the paper was 0.019. For the study by van Ravesteijn et al.,143 the QALY
gain was calculated to be 0.015, after adjusting for baseline differences, whereas the equivalent figure
when using the SF-6D was reported to be 0.012 in the paper. Therefore, the choice of method to obtain
utility estimates does appear to be important and the mid-point ICERs for these two studies may be
overestimated in the base-case analysis because of the use of utility values measured using the SF-6D
rather than the EQ-5D.
Results: cost-effectiveness analysis
A summary of the cost-effectiveness evidence is provided in Table 26, with the detailed results for
each study reported in Table 27. In the summary table, for each comparison we have recorded whether
the mid-point ICER is under or over £30,000 per QALY (denoted by ‘< £30K’ or ‘> £30K’, respectively).
This cut-off point has been chosen as it is the upper limit of the range considered to be cost-effective
by NICE (£20,000 to £30,000 per QALY)244 so interventions with a mid-point ICER above this range are
unlikely to be considered cost-effective when applying the NICE threshold. Where the mid-point ICER
is under £30,000 but the upper range of the ICER is above £30,000, then the intervention may not
be considered cost-effective because of the degree of uncertainty in the ICER. For this reason, where
the IQR crosses £30,000, we have added ‘W’ to indicate that there is a wide IQR and there may be
uncertainty regarding the cost-effectiveness. Comparisons where one intervention was dominated are
also indicated (denoted by ‘Dom’); an intervention is dominated by another if it has higher costs but
lower QALY gains.
There is a large degree of heterogeneity in the estimates of cost-effectiveness for individual studies,
with some interventions having mid-point ICERs in the range that would normally be considered
cost-effective by NICE (i.e. below £20,000 to £30,000 per QALY) and others having ICERs well above
this range. Some interventions were also found to be dominated by usual care or dominated by other
behavioural modification interventions.
Where there was more than one study providing an estimate of cost-effectiveness for a particular
comparison, the evidence was often inconsistent. For example, the ICERs for two studies125,137 that
compared CBTHI with usual care were below £20,000 with an upper IQR above £30,000, suggesting
that CBTHI is potentially cost-effective. However, a third study141 had an ICER of £56,792 (IQR
£45,400–£76,816). This was despite the Zonneveld et al.141 study having a higher intervention cost than
one of the other two studies, indicating a higher intensity of CBT. These inconsistencies may be driven
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TABLE 25 Estimates of incremental QALY gain for individual studies
First author and year
of publication Treatment strategies Utility measurement method
Baseline
utility
Utility at last
follow-up
ΔQALYs using
unadjusted data
ΔQALYs using adjustment for baseline
differences
Aiarzaguena, 2007136 1. GP modified
reattribution
2. GP reattribution
SF-6D at baseline and 1 year 1. 0.640
2. 0.623
1. 0.710
2. 0.655
1 vs. 2: 0.036 1 vs. 2: 0.019a (95% CI 0.002 to 0.036)a
(mid-point of 0.028 when using EQ-5D
mapped from SF-36)
Alda, 2011137 1. CBTHI
2. Pharmaceutical
3. Usual care
EQ-5D with Spanish tariff at
baseline and 6 months and
QALYs reported directly
1. 0.40
2. 0.40
3. 0.38
1. 0.61
2. 0.53
3. 0.54
1 vs. 3: 0.02
2 vs. 3: 0.00
1 vs. 3: 0.02 (95% CI –0.00 to 0.03)b
2 vs. 3: 0.00 (95% CI –0.01 to 0.02)b
Burton, 2012157 1. GP MUS
2. Usual care
EQ-5D mapped from SF-12
using Lawrence and
Fleishman’s362 algorithm
1. 0.520
2. 0.546
1. 0.563
2. 0.606
1 vs. 2: 0.008 1 vs. 2: 0.004 (IQR –0.015 to 0.023)
Cuesta-Vargas, 2012118 1. Multimodal
2. GSH
EQ-5D mapped from SF-12
using Lawrence and
Fleishman’s362 algorithm
1. 0.427
2. 0.472
1. 0.678c
2. 0.576
NR 1 vs. 2: 0.074c (IQR 0.049 to 0.100)d
Gili, 2014144 1. CBTHI (individual)
2. CBTHI (group)
3. Usual care plus
EQ-5D mapped from SF-36
using Ara and Brazier352
1. 0.537
2. 0.485
3. 0.448
1. 0.673
2. 0.567
3. 0.484
1 vs. 3: 0.164
2 vs. 3: 0.025
1 vs. 3: 0.075e (IQR 0.053 to 0.097)d
2 vs. 3: –0.012e (IQR –0.034 to 0.010)d
Ho, 2012150 1. RSSE
2. Usual care
EQ-5D mapped from SF-12
using Lawrence and
Fleishman’s362 algorithm
1. 0.463
2. 0.456
1. 0.607
2. 0.507
1 vs. 2: 0.029 1 vs. 3: 0.027e (IQR 0.020 to 0.033)d
Larisch, 2004158 1. GP modified
reattribution
2. Usual care
EQ-5D mapped from SF-12
using Lawrence and
Fleishman’s362 algorithm
1. 0.576
2. 0.613
1. 0.650
2. 0.680
1 vs. 2: –0.015 1 vs. 2: 0.041f (IQR 0.01 to 0.068)d
LeFort, 1998342 1. GSH
2. Usual care
EQ-5D mapped from SF-36
using Ara and Brazier352
1. 0.484
2. 0.473
1. 0.540
2. 0.479
1 vs. 2: 0.009 1 vs. 2: 0.007e (IQR 0.005 to 0.009)d
Marques, 2015133 1. Graded activity
2. GSH
EQ-5D mapped from SF-12
using Lawrence and
Fleishman’s362 algorithm
1. 0.570
2. 0.433
1. 0.692
2. 0.381
1 vs. 2: 0.052 1 vs. 2: 0.020e (IQR 0.010 to 0.031)d
continued
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TABLE 25 Estimates of incremental QALY gain for individual studies (continued )
First author and year
of publication Treatment strategies Utility measurement method
Baseline
utility
Utility at last
follow-up
ΔQALYs using
unadjusted data
ΔQALYs using adjustment for baseline
differences
McBeth, 2012125 1. Multimodal
2. CBTHI
3. SES
4. Usual care
EQ-5D measured in study 1. 0.681
2. 0.730
3. 0.686
4. 0.649
1. 0.682
2. 0.730
3. 0.712
4. 0.631
1 vs. 4: 0.1272 vs. 4:
0.2293 vs. 4: 0.151
1 vs. 4: 0.047 (95% CI –0.086 to 0.182)b
2 vs. 4: 0.097 (95% CI –0.048 to 0.240)b
3 vs. 4: 0.025 (95% CI –0.099 to 0.154)b
(Discounted)
Peters, 2002106 1. SES
2. RSSE
EQ-5D mapped from SF-36
using Ara and Brazier352
NE
g
NE
g
NE
g
NE
g
Pols, 2008145 1. Multimodal EQ-5D mapped from SF-36
using Ara and Brazier352
NEh NEh NEh 1 vs. 2: –0.003i (IQR NE as no measure
of variance presented)
Robinson, 2006131 1. Multimodal
(GSH + RSSE)
2. GSH
3. Usual care
EQ-5D mapped from SF-36
using Ara and Brazier352
NE
j
NE
j
NE
j
2 vs. 3: 0.013i (IQR 0.006 to 0.020)d
Rosendal, 2007146 1. GP MUS
management
2. Usual care
EQ-5D mapped from SF-36
using Ara and Brazier352
NE
j
NE
j
NE
j
1 vs. 2: –0.018i (IQR –0.023 to –0.003)d
Schaefert, 2013147 1. GP multimodal
2. GP MUS
management
EQ-5D mapped from SF-36
using Ara and Brazier352
1. 0.657
2. 0.626
1. 0.714
2. 0.679
1 vs. 2: 0.039 1 vs. 2: 0.008d (IQR –0.004 to 0.020)d
van der Roer, 2008340 1. Multimodal
2. SES
QALY gains estimated from
EQ-5D with Dutch tariff
reported but not utility values
NE NE NE 1 vs. 2: 0.03 (95% CI –0.06 to 0.12)b
A
SSE
SSM
E
N
T
O
F
C
O
ST
-E
F
F
E
C
T
IV
E
N
E
SS
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
a
lslib
ra
ry
.n
ih
r.a
c.u
k
1
6
6
First author and year
of publication Treatment strategies Utility measurement method
Baseline
utility
Utility at last
follow-up
ΔQALYs using
unadjusted data
ΔQALYs using adjustment for baseline
differences
van Ravesteijn, 2013143 1. Other
psychotherapy
2. Usual care plus
SF-6D utility values reported
in study
1. 0.632
2. 0.639
1. 0.69
2. 0.68
1 vs. 2: 0.010k 1 vs. 2: 0.012 (95% CI −0.019 to 0.041)b
(mid-point of 0.015 when using EQ-5D
mapped from SF-36)
Wearden, 2010111 1. Graded activity
2. Other
psychotherapy
3. Usual care
EQ-5D reported in study 1. 0.444
2. 0.461
3. 0.421
1. 0.532
2. 0.509
3. 0.523
1 vs. 3: 0.016
2 vs. 3: –0.019
1 vs. 3= –0.012 (95% CI –0.088 to 0.065)b
2 vs. 3= –0.042 (95% CI –0.122 to 0.038)b
(Discounted)
Zonneveld, 2012141 1. CBTHI
2. Usual care
EQ-5D mapped from SF-36
using Ara and Brazier352
1. 0.538
2. 0.541
1. 0.598l
2. 0.548l
2 vs. 1: 0.006l 2 vs. 1: 0.007l (IQR 0.005 to 0.008)d
GSH, guided self-help; NE, not estimable.
a Based on 95% CI for utility difference between arms after adjusting for baseline characteristics.
b As reported directly in the paper.
c Mapping directly from SF-12 values at 12 months gave utility > 1, so difference between arms used to estimate utilities in intervention arm instead.
d IQR for QALYs calculated using IQR for utility values (IQR is ± 0.675 × SE when assuming normal distribution).
e Adjusted by setting the utility at baseline equal to the utility in the control arm (i.e. highest intervention number) and using differences from baseline to calculate post-baseline
utilities.
f Based on differences between arms reported in table 3 of publication.
g Mean values were not reported for all eight domains of SF-36.
h Only differences from baseline were reported.
i QALY gain estimated by assuming no difference between arms at baseline, no change for comparator arm and linear change over 12 months for intervention arm.
j Only difference between arms reported.
k Estimated from graphed utility data.
l At 13 weeks as no follow-up beyond 13 weeks for usual care.
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TABLE 26 Summary of cost-effectiveness evidence based on within-trial analyses
Intervention UC UC+ CBTHI GSH SES Graded activity GP reattribution GP MUS management
CBTHI < £30KW137
< £30KW125
> £30K141
< £30K144
Dom144
< £30K144a
Other psychotherapy Dom111 < £30KW143 Dom111
GA Dom111 < £30KW133
SES > £30K125 Dom125
GSH < £30KW131
< £30KW342
RSSE < £30KW150
GP modified reattribution < £30KW158 > £30KW136
Pharmaceutical Dom137
Multimodal > £30K125
Dom145
Dom125 < £30K118 < £30KW125
> £30KW340
GP MUS Dom146
> £30KW157
GP multimodal > £30K147
< £30K, ICER under £30,000 per QALY; > £30K, ICER above £30,000 per QALY; dom, dominated (i.e. the intervention in the row has a higher cost and lower QALY gain than the
comparator in the column); GSH, guided self-help; W, IQR or 95% CI crosses £30,000.
a Individual vs. group.
Data are summarised for the intervention in the row vs. the intervention in the column (i.e. data in first column relates to comparisons against usual care).
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TABLE 27 Within-trial estimates of cost-effectiveness for individual studies
First author and year
of publication Treatment strategies
ΔQALYs using
adjustment for
baseline differences
Intervention
costsa Other costs ICER IQR for ICER
Aiarzaguena, 2007136 1. GP modified reattribution
2. GP reattribution
1 vs. 2: 0.019b (95% CI
0.002 to 0.036)b
1. £1534.50
2. £792.75
NR 1 vs. 2: £39,142 (£26, 638
when using EQ-5D mapped
from SF-36 instead of SF-6D)
1 vs. 2: £20,719 to £353,214
Alda, 2011137 1. CBTHI
2. Pharmaceutical
3. Usual care
1 vs. 3: 0.02 (95% CI
0.00 to 0.03)c
2 vs. 3: 0.00 (95% CI
–0.01 to 0.02)c
1. £200.50
2. £217.60
3. £0
Non-UK resource
use
1 vs. 3: £10,025
2 vs. 1: 2 is dominated by 1
1 vs. 3: £6683 to > £40,000
Burton, 2012157 1. GP MUS
2. Usual care
1 vs. 2: 0.004 (IQR
–0.103 to 0.018)
1. £468
2. £0
NR 1 vs. 2: £129,267 1 vs. 2: £20,658 to dominated
Cuesta-Vargas, 2012118 1. Multimodal
2. GSH
1 vs. 2: 0.074d (IQR
0.049 to 0.100)e
1. £1855.13
2. £468.00
NR 2 vs. 1: £18,641 2 vs. 1: £13,883 to £28,261
Gili, 2014144 1. CBTHI (individual)
2. CBTHI (group)
3. Usual care plus
1 vs. 3: 0.075f (IQR
0.053 to 0.097)e
2 vs. 3: –0.012f (IQR
–0.034 to 0.010)e
1. £1,058.18
2. £231.48
3. £0
NR 1 vs. 3: £14,146
2 is dominated by 3
1 vs. 2: £9502
1 vs. 3: £10,928 to £20,049
2 vs. 3: £23,199 to dominated
Ho, 2012150 1. RSSE
2. Usual care
1 vs. 2: 0.027f (IQR
0.020 to 0.033)e
1. £37.36
2. £0
NR 1 vs. 2: £1397 (£23,048 if
sessions are one to one)
1 vs. 2: £1124 to £1843
(£18,558 to £30,406 if group
sessions are two to one)
Larisch, 2004158 1. GP modified reattribution
2. Usual care
1 vs. 2: 0.041
g
(IQR 0.01 to 0.068)e
1. £483.29
2. £0
Non-UK resource
use
1 vs. 2: £11,863 1 vs. 2: £7,115 to £47,022
LeFort, 1998342 1. GSH
2. Usual care
1 vs. 2: 0.007f
(IQR 0.005 to 0.009)e
1. £142.89
2. £0
NR 1 vs. 2: £21,755 1 vs. 2: £16,632 to £31,437
Marques, 2015133 1. Graded activity
2. GSH
1 vs. 2: 0.020f
(IQR 0.010 to 0.031)e
1. £564.35
2. £0
NR 1 vs. 2: £27,894 1 vs. 2: £18.358 to £58,052
continued
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TABLE 27 Within-trial estimates of cost-effectiveness for individual studies (continued )
First author and year
of publication Treatment strategies
ΔQALYs using
adjustment for
baseline differences
Intervention
costsa Other costs ICER IQR for ICER
McBeth, 2012125,126 1. Multimodal
2. CBTHI
3. SES
4. Usual care
1 vs. 4: 0.047 (95% CI
–0.086 to 0.182)c
2 vs. 4: 0.097 (95% CI
–0.048 to 0.240)c
3 vs. 4: 0.025 (95% CI
–0.099 to 0.154)c
(Discounted)
Estimated
from resource
use:
1. £1221.18
2. £617.27
3. £628.59
4. £0
1. 3017h
2. 2720h
3. 3106h
4. 2387h
2 vs. 4: £9797
3 and 1 are dominated
by 2
3 vs. 4: £56,064
1 vs. 4: £39,387
1 vs. 3: £20,436
2 vs. 4: £3,959 to dominated
Peters, 2002106 1. SES
2. RSSE
NEg 1. £127.55
2. £123.30
No significant
difference in
resource use
between arms
(costs not reported)
NE NE
Pols, 2008145 1. Multimodal
2. UC
1 vs. 2: –0.003i
(IQR NE as no
measure of variance
presented)
1. £390.00
2. £0
Some resource use
reported but non-UK
1 dominated by 2 NE
Robinson, 2006131 1. Multimodal (GSH+ RSSE)
2. GSH (guidebook)
3. Usual care
2 vs. 3: 0.013i
(IQR 0.006 to 0.020)e
1 vs. 2: NE
1. £12.24
(for RSSE
component)
2. NE
3. £0
2 vs. 3: –£72.741 vs.
2: £7.53
2 vs. 3: NE (Guidebook
would dominate UC if it
cost under £72.74)
1 vs. 2: NE
NE
Rosendal, 2007146 1. GP MUS management
2. Usual care
1 vs. 2: –0.018i (IQR
–0.023 to –0.003)e
1. £159.78
2. £0
NR 1 is dominated by 2 1 vs. 2: dominated to
dominated
Schaefert, 2013147 1. GP multimodal
2. GP MUS management
1 vs. 2: 0.008f (IQR
–0.004 to 0.020)e
1. £1298.74
2. £289.06
Some resource use
reported but non-UK
1 vs. 2: £124,535 1 vs. 2: £51,184 to dominated
van der Roer, 2008340 1. Multimodal
2. SES
1 vs. 2: 0.03 (95% CI
–0.06 to 0.12)c
1. £2088.06
2. £801.45
Some resource use
reported but non-UK
1 vs. 2: £42,887 1 vs. 2: £10,722 to dominated
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First author and year
of publication Treatment strategies
ΔQALYs using
adjustment for
baseline differences
Intervention
costsa Other costs ICER IQR for ICER
van Ravesteijn, 2013143 1. Other psychotherapy
2. Usual care plus
1 vs. 2: 0.012 (95% CI
−0.019 to 0.041)c
1. £165.89
2. £0
Some resource use
reported but non-UK
1 vs. 2: £13,825 (£11,171
when using EQ-5D mapped
from SF-36 instead of
SF-6D)
£4046 to dominated
Wearden, 2010111 1. Graded activity
2. Other psychotherapy
3. Usual care
1 vs. 3 = –0.012
(95% CI –0.088 to
0.065)c
2 vs. 3 = –0.042
(95% CI –0.122 to
0.038)c
(Discounted)
Estimated
from resource
use
1. £412.80
2. £412.80
3. £0
1. £468c
2. £655c
3. £739c
1 vs. 3: dominated
2 vs. 3: dominated
1 vs. 3: £2182 to dominated
2 vs. 3: £8653 to dominated
Zonneveld, 2012141 1. CBTHI
2. Usual care
2 vs. 1: 0.007
j
(IQR
0.005 to 0.008)e
1. £379.49
2. £0
NR 1 vs. 2: £56,792 2 vs. 1: £45,400 to £76,816
GSH, guided self-help; NE, not estimable; UC, usual care.
a For papers which report a full economic evaluation, the intervention costs presented here are those estimated from resource use by the authors (see Tables 77–96), not those
reported in study.
b Based on 95% CI for utility difference between arms after adjusting for baseline characteristics.
c As reported directly in the paper.
d Mapping directly from SF-12 values at 12 months gave utility > 1, so difference between arms used to estimate utilities in intervention arm instead.
e IQR for QALYs calculated using IQR for utility values (IQR is ± 0.675 × SE when assuming normal distribution).
f Adjusted by setting the utility at baseline equal to the utility in the control arm (i.e. highest intervention number) and using differences from baseline to calculate post-baseline
utilities.
g Based on differences between arms reported in table 3 of publication.
h Intervention costs have been subtracted from total costs to estimate non-intervention costs for each arm using data from Beasley et al.126
i QALY gain estimated by assuming no difference between arms at baseline, no change for comparator arm and linear change over 12 months for intervention arm.
j At 13 weeks as no follow-up beyond 13 weeks for usual care.
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by differences in the response of different study populations to CBT or differences in the delivery
of the CBT that are not reflected in the cost estimates. In this case, the two studies with favourable
mid-point ICERs125,137 were both studies in patients with chronic pain (fibromyalgia in both cases),
whereas the study141 with the higher ICER had a broader population that included both patients with
chronic pain and those with somatoform disorder.
High-intensity CBTwas also found to have inconsistent cost-effectiveness compared with usual care plus,
although it should be noted that this was based on a single study144 that found that individual CBTHI had
an ICER < £30,000 compared with usual care plus, whereas group CBTHI was dominated by usual care
plus.144 This suggests that, although these interventions have been grouped together under the heading
of CBTHI, the particular mode of delivery (i.e. group vs. individual) is capable of producing important
differences in the estimates of benefits and the estimates of cost-effectiveness. Therefore, caution
should be exercised when comparing interventions that have been grouped together but that may
differ significantly.
The two studies that provide ICERs for guided self-help versus usual care suggest that this intervention
has the potential to be cost-effective but there remains some uncertainty regarding its cost-effectiveness
as the CIs crossed £30,000 per QALY. The study by Robinson et al.131 found that guided self-help,
delivered as a guidebook, was cost-saving and produced a QALY gain and, therefore, guided self-help
would dominate usual care provided the guidebook cost less than the cost-saving (£72.74). It seems
likely, therefore, that this intervention would be cost-effective but this cannot be confirmed without
an estimate of the cost of the guidebook (the ICER has been summarised in Table 26 as ‘< £30KW’).
The other study comparing guided self-help with usual care, by LeFort et al.,342 gave a mid-point ICER of
£21,775 with an IQR of £16,632–£31,437. These two studies also had different populations (i.e. IBS and
chronic pain), suggesting that guided self-help has the potential to be cost-effective across a number of
different subsets of the MUS population, but the cost-effectiveness remains uncertain.
The ICER for RSSE versus usual care based on the study by Ho et al.150 was £1397 with a narrow IQR
(£1124–£1843), but there was additional uncertainty related to this study because the intervention
was described as being a group intervention but the group size was not indicated. The mid-point
estimate was calculated assuming that the intervention was delivered to all patients at the same time
in a single group but a sensitivity analysis exploring the impact of lower group sizes (two patients per
group) gave a mid-point ICER of £23,048 (IQR £18,558–£30,406). For this reason, this study has been
denoted as having wide uncertainty in Table 26.
Two studies provided estimates of the cost-effectiveness of GA in patients with chronic fatigue, but
the comparator arms differed. The analysis based on Wearden et al.111 found that GA was dominated
by usual care. Conversely, the analysis based on Marques et al.133 found a positive QALY gain but an
ICER at the upper limit of the NICE cost-effectiveness range (£27,894) for GA compared with guided
self-help, which in this study consisted of usual care plus the provision of information about physical
activity. These two studies therefore appear to give inconsistent results. However, it should be noted
that, in the study by Wearden et al.,111 the QALY gains were estimated from directly measured EQ-5D
utility values, whereas, in the study by Marques et al.,133 the QALY gains were estimated via mapping
from SF-36 MCS and PCS scores to EQ-5D utilities, which is associated with additional uncertainty.
The analysis based on the study by Wearden et al.111 also found that GA dominated other psychotherapy,
but other psychotherapy itself was also dominated by usual care. The only other study to examine other
psychotherapy, by van Ravesteijn et al.,143 had usual care plus as the comparator, and for this study we
estimated a low mid-point ICER but a broad IQR, with other psychotherapy being dominated at the
upper limit. The study by van Ravesteijn et al.143 also had a broader MUS population than the study by
Wearden et al,111 which was restricted to patients with chronic fatigue.
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The evidence of cost-effectiveness for SES versus usual care was limited to a single study by McBeth
et al.,125 from which we estimated a high ICER versus usual care in patients with chronic pain. The same
study also found that SES was dominated by CBTHI.
Pharmaceutical therapy was only included in one study, by Alda et al.,137 and was found to be
dominated by CBTHI in patients with chronic pain.
In general, the GP interventions were not particularly cost-effective. Modified reattribution had a high
ICER versus reattribution in patients with MUS based on the study by Aiarzaguena et al.,136 although
the mid-point ICER was reduced to < £30,000 when EQ-5D utility values obtained by mapping from
the SF-36 to the EQ-5D were used instead of using SF-6D utility values. GP MUS management was
dominated by usual care in patients with somatoform disorder based on the study by Rosendal
et al.,146 and GP MUS management had a higher ICER (£129,000) with a wide IQR based on the pilot
study by Burton et al.,157 also in patients with MUS. GP multimodal intervention had a high ICER
(£124,000) versus GP MUS management in patients with MUS, based on the study by Schaefert et al.147
However, there was an exception for GP-modified reattribution compared with usual care that was
found to have an ICER of £11,863 (IQR £7115–47,022) in patients with somatoform disorder based
on the paper by Larisch et al.158
Only one study118 compared a multimodal intervention combining guided self-help and SES with guided
self-help alone in patients with back pain. The mid-point ICER was < £20,000 per QALY and the upper
limit of the IQR for the ICER was < £30,000 per QALY, suggesting reasonable confidence in the
cost-effectiveness of the multimodal intervention.
Two studies compared a multimodal intervention with SES in patients with chronic pain. van der Roer
et al.340 compared a multimodal intervention combining sport, education and a behavioural programme
to SES in patients with back pain, but the ICER estimated for this comparison was above the range
usually considered cost-effective. McBeth et al.125 compared a combination of CBTHI with SES against
SES alone in patients with chronic widespread pain. Multimodal intervention versus SES alone had
an ICER in the range usually considered cost-effectiveness by NICE. However, the same study also
included a CBTHI arm and multimodal therapy was dominated by CBTHI alone. Therefore, CBTHI
would be the optimal intervention based on this study in preference to SES.
Conclusions and discussion
The behavioural modification interventions for patients with MUS identified in our review were found to
have a very broad range of interventions costs. Interventions delivered to groups were generally found to
have a cost per patient that is lower than the cost per patient for interventions of the same type delivered
to individuals. For interventions delivered to groups, the cost per patient is dependent on the group size.
In studies where the group size or number of groups was not reported, we have assumed that all patients
received the intervention as part of a single group that may have underestimated the cost per patient
if smaller groups were in fact used. The cost per patient for interventions that involve training GPs to
manage MUS in a particular way is very dependent on the number of patients treated by each GP who
is trained. The broad range of intervention costs is indicative of the high degree of heterogeneity in the
behavioural modification interventions included in our review. In future research, it would be helpful to
investigate whether or not more intensive interventions with higher costs generate greater QALY gains.
Utility estimates were often not equal at baseline, making adjustment for baseline differences necessary.
Where outcomes adjusted for baseline differences were not reported in the study paper, adjustment
for baseline differences was achieved by setting the starting utility of the intervention arm equal to
that of the control arm and using either the difference from baseline or the difference between arms to
estimate utility thereafter. This is a fairly crude method for adjusting for baseline differences and may
have introduced bias, particularly if the utility changes that can be achieved in an individual are not
independent of their baseline utility.
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In general, those interventions that achieved a difference in utility at short-term follow-up were able
to maintain that utility gain in the long term. However, as different interventions may have different
capacities to achieve treatment effects that persist, we decided not to extrapolate the maintenance of
treatment effects from those studies with long-term data to other studies with only short-term data.
For this reason, our analysis of QALYs gained was limited to the last study time point reporting a
randomised comparison of outcomes for each individual study.
Using a different time frame for each study was considered appropriate when the focus was on the
within-trial estimates of cost-effectiveness for each study. However, the use of differing time frames
for each study makes the estimates of QALY gains not comparable across studies. It would therefore
not have been appropriate to have used these estimates of QALY gain to conduct an incremental
analysis that compared interventions across multiple studies.
In general, the QALY gains estimated for behavioural modification interventions from individual studies
were small, but our analysis may have underestimated the true long-term QALY gains if the differences
between trial arms observed during the trial period persist in the long term beyond the trial follow-up.
The uncertainty in the QALY estimates has been captured in a fairly crude manner by using the upper
and lower IQR for the HRQoL scores going into the utility mapping algorithm to explore the uncertainty
in the incremental QALYs gained. The IQR values presented for the QALY gains are intended to give only
an indication of the potential variation in the QALY gain that arises from uncertainty in the SF-36/SF-12
scores used within the mapping algorithm to calculate utilities. A more complex approach would have
been necessary to allow a full probabilistic assessment of the uncertainty in the QALY gains but we felt
that this may not provide a more unbiased estimate because of a lack of information on the correlation
between changes in the various domain scores used in the mapping algorithm. Although our method
assumes that changes in these domains are perfectly correlated and may therefore overestimate the
variance, the use of the IQR rather than the full distribution for each input to the algorithm should
mitigate any overestimation of the uncertainty. However, the true uncertainty around the QALY gains
may be greater as our approach does not quantify uncertainty around the mapping algorithm itself.
This set of within-trial estimates of cost-effectiveness has several important limitations. The estimates of
QALYs are based on the data and time points reported for each individual study rather than the outputs of
the NMA.We have therefore not been able to benefit from pooling clinical efficacy data across studies,
but this was considered to be a fairly minor limitation given that, in general, there were only one or two
studies for each comparison in the NMA. The conclusions that can be drawn are also limited to the direct
comparisons presented in the individual studies whereas the NMA allows indirect comparisons to be made
regarding the clinical effectiveness of interventions not compared directly in a single study.
The included studies cover many different populations classified as having MUS including those
with chronic pain, chronic fatigue, IBS and somatoform disorders. It is not clear from the evidence
that we have identified if interventions that are cost-effective in one population would be similarly
cost-effective in another population with MUS. Many of the interventions that have received the same
intervention classification differ considerably in terms of their intensity or in terms of their content,
owing to the broad intervention groupings. Although differences in intensity are easier to identify,
as these usually translate into differences in cost, it may be harder to identify where differences in
the content are responsible for inconsistencies in the cost-effectiveness evidence.
Very few of the studies reported UK estimates of resource use so the cost-effectiveness of the
interventions may be overestimated or underestimated depending on whether the interventions reduced
or increased health service resource use not directly related to the delivery of the intervention. Although
several studies reported non-UK resource use or costs, we did not convert these to UK NHS costs as we
were concerned that changes in the number of health-care contacts in one health-care system may not
translate into an equivalent change in a different health-care system.
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Finally, the estimates of uncertainty around the ICER should be considered to be providing only an
indication of the potential uncertainty around the ICERs in a manner similar to a univariate sensitivity
analysis because of the limitations in method used to estimate the uncertainty in the QALY gains, as
described above.
We had originally planned to use the outcomes of the NMA to conduct an incremental cost-effectiveness
analysis for each of the intervention categories included in the NMA. However, there were several
issues with this approach. First, the individual interventions grouped within the same categories for
the purposes of the NMA were often very different in terms of the resources that would be required
to deliver them, as demonstrated in the costing analysis. Therefore, an individual estimate of cost-
effectiveness would be required even if we assumed a consistent treatment effect across each category;
an assumption that may not itself be justified given that we were not able to explore whether or not
differences in the interventions or the population led to differences in effectiveness within the NMA
because of the sparsity of the data informing the networks. Second, it was unclear how to generate a
single estimate of health utility from the diverse range of outcomes analysed, particularly given that all of
the outcomes have the potential to influence quality of life and their influence may not be independent of
each other. This complication was avoided in the within-study estimates of cost-effectiveness by limiting
the analysis to those studies that provided either a direct estimate of health utility (or incremental
QALYs) or a generic measure of HRQoL that could be mapped to provide an estimate of health utility.
The main disadvantage of the approach that we have used is that we have not been able to provide
estimates of cost-effectiveness for all of the comparisons represented within the full set of clinical trials,
as not all of the studies reported a generic measure of HRQoL.
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Chapter 7 Discussion
Statement of principal findings
A total of 59 studies were identified that met the inclusion criteria for the clinical effectiveness review.
These studies covered a broad and diverse range of populations, interventions and outcomes. A series
of network meta-analyses of clinical effectiveness compared intervention types with usual care. There
was moderate to high heterogeneity of intervention effects between studies. Networks were sparse
and the results of the meta-analysis must therefore be evaluated with caution. In terms of symptom
severity outcomes, results indicated some beneficial effects for behavioural interventions targeting
specific physical symptoms (e.g. pain, fatigue, bowel symptoms), but not somatisation or generic
physical symptom measures. Results also indicated beneficial effects of some behavioural interventions
on physical functioning, impact of symptoms on daily activities and psychological symptoms (depression,
anxiety and emotional distress). Across outcomes, significant beneficial effects were most frequently
seen for CBTHI and multimodal therapy interventions. There were no significant effects for any of the
GP interventions (e.g. reattribution or GP MUS management).
Pain
At the end of treatment, only CBTHI and multimodal interventions were statistically more beneficial
than usual care, with medium effect sizes. At short-term follow-up, only CBTHI was statistically
more beneficial than usual care, with large effect size. By long-term follow-up, no interventions were
statistically more beneficial than usual care. The number of studies included at the end of treatment
was 10, and by long-term follow-up this had reduced to seven.
Fatigue
At the end of treatment, CBTLI (large effect size), multimodal interventions (large effect size), GA
(medium effect size) and RSSE interventions (medium effect size) were statistically more beneficial
than usual care. At short-term follow-up, only CBTLI (medium effect size) and RSSE (small effect size)
were statistically more beneficial than usual care. By long-term follow-up, only CBTLI was statistically
more beneficial than usual care. The number of studies included at the end of treatment was nine and
by long-term follow-up this had reduced to five.
Bowel symptoms
There were insufficient data to conduct meta-analyses for end-of-treatment or short-term follow-up.
At long-term follow-up, only CBTLI had a statistically significant beneficial effect compared with
usual care.
Somatisation and generic physical symptoms
There were no significant beneficial effects for any intervention types for somatisation at end-of-
treatment, short-term or long-term follow-up. There were no significant beneficial effects found for
generic physical symptoms at any time point.
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Physical functioning
At the end of treatment, only the multimodal therapy intervention type was statistically more beneficial
than usual care, with a small effect size. This effect was also found at short-term follow-up, with medium
effect size, but no intervention types were statistically more beneficial than usual care at long-term
follow-up. This outcome was well represented, with 13 out of 14 studies remaining in the network at
long-term follow-up.
Impact of symptoms on daily activities
At the end of treatment, only CBTHI was statistically more beneficial than usual care (large effect size).
This effect was also found at short-term follow-up (large effect size), but by long-term follow-up there
were no statistically significant results. The number of studies informing the network reduced from
nine at the end of treatment to four at long-term follow-up.
Anxiety
At the end of treatment, only CBTHI was statistically more beneficial than usual care (medium effect size).
This was repeated at both short- and long-term follow-up (large effect, 14 studies informed the network
at the end of treatment, reducing to 11 by long-term follow-up).
Depression
At the end of treatment, only CBTHI was statistically more beneficial than usual care (large effect size).
At short-term follow-up, only CBTHI (large effect size) was statistically more beneficial than usual
care. At long-term follow-up, only the multimodal intervention type was statistically significant (small
effect size). Depression was well represented in the network, with 13 studies at the end of treatment
and 14 studies by long-term follow-up.
Emotional distress
At the end of treatment, CBTHI, other psychotherapy, RSSE and SES intervention types were
statistically more beneficial than usual care (small to medium effect sizes). Only RSSE and multimodal
interventions were statistically more beneficial at short-term follow-up (large and small effect sizes,
respectively). By long-term follow-up, no intervention was statistically more beneficial than usual
care. The number of studies in the network reduced from 15 at the end of treatment to only nine at
long-term follow-up.
Results were not consistent across intervention type and outcome. Across outcomes, significant
beneficial effects were most frequently seen for CBTHI and multimodal interventions. The outcome
on which positive benefits were demonstrated across behavioural interventions was emotional distress,
where four different intervention types were seen to have significant beneficial effects at the end of
treatment. The outcome that appeared least affected by the interventions was somatisation, with no
statistically significant treatment effects, despite there being 13 studies that measured this outcome
at the end of treatment. No effects were found for generic physical symptoms, although this outcome
was poorly represented in the network (three studies). It was not possible to explore the observed
moderate to high heterogeneity seen across all outcomes with metaregression because of insufficient
replication of each treatment effect across studies. There were no significant effects for any of the GP
interventions (i.e. reattribution) or GP MUS management.
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Although there was variation in the study population, these were all patients with chronic conditions.
The nature of these conditions has implications for the interpretation of results. Long-term follow-up
time periods were generally no longer than 1 year, which is relatively short within the context of a
chronic condition. Symptoms may wax and wane over time. A number of individual studies reported
significant improvements for both the intervention and the control groups, and this was seen in studies
with active control arms as well as studies with passive control arms (i.e. usual care and waiting list
control). Improvement in passive control groups over time may indicate natural remission of symptoms.
Many of the observed effects seen at the end of treatment and at short-term follow-up were no longer
apparent at long-term follow-up. This may in part be influenced by a lack of long-term follow-up data
for studies for which the final follow-up was < 6 months after the end of intervention. However, it may
also indicate a decline in the beneficial effects of behavioural interventions once treatment has ceased.
A review of CBT for CFS366 found a slight trend to suggest that effect size increased with longer
follow-up. This could be explained by the possibility that patients in waiting list control groups were
able to access the trial interventions once the study period was completed; however, this was not
tested in the current review. The NMA allowed active control arms to be categorised into intervention
types, where appropriate, and evaluated alongside all other interventions. These active controls
were often classified into the RSSE intervention type or guided self-help, and the RSSE category of
interventions was found to have a small effect size for fatigue, which suggests that, when interventions
are compared against active controls with a RSSE component, this may influence the relative effect
size measured.
Behavioural interventions appeared to be more beneficial for specific physical symptoms compared with
outcomes where multiple symptoms were measured (i.e. somatisation and generic physical symptoms).
This finding is consistent with other meta-analyses that evaluated the effectiveness of psychotherapies
for specific physical symptoms. Kleinstäuber et al.76 highlight that meta-analyses evaluating specific
physical symptoms (e.g. Kisely et al.367 for non-cardiac chest pain) report larger effect sizes than those that
evaluate psychotherapies for multiple MUS. They suggest that psychotherapies for somatoform disorders
are more likely to focus on coping strategies rather than on curing specific symptoms. These results may
be an artefact of either classification of condition or type of protocol. In terms of condition, measures of
somatisation were more frequently used in populations classified as having ‘MUS/somatoform disorder’
rather than IBS, chronic pain or chronic fatigue. Studies of ‘MUS/somatoform disorder’ populations may
have also measured individual symptoms, but it is not clear which symptoms were dominant at that
time. Studies were also statistically powered based on their primary outcome, which was often the
predominant symptom in the target population (e.g. fatigue in chronic fatigue populations); therefore,
it is possible that they were insufficiently powered to detect differences in secondary outcomes.
Alternatively, it may be that treatment protocols that focus on a specific diagnosis of a functional
condition or specific symptom group are more effective than interventions that are designed to focus
more broadly on the concept of somatisation or MUS. There is a substantive literature showing that the
term MUS is offensive to many patients so these interventions may also seem less acceptable.4,368 The
observed statistical lack of effectiveness of GP interventions may in part be due to these interventions
mainly targeting MUS/somatoform patients, with somatisation perhaps more complex and appearing to
be more difficult to treat.
Although the current review is, to our knowledge, the first to look at a broad range of behavioural
interventions for diverse populations of patients meeting our broad inclusion criteria for ‘MUS’,
specifically within a primary care setting, results are consistent with other reviews in this area. The
current review found no significant beneficial effects for GP-delivered interventions included in the
meta-analysis. Although there were some significant effects for GP interventions in individual studies,
this is consistent with the review by Rosendal et al.,77 who found no conclusive evidence to show any
beneficial effects for enhanced generalist care, and Gerger et al.,78 who found psychological therapy
to be effective only when delivered by psychologists rather than GPs. Price et al.66 found significant
effects for CBT for CFS at the end of treatment, not only when compared with usual care, but also
when compared with other psychological therapies (which included relaxation, counselling, educational
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support – which would be defined as RSSE/guided self-help in the current review). However, by
follow-up, effects were heterogeneous and inconsistent. For IBS, Pajak et al.369 found minimal contact
CBT to show promise in symptom management. The results of the current review are not consistent
with van Dessel et al.,75 who reported less severe somatic symptoms for all psychotherapies (with no
superiority of CBT over other psychotherapies) at the end of treatment. However, their review was
not restricted to primary care and it may be that differences in setting (i.e. inclusion of tertiary care)
contribute to different treatment effects. A review of GA and graded exposure for non-specific low
back pain370 found GA to be slightly more effective than minimal intervention, but the effect was no
greater than other types of exercise for pain. The most populated networks were for psychological
symptoms (i.e. depression, anxiety and emotional distress). Examination of baseline scores showed
some variation in anxiety and depression, with, for example, HADS-A baseline scores ranging from
6 to 12 (normal to moderate), whereas HADS-D scores generally fell within the range from 5 to 9
(normal to mild), although Escobar et al.156 reported severe baseline depression. When baseline
psychological symptoms are low, one would not generally expect to find large effect sizes.
Although the behavioural interventions reviewed in the current review showed some effectiveness
for improvement of specific physical symptoms compared with usual care, there was less success at
improvement in subjective ratings of physical functioning. Furthermore, few studies reported objective
measures of functioning, such as return to work. The variability in range and severity of symptoms
means that, although some patients with MUS may be able to work, others may not. The Action for
M.E. survey371 found that only 10% of respondents were in full-time work, education or training, and a
further 14% were in part-time work, education or training. Rask et al.372 found both patients with MUS
of recent onset and those with persistent somatoform disorders to be at increased risk of sick leave
and work disability over a 10-year period. It was not possible to explore severity of symptoms as a
moderator of treatment effects because of the sparsity of the networks; however, it is unlikely that
the interventions explored in this study were trialled on patients at the more severe end of the
spectrum, who would be more likely to be treated in tertiary care. It is unlikely that patients in the
studies reviewed here would, for example, be non-ambulatory and, therefore, the results should not
be generalised to these patients. Furthermore, few of the included studies framed their effectiveness
in terms of ‘cure’ or ‘recovery’ and, therefore, the findings should not be interpreted as such.
The qualitative review focused on the perceptions of patients who had received a specific behavioural
intervention for MUS. It did not include the perspectives of patients about their general care, or of
those patients who had not received such an intervention.
Prior perceptions of behavioural interventions are important as they may influence patient acceptance/
uptake. The current review summarised information on acceptance/uptake from the included trials.
There was wide variability in the number of patients declining to take part in the studies, and in the
number of participants dropping out of the studies. Where reasons were given, these often included
lack of time, a lack of faith in therapy,113,133,143,149 or an exacerbation in symptoms.121 In the study by
Robinson et al.,131 most participants did not attend the group meeting, some of whom stated that they
were unwilling to discuss bowel symptoms with strangers. Some participants dropped out because
they felt that the intervention was not helping120 or that their symptoms had reduced.109 Some of
these themes were reflected in the qualitative review, with patients reporting that they did not believe
that behavioural interventions would address their symptoms178 or that they felt that the intervention
would do harm or make things worse.179,182 The issue of acceptability of behavioural interventions is
further highlighted by a recent feasibility study of an early intervention for patients with a history of
fatigue lasting 1 to 4 months.373,374 The intervention consisted of an information booklet and support
from a fatigue specialist. The study was able to recruit fewer than half of the participants it aimed to
and the authors therefore concluded that this type of study was not feasible and that the type of
intervention was not acceptable to many of the participants.
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Few of the studies in the clinical effectiveness review reported adverse events, and it is not clear if
this is a result of there being no adverse events or if adverse events were not reported. A concern
identified in the realist synthesis was that of potential misdiagnosis. Few of the trials included in the
clinical effectiveness review reported on whether participants were misdiagnosed with MUS or one
of the functional somatic disorders. Tummers et al.149 reported that 12 participants had received an
incorrect diagnosis of CFS, with four having an identified somatic explanation for their fatigue and eight
found to have a psychiatric disorder. The potential for a wrong diagnosis is a concern for both GPs and
for patients. In general, adverse events have not been reported systematically in psychological therapy
trials and deterioration rates are rarely reported.375,376 This should be addressed in future trials.
A pragmatic approach to the treatment of MUS has been suggested that takes account of patient
preferences. Studies included in the current review offered behavioural interventions to primary care
patients; however, there was a large range of variability in the nature of the primary care settings. At
one end of the spectrum, GP practices were randomised and participating GPs were trained to manage
patients with MUS within the course of their everyday practice. Other GP-delivered interventions were
more structured, with GPs delivering a specific intervention to patients over a prescribed number of
sessions. At the opposite end of the spectrum, participants were recruited in primary care but received
an intervention from a specialist HP, sometimes on the GPs’ premises, but alternatively the intervention
may have been delivered elsewhere – in community health centres, or gymnasiums or swimming pools.
These differences are one of many sources of heterogeneity within the review, and they offer an
opportunity to explore issues around pragmatism in clinical trials. There has been increasing interest in
how well the results of clinical trials can be applied to everyday clinical practice. Explanatory trials test
the efficacy of interventions under conditions strictly controlled for errors and biases. At the opposite
end of the continuum, pragmatic trials are designed to test the effectiveness of an intervention when
applied to real-world conditions.377 Although the GP interventions were not shown to be effective
compared with usual care in this review, it is possible that these trials represent the most pragmatic
end of the continuum. In particular, this review may represent those trials that involved the cluster
randomisation of GP practices and where the GPs used MUS training in their everyday practice, rather
than with specific patients considered to need to be treated in a prescribed way at a prescribed time.
In this review, trials of interventions delivered to primary care patients by other professionals showed
more of a trend towards reducing physical symptoms. It is possible that these trials were, in fact, less
pragmatic and, therefore, may be less likely to be effective when delivered in a less controlled manner.
That having been said, we have no definitive evidence for or against this view. Thorpe et al.378 developed
the PRagmatic Explanatory Continuum Indicator Summary (PRECIS) tool to evaluate trials according to
relevant domains, including flexibility in the experimental and comparator interventions, practitioner
expertise, the intensity of follow-up, clinical meaningfulness of outcomes, flexibility in practitioner
adherence to the protocol, and strictness of eligibility criteria. For example, many of the trials included
in this review required the application of diagnostic criteria to their patients to screen for eligibility.
In practice, general practice ‘Read’ codes for MUS may not always be applied. A future review could
apply the PRECIS criteria to included trials to assess to what extent they are pragmatic and more likely
to be effective when applied to real-world clinical practice.
Cost-effectiveness
A range of methods were utilised to evaluate the cost-effectiveness of behavioural modification
interventions for MUS, including a systematic literature review of cost-effectiveness studies using QALYs
as the measure of benefit, an evaluation of cost–consequence studies and an independent economic
assessment. With only two relevant studies,131,284 findings from UK studies of cost-effectiveness were
heterogeneous, although differences in the findings may be explained by differences in the populations
and interventions studied. For cost–consequence studies, the net impact on health-care costs varied
between studies, with some but not all the interventions being found to have a favourable impact on
either overall costs or costs unrelated to delivery of the intervention. From this we can conclude that
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future studies should measure the impact of behavioural modification interventions on health-care costs.
Although exploring possible approaches for estimating QALY gains from study outcomes, we found that
estimating QALY differences based on mapping from changes on a single domain of the SF-36 to changes
on the EQ-5D was unlikely to provide a robust estimate of QALY differences. This may be because the
interventions may affect more than one domain of quality of life (e.g. vitality and physical functioning)
such that using a single domain would overestimate or underestimate the QALY gain depending on
the correlation between changes in different domains. We therefore conclude that future studies
should include either a direct measure of utility such as the EQ-5D or a generic measure of HRQoL
that covers all relevant domains and that allows utility values to be estimated via mapping, such as the
SF-36. Cost analysis of all studies included in the clinical effectiveness review revealed a broad range of
costs per patient within each intervention type. Although the ranges for each type of intervention were
wide, the median values across different types of interventions were less variable, with median costs
of intervention influenced by group versus individual mode of delivery. The median costs ranged from
£62 for seven studies106,110,122,123,150,161 that examined RSSE delivered to groups (see Table 87), to £892 for
five studies107,118,121,125,145 of multimodal interventions delivered to individuals. GP interventions had a
wide range of costs, from £160 to £2560 (median £546) (see Table 91). Variation in costs was influenced
by significant variation in the number of patients treated for each GP trained.
In general, the QALY gains estimated for behavioural modification interventions from individual studies
were small, with mid-point estimates consistently < 0.1. None of the studies that reported 95% CIs
for QALY gains measured directly in the study found a statistically significant difference between trial
arms. The method used to estimate the uncertainty around the QALY gains for studies where utility
values were mapped from the SF-36 or SF-12 was crude, so although some studies had a positive
lower IQR for the QALY gain, this does not allow us to conclude that a statistically significant
difference in QALYs was observed.
The independent economic assessment found a large degree of heterogeneity in estimates of
cost-effectiveness. Some studies had mid-point ICERs in the range that NICE considers cost-effective,
whereas others had ICERs that were above the NICE threshold. Two studies of CBTHI suggest that
this intervention is cost-effective, although a third study had an ICER above the NICE threshold.
The cost-effective ICERs were for populations with chronic pain, whereas the intervention with the
higher ICER had a population that included both patients with chronic pain and those with somatoform
disorders. Two studies suggested that guided self-help has the potential to be cost-effective, but one
of these studies131 was associated with some uncertainty as there was no estimate of the cost of the
self-help guidebook. One study suggested that RSSE has the potential to be cost-effective; however,
additional uncertainty arose from the fact that the intervention was delivered to groups, but there
was no indication of group size, which is an important determinant of cost per person. Evidence for
GA interventions was inconsistent, with one study showing a positive QALY gain compared with guided
self-help, albeit with an ICER at the upper limit of the NICE threshold, and the other finding that GA
was dominated by usual care. CBTHI dominated medication in one study of a population with chronic
pain. CBTHI was also shown to dominate SES in one study. GP interventions were generally not found
to be cost-effective, with the exception of modified reattribution compared with usual care in patients
with somatoform disorder, where the mid-point ICER was < £30,000 per QALY but was associated with
significant uncertainty. Multimodal interventions were inconsistent in patients with chronic pain, with
one study showing an estimated ICER above the NICE limit and another within the range considered
cost-effective when compared with SES. However, the same study found that the multimodal intervention
was dominated by CBTHI, which was estimated to be the optimal intervention based on that study, as seen
in Table 27.
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Discussion of qualitative findings
In identifying qualitative intervention studies conducted in a UK setting, we were able to explore
the perspectives of patients and health-care providers of interventions delivered within a UK setting.
However, we acknowledge that this perspective is necessarily limited by including only intervention-
based studies and by operating within a tight geographical definition. The value of qualitative studies
examining the experience of a condition and of studies from a broader range of geographical contexts
and settings could prove valuable. Generally, the qualitative evidence base has identified features
considered important by those receiving interventions. However, our ability to identify the most useful,
acceptable or efficacious components of intervention packages was constrained by the limited detail of
reporting of each intervention. Nevertheless, we believe that the qualitative synthesis, informed and
enhanced by the wider scope of the realist synthesis that extends beyond intervention-based studies,
offers a potentially useful contribution to the design of future primary care-based interventions.
Implications for individual interventions
Several hypothesised features for successful inclusion in a primary care-based intervention for MUS
are presented within the realist synthesis. Many of these features receive clear support, with the
exception of the value of ‘labelling’ and the ongoing controversy regarding initiation of psychosocial
cues. At a minimum, an intervention should allow patient and care provider to maintain a relationship
in which the patient feels supported and believed. Avoidance of an unproductive diagnostic cycle and
a seemingly endless pattern of referral are key. The important role of non-intervention-specific factors
has been recognised in a variety of contexts for treatment of chronic disease more generally in primary
care, and this has been confirmed in this review. Above all, patients should be encouraged to pursue
opportunities for self-management while drawing on the resources and skills available via the primary
care provider.
Strengths and limitations of the assessment
We undertook a rigorous systematic review following accepted standards for the conduct and reporting of
an effects review and using comprehensive search strategies to identify relevant trials evaluating the clinical
effectiveness of interventions to treat MUS in primary care. Although we appraised and summarised a
relatively large number of trials, much of the evidence was inconclusive because of heterogeneity within
interventions and across groups of interventions. Pragmatically, we have employed an approach that differs
from that typically used in Cochrane reviews and other reviews by not distinguishing between interventions
within trials in terms of the control or comparator interventions. A further strength was the use of multiple
review strategies to address diverse questions relating to the overall review aim. Hence, the qualitative data
were able to explore the acceptability of interventions to patients, and the economic evaluation studies
were able to explore cost implications while the realist synthesis examined features of the patient–clinician
consultation in primary care.
Inclusion criteria were kept broad for many elements of the review. This was because of variation in
the use of labels for MUS; inconsistencies in diagnostic criteria; a range of interventions meeting our a
priori definition of ‘behavioural modification’; a range of ways of incorporating the primary care setting
into the intervention; and multiple and diverse outcomes measures employed in the studies. The use
of broad criteria has allowed a comprehensive presentation of the potential sources of heterogeneity
both within and between studies and these are apparent from the narrative synthesis. The NMA
also identified moderate to high heterogeneity of intervention effects between studies. Insufficient
replication of treatment effects across studies made it impossible to perform a metaregression to
statistically explain the heterogeneity of effects, and this represents a key limitation of the analysis of
clinical effectiveness. Differences in point estimates for treatments (vs. usual care), however, indicate
that the effectiveness of the interventions may differ by condition grouping, although overlapping CIs
demonstrate uncertainty around this finding.
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Despite the large number of studies, the network was sparse because of the considerable heterogeneity
between interventions and the resulting large number of intervention types. Individual studies also
varied in follow-up time periods and this meant that data from many studies were not available for all
three time points. Additional reasons why it was not possible to include data from some of the included
studies included both arms being categorised into the same intervention type, incomplete reporting
of data for non-significant outcomes, only graphical data presented, or no reported variance. Sparsity
of the networks meant that the observed effects were often informed by only one study in each
intervention type for each outcome at each time point. Results from the network meta-analyses can
therefore only give an indication of effects and should be considered within the context of the narrative
summaries of individual studies, with consideration to the considerable heterogeneity identified.
Evidence from both the network meta-analyses and the narrative summaries of all individual studies
suggests the presence of differences in effects between intervention types. However, scrutiny of the
individual studies shows variability in their design and conduct, to such an extent that interpretation of
the results is not straightforward and, therefore, firm conclusions cannot be drawn. Although combining
all intervention types into one ‘behavioural modification’ intervention type would have potentially
allowed a metaregression to identify moderators of effects, it was considered that this would be
inappropriate because of these differences.
The diversity in the interventions meant that to synthesise the data, individual interventions needed
to be categorised into broader intervention groups. This process necessitated subjective judgements.
Although every effort was made to reach decisions on intervention groupings by expert consensus,
the prevalence of borderline cases resulted in the inclusion within one category of interventions
that could have arguably met the criteria of a different category. With a sparse network, it is possible
that such borderline cases could influence the results of the meta-analysis. However, while this is to
our knowledge the first review to address this specific research question, the results are generally
consistent with existing reviews that have addressed similar questions. We were unable to investigate
publication bias via funnel plots owing to there being < 10 trials per comparison (of the same
interventions) (Cochrane handbook)87 for all outcomes, and we are therefore unable to address the
possibility of small study effects.
Owing to the diversity of interventions and sparsity of the network, we were unable to address
the question as to which components of effective interventions were most influential. Results from
the NMA suggest that multimodal therapy interventions have beneficial effects across outcomes and
time points, but there was considerable diversity in the individual components across multimodal
interventions and it has not been possible to identify if specific components were driving the
effectiveness or if the effects were due to the combination of components or increased intensity
of the treatment.
There was limited information available from published cost-effectiveness analyses that reported
outcomes using QALYs. The main strength of our approach to the independent economic assessment is
that we have been able to provide an indication of within-study cost-effectiveness for a large number
of studies covering a diverse range of interventions and populations. The main disadvantages of the
approach that we have used is that we have not been able to provide estimates of cost-effectiveness
for all of the comparisons represented within the full set of clinical trials, as not all of the studies
reported a generic measure of HRQoL and we have been unable to conduct a full incremental analysis
to identify the optimal behavioural modification intervention using evidence from multiple studies.
The review is further limited by the dates of the searches, which were conducted between November
2015 and August 2016. Studies published since this time may therefore offer more evidence to inform
the research questions addressed in this review.
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Conclusions
Evidence from the current review offers some support for the value of behavioural interventions in
primary care for improvement in specific symptoms (pain, fatigue and bowel symptoms), with both
CBTLI and CBTHI showing some beneficial effects in different conditions, and multimodal therapy
supported across a number of outcomes. No one intervention was found to be effective across all
MUS, suggesting that there is no generic treatment that can be applied across all MUS. Only CBTHI
had support over usual care for anxiety, but a range of therapies showed effects in emotional distress
including other psychotherapies. The beneficial effects shown for chronic pain were short term. There
was no clear evidence for these interventions in somatisation disorders and multiple symptoms. GP-led
interventions, such as reattribution, were not supported by the evidence. Further interrogation of the
results may indicate whether or not this is because of a lack of effectiveness of the more pragmatic
trials. Developing a clear referral pathway in primary care to therapist-supported CBT or multimodal
therapy for specific symptoms or FSSs may be most indicated at this point. The synthesis of qualitative
evidence on process suggests that the quality of relationship between the service user and their GP is
vital, and this ‘therapeutic alliance’ is the determining factor for how successfully these interventions
can be implemented. These conclusions must be read with caution because of the large degree of
heterogeneity of studies. There was also a low level of replication of intervention types within the
networks, which coupled with the observed between-study heterogeneity of effects means that
conclusions on specific therapies could be altered by addition or exclusion of one study. These findings
were mirrored in the economic analysis, which found that where there was more than one study providing
an estimate of cost-effectiveness for a particular comparison, the evidence was often inconsistent.
Suggested research priorities
The following research priorities are suggested, based on the findings of the review:
1. Explanation of observed between-study differences in effects within the same intervention type.
This may be addressed by –
i. More detailed reporting of information regarding the defined mechanisms of the behavioural
interventions under study, and how these map onto a theoretical and empirical understanding of
the conditions.
ii. More research on potentially influencing factors such as effective dosage and therapist
competency within the more promising behavioural interventions.
iii. Within-trial comparisons of interventions targeting specific syndromes with those targeting
general somatic symptoms.
2. Testing the therapeutic effect of the GP–patient relationship. This may be addressed by –
i. Increased awareness of likely GP effects by researchers conducting trials of behavioural
interventions for MUS, with planned assessment of these as potential confounders.
ii. More research aimed at better understanding the therapeutic elements behind a successful
therapeutic GP–patient alliance, which are key to a successful outcome, and how these elements
can be formalised as GP (and health-care practitioner) skills.
iii. Development of standardised measures of adverse effects in trials of behavioural interventions
for MUS.
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Appendix 1 Literature search strategies
A ll searches comprised the same population and setting terms, translated for each database, asdetailed below. These were combined with search filters to identify systematic reviews, RCTs,
qualitative research (UK studies) and economic evaluations, details of which are included below.
See Chapter 3 for the search strategy date ranges and dates of searches.
MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations,
Epub Ahead of Print, MEDLINE without Revisions via OvidSP
1. medically unexplained symptom*.ti,ab.
2. MUS.ti,ab.
3. medically unexplained physical symptom*.ti,ab.
4. MUPS.ti,ab.
5. (unexplain* adj1 medical*).ti,ab.
6. (unexplain* adj1 (sympt* or problem* or condition* or complain*)).ti,ab.
7. ((non specific or nonspecific) adj2 (sympt* or problem* or condition* or complain*)).ti,ab.
8. ((unexplain* or inexpl*) and (health* or medical* or physical*) and (sympt* or problem* or
condition* or complain*)).ti,ab.
9. unexplained physical symptom*.ti,ab.
10. (Persistent adj2 physical symptom*).ti,ab.
11. distress syndrome.ti,ab.
12. polydistress disorder.ti,ab.
13. medically unexplained syndrome*.ti,ab.
14. or/1-13
15. (functional adj2 (disorder* or syndrome* or symptom* or pain*)).ti,ab.
16. Fibromyalgia/
17. fibromyalgi*.ti,ab.
18. Fatigue Syndrome, Chronic/
19. CFS.ti,ab.
20. (chronic fatigue adj3 (syndrome* or disorder*)).ti,ab.
21. myalgic encephalomyelitis.ti,ab.
22. fatigue syndrome.ti,ab.
23. Colonic Diseases, Functional/
24. Irritable Bowel Syndrome/
25. irritable bowel syndrome*.ti,ab.
26. IBS.ti,ab.
27. Temporomandibular Joint Dysfunction Syndrome/
28. ((temporomandibular joint or TMJ) adj2 (disease* or disorder* or dysfunction*)).ti,ab.
29. Myofascial Pain Syndromes/
30. myofascial pain disorder*.ti,ab.
31. Facial Neuralgia/
32. atypical facial pain.ti,ab.
33. facial pain syndrome*.ti,ab.
34. Hyperventilation/
35. hyperventilation.ti,ab.
36. dysfunctional breathing.ti,ab.
37. loin pain h?ematuria syndrome*.ti,ab.
38. Muscle Weakness/
39. functional weakness*.ti,ab.
40. Movement Disorders/
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41. movement disorder*.ti,ab.
42. (non-epileptic adj (attack* or seizure*)).ti,ab.
43. Dysmenorrhea/
44. dysmenorrhoea.ti,ab.
45. neurasthen*.ti,ab.
46. Neurasthenia/
47. Multiple Chemical Sensitivity/
48. multiple chemical sensitivity.ti,ab.
49. idiopathic environmental intolerance.ti,ab.
50. Tension-Type Headache/
51. ((tension type or idiopathic or psychogenic) adj2 headache*).ti,ab.
52. Neurocirculatory Asthenia/
53. *Asthenia/
54. chronic asthenia.ti,ab.
55. functional atrial arrhythmia.ti,ab.
56. Da Costa’s Syndrome.ti,ab.
57. effort syndrome.ti,ab.
58. functional cardiovascular disease*.ti,ab.
59. subacute asthenia.ti,ab.
60. functional disturbance*.ti,ab.
61. (symptom adj syndrome*).ti,ab.
62. Post-Concussion Syndrome/
63. (post concussi* syndrome* or post-concussi* syndrome*).ti,ab.
64. or/15-63
65. Psychophysiologic Disorders/
66. ((psychosomatic or pyschophysiologic) adj (disorder* or syndrome* or symptom*)).ti,ab.
67. briquet syndrome*.ti,ab.
68. Psychosomatic Medicine/
69. psychophysiologic*.ti,ab.
70. psychosomat*.ti,ab.
71. psychogen*.ti,ab.
72. *Somatoform Disorders/
73. somatic symptom*.ti,ab.
74. Somatoform Disorder*.ti,ab.
75. somati?at*.ti,ab.
76. (somatic adj2 syndrome*).ti,ab.
77. *Conversion Disorder/
78. conversion disorder*.ti,ab.
79. subjective health complaint*.ti,ab.
80. cardiac neurosis.ti,ab.
81. or/65-80
82. (Habits/or Tics/or Tic Disorders/) and Cough/
83. (chronic adj2 cough).ti,ab.
84. (habit cough or tic cough).ti,ab.
85. chronic pelvic pain*.ti,ab.
86. chronic widespread pain.ti,ab.
87. ((non cardiac or noncardiac or non specific or nonspecific) adj2 chest pain*).ti,ab.
88. NCCP.ti,ab.
89. atypical chest pain*.ti,ab.
90. *Low Back Pain/
91. chronic low back pain*.ti,ab.
92. *chronic pain/
93. (chronic adj2 pain).ti,ab.
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94. regional pain.ti,ab.
95. ((non ulcer or nonulcer or non-ulcer or functional) adj2 dyspepsia).ti,ab.
96. or/82-95
97. *Sexual Dysfunctions, Psychological/
98. *Vaginismus/
99. (psychological adj2 sexual dysfunction*).ti,ab.
100. vaginismus.ti,ab.
101. psycho-sexual dysfunction*.ti,ab.
102. psychosexual dysfunction*.ti,ab.
103. *Erectile Dysfunction/
104. (impotence or erectile dysfunction).ti,ab.
105. *Vulvodynia/
106. vulvodynia.ti,ab.
107. anorgasmia.ti,ab.
108. or/97-107
109. 14 or 64 or 81 or 96 or 108
110. exp Primary Health Care/
111. exp Family Practice/or exp General Practice/
112. PHYSICIANS, FAMILY/
113. FAMILY HEALTHCARE/
114. NURSE PRACTITIONERS/
115. ((family or community) adj (medic$or doctor$or physician$or nurs$or health)).ti,ab.
116. ((general or family or nurs$) adj1 (practice$or practitioner$)).ti,ab.
117. (primary care or primary healthcare or primary health care or primary health service$or
homecare or care in the community).ti,ab.
118. (GP$or generalist$).ti,ab.
119. Occupational Health/
120. (occupational adj (health* or therap*)).ti,ab.
121. or/110-120
122. 109 and 121
Search filters
l To retrieve systematic reviews: Scottish Intercollegiate Guidelines Network (SIGN). Search Filters:
Systematic Reviews. URL: www.sign.ac.uk/methodology/filters.html#systematic (accessed 7 April 2017).
l To retrieve RCTs: SIGN. Search Filters: Randomised Controlled Trials. URL: www.sign.ac.uk/
methodology/filters.html#random (accessed 7 April 2017).
l To retrieve economic evaluations: SIGN. Search Filters: Economic Studies. URL: www.sign.ac.uk/
methodology/filters.html#econ (accessed 7 April 2017).
l To retrieve qualitative research: University of Texas School of Public Health. Search Filters for
Various Databases: Ovid MEDLINE – Qualitative studies. URL: http://libguides.sph.uth.tmc.edu/search_
filters/ovid_medline_filters (accessed 7 April 2017) combined with (AND) terms to identify UK
studies: exp Great Britain/ OR (Britain or british or wales or welsh or Scottish or scots or Scotland
or England or English or Birmingham or leeds or London or Liverpool or Manchester or Glasgow or
Edinburgh or Cardiff or Belfast or UK or GB or aberdeen).ti,ab,in,hw.
EMBASE (via OvidSP)
1. medically unexplained symptom*.ti,ab.
2. MUS.ti,ab.
3. medically unexplained physical symptom*.ti,ab.
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4. MUPS.ti,ab.
5. (unexplain* adj1 medical*).ti,ab.
6. (unexplain* adj1 (sympt* or problem* or condition* or complain*)).ti,ab.
7. ((non specific or nonspecific) adj2 (sympt* or problem* or condition* or complain*)).ti,ab.
8. ((unexplain* or inexpl*) and (health* or medical* or physical*) and (sympt* or problem* or
condition* or complain*)).ti,ab.
9. unexplained physical symptom*.ti,ab.
10. (Persistent adj2 physical symptom*).ti,ab.
11. distress syndrome.ti,ab.
12. polydistress disorder.ti,ab.
13. medically unexplained syndrome*.ti,ab.
14. or/1-13
15. (functional adj2 (disorder* or syndrome* or symptom* or pain*)).ti,ab.
16. fibromyalgia/
17. fibromyalgi*.ti,ab.
18. chronic fatigue syndrome/
19. CFS.ti,ab.
20. (chronic fatigue adj3 (syndrome* or disorder*)).ti,ab.
21. myalgic encephalomyelitis.ti,ab.
22. fatigue syndrome.ti,ab.
23. irritable colon/
24. irritable bowel syndrome*.ti,ab.
25. IBS.ti,ab.
26. temporomandibular joint disorder/
27. ((temporomandibular joint or TMJ) adj2 (disease* or disorder* or dysfunction*)).ti,ab.
28. myofascial pain/
29. myofascial pain disorder*.ti,ab.
30. face pain/
31. atypical facial pain.ti,ab.
32. facial pain syndrome*.ti,ab.
33. hyperventilation syndrome/or hyperventilation/
34. hyperventilation.ti,ab.
35. dysfunctional breathing.ti,ab.
36. loin pain h?ematuria syndrome*.ti,ab.
37. muscle weakness/
38. functional weakness*.ti,ab.
39. motor dysfunction/
40. movement disorder*.ti,ab.
41. (non-epileptic adj (attack* or seizure*)).ti,ab.
42. dysmenorrhea/
43. dysmenorrhoea.ti,ab.
44. neurasthenia/
45. neurasthen*.ti,ab.
46. multiple chemical sensitivity/
47. multiple chemical sensitivity.ti,ab.
48. idiopathic environmental intolerance.ti,ab.
49. tension headache/
50. ((tension type or idiopathic or psychogenic) adj2 headache*).ti,ab.
51. cardiac anxiety/
52. *asthenia/
53. chronic asthenia.ti,ab.
54. functional atrial arrhythmia.ti,ab.
55. Da Costa’s Syndrome.ti,ab.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
230
56. effort syndrome.ti,ab.
57. functional cardiovascular disease*.ti,ab.
58. subacute asthenia.ti,ab.
59. functional disturbance*.ti,ab.
60. (symptom adj syndrome*).ti,ab.
61. postconcussion syndrome/
62. (post concussi* syndrome* or post-concussi* syndrome*).ti,ab.
63. or/15-62
64. psychosomatic disorder/
65. ((psychosomatic or pyschophysiologic) adj (disorder* or syndrome* or symptom*)).ti,ab.
66. briquet syndrome*.ti,ab.
67. psychosomatics/
68. psychophysiologic*.ti,ab.
69. psychosomat*.ti,ab.
70. psychogen*.ti,ab.
71. *somatoform disorder/
72. somatic symptom*.ti,ab.
73. Somatoform Disorder*.ti,ab.
74. somati?at*.ti,ab.
75. (somatic adj2 syndrome*).ti,ab.
76. conversion disorder/
77. conversion disorder*.ti,ab.
78. subjective health complaint*.ti,ab.
79. cardiac neurosis.ti,ab.
80. or/64-79
81. habit/and coughing/
82. tic/and coughing/
83. (chronic adj2 cough).ti,ab.
84. (habit cough or tic cough).ti,ab.
85. chronic pelvic pain*.ti,ab.
86. chronic widespread pain.ti,ab.
87. ((non cardiac or noncardiac or non specific or nonspecific) adj2 chest pain*).ti,ab.
88. NCCP.ti,ab.
89. atypical chest pain*.ti,ab.
90. *low back pain/
91. chronic low back pain*.ti,ab.
92. *chronic pain/
93. (chronic adj2 pain).ti,ab.
94. regional pain.ti,ab.
95. ((non ulcer or nonulcer or non-ulcer or functional) adj2 dyspepsia).ti,ab.
96. or/81-95
97. psychological aspect/and sexual dysfunction/
98. vaginism/
99. (psychological adj2 sexual dysfunction*).ti,ab.
100. vaginismus.ti,ab.
101. psycho-sexual dysfunction*.ti,ab.
102. psychosexual dysfunction*.ti,ab.
103. *erectile dysfunction/
104. (impotence or erectile dysfunction).ti,ab.
105. vulvodynia.ti,ab.
106. anorgasmia.ti,ab.
107. or/97-106
108. 14 or 63 or 80 or 96 or 107
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109. exp primary health care/
110. exp general practice/
111. general practitioner/
112. family health/
113. nurse practitioner/
114. ((family or community) adj (medic$ or doctor$ or physician$ or nurs$ or health)).ti,ab.
115. ((general or family or nurs$) adj1 (practice$ or practitioner$)).ti,ab.
116. (primary care or primary healthcare or primary health care or primary health service$ or
homecare or care in the community).ti,ab.
117. (GP$ or generalist$).ti,ab.
118. occupational health/
119. (occupational adj (health* or therap*)).ti,ab.
120. or/109-119
121. 108 and 120
122. limit 121 to embase
Search filters
l To retrieve systematic reviews: Scottish Intercollegiate Guidelines Network (SIGN). Search Filters:
Systematic Reviews. URL: www.sign.ac.uk/methodology/filters.html#systematic (accessed 7 April 2017).
l To retrieve RCTs: SIGN. Search Filters: Randomised Controlled Trials. URL: www.sign.ac.uk/
methodology/filters.html#random (accessed 7 April 2017).
l To retrieve economic evaluations: Canadian Agency for Drugs and Technologies in Health (CADTH).
Strings Attached: CADTH’s Database Search Filters: Economic Evaluations/Cost/Economic Models. URL:
www.cadth.ca/resources/finding-evidence/strings-attached-cadths-database-search-filters#eco
(accessed 7 April 2017).
l To retrieve qualitative research: McMaster University Health Information Research Unit. Search
Strategies for EMBASE in Ovid Syntax: Qualitative (Best Balance of Sensitivity and Specificity). URL:
http://hiru.mcmaster.ca/hiru/HIRU_Hedges_EMBASE_Strategies.aspx#Economics (accessed 7 April 2017)
combined with (AND) terms to identify UK studies: exp Great Britain/ OR (Britain or british or wales or
welsh or Scottish or scots or Scotland or England or English or Birmingham or leeds or London or
Liverpool or Manchester or Glasgow or Edinburgh or Cardiff or Belfast or UK or GB or aberdeen).ti,ab,
in,hw.
CINAHL (via EBSCOhost)
S1 TI medically unexplained symptom* OR AB medically unexplained symptom*
S2 TI MUS OR AB MUS
S3 TI medically unexplained physical symptom* OR AB medically unexplained physical symptom*
S4 TI MUPS OR AB MUPS
S5 TI (unexplain* n1 medical*) OR AB (unexplain* n1 medical*)
S6 TI ( (unexplain* n1 (sympt* or problem* or condition* or complain*)) ) OR AB ( (unexplain* n1
(sympt* or problem* or condition* or complain*)) )
S7 TI ( ((non specific or nonspecific) n2 (sympt* or problem* or condition* or complain*)) ) OR AB
( ((non specific or nonspecific) n2 (sympt* or problem* or condition* or complain*)) )
S8 TI ( ((unexplain* or inexpl*) and (health* or medical* or physical*) and (sympt* or problem* or
condition* or complain*)) ) OR AB ( ((unexplain* or inexpl*) and (health* or medical* or physical*)
and (sympt* or problem* or condition* or complain*)) )
S9 TI unexplained physical symptom* OR AB unexplained physical symptom*
S10 TI (Persistent n2 physical symptom*) OR AB (Persistent n2 physical symptom*)
S11 TI distress syndrome OR AB distress syndrome
S12 TI polydistress disorder OR AB polydistress disorder
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S13 TI medically unexplained syndrome* OR AB medically unexplained syndrome*
S14 (MH “Medically Unexplained Symptoms“)
S15 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
OR S14
S16 TI ( (functional n2 (disorder* or syndrome* or symptom* or pain*)) ) OR AB ( (functional n2
(disorder* or syndrome* or symptom* or pain*)) )
S17 (MH “Fibromyalgia”)
S18 TI fibromyalgi* OR AB fibromyalgi*
S19 (MH “Fatigue Syndrome, Chronic”)
S20 TI CFS OR AB CFS
S21 TI ( (chronic fatigue n3 (syndrome* or disorder*)) ) OR AB ( (chronic fatigue n3 (syndrome* or
disorder*)) )
S22 TI myalgic encephalomyelitis OR AB myalgic encephalomyelitis
S23 TI fatigue syndrome OR AB fatigue syndrome
S24 (MH “Colonic Diseases, Functional”)
S25 (MH “Irritable Bowel Syndrome”)
S26 TI irritable bowel syndrome* OR AB irritable bowel syndrome*
S27 TI IBS OR AB IBS
S28 (MH “Temporomandibular Joint Syndrome”)
S29 TI ( ((temporomandibular joint or TMJ) n2 (disease* or disorder* or dysfunction*)) ) OR AB
( ((temporomandibular joint or TMJ) n2 (disease* or disorder* or dysfunction*)) )
S30 (MH “Myofascial Pain Syndromes”)
S31 TI myofascial pain disorder* OR AB myofascial pain disorder*
S32 (MH “Facial Neuralgia”)
S33 TI atypical facial pain OR AB atypical facial pain
S34 TI facial pain syndrome* OR AB facial pain syndrome*
S35 (MH “Hyperventilation”)
S36 TI hyperventilation OR AB hyperventilation
S37 TI dysfunctional breathing OR AB dysfunctional breathing
S38 TI loin pain h?ematuria syndrome* OR AB loin pain h?ematuria syndrome*
S39 (MH “Muscle Weakness”)
S40 TI functional weakness* OR AB functional weakness*
S41 (MH “Movement Disorders”)
S42 TI movement disorder* OR AB movement disorder*
S43 TI ( (non-epileptic n1 (attack* or seizure*) ) OR AB ( (non-epileptic n1 (attack* or seizure*) )
S44 (MH “Dysmenorrhea”)
S45 TI dysmenorrhoea OR AB dysmenorrhoea
S46 TI neurasthen* OR AB neurasthen*
S47 (MH “Multiple Chemical Sensitivity”)
S48 TI multiple chemical sensitivity OR AB multiple chemical sensitivity
S49 TI idiopathic environmental intolerance OR AB idiopathic environmental intolerance
S50 (MH “Tension Headache”)
S51 TI ( ((tension type or idiopathic or psychogenic) n2 headache*) ) OR AB ( ((tension type or
idiopathic or psychogenic) n2 headache*) )
S52 (MM “Asthenia”)
S53 TI chronic asthenia OR AB chronic asthenia
S54 TI functional atrial arrhythmia OR AB functional atrial arrhythmia
S55 TI Da Costa’s Syndrome OR AB Da Costa’s Syndrome
S56 TI effort syndrome OR AB effort syndrome
S57 TI functional cardiovascular disease* OR AB functional cardiovascular disease*
S58 TI subacute asthenia OR AB subacute asthenia
S59 TI functional disturbance* OR AB functional disturbance*
S60 TI (symptom n1 syndrome*) OR AB (symptom n1 syndrome*)
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S61 (MH “Postconcussion Syndrome”)
S62 TI ( (post concussi* syndrome* or post-concussi* syndrome*) ) OR AB ( (post concussi* syndrome*
or post-concussi* syndrome*) )
S63 S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27
OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR
S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50
OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61
OR S62
S64 (MH “Psychophysiologic Disorders”)
S65 TI ( ((psychosomatic or pyschophysiologic) n1 (disorder* or syndrome* or symptom*)) ) OR AB
( ((psychosomatic or pyschophysiologic) n1 (disorder* or syndrome* or symptom*)) )
S66 TI briquet syndrome* OR AB briquet syndrome*
S67 TI psychophysiologic* OR AB psychophysiologic*
S68 TI psychosomat* OR AB psychosomat*
S69 TI psychogen* OR AB psychogen*
S70 (MM “Somatoform Disorders”)
S71 TI somatic symptom* OR AB somatic symptom*
S72 TI somatoform disorder* OR AB somatoform disorder*
S73 TI somati?at* OR AB somati?at*
S74 TI (somatic n2 syndrome*) OR AB (somatic n2 syndrome*)
S75 TI conversion disorder* OR AB conversion disorder*
S76 TI subjective health complaint* OR AB subjective health complaint*
S77 TI cardiac neurosis OR AB cardiac neurosis
S78 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75
OR S76 OR S77
S79 (MH “Habits”) AND (MH “Cough”)
S80 (MH “Tic”) AND (MH “Cough”)
S81 TI (chronic n2 cough) OR AB (chronic n2 cough)
S82 TI ( (habit cough or tic cough) ) OR AB ( (habit cough or tic cough) )
S83 TI chronic pelvic pain* OR AB chronic pelvic pain*
S84 TI chronic widespread pain OR AB chronic widespread pain
S85 TI ( ((non cardiac or noncardiac or non specific or nonspecific) n2 chest pain*) ) OR AB
( ((non cardiac or noncardiac or non specific or nonspecific) n2 chest pain*) )
S86 TI NCCP OR AB NCCP
S87 TI atypical chest pain* OR AB atypical chest pain*
S88 (MM “Low Back Pain”)
S89 TI chronic low back pain* OR AB chronic low back pain*
S90 (MM “Chronic Pain”)
S91 TI (chronic n2 pain) OR AB (chronic n2 pain)
S92 TI regional pain OR AB regional pain
S93 TI ( ((non ulcer or nonulcer or non-ulcer or functional) n2 dyspepsia) ) OR AB ( ((non ulcer or
nonulcer or non-ulcer or functional) n2 dyspepsia) )
S94 S79 OR S80 OR S81 OR S82 OR S83 OR S84 OR S85 OR S86 OR S87 OR S88 OR S89 OR S90
OR S91 OR S92 OR S93
S95 (MM “Psychosexual Disorders”)
S96 TI (psychological n2 sexual dysfunction*) OR AB (psychological n2 sexual dysfunction*)
S97 TI vaginismus OR AB vaginismus
S98 TI psycho-sexual dysfunction* OR AB psycho-sexual dysfunction*
S99 TI psychosexual dysfunction* OR AB psychosexual dysfunction*
S100 (MM “Impotence”)
S101 TI ( (impotence or erectile dysfunction) ) OR AB ( (impotence or erectile dysfunction) )
S102 TI vulvodynia OR AB vulvodynia
S103 TI anorgasmia OR AB anorgasmia
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S104 S95 OR S96 OR S97 OR S98 OR S99 OR S100 OR S101 OR S102 OR S103
S105 S15 OR S63 OR S94 OR S104
S106 (MH “Primary Health Care”)
S107 (MH “Family Practice”)
S108 (MH “Physicians, Family”)
S109 (MH “Nurse Practitioners”)
S110 TI ( ((family or community) n1 (medic$ or doctor$ or physician$ or nurs$ or health)) ) OR AB
( ((family or community) n1 (medic$ or doctor$ or physician$ or nurs$ or health)) )
S111 TI ( ((general or family or nurs$) n1 (practice$ or practitioner$)) ) OR AB ( ((general or family or
nurs$) n1 (practice$ or practitioner$)) )
S112 TI ( (primary care or primary healthcare or primary health care or primary health service$ or
homecare or care in the community) ) OR AB ( (primary care or primary healthcare or primary
health care or primary health service$ or homecare or care in the community) )
S113 TI ( (GP$ or generalist$) ) OR AB ( (GP$ or generalist$) )
S114 (MH “Occupational Health”)
S115 TI ( (occupational n1 (health* or therap*)) ) OR AB ( (occupational n1 (health* or therap*)) )
S116 S106 OR S107 OR S108 OR S109 OR S110 OR S111 OR S112 OR S113 OR S114 OR S115
S117 S105 AND S116
Search filters
l To retrieve systematic reviews: Scottish Intercollegiate Guidelines Network (SIGN). Search Filters:
Systematic Reviews. URL: www.sign.ac.uk/methodology/filters.html#systematic (accessed 7 April 2017).
l To retrieve RCTs: SIGN. Search Filters: Randomised Controlled Trials. URL: www.sign.ac.uk/
methodology/filters.html#random (accessed 7 April 2017).
l To retrieve economic evaluations: Centre for Reviews and Dissemination (CRD), The University of
York. Search strategies: NHS EED. URL: www.crd.york.ac.uk/crdweb/searchstrategies.asp#nhseedcinahl
(accessed 7 April 2017).
l To retrieve Qualitative Research: University of Washington Health Sciences Library. Finding
Qualitative Research Articles: CINAHL. URL: http://guides.lib.uw.edu/c.php?g%20=%2099112&p%20=
%20642298 (accessed 7 April 2017) combined with (AND) terms to identify UK studies:
l (MH “Great Britain”) OR (Britain or british or wales or welsh or Scottish or scots or Scotland or
England or English or Birmingham or leeds or London or Liverpool or Manchester or Glasgow or
Edinburgh or Cardiff or Belfast or UK or GB or aberdeen).
PyscINFO (via OvidSP)
1. medically unexplained symptom*.ti,ab.
2. MUS.ti,ab.
3. medically unexplained physical symptom*.ti,ab.
4. MUPS.ti,ab.
5. (unexplain* adj1 medical*).ti,ab.
6. (unexplain* adj1 (sympt* or problem* or condition* or complain*)).ti,ab.
7. ((non specific or nonspecific) adj2 (sympt* or problem* or condition* or complain*)).ti,ab.
8. ((unexplain* or inexpl*) and (health* or medical* or physical*) and (sympt* or problem* or
condition* or complain*)).ti,ab.
9. unexplained physical symptom*.ti,ab.
10. (Persistent adj2 physical symptom*).ti,ab.
11. distress syndrome.ti,ab.
12. polydistress disorder.ti,ab.
13. medically unexplained syndrome*.ti,ab.
14. or/1-13
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15. (functional adj2 (disorder* or syndrome* or symptom* or pain*)).ti,ab.
16. exp Fibromyalgia/
17. fibromyalgi*.ti,ab.
18. Chronic Fatigue Syndrome/
19. CFS.ti,ab.
20. (chronic fatigue adj3 (syndrome* or disorder*)).ti,ab.
21. myalgic encephalomyelitis.ti,ab.
22. fatigue syndrome.ti,ab.
23. Irritable Bowel Syndrome/
24. irritable bowel syndrome*.ti,ab.
25. IBS.ti,ab.
26. ((temporomandibular joint or TMJ) adj2 (disease* or disorder* or dysfunction*)).ti,ab.
27. exp Syndromes/and Myofascial Pain/
28. myofascial pain disorder*.ti,ab.
29. atypical facial pain.ti,ab.
30. facial pain syndrome*.ti,ab.
31. Hyperventilation/
32. hyperventilation.ti,ab.
33. dysfunctional breathing.ti,ab.
34. loin pain h?ematuria syndrome*.ti,ab.
35. functional weakness*.ti,ab.
36. Movement Disorders/
37. movement disorder*.ti,ab.
38. (non-epileptic adj (attack* or seizure*)).ti,ab.
39. Dysmenorrhea/
40. dysmenorrhoea.ti,ab.
41. neurasthen*.ti,ab.
42. Neurasthenia/
43. multiple chemical sensitivity.ti,ab.
44. idiopathic environmental intolerance.ti,ab.
45. exp Muscle Contraction Headache/
46. ((tension type or idiopathic or psychogenic) adj2 headache*).ti,ab.
47. *Asthenia/
48. chronic asthenia.ti,ab.
49. functional atrial arrhythmia.ti,ab.
50. Da Costa’s Syndrome.ti,ab.
51. effort syndrome.ti,ab.
52. functional cardiovascular disease*.ti,ab.
53. subacute asthenia.ti,ab.
54. functional disturbance*.ti,ab.
55. (symptom adj syndrome*).ti,ab.
56. (post concussi* syndrome* or post-concussi* syndrome*).ti,ab.
57. or/15-56
58. Somatoform Disorders/
59. ((psychosomatic or pyschophysiologic) adj (disorder* or syndrome* or symptom*)).ti,ab.
60. briquet syndrome*.ti,ab.
61. Psychosomatic Medicine/
62. psychophysiologic*.ti,ab.
63. psychosomat*.ti,ab.
64. psychogen*.ti,ab.
65. somatic symptom*.ti,ab.
66. Somatoform Disorder*.ti,ab.
67. somati?at*.ti,ab.
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68. (somatic adj2 syndrome*).ti,ab.
69. *Conversion Disorder/
70. conversion disorder*.ti,ab.
71. subjective health complaint*.ti,ab.
72. cardiac neurosis.ti,ab.
73. or/58-72
74. (chronic adj2 cough).ti,ab.
75. (habit cough or tic cough).ti,ab.
76. chronic pelvic pain*.ti,ab.
77. chronic widespread pain.ti,ab.
78. ((non cardiac or noncardiac or non specific or nonspecific) adj2 chest pain*).ti,ab.
79. NCCP.ti,ab.
80. atypical chest pain*.ti,ab.
81. *Back Pain/
82. chronic low back pain*.ti,ab.
83. *Chronic Pain/
84. (chronic adj2 pain).ti,ab.
85. regional pain.ti,ab.
86. ((non ulcer or nonulcer or non-ulcer or functional) adj2 dyspepsia).ti,ab.
87. or/74-86
88. *Sexual Function Disturbances/
89. (psychological adj2 sexual dysfunction*).ti,ab.
90. *Vaginismus/
91. vaginismus.ti,ab.
92. psycho-sexual dysfunction*.ti,ab.
93. psychosexual dysfunction*.ti,ab.
94. *Erectile Dysfunction/
95. (impotence or erectile dysfunction).ti,ab.
96. vulvodynia.ti,ab.
97. anorgasmia.ti,ab.
98. or/88-97
99. 14 or 57 or 73 or 87 or 98
100. exp Primary Health Care/
101. exp General Practitioners/
102. Family Physicians/
103. Family Medicine/
104. ((family or community) adj (medic$or doctor$or physician$or nurs$or health)).ti,ab.
105. ((general or family or nurs$) adj1 (practice$or practitioner$)).ti,ab.
106. (primary care or primary healthcare or primary health care or primary health service$or
homecare or care in the community).ti,ab.
107. (GP$or generalist$).ti,ab.
108. Occupational Health/
109. (occupational adj (health* or therap*)).ti,ab.
110. or/100–109
111. 99 and 110
Search fiilters
l To retrieve systematic reviews: The University of Texas School of Public Health. Search Filters for
Various Databases: Ovid PsycINFO (Systematic reviews and meta-analyses). URL: http://libguides.sph.uth.
tmc.edu/search_filters/ovid_psycinfo_filters (accessed 7 April 2017).
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l To retrieve RCTs: The University of Texas School of Public Health. Search Filters for Various
Databases: Ovid PsycINFO (Clinical trials). URL: http://libguides.sph.uth.tmc.edu/search_filters/
ovid_psycinfo_filters (accessed 7 April 2017).
l To retrieve economic evaluations: Centre for Reviews and Dissemination (CRD), The University of York.
Search strategies: NHS EED. URL: www.crd.york.ac.uk/crdweb/searchstrategies.asp#nhseedpsycinfo
(accessed 7 April 2017).
l To retrieve qualitative research: The University of Texas School of Public Health. Search Filters for
Various Databases: Ovid PsycINFO (Qualitative studies). URL: http://libguides.sph.uth.tmc.edu/search_
filters/ovid_psycinfo_filters (accessed 7 April 2017) combined with (AND) terms to identify UK
studies: (Britain or british or wales or welsh or Scottish or scots or Scotland or England or English
or Birmingham or leeds or London or Liverpool or Manchester or Glasgow or Edinburgh or Cardiff
or Belfast or UK or GB or aberdeen).ti,ab,in,hw.
The Cochrane Library (DARE, CDSR, CENTRAL, HTA, NHS EED)
1. medically unexplained symptom*:ti or medically unexplained symptom*:ab
2. MUS:ti or MUS:ab
3. medically unexplained physical symptom*:ti or medically unexplained physical symptom*:ab
4. MUPS:ti or MUPS:ab
5. (unexplain* near/1 medical*):ti or (unexplain* near/1 medical*):ab
6. (unexplain* near/1 (sympt* or problem* or condition* or complain*)):ti or (unexplain* near/1
(sympt* or problem* or condition* or complain*))
7. ((non specific or nonspecific) near/2 (sympt* or problem* or condition* or complain*)):ti or
((non specific or nonspecific) near/2 (sympt* or problem* or condition* or complain*)):ab
8. ((unexplain* or inexpl*) and (health* or medical* or physical*) and (sympt* or problem* or
condition* or complain*)):ti or ((unexplain* or inexpl*) and (health* or medical* or physical*) and
(sympt* or problem* or condition* or complain*)):ab
9. unexplained physical symptom*:ti or unexplained physical symptom*:ab
10. (Persistent near/2 physical symptom*):ti or (Persistent near/2 physical symptom*):ab
11. distress syndrome:ti or distress syndrome:ab
12. polydistress disorder:ti or polydistress disorder:ab
13. medically unexplained syndrome*:ti or medically unexplained syndrome*:ab
14. 56-#13
15. (functional near/2 (disorder* or syndrome* or symptom* or pain*)):ti or (functional near/2
(disorder* or syndrome* or symptom* or pain*)):ab
16. MeSH descriptor: [Fibromyalgia] explode all trees
17. fibromyalgi*:ti or fibromyalgi*:ab
18. MeSH descriptor: [Fatigue Syndrome, Chronic] explode all trees
19. CFS:ti or CFS:ab
20. (chronic fatigue near/3 (syndrome* or disorder*)):ti or (chronic fatigue near/3 (syndrome* or
disorder*)):ab
21. myalgic encephalomyelitis:ti or myalgic encephalomyelitis:ab
22. fatigue syndrome:ti or fatigue syndrome:ab
23. MeSH descriptor: [Colonic Diseases, Functional] explode all trees
24. MeSH descriptor: [Irritable Bowel Syndrome] explode all trees
25. irritable bowel syndrome*:ti or irritable bowel syndrome*:ab
26. IBS:ti or IBS:ab
27. MeSH descriptor: [Temporomandibular Joint Dysfunction Syndrome] explode all trees
28. ((temporomandibular joint or TMJ) near/2 (disease* or disorder* or dysfunction*)):ti or
((temporomandibular joint or TMJ) near/2 (disease* or disorder* or dysfunction*)):ab
29. MeSH descriptor: [Myofascial Pain Syndromes] explode all trees
30. myofascial pain disorder*:ti or myofascial pain disorder*:ab
31. MeSH descriptor: [Facial Neuralgia] explode all trees
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32. atypical facial pain:ti or atypical facial pain:ab
33. facial pain syndrome*:ti or facial pain syndrome*:ab
34. MeSH descriptor: [Hyperventilation] explode all trees
35. hyperventilation:ti or hyperventilation:ab
36. dysfunctional breathing:ti or dysfunctional breathing:ab
37. loin pain h?ematuria syndrome*:ti or loin pain h?ematuria syndrome*:ab
38. MeSH descriptor: [Muscle Weakness] explode all trees
39. functional weakness*:ti or functional weakness*:ab
40. MeSH descriptor: [Movement Disorders] this term only
41. movement disorder*:ti or movement disorder*:ab
42. (non-epileptic next (attack* or seizure*)):ti or (non-epileptic next (attack* or seizure*)):ab
43. MeSH descriptor: [Dysmenorrhea] explode all trees
44. dysmenorrhoea:ti or dysmenorrhoea:ab
45. neurasthen*:ti or neurasthen*:ab
46. MeSH descriptor: [Neurasthenia] explode all trees
47. MeSH descriptor: [Multiple Chemical Sensitivity] explode all trees
48. multiple chemical sensitivity:ti or multiple chemical sensitivity:ab
49. idiopathic environmental intolerance:ti or idiopathic environmental intolerance:ab
50. MeSH descriptor: [Tension-Type Headache] explode all trees
51. ((tension type or idiopathic or psychogenic) near/2 headache*):ti or ((tension type or idiopathic or
psychogenic) near/2 headache*):ab
52. MeSH descriptor: [Neurocirculatory Asthenia] explode all trees
53. MeSH descriptor: [Asthenia] explode all trees
54. chronic asthenia:ti or chronic asthenia:ab
55. functional atrial arrhythmia:ti or functional atrial arrhythmia:ab
56. Da Costa’s Syndrome:ti or Da Costa’s Syndrome:ab
57. effort syndrome:ti or effort syndrome:ab
58. functional cardiovascular disease*:ti or functional cardiovascular disease*:ab
59. subacute asthenia:ti or subacute asthenia:ab
60. functional disturbance*:ti or functional disturbance*:ab
61. (symptom next syndrome*):ti or (symptom next syndrome*):ab
62. MeSH descriptor: [Post-Concussion Syndrome] explode all trees
63. (post concussi* syndrome* or post-concussi* syndrome*):ti or (post concussi* syndrome* or
post-concussi* syndrome*):ab
64. {or #15-#63}
65. MeSH descriptor: [Psychophysiologic Disorders] explode all trees
66. ((psychosomatic or pyschophysiologic) next (disorder* or syndrome* or symptom*)):ti or
((psychosomatic or pyschophysiologic) next (disorder* or syndrome* or symptom*)):ab
67. briquet syndrome*:ti or briquet syndrome*:ab
68. MeSH descriptor: [Psychosomatic Medicine] explode all trees
69. psychophysiologic*:ti or psychophysiologic*:ab
70. psychosomat*:ti or psychosomat*:ab
71. psychogen*:ti or psychogen*:ab
72. MeSH descriptor: [Somatoform Disorders] explode all trees
73. somatic symptom*:ti or somatic symptom*:ab
74. Somatoform Disorder*:ti or Somatoform Disorder*:ab
75. somati?at*:ti or somati?at*:ab
76. (somatic near/2 syndrome*):ti or (somatic near/2 syndrome*):ab
77. MeSH descriptor: [Conversion Disorder] explode all trees
78. conversion disorder*:ti or conversion disorder*:ab
79. subjective health complaint*:ti or subjective health complaint*:ab
80. cardiac neurosis:ti or cardiac neurosis:ab
81. {or #65-#80}
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82. MeSH descriptor: [Habits] this term only
83. MeSH descriptor: [Tics] explode all trees
84. MeSH descriptor: [Tic Disorders] explode all trees
85. {or #82-#84}
86. MeSH descriptor: [Cough] this term only
87. #85 and #86
88. (chronic near/2 cough):ti or (chronic near/2 cough):ab
89. (habit cough or tic cough):ti or (habit cough or tic cough):ab
90. chronic pelvic pain*:ti or chronic pelvic pain*:ab
91. chronic widespread pain:ti or chronic widespread pain:ab
92. ((non cardiac or noncardiac or non specific or nonspecific) near/2 chest pain*):ti or ((non cardiac
or noncardiac or non specific or nonspecific) near/2 chest pain*):ab
93. NCCP:ti or NCCP:ab
94. atypical chest pain*:ti or atypical chest pain*:ab
95. MeSH descriptor: [Low Back Pain] this term only
96. chronic low back pain*:ti or chronic low back pain*:ab
97. MeSH descriptor: [Chronic Pain] this term only
98. (chronic near/2 pain):ti or (chronic near/2 pain):ab
99. regional pain:ti or regional pain:ab
100. ((non ulcer or nonulcer or non-ulcer or functional) near/2 dyspepsia):ti ((non ulcer or nonulcer or
non-ulcer or functional) near/2 dyspepsia):ab
101. {or #87-#100}
102. MeSH descriptor: [Sexual Dysfunctions, Psychological] this term only
103. (psychological near/2 sexual dysfunction*):ti or (psychological near/2 sexual dysfunction*):ab
104. MeSH descriptor: [Vaginismus] explode all trees
105. vaginismus:ti or vaginismus:ab
106. psycho-sexual dysfunction*:ti or psycho-sexual dysfunction*:ab
107. psychosexual dysfunction*:ti or psychosexual dysfunction*:ab
108. MeSH descriptor: [Erectile Dysfunction] this term only
109. (impotence or erectile dysfunction):ti or (impotence or erectile dysfunction):ab
110. MeSH descriptor: [Vulvodynia] explode all trees
111. vulvodynia:ti or vulvodynia:ab
112. anorgasmia:ti or anorgasmia:ab
113. [or #102-#112]
114. #14 or #64 or #81 or #101 or #113
115. MeSH descriptor: [Primary Health Care] explode all trees
116. MeSH descriptor: [Family Practice] explode all trees
117. MeSH descriptor: [General Practice] explode all trees
118. MeSH descriptor: [Physicians, Family] explode all trees
119. FAMILY HEALTHCARE
120. MeSH descriptor: [Nurse Practitioners] explode all trees
121. ((family or community) next (medic* or doctor* or physician* or nurs* or health)):ti or ((family or
community) next (medic* or doctor* or physician* or nurs* or health)):ab
122. ((general or family or nurs*) next/1 (practice* or practitioner*)):ti or ((general or family or nurs*)
next/1 (practice* or practitioner*)):ab
123. (primary care or primary healthcare or primary health care or primary health service* or
homecare or care in the community):ti or (primary care or primary healthcare or primary health
care or primary health service* or homecare or care in the community):ab
124. (GP* or generalist*):ti or (GP* or generalist*):ab
125. MeSH descriptor: [Occupational Health] explode all trees
126. (occupational next (health* or therap*)):ti or (occupational next (health* or therap*)):ab
127. [or #115-#126]
128. and #127
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Search filters
No search filters were applied to the Cochrane Library searches.
Science Citation Index and Social Sciences Citation Index (via Web of Science)
1. TOPIC: (((medically unexplained symptom* or MUS or medically unexplained physical symptom*
or MUPS)))
2. TOPIC: ((unexplain*) NEAR/1 (medical* or sympt* or problem* or condition* or complain*))
3. TOPIC: (((non-specific or nonspecific) NEAR/2 (sympt* or problem* or condition* or complain*)))
4. TOPIC: ((unexplain* or inexpl*) and (health* or medical* or physical*) and (sympt* or problem* or
condition* or complain*))
5. TOPIC: ((unexplained physical symptom* or (persistent NEAR/2 symptom*) or distress syndrome or
polydistress disorder or medically unexplained syndrome*))
6. TOPIC: ((functional) NEAR/2 (disorder* or syndrome* or symptom* or pain*))
7. TOPIC: ((fibromyalgi* or CFS or (fatigue NEAR/3 syndrome* or disorder*) or myalgic
encephalomyelitis or irritable bowel syndrome* or IBS))
8. TOPIC: ((temporomandibular or TMJ) NEAR/2 (disease* or disorder* or dysfunction*))
9. TOPIC: ((myofascial pain disorder* or atypical facial pain or facial pain syndrome* or
hyperventilation or dysfunctional breathing or loin pain h?ematuria syndrome* or functional
weakness* or movement disorder*))
10. TOPIC: ((non-epileptic NEAR attack* or seizure*) or (dysmenorrhoea or neurasthen* or multiple
chemical sensitivity or idiopathic environmental intolerance))
11. TOPIC: ((tension or idiopathic or psychogenic) NEAR/2 (headache*))
12. TOPIC: ((chronic asthenia or functional atrial arrhythmia or da costa’s syndrome or effort
syndrome or functional cardiovascular disease* or subacute asthenia or functional disturbance* or
(symptom NEAR syndrome*)))
13. TOPIC: ((post concussi* syndrome* or post-concussi* syndrome*))
14. TOPIC: ((psychosomatic or pyschophysiologic) NEAR/2 (disorder* or syndrome* or symptom*))
15. TOPIC: ((briquet syndrome* or pyschophysiologic* or psychosomatic* or psychogen* or somatic
symptom* or somati?at*))
16. TOPIC: (((somatic NEAR/2 syndrome*) or (conversion disorder* or subjective health complaint* or
cardiac neurosis)))
17. TOPIC: ((chronic NEAR/2 cough) or (habit cough or tic cough or chronic pelvic pain* or chronic
widespread pain))
18. TOPIC: ((non-cardiac or noncardiac or non-specific or nonspecific) NEAR/2 (chest NEAR pain*))
19. TOPIC: (NCCP or atypical chest pain* or chronic low back pain* or (chronic NEAR/2 pain) or
regional pain)
20. TOPIC: ((non-ulcer or nonulcer or functional) NEAR/2 dyspepsia)
21. TOPIC: ((pyschological NEAR/2 sexual NEAR dysfunction*) or vaginismus or psycho-sexual
dysfunction* or pyschosexual dysfunction* or impotence or erectile dysfunction or vulvodynia
or anorgasmia)
22. #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10
OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
23. TOPIC: ((family or community) NEAR (medic* or doctor* or physician* or nurs* or health))
24. TOPIC: ((general or family or nurs*) NEAR/1 (practice* or practitioner*))
25. TOPIC: ((primary care or primary healthcare or primary health care or primary health service* or
homecare or care in the community))
26. TOPIC: (GP or GPs or generalist*)
27. TOPIC: (((occupational) NEAR (health* or therap*)))
28. #27 OR #26 OR #25 OR #24 OR #23
29. #28 AND #22
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Search filters
Methodological search filters are not available for Web of Science; therefore, the following terms were
combined with the above search strategy using the operator “AND” to identify the specific study types.
l To retrieve systematic reviews: TI = ((meta analy* or metaanaly* or systematic review*))
l To retrieve RCTs: TI = (clinical trial* or random* control* trial* or RCT*)
l To retrieve economic evaluations: TI = ((cost benefit analys* OR health care costs)) OR (budget*) OR
((economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*
or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or
finance or finances or financed)) OR ((value NEAR/2 (money or monetary))) OR ((decision* NEAR/2
(tree* or analy* or model*)))
l To retrieve qualitative research: TOPIC = ((((“semi-structured” or semistructured or unstructured or
informal or “in-depth” or indepth or “face-to-face” or structured or guide) NEAR/3 (interview* or
discussion* or questionnaire*))) or (focus group* or qualitative or ethnograph* or fieldwork or “field
work” or “key informant”))] combined with (AND) terms to identify UK studies: TOPIC = ((Britain or
british or wales or welsh or Scottish or scots or Scotland or England or English or Birmingham or
leeds or London or Liverpool or Manchester or Glasgow or Edinburgh or Cardiff or Belfast or UK or
GB or aberdeen)).
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Appendix 2 Summary characteristics of
included studies
T ables 28–35 show the diagnostic criteria used for individual studies, by condition.
TABLE 28 Interventions as described in individual studies with current review intervention grouping
First author and
year of publication Condition Intervention Intervention description Grouping
Aiarzaguena, 2007136 MUS/somatoform Psychosocial
intervention
1. To explain symptoms to the
patient in a physical and
tangible manner as a result
of a hormonal imbalance
2. To explore psychosocial
aspects through an
indirect approach
3. To attribute hormone release
to irrational thoughts
GP – reattribution
(modified)
Goldberg reattribution
technique
Active control. GPs were
trained to emphasise a link
between symptoms and
emotions based on Goldberg’s
reattribution technique
GP – reattribution
Alda, 2011137 Pain – multisite
(fibromyalgia)
CBT Cognitive restructuring, which
focuses on reducing pain-
specific dysfunctional cognitions
(primarily PC), and coping,
which focuses on teaching
cognitive and behavioural
coping strategies
CBTHI
Recommended
pharmacological
treatment
Treatment with pregabalin
(300–600mg per day) and
duloxetine (60–120 mg per day)
was administered to patients
with major depressive disorder
ME
GP treatment as usual Control group. However, the
treatment recommended in the
guide that they received matched
that of the recommended
pharmacological intervention
UC
Burton, 2012157 MUS/somatoform Primary care
symptoms clinic
Structured set of consultations
with a specially trained GP with
specialist interest in MUS. GP
explores acceptable explanation
for symptoms in terms of
biological mechanisms rather
than psychological cause
GP-MM
Usual care Usual primary care alone UC
continued
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Chalder, 1997114 Chronic fatigue Self-help intervention A booklet suggesting that
fatigue may be associated
both with doing too much
and with doing too little,
and the emphasis being on
achieving a balance between
the two. A section on how to
improve sleep. Basic cognitive
techniques such as identifying
and challenging unhelpful
thoughts
GSH
No treatment Control group UC
Cuesta-Vargas,
2012118
Pain – single site
(back)
DWR plus general
practice
During DWR axial compression
on the lumbar spine is
minimised compared with
exercising on a motor-driven
treadmill or shallow-water
running. DWR guarantees
predominantly aerobic exercise
while at the same time
improving mobility, strength and
MUS/somatoform endurance
associated with reduced pain
and physical disability
MM (sport +
Education)
General practice Booklet and verbal presentation GSH
Escobar, 2007156 MUS/somatoform CBT-type intervention
plus a consultation
letter
Time-limited CBT-type
intervention expressly designed
for patients with somatisation
problems. The intervention
focuses on the reduction of
physical distress and somatic
preoccupation through training
in relaxation techniques, activity
regulation, facilitation of
emotional awareness, cognitive
restructuring and interpersonal
communication
CBTHI
Usual clinical care
from their PCP plus a
consultation letter
(control condition)
Control group UC+ (letter)
Friedberg, 2013151 Chronic fatigue Fatigue self-
management
Based on cognitive–behavioural
treatment programme
CBTLI
Attention control To control for therapist
attention, homework
assignments, and other
non-specific effects
RSSE
Usual care Control condition UC
Gili 2014/Moreno,
2013144,148
MUS/somatoform Individual CBT The CBT intervention is
structured as follows:
l Session 1: the connection
between stress and pain
l Session 2: identification of
automated thoughts
l Session 3: evaluation of
automated thoughts
CBTHI
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
l Session 4: questioning the
automatic thoughts and
constructing alternatives
l Session 5: nuclear beliefs
l Session 6: nuclear beliefs
on pain
l Session 7: changing coping
mechanisms
l Session 8: coping with
ruminations, obsessions
and worrying
l Session 9: expressive writing
l Session 10: assertive
communication
Group CBT Identical to intervention 1 in a
group format
CBTHI
GP usual care improved
with Smith’s norms
Control group UC+ (letter)
Ho, 2012150 Chronic fatigue Qigong training Education and exercise.
Introduction to the basic
theories of traditional Chinese
medicine or educational session
on the physiology of mind–body
connections (30–40 minutes),
followed by mindful meditation
for relaxation and mind
concentration and then gentle
movement or body stretching in
standing postures to facilitate a
harmonious flow of qi along the
energy channels (20 minutes).
Followed by 1 hour’s qigong
exercise
RSSE
Waiting list control Control condition. Participants
assigned to the control group
were advised to undertake
normal activities but were asked
to refrain from joining any
outside qigong training class
UC
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue CBT The goals of the intervention
were to diminish fatigue and
other complaints, establish
work resumption and other
personal goals, and to establish
self-perceived recovery
GP-CBT
GP usual care Control group UC
Kashner, 1995161 MUS/somatoform
disorder
Group therapy Develop a source of peer
support, share methods of
coping with physical problems,
enable patients to increase their
ability to perceive and express
emotion, and enjoy the
experience of participating in
the group
RSSE
Psychiatric
consultation letter
Control group – standard
consultation liaison
UC+ (letter)
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Kennedy, 2005129 IBS CBT plus 270mg
of mebeverine × 3
per day
Based on Lang’s three systems
model (which explains how
cognitive, behavioural and
emotional or physiological
responses are linked and how
changes in one system may
cause a change in another).
Therapy included education
about the nature of IBS,
behavioural techniques aimed
at improving bowel habits,
cognitive techniques to address
unhelpful thoughts related to
the syndrome, and techniques
to reduce symptom focusing,
manage stress and prevent
relapse
MM (CBTLI+ME)
270mg of
mebeverine × 3
per day
Control group ME
Kobeissi, 2012110 MUS/somatoform
(MUVD)
Relaxation exercise
and social support
(RESST trial)
Psychosocial component
(social support, problem-solving
and venting) and relaxation
exercises (including visual
guided imagery exercises,
stretching and progressive
MUS/somatoform relaxation).
Aims to reduce the burden of
MUVD by focusing on common
mental disorders
RSSE
Usual care, treat later Control group. Offered
treatment after intervention
completed
UC
Kocken, 2008103 MUS/somatoform Counselling,
information transfer
and facilitation of
communication
between GP and
patient by migrant
health educator
Counselling with help from the
migrant health educator. The
intervention protocol comprised
the following phases of patient
support:
1. clarification of physical and
psychological complaints to
the patient
2. clearly formulating the
request for help and
optimising communication
between patient and GP
3. providing information to
increase the patient’s ability
to restore balance in
stressors and coping in
personal life in eight sessions
of group education
4. conclusion and evaluation
OP
Usual care (GP
without help of
migrant health
educator)
Control group UC
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Kolk, 2004104 MUS/somatoform Psychological
intervention
Depending on the therapist
orientation a cognitive–
behavioural, client-centred or
eclectic therapy was provided,
thereby reflecting usual
treatment practice
OP
Usual care Control group, usual care with
no psychological therapy
element
UC
Lansinger, 2007123 Pain single site
(neck)
Qigong Qigong was performed
according to medical qigong and
was conducted in groups of
10–15 participants. Each qigong
session started with information
about the philosophy of medical
qigong, followed by selected
qigong exercises according to
the Biyun method
RSSE
Exercise therapy Exercise therapy was performed
according to an individually
adjusted training programme.
The resistance was between
30% and 70% of a person’s
maximal voluntary capacity,
and for each exercise between
one and three sets of 10 to
30 repetitions were performed.
The amount of resistance and
the number of repetitions started
at a pain-free level and were
gradually increased throughout
the treatment period
SES
Larisch, 2004158 MUS/somatoform PPC and reattribution Whether additional training in
reattribution could improve the
treatment results of somatising
patients compared with PPC
alone
GP – reattribution
Usual care (PPC) Control group (PPC alone) UC
LeFort, 1998128 Pain multisite
(mixed)
Community-based
psychoeducation
programme for the
self-management of
chronic pain
Designed to maximise discussion
and group problem-solving,
encourage individual participation
and experimentation with various
cognitive/behavioural
self-management techniques, and
facilitate mutual support
GSH
Waiting list 3-month waiting list control
group
UC
Loew, 2000122 Pain single site
(headache)
Elements of functional
relaxation and usual
treatment with
analgesics
Concentration of body
perception while moving the
joints of the skeleton smoothly
and simultaneously breathing out
RSSE
Alternative
intervention technique
and usual treatment
with analgesics
Control RSSE
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Luciano, 2011139 Pain multisite
(fibromyalgia)
Psychoeducational
programme plus
usual care
Based on education about the
illness and autogenic relaxation
training. The educative part of
the programme (five sessions)
included information about
typical symptoms, usual course,
comorbid medical conditions,
potential causes of the illness,
the influence of psychosocial
factors on pain, current
pharmacological and non-
pharmacological treatments, the
benefits of regular exercise, and
the typical barriers to behaviour
change. The autogenic training
(four sessions), especially
recommended for immediate
physical and mental relaxation,
pain relief and stress reduction
MM (GSH+ RSSE)
Usual care Control group UC
Luciano, 2014138 Pain multisite
(fibromyalgia)
Group ACT Specific exercises and topics
with the ACT practice and
training including mindfulness
practice
CBTHI
Recommended
pharmaceutical
therapy
30–600mg per day of
pregabalin. Those with
depression also received
60–120mg per day of
duloxetine
ME
Waiting list Control group. No active
treatment
UC
Macedo, 2012119 Pain single site
(back)
CBT-based GA Based on the treatment
programme reported by
Lindström et al.379 A primary
goal of the programme was
to increase activity tolerance
by performing individualised
and submaximal exercises, in
addition to ignoring illness
behaviours and reinforcing
wellness behaviours.
Cognitive–behavioural principles
were used to help the
participants overcome the
natural anxiety associated
with pain and activities
GA
Motor control
exercises
Based on the treatment
programme reported by
Hodges and Richardson.380
A primary goal was to enable
the patient to regain control
and co-ordination of the spine
and pelvis using principles
of motor learning such as
segmentation and simplification.
Based on assessment of the
individual participant’s motor
control impairments and
treatment goals
GA
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Margalit, 2008268 MUS/somatoform Short-term family
therapy in ambulatory
care
Advice and recommendations
about lifestyle changes (e.g.
tobacco use, body weight,
relaxation techniques and
exercise), basic psychotherapy
(i.e. awareness of defence
mechanisms and empathy),
patient empowerment in self-
monitoring of medical regimens
(e.g. diabetes, blood pressure),
involvement of the family and, if
appropriate, further diagnostic
tests, consultations and change
in medication. The intervention
tools consisted of various
therapeutic methods (CBT,
hypnosis, family/systems
therapy, etc.) in a ‘tailor-made’
manner
OP
Usual care NR UC
Marques, 2015133 Chronic fatigue 4-STEPS to control
your fatigue
A brief SR-based intervention
to promote physical activity
in chronic fatigue patients.
Structured around the SR
phases of goal pursuit (goal
selection and setting, active goal
pursuit and goal attainment,
maintenance and
disengagement)
GA
Enhanced standard
care
Control group. In addition to
standard medical care, patients
assigned to the control
condition received a flyer with
information about the general
health benefits of physical
activity and current physical
activity guidelines for adults and
set a personal physical activity
goal for the upcoming months
GSH
Martin, 200799 MUS/somatoform CBT With only one treatment session
and the recruitment of subjects
from primary care practices,
the treatment was tailored to
the needs of primary care
management of somatisation.
Psychophysiological explanation
of symptoms, relaxation, the
importance of cognitions,
activity instead of avoidance
behaviours, treatment options
and health-care utilisation
CBTLI
Waiting list Control group UC
McBeth, 2012125/
Beasley, 2015126
Pain multisite
(widespread)
Telephone CBT Therapists conducted a patient-
centred assessment, developed
a shared understanding and
formulation of the current
problem, and identified two or
three patient-defined goals.
CBTHI
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Patients received a self-
management CBT manual:
Managing Chronic Widespread
Pain
Exercise Leisure facility- and gym-based
exercise programme consistent
with the American College of
Sport Medicine’s guidelines for
improving cardiorespiratory
fitness
SES
Combined Telephone CBT and exercise
protocols as above
MM
Treatment as usual Usual care from their family
physician
UC
McLeod, 1997105 MUS/somatoform Ways to wellness
(behavioural medicine
intervention)
A general behavioural medicine
intervention developed to
address the needs of primary
care patients with un diagnosable
complaints related to mood
OP
Waiting list for
2 months, then
received behavioural
intervention treatment
Control group UC
Morriss, 2007108 MUS/somatoform Reattribution Feeling understood: elicit
physical symptoms, psychosocial
problems, mood state, beliefs
held by patient about their
problem, relevant physical
examination and investigations.
Broadening the agenda.
Summarise physical and
psychosocial findings. Negotiate
these findings with patient.
Making the link: give
explanation relating physical
symptom to psychosocial
problems of lifestyle because
of link in time or physiology.
Negotiating further treatment:
arrange follow-up or treatment
of symptoms, psychosocial
problems or mental disorder
GP – reattribution
Treatment as usual Control group UC
Moss-Morris,
2005152
Chronic fatigue GET The rationale behind the graded
exercise programme was
explained using an adapted
version of the cognitive–
behavioural model of CFS.
The model focused on the
downwards spiral of activity
reduction, physical
deconditioning and symptoms
GA
Standard care Control group. Standard medical
care from their CFS specialist
UC
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Moss-Morris,
2010130
IBS Cognitive–behavioural
self-management
programme plus
treatment as usual
Focuses on changing cognitive
and behavioural responses to
IBS symptoms, reducing stress
and anxiety levels, and altering
unhelpful beliefs associated with
perfectionism
CBTLI
Treatment as usual Control group UC
Peters, 2002106 MUS/somatoform Group aerobic
exercise
Exercise presented as a way of
keeping the body conditioned
so better able to cope with the
strains put on it by everyday life
SES
Stretching Active control group consisting
of group activity, contact with
therapist and mastery of
physical skills
RSSE
Pols, 2008145 MUS/somatoform Co-ordinated care Patient self-management, using a
patient-derived ‘problems and
goals approach’ integrated with
medical and community care.
Patients’ services and medication
use were monitored, with
associated Medicare Benefits
Scheme and Pharmaceutical
Benefits Scheme information
being fed back to GPs on a
monthly basis on CD-ROM.
Active listening, examination
of the affected part being
complained of, reassurance that
no further investigations or
referrals were required, and
positive encouragement for living
effectively despite ongoing
symptoms
MM (self-
management +
medication +CBT)
Standard treatment Control group UC
Posse, 200496 MUS/somatoform Jungian psychotherapy
and usual care
Non-verbal communication in
the form of dreams, pictures,
myths and fairy tales. These
approaches can be the link to
the verbally non-communicating
alexithymic patient’s world and
psyche
OP
Usual care and
waiting list
Control UC
Ridsdale, 2001112 Chronic fatigue CBT Based on a model of
understanding fatigue that
makes a distinction between
precipitating and perpetuating
factors. Perpetuating factors
were the focus of the
intervention
CBTHI
Counselling Active control group OP
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Ridsdale, 2004113 Chronic fatigue CBT Based on a model that
distinguishes between
precipitating and perpetuating
factors, with the perpetuating
factors becoming the focus of
the intervention
CBTLI
GET GET is structured and
supervised activity management
that aims for a gradual but
progressive increase in aerobic
activities, usually walking
GA
Ridsdale, 2012115 Chronic fatigue GET Supervised exercise, adapted to
each patient’s current physical
capacity, that is gradually
increasing in duration according
to a protocol designed for
patients with CFS
GA
Counselling Rogerian client-centred
counselling. Non-directive
format that encouraged the
patient to talk through
difficulties, and reflect on their
experiences and thoughts so as
to understand themselves
better, to arrive at alternative
understandings, to uncover the
links between current distress
and past experience, and to
provide the conditions for
growth and healing
OP
Usual care with CBT
booklet
Control group received usual
care treatment from their family
doctors. To encourage practice
and patient participation, this
was coupled with a booklet
describing causes of fatigue and
providing self-help techniques
based on CBT principles
GSH
Rief, 2006102 MUS/somatoform MUS management
training package
for GPs
‘The Training Package: How
to Manage Patients With
Unexplained Physical Symptoms’.
Information on the diagnosis of
somatoform disorders, anxiety
disorders and depression was
provided.Topics included how to
communicate with these patients,
when to start and when to stop
medical examinations, how to
handle the organic health beliefs
of the patients, their need for
reassurance, and their avoidance
of physical activity
GP-MM
No training package Control group UC
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Robinson, 2006131 IBS Self-help guidebook
plus group meetings
Focus group meetings with other
IBS patients who described the
information they required to help
them cope with their symptoms
better. The guidebook contained
information about lifestyle, diet,
and pharmacological and
alternative therapies, and was
based on up-to-date evidence
and patients’ own anecdotal
experiences
GSH
Self-guidebook plus
one group meeting
The guidebook plus a one-off
self-help group meeting (8–12
patients). Patients shared their
experiences of living with their
functional bowel symptoms and
described approaches that
helped them to manage their
illness
MM (RSSE +GSH)
Usual care Control group UC
Rosendal, 2007146 MUS/somatoform The extended
reattribution and
management model
Intervention comprised a
multifaceted educational
programme on the assessment,
treatment and management of
MUPS (the TERM model)
GP – MUS
management
Control FPs were
only informed about
the definitions of
somatisation in writing
and during meetings
with the project leader
Control group UC
Rothman, 2013127 Pain multisite Multimodal
assessment and
reattribution/
rehabilitation
MM assessment followed
principles for MM teamwork
according to the Swedish
Guidelines for rehabilitation
complemented with the concepts
of motivational interviewing and
psychosomatic integrated
assessment.381 Avoidance of
arguing with the patient about
the causes of pain and instead try
to understand and encourage
patient’s own reflections
concerning factors that might
influence their perceptions and
experiences of pain. MM
treatment reflected patients’
own preferences and could be
multidisciplinary group therapy,
individual multidisciplinary
therapy or referral back for
conventional treatment
GP –
multidisciplinary
assessment +
motivational
interview +
psychotherapy
continued
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Conventional
assessment and
multidisciplinary pain
management or
unidisciplinary
treatment from the
GP or associated staff
Assessment followed
conventional, actual applied
medical principles for patients
with chronic pain. GP
determined how the continuing
investigation should be
performed. Treatment options
were conventional
multidisciplinary pain
management or unidisciplinary
treatment from the GP or
associated staff. Addressed
physical symptoms, function
and/or psychosocial problems
and could include pain
management, treatment by a
physiotherapist or psychologist,
or medical treatment by the GP
UC+
(multidisciplinary
assessment +
choice of
treatment)
Ryan, 2004109 MUS/somatoform
(mixed)
Biofeedback,
progressive relaxation
training, breathing
retraining, problem-
solving
Aimed at cultivated low arousal
in general and thus used
traditional modalities such as
finger temperature training and
forehead EMG. Heart rate
variability feedback was also
used as a core technique for all
of the protocols
OP
No treatment Control group UC
Sañudo, 2010140 Pain – multisite
(fibromyalgia)
Aerobic exercise Slow walks, easy movements of
progressive intensity. Including
continuous walking with arm
movements and jogging; interval
training
SES
Combined exercise Combined aerobic exercise and
resistance exercise, MUS/
somatoform strengthening
exercises, flexibility exercises
SES
Usual care Control group, continued their
normal daily activities during
the intervention period, which
did not include structured
exercise
UC
Schade, 2011272 MUS/somatoform BFI BFI was designed by the two
authors as a new way of
implementing family counselling
with somatoform patients. BFI
integrates the main concepts of
brief systemic therapy into a
broader, co-operation-based
approach adapted to the
Chilean social and cultural
environment. The goal of BFI is
that patients activate their
personal and interpersonal
resources to handle and
improve their problems and
function autonomously again
OP
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Treatment as usual.
Varying mixture of
interventions, from
direct advice giving
to Rogerian active
listening, history
taking, and home visits
Control group UC
Schaefert, 2013147 MUS/somatoform Collaborative group
intervention
Psychodynamically based
therapy embedding
cognitive–behavioural elements
into the framework. Aimed to
empower interpersonal factors
through group work and build
strong therapeutic relationships
between group members. Build
understanding of interaction
between biopsychosocial illness
factors, physical and mental
stabilisation, and strengthening
self-functioning
MM (GP –MUS
Management+OP)
GP training in
diagnosis and
management of
MUS/somatoform
Control group, aimed at building
a sustainable working alliance
between patient and GP
GP – MUS
management
Schilte, 2001159 MUS/somatoform Usual care + disclosure
intervention
Use of emotional expression
techniques. The disclosure
doctor asked open questions
about family life, health, work
situation and childhood.
Evocative interview style, using
non-directive consultation
techniques, such as open
questions, reflection of
emotions, inquiry on vague
or unclear statements, and
summarising. The disclosure
doctor showed sincere interest
in the patient’s story
GP – OP
Usual care An extra control group to test
for contamination of the effect
of the trial as a whole. No
intervention (data not
presented)
N/A
Usual care Control group UC
Smith, 1995100
(Linked to Kashner,
1995161)
MUS/somatoform Psychiatric
consultation
intervention
Psychiatric letter told the
physician that the patient met
criteria for somatisation
syndrome. Recommended
regularly scheduled brief
appointments with the PCP
for the patient, and to avoid
as-needed appointments. Avoid
hospitalisation, diagnostic
procedures, surgery and
laboratory evaluations unless
clearly indicated. Physician
encouraged not to tell the
patient that the disorder was
UC+
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
‘all in your head’ but was
instead encouraged to view the
development of symptoms as an
unconscious process
Usual care Control group UC
Smith, 2006107 MUS/somatoform A behaviourally
defined patient-
centred intervention
A behaviourally defined, five-
step patient-centred method to
establish a positive patient–
provider relationship and
communicate effectively and
a three-step patient-centred
method to inform and motivate
patients specifically about
treatment. NPs used a
collaborative stepped-care
method. Treatment included
antidepressants, reduction/
elimination of controlled
substance medications that
were ineffective, exercise,
relaxation training, physical
therapy and comorbid organic
disease management
MM
Usual care Control group UC
Smith, 2009142 MUS/somatoform Primary care
management
CBT in the context of a
behaviourally defined, evidence-
based patient-centred method to
maximise communication and the
provider–patient relationship.
See Smith et al.107 – delivered for
this study by PCPs not NPs
MM (GP-CBT+
medication)
Usual care Control group UC
Sumathipala, 2000116 MUS/somatoform CBT The intervention aimed to
‘contain’ the patient at the level
of detection in primary care, by
offering structured regular visits
to one professional carer,
thereby hoping to reduce
unstructured visits to different
practitioners and co-ordinating
the care. The treatment was
based on the principles of CBT,
using modifications of that
described by Salkovoskis et al.382
and Sharpe et al.234 and
Goldberg et al.’s45 reattribution
technique
CBTLI
Standard clinical care Control group UC
Sumathipala, 2008117 MUS/somatoform CBT Intervention aimed to contain
the patient’s help-seeking
behaviour by offering structured
regular visits to one HP.
Treatment based on principles of
CBT and reattribution technique
MM (GP-MM+
CBTLI)
Structured care Active control. The same as
intervention apart from no
CBT component
GP-MM
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Toft, 201097 MUS/somatoform TERM model Treatment model developed
for GPs and based on both the
original reattribution model
and principles from cognitive
therapy, called TERM model. The
model provides GPs with both
theoretical knowledge about
FSSs and the practical skills
necessary for the assessment and
treatment of functional somatic
symptoms (MUS) patients
GP-MM
UC Control group UC
Tummers, 2012149 Chronic fatigue Minimal guided
self-instruction
intervention
Based on the protocol of
CBT for CFS. Precipitating
(triggering) and perpetuating
(maintaining) factors are
explained and individualised.
Fatigue-related cognitions
are challenged and patients
encouraged to develop a sense
of control over their symptoms.
Patients learn to reduce the
focus on fatigue and gradually
increase their physical activity
CBTLI
Waiting list control Control group UC
van der Feltz-
Cornelis, 2006160
MUS/somatoform Collaborative care
model
Consultation with a psychiatrist
plus MUS management based
on techniques by Gask et al.383 –
CBT techniques based on
reattribution
MM
(reattribution +
collaborative care)
Training in MUS case
management
MUS management based on
techniques by Gask et al.383 –
CBT techniques based on
reattribution
GP reattribution
van der Roer,
2008120
Pain – single site
(back)
Intensive group
training
Combines exercise therapy,
back school and behavioural
principles. Operant-conditioning
behavioural principles based on
baseline functional capacity
MM (sport +
education +
behavioural
programme)
Guideline
physiotherapy
Physiotherapy SES
van Ravesteijn,
2013143
MUS/somatoform MBCT Based on MBCT format for
depression. Formal meditation
exercises such as body
scan, sitting meditation and
mindful movement. Cultivate
awareness of everyday
activities. Cognitive techniques,
such as psychoeducation,
monitoring and scheduling of
activities, identification of
negative automatic thoughts
and relapse prevention planning
OP
Enhanced usual care Control group. Offered MBCT
after treatment phase of trial
complete
UC+
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Walti, 2015121 Pain – single site
(back)
MM treatment MM treatment includes:
1. neurophysiological education
on the perception of pain
to decrease self-limitation
because of catastrophising
beliefs about the nature
of NSCLBP
2. sensory training of the lower
trunk because these patients
predominantly show poor
sensory acuity of the trunk
3. motor training to regain
definite movement control of
the trunk
MM (education+
sport + sensory
discrimination)
Usual physiotherapy
treatment
Control SES
Wearden, 2010111 Chronic fatigue Pragmatic
rehabilitation
A programme of graded
return to activity is designed
collaboratively by the patient
and the therapist on the basis of
a physiological dysregulation
model of CFS/myalgic
encephalomyelitis
GA
Supportive listening A listening therapy based on
non-directive counselling in
which the therapist aims to
provide an empathic and
validating environment in which
the patient can discuss his or
her concerns and work towards
resolution of whichever
problems the patient wishes
to prioritise
OP
GP care as usual GPs were asked to manage
their cases as they saw fit, but
not to refer for systematic
psychological therapies for
CFS/myalgic encephalomyelitis
during the 18-week treatment
period
UC
Whitehead, 2002154 Chronic fatigue Management package
for GPs
Management package to train
GPs in the diagnosis and
management of CFS. To provide
GPs with the skills necessary to
make a diagnosis of CFS and to
manage patients with CFS in
primary care
GP-MM
Usual care GPs encouraged to treat
patients as usual, which
included referrals to
secondary care
UC
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TABLE 28 Interventions as described in individual studies with current review intervention grouping (continued )
First author and
year of publication Condition Intervention Intervention description Grouping
Zonneveld, 2012141 MUS/somatoform CBT CBT based on the consequences
model. Psychological and social
factors that are commonly
labelled as causes, are labelled
as consequences of UPS. The
objective of the consequences
model is to alleviate symptoms.
The model was tailored to
primary care patients
CBTHI
Waiting list Control group UC
BFI, brief family intervention; CD-ROM, compact disc read-only memory; DWR, deep-water running; EMG,
electromyography; FP, family practitioner; GP-CBT, GP-delivered cognitive–behavioural therapy; GP-reattribution,
GP-delivered reattribution therapy; GPMM, GP-delivered MUS management; GP –MUS, GP-delivered MUS management;
GSH, guided self-help; MBCT, mindfulness-based cognitive therapy; ME, medication; MM, multimodal; MUVD, medically
unexplained vaginal discharge; N/A, not applicable; NP, nurse practitioner; NR, not reported; NSCLBP, non-specific chronic
lower back pain; OP, other psychotherapy; PC, pain catastrophising; PPC, psychosocial primary care; SR, self-regulation;
TERM,The Extended Reattribution and Management; UC, usual care; UC+, usual care plus.
TABLE 29 MUS/somatoform disorder
First author and year
of publication Condition Diagnostic criteria Diagnosis by
Aiarzaguena, 2007136 MUS/somatoform Abridged somatisation disorder (Escobar
et al.98) – lifetime six or more medically
unexplained symptoms for females, four or
more for males, including one in the past year
GP
Burton, 2012157 MUS/somatoform A score of ≥ 10 on the PHQ-14 GPs
Escobar, 2007156 MUS/somatoform Abridged somatisation disorder (Escobar et al.98)
– lifetime six or more MUS for females, four or
more for males, including one in the past year
PCP and psychologists
Gili, 2014/Moreno,
2013144,148
MUS/somatoform Abridged somatisation disorder (Escobar et al.98) GPs and researchers
Kashner, 1995161 MUS/somatoform Somatisation disorder meeting DSM-III-R
criteria
Research psychiatrist
Kocken, 2008103 MUS/somatoform Symptoms rated by GPs as psychosomatic
in origin
GPs
Kolk, 2004104 MUS/somatoform GP confirmed medically unexplained nature of
patient symptoms
GP and researchers
Larisch, 2004158 MUS/somatoform Four somatoform symptoms for men or six for
women, GHQ cut-off point of 2 +. Screen
positive on SOMS-2 and GHQ-12
GPs and researchers
Margalit, 2008268 MUS/somatoform Highest costing patients with no apparent
reason or diagnosis for high annual cost of care
Community clinic data
Martin, 200799 MUS/somatoform Two or more MUS within past 6 months GP and researchers
McCleod, 1997105 MUS/somatoform PCPs had recognised that emotional status may
have been related to their patients’ symptoms
PCPs
Morriss, 2007108 MUS/somatoform > 3 months’ physical symptoms not explained
by physical pathology
GP and independent
GP
Peters, 2002106 MUS/somatoform Duration of unexplained complaints of at least
12 months and unexplained after specialist
investigation
GP and researchers
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TABLE 29 MUS/somatoform disorder (continued )
First author and year
of publication Condition Diagnostic criteria Diagnosis by
Pols, 2008145 MUS/somatoform Diagnosis of somatisation including
unexplained physical symptoms as part of
anxiety, chronic benign pain or somatoform
disorder. Checked by CIDI interview against
ICD-10 criteria
GP and researchers
Rief, 2006102 MUS/somatoform Multiple unexplained symptoms GP and researchers
Rosendal, 2007146 MUS/somatoform Positive score on SCL-SOM orWhiteley Index-7.
Cut-off points of 3/4 for SCL-SOM and of 1/2 for
Whiteley Index-7
Family physicians
Schade, 2011272 MUS/somatoform Diagnosis of somatoform disorder, diagnostic
criteria no described
NR
Schaefert, 2013147 MUS/somatoform At least mild somatic severity on PHQ-15,
represented by a cut-off point of 5; or relevant
health anxiety on Whitely Index-7
GP and consultation
with psychosomatic
specialist if necessary
Schilte, 2001159 MUS/somatoform 15 contacts or more with the doctor in the
past 3 years, plus five or more somatisation
symptoms (Somatisation Questionnaire, based
on DSM-III-R)
NR
Smith, 1995100 MUS/somatoform Lifetime history of 6–12 unexplained medical
symptoms. Meeting DSM-III-R diagnostic
criteria for somatisation disorder
Research psychiatrist
Smith, 2006107 MUS/somatoform Having no documented organic disease to
explain symptoms of at least 6 months’ duration
Research team
Smith, 2009142 MUS/somatoform At least 8 yearly visits for 2 previous years.
ICD-9 diagnosis codes suggesting MUS used to
identify patients
Research team
Sumathipala, 2000116 MUS/somatoform Five or more symptoms meeting the definition
of unexplained
PCP and research
team
Sumathipala, 2008117 MUS/somatoform Five or more symptoms meeting the definition
of unexplained during past 6 months
Trial physician
Toft, 201097 MUS/somatoform Functional somatic/MUS. Scoring ≥ 2 on
dichotomised Whiteley Index-7, SCL-8 or
CAGE,384 or ≥ 4 on dichotomised SCL-SOM
identified by SCAN interview. Three groups:
1. meeting ICD-10 criteria for SD
2. subgroup of SD patients with
somatisation disorder
3. ≥ 2 incapacitating FSSs but not meeting
ICD-10 criteria for SD
GP and psychiatrist
van der Feltz-Cornelis,
2006160
MUS/somatoform Serious persistent MUS: Symptoms remain
unexplained after specialist diagnostic examination
and continuing patient requests for further
diagnostic testing. Meeting ICD-10 somatoform
disorder criteria and Whiteley Index threshold
GP
van Ravesteijn, 2013143 MUS/somatoform Physical symptoms for at least 6 months
not fully explained by a physical disease or
substance abuse. Symptoms causing functional
impairment. Confirmed with MINI interview
and somatoform disorders section on DSM-IV
structured clinical interview
GP and trainee
psychiatrist
Zonneveld, 2012141 MUS/somatoform Undifferentiated somatoform disorder or
chronic pain disorder according to DSM-IV
GP and researchers
CIDI, composite international diagnostic interview; MINI, mini international neuropsychiatric interview;
SCAN, schedules of clinical assessment in neuropsychiatry.
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TABLE 30 MUS/somatoform disorder: single MUS
First author and
year of publication Condition Diagnostic criteria Diagnosis by
Kobeissi, 2012110 MUVD Symptom-reporting questionnaire, laboratory tests,
physical examination
Gynaecologists
MUVD, medically unexplained vaginal discharge.
TABLE 31 MUS/somatoform disorder: mixed MUS
First author and
year of publication Condition Diagnostic criteria Diagnosis by
Ryan, 2004109 Mixed
functional
disorders
Any functional disorder: IBS, fibromyalgia, CFS,
myofascial pain, anxiety with somatic features, or
non-cardiac chest pain. Confirmed no underlying
organic cause of pain
Physician and
research team
TABLE 32 Chronic fatigue
First author and
year of publication Condition Diagnostic/inclusion criteria Diagnosis by
Chalder, 1997114 Chronic fatigue Chronic fatigue, scoring ≥ 4 on the Chalder Fatigue
Scale.385 Not CFS
GP and research
nurse
Friedberg, 2013151 Chronic fatigue US CDC criteria for CFS6 PCP and researcher
Ho, 2012150 Chronic fatigue US CDC criteria for CFS6 NR
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue A score of 35 or more on the fatigue subscale of
the Dutch Checklist Individual Strength
Researcher
Marques, 2015133 Chronic fatigue CDC criteria for idiopathic chronic fatigue6 Researcher
Moss-Morris, 2005152 Chronic fatigue US CDC criteria for CFS6 Specialist GP
Ridsdale, 2001112 Chronic fatigue US CDC criteria for CFS6 or Chalder Fatigue Scale
score of ≥ 4385
Researcher
Ridsdale, 2004113 Chronic fatigue > 3 months unexplained fatigue. Met either US
CDC criteria for CFS6 or Chalder Fatigue Scale
score of ≥ 4385
Researcher
Ridsdale, 2012115 Chronic fatigue > 3 months’ fatigue. Excluded if scored < 4 on the
Chalder Fatigue Scale385
GP
Tummers, 2012149 Chronic fatigue US CDC criteria for CFS6 GP and research team
and psychiatric nurse
Wearden, 2010111 Chronic fatigue Oxford criteria for CFS/ME (Chalder Fatigue Scale) GP and research team
Whitehead, 2002154 Chronic fatigue US CDC criteria for CFS6 GP
ME, myalgic encephalomyelitis.
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TABLE 33 Chronic pain: single site
First author and
year of publication Condition Diagnostic criteria Diagnosis by
Cuesta-Vargas,
2012118
Back pain > 3 months’ non-specific chronic low back pain
without radiation to lower limbs
GP
Lansinger, 2007123 Neck pain > 3 months’ non-specific chronic neck pain Physiotherapist
Loew, 2000122 Headache Subgroup 2 but not 3–13 of IHS criteria.
Pain > 1 year. Exclusion of organic disease
NR
Macedo, 2012119 Back pain Chronic non-specific low back pain > 3 months’
duration, with or without leg pain
NR
van der Roer, 2008120 Back pain Non-specific chronic low back pain Physiotherapist
Walti, 2015121 Back pain Non-specific chronic low back pain NR
IHS, International Headache Society; NR, not reported.
TABLE 34 Chronic pain: multisite
First author and
year of publication Condition Diagnostic criteria Diagnosis by
LeFort, 1998128 Mixed chronic
pain
Chronic idiopathic pain lasting longer than expected
healing time (> 3–6 months)386
HPs and researchers
Rothman, 2013127 Mixed chronic
pain
Pain classified into chronic generalised or chronic
regional pain according to ACR. Organic
explanations for pain ruled out
GP
McBeth, 2012125 Mixed chronic
pain
Chronic widespread pain, classified according to the
definition used in the ACR criteria for fibromyalgia
Research nurse
TABLE 35 Chronic pain: multisite – fibromyalgia
First author and
year of publication Condition Diagnostic criteria Diagnosis by
Alda, 2011137 Fibromyalgia 1990 ACR diagnostic criteria for fibromyalgia124 Primary care doctors
Luciano, 2011139 Fibromyalgia 1990 ACR diagnostic criteria for fibromyalgia124 GP and
rheumatologist
Luciano, 2014138 Fibromyalgia 1990 ACR diagnostic criteria for fibromyalgia124 Rheumatologists, GPs
and researcher
Sañudo, 2010140 Fibromyalgia 1990 ACR diagnostic criteria for fibromyalgia124 NR
NR, not reported.
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TABLE 36 Irritable bowel syndrome
First author and
year of publication Condition
Diagnostic criteria/inclusion
criteria Diagnosis by
Kennedy, 2005129 IBS Rome I diagnostic criteria387 GP and research nurse
Moss-Morris, 2010130 IBS Rome I or Rome II diagnostic
criteria387
GP
Robinson, 2006131 IBS Functional gastrointestinal symptoms
diagnosed as IBS, but not necessarily
fulfilling Rome II criteria387
GP or specialist
TABLE 37 Primary and secondary outcomes as reported in individual studies
First author and
year of publication Condition Primary outcomes Secondary outcomes
Aiarzaguena, 2007136 MUS/somatoform HRQoL – Medical Outcomes Study –
36-item (SF-36)388
Symptoms – number of active
explained and unexplained symptoms
in the past year reported at CIDI
interview389
Mental disorders – primary care
evaluation of mental disorders390
Stressful life events391
Negative affect – negative
affectivity scale392
Alda, 2011137 Chronic pain –
multisite
(fibromyalgia)
Pain catastrophisation – Pain
Catastrophisation Scale (Spanish
version393)
Depression – HAM-D394
Anxiety – HAM-A395
Pain – VAS396
Global function – Fibromyalgia
Impact Scale397
Quality of life – EQ-5D (Spanish
version398)
Burton, 2012157 MUS/somatoform Acceptability – Client Satisfaction Questionnaire; Physical Symptoms –
PHQ-14;9 health status (Medical Outcomes Short Form (SF-12); depression –
PHQ-9;399 anxiety – General Anxiety Disorder 7 Questionnaire;400 and
patient global impression of change
Chalder, 1997114 Chronic fatigue Psychiatric morbidity – Revised
Clinical Interview Scale401
Fatigue – The Fatigue Scale
(11-item)385
HRQoL – GHQ 12402
Physical functioning –Medical
Outcome Study physical
functioning subscale403
Cuesta-Vargas,
2012118
Chronic pain –
single site
(back pain)
Pain – 100-mm VAS;404 Disability – RMDQ (Spanish version;405 General Health,
physical and mental – SF-12 (Spanish version, adapted from SF-36 for people
with back pain406)
continued
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TABLE 37 Primary and secondary outcomes as reported in individual studies (continued )
First author and
year of publication Condition Primary outcomes Secondary outcomes
Escobar, 2007156 MUS/somatoform
disorder
Global rating of severity of symptoms
– Clinical Global Impressions Scale
(study specific)
Physical functioning – Medical
Outcomes Study (MOS-10)407
Anxiety – HAM-A395
Depression – HAM-D394
Symptoms – Severity of Current
Symptoms 0–100 VAS
Severity of somatic complaints –
PHQ-15399
Friedberg, 2013151 Chronic fatigue Fatigue – Fatigue Severity Scale Physical function – SF-36 physical
function subscale
Depression – BDI – second edition408
Anxiety – BAI
Activities, symptoms and stress
ratings – web diary
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform
disorder
Somatic symptoms – SOMS;10 Severity of somatic symptoms –VAS;409
Psychiatric morbidity – SPPI;410 Anxiety – HAM-A;395 and depression –
Hamilton Depression Rating Scale;394 HRQoL– SF-36411
Ho, 2012150 Chronic fatigue Fatigue – Chalder’s Fatigue Scale (14-item385); physical and mental
functioning – SF-12 (Chinese version412) and telomerase activity – TeloTAGG
telomerase PCR ELISA (F. Hoffman-La Roche Ltd, Basel, Switzerland)
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue Fatigue – fatigue subscale of
the CIS413
Absenteeism – self-reported work-
resumption/number of sick days
Clinical recovery – CIS score of
≤ 34 and return to work
Global perceived effect –
7-point scale414
Physical functioning – SF-36411
Psychological distress – Symptom
Checklist 90415
Kashner, 1995161 MUS/somatoform
disorder
Health status – RAND;416 and health-care utilisation – medical and
billing records
Kennedy, 2005129 IBS Symptom severity –
IBS Severity Score417
Anxiety and Depression – Hospital
Anxiety and Depression Scale418
Impact – Work and Social
Adjustment Scale162
Kobeissi, 2012110 MUVD MUVD – one item Common Mental Disorder –
Hopkins Symptom Checklist 25419
Somatisation – Scale for Assessment
of Somatic Symptoms
Kocken, 2008103 MUS/somatoform
disorder
Perceived stressful situations – 14 items adapted from biographical problem
inventory list (BIOPRO);420 social support – Social Support List;421 general
health – SF-36 (Dutch version422); Perceived pain – SF-36 (Dutch version422);
and mental health – SCL-90 psychological discomfort415
Kolk, 2004104 MUS/somatoform
disorder
MUPS – Symptom Checklist 90 Somatisation Scale psychological symptoms –
Symptom Checklist 90 Anxiety and Depression;423 registered unexplained
symptoms; GP consultations; tendency to selective attention to the body –
The Somatic Awareness Questionnaire;424 tendency to somatic and
psychological attribution – Symptom Interpretation Questionnaire;425
and negative affectivity – Positive and Negative Affectivity Scale426
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TABLE 37 Primary and secondary outcomes as reported in individual studies (continued )
First author and
year of publication Condition Primary outcomes Secondary outcomes
Lansinger, 2007123 Chronic pain –
single site
(neck pain)
Pain intensity – VAS; pain over 1 week – pain diary; disability –
Neck Disability Index;427 grip strength – Grippit; and cervical range of
motion – Myrin goniometer
Larisch, 2004158 MUS/somatoform
disorder
MUPS – SOMS-7;10 general health – GHQ;428 HRQoL – 12-item short form of
the SF-36;388 anxiety and depression – Hospital Anxiety and Depression
Scale;418 doctor visits; and medication use
LeFort, 1998128 Chronic pain Self-help – Inventory of Adult Role Behaviours;429 life satisfaction –
Satisfaction with Life Domains Scale;430 HRQoL – SF-36;388 pain quality –
The Pain Rating Index of the Short-Form McGill Pain Questionnaire;431
depression – BDI;432 perceived level of disability – disability subscale of the
Survey of Pain Attitudes;433 severity of pain – VAS; dependency – single item
100-mm VAS; Uncertainty – Mishel’s Uncertainty in Illness Scale;434 enabling
skill – Self-Efficacy Scale;435 and resourcefulness – 100-mm VAS version of
Self Control Schedule436
Loew, 2000122 Chronic pain –
single site
Pain – German Headache Diary (German version of ASTRA headache diary437)
Luciano, 2011139 Chronic pain –
multisite
(fibromyalgia)
Functional status – FIQ (Spanish version438); and anxiety – the State–Trait
Anxiety Inventory (Spanish version439)
Luciano, 2014138 Chronic pain –
multisite
(fibromyalgia)
Impact – FIQ397 Pain catastrophising – Pain
Catastrophisation Scale393
Anxiety – Hospital Anxiety and
Depression Scale418
Depression – Hospital Anxiety and
Depression Scale418
Chronic pain acceptance – Chronic
Pain Acceptance Questionnaire440
Pain – 100-mm VAS
HRQoL – EQ-5D398
Macedo, 2012119 Chronic pain –
single site
(back pain)
Pain intensity over past
week – 0–10 NRS441
Function – 0–10 Patient-Specific
Functional Scale442
Global impression of change –
Global Perceived Effect Scale442
Disability – RMDQ443
Quality of life – SF-36444
Recovery defined as a pain-free
period that lasted 1 month
Credibility of treatment445
Therapist ratings446
Adherence to home exercises
Margalit, 2008268 MUS/somatoform
disorder
Health-care utilisation with associated costs – medical records
continued
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TABLE 37 Primary and secondary outcomes as reported in individual studies (continued )
First author and
year of publication Condition Primary outcomes Secondary outcomes
Marques, 2015133 Chronic fatigue Fatigue severity – Checklist of Individual Strength (Portuguese version447);
fatigue impact – Brief Pain Inventory;448 physical activity – Short
Questionnaire to Assess Health-Enhancing Physical Activity449 plus
pedometer plus goal progress VAS; HRQoL – SF-12;450 somatic distress –
Patient Health Questionnaire-15;9 and psychological distress – Brief
Symptom Inventory Depression and Anxiety subscales451
Martin, 200799 MUS/somatoform
disorder
Health-care utilisation – structured
interview, patient-reported GP and
specialist visits
Somatoform symptoms – Brief
Symptom Inventory454 and SOMS-7455
Hypochondriacal anxiety and
concern – Whiteley Index452
Depression – BDI453
Health-related locus of control –
Self-Report Questionnaire456
McBeth, 2012125/
Beasley, 2015126
Chronic pain Clinical Global Impression Score –
change since entering trial
Fatigue Scale385
Vanderbildt Pain Management
Inventory457
GHQ
The Sleep Scale458
Tampa Scale for Kinesiophobia459
SF-36411
McLeod, 1997105 MUS/somatoform
disorder
Somatisation – Symptom Checklist-90 Revised;423 depression – Symptom
Checklist-90 Revised;423 and anxiety – Symptom Checklist-90 Revised423
Morriss, 2007108 MUS/somatoform
disorder
Overall proportion of GP
consultation that was consistent
with the Goldberg Reattribution
Model – audio-taped transcripts of
GP–patient consultations
Satisfaction with GP communication –
Patient Satisfaction Questionnaire460
Patient’s symptom beliefs – Revised
Illness Perception Questionnaire461
Anxiety – Hospital Anxiety Scale418
% caseness
Depression – Hospital Depression
Scale418 % caseness
Health anxiety – Whiteley Index462
Quality of Life – EQ-5D463
Prescriptions, investigations, health
contacts – patient records
Moss-Morris, 2005152 Chronic fatigue Global rating of improvement –
single item464
CFS-related impairment – The Fatigue
Scale (14-item385)
Physical functioning – physical
functioning subscale of SF-36
Physiological assessments
Illness beliefs – The Illness
Perception Questionnaire-Revised461
Symptom focusing – Illness
Management Questionnaire –
symptoms subscale465
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TABLE 37 Primary and secondary outcomes as reported in individual studies (continued )
First author and
year of publication Condition Primary outcomes Secondary outcomes
Moss-Morris, 2010130 IBS Subject’s Global Assessment
of Relief466
Irritable Bowel Severity
Scoring System417
Work and Social Adjustment Scale467
Hospital Anxiety and Depression
Scale418
Acceptability of treatment –
three questions
Engagement and adherence – quantity
of homework completed 0–10
Peters, 2002106 MUS/somatoform
disorder
Clinical data: symptoms (number and type), number of doctor consultations,
number of referrals to secondary care, number of prescriptions – medical
records/GP report; emotional state – Hospital Anxiety and Depression
scale;418 somatisation – Hopkins Symptom Checklist468 and Modified Somatic
Perception Questionnaire;469 and perceived disability – Health Outcomes
Questionnaire (SF-36)470
Pols, 2008145 MUS/somatoform
disorder
Depression – BDI, second edition;408 anxiety – State–Trait Anxiety
Inventory;439 hostility – Hostility and Direction of Hostility Questionnaire;471
and HRQoL – SF-36
Posse, 200496 MUS/somatoform
disorder
Somatisation – Patient Pain Drawing Test472 and Symptom List;473 alexithymia –
Schalling Sifneos Personality scale474 and personality traits – Karolinska Scale
of Personality475
Ridsdale, 2001112 Chronic fatigue Fatigue – The Fatigue Questionnaire (11-item385); Anxiety and Depression –
Hospital Anxiety and Depression Rating;418 attribution – attributions scale;476
social adjustment – MOS-SF;411 general health – MOS-SFGHS;411 and
satisfaction with therapy – 10-item questionnaires
Ridsdale, 2004113 Chronic fatigue Fatigue – The Fatigue Scale385 Anxiety and Depression – Hospital
Anxiety and Depression Scale418
Functional impairment – WASA
(cited as Ware et al.411)
Illness attributions –
attributions scale476
Step test
Ridsdale, 2012115 Chronic fatigue Fatigue – The Fatigue
Questionnaire385
Anxiety and Depression – Hospital
Anxiety and Depression Scale418
Functional impairment – Work and
Social Adjustment Scale (cited as
Ware et al.411)
Patient satisfaction with treatment –
seven-category questionnaire
HRQoL – EQ-5D477
Rief, 2006102 MUS/somatoform Health-care use, past 6 months –
structured interview and GP records
Symptoms – Screening for
Somatoform Disorders (SOMS)10
Health anxiety – Whiteley Index462
Depression – BDI453
Anxiety – BAI478
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TABLE 37 Primary and secondary outcomes as reported in individual studies (continued )
First author and
year of publication Condition Primary outcomes Secondary outcomes
Robinson, 2006131 IBS Number of primary care
consultations
Clinical Global Impression Score –
Severity and Improvement
Hospital consultation rates
Symptom severity417,479
Quality of life – IBS QOL480
Health status – GHQ-28;402
SF-36481
Rosendal, 2007146 MUS/somatoform
disorder
Quality of life – Medical Outcomes Study 36-Item Short-Form;482 disability
days – one item from WHO’s Disability Assessment Schedule (WHO-DAS);
illness worry and conviction – Whiteley Index-7;483 somatisation – Hopkins
Symptom Checklist (SCL-SOM);415 mental Illness – Hopkins Symptom
Checklist (SCL-8)415
Rothman, 2013127 Chronic pain Pain intensity during past week (VAS); Depression – Zung Self-Rating
Depression scale;484 Stress – The Stress and Crisis Inventory-93;485 quality of
life – SF-36, Swedish version;393 disability – ODI;486 work ability; and patient
satisfaction (study-specific questionnaire)
Ryan, 2004109 MUS/somatoform
disorder (mixed)
Specific referral symptoms – symptom log 1–10 scale; overall functioning –
quality of well-being measure;487 costs – medical records
Sañudo, 2010140 Chronic pain –
multisite
(fibromyalgia)
Impact – Fibromyalgia Impact Scale
(Spanish version438)
HRQoL – SF-36 (Spanish version488)
Depression – BDI489
Aerobic capacity – 6-minute walk test490
Hand grip strength – hand dynometer491
Range of motion – manual goniometer
Schade, 2011272 MUS/somatoform
disorder
Health-care visits – number of visits to the primary health-care team in
relation to psychosomatic complaints; medical tests – number of medical
analyses taken; and medications – number of prescribed medications taken
Schaefert, 2013147 MUS/somatoform
disorder
Quality of life – SF-36492 Somatic symptom severity – PHQ-15
somatic symptom severity scale493
Depressive symptoms – PHQ-9
depressive symptom severity scale493
Generalised anxiety – PHQ anxiety493
Panic – 5-item PHQ panic module494
Health anxiety – 7-item Whitely
Index483
Schilte, 2001159 MUS/somatoform
disorder
Use of medical services – number of GP and health-care professional visits;
subjective health – combined score of seven items of 0–100; sick leave –
weeks off in previous 6 months; severity of symptoms – Symptom checklist-
90 somatisation, depression, anxiety and agoraphobia subscales;423 quality of
life (patient rated) – 0–100 VAS; and somatisation (doctor rated) – five-point
Likert Scale495
Smith, 1995100 MUS/somatoform
disorder
Health status – RAND Health
Status Measures416
Days in bed during last month
Health-care utilisation – charges from
medical and billing records
Smith, 2006107 MUS/somatoform
disorder
HRQoL – SF-36;481 depression – Center for Epidemiological Studies Depression
Scale (CES-D);496 anxiety – Spielberger State Anxiety Scale (SSAS);439 and
antidepressant and controlled substance use – medical records
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TABLE 37 Primary and secondary outcomes as reported in individual studies (continued )
First author and
year of publication Condition Primary outcomes Secondary outcomes
Smith, 2009142 MUS/somatoform
disorder
HRQoL – SF-36;481 depression – Center for Epidemiological Studies
Depression Scale (CES-D);496 anxiety – Spielberger State Anxiety Scale
(SSAS);439 physical symptom evaluation – Patient Health Questionnaire-15;9
and satisfaction with the patient–provider relationship (SQ-1)497
Sumathipala, 2000116 MUS/somatoform
disorder
Level of distress/psychiatric morbidity – GHQ-30498 (Sri Lankan version499);
symptom score – Bradford Somatic Inventory;11 and satisfaction – VAS 0–5
(patient and carer reports); health-care visits – diary
Sumathipala, 2008117 MUS/somatoform
disorder
Psychological morbidity – GHQ-30498 Number of symptoms, patient-
reported – Bradford Somatic
Inventory11
Health-care visits (patient initiated)
Toft, 201097 MUS/somatoform
disorder
Physical functioning – SF-36
physical functioning subscale
Mental and social functioning,
perceived health, vitality and
pain – SF-36 subscales
Somatic symptoms – SCL-SOM
Health anxiety – Whitely-7 Index
Tummers, 2012149 Chronic fatigue Fatigue severity – CIS fatigue
severity subscale413
Disabilities – SF-36 physical
functioning and social functioning
subscales403
Psychological distress – Brief
Symptom Inventory (BSI)500
van der Feltz-
Cornelis, 2006160
MUS/somatoform Physical well-being – severity
and number of MUS501
Psychological symptoms –
Symptom Checklist-90-Revised503
General functioning – sickness
impact profile, household, work
and recreational activities and
social interaction subscales502
Health-care use – scale ‘Visits to
Doctors and Other Health Care
Professionals’504
van der Roer,
2008120
Chronic pain –
single site
(back pain)
Functional status – RMDQ443
Pain Intensity – 11-point NRS
Global Perceived Effect –
6-point scale
Work absenteeism – HLQ508
Fear of movement/reinjury –
17-item Tampa Scale505
Pain coping strategies –
Pain Coping Inventory506
Self-efficacy beliefs – Pain
Self-Efficacy Questionnaire507
van Ravesteijn,
2013143
MUS/somatoform
disorder
General Health Status –
EQ-5D VAS463
Mental and physical functioning –
Medical Outcomes Study 36-item
Short-Form (SF-36)519
Physical and mental symptoms –
Patient Health Questionnaire (PHQ)
scale for somatisation399
Depression – PHQ-9399
Health anxiety – Whiteley Index462
Mindfulness skills – Five-Facet
Mindfulness Questionnaire509
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TABLE 37 Primary and secondary outcomes as reported in individual studies (continued )
First author and
year of publication Condition Primary outcomes Secondary outcomes
Walti, 2015121 Chronic pain –
single site
(back pain)
Mean pain intensity over the
past 7 days – NRS 0–10
Disability – RMDQ443
Patient-specific disability – PSFS510
Fear avoidance beliefs – Fear
Avoidance Beliefs Questionnaire511
Catastrophising thoughts –
Pain Catastrophising Scale393
Movement control impairment –
six movement control tests
Sensory acuity of the lower back –
TPD threshold512
Sick leave during past 7 days
Analgesic intake past 7 days
Wearden, 2010111 Chronic fatigue Physical functioning – SF-36
physical functioning subscale411
Fatigue – Fatigue Scale (11-item)385
Anxiety and depression – Hospital
Anxiety and Depression Scales418
Sleep problems – Sleep Scale458
Costs
Whitehead, 2002154 Chronic fatigue Health status – London Handicap Scale;513 fatigue – The Fatigue Scale
(11-item);385 and, anxiety and depression – Hospital Anxiety and
Depression Scale418
Zonneveld, 2012141 MUS/somatoform
disorder
Functional health and well-being,
component summaries – Medical
Outcomes Short Form General
Health Survey (SF-36)388
Functional health and well-being,
individual scales – Medical Outcomes
Short Form General Health Survey
(SF-36)388
Psychological problems and
psychopathological symptoms –
Revised 90-Item Symptom
Checklist (SCL-90)514
CIDI, composite international diagnostic interview; MOS-SFGHS, medical outcomes survey – short form general
health survey.
Cells merged where outcomes not distinguished as primary or secondary in the original study report.
Scales are described as reported by the individual study authors.
References for scales are cited as reported by the individual study authors.
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TABLE 38 Key outcomes by individual study with measure used
First author and
year of publication Condition Pain Fatigue
Bowel
symptoms Somatisation
Generic
physical
symptoms
Emotional
distress Anxiety Depression
Physical
functioning Impact
Aiarzaguena, 2007136 MUS/somatoform SF-36 BP ✗ ✗ ✗ ✗ SF-36 MH ✗ ✗ SF-36 PF ✗
Alda, 2011137 Pain-MS (fibromyalgia) VAS ✗ ✗ ✗ ✗ ✗ HARS HAM-D ✗ FIQ total
Burton, 2012157 MUS/somatoform ✗ ✗ ✗ PHQ-14 ✗ SF-12-MCS GAD-7 PHQ-9 SF-12-PCS ✗
Chalder, 1997114 Chronic fatigue ✗ CFQ ✗ ✗ ✗ GHQ-12 ✗ ✗ SF-36 PF ✗
Cuesta-Vargas,
2012118
Pain-SS (back) VAS ✗ ✗ ✗ ✗ SF-12 – MH ✗ ✗ SF-12 PF 24-RMDQ
Escobar, 2007156 MUS/somatoform ✗ ✗ ✗ PHQ-15 Severity –
VAS
✗ HAM-A HAM-D MOS-10 PF ✗
Friedberg, 2013151 Chronic fatigue ✗ FSS ✗ ✗ ✗ ✗ BAI BDI SF-36 PF ✗
Gili, 2014/Moreno,
2013144,148
MUS/somatoform SF-36 BP ✗ ✗ SOMS ✗ SF-36 – MH HAM-A HAM-D SF-36 PF ✗
Ho, 2012150 Chronic fatigue ✗ CFQ ✗ ✗ ✗ SF-12 – MH ✗ ✗ SF-12 PF ✗
Huibers, 2004/Leone,
2006153,155
Chronic fatigue ✗ CIS ✗ ✗ ✗ SCL-90 ✗ ✗ SF-36 PF ✗
Kashner, 1995161 MUS/somatoform ✗ ✗ ✗ ✗ ✗ RAND – MH ✗ ✗ RAND – PF ✗
Kennedy, 2005129 IBS ✗ ✗ IBS-SSS ✗ ✗ HADS total HADS-Ab HADS-Db ✗ WASA – FI
Kobeissi, 2012110 MUVD ✗ ✗ ✗ SASS ✗ ✗ HSCL-25-A HSCL-25-D ✗ ✗
Kocken, 2008103 MUS/somatoform SF-36 1 item ✗ ✗ ✗ ✗ SCL-90 ✗ ✗ ✗ Restriction of
daily activities
Kolk, 2004104 MUS/somatoform ✗ ✗ ✗ SCL-90 Unexplained
symptoms
✗ SCL-90-A SCL-90-D ✗ ✗
Lansinger, 2007123 Pain-SS (neck) VAS ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ NDI
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TABLE 38 Key outcomes by individual study with measure used (continued )
First author and
year of publication Condition Pain Fatigue
Bowel
symptoms Somatisation
Generic
physical
symptoms
Emotional
distress Anxiety Depression
Physical
functioning Impact
Larisch, 2004158 MUS/somatoform ✗ ✗ ✗ SOMS-7 ✗ SF-12 MH HADS-A HADS-D SF-12 PF ✗
LeFort, 1998128 Pain-MS Pain severity
– VAS
✗ ✗ ✗ ✗ SF-36 MH ✗ BDI SF-36 PF SOPA-D
Loew, 2000122 Pain-SS Days ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Luciano, 2011139 Pain-MS (fibromyalgia) FIQ P FIQ GF ✗ ✗ ✗ ✗ FIQ-A FIQ-D FIQ PF FIQ total
Luciano, 2014138 Pain-MS (fibromyalgia) VAS ✗ ✗ ✗ ✗ ✗ HADS-A HADS-D ✗ FIQ total
Macedo, 2012119 Pain-SS (back) NRS ✗ ✗ ✗ ✗ SF-36 MH ✗ ✗ SF-36 PF RMDQ-24
Margalit, 2008268a MUS/somatoform ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Marques, 2015133 Chronic fatigue ✗ CIS20-P ✗ PHQ-15 ✗ SF-12 MH BSI-A BSI-D SF-12 PF ✗
Martin, 200799 MUS/somatoform ✗ ✗ ✗ SOMS-7 ✗ ✗ ✗ BDI ✗ ✗
McBeth, 2012125/
Beasley, 2015126
Pain-MS SF-36 BP CFQ ✗ ✗ ✗ SF-36 MH ✗ ✗ SF-36 PF ✗
McLeod, 1997105 MUS/somatoform ✗ ✗ ✗ SCL-90-R ✗ ✗ SCL-90-R A SCL-90-R D ✗ ✗
Morriss, 2007108 MUS/somatoform ✗ ✗ ✗ ✗ ✗ ✗ HADS-A HADS-D ✗ ✗
Moss-Morris,
2005152
Chronic fatigue ✗ CFQ ✗ ✗ ✗ ✗ ✗ ✗ SF-36 PF ✗
Moss-Morris,
2010130
IBS ✗ ✗ IBS-SSS ✗ ✗ ✗ HADS-A HADS-D ✗ WSAS
Peters, 2002106 MUS/somatoform SF-36 BP ✗ ✗ HSCL ✗ SF-36 MH HADS-A HADS-D SF-36 PF ✗
Pols, 2008145 MUS/somatoform SF-36 ✗ ✗ ✗ ✗ SF-36 MH STAI BDI-II SF-36 PF ✗
Posse, 200496 MUS/somatoform ✗ ✗ ✗ ✗ Symptom
list
✗ Somatic
anxiety
✗ ✗ ✗
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First author and
year of publication Condition Pain Fatigue
Bowel
symptoms Somatisation
Generic
physical
symptoms
Emotional
distress Anxiety Depression
Physical
functioning Impact
Ridsdale, 2001112 Chronic fatigue ✗ CFQ ✗ ✗ ✗ ✗ HADS-A HADS-D ✗ MOS-SF SA
Ridsdale, 2004113 Chronic fatigue ✗ CFQ ✗ ✗ ✗ ✗ HAD-A HAD-D ✗ WASA
Ridsdale, 2012115 Chronic fatigue ✗ CFQ ✗ ✗ ✗ ✗ HADS-A HADS-D ✗ WASA
Rief, 2006102 MUS/somatoform ✗ ✗ ✗ SOMS ✗ ✗ BAI BDI ✗ ✗
Robinson, 2006131 IBS ✗ ✗ CGIS ✗ ✗ SF-36 MH ✗ ✗ SF-36 PF ✗
Rosendal, 2007146 MUS/somatoform SF-36 BP ✗ ✗ SCL-90 ✗ SF-36 MH ✗ ✗ SF-36 PF WHO-DAS
Rothman, 2013127 Pain-MS VAS ✗ ✗ ✗ ✗ ✗ SCI-93 Zung SF-36 PF ODI
Ryan, 2004109 MUS/somatoform ✗ ✗ ✗ ✗ Symptom
log
✗ ✗ ✗ ✗ ✗
Sañudo, 2010140 Pain-MS (fibromyalgia) SF-36 Pain ✗ ✗ ✗ ✗ SF-36 MH ✗ BDI SF-36 PF FIQ Total
Schade, 2011272 MUS/somatoform ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Schaefert, 2013147 MUS/somatoform SF-36-Pain ✗ ✗ PHQ-15 ✗ SF-36 MH ✗ PHQ-9 SF-36 PF ✗
Schilte, 2001159 MUS/somatoform ✗ ✗ ✗ SCL-90 ✗ ✗ SCL-90-A SCL-90-D ✗ SCL-90 Total
Smith, 1995100 MUS/somatoform ✗ ✗ ✗ ✗ ✗ RAND MH ✗ ✗ RAND PF ✗
Smith, 2006107 MUS/somatoform ✗ ✗ ✗ PSC ✗ SF-36 MH SSAS CES-D SF-36 PF ✗
Smith, 2009142 MUS/somatoform SF-36 ✗ ✗ PHQ-15 ✗ SF-36 MH SSAS CES-D SF-36 PF ✗
Sumathipala, 2000116 MUS/somatoform ✗ ✗ ✗ Bradford
Somatic
Inventory
✗ GHQ-30 ✗ ✗ ✗ ✗
Sumathipala, 2008117 MUS/somatoform ✗ ✗ ✗ Bradford
Somatic
Inventory
✗ GHQ-30 ✗ ✗ ✗ ✗
Toft, 201097 MUS/somatoform ✗ ✗ ✗ SCL – SOM ✗ SF-36 MH ✗ ✗ SF-36 PF ✗
Tummers, 2012149 Chronic fatigue ✗ CIS ✗ ✗ ✗ ✗ Bradford
Somatic
Inventory
✗ SF-36 PF ✗
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TABLE 38 Key outcomes by individual study with measure used (continued )
First author and
year of publication Condition Pain Fatigue
Bowel
symptoms Somatisation
Generic
physical
symptoms
Emotional
distress Anxiety Depression
Physical
functioning Impact
van der Feltz-
Cornelis, 2006160
MUS/somatoform ✗ ✗ ✗ ✗ Speckens SIP P ✗ ✗ ✗ SIP total
van der Roer,
2008120
Pain-SS (back) NRS ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ RMDQ
van Ravesteijn,
2013143
MUS/somatoform SF-36 BP ✗ ✗ PHQ-15 ✗ SF-36 MH ✗ PHQ-9 SF-36 PF ✗
Walti, 2015121 Pain-SS (back) NRS ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ RMDQ
Wearden, 2010111 Chronic fatigue ✗ CFQ ✗ ✗ ✗ ✗ HADS-A HADS-D SF-36 PF ✗
Whitehead, 2002154 Chronic fatigue ✗ CFQ ✗ ✗ ✗ ✗ HADS HADS ✗ LHS
Zonneveld, 2012141 MUS/somatoform SF-36 BP ✗ ✗ SCL-90-R S ✗ SF-36 MH SCL-90-R-A SCL-90-R-D SF-36 PF SCL-90-R G
BSI, Brief Symptom Inventory; CES-D, Center for Epidemiological Studies Depression Scale; CFQ, Chalder Fatigue Questionnaire; CIS, Checklist of Individual Strength (P, Portuguese
version); FIQ, Fibromyalgia Impact Questionnaire (P, pain; GF, general fatigue; A, anxiety; D, depression; PF, physical functioning); GAD, general anxiety disorder; HADS, Hospital
Anxiety and Depression Scale; HAM-D, Hamilton Depression Scale; HARS, Hamilton Anxiety Rating Scale; HSCL, Hopkins Symptom Checklist; IBS-SSS, Irritable Bowel Questionnaire
Symptom Severity Scale; LHS, London Handicap Scale; pain-MS, pain multisite; pain-SS, pain single site; PHQ, Patient Health Questionnaire; SF-36/SF-12, Medical Outcomes Survey
Short Form (36/12 items) (MH, mental health subscale; PF, physical functioning subscale; BP, bodily pain subscale; P, psychological; A, anxiety; D, depression); SCI, Symptoms Clinic
Intervention; SSAS, Spielberger State Anxiety Scale; STAI, State–Trait Anxiety Inventory; VAS, visual analogue scale; WI, Whiteley Index.
a No key outcomes included (outcomes are health-care utilisation and costs only for Margalit and El-Ad268 and Schade et al.272).
b Baseline data only.
Note
Full details with references of scales used for individual studies are provided in Table 37.
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TABLE 39 Calculated and converted assessment time points for individual studies
First author and year
of publication Baseline
End of treatment
(duration, months)
Short term (time since
end of treatment, months)
Long term (time since end
of treatment, months)
Aiarzaguena, 2007136 Y 8 4
Alda, 2011137 Y 2.76 6
Burton, 2012157 Y 2.76b
Chalder, 1997114 Y 3b
Cuesta-Vargas, 2012118 Y 4 2 8
Escobar, 2007156 Y 3 6
Friedberg, 2013151 Y 3 12
Gili, 2014/
Moreno, 2013144,148
Y 2.3 12
Ho, 2012150 Y 1.15 2.85
aHuibers, 2004153 Y 4 12
Kashner, 1995161 N 4 8
Kennedy, 2005129 Y 1.38 3 12
Kobeissi, 2012110 Y 1.38 4.5
Kocken, 2008103 Y 12
Kolk, 2008104 Y 6 6
Lansinger, 2007123 Y 3 12
Larisch, 2004158 Y 3 3 9
LeFort, 1998128 Y 1.38
Loew, 2000122 Y 1.97
Luciano, 2011139 Y 2
Luciano, 2014138 Y 3 3
Macedo, 2012119 Y 2 4 10
Marques, 2015133 Y 2.76
Martin, 200799 Y 0.92 6
McBeth, 2012125/
Beasley, 2015126
Y 6 3
McLeod, 1997105 Y 1.6 6
Morriss, 2007108 Y 3
Moss-Morris, 2005152 Y 2.76 6
Moss-Morris, 2010130 Y 2 3 6
Peters, 2002106 Y 2.3 6
Pols, 2008145 Y 12
Posse, 200496 Y 6
Ridsdale, 2001112 Y 3 3
Ridsdale, 2004113 Y 3 2.5
Ridsdale, 2012115 Y 2 10
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TABLE 39 Calculated and converted assessment time points for individual studies (continued )
First author and year
of publication Baseline
End of treatment
(duration, months)
Short term (time since
end of treatment, months)
Long term (time since end
of treatment, months)
Rief, 2006102 Y 0.92b 6b
Robinson, 2006131 Y 12
Rosendal, 2007146 Y 3b 12b
Rothman, 2013127 Y 15
Ryan, 2004109 Y 15
Sañudo, 2010140 Y 5.52
Schaefert, 2013132 Y 3 9
Schilte, 2001159 Y 24
Smith, 1995100 Y 12b
Smith, 2006107 Y 12
Smith, 2009142 Y 12
Sumathipala, 2000116 Y 3
Sumathipala, 2008117 Y 3 3 9
Toft, 201097 Y 3b 24b
Tummers, 2012149 Y 6
van der Feltz-Cornelis,
2006160
Y 1.38b 6b
van der Roer, 2008120 Y 2.99 6 12
van Ravesteijn, 2013143 Y 3 9
Walti, 2015121 Y 0.92
Wearden, 2010111 Y 4.6 12
Whitehead, 2002154 Y 6b 12b
Zonneveld, 2012141 Y 2.99 12
a Leone et al.155 A 4-year follow-up is summarised in the narrative section only as 4 years was substantially longer
than any other follow-up period.
b Where treatment is one-off training or one session only, time is time since baseline.
Time points: baseline = baseline measurement yes/no; end of treatment: measurement taken directly at the end of
treatment (i.e. will correspond with duration of treatment); short term = time since end of treatment < 6 months.
Where not explicit, calculated by subtracting duration of treatment from baseline to short-term follow-up
measurement; long-term = time since end of treatment ≥ 6 months. Where not explicit, calculated by subtracting
duration of treatment from baseline to long-term follow-up measurement.
Months calculated by using 1 week = 0.230137 months conversion tool.
End-of-treatment time scale may be more than short- or long-term numbers where treatment duration was lengthy.
APPENDIX 2
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TABLE 40 Setting detail for individual studies
First author and year
of publication Condition Setting Setting: referral Setting: assessment Setting: intervention
Setting: outcome
assessment
Aiarzaguena, 2007136 MUS/somatoform Primary care Recruited by GP GP and home GP practices Home interview
Alda, 2011137 Pain–MS (fibromyalgia) Primary care Recruited by doctors working
in primary care
NR At the health centre Research team
Burton, 2012157 MUS/somatoform Primary care
specialist clinic
GP practices GPs and researcher At the treatment centre Researcher team
Chalder, 1997114 Chronic fatigue Primary care GP GP and research nurse Self-help booklet NR
Cuesta-Vargas, 2012118 Pain–SS (back) Adjunct to GP care PCPs Primary care practices Health centre In clinic
Escobar, 2007156 MUS/somatoform Primary care Eight physicians performed
the initial evaluations and
referred patients to the
research team
Research team Two university-based
primary care clinics
Research team
Friedberg, 2013151 Chronic fatigue Primary care and
home based
Stony Brook family medicine/
primary care practice
Stony Brook practice Guided sessions in primary
care setting, with home-
based self-management
Face-to-face follow-up
assessments
Moreno, 2013/Gili,
2014144,148
MUS/somatoform Primary care Primary health-care centres NR Primary care NR
Ho, 2012150 Chronic fatigue Community based Community recruitment Web-based screening Group and home based NR
Huibers, 2004/Leone,
2006153,155
Chronic fatigue Primary care Occupational health service Research centre GP practices but outside
normal hours
Research centre
Kashner, 1995161 MUS/somatoform Primary care PCPs Home based NR Home based
Kennedy, 2005129 IBS General practice GP GP/study nurse Not explicitly reported Not explicitly reported
Kobeissi, 2012110 MUS/somatoform Community based Schools, factories,
gynaecology clinics, satellite
networks
Research team Local facilities Research team
Kocken, 2008103 MUS/somatoform General practice Doctors’ practices NR General practices NR
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TABLE 40 Setting detail for individual studies (continued )
First author and year
of publication Condition Setting Setting: referral Setting: assessment Setting: intervention
Setting: outcome
assessment
Kolk, 2004104 MUS/somatoform NR Recruited via general
practices and advertisements
in local newspapers
Research team first and
then confirmed by GP
Therapist referred regularly
to the subject’s GP
Research team
Lansinger, 2007123 Pain–SS (neck) Primary care
physiotherapy
departments
Newspaper advertisements NR Physiotherapy departments
in primary care
NR
Larisch, 2004158 MUS/somatoform General practice GP GPs General practice NR
LeFort, 1998128 Pain–MS (mixed) Community based Referred from pain
clinic, community HP,
or self-referred
Research team A range of community
settings
Research team
Loew, 2000122 Pain–SS (headache) Primary care,
ambulatory private
practice
GP NR NR NR
Luciano, 2011139 Pain–MS (fibromyalgia) General practice GPs at these centres refer
those patients who are
suspected of having FM to
the Viladecans Hospital
Rheumatology Unit
Screened through an
initial telephonic
interview by
researchers
Three general practices NR
Luciano, 2014138 Pain–MS (fibromyalgia) Primary health-care
centres
Primary health-care centres GP Group sessions with
home-based tasks
NR
Macedo, 2012119 Pain–MS (back) Primary care Primary care, outpatient
clinic
NR Private clinical practices or
at the university clinic
Telephone
Margalit, 2008268 MUS/somatoform Primary care clinic Referred/offered the
treatment by their PCP
Research team A multidisciplinary primary
care clinic
Primary care clinic
Marques, 2015133 Chronic fatigue Four primary health-
care centres and
one private practice
Patients from the health-care
centres were referred by
their medical doctor
In the health-care
centre, inclusion and
exclusion criteria were
checked by the research
team using self-report
measures based on the
CDC criteria
Health-care institutions
(four public primary care
centres and one private
practice) and in the
Portuguese Fibromyalgia
and Chronic Fatigue
Syndrome Patient
Association
Not explicitly reported
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First author and year
of publication Condition Setting Setting: referral Setting: assessment Setting: intervention
Setting: outcome
assessment
Martin, 200799 MUS/somatoform Aim is to design
primary care
intervention
Recruited in primary care
practices
Research team An outpatient treatment
centre with GP support
Four trained and
supervised research
assistants
McBeth, 2012125/
Beasley, 2015126
Pain–MS (widespread) Home-based/
community settings
to primary care
patients
Primary care patients from
general practices
Research team
telephone interview or
postal questionnaire
Telephone delivered or
leisure centre/gym based
Research team
telephone interview or
postal questionnaire
McLeod, 1997105 MUS/somatoform Primary care as
adjunctive
treatment
Large health maintenance
organisation
Primary care Primary care NR
Morriss, 2007108 MUS/somatoform Primary care Recruited by a researcher in
a surgery waiting room
NR GP practices NR
Moss-Morris, 2005152 Chronic fatigue Mainly home-based
intervention with
general practice
consultation
Recruited from a specialist
CFS private general practice
Assessed by the
specialist GP
Mostly home-based
exercises with some
face-to-face contact
with researchers
Not explicitly reported
Moss-Morris, 2010130 IBS Primary care and
home based
Referred from previous
IBS trial
Assessment by GP Home based Research team
Peters, 2002106 MUS/somatoform Primary care Referred by GP Research team University gymnasium and
home based
Primary care
Pols, 2008145 MUS/somatoform Primary care Recruited by participating
GPs
GPs and research team GP practices Service co-ordinators
Posse, 200496 MUS/somatoform Primary care Primary care NR NR NR
Ridsdale, 2001112 Chronic fatigue Primary care 10 general practices
collaborated in recruiting
patients to the trial
Assessment of the
patients was undertaken
at their doctor’s
practice by one of the
authors
Not explicitly reported Questionnaire given to
patient by therapist at
the end of treatment,
follow-up questionnaire
by post
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TABLE 40 Setting detail for individual studies (continued )
First author and year
of publication Condition Setting Setting: referral Setting: assessment Setting: intervention
Setting: outcome
assessment
Ridsdale, 2004113 Chronic fatigue Primary care Recruited from 22 general
practices
NR Treatment was offered on
the premises of each
patient’s doctor in primary
care. Homework exercises
NR
Ridsdale, 2012115 Chronic fatigue Primary care and
home based
Recruited from general
practices
GP assessed patients for
eligibility and referred
to researcher
Face-to-face sessions at
their local primary care
practice with homework
Follow-up
questionnaires sent by
post and analysed by
researchers
Rief, 2006102 MUS/somatoform Primary care GP practices Research team GP practices Telephone – research
team
Robinson, 2006131 IBS Primary care and
home based
Primary care centres GP and research team Self-help booklet or
self-help book plus group
meeting
NR
Rosendal, 2007146 MUS/somatoform Primary care Primary care Waiting room Routine practice Postal questionnaires
Rothman, 2013127 Pain–MS Psychosomatic clinic Referral from GP NR Psychosomatic clinic or GP NR
Ryan, 2004109 MUS/somatoform HMOs Recruited from a local HMO Research team Within a HMO medical
group, only sites that
hosted family and internal
medicine specialists
Research team
Sañudo, 2010140 Fibromyalgia Unclear Recruited from physician
practices and local FMS
support groups
Research team Unclear Research team
Schade, 2011272 MUS/somatoform Family health
centres. These
centres are in
charge of primary
health care
Primary care NR Family counselling
implemented in primary
care
N/A
Schaefert, 2013147 MUS/somatoform GP practices Recruited by GPs in
consultation with
psychosomatic specialist
when necessary
Specifically trained GP GP practices
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First author and year
of publication Condition Setting Setting: referral Setting: assessment Setting: intervention
Setting: outcome
assessment
Schilte, 2001159 MUS/somatoform Patient’s home and
primary care
Postal questionnaire NR GP practice and patient’s
home for disclosure
intervention
NR
Smith, 1995100 MUS/somatoform Primary care PCPs Home-based by
research team
Primary care practice Home based by
research team
Smith, 2006107 MUS/somatoform Primary care Primary care chart review Chart rater in primary
care
HMOs NR
Smith, 2009142 MUS/somatoform Primary care Henry Ford Health System Research team Henry Ford Health System Research team
Sumathipala, 2000116 MUS/somatoform Primary care
outpatient clinic
Referred from primary care
clinician
Research team A general outpatient clinic
that provided primary care,
where patients initiated
their own visits, without
prior appointments
Research team
Sumathipala, 2008117 MUS/somatoform Primary care
outpatient clinic
Patients screened at clinic Research team Primary care outpatient
clinic
Primary care
outpatient clinic
Toft, 201097 MUS/somatoform Primary care GP practices GP and psychiatrists GP practices Postal questionnaire
Tummers, 2012149 Chronic fatigue Community-based
mental health centre
Referred by a GP or
consultant
GP, research team, CFS
expert, psychiatric nurse
Mostly home-based
activities but based at a
community mental health
centre
Not explicitly reported
van der Feltz-Cornelis,
2006160
MUS/somatoform Primary care GPs at each general practice GPs Psychiatrist visits the GP
practice
Research team
van der Roer, 2008120 Pain–SS (back) Primary
physiotherapy care
setting
Referred by participating
physiotherapists
Local research centres Local research centres Local research centres
van Ravesteijn, 2013143 MUS/somatoform Primary care
patients with home-
based intervention
Frequently attending
primary care patients from
participating GP practices
GPs assessed patient’s
for inclusion criteria
Group intervention setting
unclear. Home-based
practice
Research team
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TABLE 40 Setting detail for individual studies (continued )
First author and year
of publication Condition Setting Setting: referral Setting: assessment Setting: intervention
Setting: outcome
assessment
Walti, 2015121 Pain–SS (back) Primary care
physiotherapy
centre
GP practice NR Primary care physiotherapy
centre
NR
Wearden, 2010111 Chronic fatigue Primary care
patients with home-
based intervention
GPs referred Patients were assessed
at home by a researcher
after referral
In patients’ homes Assessments were
performed by trained
researchers
Whitehead, 2002154 Chronic fatigue Primary care GP referral GP with research team
assistance
GP practice Research team
Zonneveld, 2012141 MUS/somatoform Primary care GPs referred to research
team
Research team Local medical settings Research team
HMO, health maintenance organisation; N/A, not applicable; NR, not reported; pain–MS, pain multisite; pain–SS, pain single site.
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TABLE 41 Table of intervention groupings with individual/group
First author and year
of publication Intervention 1 I/G
Intervention 2
(control) I/G
Intervention 3
(where applicable) I/G
Aiarzaguena, 2007136 GP intervention –
reattribution (modified)
I GP intervention –
reattribution
I
Alda, 2011137 CBT high intensity G UC Medication
Burton, 2012157 GP-MM I UC I
Chalder, 1997114 Guided self-help I UC
Cuesta-Vargas, 2012118 Multimodal
(sport + education)
I Guided self-help I
Escobar, 2007156 CBT high intensity I UC+ (letter)
Friedberg, 2013151 CBT low intensity I UC Relaxation/stretching/
social support/
emotional support
I
Gili 2014/
Moreno, 2013144,148
CBT high intensity –
individual
I UC+ (letter) CBT high intensity –
group
G
Ho, 2012150 Relaxation/stretching/social
support/emotional support
G UC
Huibers, 2004/Leone,
2006153,155
GP – CBT I UC
Kashner, 1995161 UC+ (letter) Relaxation/stretching/
social support/
emotional support
G
Kennedy, 2005129 Multimodal (CBT low
intensity +medication)
I Medication
Kobeissi, 2012110 Relaxation/stretching/social
support/emotional support
G UC
Kocken, 2008103 Other psychotherapy G UC
Kolk, 2004104 Other psychotherapy I UC
Lansinger, 2007123 Relaxation/stretching/social
support/emotional support
G SES I
Larisch, 2004158 GP intervention –
reattribution (modified)
I UC
LeFort, 1988128 Guided self-help G UC
Loew, 2000122 Relaxation/stretching/social
support/emotional support
G Relaxation/stretching/
social support/
emotional support
G
Luciano, 2011139 Multimodal G UC
Luciano, 2014138 CBT – high intensity G Medication
Macedo, 2012119 Graded activity I Graded activity I
Margalit, 2008268 Other psychotherapy I UC
Marques, 2015133 Graded activity I Guided self-help
Martin, 200799 CBT – low intensity G UC
McBeth, 2012125/
Beasley, 2015126
CBT – high Intensity I Exercise + fourth
group of UC
Multimodal
(CBT+ exercise)
I
McLeod, 1997105 Other psychotherapy G UC
Morriss, 2007108 GP intervention –
reattribution
I UC
continued
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TABLE 41 Table of intervention groupings with individual/group (continued )
First author and year
of publication Intervention 1 I/G
Intervention 2
(control) I/G
Intervention 3
(where applicable) I/G
Moss-Morris, 2005152 Graded activity I UC
Moss-Morris, 2010130 CBT low intensity I UC
Peters, 2002106 SES G Relaxation/stretching/
social support/
emotional support
G
Pols, 2008145 Multimodal
(self-management +
medication +CBT)
I UC
Posse, 200496 Other psychotherapy UC
Ridsdale, 2001112 CBT high intensity I Other psychotherapy I
Ridsdale, 2004113 CBT low intensity I Graded activity I
Ridsdale, 2012115 Graded exercise I Guided self-help OP I
Rief, 2006102 GP intervention – MUS
management
I UC
Robinson, 2006131 Guided self-help I UC Multimodal G
Rosendal, 2007146 GP intervention – MUS
management
I UC
Rothman, 2013127 GP intervention –
multidisciplinary
assessment +motivational
interview + psychotherapy
I/G UC+ (multidisciplinary
assessment + choice
of treatment)
I/G
Ryan, 2004109 Other psychotherapy I UC
Sañudo, 2010140 SES I UC SES I
Schade, 2011272 Other psychotherapy I UC
Schaefert, 2013147 Multimodal (GP
intervention – MUS
management + other
psychotherapy)
G GP intervention –
MUS management
I
Schilte, 2001159 GP intervention – other
psychotherapy
I UC
Smith, 1995100 UC+ (letter) UC
Smith, 2006107 Multimodal I UC
Smith, 2009142 Multimodal (GP
intervention
CBT+Medication)
I UC
Sumathipala, 2000116 CBT low intensity I UC
Sumathipala, 2008117 Multimodal (GP-CBT+GP
intervention – MUS
management)
I GP intervention –
MUS management
Toft, 201097 GP intervention – MUS
management
I UC
Tummers, 2012149 CBT low intensity I UC
van der Feltz-Cornelis,
2006160
Multimodal
(reattribution +
collaborative care)
I GP intervention –
reattribution
van der Roer, 2008120 Multimodal
(sport + education +
behavioural programme)
G SES I
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TABLE 41 Table of intervention groupings with individual/group (continued )
First author and year
of publication Intervention 1 I/G
Intervention 2
(control) I/G
Intervention 3
(where applicable) I/G
van Ravesteijn, 2013143 Other psychotherapy G UC+
Walti, 2015121 Multimodal (education+
sport+ sensory
discrimination)
I SES I
Wearden, 2010111 Graded activity I UC OP I
Whitehead, 2002154 GP intervention – MUS
management
I UC
Zonneveld, 2012141 CBT high intensity G UC
G, group; I, individual; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
TABLE 42 Basic study design
First author and
year of publication Condition Total number Arms Interventions Assessment points
Aiarzaguena, 2007136 MUS Clusters of four
patients attended by
39 GPs. 156 patients
2 GP-re vs. GP-re Baseline, 3 months (when
both study groups had
completed five sessions),
after 8 months (when the
intervention was finished),
and 12 months after
enrolment
Alda, 2011137 Fibromyalgia 169 randomised 3 CBTHI vs. ME
vs. UC
Baseline, end of treatment,
6-month follow-up
Burton, 2012157 MUS/somatoform 32 randomised 2 GP-MM vs. UC Baseline, 12 weeks
Chalder, 1997114 Chronic fatigue 150 randomised 2 GSH vs. UC Baseline, 3 months
Cuesta-Vargas,
2012118
Chronic pain –
single site
58 patients 2 MM vs. GSH Pre intervention (baseline),
post intervention 4 months,
post intervention 6 months,
1-year follow-up
Escobar, 2007156 MUS 172 randomised 2 CBTHI vs. UC+ Screening, baseline (1 to
2 weeks later), end of
treatment (approximately
3 months after baseline),
6-month follow-up
Friedberg, 2013151 Chronic fatigue 111 randomised 3 CBTLI vs. RSSE
vs. UC
Baseline and 3 months and
12 months post treatment
Moreno, 2013/
Gili, 2014144,148
Somatoform
disorder
168 patients
randomised, from 21
primary health-care
centres
3 CBTHI vs.
CBTHI vs. UC+
Baseline, post treatment,
6 and 12 months
Ho, 2012150 Chronic fatigue 64 randomised 2 RSSE vs. UC Baseline, 5 weeks after,
4 months after
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue 151 randomised 2 GP-CBT vs. UC Data collected on four
occasions: baseline, end
of the treatment period
(4 months) and at two
follow-up points (i.e.
8 months and 12 months).
Leone 2006155 is 4-year
follow-up
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TABLE 42 Basic study design (continued )
First author and
year of publication Condition Total number Arms Interventions Assessment points
Kashner, 1995161
(follow-on study to
Smith, 1995100)
Somatoform
disorder
70 randomised 2 RSSE vs. UC+ Data collected every
4 months
Kennedy, 2005129 IBS 149 randomised 2 MM vs. ME Baseline, 6 weeks after
randomisation, 3 months,
6 months, 12 months after
completion of therapy
Kobeissi, 2012110 Single MUS 271 randomised 2 RSSE vs. UC Baseline, 1.5 months,
6 months
Kocken, 2008103 Somatoform
disorder
104 randomised 2 OP vs. UC Baseline and post treatment
Kolk, 2004104 MUS 106 randomised 2 OP vs. UC Baseline, 6 months (end of
treatment), 12 months (end
of follow-up)
Lansinger, 2007123 Neck pain 122 randomised 2 RSSE vs. SES Baseline, end of treatment,
6- and 12-month follow-up
Larisch, 2004158 Somatoform
disorder
42 GPs randomised;
127 patients
2 GP-re vs. UC Baseline, 3-, 6- and
12-month follow-up
LeFort, 1998128 Chronic pain 110 randomised 2 GSH vs. UC Baseline, 12 weeks
(3 months post treatment)
Loew, 2000122 Single chronic
pain
54 patients 2 RSSE vs. RSSE 60 days pre treatment,
60 days post treatment
Luciano, 2011139 Fibromyalgia 108 randomised 2 MM vs. UC Baseline, post treatment
Luciano, 2014138 Fibromyalgia 156 randomised 3 CBTHI vs. ME
vs. UC
Baseline, end of treatment,
3 months, 6 months
Macedo, 2012119 Back pain 172 patients 2 GA vs. GA Baseline, 2, 6 and 12
months post intervention
Margalit, 2008268 MUS 42 randomised 2 OP vs. UC Baseline, one and 2 years
after randomisation, 3 years,
5 years
Marques, 2015133 Chronic fatigue 99 randomised 2 GA vs. GSH Baseline and 12 weeks later
(post treatment)
Martin, 200799 MUS 140 randomised 2 CBTLI vs. UC Baseline, 4 weeks, 6 months
later
McBeth, 2012125/
Beasley, 2015126
Chronic pain 442 randomised 4 CBTHI vs. SES
vs. MM vs. UC
Baseline, 6 months (post
treatment), 9 months,
2 years
McLeod, 1997105 Somatoform
disorder
96 randomised 2 OP vs. UC 1 week prior, 1 week post
treatment, 6-month follow-up
Morriss, 2007108 MUS 16 GP practices
randomised, with
74 GPs and 141
patients
2 GP-re vs. UC Baseline, 1- and 3-month
follow-up
Moss-Morris,
2005152
Chronic fatigue 49 randomised 2 GA vs. UC End of treatment at
12 weeks and at 6-month
follow-up
Moss-Morris,
2010130
IBS 64 randomised 2 CBTLI vs. UC Baseline (pre treatment),
post treatment (2 months)
and 3 and 6 months post
treatment
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TABLE 42 Basic study design (continued )
First author and
year of publication Condition Total number Arms Interventions Assessment points
Peters, 2002106 MUS 228 randomised 2 SES vs. RSSE Baseline (T1 randomisation),
T2 start of programme,
T3 mid-programme, T4 end
of programme, T5 6-month
follow-up
Pols, 2008145 MUS 133 randomised 2 MM vs. UC Baseline, 12 months
Posse, 200496 Somatoform
disorder
10 2 OP vs. UC Baseline and 6-month
follow-up
Ridsdale, 2001112 Chronic fatigue 160 randomised 2 CBTHI vs. OP Baseline, 3 months
(completion of treatment),
6 months
Ridsdale, 2004113 Chronic fatigue 123 randomised 2 CBTLI vs. GA Baseline, 3 months,
8 months from baseline.
Mean of the two periods
used as primary outcome
Ridsdale, 2012115 Chronic fatigue 222 randomised 3 GA vs. OP vs.
GSH
Baseline, 3 and 12 months
Rief, 2006102 Somatoform
disorder
26 GPs, 295 patients 2 GP-MM vs. UC Baseline, 6-month follow-up
Robinson, 2006131 IBS 420 randomised 3 GSH vs. MM vs.
UC
Baseline, 12-month follow-up
Rosendal, 2007146 Somatoform
disorder
27 practices
randomised, 22 GPs,
506 patients
2 GP-MM vs. UC Baseline, 3-month follow-up,
12-month follow-up
Rothman, 2013127 Chronic pain 220 randomised 2 GP-O vs. UC+ Baseline, 15-month follow-up
Ryan, 2004109 Mixed MUS 70 randomised 2 OP vs. UC Pre-treatment phase
(6 months prior to treatment,
T1), 8-week treatment phase
(T2), 6 months post
treatment (T3)
Sañudo, 2010140 Fibromyalgia 64 randomised 3 SES vs. SES vs.
UC
Baseline and 24 weeks
(immediately post treatment)
Schade, 2011272 Somatoform
disorder
256 patients,
102 professionals
2 OP vs. UC 6 months pre treatment,
6 months post treatment,
1-year follow-up
Schaefert, 2013147 MUS 39 GPs randomised,
328 patients
2 MM vs. GP-MM Baseline, 6 months
(3 months after 3 month
intervention phase),
12 months (9 months after
intervention phase)
Schilte, 2001159 Somatoform
disorder
161 patients 2 GP-OP vs. UC Baseline, 6, 12 and
24 months
Smith, 1995100
(see Kashner, 1995161
for post 1 year)
MUS 56 patients 2 UC+ vs. UC Baseline, then every
4 months until 1 year
crossover
Smith, 2006107 MUS 206 randomised 2 MM vs. UC Baseline, 12 months
Smith, 2009142 MUS 30 randomised 2 MM vs. UC Baseline and 12 months
Sumathipala, 2000116 MUS 68 randomised 2 CBTLI vs. UC Baseline and 3 months
(end of treatment)
Sumathipala, 2008117 MUS 150 randomised 2 MM vs. GP-MM Baseline and 3, 6 and
12 months post baseline
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TABLE 43 Intervention delivery: duration of treatment sessions
First author and
year of publication Condition
Intervention 1 delivery:
duration of sessions
Intervention 3
delivery: duration
of sessions
Intervention 2 delivery:
duration of sessions
Aiarzaguena, 2007136 MUS 30 minutes × 6 sessions N/A 30 minutes × 6 sessions
Alda, 2011137 Fibromyalgia 90 minutes × 10 sessions N/A N/A
Burton, 2012157 MUS 1 session × 1 hour
duration + 3 sessions ×
20 minutes
N/A N/A
Chalder, 1997114 Chronic fatigue 1 × 10–15 minutes N/A N/A
Cuesta-Vargas,
2012118
Back pain 30-minute sessions of
DWR. Educational session
of 1 hour
N/A Educational session of
1 hour
Escobar, 2007156 MUS 9 × 50-minute sessions,
(range, 45–60 minutes),
1 × 90-minute session
N/A N/A
Friedberg, 2013151 Chronic fatigue Up to 60 minutes N/A N/A
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue 30 minutes N/A N/A
TABLE 42 Basic study design (continued )
First author and
year of publication Condition Total number Arms Interventions Assessment points
Toft, 201097 MUS 40 GPs randomised.
524 patients
included
2 GP-MM vs. UC Baseline and 3-, 12- and
24-month follow-up
Tummers, 2012149 Chronic fatigue 123 randomised 2 CBTLI vs. UC Baseline and 6-month
post-baseline assessment
van der Feltz-
Cornelis, 2006160
MUS 36 general practices,
81 patients
2 MM vs. GP-re Baseline, 6 weeks and
6 months
van der Roer,
2008120
Back pain 114 randomised 2 MM vs. SES Baseline and 6, 13, 26 and
52 weeks after randomisation
van Ravesteijn,
2013143
MUS 125 randomised 2 OP vs. UC+ Baseline, end of treatment
(3 months from baseline),
9 months after treatment
(12 months from baseline)
Walti, 2015121 Back pain 28 patients 2 MM vs. SES Baseline, 12 weeks after
baseline
Wearden, 2010111 Chronic fatigue 296 randomised 3 GA vs. OP vs.
UC
Baseline, week 20
(completion of treatment),
70 weeks (1 year post
treatment completion)
Whitehead, 2002154 CFS 65 randomised 2 GP-MM vs. UC Baseline and 6- and
12-month follow-up
Zonneveld, 2012141 MUS 162 randomised 2 CBTHI vs. UC Baseline, end of treatment
(13 weeks), 1-year follow-up
GP-O, GP – other; GP-re, general practitioner-delivered reattribution; GSH, guided self-help; ME, medication; OP, other
psychotherapy; UC, usual care; UC+, usual care plus.
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TABLE 43 Intervention delivery: duration of treatment sessions (continued )
First author and
year of publication Condition
Intervention 1 delivery:
duration of sessions
Intervention 3
delivery: duration
of sessions
Intervention 2 delivery:
duration of sessions
Kashner, 1995161 Somatoform
disorder
NR N/A N/A
Kennedy, 2005129 IBS 50 minutes N/A N/A
Kobeissi, 2012110 Single MUS 75 minutes (psychosocial
component), 30 minutes
relaxation sessions
N/A N/A
Kocken, 2008103 Somatoform
disorder
NR N/A NR
Kolk, 2004104 MUS 1-hour sessions N/A N/A
Lansinger, 2007123 Neck pain 1 hour N/A 1 hour
Larisch, 2004158 Somatoform
disorder
20 minutes planned, but in
practice shorter duration
N/A 20 minutes planned,
but in practice shorter
duration
LeFort, 1998128 Chronic pain 2 hours per week N/A N/A
Loew, 2000122 Single chronic pain 45-minute introduction
to eFR
N/A 45-minute introduction
to UIR
Luciano, 2011139 Fibromyalgia 2-hour sessions N/A N/A
Luciano, 2014138 Fibromyalgia 8 × 2.5 hour sessions plus
10–15 minutes daily
homework
N/A N/A
Macedo, 2012119 Back pain 1 hour, recommended
30 minutes extra per week
at home in the first month
and 1 hour extra per week
at home in the second
month
N/A 1 hour, recommended
30 minutes extra per
week at home in the
first month and 1 hour
extra per week at home
in the second month
Margalit, 2008268 MUS Duration of initial
encounters NR. Follow-up
sessions 30 minutes
N/A N/A
Marques, 2015133 Chronic fatigue Up to 60 minutes N/A NR
Martin, 200799 MUS 3–4 hours N/A N/A
McBeth, 2012125/
Beasley, 2015126
Chronic pain 30–45 minutes 20–60 minutes N/A Group 4 combined
CBT and exercise
McLeod, 1997105 Somatoform
disorder
NR N/A NR
Moreno, 2013/
Gili, 2014144,148
Somatoform
disorder
1 hour 2 hours NR
Morriss, 2007108 MUS N/A for patients N/A N/A
Moss-Morris, 2005152 Chronic fatigue Two 1-hour face-to-face
individual motivational
interviewing sessions
and two brief SR-based
telephone counselling
sessions
N/A N/A
Moss-Morris, 2010130 IBS 1 × 1 hour face to face
with health psychologist,
2 × 1-hour telephone sessions
N/A N/A
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TABLE 43 Intervention delivery: duration of treatment sessions (continued )
First author and
year of publication Condition
Intervention 1 delivery:
duration of sessions
Intervention 3
delivery: duration
of sessions
Intervention 2 delivery:
duration of sessions
Peters, 2002106 MUS 1 hour supervised with
three times per week
20 minutes’ homework
N/A 1 hour supervised with
3 times per week
20 minutes’ homework
Pols, 2008145 MUS NR N/A N/A
Posse, 200496 Somatoform
disorder
NR N/A NR
Ridsdale, 2001112 Chronic fatigue Initial 1 hour interview
for goal-setting. Home-
based exercise starting at
10–15 minutes four or five
times a week. Increases
generally involved duration
increases of 3–5 minutes per
week. The final goal was
for each participant to be
exercising for approximately
30 minutes for 5 days per
week
N/A N/A
Ridsdale, 2004113 Chronic fatigue 6 × 1-hour sessions N/A 6 × 1-hour sessions
Ridsdale, 2012115 Chronic fatigue 6 × 45-minute sessions over
12 weeks
N/A 6 × 45-minute sessions
over 12 weeks
Rief, 2006102 MUS Not specified – dependent
on patient
N/A N/A
Robinson, 2006131 IBS Several group sessions and
self-help
1 x session and
self-help
N/A
Rosendal, 2007146 Somatoform
disorder
NR N/A NR
Rothman, 2013127 Chronic pain Not specified – dependent
on individual
N/A Not specified –
dependent on individual
Ryan, 2004109 Mixed MUS 1-hour weekly sessions N/A N/A
Sañudo, 2010140 Fibromyalgia Two sessions per week of
45–60 minutes’ duration
Two sessions per
week of 45 to
60 minutes’
duration
N/A
Schade, 2011272 Somatoform
disorder
First session 1 hour,
subsequent sessions
between 30 and 45 minutes
NR First session 1 hour,
subsequent sessions
between 30 and
45 minutes
Schaefert, 2013147 MUS 10 × 90-minute sessions
plus two booster meetings
‘of equal length’ 3 and
9 months after group phase
N/A N/A
Schilte, 2001159 Somatoform
disorder
First meeting 2 hours,
second meeting 1 hour, third
meeting (where applicable)
30 minutes to 1 hour
NR First meeting 2 hours,
second meeting 1 hour,
third meeting (where
applicable) 30 minutes
to 1 hour
Smith, 1995100 MUS Regular consultations every
4–6 weeks but duration not
specified
N/A N/A
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TABLE 43 Intervention delivery: duration of treatment sessions (continued )
First author and
year of publication Condition
Intervention 1 delivery:
duration of sessions
Intervention 3
delivery: duration
of sessions
Intervention 2 delivery:
duration of sessions
Smith, 2006107 MUS 12 × 20-minute visits were
scheduled but additional
visits could occur.
Telephone contact
(5–10 minutes) was
scheduled between visits
N/A N/A
Smith, 2009142 MUS Mean number of
encounters (minutes per
encounter) encounter:
office visits – 7 (38.3);
scheduled phone – 3 (20.5);
after-hours phone – 3
(14.7); co-ordination of
care – 1 (20)
N/A N/A
Sumathipala, 2000116 MUS 6 × 30-minute sessions N/A N/A
Sumathipala, 2008117 MUS 3 × 30-minute sessions over
3 weeks, 3 × optional
fortnightly follow-up
sessions
N/A 3 × 30-minute sessions
over 3 weeks,
3 × optional fortnightly
follow-up sessions
Toft, 201097 MUS NR N/A NR
Tummers, 2012149 Chronic fatigue 30-minute sessions with
physiotherapists plus daily
home-based exercise
tailored 5–30 minutes
per day
50-minute sessions
with counsellors
N/A
van der Feltz-
Cornelis, 2006160
MUS NR N/A NR
van der Roer, 2008120 Back pain NR N/A NR
van Ravesteijn,
2013143
MUS 8 × 2.5-hour group sessions.
Home practice 6 days
per week for 45 minutes
per day
N/A N/A
Walti, 2015121 Back pain 30-minute physiotherapy
sessions. Home assignments
to be performed for
30 minutes
N/A 30-minute physiotherapy
sessions. Home
assignments to be
performed for
30 minutes
Wearden, 2010111 Chronic fatigue 90-minute home visit on
week 1; 1-hour home visits
on weeks 2, 4, 10 and 19;
and 30-minute telephone
calls on weeks 3, 6, 8, 12,
and 15
90-minute home
visit on week 1;
1-hour home visits
on weeks 2, 4, 10,
and 19; and 30-
minute telephone
calls on weeks 3,
6, 8, 12, and 15
N/A
Whitehead, 2002154 Chronic fatigue 10 minutes on average N/A 10 minutes on average
Zonneveld, 2012141 MUS 13 × 2-hour group sessions N/A N/A
eFR, elements of functional relaxation; N/A, not applicable; NR, not reported; SR, self-regulation; UIR, unspecific
intervention technique.
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TABLE 44 Intervention delivery: number of sessions
First author and
year of publication Condition
Intervention 1 delivery:
number of sessions
Intervention 3
delivery: number
of sessions
Intervention 2 delivery:
number of sessions
Intervention 1
delivery: time period
Intervention 3
delivery: time period
Intervention 2
delivery: time period
Aiarzaguena, 2007136 MUS 6 sessions N/A 6 sessions 8 months N/A 8 months
Alda, 2011137 Fibromyalgia 10 sessions 6 months 6 months 10–12 weeks 6 months 6 months
Burton, 2012157 MUS N/A N/A
Chalder, 1997114 Chronic fatigue 1 session with nurse
then self-help
N/A N/A 3 months N/A 3 months
Cuesta-Vargas,
2012118
Back pain 3 sessions per week for
15 weeks. A lower limit
of training compliance
was set to 80% of the
training sessions. 1
educational session
N/A 1 educational session 4 months N/A N/A
Escobar, 2007156 MUS 10 sessions N/A N/A 3 months N/A 3 months
Friedberg, 2013151 Chronic fatigue 2 sessions 2 sessions None 3 month self-
management period
Face-to-face sessions
were 2 weeks apart,
homework diaries
were for 3 months’
duration
N/A
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue 5–7 sessions N/A N/A Over the course of
4 months
N/A N/A
Kashner, 1995161 Somatoform
disorder
8 sessions every other
week
N/A 4 months N/A
Kennedy, 2005129 IBS 6 sessions N/A N/A 6 weeks N/A > 6 weeks (patients
already on drug)
Kobeissi, 2012110 Single MUS 12 sessions N/A Telephone call every
2 weeks
6 weeks N/A 6 weeks
Kocken, 2008103 Somatoform
disorder
Average 3.2 counselling
sessions per patient, 2.1
sessions with GP and
health educator, 6.3
education group sessions
N/A NR Mean duration
12 months
N/A NR
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First author and
year of publication Condition
Intervention 1 delivery:
number of sessions
Intervention 3
delivery: number
of sessions
Intervention 2 delivery:
number of sessions
Intervention 1
delivery: time period
Intervention 3
delivery: time period
Intervention 2
delivery: time period
Kolk, 2004104 MUS Once per week or every
2 weeks
N/A N/A Maximum 12 weeks N/A N/A
Lansinger, 2007123 Neck pain 10 to 12 sessions, 1 or
2 times per week
N/A 10 to 12 sessions, 1 or
2 times per week
3 months N/A 3 months
Larisch, 2004158 Somatoform
disorder
6 sessions every other
week
N/A 6 sessions every other
week
3 months N/A 3 months
LeFort, 1998128 Chronic pain 6 sessions N/A N/A 6 weeks N/A 6 weeks
Loew, 2000122 Single chronic
pain
1 session N/A 1 session NR N/A NR
Luciano, 2011139 Fibromyalgia 9 sessions N/A N/A Sessions delivered
over a 2-month
period (1 afternoon
session per week)
N/A N/A
Luciano, 2014138 Fibromyalgia 8 sessions N/A N/A N/A
Macedo, 2012119 Back pain 14 sessions; 12 initial,
twice a week for the
first 4 weeks and once a
week for the remaining
4 weeks. Plus 2 booster
sessions
N/A 14 sessions; 12 initial,
twice a week for the
first 4 weeks and once a
week for the remaining
4 weeks. Plus 2 booster
sessions
8 weeks (initial
sessions), 1 booster
session at 4 months
following
randomisation, 1
booster session at
10 months following
randomisation
N/A 8 weeks (initial
sessions), 1 booster
session at 4 months
following
randomisation,
1 booster session at
10 months following
randomisation
Margalit, 2008268 MUS 3–28 (mean: 7.3)
encounters over a period
of 1.5–12 months.
Follow-up once per
week
N/A N/A 1.5–12 months N/A 12 months
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TABLE 44 Intervention delivery: number of sessions (continued )
First author and
year of publication Condition
Intervention 1 delivery:
number of sessions
Intervention 3
delivery: number
of sessions
Intervention 2 delivery:
number of sessions
Intervention 1
delivery: time period
Intervention 3
delivery: time period
Intervention 2
delivery: time period
Marques, 2015133 Chronic fatigue Two 1-hour face-to-face
individual motivational
interviewing sessions
and two brief SR-based
telephone counselling
sessions
N/A N/A 12-week intervention
period
N/A 12 weeks
Martin, 200799 MUS 1 session N/A N/A 1 session only N/A Unclear – presume
4 weeks
McBeth, 2012125/
Beasley, 2015126
Chronic pain 7 weekly sessions
(each 30–45 minutes),
and 1 session 3 months
and 1 session 6 months
after randomisation
3–5 days per
week
N/A
Group 4 combined CBT
and exercise
6 months 6 months 6 months
Group 4 6 months
McLeod, 1997105 Somatoform
disorder
6 sessions, 1 per week.
Plus daily homework
assignments
N/A 6 sessions, 1 per week.
Plus daily homework
assignments
6 weeks N/A After 2 months’ wait,
6 weeks
Moreno, 2013/
Gili, 2014144,148
Somatoform
disorder
10 per week 10 per week NR NR NR NR
Morriss, 2007108 MUS N/A for patients N/A N/A N/A for patients N/A N/A for patients
Moss-Morris, 2005152 Chronic fatigue One initial meeting
followed by 12 weekly
meetings. Exercises were
4/5 times per week for
12 weeks
N/A N/A 12 weeks N/A 12 weeks
Moss-Morris, 2010130 IBS 7 chapters of self-help
manual, 1 face-to-face
session, 2 telephone
sessions
N/A N/A 7 to 8 weeks N/A 7 to 8 weeks
Peters, 2002106 MUS 2 sessions per week for
20 sessions supervised
plus 3 times per week
for 10 weeks homework
N/A 2 sessions per week for
20 sessions supervised
plus 3 times per week
for 10 weeks homework
10 weeks N/A 10 weeks
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First author and
year of publication Condition
Intervention 1 delivery:
number of sessions
Intervention 3
delivery: number
of sessions
Intervention 2 delivery:
number of sessions
Intervention 1
delivery: time period
Intervention 3
delivery: time period
Intervention 2
delivery: time period
Pols, 2008145 MUS 4- to 6-weekly
appointments
N/A N/A 12-month care plan
that was reviewed
quarterly
N/A N/A
Posse, 200496 Somatoform
disorder
One per week N/A NR 6 months N/A NR
Ridsdale, 2001112 Chronic fatigue 6 sessions N/A 6 sessions 3 months N/A 3 months
Ridsdale, 2004113 Chronic fatigue 6 sessions N/A 6 sessions 12 weeks N/A 12 weeks
Ridsdale, 2012115 Chronic fatigue 8 sessions at 2-week
intervals
8 sessions at
2-week intervals
None 16 weeks 16 weeks 16 weeks
Rief, 2006102 MUS 1-day training for GPs N/A N/A 1-day training for
GPs
N/A N/A
Robinson, 2006131 IBS Several group sessions 1 session N/A NR NR N/A
Rosendal, 2007146 Somatoform
disorder
NR N/A NR NR N/A NR
Rothman, 2013127 Chronic pain Not specified –
dependent on individual
N/A Not specified –
dependent on individual
Not specified –
dependent on
individual
N/A Not specified –
dependent on
individual
Ryan, 2004109 Mixed MUS 8 sessions followed
by monthly optional
maintenance sessions
N/A N/A 8 weeks plus
follow-up visits
N/A 8 weeks
Sañudo, 2010140 Fibromyalgia 2 sessions per week 2 sessions per
week
N/A 24 weeks 24 weeks 24 weeks
Schade, 2011272 Somatoform
disorder
NR N/A NR NR N/A NR
Schaefert, 2013147 MUS 10 weekly sessions N/A N/A 10 weeks group
sessions, plus 2
booster sessions at 3
and 9 months later
N/A 12 months
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TABLE 44 Intervention delivery: number of sessions (continued )
First author and
year of publication Condition
Intervention 1 delivery:
number of sessions
Intervention 3
delivery: number
of sessions
Intervention 2 delivery:
number of sessions
Intervention 1
delivery: time period
Intervention 3
delivery: time period
Intervention 2
delivery: time period
Schilte, 2001159 Somatoform
disorder
2 disclosure meetings
and an additional third
meeting if the patient
agreed
N/A NR First meeting within
2 weeks after
inclusion, second
meeting 1 week later,
third meeting (where
applicable) another
week later
N/A NR
Smith, 1995100 MUS Regular scheduled
meeting perhaps every
4–6 weeks
N/A N/A 12 months N/A 12 months
Smith, 2006107 MUS 12 face-to-face sessions
minimum plus telephone
contact
N/A N/A 12 months N/A 12 months
Smith, 2009142 MUS 7 visits with the PCP
(and 3 with the CM
who also made eight
scheduled phone calls)
N/A N/A 12 months N/A 12 months
Sumathipala, 2000116 MUS 6 sessions N/A N/A 3 months N/A 3 months
Sumathipala, 2008117 MUS 6 sessions N/A 6 sessions 10 weeks N/A 10 weeks
Toft, 201097 MUS Not specified N/A N/A 2 years N/A 2 years
Tummers, 2012149 Chronic Fatigue Week-by-week
programme
N/A N/A Minimum 20 weeks N/A N/A
van der Feltz-
Cornelis, 2006160
MUS No specified number
of sessions
N/A No specified number
of sessions
6 months N/A 6 months
van der Roer, 2008120 Back Pain 10 individual sessions
and 20 group sessions
N/A Number of sessions
at the discretion of
physiotherapist. Mean
number of sessions
was 13
Unclear N/A Unclear
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First author and
year of publication Condition
Intervention 1 delivery:
number of sessions
Intervention 3
delivery: number
of sessions
Intervention 2 delivery:
number of sessions
Intervention 1
delivery: time period
Intervention 3
delivery: time period
Intervention 2
delivery: time period
van Ravesteijn,
2013143
MUS 8 group sessions, 48
home exercise sessions
N/A N/A 8 weeks N/A 8 weeks
Walti, 2015121 Back pain 1 or 2 sessions per week
(maximum of 16 sessions)
plus 1 home session
5 days per week
N/A 1 or 2 sessions per week
(maximum of 16 sessions)
plus 1 home session
5 days per week
8 weeks N/A 8 weeks
Wearden, 2010111 Chronic fatigue 10 sessions 10 sessions N/A 18 weeks 18 weeks 18 weeks
Whitehead, 2002154 Chronic fatigue Weekly or biweekly
visits over 12-month
study period
N/A N/A 12 months N/A 12 months
Zonneveld, 2012141 MUS 13 weekly sessions N/A N/A 13 weeks N/A 13 weeks
CM, case manager; N/A, not applicable; NR, not reported; SR, self-regulation.
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TABLE 45 Intervention delivery: treatment provider
First author and
year of publication Condition
Intervention 1
provider: position
Intervention 3
provider: position
Intervention 2
provider: position
Intervention 1 provider:
time spent on delivery
Intervention 23
provider: time
spent on delivery
Intervention 2
provider: time
spent on delivery
Aiarzaguena, 2007136 MUS GP N/A GP Six sessions of 30 minutes’
duration
N/A Six sessions of
30 minutes’ duration
Alda, 2011137 Fibromyalgia Trained therapists 2 × psychiatrists Family doctors 10 × 90 minutes NR 1 × per month for
6 months
Burton, 2012157 MUS Specialist GP N/A GP 120 minutes N/A NR
Chalder, 1997114 Chronic fatigue Nurse N/A NR 10–15 minutes N/A N/A
Cuesta-Vargas,
2012118
Back pain A physiotherapist
supervised both the
technique and the
intensity of exercise and
controlled and supervised
the sessions including the
exercise workloads
N/A GP Three 30-minute sessions
per week for 15 weeks.
Plus 1-hour education
session
N/A 1 hour in education
session
Escobar, 2007156 MUS 4 doctoral-level
psychologists and 4
psychology doctoral
candidates
N/A GP 9 × 50 minutes and
1 × 90-minutes session
N/A N/A
Friedberg, 2013151 Chronic fatigue Nurse Nurse therapist N/A Up to 2 hours NR N/A
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue GP N/A GP 150 minutes N/A NR
Kashner, 1995161 Somatoform
disorder
Family doctor N/A Family doctor Regular schedules
meetings
N/A N/A
Kennedy, 2005129 IBS 4 general practice nurses N/A Unclear – GP
prescription
6 × 50-minute sessions
at weekly intervals of
face-to-face contact
N/A N/A
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First author and
year of publication Condition
Intervention 1
provider: position
Intervention 3
provider: position
Intervention 2
provider: position
Intervention 1 provider:
time spent on delivery
Intervention 23
provider: time
spent on delivery
Intervention 2
provider: time
spent on delivery
Kobeissi, 2012110 Single MUS 5 × clinical psychologists
and physical trainers
N/A Clinical psychologist 12 × 75 minutes clinical
psychologist, 12 ×
30 minutes physical trainer
N/A 3 × telephone calls
Kocken, 2008103 Somatoform
disorder
Health educators and GP GP NR NR
Kolk, 2004104 MUS 15 psychologists qualified
as therapists
N/A GP 1-hour sessions, once a
week, or every 2 weeks,
with a maximum of
12 sessions
N/A N/A
Lansinger, 2007123 Neck pain Physiotherapists N/A Physiotherapists 10–12 × 1-hour sessions N/A 10–12 × 1-hour
sessions
Larisch, 2004158 Somatoform
disorder
GP N/A GP Six 20-minute sessions
every other week for
3 months
N/A Six 20-minute
sessions every
other week for
3 months
LeFort, 1998128 Chronic pain The author N/A N/A 6 × 2-hour sessions N/A N/A
Loew, 2000122 Single chronic
pain
Experienced eFR
therapists
N/A Experienced eFR
therapists
1 hour N/A 1 hour
Luciano, 2011139 Fibromyalgia Speakers included 4 GPs
and 1 rheumatologist
(educative training), and
a clinical psychologist
(autogenic training)
N/A GPs 9 × 2-hour sessions N/A N/A
Luciano, 2014138 Fibromyalgia Clinical psychologist Clinicians supervised
by GP
N/A 8 × 2.5 hours N/A N/A
Macedo, 2012119 Back pain Physical therapists N/A Physical therapists Fourteen 1-hour sessions
per patient for 8 weeks
N/A Fourteen 1-hour
sessions per
patient for 8 weeks
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TABLE 45 Intervention delivery: treatment provider (continued )
First author and
year of publication Condition
Intervention 1
provider: position
Intervention 3
provider: position
Intervention 2
provider: position
Intervention 1 provider:
time spent on delivery
Intervention 23
provider: time
spent on delivery
Intervention 2
provider: time
spent on delivery
Margalit, 2008268 MUS A primary care team
with expertise in the
biopsychosocial approach
N/A PCP 3–28 (mean: 7.3)
encounters over a period of
1.5–12 months. Follow-up
lasting 30 minutes once
per week
N/A NR
Marques, 2015133 Chronic fatigue Health psychologist N/A N/A 4 hours N/A N/A
Martin, 200799 MUS A clinical psychologist
and a medical specialist
for psychotherapeutic
medicine
N/A GP 3–4 hours N/A N/A
McBeth, 2012125/
Beasley, 2015126
Chronic pain 4 therapists accredited by
the British Association for
Behaviour and Cognitive
Psychotherapies
Fitness instructor Family physician
Group 4 combination
of CBT and exercise
Initial assessment
(45–60 minutes),
7 × weekly sessions
(30–45 minutes), 1 session
3 months and 1 session
6 months post
randomisation
6 x monthly
20–60 minutes
sessions
N/A
Group 4
combination CBT
and exercise
McLeod, 1997105 Somatoform
disorder
Led by trained leaders
including physicians,
nurses, social workers,
and psychologists
N/A Led by trained
leaders including
physicians, nurses,
social workers, and
psychologists
1 weekly session for
6 weeks
N/A After 2 months,
1 weekly session
for 6 weeks
Moreno, 2013/
Gili, 2014144,148
Somatoform
disorder
2 psychologists 2 psychologists GPs 10 weekly 1-hour sessions 10 weekly 2-hour
sessions
NR
Morriss, 2007108 MUS 3 nurses and a
psychologist (health
facilitators) with
professional experience in
primary care or liaison
psychiatry but not
reattribution therapy
N/A GP NR N/A N/A
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First author and
year of publication Condition
Intervention 1
provider: position
Intervention 3
provider: position
Intervention 2
provider: position
Intervention 1 provider:
time spent on delivery
Intervention 23
provider: time
spent on delivery
Intervention 2
provider: time
spent on delivery
Moss-Morris, 2005152 Chronic fatigue Researcher N/A GP 12 hours N/A NR
Moss-Morris, 2010130 IBS Health psychologist N/A N/A 1-hour face to face and
2 × 1-hour telephone
sessions
N/A N/A
Peters, 2002106 MUS 1 of 2 physiotherapists N/A 1 of 2
physiotherapists
20 × 1-hour sessions N/A 20 × 1-hour
sessions
Pols, 2008145 MUS GP N/A GP 4–6 weekly appointments N/A N/A
Posse, 200496 Somatoform
disorder
Author and diploma
candidate under the
supervision of training
analysts
N/A GP 1 hour per patient per
week for 6 months
N/A NR
Ridsdale, 2001112 Chronic fatigue 3 qualified CBT therapists N/A Three qualified
counsellors
6 × 1-hour sessions N/A 6 × 1-hour sessions
Ridsdale, 2004113 Chronic fatigue 6 cognitive–behaviour
therapists
N/A Five physiotherapists 6 × 45-minute sessions N/A 6 × 45-minute
sessions
Ridsdale, 2012115 Chronic fatigue 8 registered
physiotherapists
8 British Association
for Counselling and
Psychotherapy-
registered therapists
Usual care with GP 8 × 30-minute sessions
plus 2 telephone calls as
follow-up
8 × 50 minute
sessions plus 2
telephone calls as
follow-up
N/A
Rief, 2006102 MUS GP N/A GP NR N/A NR
Robinson, 2006131 IBS NR Trial co-ordinator PCP NR NR N/A
Rosendal, 2007146 Somatoform
disorder
Family physician N/A Family physician NR N/A NR
Rothman, 2013127 Chronic pain Multidisciplinary – GP,
physiotherapist,
psychologist
N/A Multidisciplinary –
GP, physiotherapist,
psychologist
NR – depended on patient N/A NR – depended on
patient
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TABLE 45 Intervention delivery: treatment provider (continued )
First author and
year of publication Condition
Intervention 1
provider: position
Intervention 3
provider: position
Intervention 2
provider: position
Intervention 1 provider:
time spent on delivery
Intervention 23
provider: time
spent on delivery
Intervention 2
provider: time
spent on delivery
Ryan, 2004109 Mixed MUS 4 × clinical or health
psychology graduate
students
N/A N/A 8 × 1-hour sessions N/A N/A
Sañudo, 2010140 Fibromyalgia NR NR Family physician 2 × 45–60 minutes per
week for 24 weeks
2 × 45–60
minutes per week
for 24 weeks
N/A
Schade, 2011272 Somatoform
disorder
The professionals had
different professional
backgrounds (family
doctors, general
medical practitioners,
psychologists,
physiotherapists, social
workers, nurses, birth
assistants and dentists)
N/A GPs and other
professionals
NR N/A NR
Schaefert, 2013147 MUS GP N/A GP 10 × 90-minute sessions
plus 2 booster sessions
N/A N/A
Schilte, 2001159 Somatoform
disorder
Disclosure doctor in the
first and second meetings.
Both disclosure doctor
and GP together in third
meeting (where applicable)
N/A GP 3 hours (in some cases an
additional 30 minutes to
1 hour)
N/A NR
Smith, 1995100 MUS Family
doctor + psychiatrist
N/A N/A Regular schedules
meetings, perhaps every
4–6 weeks
N/A N/A
Smith, 2006107 MUS 4 nurse practitioners N/A NR Minimum 12 × 20 minutes
face to face with additional
telephone contacts
N/A N/A
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First author and
year of publication Condition
Intervention 1
provider: position
Intervention 3
provider: position
Intervention 2
provider: position
Intervention 1 provider:
time spent on delivery
Intervention 23
provider: time
spent on delivery
Intervention 2
provider: time
spent on delivery
Smith, 2009142 MUS 4 PCPs and 1
experienced case
manager
N/A GP 7 visits with the PCP (and
3 with the CM who also
made eight scheduled
telephone calls). Mean
number of encounters
(minutes per encounter):
office visits – 7 (38.3);
scheduled telephone calls
– 3 (20.5); after-hours
telephone calls – 3 (14.7);
co-ordination of care
– 1 (20)
N/A N/A
Sumathipala, 2000116 MUS A psychiatrist trained in
CBT
N/A Their own primary
care provider
although they may
have consulted
with a number of
practitioners over
the study period
6 × 30-minute sessions N/A N/A
Sumathipala, 2008117 MUS 8 × PCPs N/A 3 × PCPs 6 × 30-minute sessions N/A 6 × 30-minute
sessions
Toft, 201097 MUS GPs N/A GPs Not specified N/A N/A
Tummers, 2012149 Chronic fatigue 8 psychiatric nurses N/A N/A NR but fortnightly e-mail
contact
N/A N/A
van der Feltz-
Cornelis, 2006160
MUS N/A N/A
van der Roer, 2008120 Back pain 105 primary care
physiotherapists
N/A 105 primary care
physiotherapists
Unclear but 30 sessions N/A Unclear but mean
13 sessions
van Ravesteijn,
2013143
MUS 2 ×mindfulness trainers N/A GP 8 × 2.5-hour sessions N/A N/A
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TABLE 45 Intervention delivery: treatment provider (continued )
First author and
year of publication Condition
Intervention 1
provider: position
Intervention 3
provider: position
Intervention 2
provider: position
Intervention 1 provider:
time spent on delivery
Intervention 23
provider: time
spent on delivery
Intervention 2
provider: time
spent on delivery
Walti, 2015121 Back pain Physiotherapist A N/A Physiotherapist B 30 minutes once or twice
per week for 8 weeks per
patient
N/A 30 minutes once or
twice per week for
8 weeks per patient
Wearden, 2010111 Chronic fatigue 3 registered, adult
specialty, general nurses
3 registered, adult
specialty, general
nurses
GP 90-minute home visit on
week 1; 1-hour home visits
on weeks 2, 4, 10 and 19;
and 30-minute telephone
calls on weeks 3, 6, 8, 12
and 15
90-minute home
visit on week 1;
1-hour home
visits on weeks 2,
4, 10 and 19;
and 30-minute
telephone calls on
weeks 3, 6, 8, 12
and 15
N/A
Whitehead, 2002154 Chronic fatigue GPs N/A GPs 10 minute biweekly
sessions over 12 months
N/A 10-minute biweekly
sessions over
12 months
Zonneveld, 2012141 MUS 6 psychologists N/A NR 13 × 2-hour sessions N/A N/A
eFR, elements of functional relaxation; N/A, not applicable; NR, not reported.
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Narrative synthesis of results
TABLE 46 Pain
First author and year
of publication Condition
Interventions
Scale Results summary
Cuesta-Vargas, 2012118 Pain single site MM vs. GSH
VAS
DWR+GP intervention group significantly better
than GP group alone at all time points
Macedo, 2012119 Pain single site GA vs. GA
NRS
No significant or clinically important differences
between groups at any time point
van der Roer, 2008120 Pain single site MM vs. SES
NRS
Significantly lower pain intensity for MM group at
26 weeks. No significant difference at 1 year
Walti, 2015121 Pain single site MM vs. SES
NRS
Mean pain decreased significantly more in
MM group
LeFort, 1998128 Pain multisite GSH vs. UC
VAS
Intervention group showed reduced pain problem
severity compared with control group
Alda, 2011137 Pain multisite CBTHI vs. ME
vs. UC
VAS
No significant differences in pain between groups
at the end of treatment. Greater reduction in pain
for RPT group compared with TAU group at
6-month follow-up
Luciano, 2014138 Pain multisite CBTHI vs. ME
vs. UC
VAS
ACT was more effective than medication and
waiting list in subjective pain reduction
Luciano, 2011139 Pain multisite MM vs. UC
FIQ – Pain
Subscale
Psychoeducation group showed less pain than
usual-care group at follow-up
Sañudo, 2010140 Pain multisite SES vs. SES vs. UC
SF-36 Pain
Significant improvement from baseline only
for combined exercise group at 24 weeks.
No improvement for usual-care group
Aiarzaguena, 2007136 MUS/somatoform GP-re vs. GP-re
SF-36 Pain
Both groups showed an improvement in bodily pain
at 12-month follow-up. Modified reattribution
group showed significantly greater improvement
than standard reattribution group
Peters, 2002106 MUS/somatoform SES vs. RSSE
SF-36 Pain
No significant change over time or between groups
Gili, 2014/Moreno,
2013144,148
MUS/somatoform CBTHI vs. CBTHI
vs. UC+
SF-36 Pain
Individual CBT group showed greater improvement
in pain compared with group at follow-up and at
6 months. Group CBT was no more effective than
TAU at any time point
Rothman, 2013127 Pain multisite GP-O vs. UC+
VAS
No significant difference in pain intensity between
groups
Loew, 2000122 Pain single site RSSE vs. RSSE
Pain days
Functional relaxation group showed greater
reduction of intense pain; medium pain; and
significantly fewer total pain days than the placebo
relaxation technique
continued
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TABLE 46 Pain (continued )
First author and year
of publication Condition
Interventions
Scale Results summary
Rosendal, 2007146 MUS/somatoform GP-MM vs. UC
SF-36 Pain
Significantly greater improvement in pain in
control group than in intervention group.
Significance disappeared after controlling for
multiple comparisons
van Ravesteijn, 2013143 MUS/somatoform OP vs. UC+
SF-36 Pain
No significant differences between groups at any
time point.Within-group analyses showed significant
improvement in bodily pain in MBCT group at
9-month follow-up but not in the enhanced
usual-care group
Zonneveld, 2012141 MUS/somatoform CBTHI vs. UC
SF-36 Pain
Significantly better improvement in bodily pain in
the intervention group than in the control group
McBeth, 2012125/
Beasley, 2015126
Pain multisite CBTHI vs. SES
vs. MM vs. UC
SF-36 Pain
Summaries not given. Means show trends towards
6 months TAU being the lowest, then exercise,
then combined and then TCBT. 9 months pain
lowest then exercise and combined, then TCBT
Lansinger, 2007123 Pain single site RSSE vs. SES
VAS
No significant differences in average neck pain in
past week between groups at any time point but
both groups improved from baseline to end of
treatment and at 6 and 12 months
Pols, 2008145 MUS/somatoform MM vs. UC
SF-36 Pain
No significant improvement
Kocken, 2008103 MUS/somatoform OP vs. UC
SF-36
(1 pain item)
Significant improvement for intervention group on
SF-36 (1 item measured)
Schaefert, 2013132 MUS/somatoform MM vs. GP-MM
SF-36 Pain
No significant improvement
Smith, 2009142 MUS/somatoform MM vs. UC
SF-36 Pain
Significance not reported
GP-O, GP – other; GP-re, general practitioner-delivered reattribution; GSH, guided self-help; MBCT, mindfulness-based
cognitive therapy; ME, medication; MM, multimodal; OP, other psychotherapy; RPT, recommended pharmacological
treatment; TAU, treatment as usual; TCBT, telephone CBT; UC, usual care; UC+, usual care plus.
TABLE 47 Fatigue
First author and year
of publication Condition
Interventions
scale Results summary
Ho, 2012150 Chronic fatigue RSSE vs. UC
The Fatigue Scale
Total fatigue score was significantly improved at
5 weeks and 4 months for both the qigong group
and the waiting list group
Friedberg, 2013151 Chronic fatigue CBTLI vs. RSSE
vs. UC
Fatigue Severity
Scale
Changes in Fatigue Severity Scale scores from
baseline to 12 months were unrelated to diagnostic
group. Significantly greater improvement in fatigue
for CBT group compared with support or usual-
care groups. Only CBT group showed significant
within-group improvement in fatigue
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 47 Fatigue (continued )
First author and year
of publication Condition
Interventions
scale Results summary
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue GP-CBT vs. UC
CIS – Fatigue
Severity Subscale
No significant difference between CBT and usual-
care groups at any point including 4 years’ follow-up
Marques, 2015133 Chronic fatigue GA vs. GSH
CIS20-P Total
Fatigue severity
Significant effect of GA intervention on fatigue
severity after controlling for the effects of
covariates
Moss-Morris, 2005152 Chronic fatigue GA vs. UC
14-item Fatigue
Scale
GA group scored lower on total fatigue at 12 weeks’
follow-up compared with usual-care group after
controlling for age and baseline differences. Effect
persisted at 6 months
Ridsdale, 2001112 Chronic fatigue CBTHI vs. OP
11-item Fatigue
Questionnaire
Fatigue scores fell in both groups. Analyses showed
a non-significant trend in favour of counselling at
6-month follow-up
Ridsdale, 2004113 Chronic fatigue CBTLI vs. GA
11-item Fatigue
Questionnaire
Significant fall in fatigue in both groups for average
follow-up time. A small difference between groups
favoured CBT over GA. This pattern was replicated
when analysing data only from patients who
completed all six sessions
Ridsdale, 2012115 Chronic fatigue GA vs. OP vs. GSH
11-item Fatigue
Questionnaire
Significant improvement in fatigue score at 6 and
12 months for all three groups, with no significant
difference between groups
Tummers, 2012149 Chronic fatigue CBTLI vs. UC
CIS – Fatigue
Severity Subscale
Significantly greater decrease in fatigue severity for
patients in the CBT group
Wearden, 2010111 Chronic fatigue GA vs. OP vs. UC
The Fatigue Scale
Patients in GA group had significantly improved
fatigue compared with UC group at 20 weeks but
no longer significant at 70 weeks. No significant
effect for OP intervention at either time point
Luciano, 2011139 Pain multisite MM vs. RSSE
FIQ – Fatigue
Subscale
Psychoeducation group showed less general fatigue
than usual-care group at follow-up
Whitehead, 2002154 Chronic fatigue GP-MM vs. UC
The Fatigue Scale
Fatigue fell in both groups but no significant
difference between groups at 6 or 12 months.
Fatigue remained abnormally high in both groups
Chalder, 1997114 Chronic fatigue GSH vs. UC
Fatigue
Questionnaire
Total fatigue scores fell in both groups. Patients in
the intervention group were less fatigued over
average of all time points than control group when
pre-intervention fatigue was controlled for
McBeth, 2012125/
Beasley, 2015126
Pain multisite CBTHI vs. SES vs.
MM vs. UC
CFQ
Improvements observed but not significant after
adjusting for multiple comparisons
CFQ, Chalder Fatigue Questionnaire; GSH, guided self-help; OP, other psychotherapy; UC, usual care; UC+, usual
care plus.
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TABLE 49 Somatisation
First author and
year of publication Condition Interventions scale Results summary
Peters, 2002106 MUS/somatoform SES vs. RSSE
HSCL – somatisation
Significant decline in somatisation (HSCL) over time,
from start of treatment to 6-month follow-up, but
was not significant at mid-programme or end of
programme. No significant difference between groups
Zonneveld, 2012141 MUS/somatoform CBTHI vs. UC
SCL-90-S
Significantly better improvement in SCL-90-S for
the intervention group compared with the control
group
Kobeissi, 2012110 MUVD RSSE vs. UC
SASS – somatisation
Small reduction favours intervention, not significant
Larisch, 2004158 MUS/somatoform GP-re vs. UC
SOMS-7
Significant improvement of symptoms in the
intervention group compared with the control
group at 3 months. This effect was lost after
controlling for confounders and baseline variables.
At 6 months this effect was significant even after
controlling for confounding factors
McLeod, 1997105 MUS/somatoform OP vs. UC
SCL-90-S
Significantly greater decrease in somatisation for
the intervention group compared with the waiting
list group
Rosendal, 2007146 MUS/somatoform GP-MM vs. UC
SCL-90-S
No significant difference between groups
Schilte, 2001159 MUS/somatoform GP-OP vs. UC
SCL-90-S
No significant difference between groups at any
time point
Toft, 201097 MUS/somatoform GP-MM vs. UC
SCL SOM
Patients in GP MUS management group meeting
criteria for SD or somatisation disorder showed a
smaller improvement in symptoms than patients in
the usual-care group
Rief, 2006102 MUS/somatoform GP-MM vs. UC
SOMS
Significant reduction in somatoform symptoms for
patients in the trained GP group compared with the
untrained GP group for the SSI interview, but no
difference between groups on the SOMS
TABLE 48 Bowel Symptoms
First author and
year of publication Condition Interventions scale Results summary
Kennedy, 2005129 IBS MM vs. ME
IBS-SSS
CBT plus medication had a beneficial summary effect
over medication alone. Benefits of CBT declined over
time. No significant effect by 12 months after
treatment
Moss-Morris,
2010130
IBS CBTLI vs. UC
IBS-SSS
No difference at the end of treatment. 3- and 6-month
follow-ups favoured SM group over TAU
Robinson, 2006131 IBS GSH vs. MM vs. UC
CGIS – Severity of
Symptoms
Neither guidebook nor self-help group intervention
had an effect on scores on the severity subscale of
the CGIS over 1 year compared with controls
GSH, guided self-help; IBS-SSS, Irritable Bowel Questionnaire Symptom Severity Scale; OP, other psychotherapy;
SM, self-management; TAU, treatment as usual; UC, usual care; UC+, usual care plus.
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TABLE 49 Somatisation (continued )
First author and
year of publication Condition Interventions scale Results summary
Martin, 200799 MUS/somatoform CBTLI vs. UC
SOMS-7/Bradford
Somatic Inventory
Significant reduction in number of symptoms in
both groups on SOMS-7. For Bradford Somatic
Inventory severity of symptoms, CBT group showed
a greater reduction than control group. No
improvement in severity for the control group
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform CBTHI vs. CBTHI
vs. UC+
SOMS
CBT groups showed greater improvement at the
end of treatment than TAU. Individual CBT was
more effective than group CBT. Effects remained
but decreased over 6 and 12 months’ follow-up
Kolk, 2004104 MUS/somatoform OP vs. UC
SCL-90-S
No significant difference between intervention
groups, although a positive main effect for time
from baseline to end of treatment and follow-up
was found
Escobar, 2007156 MUS/somatoform CBTHI vs. UC+
PHQ-15 – somatic
complaints
Significant improvement in physical symptoms for
the intervention group compared with the control
at the end of treatment and at 6-month follow-up
Schaefert, 2013147 MUS/somatoform MM vs. GP-MM
PHQ-15 – somatic
complaints
Significantly greater increase in somatic symptom
severity for MM group compared with GP-MM
group at 6 months was no longer significant at
12 months
Smith, 2009142 MUS/somatoform MM vs. UC
PHQ-15 – somatic
complaints
Significant effect for the intervention on the PHQ-15
over time. Trend towards greater improvement for
the intervention compared with controls but not
significant
Sumathipala, 2000116 MUS/somatoform CBTLI vs. UC
Bradford Somatic
Inventory somatic
symptoms
Significantly greater reduction in Bradford Somatic
Inventory score for the intervention group compared
with the control group
Sumathipala, 2008117 MUS/somatoform MM vs. GP-MM
Bradford Somatic
Inventory – somatic
symptoms
No significant difference in change in Bradford
Somatic Inventory between intervention and
control group, although both groups improved
over time
van Ravesteijn,
2013143
MUS/somatoform OP vs. UC+
PHQ-15 – somatic
complaints
No significant differences between groups at
either time point. Within-group analyses showed
improvement for the MBCT group at the end of
treatment and at 9 months’ follow-up, whereas
the enhanced usual-care group did not show
improvement
Marques, 2015133 Chronic fatigue GA vs. GSH
PHQ-15 – somatic
complaints
Intervention showed no significant effect
Burton, 2012157 MUS/somatoform GP-MM vs. UC
PHQ-14
Difference favours symptoms clinic over usual care.
No measures of significance given due to small
sample size
Smith, 2006107 MUS/somatoform MM vs. UC
PSC
PSC findings not reported
GP-re, general practitioner-delivered reattribution; GSH, guided self-help; HSCL, Hopkins Symptom Checklist;
MBCT, mindfulness-based cognitive therapy; OP, other psychotherapy; TAU, treatment as usual; UC, usual care;
UC+, usual care plus.
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TABLE 50 Emotional distress
First author and
year of publication Condition Interventions scale Results summary
Cuesta-Vargas,
2012118
Pain single site MM vs. GSH
SF-12-MH
DWR +GP intervention group significantly
better than GP group alone at all time points
Macedo, 2012119 Pain single site GA vs. GA
SF-36-MCS
No significant or clinically important differences
between groups at any time point
Ho, 2012150 Chronic fatigue RSSE vs. UC
SF-12-MH
Mental functioning was significantly improved
at 5 weeks and 4 months for the qigong group
but not in the waiting list group
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue GP-CBT
SCL-90
No significant difference between CBT and
usual-care groups at any point including 4-year
follow-up
Marques, 2015133 Chronic fatigue GA vs. GSH
SF-12-MH
Significant time-by-group interaction after
controlling for covariates in favour of intervention
group
LeFort, 1998128 Pain multisite GSH vs. UC
SF-36-MH
Positive trend to improvement for intervention
group compared with controls
Aiarzaguena, 2007136 MUS/somatoform GP-re vs. GP-re
SF-36-MH
Both groups showed an improvement in mental
health at 12-month follow-up. Modified
reattribution group showed a greater
improvement than standard reattribution
group; this effect almost reached significance
Peters, 2002106 MUS/somatoform SES vs. RSSE
SF-36-MH
Mental health (SF-36) significantly improved
over time from start of treatment to 6-month
follow-up, with significance at end of programme.
No significant difference between groups
Pols, 2008145 MUS/somatoform MM vs. UC
SF-36-MH
Almost significant trend towards greater
improvement for intervention group for mental
health subscale compared with controls at
12 months
Smith, 2009142 MUS/somatoform MM vs. UC
SF-36-MCS
Significant effect for the intervention on the
SF-36 MCS over time. Trend towards greater
improvement for the intervention compared
with controls but not significant
Sumathipala, 2008117 MUS/somatoform MM vs. GP-MM
GHQ-30 –
Psychological
Morbidity
No significant difference in change in emotional
distress between intervention and control
group, although both groups improved over
time
van Ravesteijn,
2013143
MUS/somatoform OP vs. UC+
SF-36-MH
Significantly greater improvement in MCS but
not MH subscale at the end of treatment for
MBCT group only. At 9-month follow-up, within
group analyses for MCS and MH subscale
showed significantly improved scores for
both groups
Zonneveld, 2012141 MUS/somatoform CBT-HI
SF-36-MH
No significant differences for mental health
between groups, nor for the MCS
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TABLE 50 Emotional distress (continued )
First author and
year of publication Condition Interventions scale Results summary
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform CBTHI vs. CBTHI vs.
UC+
SF-36-MH
Individual CBT showed greater improvement in
mental health than TAU at 6- and 12-month
follow-up. No other significant differences
between groups
Kocken, 2008103 MUS/somatoform OP vs. UC
SCL-90 Anxiety and
Depression
Significant improvement in mental health
compared with control group
Larisch, 2004158 MUS/somatoform GP-re vs. UC
SF-12
No significant differences between groups
Rosendal, 2007146 MUS/somatoform GP-MM vs. UC
SF-36-MH
No significant difference between groups
Schaefert, 2013147 MUS/somatoform MM vs. GP-MM
SF-36-MCS
Significantly greater increase in mental
component summary for MM group compared
with GP-MM group, significant for per-protocol
analysis at 6 and 12 months, only at 12 months
for ITT analysis
Smith, 1995100 MUS/somatoform UC+ vs. UC
RAND MHI
No statistical differences between groups
Toft, 201097 MUS/somatoform GP-MM vs. UC
SF-36-MH
No significant differences between intervention
groups for any diagnostic subgroups
van der Feltz-
Cornelis, 2006160
MUS/somatoform MM vs. GP-re
SIP
No significant difference between groups for
SCL-90 psychological symptoms. Note that no
means were reported because of a lack of
significance
Robinson, 2006131 IBS GSH vs. MM vs. UC
SF-36 – MH
No significant effect for guidebook on mental
health, although difference favoured guidebook
Kashner, 1995161 MUS/somatoform RSSE vs. UC+
RAND MHI
Significant improvement in mental health for
therapy group compared with UC group. Trend
towards patients who attended one or more
sessions showing greater improvement but not
statistically significant. The more sessions
attended, the greater the improvement in
mental health
McBeth, 2012125 Pain multisite CBTHI vs. SES vs.
MM vs. UC
SF-36-MCS
Summaries not given. The means show trends
towards 6 months’ TAU being the lowest, then
combined, then TCBT, then exercise highest.
9 months’ TAU is the lowest, then combined,
then exercise then TCBT
Sumathipala, 2000116 MUS/somatoform CBTLI vs. UC
GHQ-30
Significantly greater reduction in level of
distress for intervention group compared with
control group
Chalder, 1997114 Chronic fatigue GSH vs. UC
GHQ-12
The self-help group slightly improved, whereas
the control group deteriorated
Kennedy, 2005129 IBS MM vs. ME
HADS total
Summary effect of CBT over 1 year was
significant reduction in HADS score
continued
DOI: 10.3310/hta24460 Health Technology Assessment 2020 Vol. 24 No. 46
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Leaviss et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
311
TABLE 51 Anxiety
First author and
year of publication Condition Interventions scale Results summary
Friedberg, 2013151 Chronic fatigue CBTLI vs. RSSE vs.
UC
BAI
No significant differences for change in anxiety
change by time, treatment group, or diagnostic
group and no significant interactions between
any of the above factors
Marques, 2015133 Chronic fatigue GA vs. GSH
BSI – Anxiety
Intervention showed no significant effect
Ridsdale, 2001112 Chronic fatigue CBTHI vs. OP
HADS-A
No significant differences between groups
Ridsdale, 2004113 Chronic fatigue CBTLI vs. GA
HADS-A
Anxiety scores fell in both groups following
treatment. Anxiety scores were significantly
lower for CBT group compared with GA group
Ridsdale, 2012115 Chronic fatigue GA vs. OP vs. GSH
HADS-A
Reduction in anxiety at 6 months of similar
magnitude for all three groups
Wearden, 2010111 Chronic fatigue GA vs. OP vs. UC
HADS-A
No significant effect for OP intervention
Alda, 2011137 Pain multisite CBTHI vs. ME vs. UC
HARS
Equal significant reduction in anxiety at the end
of treatment and at 6-month follow-up for CBT
and RPT groups compared with TAU
Luciano, 2014138 Pain multisite CBTHI vs. ME vs. UC
HADS-A
ACT more effective than medication and
waiting list in reduction in anxiety short and
long term
Luciano, 2011139 Pain multisite MM vs. UC
FIQ – Anxiety
Subscale
Psychoeducation group showed lower anxiety
than usual-care group at follow-up
Moss-Morris, 2010130 IBS CBTLI vs. UC
HADS-A
Small group-by-time interaction. No between
groups differences. Within-groups significant
reduction in anxiety from baseline to 6 months’
follow-up for SM, none for TAU
TABLE 50 Emotional distress (continued )
First author and
year of publication Condition Interventions scale Results summary
Sañudo, 2010140 Pain multisite SES vs. SES vs. UC
SF-36-MH
Significant improvement from baseline only
for combined exercise group at 24 weeks.
No improvement for usual-care group
Burton, 2012157 MUS/somatoform GP-MM vs. UC
SF-12-MCS
No measures of statistical significance included
as a result of the small sample size
Smith, 2006107 MUS/somatoform MM vs. UC
SF-36-MH
Findings not reported
GP-re, general practitioner-delivered reattribution; GSH, guided self-help; ITT, intention to treat; MBCT, mindfulness-based
cognitive therapy; ME, medication; MH, mental health; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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TABLE 51 Anxiety (continued )
First author and
year of publication Condition Interventions scale Results summary
Escobar, 2007156 MUS/somatoform CBTHI vs. UC+
HAM-A
No significant difference between groups at
either time point
Kolk, 2004104 MUS/somatoform OP vs. UC
SCL-90 – Anxiety
No significant difference between intervention
groups. Although a positive main effect for time
from baseline to end of treatment was found
Morriss, 2007108 MUS/somatoform GP-re vs. UC
HADS-A % caseness
No significant difference between groups for
anxiety caseness
Peters, 2002106 MUS/somatoform SES vs. RSSE
HADS-A
Significant decline in anxiety from start of
treatment to 6-month follow-up. This decline was
significant from mid-programme. No significant
difference between groups
Smith, 2009142 MUS/somatoform MM vs. UC
SSAS
No significant effects
Zonneveld, 2012141 MUS/somatoform CBTHI vs. UC
SCL-90A
No significant differences between groups for
anxiety
Kobeissi, 2012110 MUVD RSSE vs. UC
HSCL-25 – Anxiety
Marginal reduction for intervention, not
significant
Gili, 2014/Moreno,
2013144,148
MUS/somatoform CBTHI vs. CBTHI
vs. UC+
HAM-A
Individual CBT group had more improved
anxiety than group CBT or TAU at the end of
treatment. By 12 months, only group CBT had
maintained improvement
Larisch, 2004158 MUS/somatoform GP-re vs. UC
HADS-A
Significant improvement in anxiety in the
intervention group compared with the control
group at 3 months. This effect was lost after
controlling for confounders and baseline variables
McLeod, 1997105 MUS/somatoform OP vs. UC
SCL-90 Anxiety
Significantly greater decrease in anxiety for the
intervention group compared with the waiting
list group
Schilte, 2001159 MUS/somatoform GP-OP vs. UC
SCL-90 Anxiety
No significant difference between groups at any
time point
Posse, 200496 MUS/somatoform OP vs. UC
Somatic Anxiety
No significant change after therapy
Rothman, 2013127 Pain multisite GP-O vs. UC+
SCI-93 Stress
No significant difference between groups for
perceived stress
Rief, 2006102 MUS/somatoform GP-MM vs. UC
BAI
Significant improvement in anxiety for the
patients in the trained GP group compared with
those in the untrained GP group
Whitehead, 2002154 Chronic fatigue GP-MM vs. UC
HAD
No significant differences between groups at
any time point
Pols, 2008145 MUS/somatoform MM vs. UC
STAI
Significant improvement in anxiety at 12 months
for intervention group
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TABLE 51 Anxiety (continued )
First author and
year of publication Condition Interventions scale Results summary
Burton, 2012157 MUS/somatoform GP-MM vs. UC
GAD-7
No measures of statistical significance included
due to small sample size
Tummers, 2012149 Chronic fatigue CBTLI vs. UC
BSI
No significant difference between groups
Smith, 2006107 MUS/somatoform MM vs. UC
SSAS
Findings not reported
Kennedy, 2005129 IBS MM vs. ME
HADS
Summary effect of CBT over 1 year was a
significant reduction in HADS anxiety and
depression
FIQ, Fibromyalgia Impact Questionnaire; GAD, general anxiety disorder; GP-O, GP – other; GP-re, general practitioner-
delivered reattribution; GSH, guided self-help; HSCL, Hopkins Symptom Checklist; ME, medication; OP, other
psychotherapy; SCI, Symptoms Clinic Intervention; SM, self-management; SSAS, Spielberger State Anxiety Scale;
STAI, State–Trait Anxiety Inventory; UC, usual care; UC+, usual care plus.
TABLE 52 Depression
First author and
year of publication Condition Interventions scale Results summary
Friedberg, 2013151 Chronic fatigue CBTLI vs. RSSE
vs. UC
BDI
No significant differences for change in depression
by time, treatment group, or diagnostic group
and no significant interactions between any of the
above factors
Marques, 2015133 Chronic fatigue GA vs. GSH
BSI – Depression
Intervention showed no significant effect
Ridsdale, 2001112 Chronic fatigue CBTHI vs. OP
HADS–D
No significant differences between groups
Ridsdale, 2004113 Chronic fatigue CBTLI vs. GA
HADS–D
Depression scores fell in both groups following
treatment. No significant difference between
groups
Ridsdale, 2012115 Chronic fatigue GA vs. OP vs. GSH
HADS–D
Reduction in depression at 6 months of similar
magnitude for all three groups
Wearden, 2010111 Chronic fatigue GA vs. OP vs. UC
HADS–D
Patients in GA group had significantly improved
depression. No significant effect for OP
intervention
LeFort, 1998128 Pain multisite GSH vs. UC
BDI
No significant difference between groups
Alda, 2011137 Pain multisite CBTHI vs. ME vs. UC
HAM-D
No significant differences between the groups
at the end of treatment. Significantly greater
reduction in depression at 6-month follow-up
for the CBT group than in the TAU group
Luciano, 2014138 Pain multisite CBTHI vs. ME vs. UC
HADS–D
ACT more effective than medication and
waiting list in reduction of depression
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TABLE 52 Depression (continued )
First author and
year of publication Condition Interventions scale Results summary
Luciano, 2011139 Pain multisite MM vs. UC
FIQ – Depression
Subscale
Psychoeducation group were less depressed
than usual-care group at follow-up
Sañudo, 2010140 Pain multisite SES vs. SES vs. UC
BDI
Significant improvement from baseline for both
exercise groups at 24 weeks. No improvement
for usual-care group
Moss-Morris, 2010130 IBS CBTLI
HADS
No significant group-by-time interaction
Escobar, 2007156 MUS/somatoform CBTHI vs. UC+
HAM-D
Significant improvement in depression for the
intervention group compared with the control
group at the end of treatment. This effect was
no longer significant at 6-month follow-up
Kolk, 2004104 MUS/somatoform OP vs. UC
SCL-90 – Depression
No significant difference between intervention
groups. Although a positive main effect for time
from baseline to end of treatment was found
Martin, 200799 MUS/somatoform CBTLI vs. UC
BDI
Both groups showed a significant reduction
in depression at follow-up. No significant
difference between groups
Morriss, 2007108 MUS/somatoform GP-re vs. UC
HADS–D
% caseness
No significant difference between groups for
depression caseness
Peters, 2002106 MUS/somatoform SES vs. RSSE
HADS-D
Significant decline in depression from start of
treatment to 6-month follow-up. This decline
was significant from mid-programme
Smith, 2009142 MUS/somatoform MM vs. UC
CES-D
Significant effect for the intervention on the
CES-D over time and compared with the
control group
van Ravesteijn,
2013143
MUS/somatoform OP vs. UC+
PHQ-9
No significant differences between groups at
either time point. The enhanced usual-care
group showed improvement in depressive
symptoms at the 9-month follow-up, whereas
the MBCT group did not
Zonneveld, 2012141 MUS/somatoform CBTHI vs. UC
SCL-90 Depression
No significant differences between groups for
depression
Kobeissi, 2012110 MUVD RSSE vs. UC
HSCL-25 –
Depression
Marginal reduction for intervention, not
significant
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform CBTHI vs. CBTHI
vs. UC+
HAM-D
Individual CBT group had more improved
depressive symptoms than group CBT or TAU
at the end of treatment. Individual CBT group
more improved than TAU at 6 months.
No differences at 12-month follow-up
Larisch, 2004158 MUS/somatoform GP-re vs. UC
HADS-D
Significant improvement in depression in the
intervention group compared with the control
group at 3 months. This effect was lost after
controlling for confounders and baseline variables
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TABLE 52 Depression (continued )
First author and
year of publication Condition Interventions scale Results summary
McLeod, 1997105 MUS/somatoform OP vs. UC
SCL-90 Depression
Significantly greater decrease in depression
for the intervention group than in the waiting
list group
Schilte, 2001159 MUS/somatoform GP-OP vs. UC
SCL-90 Depression
No significant difference between groups at any
time point
Rothman, 2013127 Pain multisite GP-O vs. UC+
Zung
No significant difference between groups for
depression
Rief, 2006102 MUS/somatoform GP-MM vs. UC
BDI
Both groups showed a significant reduction
in symptoms over time, but there was no
significant difference between groups
Whitehead, 2002154 CFS GP-MM vs. UC
HADS
No significant differences between groups at
any time point
Pols, 2008145 MUS/somatoform MM vs. UC
BDI-II
Significant improvement in depression for
intervention group at 12 months
Schaefert, 2013147 MUS/somatoform MM vs. GP-MUS
PHQ-9
No significant differences between groups
Smith, 2006107 MUS/somatoform MM vs. UC
CES-D
Significant improvement in depression score
from baseline to the 12-month follow-up for
the intervention group but not the UC group
Burton, 2012157 MUS/somatoform PHQ-12 No measures of statistical significance included
as a result of the small sample size
GP-O, GP – other; GP-re, general practitioner-delivered reattribution; GSH, guided self-help; HSCL, Hopkins Symptom
Checklist; ME, medication; MUVD, medically unexplained vaginal discharge; OP, other psychotherapy; TAU, treatment
as usual; UC, usual care; UC+, usual care plus.
TABLE 53 Physical functioning
First author and
year of publication Condition
Interventions
scale Results summary
Cuesta-Vargas,
2012118
Pain single site MM vs. GSH
SF-12-PF
DWR+GP intervention group significantly better
than GP group alone at all time points
Macedo, 2012119 Pain single site GA vs. GA
SF-36-PCS
No significant or clinically important differences
between groups at any time point
Friedberg, 2013151 Chronic fatigue CBTLI vs. RSSE
vs. UC
SF-36-PF
No significant differences for change in physical
function by time, treatment group or diagnostic
group and no significant interactions between
any of the above factors
Ho, 2012150 Chronic fatigue RSSE vs. UC
SF-12-PF
Physical functioning did not improve in either
qigong or waiting list groups
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TABLE 53 Physical functioning (continued )
First author and
year of publication Condition
Interventions
scale Results summary
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue GP-CBT
SF-36-PF
No significant difference between CBT and
usual-care groups at any point including at
the 4-year follow-up
Marques, 2015133 Chronic fatigue GA vs. GSH
SF-12-PF
Significant group by time interaction after
controlling for the effect of covariates
Moss-Morris, 2005152 Chronic fatigue GA vs. UC
SF-36-PF
No significant differences between groups at
either the 12-week or 6-month follow-up
Tummers, 2012149 Chronic fatigue CBTLI vs. UC
SF-36-PF
No significant difference between groups for
physical functioning
Wearden, 2010111 Chronic fatigue GA vs. OP vs. UC
SF-36-PF
Patients in OP group had significantly worse
physical functioning than UC group at 20 weeks.
No significant difference for GA group compared
with UC at 20 or 70 weeks
LeFort, 1998128 Pain multisite GSH vs. UC
SF-36-PF
No significant difference between groups
Luciano, 2011139 Pain multisite MM vs. UC
FIQ – PF
Psychoeducation group showed less physical
impairment than usual-care group at follow-up
Aiarzaguena, 2007136 MUS/somatoform GP-re vs. GP-re
SF-36-PF
Both groups showed an improvement in physical
functioning at 12-month follow-up. Modified
reattribution group showed significantly greater
improvement than standard reattribution group
Escobar, 2007156 MUS/somatoform CBTHI vs. UC+
MOS-10 PF
No significant difference at either time point
Peters, 2002106 MUS/somatoform SES vs. RSSE
SF-36-PF
No change for physical function
Pols, 2008145 MUS/somatoform MM vs. UC
SF-36-PF
No significant difference between groups at
12 months in physical functioning subscale or
physical component summary
Smith, 2009142 MUS/somatoform MM vs. UC
SF-36-PCS
No significant effects
van Ravesteijn,
2013143
MUS/somatoform OP vs. UC+
SF-36-PF
No significant difference between groups for
physical functioning at the end of treatment.
Significant within-group improvement at 9-month
follow-up for MBCT group but not for enhanced
usual-care group, but only for PCS not for
PF subscale
Zonneveld, 2012141 MUS/somatoform CBTHI vs. UC
SF-36-PF
No significant differences between groups for
physical functioning subscale, although PCS was
significant in favour of intervention group
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform CBTHI vs. CBTHI
vs. UC+
SF-36-PF
Individual CBT group showed greater improvement
in physical functioning than group CBT or TAU at
all time points. No improvement for group CBT
compared with TAU at any time point
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TABLE 53 Physical functioning (continued )
First author and
year of publication Condition
Interventions
scale Results summary
Larisch, 2004158 MUS/somatoform GP-re vs.
UC SF-12-PF
Significant improvement in physical functioning in
the intervention group compared with the control
group at 3 months. This effect was lost after
controlling for confounders and baseline variables
Rosendal, 2007146 MUS/somatoform GP-MM vs. UC
SF-36-PF
No significant difference between groups
Schaefert, 2013147 MUS/somatoform MM vs. GP-MM
SF-36-PCS
Increase in physical functioning in both groups at
12 months. No significant difference in physical
component summary between groups
Smith, 1995100 MUS/somatoform UC+ vs. UC
RAND – PFI
Patients in psychiatric consultation group
reported significantly greater physical functioning
compared with usual-care group during the year
after the intervention
Chalder, 1997114 Chronic fatigue GSH vs. UC
MOS – PF
Physical functioning was slightly improved in the
self-help group but deteriorated in the control
group
Toft, 201097 MUS/somatoform GP-MM vs. UC
SF-36-PF
Patients meeting diagnostic criteria for SD
(ICD-10) had greater improvement in physical
functioning compared with controls, but only at
3-month follow-up. No statistically significant
improvement for patients with somatisation
disorder or those with subthreshold SD
Robinson, 2006131 IBS GSH vs. MM
SF-36-PF
No significant effect for guidebook on physical
function, although difference favoured guidebook
Kashner, 1995161 MUS/somatoform RSSE vs. UC+
RAND – PFI
Significant improvement in physical functioning
for therapy group compared with UC group.
Trend towards patients who attended one or
more sessions showing greater improvement
but not statistically significant
McBeth, 2012125/
Beasley, 2015126
Pain multisite CBTHI vs. SES vs.
MM vs. UC
SF-36-PCS
Summaries not given. The means show a
trend towards 6 months, with TAU being the
lowest, exercise, TCBT, then combined highest.
9 months’ TAU being the lowest, TCBT, exercise,
then combined
Rothman, 2013127 Pain multisite GP-O vs. UC+ Significant improvement in physical function for
the multimodal group
Sañudo, 2010140 Pain multisite SES vs. SES vs. UC
SF-36-PF
Significant improvement from baseline for both
exercise groups at 24 weeks. No improvement
for usual-care group
Burton, 2012157 MUS/somatoform GP-MM vs. UC
SF-12-PCS
No measures of statistical significance included
as a result of the small sample size
Smith, 2006107 MUS/somatoform MM vs. UC
SF-36-PF
No significant improvement for physical functioning
DWR, deep-water running; GP-O, GP – other; GP-re, general practitioner-delivered reattribution; GSH, guided
self-help; OP, other psychotherapy; PF, physical functioning; PFI, physical functioning index; TAU, treatment as usual;
TCBT, telephone CBT; UC, usual care; UC+, usual care plus.
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TABLE 54 Satisfaction, acceptability or adherence for GP interventions
First author and
year of publication Condition Interventions scale Results summary
Aiarzaguena, 2007136 MUS/somatoform GP – reattribution
(modified) vs. GP
intervention –
reattribution
76% of patients in the ‘modified’
reattribution group attended all
six standardised sessions, compared
with 91% in the reattribution group
Larisch, 2004158 MUS/somatoform GP – reattribution
(modified) vs. UC
Reattribution group received a mean
4.8/6 sessions during the 3-month
treatment period. Usual-care group
received a mean 4.6/6 sessions of care
Morriss, 2007108 MUS/somatoform GP – reattribution
vs. UC
All eligible GPs completed the training.
91% attended all three sessions. 22/27
practitioners felt confident or very
confident about dealing with patients
with MUS after training. 5/27 were
uncertain or unchanged in their
confidence. Non-significant trend
towards increased patient satisfaction
measures for intervention group
compared with controls
Rief, 2006102 MUS/somatoform GP – MUS
management UC
GP satisfaction ratings were similar
across items. For the key item ‘how
relevant was the workshop for your
everyday practice in your GP office’ 48%
said extremely relevant, 39% said highly
relevant, 9% said partially relevant and
4% said low relevance and 0% said very
low relevance
Rosendal, 2007146 MUS/somatoform GP – MUS
management vs. UC
Practice level: three practices dropped
out before the intervention. Another
three practices were excluded as a result
of low levels of patient inclusion. Patient
level: 15% of eligible patients refused to
participate. No significant difference
between groups on patients’ satisfaction
with care (‘Very satisfied with doctor–
patient relationship’ 39.1% intervention
group compared with 36.5% control
group. ‘Very satisfied with medical-
technical care’ 29.0% intervention group,
24.7% control group. ‘Very satisfied
with information and support’ 36.8%
intervention group, 30.6% control group)
Toft, 201097 MUS/somatoform GP – MUS
management vs. UC
412/2197 potential participants refused
to participate. No reasons given
Whitehead, 2002154 CF GP intervention –
MUS management
vs. UC
Follow-up data obtained for 18/26 patients
(69%) in the intervention group and 28/39
(72%) in the control group at 6 months
and 9/26 (35%) in the intervention group
and 21/39 (54%) in the control group at
12 months. In the intervention group,
5/26 (19%) patients used the diaries for
≤ 1 month, a further 5/26 (19%) stopped
using the diaries at 3 months. 8/26 (31%)
used the diaries for ≥ 8 months. 4/26
(15%) used the diaries for ≥ 12 months.
Reasons for discontinuation included
regaining full or a satisfactory level of
health, feeling no need for the diaries, or
feeling no benefit from the diaries
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TABLE 54 Satisfaction, acceptability or adherence for GP interventions (continued )
First author and
year of publication Condition Interventions scale Results summary
Huibers, 2004/
Leone, 2006153,155
CF GP – CBT vs. UC 5/76 participants allocated to CBT refused
treatment immediately. 51/71 remaining
participants completed the intervention
according to protocol. The mean number
of sessions attended was 5.3
Schilte, 2001159 MUS/somatoform GP intervention –
other psychotherapy
vs. UC
35/362 potential participants declined to
take part. 77/81 patients in the disclosure
group completed the two meetings with
the disclosure doctor. 22/81 attended an
additional joint consultation with their
own doctor. 30 out of the 55 remaining
participants did not disclose important
information at the meetings, 11/55 did
not want to share the disclosed
information with their own doctor, 9/55
had already disclosed the information,
5/55 gave no reason for not attending the
additional meeting. 47/77 disclosure
group participants disclosed emotionally
important events. 55/77 judged the
intervention to be positive. One patient
criticised the disclosure intervention,
refusing to discuss her disclosure again
Rothman, 2013127 Pain-MS GP – multidisciplinary
assessment+
motivational
interview+
psychotherapy vs. UC
Patient satisfaction with their assessment
was significantly higher in the multimodal
group
Burton, 2012157 MUS/somatoform GP-MM vs. UC 8/11 patients responding to the client
satisfaction questionnaire reported the
intervention helped them deal with their
problems more effectively. Patients
appreciated the time and explanatory
approach
Pain-MS, pain multisite; UC, usual care.
TABLE 55 Satisfaction, acceptability or adherence in CBT intervention studies
First author and
year of publication Condition Interventions scale Results summary
Alda, 2011137 Pain-MS CBT high intensity
vs. UC
16/218 eligible patients decided not to
participate. No reasons given
Escobar, 2007156 MUS/somatoform CBT high intensity
vs. UC+
244/416 eligible patients were not
enrolled. Reasons included patient
declining to participate, being unable
to make regular visits, having severe
psychiatric problems or having medical
explanations for their symptoms
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform CBT high intensity –
individual vs. CBT
high intensity group
vs. UC+
53/518 potential participants refused to
participate. 18/152 participants dropped
out of the study of whom three were
randomised to individual CBT, one to
group CBT and 14 to TAU. Reasons
included family problems, moving away
and onset of new medical problems
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TABLE 55 Satisfaction, acceptability or adherence in CBT intervention studies (continued )
First author and
year of publication Condition Interventions scale Results summary
Luciano, 2014138 Pain-MS CBT – high intensity
vs. medication
20 participants dropped out of the study,
six in ACT group, eight in medication
group and six in waiting list group
McBeth, 2012125/
Beasley, 2015126
Pain-MS CBT – high intensity
vs. multimodal vs.
SES vs. UC
157/224 (70.1%) of TCBT group completed
at least six therapy sessions. 65/130 (50%)
of the exercise group reached the
compliance threshold of at least two
sessions per week. 21/130 (16.2%) did not
attend any sessions on their own
Ridsdale, 2001112 CF CBT high intensity
vs. other
psychotherapy
51/80 (64%) patients in the counselling
group completed all six therapy sessions.
55/80 (69%) patients in the CBT group
completed all six therapy sessions.
Reasons for not completing included not
tired any more, too busy, did not find the
intervention useful. 26/54 non-completers
across both groups had no therapy. CBT
group were significantly more satisfied
with the process of therapy than the
counselling group
Zonneveld, 2012141 MUS/somatoform CBT high intensity
vs. UC
Participants in the intervention group
attended a mean 11/20 sessions. The
minimum number of attended sessions
was six
Friedberg, 2013151 CF CBT low intensity
vs. UC
Among FSM participants, 30/37 (81%)
completed the two-session intervention
and 3 months’ follow-up, and 19/37 (51%)
completed the 12 months’ follow-up.
Among AC participants, 31/38 (82%)
completed the two-session intervention
and 3 months’ follow-up, and 22 (58%)
completed the 12 months’ follow-up.
Among UC participants, 28/36 participants
(78%) completed the two-session
intervention and 3 months’ follow-up
and 18 (47%) completed the 12 months’
follow-up. Reasons given not specified
by intervention group
Martin, 200799 MUS/somatoform CBT low intensity
vs. UC
Total drop-out rate was 15%, no significant
difference in drop-out rates between
groups (n= 10 in the CBT group, n= 11 in
the control group). Ratings of satisfaction
for CBT participants were 96% would
recommend to a friend; 96% thought the
intervention should be offered more; 94%
felt understood by the therapist; and 92%
rated the intervention as a promising
strategy for the management of their
symptoms
continued
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TABLE 55 Satisfaction, acceptability or adherence in CBT intervention studies (continued )
First author and
year of publication Condition Interventions scale Results summary
Moss-Morris, 2010130 CF CBT low intensity
vs. UC
Adherence: 24/30 (80%) in self-
management group returned homework
sheets. Mean 6.94/10 sheets completed.
Acceptability: 21/30 (70%) rated self-
management treatment as much better
or better than other treatment they had
received. 18/30 (60%) rated SM as highly
or very effective. 27/30 (90%) enjoyed
the SM treatment
Ridsdale, 2004113 CF CBT low intensity
vs. GA
Participants in the intervention groups
attended an average of 4.6 out of a
possible six sessions. Reasons for non-
completion included 13/120 (11%) too
busy, 8/120 (7%) lack of faith in therapy,
4/120 (3%) feeling better. Significantly
more patients completed all six sessions
in the CBT group (45/63, 71%) compared
with the GET group (36/60, 60%).
seven patients allocated to GET group
did not start treatment. More patients
cited lack of faith in therapy as a reason
for not starting or not completing
treatment in the GET group than in
the CBT group
Sumathipala, 2000116 MUS/somatoform CBT low intensity
vs. UC
Number of referrals to the study varied by
doctor (range 7–43 referrals). 4/80 eligible
patients declined to consent, 8/80 eligible
patients did not attend baseline assessment.
34/34 CBT group participants attended at
least one session. 29/34 (85%) attended
two or more sessions. 22/34 attended
three or more sessions. Drop-out rates
in the CBT group were 15% between
session one and two and 21% between
second and third session. Drop-out rate at
3-month follow-up was 30% for the CBT
group compared with 38% for the control
group. Two patients were diagnosed with
physical illnesses and did not complete
the follow-up at 3 months. These patients
reported that they ‘felt they did not have
the type of illness we think’ (i.e. having a
psychological basis). Satisfaction was
higher at follow-up in the intervention
group. Dissatisfaction was higher in the
control group at follow-up
Tummers, 2012149 CF CBT low intensity
vs. UC
19/142 patients (13%) refused to take
part for a number of reasons including
preference for face-to-face contact,
experiencing remission of symptoms,
having no faith in the treatment or
preferring a different treatment
AC, attention control; FSM, fatigue self-management; SM, self-management; TAU, treatment as usual; TCBT, telephone
CBT; UC, usual care; UC+ usual care plus.
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TABLE 56 Satisfaction, acceptability or adherence in RSSE intervention studies
First author and
year of publication Intervention group Condition Satisfaction, acceptability or adherence
Ho, 2012150 Relaxation/stretching/
social support/emotional
support vs. UC
CF 27/35 (81.8%) of participants completed
the qigong intervention. 25/35 (80.6%) of
participants dropped out of the waiting
list group
Kashner, 1995161 Relaxation/stretching/
social support/emotional
support vs. UC
MUS/somatoform 20/44 participants in the group therapy
group participated in one or more sessions.
Mean number of sessions attended was
2.2. 4/44 attended one or two sessions.
5/44 attended three or four sessions.
5/44 attended five or six sessions.
6/44 attended seven or eight sessions
Kobeissi, 2012110 Relaxation/stretching/
social support/emotional
support vs. UC
MUVD 49/75 (65%) participants in the intervention
group attended at least six sessions
Lansinger, 2007123 Relaxation/stretching/
social support/emotional
support vs. SES
Pain-SS During the intervention period: 12/60
withdrawals in qigong group; 6/62
withdrawals in exercise group
Loew, 2000122 Relaxation/stretching/
social support/emotional
support vs. relaxation/
stretching/social
support/emotional
support
Pain-SS Not reported
MUVD, medically unexplained vaginal discharge; Pain-SS, pain single site; UC, usual care.
TABLE 57 Satisfaction, acceptability or adherence in GSH intervention studies
First author and
year of publication Intervention group Condition Satisfaction, acceptability or adherence
Chalder, 1997114 GSH vs. UC CF 11/70 (16%) dropouts in self-help
intervention group, 14/80 (18%) dropouts
in the control group. 50/70 (71%) of
participants in the intervention group said
they had read the booklet and, of these,
42/50 (84%) said they found it helpful
LeFort, 1988128 GSH vs. UC Pain-MS 5/57 participants considered to be
dropouts. n = 1 admitted to hospital for
acute illness, n= 1 discovered ineligible
after randomisation, n = 3 attended one
or no classes and declined to complete
questionnaire. 3/53 dropouts in control
group could not be contacted at follow-up
GSH, guided self-help; Pain-MS, pain multisite; UC, usual care.
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TABLE 58 Satisfaction, acceptability or adherence in multimodal intervention studies
First author and
year of publication Intervention group Condition
Satisfaction, acceptability or
adherence
Cuesta-Vargas,
2012118
Multimodal (sport +
education) vs. guided
self-help
Pain-SS 17.2% drop-out rate across
both interventions. DWR +GP
group 25/29 completers; GP
alone 24/29 completers
Kennedy, 2005129 Multimodal (CBT low
intensity +medication)
vs. medication
IBS Fewer than half of patients
were considered to have
completed CBT. 14% declined
therapy or dropped out.
Reasons for non-attendance
included no time off work or
child care commitments
Pols, 2008145 Multimodal (self-management +
medication +CBT) vs. UC
MUS/somatoform 35/420 (8.3%) eligible GPs
approached for the study
enrolled potential participants.
Not all eligible patients were
referred. 17/320 eligible
patients were referred in one
particular GP practice. 18/89
intervention patients in the
intervention group dropped out
before completing initial
assessments, followed by a
further 22 dropouts. 25/89
intervention group patients
were referred to and attended
CBT. 15/89 were referred to
CBT but did not attend. 13/35
control patients dropped out
Luciano, 2011139 Relaxation/stretching/social
support/emotional support
vs. UC
Pain-MS 7/108 (6.5%) drop-out rate in
the psychoeducation group.
14/108 (13%) drop-out rate in
usual-care group. Reasons for
dropouts not specified by
intervention group
Schaefert, 2013147 Multimodal (GP intervention –
MUS management + other
psychotherapy) vs. GP – MUS
management
MUS/somatoform More decliners in the GP-MM
group than in the MM group.
No difference in reasons given
between groups. Reasons
included reservations about the
treatment (MM 29%, GP-MM
22%); lack of time (MM 22%,
GP-MM 20%); lack of interest
(MM 9%, GP-MM 18%); other
reasons including organic
disease, language barrier, low
degree of suffering (MM 18%,
GP-MM 9%); no reason
(MM 22%, GP-MM 32%)
Smith, 2006107 Multimodal vs. UC MUS/somatoform 200/208 (97%) participants
(98/101 intervention group,
102/105 control group)
completed the study
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TABLE 58 Satisfaction, acceptability or adherence in multimodal intervention studies (continued )
First author and
year of publication Intervention group Condition
Satisfaction, acceptability or
adherence
Smith, 2009142 Multimodal (GP intervention
CBT +medication) vs. UC
MUS/somatoform 44/82 eligible patients agreed to
take part, of whom 30 patients
were included in the study
Sumathipala, 2008117 Multimodal (GP-CBT+GP –
MUS management) vs. GP –
MUS management
MUS/somatoform 64/75 (85%) participants in
each group completed all
three mandatory sessions. Low
uptake of optional sessions.
Significantly more participants
from the structured care group
(37%) attended all six sessions,
compared with 20% of the
CBT+ structured care group
van der Feltz-
Cornelis 2006160
Multimodal (reattribution +
collaborative care) vs. GP –
reattribution
MUS/somatoform Compliance with collaborative
care model as reported by the
patient was 93.2%. Compliance
as reported by the GP was
91.2%
van der Roer, 2008120 Multimodal (sport + education +
behavioural programme) vs.
strength/endurance/sport
Pain-SS MM group 12/60 discontinued
protocol, reasons were n= 3
no time, n = 5 no reason,
n = 1 patient fell ill, n = 3
intervention not helping. SES
group 13/54 discontinued
protocol, reasons were n= 3
no time, n = 5 no reason,
n = 1 patient fell ill, n = 2
intervention not helping, n= 2
patient moved away
Walti, 2015121 Multimodal (education+ sport+
sensory discrimination) vs.
strength/endurance/sport
Pain-SS 3/14 from MM group and 3/14
from SES did not complete
8 weeks of programme
participation. Reasons included
MM group: no aid for home
training, problems with home
training interface, inappropriate
and misleading use of home
training interface. SES group:
exacerbation of pain, no time
for home training, reason
unknown
DWR, deep-water running; Pain-MS, pain multisite; Pain-SS, pain single site; UC, usual care.
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TABLE 59 Satisfaction, acceptability or adherence in other psychotherapy intervention studies
First author and year of
publication Intervention group Condition
Satisfaction, acceptability or
adherence
Kocken, 2008103 Other psychotherapy
vs. UC
MUS/somatoform 104/139 eligible patients agreed to
participate
Kolk, 2004104 Other psychotherapy
vs. UC
MUS/somatoform 3/83 intervention group patients
withdrew from the study or were
excluded due to lack of outcome data.
77/80 entered treatment. The mean
number of sessions attended was
9.2 out of a possible 12. 17/80 stopped
treatment after ≥ 1 sessions. 30/80
completed all 12 sessions. 30/80
completed 8–11 sessions (considered
completion). 43% received CBT, 36%
received eclectic therapy, 21% received
client-centred therapy. 5/23 control
group patients withdrew from the
study. 17% of the control group found
psychological therapy elsewhere
Margalit, 2008268 Other psychotherapy
vs. UC
MUS/somatoform Not reported
McLeod, 1997105 Other psychotherapy
vs. UC
MUS/somatoform 34/130 eligible participants declined to
attend a group because of scheduling
difficulties. 3/130 declined to be
studied. 13/51 (25%) dropped out of
the intervention group. 1/45 (2%)
dropped out of the waiting list group
Posse, 200496 Other psychotherapy
vs. UC
MUS/somatoform All patients attended all sessions
Ryan, 2004109 Other psychotherapy
vs. UC
MUS/somatoform 20/40 patients allocated to other
psychotherapy group refused to
participate or dropped out after
commencement of treatment.
Reasons given included lack of
interest, conflicts of time, reduction
in symptoms, or started treatment but
felt it was not helping their symptoms
Schade, 2011272 Other psychotherapy
vs. UC
MUS/somatoform Not reported
van Ravesteijn, 2013341 Other psychotherapy
vs. UC+
MUS/somatoform 500/685 (73%) eligible participants
were not interested in taking part. A
further 10 declined to participate after
initial interview because of lack of time.
four participants (8%) who started
MBCT did not complete four or
more sessions
MBCT, mindfulness-based cognitive therapy; UC, usual care; UC+, usual care plus.
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TABLE 60 Satisfaction, acceptability or adherence in GA intervention studies
First author and year
of publication Intervention group Condition Satisfaction, acceptability or adherence
Macedo, 2012119 GA vs. GA Pain-SS For the initial 8-week intervention period, both
groups attended a mean 10.3 (SD 3.6) of the planned
12 sessions. For the two booster treatment sessions
and home programme: 43% in GA group attended
the 4-month booster session and 31.4% attended the
10-month booster session. For the motor control
group, attendance was 50% and then 25.6%. For
home exercises, GA vs. MCE: all the time 23% vs.
15%; most of the time 44% vs. 42%; some of the
time 19% vs. 26%; a little of the time 6% vs. 5%;
none of the time 5% vs. 1%. No significant difference
between groups for credibility
Marques, 2015133 GA vs. GSH CF 5/49 participants in intervention group
discontinued due to lack of time
Moss-Morris, 2005152 GA vs. UC CF 68% of GA group rated the intervention as
‘effective’ or ‘highly effective’. 68% rated the
intervention as ‘better’ or ‘very much better’ than
previously received interventions
Ridsdale, 2012115 GA vs. other
psychotherapy vs.
GSH
CF Mean 5.8 out of a possible eight sessions were
attended by GET group participants. Mean 5.9 out of
8 sessions were attended by OP group participants.
Half of all participants reported they were dissatisfied
with care at 6 months. There was no significant
difference between the three intervention groups.
Regression analyses showed positive association
between duration of fatigue and dissatisfaction.
Dissatisfaction increased in UC+ group between
6 and 12 months. Satisfaction increased between
6 and 12 months in the GA and OP groups
GSH, guided self-help; MCE, motor control exercises; OP, other psychotherapy; Pain-SS, pain single site; UC, usual care;
UC+, usual care plus.
TABLE 61 Satisfaction, acceptability or adherence in SES intervention studies
First author and year
of publication Intervention group Condition Satisfaction, acceptability or adherence
Peters, 2002106 SES vs. RSSE MUS/
somatoform
No significant difference in expectations of benefit
between aerobic or stretching groups. 177/228 (78%)
patients who were randomised attended a first
training session. No significant difference in level of
attendance between groups. Median sessions
attended overall was 11 – 95 patients attended
10 or more sessions and 61 attended 15 or more
sessions. 88/177 (50%) of those who began either
intervention completed the homework diary – 42 in
the stretching group and 46 in the aerobic group.
No differences in level of homework task completion
between groups
Sañudo, 2010140 SES vs. SES vs. UC Pain-MS 4/22 participants from aerobic exercise group
dropped out: n= 2 illness, n= 1 work commitments,
n= 1 unable to exercise. 4/21 participants from
combined exercise group dropped out: n= 1 work
commitments, n= 2 illness, n= 1 family problems.
Compliance: participants in aerobic exercise
group attended on average 43/48 (89%) sessions.
Participants in combined exercise group attended on
average 41/48 (86%) of sessions
Pain-MS, pain multisite; UC, usual care.
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TABLE 62 Satisfaction, acceptability or adherence in UC+ intervention study
First author and
year of publication Intervention group Condition Satisfaction, acceptability or adherence
Smith, 1995100 UC vs. UC+ MUS/somatoform All patients agreed to participate in the study
UC, usual care; UC+, usual care plus.
TABLE 63 Health-care utilisation for GP interventions
First author and
year of publication Intervention group Condition group Health-care utilisation
Larisch, 2004158 GP – reattribution
(modified) vs. UC
MUS/somatoform Greater but non-significant reduction in number of
visits to the doctor at 6-month follow-up for the
intervention group compared with the controls
group. Intervention group 54.2% reduction (mean
7.1–3.3 visits) compared with controls 26.6%
reduction (mean 7.2 to 5.3 visits)
Morriss, 2007108 GP – reattribution
vs. UC
MUS/somatoform No significant difference between groups in use of
health-care resources
Rief, 2006102 GP – MUS
management UC
MUS/somatoform Significant time by intervention group difference in
doctor visits. Patients of GPs who had received the
training showed a significant reduction in doctor
visits compared with those in the untrained GP group
Huibers, 2004/
Leone, 2006153,155
GP – CBT vs. UC Chronic fatigue CBT group: mean 4.2 visits to the regular GP during
the intervention period. Control group: mean 3.5 visits
Schilte, 2001159 GP intervention –
other psychotherapy
vs. UC
MUS/somatoform No significant effect for disclosure intervention on
health-care utilisation
UC, usual care.
TABLE 64 Health-care utilisation in CBT intervention studies
First author and
year of publication Intervention group Condition group Health-care utilisation
Ridsdale, 2001112 CBT high intensity
vs. other
psychotherapy
Chronic fatigue Mean GP consultations reduced from 4.2 before
therapy to 3.1 after therapy, with no significant
difference between the groups
Martin, 200799 CBT low intensity
vs. UC
MUS/somatoform Both groups showed a significant reduction in GP
and medical specialist visits over time. There was a
significantly greater reduction in health-care visits
for CBT group compared with control group. The
difference in reduction was significant for GP visits
but not medical specialist visits or psychotherapist
visits
Moss-Morris,
2010130
CBT low intensity
vs. UC
Chronic fatigue During 2-month intervention period. SM group:
4/30 (13.8%) saw a GP compared with 8/33 (26.3%)
in TAU group. One patient in each group saw a
specialist for IBS symptoms (3.6% SM and 3.4% TAU)
Ridsdale, 2004113 CBT low intensity
vs. GA
Chronic fatigue Frequency of doctor consultations per year declined
in both groups following treatment. No significant
difference between groups
Sumathipala, 2000116 CBT low intensity
vs. UC
MUS/somatoform Significantly fewer doctor visits during the 3-month
period following baseline assessment for the CBT
group compared with the control group for
completers and intention-to-treat analyses
SM, self-management; TAU, treatment as usual; UC, usual care.
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TABLE 65 Health-care utilisation in RSSE intervention studies
First author and
year of publication Intervention group Condition group Health-care utilisation
Kashner, 1995161 Relaxation/
stretching/social
support/emotional
support vs. UC
MUS/somatoform Almost significantly greater decrease in costs of
medical treatments for year following treatment for
therapy group compared with UC group
Robinson, 2006131 Guided self-help vs.
multimodal vs. UC
IBS Primary care visits declined in all three groups.
Guidebook group patients saw significantly greater
decline. Estimated effect of guidebook was to reduce
GP visits by mean 1.56 visits, or 60% reduction
compared with no guidebook. No significant
impact of self-help group on GP visits. For hospital
visits, number of visits was significantly lower for
guidebook group than no guidebook. 40% reduction
compared with no guidebook. No additional effect for
self-help group
UC, usual care.
TABLE 66 Health-care utilisation in GSH intervention studies
First author and
year of publication Intervention group Condition group Health-care utilisation
Kashner, 1995161 Relaxation/
stretching/support/
stress relief/
education vs. UC
MUS/somatoform Greater decrease in costs of medical treatments for
year following treatment for therapy group compared
with UC group almost significant
Robinson, 2006131 GSH vs. multimodal
vs. UC
IBS Primary care visits declined in all three groups.
Guidebook group patients saw significantly greater
decline. Estimated effect of guidebook was to reduce
GP visits by mean 1.56 visits, or 60% reduction
compared with no guidebook. No significant
impact of self-help group on GP visits. For hospital
visits, number of visits was significantly lower for
guidebook group than no guidebook. 40% reduction
compared with no guidebook. No additional effect for
self-help group
GSH, guided self-help; UC, usual care.
DOI: 10.3310/hta24460 Health Technology Assessment 2020 Vol. 24 No. 46
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Leaviss et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
329
TABLE 67 Health-care utilisation in multimodal intervention studies
First author and
year of publication Intervention group Condition group Health-care utilisation
Pols, 2008145 Multimodal (self-management +
medication +CBT) vs. UC
MUS/somatoform No reduction in hospitalisation
Schaefert, 2013132 Multimodal (GP intervention –
MUS management + other
psychotherapy) vs. GP – MUS
management
MUS/somatoform Decrease in number of visits to the GP
in both groups, but only significant for
the MM group. No significant difference
between groups
Sumathipala,
2008117
Multimodal (GP-CBT +
GP – MUS management) vs.
GP – MUS management
MUS/somatoform No significant difference between
groups in patient-reported consultations
at 3 months
van der Feltz-
Cornelis, 2006160
Multimodal (reattribution +
collaborative care) vs.
GP – reattribution
MUS/somatoform Significant and consistent decrease in
health-care service use in both health
care and general practice settings for
the collaborative care model group
van der Roer,
2008120
Multimodal (sport +
education + behavioural
programme) vs. SES
Chronic pain –
single site
Detailed cost analysis in van der Roer et al.120
UC, usual care.
TABLE 68 Health-care utilisation in other psychotherapy intervention studies
First author and
year of publication Intervention group Condition group Health-care utilisation
Kolk, 2004104 Other psychotherapy vs. UC MUS/somatoform No interaction effect of time by
intervention group for number of GP
consultations. No significant effect for
intervention group. Both groups showed
a significant reduction in consultations
over time
Margalit, 2008268 Other psychotherapy vs. UC MUS/somatoform No significant change in health-care
utilisation over 2 years for the usual-care
group. Statistically significant decline in
consultant visits, emergency ward visits
and hospital days for the intervention
group compared with controls
Ryan, 2004109 Other psychotherapy vs. UC MUS/somatoform Data only reported as health-care
utilisation costs. Both groups showed cost
reduction over time
van Ravesteijn,
2013341
Other psychotherapy vs. UC+ MUS/somatoform No significant difference between groups
in health-care utilisation during the
12-month study period.The median number
of health-care contacts was 26 (range
0–129) in the MBCT group and 22 (range
0–166) in the usual-care group
MBCT, mindfulness-based cognitive therapy; UC, usual care; UC+, usual care plus.
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TABLE 69 Health-care utilisation in GA intervention studies
First author and
year of publication Intervention group Condition group Health-care utilisation
Wearden, 2010111 GA vs. UC Chronic fatigue Median GP visits during 18-week treatment period:
UC group 3 (range 0–16), pragmatic rehabilitation
group 2 (range 0–14), supportive listening group 3
(range 0–23). Median visits to practice nurses: UC
group 0 (range 0–22), pragmatic rehabilitation 0
(range 0–4), supportive listening 0 (range 0–5)
UC, usual care.
TABLE 70 Health-care utilisation in SES intervention studies
First author and
year of publication Intervention group Condition group Health-care utilisation
Peters, 2002106 Strength/endurance/
sport vs. relaxation/
stretching/social
support/emotional
support
MUS/somatoform No significant differences between groups in health-
care utilisation. Significant decrease for both groups
in GP consultations and number of secondary care
contacts at 6-month follow-up
TABLE 71 Health-care utilisation in UC+ intervention study
First author and
year of publication Intervention group Condition group Health-care utilisation
Smith, 1995100 UC vs. UC+ MUS/somatoform No patient in either group had frequency of visits
to the referring physician at the rate recommended
by the psychiatrist during the first year of study.
Consultation letter patients had more visits
(mean 2.1 visits) than usual-care group (mean
2.1 visits). Consultation letter patients had
0.5 fewer hospital days, 0.7 more ED visits, and
0.2 more outpatient visits than usual-care group.
No statistical significance for any of these outcomes
ED, emergency department; UC, usual care; UC+, usual care plus.
TABLE 72 Adverse events in GP interventions
First author and
year of publication Intervention group Condition group Adverse events
Huibers, 2004/
Leone, 2006153,155
GP – CBT vs. UC Chronic fatigue No adverse events reported that were attributable
to CBT
UC, usual care.
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TABLE 73 Adverse events in CBT intervention studies
First author and
year of publication Intervention group Condition group Health-care utilisation
Alda, 2011137 CBT high intensity
vs. UC
Chronic pain –
multisite
Gili, 2014/
Moreno, 2013144,148
CBT high intensity –
individual vs. CBT
high intensity group
vs. UC+
MUS/somatoform 16/168 patients across intervention groups were
withdrawn due to adverse events. Individual CBT
group n= 6, group CBT n= 6, TAU n = 4. Exact nature
of events not specified
Luciano, 2014138 CBT – high intensity
vs. medication
Chronic pain –
multisite
No severe adverse events in ACT group. In the
medication group 25% had nausea, 23.1% dry mouth,
21.2% drowsiness, 19.2% constipation, 21.2%
headache, 21.2% fatigue
McBeth, 2012125/
Beasley, 2015126
CBT – high intensity
vs. multimodal vs.
SES vs. UC
Chronic pain –
multisite
Two deaths recorded. Causes of death were
metastatic cancer and pancreatic cancer. No adverse
reactions to the interventions
Zonneveld, 2012141 CBT high intensity
vs. UC
MUS/somatoform One adverse event was reported. One patient
reported rumination about the death of a loved one,
which was tiring
Martin, 200799 CBT low-intensity
vs. UC
MUS/somatoform No formal assessment of side effects. No adverse
events were spontaneously reported
Ridsdale, 2004113 CBT low intensity
vs. GA
Chronic fatigue Adverse events not specifically reported. Two patients
died before outcome: one had bronchopneumonia, the
other committed suicide. This patient had a history of
depression, although baseline depression score was
not particularly high. This patient was in the CBT
group and received 4/6 sessions of CBT before being
referred back to the doctor
Sumathipala,
2000116
CBT low intensity
vs. UC
MUS/somatoform Not reported but no physical disorders were
detected for any participant who attended the
3-month follow-up assessment
Tummers, 2012149 CBT low intensity
vs. UC
Chronic fatigue Adverse events not explicitly reported, but
12 patients, equally distributed between intervention
and control groups, were found to have received an
incorrect diagnosis of CFS. Of these, 4/12 had a
possible somatic explanation for their fatigue
(e.g. brain damage), and 8/12 seemed to have a
psychiatric disorder
TAU, treatment as usual; UC, usual care; UC+ usual care plus.
TABLE 74 Adverse events in multimodal intervention studies
First author and
year of publication Intervention group Condition group Health-care utilisation
Cuesta-Vargas,
2012118
Multimodal (sport + education)
vs. guided self-help relief/
education
Chronic pain –
single site
One participant dropped out of GSH
group as a result of increased pain
Kennedy, 2005129 Multimodal (CBT low
intensity +medication) vs.
medication
IBS No significant harms reported
van der Roer,
2008120
Multimodal (sport + education +
behavioural programme) vs. SES
Chronic pain –
single site
No serious adverse events in either group
GSH, guided self-help.
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TABLE 75 Adverse events in other psychotherapy intervention studies
First author and
year of publication Intervention group Condition group Health-care utilisation
Margalit, 2008268 Other psychotherapy
vs. UC
MUS/somatoform Not reported as adverse events but mortality rate
at 5 years was 6/21 in the intervention group and
17/21 in the usual-care group. Note that population is
patients with general medical problem confounded by
psychological problems, with unexplained high costs
due to symptoms that were medically unexplained.
UC, usual care.
TABLE 76 Adverse events in GA intervention studies
First author and
year of publication Intervention group Condition group Health-care utilisation
Macedo, 2012119 GA vs. GA Chronic pain –
single site
Mild adverse events reported in both groups.
17 adverse events in GA vs. 19 in motor control.
n = 27 exacerbation of pain; n= 7 increase in pain
in pre-existing conditions; n = 1 shin splints; n = 1
hip bursitis
Wearden, 2010111 GA vs. UC Chronic fatigue Four events considered unrelated to the interventions
were recorded during the trial period: one herpes
simplex infection, one attempted suicide, one bleeding
peptic ulcer and one recurrence of cancer
UC, usual care.
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Appendix 3 Quality assessment: Higgins’
risk-of-bias tool515
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Individual risk-of-bias assessments
Aiarzaguena 2007136
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Cluster randomised by the study epidemiologist Unknown risk of bias. Randomisation
method not described
Allocation
concealment
GPs unaware of randomisation sequence. Recruitment of
patients was performed before assignment of GPs to the
study groups performed by the epidemiologist of the
research team
Low risk of bias. Adequate allocation
concealment
Performance bias
NR Unknown risk of bias. No description
of blinding of patients
Detection bias
Patients completed the outcome measure with the help
of an interviewer blind to the study group
Low risk of detection bias due to
blinding of outcome assessment
Attrition bias
4/74 dropouts in active control group by end of study
compared with 1/72 dropouts in intervention group
Low risk of bias. Similar rates of
dropout between groups
Reporting bias
SF-36 reported as primary outcome in protocol. No
secondary outcomes listed in protocol
Low risk of bias. Primary reported
outcome is SF-36
NR, not reported.
Alda 2011137
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomised, parallel-group, controlled trial in which
patients were randomly assigned to one of three study
arms (ratio 1 : 1 : 1). Computer-generated random
number sequence, stratified by presence of comorbidities
Low risk of bias, adequate
randomisation
Allocation
concealment
Central telephone allocation sequence performed by
researcher unconnected to study and concealed until
interventions were assigned
Low risk of bias, adequate
randomisation
Performance bias
Patients and therapists not blinded due to nature of
interventions
High risk of bias due to lack of
blinding
Detection bias
Evaluators were blinded to participants’ treatment group
assignments
Low risk of bias, adequate blinding of
outcome assessment
Attrition bias
83.9% completed the study, comprising 85.9% in CBT
group, 82.1% in RPT group and 83.6% in the treatment-
as-usual group
Low risk of bias. Similar rates of
attrition in each group
Reporting bias
Outcomes in protocol are reported in the study paper,
with the addition of EQ-5D data
Unclear risk of bias. EQ-5D outcome
is not stated in protocol
RPT, recommended pharmacological treatment.
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Burton 2012157
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation by automated telephone system using
block allocation with variable block size
Low risk of bias. Adequate method
of randomisation
Allocation
concealment
Automated telephone system Low risk of bias. Adequate method
of allocation concealment
Performance bias
Patients were not blinded to allocation High risk of bias. No blinding of
patients or providers
Detection bias
Follow-up assessments conducted by an investigator with
no involvement in the trial
Unclear risk of bias. Unclear whether
the investigator was aware of
allocation
Attrition bias
15/16 participants in usual care completed follow-up
compared with 11/16 in symptoms clinic
High risk of bias. > 20% attrition in
intervention group
Reporting bias
Outcomes stated in protocol reported in study paper Low risk of bias. Outcomes reported
as per protocol
Chalder 1997114
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated randomisation sequence Low risk of bias. Adequate
randomisation procedure
Allocation
concealment
No description of allocation concealment strategy Unclear risk of bias
Performance bias
No blinding described, but unlikely due to nature of
intervention vs. usual care
High risk of bias. Patients not
blinded
Detection bias
NR Unclear risk of bias. Outcome
assessor not described
Attrition bias
11 dropouts in the intervention group and 14 dropouts
in the control group
Low risk of bias. Similar proportion
of dropout between groups
Reporting bias
Protocol not located
NR, not reported.
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Cuesta-Vargas 2012118
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer generated random sequence generation Low risk of bias. Adequate
randomisation procedure
Allocation
concealment
Sealed, sequentially numbered envelopes Low risk of bias. Adequate allocation
concealment
Performance bias
Study described as single blind Unclear risk of bias. Unclear whether
patients in the exercise group would
be aware that theirs was the active
intervention
Detection bias
No description of blinding of outcome assessors Unclear risk of bias. Described as
single-blind but unclear whether
patients or outcome assessors
were blind
Attrition bias
Similar rates of dropout between groups Low risk of bias. No significant rates
of dropout or differences between
groups
Reporting bias
All outcomes stated in protocol reported in study paper Low risk of bias. All outcomes
reported as per protocol
Escobar 2007156
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated random number sequence for
patient allocation
Low risk of bias. Adequate
randomisation sequence
Allocation
concealment
NR Unclear risk of bias. No reporting of
allocation concealment
Performance bias
Not described High risk of bias. Patients in
intervention group unlikely to be
able to be blinded due to nature of
intervention
Detection bias
Outcome assessors blinded to study group Low risk of bias. Adequate blinding
of outcome assessment
Attrition bias
12/87 dropped out of intervention group compared with
21/85 who dropped out of control group
High risk of bias. > 20% drop-out
rate in control group
Reporting bias
All outcomes stated in protocol are reported in the study
paper. Physical functioning is reported in the study paper
but not in the protocol
Low risk of bias. All outcomes
reported as per protocol with the
additional of MOS-10
NR, not reported.
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Friedberg 2013151
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated block randomisation schedule Low risk of bias. Adequate
randomisation procedure
Allocation
concealment
Randomisation performed by project team. Nurse
interventionist sent allocation by project team
Low risk of bias. Adequate allocation
concealment
Performance bias
No blinding of patients described Unclear risk of bias. Unlikely that
patients in control group were
unaware of a lack of intervention,
although the two active intervention
groups may have been
Detection bias
Outcome assessors blinded to treatment condition Low risk of bias. Adequate blinding
of outcome assessors
Attrition bias
For the intervention group, 51% completed the
12-month follow-up. For the active control group,
58% completed the 12-month follow-up. For the UC
group, 47% completed the 12-month follow-up
High risk of bias. > 20% dropouts in
all group at follow-up. However,
similar drop-out rates between
groups, no significant difference in
baseline measures for dropouts
Reporting bias
Unclear whether secondary outcome of Global
Impression of Change (GIC) relates to the diary.
No scale reported for this outcome in the protocol
and no outcome described as GIC in the study paper
Unclear risk of bias. Unclear whether
global impression of change outcome
is reported
UC, usual care.
Moreno 2013/Gili 2014144,148
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated random number sequence used Low risk of bias. Adequate
randomisation method
Allocation
concealment
Allocation was carried out by personnel not involved in
the study
Low risk of bias
Performance bias
Patients did not know which condition they were
allocated to. GPs were blinded to condition
Low risk of bias. Patients and GPs
were blinded
Detection bias
NR Unclear risk. No description of
blinding of outcome assessors
Attrition bias
47/56 CBT individual, 57/64 CBT group, and 30/48 TAU
completed final follow-up
High risk of bias. < 20% attrition in
both intervention arms, although
> 20% in TAU group
Reporting bias
All outcomes from protocol reported in study papers Low risk of bias. All outcomes
reported as per protocol
NR, not reported; TAU, treatment as usual.
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Ho 2012150
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated list of random numbers Low risk of bias. Adequate
randomisation procedure
Allocation
concealment
Participants were assigned a study order number before
randomisation
Low risk of bias. Adequate allocation
concealment method
Performance bias
Blinding participants not possible due to the nature of
intervention
High risk of bias. No blinding of
participants
Detection bias
Group allocation blinded for laboratory technicians Low risk of bias. Adequate blinding
of outcome assessors
Attrition bias
81.8% completers in intervention group. 80.6% in the
control group completed the programme
Low risk of bias. < 20% drop-out
rates and similar between groups
Reporting bias
Protocol not located
Huibers 2004/Leone 2006153,155
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated list Low risk of bias. Adequate
randomisation procedure
Allocation
concealment
Sealed opaque envelopes prepared by non-study
personnel
Low risk of bias. Adequate allocation
concealment
Performance bias
Patients unaware of randomisation procedure and
existence of other group
Unclear risk of bias. Unclear whether
participants would guess they were
in the active intervention group
Detection bias
Researchers and GPs were not blind to treatment
allocation
High risk of bias. No blinding of
outcome assessors
Attrition bias
70/76 intervention group participants completed final
follow-up compared with 68/75 control participants
Low risk of bias. < 20% and similar
drop-out rates between groups
Reporting bias
All outcomes reported in protocol are reported in the
study papers
Low risk of bias. Outcome reporting
as per protocol
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Kashner 1995161
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Stratified randomisation by distance from practice Unclear risk of bias. Randomisation
procedure not described
Allocation
concealment
NR Unclear risk of bias. No allocation
concealment method reported
Performance bias
NR Unclear risk of bias. No blinding
reported
Detection bias
Outcome assessment by research assistant who was
unaware of group allocation
Low risk of bias. Adequate blinding
of outcome assessment
Attrition bias
No comparison of attrition between groups Unclear risk of bias
Reporting bias
Protocol not located
NR, not reported.
Kennedy 2005129
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Random numbers in blocks of four generated from
random number tables
Low risk of bias. Adequate
randomisation procedure
Allocation
concealment
Planned allocation concealment involved non-study
personnel keeping allocation details. However, on occasion,
the research nurse became aware of the allocation
High risk of bias. Intervention nurse
aware of allocation for some
participants
Performance bias
NR Unclear risk of bias. No blinding of
patients reported
Detection bias
NR Unclear risk of bias. No blinding of
outcome assessors reported
Attrition bias
Fewer than half of patients completed therapy.
41% declined therapy or dropped out
High risk of bias. High drop-out rate
from intervention group
Reporting bias
No distinction between primary and secondary outcomes
in protocol
Unclear risk of bias, no distinction
between primary and secondary
outcomes
NR, not reported.
Kobeissi 2012110
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation by computer-generated allocation
schedule
Low risk of bias. Adequate
randomisation method
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Kobeissi 2012110
Domain Support for judgement Reviewer judgement
Allocation
concealment
Remote allocation by telephone was planned but actually
took place in the field. Computerised allocation conducted
Low risk of bias. Adequate allocation
concealment
Performance bias
Blinding of allocation was not feasible due to the nature
of the intervention
Detection bias
Blinding of outcome assessors not described Unclear risk of bias. No description
of outcomes assessors
Attrition bias
10/99 in the intervention group lost to follow-up.
16/97 in the control group lost to follow-up
Low risk of bias. < 20% and similar
rates of attrition in both groups
Reporting bias
Protocol not located
Kocken 2008103
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Blocked randomisation procedure used. No further
details
Unclear risk of bias. No description
of randomisation method
Allocation
concealment
No description of allocation concealment Unclear risk of bias. Allocation
concealment not known
Performance bias
No description of blinding of patients High risk of bias. Blinding unlikely
due to nature of interventions
Detection bias
No description of blinding of outcome assessors Unclear risk of bias. Blinding of
outcome assessors unclear
Attrition bias
8 dropouts in intervention group compared with 8 lost
to follow-up in control group
Low risk of bias. Similar dropouts in
each group
Reporting bias
All outcomes reported from protocol Low risk of bias. Outcomes reported
as per protocol
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Kolk 2004104
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation code generated from randomisation table Low risk of bias. Adequate
randomisation method
Allocation
concealment
Sealed envelopes with sequence numbers Low risk of bias. Adequate method
of allocation concealment
Performance bias
Participants blind to allocation until pre test High risk of bias. Nature of
intervention did not enable blinding
throughout the intervention
Detection bias
NR Unclear risk of bias. No description
of blinding of outcome assessor
Attrition bias
55/83 in intervention group remained at long-term follow-up.
13/23 in control group remained after follow-up
High risk of bias. > 20% loss to
follow-up in both groups
Reporting bias
Protocol not located
NR, not reported.
Lansinger 2007123
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Block randomisation, no further description of method Unclear risk of bias. Insufficient
description of randomisation method
Allocation
concealment
Sealed enveloped technique used Low risk of bias. Adequate method
of allocation concealment
Performance bias
Blinding not possible due to nature of intervention High risk of bias. No blinding of
groups allocation
Detection bias
No blinding of outcome assessors High risk of bias. No blinding of
outcome assessors
Attrition bias
12 participants in the qigong group and five in the
exercise group refused to participate after allocation.
46/72 qigong completed follow-up, 54/67 exercise group
completed follow-up
High risk of bias. High drop-out rate
for qigong group
Reporting bias
Protocol not located
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Larisch 2004158
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Cluster randomised using table of random numbers Low risk of bias. Adequate
randomisation method
Allocation
concealment
Randomisation by statistician blinded to the GPs Low risk of bias. Adequate allocation
concealment
Performance bias
Patients unaware of the allocation of their GP Low risk of bias. Blinding of patients
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessor not described
Attrition bias
44/70 patients in intervention group remained at final
follow-up compared with 34/64 in control group
High risk of bias. > 20% drop-out
rates in both groups
Reporting bias
Protocol not located
NR, not reported.
LeFort 1998128
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Stratified block randomisation Low risk of bias. Adequate
randomisation method
Allocation
concealment
Opaque, sealed, numbered envelopes Low risk of bias. Adequate allocation
concealment method
Performance bias
Not possible to blind participants due to nature of
intervention
High risk of bias. No blinding of
participants
Detection bias
Research assistant blinded to treatment allocation
conducted post-treatment assessments
Low risk of bias. Blinded outcome
assessors
Attrition bias
Low and equal rate of attrition in both groups Low risk of bias. Both groups
demonstrated low dropout
Reporting bias
Protocol not located
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
346
Loew 2000122
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
‘Randomly controlled’ but no description of
randomisation method
Unclear risk of bias. No description
of randomisation method
Allocation
concealment
No description of allocation concealment method Unclear risk of bias. No description
of allocation concealment
Performance bias
Patients told they were in one of two different relaxation
technique groups
Low risk of bias. Blinding was
conducted
Detection bias
NR Unclear risk of bias. No description
of blinding of outcome assessors
Attrition bias
24/27 intervention group completed diaries. 12/27 in the
control group completed diaries
High risk of bias. > 20% drop-out
rate in control group
Reporting bias
Protocol not located
NR, not reported.
Luciano 2011139
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated randomisation list Low risk of bias. Adequate
randomisation method
Allocation
concealment
NR Unclear risk of bias. No reported
methods of allocation concealment
Performance bias
Blinding of participants not possible due to nature of
intervention and control
High risk of bias. No blinding of
participants
Detection bias
Outcome assessment by research assistant blind to group
allocation
Low risk of bias. Blind outcome
assessment
Attrition bias
6.5% drop-out rate in intervention group compared with
13% in the control group
Low risk of bias. < 20% drop-out rate
in each group
Reporting bias
Primary outcome as stated in protocol. Study paper also
included STAI anxiety
Low risk of bias. All primary
outcomes as stated in protocol
NR, not reported; STAI, State–Trait Anxiety Index.
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Luciano 2014138
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated randomisation list. Randomisation
stratified by comorbid depression
Low risk of bias. Adequate
randomisation method
Allocation
concealment
Randomisation sequence concealed by researcher not
involved in the study
Low risk of bias. Adequate allocation
concealment
Performance bias
Participants not blinded to treatment allocation due to
nature of intervention
High risk of bias. No blinding of
participants possible
Detection bias
Outcome assessors blind to allocation groups Low risk of bias. Blind outcome
assessment
Attrition bias
Similar rates of attrition across intervention groups Low risk of bias. Low drop-out rates
for all groups
Reporting bias
All outcomes stated in protocol reported in the
study paper
Low risk of bias. All outcomes
reported as per protocol
Macedo 2012119
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated randomisation sequence Low risk of bias. Adequate
randomisation method
Allocation
concealment
Allocations concealed in numbered, opaque, sealed
envelopes by a researcher not involved in the study
Low risk of bias. Adequate method
of allocation concealment
Performance bias
NR Unclear risk of bias. No reporting of
participant blinding
Detection bias
Outcomes measured by blinded assessors Low risk of bias. Blind outcome
assessment
Attrition bias
Good adherence to treatment during intervention period
but adherence reduced for booster sessions. 6/86 in GA
group were lost to follow-up compared with 11/86 in the
motor control group
Low risk of bias. < 20% drop-out rate
in each group
Reporting bias
All outcomes outlined in protocol reported in study
paper
Low risk of bias. All outcomes
reported as per protocol
NR, not reported.
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Margalit 2008268
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Assignment to groups by odd or even numbers on list Moderate risk of bias. Method of
randomisation not robust
Allocation
concealment
NR Unclear risk of bias. No description
of allocation concealment
Performance bias
NR Unclear risk of bias. Blinding of
participants unclear
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessors not reported
Attrition bias
NR Unclear risk of bias. Drop-out
numbers by group unclear
Reporting bias
Protocol not located
NR, not reported.
Marques 2015133
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated randomisation sequence Low risk of bias. Adequate
randomisation method
Allocation
concealment
Randomisation and allocation undertaken by an
external researcher
Low risk of bias. Adequate allocation
concealment method
Performance bias
No blinding of patients or intervention providers High risk of bias. Group allocation
known to patients and intervention
providers
Detection bias
No blinding of outcome assessors High risk of bias. Group allocation
known to outcome assessors
Attrition bias
Attrition to the trial was > 20% High risk of bias. High attrition rate
Reporting bias
All outcomes stated in protocol reported in the
study paper
Low risk of bias. All outcomes as
stated in study protocol
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Martin 200799
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation based on predefined list of binary
variables, using blocking procedures to ensure sample
sizes were comparable
Low risk of bias. Adequate
randomisation method
Allocation
concealment
Assignment to groups undertaken by study assistants Low risk of bias. External group
allocation
Performance bias
NR High risk of bias. Blinding likely not
possible due to nature of intervention
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessors not reported
Attrition bias
59/70 participants remained in the study at final
follow-up for both groups
Low risk of bias. < 20% equal drop-out
rates for both groups
Reporting bias
Protocol not located
NR, not reported.
McBeth 2012125/Beasley 2015126
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Electronic individual randomisation Low risk of bias. Adequate
randomisation method
Allocation
concealment
NR Unclear risk of bias. No reporting on
allocation concealment method
Performance bias
Patients and therapists were not blinded to group
allocation
High risk of bias. No blinding for
both participants and intervention
providers
Detection bias
Outcome assessors were blind to group allocation Low risk of bias. Blind outcome
assessors
Attrition bias
High follow-up rate. Twice as many lost to follow-up in
telephone CBT group
Moderate risk of bias. Unequal
drop-out rate for one group
Reporting bias
Outcomes reported in protocol however no specific
measures given
Unclear risk of bias. No measures
specified
NR, not reported.
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McLeod 1997105
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation by table of random numbers Low risk of bias. Adequate
randomisation sequence
Allocation
concealment
NR Unclear risk of bias. No reporting of
allocation concealment
Performance bias
No blinding of participants reported High risk of bias. Blinding not
possible due to nature of the
interventions
Detection bias
NR Unclear risk of bias. Unclear whether
outcome assessors were blind to
group allocation
Attrition bias
13 participants dropped out of treatment group
compared with one in the control group
High risk of bias. High attrition in
intervention group compared with
control group
Reporting bias
Protocol not located
NR, not reported.
Morriss 2007108
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Cluster randomised. Randomisation by computer-
generated sequence
Low risk. Adequate randomisation
procedure
Allocation
concealment
Group allocation communicated by telephone Low risk. Adequate allocation
concealment method
Performance bias
NR Unclear risk of bias. Unclear whether
participants were blind
Detection bias
NR Unclear risk of bias. Unclear whether
outcome assessors were blind
Attrition bias
High rates of follow-up, no attrition bias Low risk of bias. Low attrition
Reporting bias
All outcomes stated in protocol reported in study paper,
with the addition of EQ-5D QoL
Low risk of bias. All outcomes stated
as per protocol with the addition of
HRQoL from EQ-5D
NR, not reported.
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Moss-Morris 2005152
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation by computer-generated random numbers Low risk. Adequate randomisation
sequence
Allocation
concealment
Sealed opaque envelopes distributed by independent
administrator
Low risk. Adequate allocation
concealment
Performance bias
NR Unclear risk. Patient blinding not
reported
Detection bias
Testing conducted by a research assistant blind to
intervention group
Low risk. Blinding of outcome
assessment
Attrition bias
3 participants in each group lost to follow-up Low risk. Low attrition rates in both
groups
Reporting bias
Protocol not located Unclear risk of bias
NR, not reported.
Moss-Morris 2010130
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
The words control or treatment were placed in sealed
opaque envelopes by an administrator. Envelopes were
ordered using a computer-generated random sequence
Low risk of bias. Adequate
randomisation method
Allocation
concealment
Sealed envelopes distributed by a different administrator Low risk of bias. Adequate allocation
concealment method
Performance bias
Participants not blinded High risk of bias. No blinding of
participants due to nature of
intervention and control
Detection bias
Research assistant who assessed outcomes was blind to
group allocation
Low risk of bias. Blind outcome
assessment
Attrition bias
26/31 returned the 8-month follow-up questionnaires
in the intervention group compared with 26/33 in the
control group
Low risk of bias. Low and similar
attrition rates in each group
Reporting bias
Retrospective protocol registration Unclear risk of bias
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Peters 2002106
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomised trial but method of randomisation not
reported
Unclear risk of bias. Randomisation
method not reported
Allocation
concealment
NR Unclear risk of bias. Method of
allocation concealment not reported
Performance bias
Participants were blinded to the hypothesis and to the
nature of the other intervention
Low risk of bias. Participants blinded
Detection bias
Researchers and intervention providers were not blinded
to group allocation
High risk of bias
Attrition bias
Long-term attrition by group not reported Unclear risk of bias. Dropouts at last
follow-up not reported by group
Reporting bias
Protocol not located
NR, not reported.
Pols 2008145
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Random number allocation Low risk of bias. Adequate
randomisation method
Allocation
concealment
Allocation group provided to the research officer by
telephone
Low risk of bias. Adequate method
of allocation concealment
Performance bias
GPs not blinded to allocation group. Blinding of
participants not reported
Unclear risk of bias. Participant
blinding not reported
Detection bias
Local evaluation team blinded to allocation group Low risk of bias. Blind outcome
assessment
Attrition bias
42/89 intervention group participants assessed at
follow-up compared with 22/44 control participants
High risk of bias. > 20% attrition at
longest follow-up in both groups
Reporting bias
Protocol not located
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Posse 200496
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Patients randomly assigned to treatment groups Unclear risk of bias. No description
of randomisation method reported
Allocation
concealment
NR Unclear risk of bias. No description
allocation concealment
Performance bias
Blinding of participants not possible due to nature of
intervention
High risk of bias. No blinding of
participants
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessment not reported
Attrition bias
No dropouts in either group Low risk of bias. No attrition
Reporting bias
Protocol not located
NR, not reported.
Ridsdale 2001112
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation in blocks of 10 by computer-generated
random number combinations
Low risk of bias. Adequate
randomisation method
Allocation
concealment
Opaque sealed envelopes bearing sequential ID numbers Low risk of bias. Adequate allocation
concealment method
Performance bias
NR Unclear risk of bias. Blinding of
participants not reported
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessment not reported
Attrition bias
81% of participants in the counselling group vs. 80% in
the CBT group completed the final follow-up
Low risk of bias. ≤ 20% attrition in
both groups
Reporting bias
Protocol not located
NR, not reported.
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Ridsdale 2004113
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Stratified and blocked (size 10) randomisation to four
sets of random combinations
Low risk of bias. Adequate
randomisation method
Allocation
concealment
Allocation concealed in four series of consecutive,
opaque, sealed envelopes
Low risk of bias. Adequate method
of allocation concealment
Performance bias
NR Unclear risk of bias. Blinding of
participants unclear
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessors unclear
Attrition bias
94% (CBT), 97% (GET) and 93% (TAU) of participants
completed the last follow-up
Low risk of bias. Low attrition across
all groups
Reporting bias
Protocol not located
NR, not reported; TAU, treatment as usual.
Ridsdale 2012115
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Block randomisation prepared by a statistician Low risk of bias. Adequate
randomisation method
Allocation
concealment
Opaque sealed envelopes bearing sequential ID numbers Low risk of bias. Adequate allocation
concealment method
Performance bias
NR Unclear risk of bias. Blinding of
participants not reported
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessor not reported
Attrition bias
73% of graded exercise group assessed at longest
follow-up compared with 85% of counselling group
High risk of bias. Higher rate of
dropouts and > 20% for graded
exercise group than counselling
group
Reporting bias
All outcomes from protocol reported with the exception
of illness attributions
Low risk of bias. All outcomes
reported as per protocol apart from
illness attributions. Judged low risk
of bias as this is not a relevant
outcome in our review
NR, not reported.
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Rief 2006102
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Cluster randomised. Method not described Unclear risk of bias. Method of
randomisation not described
Allocation
concealment
NR Unclear risk of bias. No allocation
concealment method reported
Performance bias
NR Unclear risk of bias. Blinding of
participants not reported
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessor not reported
Attrition bias
NR Unclear reporting of dropouts
by group
Reporting bias
Protocol not located
NR, not reported.
Robinson 2006131
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation based on minimisation Low risk of bias. Adequate
randomisation method
Allocation
concealment
Central telephone randomisation system Low risk of bias. Adequate method
of allocation concealment
Performance bias
NR Unclear risk. Blinding of participants
not reported
Detection bias
NR Unclear risk. Blinding of participants
not reported
Attrition bias
Similar attrition across groups by longest follow-up Low risk of bias. Low attrition across
groups
Reporting bias
Protocol not located
NR, not reported.
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Rosendal 2007146
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Cluster randomisation. Non-transparent lots containing
code numbers
Low risk of bias. Adequate method
of randomisation
Allocation
concealment
A person not involved in the study performed the
randomisation
Low risk of bias. Adequate method
of allocation concealment
Performance bias
It was not possible to blind GPs, but their patients
were blind
Low risk of bias. Patients unaware
of group allocation
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessor unclear
Attrition bias
65% response rate at 12-month follow-up for the
intervention group compared with 74% for the
control group
High risk of bias. > 20% attrition for
both groups at follow-up
Reporting bias
Protocol not located
NR, not reported.
Rothman 2013127
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Block randomisation by computer-generated list Low risk of bias. Adequate
randomisation method
Allocation
concealment
Closed envelopes Low risk of bias. Adequate allocation
concealment method
Performance bias
NR Unclear risk of bias. Blinding of
participants not reported
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessors not reported
Attrition bias
8/99 participants in the intervention group and 17/108
participants in the control group did not complete the
15-month follow-up
Low risk of bias. < 20% attrition in
both groups
Reporting bias
Protocol not located
NR, not reported.
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Ryan 2004109
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Participants were randomised but method is not
described
Unclear risk of bias. No description
of randomisation method
Allocation
concealment
NR Unclear risk of bias. No description
of method of allocation concealment
Performance bias
NR Unclear risk of bias. Blinding of
participants not reported
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessor not reported
Attrition bias
21/40 intervention group participants dropped out
before treatment or refused to participate
High risk of bias. > 20% drop-out
rate in intervention group
Reporting bias
Protocol not located
NR, not reported.
Sañudo 2010140
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation by computer-generated random number
sequence
Low risk of bias. Adequate
randomisation method
Allocation
concealment
Randomisation by personnel not directly involved in the
recruitment or assessment of patients. Randomisation list
kept at a separate location in a locked cabinet
Low risk of bias. Adequate method
of allocation concealment
Performance bias
NR Unclear risk of bias. Blinding of
participants not reported
Detection bias
Outcome assessment performed by personnel who were
unaware of group allocation
Low risk of bias. Outcomes assessor
blinded
Attrition bias
Four participants from each exercise group dropped out
of the study. One participant from the control group
dropped out of the study
Low risk of bias. Low attrition in
both intervention groups, although
marginally higher than control group
Reporting bias
All outcomes stated in the protocol are reported in the
study paper, but there are differences in whether
outcomes are stated as primary or secondary. SF-36 and
physical fitness measures are stated as primary outcomes
in the protocol but as secondary outcomes in the paper
Unclear risk of bias. All outcomes
reported but differences in reporting
as primary/secondary
NR, not reported.
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Schade 2011272
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Participants randomised but no description of
method given
Unclear risk of bias. No method of
randomisation given
Allocation
concealment
NR Unclear risk of bias. No method of
allocation concealment given
Performance bias
No blinding due to the nature of the interventions High risk of bias. No blinding of
participants
Detection bias
Outcome assessors were blind to the study conditions Low risk of bias. Adequate allocation
concealment
Attrition bias
NR Unclear risk of bias. No reporting of
drop-out rates
Reporting bias
Protocol not located
NR, not reported.
Schaefert 2013132
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Cluster randomised. Exact method not described,
although was performed by a statistician
Low risk of bias. Statistical method
of randomisation
Allocation
concealment
Blinded randomisation at a research centre Low risk of bias. Adequate
randomisation method
Performance bias
NR Unclear risk of bias. Participant
blinding not reporting
Detection bias
Outcomes assessed by blinded research assistants Low risk of bias. Blinded outcome
assessment
Attrition bias
Attendance at intervention sessions dropped to 56%
by final booster session. Questionnaire completion
significantly higher in the intervention group than
with controls
High risk of bias. > 20% did not
complete intervention and significant
difference in completion of follow-up
questionnaires between group (lower
completion for control group)
Reporting bias
Protocol not located
NR, not reported.
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Schilte 2001159
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomised sequence performed. Exact method not
specified
Unclear risk of bias. Unspecified
randomisation technique
Allocation
concealment
An independent person performed the randomisation.
Opaque, sealed numbered envelopes used
Low risk of bias. Adequate allocation
concealment
Performance bias
GPs knew which patients received the intervention,
but not which patients were controls. Unclear whether
patients were blinded
Moderate risk of bias. Unblinded
GPs and unclear about patient
blinding
Detection bias
NR Unclear risk of bias. Outcome
assessment not reported
Attrition bias
70/81 participants in the intervention group remained at
follow-up compared with 67/80 in the control group
Low risk of bias. < 20% attrition and
similar between groups
Reporting bias
Protocol not located
NR, not reported.
Smith 1995100
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomised trial with one-way crossover. Related to
Kashner 1995.161 Randomisation method not reported
Unclear risk of bias. Randomisation
method not reported
Allocation
concealment
NR Unclear risk of bias. Allocation
concealment method not reported
Performance bias
NR Unclear risk of bias. No reporting of
patient blinding
Detection bias
NR Unclear risk of bias. No reporting of
blinding of outcome assessor
Attrition bias
96% of participants completed all four follow-ups Low risk of bias. Low attrition
Reporting bias
Protocol not located
NR, not reported.
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Smith 2006107
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation sequence by computerised random
number generator
Low risk of bias. Adequate
randomisation method
Allocation
concealment
Randomisation by statistician with no patient knowledge Low risk of bias. Adequate allocation
concealment method
Performance bias
Patients and intervention providers not blinded High risk of bias. No blinding of
participants
Detection bias
Outcome assessors were blinded Low risk of bias. Blinded outcome
assessment
Attrition bias
98/101 participants in the intervention condition
completed all follow-ups compared with 102 out of 105
in control group
Low risk of bias. Low attrition and
similar between groups
Reporting bias
Protocol not located
Smith 2009142
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Random number generator used Low risk of bias. Adequate method
of randomisation
Allocation
concealment
NR Unclear risk of bias. No reporting of
allocation concealment
Performance bias
NR Unclear risk of bias. No reporting of
participant blinding
Detection bias
NR Unclear risk of bias. No reporting of
outcome assessor blinding
Attrition bias
No dropouts in either group, although small sample of
15 in each group
Low risk of bias. No attrition
Reporting bias
Protocol not located
NR, not reported.
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Sumathipala 2008117
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation by permuted block design, with block size
of four. Randomisation codes generated by a statistician
Low risk of bias. Adequate
randomisation method
Allocation
concealment
An independent epidemiologist executed the random
allocation
Low risk of bias. Adequate allocation
concealment method
Performance bias
Patients could not be blinded due to the nature of the
intervention
High risk of bias. No blinding of
patients
Detection bias
The study physician and all research assistants were
blinded to the group allocation
Low risk of bias. Blinded outcome
assessors
Attrition bias
5/75 lost to follow-up in intervention group. 8/75 lost to
follow-up in control group
Low risk of bias. Low attrition and
similar between groups
Reporting bias
Protocol not located
Sumathipala 2000116
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Random numbers generated from a calculator Low risk of bias. Adequate
randomisation method
Allocation
concealment
Independent epidemiologist performed the
randomisation. Sealed opaque envelopes bearing
sequential registration numbers used
Low risk of bias. Adequate allocation
concealment method
Performance bias
Patients not blinded due to nature of intervention High risk of bias. Patients not
blinded
Detection bias
Non-clinical research assistant remained blind to group
allocation throughout the study
Low risk of bias. Blinded outcome
assessment
Attrition bias
4/12 patients who attended either one or two sessions,
were present at follow-up. Considerable drop-out rates
from both treatment and follow-up
High risk of bias. > 20% attrition
Reporting bias
Protocol not located
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Toft 201097
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Cluster randomised, stratified by number of GPs in the
practice and block-randomised by drawing lots
Low risk of bias. Adequate
randomisation method
Allocation
concealment
A neutral party performed the randomisation Low risk of bias. Adequate method
of allocation concealment
Performance bias
Patients not informed about assignment of their GP to
either the intervention or control group
Low risk of bias. Patients were
blinded
Detection bias
Interviewers were blinded to group allocation Low risk of bias. Blinded outcome
assessment
Attrition bias
Attrition not reported Unclear risk of bias. Attrition not
discussed
Reporting bias
Protocol not located
Tummers 2012149
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated randomisation Low risk of bias. Adequate
randomisation method
Allocation
concealment
A statistical advisor, independent of the study, prepared
numbered and sealed envelopes
Low risk of bias. Adequate allocation
concealment method
Performance bias
Blinding of patients not possible due to nature of
interventions
High risk of bias. No blinding of
patients
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessor not reported
Attrition bias
55/62 in intervention group completed follow-up
assessment compared with 56/61 in control group
Low risk of bias. < 20% attrition and
similar between groups
Reporting bias
All outcomes stated in protocol reported in study paper Low risk of bias. All outcomes
reported as per protocol
NR, not reported.
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van der Feltz-Cornelis 2006160
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Cluster randomised. Method not described Unclear risk of bias. No description
of randomisation method
Allocation
concealment
Randomisation conducted by a research assistant Low risk of bias. Allocation
conducted independently of the
practices
Performance bias
Practices not informed about group allocation until
6 weeks after first patient included, although
interventions not blinded
Moderate risk of bias. Patients and
practices blinded to intervention
group for 6 weeks
Detection bias
Research assistant was not aware of the treatment
allocation
Low risk of bias. Blinded outcome
assessment
Attrition bias
None lost to follow-up in either group Low risk of bias. Low attrition
Reporting bias
All outcomes outlined in protocol are reported in the
study paper
Low risk of bias. Outcomes reported
as per protocol
van der Roer 2008120
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Randomisation lists generated using series of random
numbers
Low risk of bias. Adequate
randomisation sequence
Allocation
concealment
Prepared opaque, sealed envelopes Low risk of bias. Adequate allocation
concealment
Performance bias
Patients and physiotherapist could not be blinded due to
the nature of the interventions
High risk of bias. No blinding of
patients and practitioners
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessor not reported
Attrition bias
Number of patients lost to follow-up similar in both
groups indicating non-selective dropout
Low risk of bias. Similar attrition in
both groups
Reporting bias
All primary and secondary outcomes reported in protocol
are reported in the paper
Low risk of bias. All outcomes
reported as per protocol
NR, not reported.
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van Ravesteijn 2013143
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated permuted-block randomisation
table with a block size of 20
Low risk of bias. Adequate
randomisation method
Allocation
concealment
Research assistant blinded to the interview data
performed the randomisation
Low risk of bias. Adequate allocation
concealment
Performance bias
NR Unclear risk of bias. No reporting of
whether patients were blinded
Detection bias
NR Unclear risk of bias. No reporting of
blinding of outcome assessor
Attrition bias
12/49 mindfulness group dropped out of treatment
with additional four participants lost to follow-up.
1/55 control group received intervention due to strong
preference, with an additional six particpants lost to
follow-up
High risk of bias. > 20% attrition
from intervention group and
deviation from the protocol in
control group
Reporting bias
Protocol not located
NR, not reported.
Walti 2015121
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Electronically generated randomisation list Low risk of bias. Adequate
randomisation method
Allocation
concealment
Allocation stated as concealed Low risk of bias. Explicit allocation
concealment, although method not
described
Performance bias
Patients not blinded High risk of bias. Patients not blinded
Detection bias
Outcome assessments conducted by independent
physiotherapist blinded to the group assignment
Low risk of bias. Blinded outcome
assessment
Attrition bias
Six patients dropped out of treatment (three each from
the MMT and UPT groups). All patients, except one,
in the UPT attended post-therapy outcome assessment
Low risk of bias. Low attrition and
comparable between groups
Reporting bias
All outcomes stated in protocol are reported in the
study paper
Low risk of bias. All outcomes
reported as per protocol
MMT, multimodal treatment; UPT, usual physiotherapy treatment.
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Wearden 2010111
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated randomised permuted blocks Low risk of bias. Adequate
randomisation method
Allocation
concealment
Random allocation was e-mailed to the trial manager Low risk of bias. Adequate random
sequence generation
Performance bias
Patients not blinded to allocation High risk of bias. No blinding of
patients
Detection bias
Assessments by trained researchers blind to treatment
allocation
Low risk of bias. Blinded outcome
assessment
Attrition bias
Low drop-out rates and high rates of follow-up Low risk of bias. Low attrition
Reporting bias
Protocol reports ‘time to take 20 steps, (or number of
steps taken, if this is not achieved) and maximum heart
rate reached on a step-test’ as a secondary outcome.
This is not reported in the study paper
Unclear risk of bias. No report of
number of steps fatigue secondary
outcome outlined in protocol
Whitehead 2002154
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Cluster randomised. Randomisation method not
described
Unclear risk of bias. No description
of method of randomisation
Allocation
concealment
NR Unclear risk of bias. No description
of allocation concealment
Performance bias
NR Unclear risk of bias. Blinding of
patients or practices not reported
Detection bias
NR Unclear risk of bias. Blinding of
outcome assessors not reported
Attrition bias
18/26 participants in the intervention group and 28/39
in the control group provided data at first follow-up.
Data from 9/26 and 21/39 at last follow-up
High risk of bias. High attrition in
both groups
Reporting bias
Protocol not located
NR, not reported.
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Zonneveld 2012141
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated randomisation list Low risk of bias. Adequate
randomisation method
Allocation
concealment
Allocation concealed for patients and assessors due to
randomisation list generated after assessment for
eligibility and enrolment
Low risk of bias. Adequate allocation
concealment
Performance bias
Patients and trainers not blinded due to nature of
the interventions
High risk of bias. No blinding of
patients and trainers
Detection bias
NR Unclear risk of bias. No reporting of
blinding of outcome assessor
Attrition bias
23/84 dropped out of intervention group. 6/78 dropped
out of control group
High risk of bias. > 20% attrition in
intervention group
Reporting bias
All outcomes stated in protocol are reported in
study paper
Low risk of bias. All outcomes
reported as per protocol
NR, not reported.
A 20% attrition rate was taken as the cut-off point for low risk of bias.134
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Appendix 4 Table of excluded studies
with rationale
Citation Reason for exclusion
Brealey S, Burton K, Coulton S, Farrin A, Garratt A, Harvey E, et al. UK Back pain
Exercise And Manipulation (UK BEAM) trial – national randomised trial of physical
treatments for back pain in primary care: objectives, design and interventions
[ISRCTN32683578]. BMC Health Serv Res 2003;3:16. https://doi.org/10.1186/
1472-6963-3-16
Population not all meeting inclusion
for unexplained
van Erp RM, Huijnen IP, Verbunt JA, Smeets RJ. A biopsychosocial primary care
intervention (Back on Track) versus primary care as usual in a subgroup of
people with chronic low back pain: protocol for a randomised, controlled trial.
J Physiother 2015;61:155. https://doi.org/10.1016/j.jphys.2015.03.003
Population not all meeting inclusion
for unexplained
Arnold IA, de Waal MW, Eekhof JA, Assendelft WJ, Spinhoven P, van Hemert
AM. Medically unexplained physical symptoms in primary care: a controlled
study on the effectiveness of cognitive-behavioral treatment by the family
physician. Psychosomatics 2009;50:515–24. https://doi.org/10.1176/appi.psy.50.
5.515
Not a RCT
Senlöf P, Denison E, Lindberg P. Long-term follow-up of tailored behavioural
treatment and exercise based physical therapy in persistent musculoskeletal
pain: a randomized controlled trial in primary care. Eur J Pain 2009;13:1080–8.
https://doi.org/10.1016/j.ejpain.2009.01.010
Population not all meeting inclusion
for unexplained
Basler HD. Follow-up results of a cognitive-behavioural treatment for chronic
pain in a primary care setting. Pychol Health 1990;4:293–304
Population not all meeting inclusion
criteria for unexplained
Becker N, Sjøgren P, Bech P, Olsen AK, Eriksen J. Treatment outcome of chronic
non-malignant pain patients managed in a danish multidisciplinary pain centre
compared to general practice: a randomised controlled trial. Pain 2000;84:203–11
Not in a primary care setting, the
intervention is in a pain centre
Becker N, Sjogren P, Olsen A. Behandlingsresultater ved kroniske, non-maligne
smertetilstande hos patienter, behandlet i et dansk, tvaerfagligt smertecenter
sammenlignet med almen praksis. Ugeskr Laeger 2001;163:3078–82
Not in a primary care setting
Bernal Cercós A, Fusté Vallverdú R, Urbieta Solana R, Montesinos Molina I.
Tratamiento de relajación en pacientes con trastornos de ansiedad y
somatoformes en atención primaria. Aten Primaria 1995;15:499–504
Population have anxiety or
somatoform disorders
Best M, Lange M, Karpinski N, Hessel A, Söpper-Terborg B, Sieling W,
Petermann F. [Psychosomatic rehabilitation: effects of pre-treatment
counselling under the statutory pension insurance scheme.] Rehabilitation
2009;48:283–7. https://doi.org/10.1055/s-0029-1239544
Outcomes not appropriate
Bonetti F, Curti M, Curti S, Ferrari C, Mattioli S, Mugnai R, et al. Effectiveness
of a global posture reeducation program for patients with low back pain.
Physiotherapy 2011;97:eS1001
Conference abstract
Carmody TP, Duncan CL, Huggins J, Solkowitz SN, Lee SK, Reyes N, et al.
Telephone-delivered cognitive-behavioral therapy for pain management among
older military veterans: a randomized trial. Psychol Serv 2013;10:265–75.
https://doi.org/10.1037/a0030944
Population is military veterans
Chalder T, Godfrey E, Ridsdale L, King M, Wessely S. Predictors of outcome in
a fatigued population in primary care following a randomized controlled trial.
Psychol Med 2003;33:283–7
Appropriate outcomes are in
Ridsdale et al.112
Chelimsky TC, Fischer RL, Levin JB, Cheren MI, Marsh SK, Janata JW. The
primary practice physician program for chronic pain (© 4PCP): outcomes of a
primary physician-pain specialist collaboration for community-based training
and support. Clin J Pain 2013;29:1036–43. https://doi.org/10.1097/AJP.
0b013e3182851584
No patient outcomes for any controls
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Citation Reason for exclusion
Christensen SS, Frostholm L, Ørnbøl E, Schröder A. Changes in illness
perceptions mediated the effect of cognitive behavioural therapy in severe
functional somatic syndromes. J Psychosom Res 2015;78:363–70. https://doi.org/
10.1016/j.jpsychores.2014.12.005
Outcomes not appropriate
Da Costa D, Abrahamowicz M, Lowensteyn I, Bernatsky S, Dritsa M,
Fitzcharles MA, Dobkin PL. A randomized clinical trial of an individualized
home-based exercise programme for women with fibromyalgia. Rheumatology
2005;44:1422–7
Setting is not primary care
Cuesta-Vargas AI, Adams N. A pragmatic community-based intervention of
multimodal physiotherapy plus deep water running (DWR) for fibromyalgia
syndrome: a pilot study. Clin Rheumatol 2011;30:1455–62. https://doi.org/
10.1007/s10067-011-1825-z
Non-randomised pilot clinical trial
Darbishire L, Seed P, Ridsdale L. Predictors of outcome following treatment for
chronic fatigue. Br J Psychiatry 2005;186:350–1
Outcomes – predictors of successful
outcome
Del Pozo-Cruz B, Adsuar JC, Parraca J, Del Pozo-Cruz J, Moreno A, Gusi N.
A web-based intervention to improve and prevent low back pain among office
workers: a randomized controlled trial. Arch Prev Riesgos Labor 2013;16:138
Pain is subacute
del Pozo-Cruz B, del Pozo-Cruz J, Adsuar JC, Parraca J, Gusi N. Reanalysis of a
tailored web-based exercise programme for office workers with sub-acute low
back pain: assessing the stage of change in behaviour. Psychol Health Med
2013;18:687–97. https://doi.org/10.1080/13548506.2013.765019
Pain is subacute
Dobbin A, Dobbin J, Ross SC, Graham C, Ford MJ. Randomised controlled trial
of brief intervention with biofeedback and hypnotherapy in patients with
refractory irritable bowel syndrome. J R Coll Physicians Edinb 2013;43:15–23.
https://doi.org/10.4997/JRCPE.2013.104
Setting not primary care
Domenech J, Baños R, Peñalver L, Garcia-Palacios A, Herrero R, Ezzedine A,
et al. Design considerations of a randomized clinical trial on a cognitive
behavioural intervention using communication and information technologies
for managing chronic low back pain. BMC Musculoskelet Disord 2013;14:142.
https://doi.org/10.1186/1471-2474-14-142
Study design paper
Egan S, Saper R. (Predictors of adherence to treatment for chronic low back
pain in a 12-week RCT comparing yoga, physical therapy, and education.
J Altern Complement Med 2014;20:A56
Conference abstract
van Eijk-Hustings Y, Kroese M, Tan F, Boonen A, Bessems-Beks M, Landewé R.
Challenges in demonstrating the effectiveness of multidisciplinary treatment
on quality of life, participation and health care utilisation in patients with
fibromyalgia: a randomised controlled trial. Clin Rheumatol 2013;32:199–209.
https://doi.org/10.1007/s10067-012-2100-7
Setting is not primary care
Enezei HH, Alam MK. Variation in the efficacy of two different treatment
modalities used for myofacial pain dysfunction syndrome: clinical trial.
Int Med J 2015;22:410–12
Not in a primary care setting
Escobar JI, Gara M, Alex I, Allen L, Diaz-Martinez A, Warman M. Treatment of
patients presenting with unexplained physical symptoms in primary care.
Neuropsychopharmacology 2004;29(Suppl. 1):S101
Conference abstract
Everitt H, Landau S, Little P, Bishop FL, McCrone P, O’Reilly G, et al. Assessing
Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a
randomised controlled trial of clinical-effectiveness and cost-effectiveness of
therapist delivered cognitive behavioural therapy and web-based self-
management in irritable bowel syndrome in adults. BMJ Open 2015;5:e008622.
https://doi.org/10.1136/bmjopen-2015-008622
Protocol only
Everitt H, Moss-Morris R, Sibelli A, Tapp L, Coleman N, Yardley L, et al.
Management of irritable bowel syndrome in primary care: the results of an
exploratory randomised controlled trial of mebeverine, methylcellulose, placebo
and a self-management website. BMC Gastroenterol 2013;13:68. https://doi.org/
10.1186/1471-230X-13-68
Insufficient primary care involvement.
Invitation letter from practices
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Citation Reason for exclusion
Faas A, Chavannes AW, van Eijk JT, Gubbels JW. A randomized, placebo-
controlled trial of exercise therapy in patients with acute low back pain.
Spine 1993;18:1388–95
Pain is acute
Falcão DM, Sales L, Leite JR, Feldman D, Valim V, Natour J. Cognitive
behavioral therapy for the treatment of fibromyalgia syndrome: a randomized
controlled trial. J Musculoskelet Pain 2008;16:133–40
Not in a primary care setting
Moshkani Farahani D, Tavallaie SA, Ahmadi K, Fathi Ashtiani A. Comparison of
neurofeedback and transcutaneous electrical nerve stimulation efficacy on
treatment of primary headaches: a randomized controlled clinical trial. Iran Red
Crescent Med J 2014;16:e17799. https://doi.org/10.5812/ircmj.17799
Setting not primary care
Farnam A, Somi MH, Farhang S, Mahdavi N, Ali Besharat M. The therapeutic
effect of adding emotional awareness training to standard medical treatment
for irritable bowel syndrome: a randomized clinical trial. J Psychiatr Pract
2014;20:3–11. https://doi.org/10.1097/01.pra.0000442934.38704.3a
Setting not primary care
Fernandez C, Perez M, Amigo I, Linares A. Stress and contingency management
in the treatment of irritable bowel syndrome. Stress Health 1998;14:31–42
Not in a primary care setting
Fjorback L, Schroder A, Ornbol E, Rehfeld E, Arendt M, Fink P. Mindfulness
therapy for bodily distress syndrome – a randomized controlled trial.
J Psychosom Res 2011;70:292–3
Conference abstract
Fernández R, Peñarubia MT, Luciano JV, Blanco ME, Jiménez M, Montesano A,
et al. Effectiveness of a psycho-educational program for improving quality of
life of fibromyalgia patients. BMC Musculoskelet Disord 2008;9:2
Protocol
Vibe Fersum K, O’Sullivan P, Skouen JS, Smith A, Kvåle A. Efficacy of
classification-based cognitive functional therapy in patients with non-specific
chronic low back pain: a randomized controlled trial. Eur J Pain 2013;17:916–28.
https://doi.org/10.1002/j.1532-2149.2012.00252.x
Setting is not primary care
Fink P, Rosendal M, Toft T. Assessment and treatment of functional disorders
in general practice: the extended reattribution and management model – an
advanced educational program for nonpsychiatric doctors. Psychosomatics
2002;43:93–131
No study data, description of a
treatment programme
French SD, McKenzie JE, O’Connor DA, Grimshaw JM, Mortimer D, Francis JJ,
et al. Evaluation of a theory-informed implementation intervention for
the management of acute low back pain in general medical practice: the
IMPLEMENT cluster randomised trial. PLOS ONE 2013;8:e65471. https://doi.
org/10.1371/journal.pone.0065471
Pain is acute
Ben Salah Frih Z, Fendri Y, Jellad A, Boudoukhane S, Rejeb N. Efficacy and
treatment compliance of a home-based rehabilitation programme for chronic
low back pain: a randomized, controlled study. Ann Phys Rehabil Med
2009;52:485–96. https://doi.org/10.1016/j.rehab.2009.04.002
Setting not primary care – referral
from outpatient service
Gale G, Nussbaum D, Rothbart P, Hann B, Leung V, Kanetz G. A randomized
treatment study to compare the efficacy of repeated nerve blocks with
cognitive therapy for control of chronic head and neck pain. Pain Res Manage
2002;7:185–9
Insufficient primary care involvement
García-Campayo J, Arevalo E, Claraco LM, Alda M, Lopez del Hoyo Y. A
prevention programme for somatoform disorders is effective for affective
disorders. J Affect Disord 2010;122:124–32. https://doi.org/10.1016/j.jad.2009.
06.031
Prevention study
García-Campayo J, Serrano-Blanco A, Rodero B, Magallón R, Alda M, Andrés E,
et al. Effectiveness of the psychological and pharmacological treatment of
catastrophization in patients with fibromyalgia: a randomized controlled trial.
Trials 2009;10:24. https://doi.org/10.1186/1745-6215-10-24
Protocol
Gawriołek K, Azer SS, Gawriołek M, Piotrowski PR. Mandibular function
after myorelaxation therapy in temporomandibular disorders. Adv Med Sci
2015;60:6–12. https://doi.org/10.1016/j.advms.2014.05.002
Not a RCT
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Citation Reason for exclusion
Gaylord SA, Whitehead WE, Coble RS, Faurot KR, Palsson OS, Garland EL,
et al. Mindfulness for irritable bowel syndrome: protocol development for a
controlled clinical trial. BMC Complement Altern Med 2009;9:24. https://doi.org/
10.1186/1472-6882-9-24
Protocol and recruitment data only
Genç A, Sağıroğlu E. Fibromiyalji tedavisinde iki farklı egzersiz programının
karşılaştırılması
Not in a primary care setting
Geraets JJ, Goossens ME, van Haastregt JC, de Groot IJ, de Bruijn CP, de Bie RA,
et al. Implications of process evaluation for clinical effectiveness and clinical
practice in a trial on chronic shoulder complaints. Patient Educ Couns
2006;61:117–25
Outcomes not appropriate
Geraghty AW, Kirby S, Essery R, Little P, Bronstein A, Turner D, et al. Internet-
based vestibular rehabilitation for adults aged 50 years and over: a protocol
for a randomised controlled trial. BMJ Open 2014;4:e005871. https://doi.org/
10.1136/bmjopen-2014-005871
Protocol only
Gilbert JR, Taylor DW, Hildebrand A, Evans C. Clinical trial of common
treatments for low back pain in family practice. Br Med J 1985;291:791–4
Pain is acute
Godfrey E, Chalder T, Ridsdale L, Seed P, Ogden J. Investigating the active
ingredients of cognitive behaviour therapy and counselling for patients with
chronic fatigue in primary care: developing a new process measure to assess
treatment fidelity and predict outcome. Br J Clin Psychol 2007;46:253–72
Trial data are in Ridsdale113
Goldstein LH, Chalder T, Chigwedere C, Khondoker MR, Moriarty J, Toone BK,
Mellers JD. Cognitive-behavioral therapy for psychogenic nonepileptic seizures:
a pilot RCT. Neurology 2010;74:1986–94. https://doi.org/10.1212/WNL.
0b013e3181e39658
Setting not primary care
Goldstein LH, Mellers JD, Landau S, Stone J, Carson A, Medford N, et al.
COgnitive behavioural therapy vs standardised medical care for adults with
Dissociative non-Epileptic Seizures (CODES): a multicentre randomised
controlled trial protocol. BMC Neurol 2015;15:98. https://doi.org/10.1186/
s12883-015-0350-0
Study protocol
Greene B, Blanchard EB. Cognitive therapy for irritable bowel syndrome.
J Consult Clin Psychol 1994;62:576–82
Not in a primary care setting
Griffiths C, Dziedzic K, Waterfield J, Sim J. Effectiveness of specific neck
stabilization exercises or a general neck exercise program for chronic neck
disorders: a randomized controlled trial. J Rheumatol 2009;36:390–7.
https://doi.org/10.3899/jrheum.080376
Intervention is posture correction
implies pain is explained
Grundmann O, Yoon SL. Mind-body therapies for functional bowel disorders –
a review of recent clinical trials. Eur J Integr Med 2013;5:296–307
Review
Guenter D, Angeles R, Bullock L, McCarthy L, Bauer M, Wolfson M, Chacon M.
Living everyday above-and-beyond pain (LEAP): Design of an RCT evaluating
an interprofessional cognitive-behavioral group therapy in primary care.
Pain Res Manage 2011;16:118
Conference abstract
Haldorsen EM, Kronholm K, Skouen JS, Ursin H. Multimodal cognitive
behavioral treatment of patients sicklisted for musculoskeletal pain:
a randomized controlled study. Scand J Rheumatol 1998;27:16–25
Pain is less than 12 weeks’ duration
Hammerich AS, Maluf KS. Effects of biofeedback on stress-evoked activation of
the upper trapezius muscle in subjects with chronic neck pain. 2008 Combined
Sections Meeting. Nashville, TN, USA, February 6–9, 2008. J Orthop Sports Phys
Ther 2008;38:A23–24
Conference abstract
Hansen Z, Daykin A, Lamb SE. A cognitive-behavioural programme for the
management of low back pain in primary care: a description and justification
of the intervention used in the Back Skills Training Trial (BeST; ISRCTN
54717854). Physiotherapy 2010;96:87–94. https://doi.org/10.1016/
j.physio.2009.09.008
Description of trial design only
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Citation Reason for exclusion
Hassink-Franke LJ, van Weel-Baumgarten EM, Wierda E, Engelen MW,
Beek MM, Bor HH, et al. Effectiveness of problem-solving treatment by general
practice registrars for patients with emotional symptoms. J Prim Health Care
2011;3:181–9
Population not meeting the inclusion
criteria for MUS
Hay EM, Mullis R, Lewis M, Vohora K, Main CJ, Watson P, et al. Comparison of
physical treatments versus a brief pain-management programme for back pain
in primary care: a randomised clinical trial in physiotherapy practice. Lancet
2005;365:2024–30
Pain not greater than 3 months
Hayes S, Hogan M, Dowd H, Doherty E, O’Higgins S, Nic Gabhainn S, et al.
Comparing the clinical-effectiveness and cost-effectiveness of an internet-
delivered acceptance and commitment therapy (ACT) intervention with a
waiting list control among adults with chronic pain: study protocol for a
randomised controlled trial. BMJ Open 2014;4:e005092. https://doi.org/
10.1136/bmjopen-2014-005092
Protocol only
Heitkemper MM, Jarrett ME, Levy RL, Cain KC, Burr RL, Feld A, et al.
Self-management for women with irritable bowel syndrome. Clin Gastroenterol
Hepatol 2004;2:585–96
Insufficient primary care involvement
Hildebrandt VH, Proper KI, van den Berg R, Douwes M, van den Heuvel SG,
van Buuren S. [Cesar therapy is temporarily more effective in patients with
chronic low back pain than the standard treatment by family practitioner:
randomized, controlled and blinded clinical trial with 1 year follow-up.]
Ned Tijdschr Geneeskd 2000;144:2258–64
Intervention is posture correction
implies pain is explained
Hill J, Dunn KM, Lewis M, Mason E, Vohora K, Main C, et al. A randomised trial
of targeted treatment for low back pain compared with current best practice:
the start back trial [ISRCTN37113406]. Physiotherapy 2011;97:eS485–6
Conference abstract
Hill JC, Whitehurst DG, Lewis M. Risk-stratified primary care management of
low back pain reduced disability. Ann Int Med 2012;156:JC2–7
Population not meeting inclusion
criteria for unexplained
Hofmann J, Peters S, Geidl W, Hentschke C, Pfeifer K. Effects of behavioural
exercise therapy on the effectiveness of a multidisciplinary rehabilitation for
chronic non-specific low back pain: study protocol for a randomised controlled
trial. BMC Musculoskelet Disord 2013;14:89. https://doi.org/10.1186/1471-
2474-14-89
Population is inpatients
Hofmann SG. Review: cognitive behavioural interventions may be effective for
chronic fatigue syndrome and chronic back pain. Evid Based Ment Health
2003;6:55
Commentary
van der Horst HE, Schellevis FG, Eijk J. How effective is patient education and
counseling for patients with ‘irritable bowel syndrome’ in general practice? Ned
Tijdschr Geneeskd 1998;142:1417. Retrieved from http://onlinelibrary.wiley.com/
o/cochrane/clcentral/articles/834/CN-00267834/frame.html
Conference abstract
Hoving JL, de Vet HCW, Koes BW, van Mameren H, Deville W, van der Windt D,
et al. Manual therapy, physical therapy, or continued care by the general
practitioner for patients with neck pain – long-term results from a pragmatic
randomized clinical trial. Clin J Pain 2006;22:370–7. https://doi.org/10.1097/
01.ajp.0000180185.79382.3f
Duration of pain is not greater than
3 months
Huibers M, Beurskens A,Van Schayck C, Bazelmans E, Metsemakers J,
Knottnerus A, Bleijenberg G. [Efficacy of cognitive behavioral therapy by
general practitioners for unexplained fatigue among employees.] Huisarts Wet
2005;48:267–72
Dutch version of Huibers et al.153
Hurley M, Walsh NE, Jessep S. Clinical effectiveness and costs of an integrated
rehabilitation programme compared with outpatient physiotherapy for chronic
knee pain. Arthr Rheumat 2012;64:S1026. Retrieved from http://onlinelibrary.
wiley.com/o/cochrane/clcentral/articles/235/CN-01008235/frame.html
Conference abstract
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Citation Reason for exclusion
Hutting N, Bart Staal J, Engels JA, Heerkens YF, Detaille SI,
Nijhuis-van der Sanden MWG. Effect evaluation of a self-management
programme for employees with complaints of the arm, neck or shoulder:
a randomised controlled trial. Occup Environ Med 2015;72:852–61
Insufficient primary care involvement
Hutting N, Staal JB, Heerkens YF, Engels JA, Nijhuis-van der Sanden MW.
A self-management program for employees with complaints of the arm, neck,
or shoulder (CANS): study protocol for a randomized controlled trial. Trials
2013;14:258. https://doi.org/10.1186/1745-6215-14-258
Protocol only
Janse A,Worm-Smeitink M, Bussel-Lagarde J, Bleijenberg G, Nikolaus S, Knoop H.
Testing the efficacy of web-based cognitive behavioural therapy for adult patients
with chronic fatigue syndrome (CBIT): study protocol for a randomized controlled
trial. BMC Neurol 2015;15:137. https://doi.org/10.1186/s12883-015-0392-3
Protocol only
Jarrett ME, Cain KC, Burr RL, Hertig VL, Rosen SN, Heitkemper MM.
Comprehensive self-management for irritable bowel syndrome: randomized
trial of in-person vs. combined in-person and telephone sessions. Am J
Gastroenterol 2009;104:3004–14. https://doi.org/10.1038/ajg.2009.479
Setting is not primary care
Jellema P, van der Horst HE, Vlaeyen JW, Stalman WA, Bouter LM,
van der Windt DA. Predictors of outcome in patients with (sub)acute low back
pain differ across treatment groups. Spine 2006;31:1699–705. https://doi.org/
10.1097/01.brs.0000224179.04964.aa
Pain not greater than 3 months
Jellema P, van der Roer N, van der Windt DA, van Tulder MW, van der Horst HE,
Stalman WA, Bouter LM. Low back pain in general practice: cost-effectiveness of a
minimal psychosocial intervention versus usual care. Eur Spine J 2007;16:1812–21.
https://doi.org/10.1007/s00586-007-0439-2
Pain is subacute
Jellema P, van der Horst HE, Vlaeyen JW, Stalman WA, Bouter LM,
van der Windt DA. Predictors of outcome in patients with (sub)acute low back
pain differ across treatment groups. Spine 2006;31:1699–705. https://doi.org/
10.1097/01.brs.0000224179.04964.aa
Pain is subacute
Jellema P, van der Windt DA, van der Horst HE, Blankenstein AH, Bouter LM,
Stalman WA. Why is a treatment aimed at psychosocial factors not effective in
patients with (sub)acute low back pain? Pain 2005;118:350–9
Pain is subacute
Jellema P, van der Windt DA, van der Horst HE, Stalman WA, Bouter LM.
Prediction of an unfavourable course of low back pain in general practice:
comparison of four instruments. Br J Gen Pract 2007;57:15–22
Pain is subacute
Jellema P, van der Windt DAW, van der Horst HE, Twisk JWR, Stalman WAB,
Bouter LM. Should treatment of (sub)acute low back pain be aimed at
psychosocial prognostic factors? Cluster randomised clinical trial in general
practice. BMJ 2005;331:84–7. https://doi.org/10.1136/bmj.38495.686736.E0
Pain is subacute
Jensen CE, Riis A, Pedersen KM, Jensen MB, Petersen KD. Study protocol of
an economic evaluation of an extended implementation strategy for the
treatment of low back pain in general practice: a cluster randomised controlled
trial. Implement Sci 2014;9:140. https://doi.org/10.1186/s13012-014-0140-x
Protocol only
Johnson RE, Jones GT, Wiles NJ, Chaddock C, Potter RG, Roberts C, et al.
Active exercise, education, and cognitive behavioural therapy for persistent
disabling low back pain. Spine 2007;32:1578–85
Pain not unexplained
Jones GT, Mertens K, Macfarlane GJ, Palmer KT, Coggon D, Walker-Bone K,
et al. Maintained physical activity and physiotherapy in the management of
distal upper limb pain - a protocol for a randomised controlled trial (the arm
pain trial). BMC Musculoskelet Disord 2014;15:71. https://doi.org/10.1186/
1471-2474-15-71
Protocol only
Jones M, Koloski N, Boyce P, Talley NJ. Pathways connecting cognitive
behavioral therapy and change in bowel symptoms of IBS. J Psychosom Res
2011;70:278–85. https://doi.org/10.1016/j.jpsychores.2010.10.004
Setting not primary care
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Citation Reason for exclusion
Jonsbu E, Dammen T, Morken G, Moum T, Martinsen EW. Short-term cognitive
behavioral therapy for non-cardiac chest pain and benign palpitations: a
randomized controlled trial. J Psychosom Res 2011;70:117–23. https://doi.org/
10.1016/j.jpsychores.2010.09.013
Setting not primary care
Jonsbu E, Martinsen EW, Morken G, Moum T, Dammen T. Change and impact
of illness perceptions among patients with non-cardiac chest pain or benign
palpitations following three sessions of CBT. Behav Cogn Psychother
2013;41:398–407. https://doi.org/10.1017/S1352465813000179
Outcomes not appropriate
Kaleth AS, Saha CK, Jensen MP, Slaven JE, Ang DC. Effect of moderate to
vigorous physical activity on long-term clinical outcomes and pain severity in
fibromyalgia. Arthritis Care Res 2013;65:1211–18. https://doi.org/10.1002/
acr.21980
Insufficient primary care involvement
Kalmatayeva Z, Zholamanova A. Cost-effectiveness analysis of psychotherapy
in treatment of essential hypertension in primary care. Arch Psychiatry
Psychother 2014;16:57–64
Population not unexplained
Katsamanis M, Lehrer PM, Escobar JI, Gara MA, Kotay A, Liu R.
Psychophysiologic treatment for patients with medically unexplained
symptoms: a randomized controlled trial. Psychosomatics 2011;52:218–29.
https://doi.org/10.1016/j.psym.2011.01.015
Setting not primary care
Kemani MK, Olsson GL, Lekander M, Hesser H, Andersson E, Wicksell RK.
Efficacy and cost-effectiveness of acceptance and commitment therapy and
applied relaxation for longstanding pain: a randomized controlled trial. Clin J
Pain 2015;31:1004–16. https://doi.org/10.1097/AJP.0000000000000203
Includes tertiary care
Knox CR, Lall R, Hansen Z, Lamb SE. Treatment compliance and effectiveness
of a cognitive behavioural intervention for low back pain: a complier average
causal effect approach to the BeST data set. BMC Musculoskelet Disord
2014;15:17. https://doi.org/10.1186/1471-2474-15-17
Pain is not greater than 3 months
Kristjansdottir OB, Fors EA, Eide E, Finset A, Dulmen S, Wigers SH, Eide H.
The effect of web-based diaries and situational feedback on catastrophizing in
women with chronic widespread pain – a randomized trial. Eur J Pain Suppl
2011;5:259–60
Conference abstract
Kristjánsdóttir OB, Fors EA, Eide E, Finset A, Stensrud TL, van Dulmen S, et al.
A smartphone-based intervention with diaries and therapist-feedback to
reduce catastrophizing and increase functioning in women with chronic
widespread pain: randomized controlled trial. J Med Internet Res 2013;15:e5.
https://doi.org/10.2196/jmir.2249
Setting not primary care
Kroenke K, Swindle R. Cognitive-behavioral therapy for somatization and
symptom syndromes: a critical review of controlled clinical trials. Psychother
Psychosom 2000;69:205–15
Systematic review
Lahmann C, Henningsen P, Dieterich M, Radziej K, Schmid G. Tailored care for
somatoform vertigo/dizziness: study protocol for a randomised controlled trial
evaluating integrative group psychotherapy. J Neurol 2015;262:1867–75.
https://doi.org/10.1007/s00415-015-7784-6
Protocol only
Lamb SE, Hansen Z, Lall R, Castelnuova E, Withers E, Nichols V, Potter R.
Group cognitive behavioral intervention in primary care in low back pain:
a randomized, controlled study and analysis of cost-effectiveness. Osteopath
Med 2010;11:24–6
Pain is subacute
Lamb SE, Mistry D, Lall R, Hansen Z, Evans D, Withers EJ, Underwood MR,
Back Skills Training Trial Group. Group cognitive behavioural interventions for
low back pain in primary care: extended follow-up of the Back Skills Training
Trial (ISRCTN54717854). Pain 2012;153:494–501. https://doi.org/10.1016/
j.pain.2011.11.016
Pain is subacute
Lang E, Liebig K, Kastner S, Neundörfer B, Heuschmann P. Multidisciplinary
rehabilitation versus usual care for chronic low back pain in the community:
effects on quality of life. Spine J 2003;3:270–6
Study design – non randomised trial
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Citation Reason for exclusion
Leonhardt C, Keller S, Chenot JF, Luckmann J, Basler HD, Wegscheider K, et al.
TTM-based motivational counselling does not increase physical activity of low
back pain patients in a primary care setting – a cluster-randomized controlled
trial. Patient Educ Couns 2008;70:50–60
Pain includes acute
Lin J, Luking M, Ebert DD, Buhrman M, Andersson G, Baumeister H.
Effectiveness and cost-effectiveness of a guided and unguided internet-based
acceptance and commitment therapy for chronic pain: study protocol for a
three-armed randomised controlled trial. Internet Interv 2015;2:7–16
Heterogeneous pain population not
necessarily unexplained
Litt MD, Porto FB. Determinants of pain treatment response and nonresponse:
identification of TMD patient subgroups. J Pain 2013;14:1502–13. https://doi.
org/10.1016/j.jpain.2013.07.017
Setting not primary care
Ljótsson B, Andersson G, Andersson E, Hedman E, Lindfors P, Andréewitch S,
et al. Acceptability, effectiveness, and cost-effectiveness of internet-based
exposure treatment for irritable bowel syndrome in a clinical sample:
a randomized controlled trial. BMC Gastroenterol 2011;11:110. https://doi.org/
10.1186/1471-230X-11-110
Setting not primary care
Lofvander MB. Cognitive-behavioural treatment of chronic pain in primary
care: a three-year follow-up. Eur J Gen Pract 2002;8:151–8
Not a RCT
López-García-Franco A, del-Cura-González MI, Caballero-Martinez L,
Sanz-Cuesta T, Díaz-García MI, Rodriguez-Monje MT, et al. Effectiveness of
a cognitive behavioral intervention in patients with medically unexplained
symptoms: cluster randomized trial. BMC Fam Pract 2012;13:35. https://doi.org/
10.1186/1471-2296-13-35
Protocol only
Luciano JV, D’Amico F, Cerdà-Lafont M, Peñarrubia-María MT, Knapp M,
Cuesta-Vargas AI, et al. Cost-utility of cognitive behavioral therapy versus U.S. Food
and Drug Administration recommended drugs and usual care in the treatment
of patients with fibromyalgia: an economic evaluation alongside a 6-month
randomized controlled trial. Arthritis Res Ther 2014;16:451. https://doi.org/
10.1186/s13075-014-0451-y
Cost-utility
Luciano JV, Sabes-Figuera R, Cardeñosa E, T Peñarrubia-María M,
Fernández-Vergel R, García-Campayo J, et al. Cost-utility of a psychoeducational
intervention in fibromyalgia patients compared with usual care: an economic
evaluation alongside a 12-month randomized controlled trial. Clin J Pain
2013;29:702–11. https://doi.org/10.1097/AJP.0b013e318270f99a
Outcomes are costs
Luo Z, Goddeeris J, Gardiner JC, Smith RC. Costs of an intervention for
primary care patients with medically unexplained symptoms: a randomized
controlled trial. Psychiatr Serv 2007;58:1079–86
Costs data
Macfarlane GJ, Beasley M, Keeley P, Lovell K, Hannaford P, Symmons DPM,
et al. A randomised controlled trial (RCT) of telephone delivered cognitive
behaviour therapy (TCBT) and exercise in the management of chronic
widespread pain (CWP): Identifying long-term outcome and who benefits from
which treatment. Arthritis Rheum 2013;65:S1221
Conference abstract
Machado LA, Azevedo DC, Capanema MB, Neto TN, Cerceau DM. Client-
centered therapy vs exercise therapy for chronic low back pain: a pilot
randomized controlled trial in Brazil. Pain Med 2007;8:251–8
Not in a primary care setting
Magallón R, Gili M, Moreno S, Bauzá N, García-Campayo J, Roca M, et al.
Cognitive-behaviour therapy for patients with Abridged Somatization Disorder
(SSI 4,6) in primary care: a randomized, controlled study. BMC Psychiatry
2008;8:47. https://doi.org/10.1186/1471-244X-8-47
Protocol
Mannerkorpi K, Nyberg B, Ahlmén M, Ekdahl C. Pool exercise combined with
an education program for patients with fibromyalgia syndrome. A prospective,
randomized study. J Rheumatol 2000;27:2473–81
Not in a primary care setting
Marques M, De Gucht V, Maes S, Leal I. Protocol for the ‘four steps to control
your fatigue (4-STEPS)’ randomised controlled trial: a self-regulation based
physical activity intervention for patients with unexplained chronic fatigue.
BMC Public Health 2012;12:202. https://doi.org/10.1186/1471-2458-12-202
Protocol only
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Citation Reason for exclusion
Mårtensson L, Marklund B, Fridlund B. Evaluation of a biopsychosocial
rehabilitation programme in primary healthcare for chronic pain patients.
Scand J Occup Ther 1999;6:157–65
Not a RCT
Martins MR, Gritti CC, dos Santos Junior R, de Araújo MC, Dias LC, Foss MH,
et al. Randomized controlled trial of a therapeutic intervention group in
patients with fibromyalgia syndrome. Rev Bras Reumatol 2014;54:179–84
Setting is secondary care
Mason E, Hill JC, Lewis M, Dunn KM, Hay EM. Does targeted treatment for
low back pain improve patient satisfaction and better meet expectations
compared to current best care? Physiotherapy 2011;97:eS757–8
Conference abstract
McCracken LM, Sato A, Taylor GJ. A trial of a brief group-based form of
acceptance and commitment therapy (ACT) for chronic pain in general practice:
pilot outcome and process results. J Pain 2013;14:1398–406. https://doi.org/
10.1016/j.jpain.2013.06.011
Population not meeting inclusion
criteria for unexplained
McCracken LM, Sato A, Wainwright D, House W, Taylor GJ. A feasibility study
of brief group-based acceptance and commitment therapy for chronic pain in
general practice: recruitment, attendance, and patient views. Prim Health Care
Res Dev 2014;15:312–23. https://doi.org/10.1017/S1463423613000273
Population not meeting inclusion
criteria for unexplained
McCrone P, Knapp M, Kennedy T, Seed P, Jones R, Darnley S, Chalder T.
Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine
for irritable bowel syndrome. Eur J Gastroenterol Hepatol 2008;20:255–63.
https://doi.org/10.1097/MEG.0b013e3282f2519d
Cost-effectiveness from Kennedy
et al.129
McCrone P, Ridsdale L, Darbishire L, Seed P. Cost-effectiveness of cognitive
behavioural therapy, graded exercise and usual care for patients with chronic
fatigue in primary care. Psychol Med 2004;34:991–9
Cost-effectiveness from Ridsdale
et al.113
McDonough SM, Tully MA, Boyd A, O’Connor SR, Kerr DP, O’Neill SM, et al.
Pedometer-driven walking for chronic low back pain: a feasibility randomized
controlled trial. Clin J Pain 2013;29:972–81. https://doi.org/10.1097/AJP.
0b013e31827f9d81
Not in a primary care setting, referral
to hospital lists
Meijer EM, Sluiter JK, Heyma A, Sadiraj K, Frings-Dresen MH. Cost-
effectiveness of multidisciplinary treatment in sick-listed patients with upper
extremity musculoskeletal disorders: a randomized, controlled trial with one-
year follow-up. Int Arch Occup Environ Health 2006;79:654–64. https://doi.org/
10.1007/s00420-006-0098-3
Setting is not primary care
Meng H, Friedberg F, Castora-Binkley M. Cost-effectiveness of chronic fatigue
self-management versus usual care: a pilot randomized controlled trial. BMC
Fam Pract 2014;15:184. https://doi.org/10.1186/s12875-014-0184-7
Costs from Friedberg et al.151
Menzel NN, Robinson ME. Back pain in direct patient care providers: early
intervention with cognitive behavioral therapy. Pain Manag Nurs 2006;7:53–63
Setting not primary care
Miller J, MacDermid JC,Walton DM, Richardson J. Chronic pain self-management
support with pain science education and exercise (COMMENCE): study protocol
for a randomized controlled trial. Trials 2015;16:462. https://doi.org/10.1186/
s13063-015-0994-5
Protocol only
Milosavljevic S, Clay L, Bath B, Trask C, Penz E, Stewart S, et al. Walking away
from back pain: one step at a time - a community-based randomised controlled
trial. BMC Public Health 2015;15:144. https://doi.org/10.1186/s12889-015-
1496-9
Protocol only
Moffett JK, Torgerson D, Bell-Syer S, Jackson D, Llewlyn-Phillips H, Farrin A,
Barber J. Randomised controlled trial of exercise for low back pain: clinical
outcomes, costs, and preferences. BMJ 1999;319:279–83
Pain is not greater than 3 months
Mongini F, Evangelista A, Milani C, Ferrero L, Ciccone G, Ugolini A, et al.
An educational and physical program to reduce headache, neck/shoulder
pain in a working community: a cluster-randomized controlled trial. PLOS ONE
2012;7:e29637. https://doi.org/10.1371/journal.pone.0029637
Not in a primary care setting
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Citation Reason for exclusion
Monticone M, Ferrante S, Rocca B, Baiardi P, Farra FD, Foti C. Effect of a long-
lasting multidisciplinary program on disability and fear-avoidance behaviors in
patients with chronic low back pain: results of a randomized controlled trial.
Clin J Pain 2013;29:929–38. https://doi.org/10.1097/AJP.0b013e31827fef7e
Not in a primary care setting
Moore JE, Von Korff M, Cherkin D, Saunders K, Lorig K. A randomized trial of
a cognitive-behavioral program for enhancing back pain self care in a primary
care setting. Pain 2000;88:145–53
Pain not unexplained
Moreno S, Gili M, Magallon R, Bauza N, Roca M, del Hoyo YL, Garcia-Campayo J.
Effectiveness of group versus individual cognitive-behavioral therapy in patients
with abridged somatization disorder: a randomized controlled trial. Erratum.
Psychosom Med 2014;76:399
Conference abstract
Morriss R. Specific psychosocial interventions for somatizing patients by
the general practitioner: a randomised controlled trial. J Psychosom Res
2004;57:515–16
Commentary
Morriss R, Gask L, Dowrick C, Dunn G, Peters S, Ring A, et al. Randomized
trial of reattribution on psychosocial talk between doctors and patients with
medically unexplained symptoms. Psychol Med 2010;40:325–33. https://doi.org/
10.1017/S0033291709990353
Outcomes not appropriate for
quantitative review
Moseley GL, Nicholas MK, Hodges PW. A randomized controlled trial of
intensive neurophysiology education in chronic low back pain. Clin J Pain
2004;20:324–30
Setting is not primary care
Moss-Morris R, Chilcot J. Changes in illness-related cognitions rather than distress
mediate improvements in ibs symptoms and disability following a brief cognitive
behavioural therapy intervention. Psychosom Med 2013;75:A-37
Mediator analysis from Moss-Morris
et al.130
Mourad G, Stromberg A, Johansson P, Jaarsma T. Internet-based cognitive
behavioural therapy in patients with non-cardiac chest pain-design of a
randomized controlled pilot study. Europ J Cardiovasc Nursi 2014;13:S67–8
Conference abstract
Mullally WJ, Hall K, Goldstein R. Efficacy of biofeedback in the treatment of
migraine and tension type headaches. Pain Physician 2009;12:1005–11
Population is migraine
Mulet M, Decker KL, Look JO, Lenton PA, Schiffman EL. A randomised clinical
trial assessing the efficacy of adding 6 × 6 exercises to self-care for the
treatment of masticatory myofascial pain. J Orofacial Pain 2007;21:318
Population not meeting the inclusion
for unexplained
NCT. Effectiveness of a Cognitive Behavioral Intervention in Patients With
Symptoms Somatization, as Measure Quality of Life, Front the Clinical Practice Usual
Action in Primary Health Care. A Controlled Clinical Trial With Parallel Groups.
2011. http://clinicaltrials.gov/show/NCT01484223
Protocol only
Nevedal DC, Wang C, Oberleitner L, Schwartz S, Williams AM. Effects of
an individually tailored web-based chronic pain management program on
pain severity, psychological health, and functioning. J Med Internet Res
2013;15:e201. https://doi.org/10.2196/jmir.2296
Study design – not a RCT
Nicassio PM, Radojevic V, Weisman MH, Schuman C, Kim J,
Schoenfeld-Smith K, Krall T. A comparison of behavioral and educational
interventions for fibromyalgia. J Rheumatol 1997;24:2000–7
Not in a primary care setting
Nørregaard J, Lykkegaard JJ, Mehlsen J, Danneskiold-Samsøe B. Exercise
training in treatment of fibromyalgia. J Musculoskelet Pain 1997;5:71–9
Secondary care referrals
O’Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A. Cognitive
behavioural therapy in chronic fatigue syndrome: a randomised controlled trial
of an outpatient group programme. Health Technol Assess 2006;10(37)
Not in a primary care setting
Oliver K, Cronan TA, Walen HR, Tomita M. Effects of social support and
education on health care costs for patients with fibromyalgia. J Rheumatol
2001;28:2711–19
Outcomes not appropriate
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Citation Reason for exclusion
Overmeer T, Boersma K, Denison E, Linton SJ. Does teaching physical
therapists to deliver a biopsychosocial treatment program result in better
patient outcomes? A randomized controlled trial. Phys Ther 2011;91:804–19.
https://doi.org/10.2522/ptj.20100079
Duration of pain not necessarily more
than 3 months
Palsson OS. Should we incorporate psychological care into the management of
IBS? Gastroenterol Hepatol 2006;3:474
Commentary
Payne A, Blanchard EB. A controlled comparison of cognitive therapy and
self-help support groups in the treatment of irritable bowel syndrome.
J Consult Clin Psychol 1995;63:779–86
Not a primary care setting
Payne H. Pilot study to evaluate dance movement psychotherapy (the BodyMind
approach) in patients with medically unexplained symptoms: participant and
facilitator perceptions and a summary discussion. Body Mov Dance Psychother
2009;4:77–94
Study design – not a RCT
Perry J, Green A, Singh S, Watson P. A preliminary investigation into the
magnitude of effect of lumbar extension exercises and a segmental
rotatory manipulation on sympathetic nervous system activity. Man Ther
2011;16:190–5. https://doi.org/10.1016/j.math.2010.10.008
Thesis
Poleshuck EL, Gamble SA, Bellenger K, Lu N, Tu X, Sörensen S, et al.
Randomized controlled trial of interpersonal psychotherapy versus enhanced
treatment as usual for women with co-occurring depression and pelvic pain.
J Psychosom Res 2014;77:264–72. https://doi.org/10.1016/j.jpsychores.
2014.07.016
Population must meet criteria for
major depression
Puder RS. Age analysis of cognitive-behavioral group therapy for chronic pain
outpatients. Psychol Aging 1988;3:204–7
Not a primary care setting
Rasmussen-Barr E, Nilsson-Wikmar L, Arvidsson I. Stabilizing training
compared with manual treatment in sub-acute and chronic low-back pain.
Man Ther 2003;8:233–41
Duration of pain is not greater than
3 months
Reme SE, Kennedy T, Jones R, Darnley S, Chalder T. Predictors of treatment
outcome after cognitive behavior therapy and antispasmodic treatment for
patients with irritable bowel syndrome in primary care. J Psychosom Res
2010;68:385–8. https://doi.org/10.1016/j.jpsychores.2010.01.003
Predictors of outcomes from
Kennedy 2005
Ringström G, Störsrud S, Posserud I, Lundqvist S, Westman B, Simrén M.
Structured patient education is superior to written information in the
management of patients with irritable bowel syndrome: a randomized
controlled study. Eur J Gastroenterol Hepatol 2010;22:420–8. https://doi.org/
10.1097/MEG.0b013e3283333b61
Not a primary care setting
Roberts L, Little P, Chapman J, Cantrell T, Pickering R, Langridge J. The back
home trial: general practitioner-supported leaflets may change back pain
behavior. Spine 2002;27:1821–8
Pain is acute
Rooks DS, Gautam S, Romeling M, Cross ML, Stratigakis D, Evans B, et al.
Group exercise, education, and combination self-management in women with
fibromyalgia: a randomized trial. Arch Intern Med 2007;167:2192–200
Insufficient primary care involvement –
recruitment from multiple sources
Rossignol M, Abenhaim L, Séguin P, Neveu A, Collet JP, Ducruet T, Shapiro S.
Coordination of primary health care for back pain. A randomized controlled
trial. Spine 2000;25:251–8
Pain is not greater than 3 months
Saarijärvi S. A controlled study of couple therapy in chronic low back pain
patients. Effects on marital satisfaction, psychological distress and health
attitudes. J Psychosom Res 1991;35:265–72
Population not meeting inclusion
criteria for unexplained
Sabes-Figuera R, McCrone P, Hurley M, King M, Donaldson AN, Ridsdale L.
The hidden cost of chronic fatigue to patients and their families. BMC Health
Serv Res 2010;10:56. https://doi.org/10.1186/1472-6963-10-56
Costs data from Ridsdale et al.115
Salmon P, Humphris GM, Ring A, Davies JC, Dowrick CF. Primary care
consultations about medically unexplained symptoms: patient presentations and
doctor responses that influence the probability of somatic intervention. Psychosom
Med 2007;69:571–7
Outcomes not appropriate for
quantitative review
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Citation Reason for exclusion
Saner J, Kool J, de Bie RA, Sieben JM, Luomajoki H. Movement control exercise
versus general exercise to reduce disability in patients with low back pain and
movement control impairment. A randomised controlled trial. BMC Musculoskelet
Disord 2011;12:207. https://doi.org/10.1186/1471-2474-12-207
Protocol
Sattel H, Kittner A, Henningsen P. A brief psychodynamic-interpersonal
psychotherapy for patients with multisomatoform disorder (PISO) – one size
fits all? Psychother Psychosom Med Psychol 2011;61:A070
Conference abstract
Sattel H, Lahmann C, Gündel H, Guthrie E, Kruse J, Noll-Hussong M, et al. Brief
psychodynamic interpersonal psychotherapy for patients with multisomatoform
disorder: randomised controlled trial. Br J Psychiatry 2012;200:60–7.
https://doi.org/10.1192/bjp.bp.111.093526
Schaller A, Froboese I. Movement coaching: study protocol of a randomized
controlled trial evaluating effects on physical activity and participation in low
back pain patients. BMC Musculoskelet Disord 2014;15:391. https://doi.org/
10.1186/1471-2474-15-391
Protocol
Schiltenwolf M, Buchner M, Heindl B, von Reumont J, Müller A, Eich W.
Comparison of a biopsychosocial therapy (BT) with a conventional biomedical
therapy (MT) of subacute low back pain in the first episode of sick leave:
a randomized controlled trial. Eur Spine J 2006;15:1083–92. https://doi.org/
10.1007/s00586-005-0008-5
Pain is subacute
Schröder A, Rehfeld E, Ornbøl E, Sharpe M, Licht RW, Fink P. Cognitive-
behavioural group treatment for a range of functional somatic syndromes:
randomised trial. Br J Psychiatry 2012;200:499–507. https://doi.org/10.1192/
bjp.bp.111.098681
Setting is not primary care
Seferlis T, Németh G, Carlsson AM, Gillström P. Conservative treatment in
patients sick-listed for acute low-back pain: a prospective randomised study
with 12 months’ follow-up. Eur Spine J 1998;7:461–70
Pain is acute
Seferlis T, Németh G, Carlsson AM. Prediction of functional disability,
recurrences, and chronicity after 1 year in 180 patients who required sick
leave for acute low-back pain. J Spinal Disord 2000;13:470–7
Pain is acute
Semrau J, Hentschke C, Buchmann J, Meng K, Vogel H, Faller H, et al. Long-
term effects of interprofessional biopsychosocial rehabilitation for adults with
chronic non-specific low back pain: a multicentre, quasi-experimental study.
PLOS ONE 2015;10:e0118609. https://doi.org/10.1371/journal.pone.0118609
Study design – not a RCT
Sencan S, Ak S, Karan A, Muslumanoglu L, Ozcan E, Berker E. A study to
compare the therapeutic efficacy of aerobic exercise and paroxetine in
fibromyalgia syndrome. J Back Musculoskelet Rehabil 2004;17:57–61
Not in a primary care setting
Sharpe M, Hawton K, Simkin S, Surawy C, Hackmann A, Klimes I, et al.
Cognitive behaviour therapy for the chronic fatigue syndrome: a randomized
controlled trial. BMJ 1996;312:22–6
Setting is secondary care (hospitals)
Sharpe M, Walker J, Williams C, Stone J, Cavanagh J, Murray G, et al. Guided
self-help for functional (psychogenic) symptoms: a randomized controlled
efficacy trial. Neurology 2011;77:564–72. https://doi.org/10.1212/WNL.
0b013e318228c0c7
Setting not primary care
Sheeran L, van Deursen R, Caterson B, Sparkes V. Classification-guided versus
generalized postural intervention in subgroups of nonspecific chronic low back
pain: a pragmatic randomized controlled study. Spine 2013;38:1613–25.
https://doi.org/10.1097/BRS.0b013e31829e049b
Not in a primary care setting
Sheeran L, van Deursen R, Caterson B, Sparkes V. Classification-guided versus
generalized postural intervention in subgroups of nonspecific chronic low back
pain: a pragmatic randomized controlled study. Spine 2013;38:1613–25.
https://doi.org/10.1097/BRS.0b013e31829e049b
Intervention is posture correction
Sherman KJ, Cherkin DC, Erro J, Miglioretti DL, Deyo RA. Comparing yoga,
exercise, and a self-care book for chronic low back pain: a randomized,
controlled trial. Ann Intern Med 2005;143:849–56
Population not meeting the inclusion
criteria for medically unexplained
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Citation Reason for exclusion
Shpaner M, Kelly C, Lieberman G, Perelman H, Davis M, Keefe FJ, Naylor MR.
Unlearning chronic pain: a randomized controlled trial to investigate changes in
intrinsic brain connectivity following cognitive behavioral therapy. Neuroimage
Clin 2014;5:365–76. https://doi.org/10.1016/j.nicl.2014.07.008
Population not meeting the inclusion
criteria for medically unexplained
Siemonsma PC, Stuive I, Roorda LD, Vollebregt JA, Walker MF, Lankhorst GJ,
Lettinga AT. Cognitive treatment of illness perceptions in patients with chronic
low back pain: a randomized controlled trial. Phys Ther 2013;93:435–48.
https://doi.org/10.2522/ptj.20110150
Setting is not primary care
Simon D, Kriston L, von Wolff A, Buchholz A, Vietor C, Hecke T, et al.
Effectiveness of a web-based, individually tailored decision aid for depression
or acute low back pain: a randomized controlled trial. Patient Educ Couns
2012;87:360–8. https://doi.org/10.1016/j.pec.2011.10.009
Pain is acute
Sjögren T, Nissinen KJ, Järvenpää SK, Ojanen MT, Vanharanta H, Mälkiä EA.
Effects of a workplace physical exercise intervention on the intensity of
headache and neck and shoulder symptoms and upper extremity muscular
strength of office workers: a cluster randomized controlled cross-over trial.
Pain 2005;116:119–28
Setting is not primary care
Skouen JS, Grasdal A, Haldorsen EM. Return to work after comparing
outpatient multidisciplinary treatment programs versus treatment in general
practice for patients with chronic widespread pain. Eur J Pain 2006;10:145–52
Insufficient primary care involvement
Skouen JS, Grasdal AL, Haldorsen EM, Ursin H. Relative cost-effectiveness of
extensive and light multidisciplinary treatment programs versus treatment as
usual for patients with chronic low back pain on long-term sick leave: randomized
controlled study. Spine 2002;27:901–9
Setting is not primary care
Slade SC, Molloy E, Keating JL. People with non-specific chronic low back pain
who have participated in exercise programs have preferences about exercise:
a qualitative study. Aust J Physiother 2009;55:115–21
Protocol
Slater H, Davies SJ, Parsons R, Quintner JL, Schug SA. A policy-into-practice
intervention to increase the uptake of evidence-based management of
low back pain in primary care: a prospective cohort study. PLOS ONE
2012;7:e38037. https://doi.org/10.1371/journal.pone.0038037
Study design – not a RCT
Sleptsova M, Woessmer B, Grossman P, Langewitz W. Culturally sensitive
group therapy for Turkish patients suffering from chronic pain: a randomised
controlled intervention trial. Swiss Med Wkly 2013;143:w13875. https://doi.org/
10.4414/smw.2013.13875
Insufficient primary care involvement
Smith RC, Gardiner JC, Lyles JS, Sirbu C, Dwamena FC, Hodges A, et al.
Exploration of DSM-IV criteria in primary care patients with medically
unexplained symptoms. Psychosom Med 2005;67:123–9
Summary of Smith et al.107
Soares JJ, Grossi G. A randomized, controlled comparison of educational and
behavioural interventions for women with fibromyalgia. Scand J Occup Ther
2002;9:35–45
Insufficient primary care involvement
Söderberg E. No differences for acupuncture, physical training and relaxation
training in the treatment effects of patients with chronic tension-type
headache. Focus Altern Complement Ther 2007;12:109–110
Acupuncture not behavioural
intervention
Speckens A, Van Hemert A, Spinhoven P, Hawton K, Bolk J, Rooijmans H.
Gunstige effecten van cognitieve gedragstherapie voor onverklaarde
lichamelijke klachten; een gerandomiseerd onderzoek. Tijdschr Psychiatr
1996;140;1227–32
Hospital setting
Speckens AE, van Hemert AM, Spinhoven P, Hawton KE, Bolk JH,
Rooijmans HG. Cognitive behavioural therapy for medically unexplained
physical symptoms: a randomised controlled trial. BMJ 1995;311:1328–32
Setting is not primary care
Staal JB, Hlobil H, Twisk JW, Smid T, Koke ArJ, van Mechelen W. Graded
activity for low back pain in occupational health care: a randomized, controlled
trial. Ann Intern Med 2004;140:77–84
Pain is not greater than 3 months
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Citation Reason for exclusion
Storheim K, Brox JI, Holm I, Koller AK, Bø K. Intensive group training versus
cognitive intervention in sub-acute low back pain: short-term results of a
single-blind randomized controlled trial. J Rehabil Med 2003;35:132–40
Pain is subacute
Thorn BE, Day MA, Burns J, Kuhajda MC, Gaskins SW, Sweeney K, et al.
Randomised trial of group cognitive behavioural therapy compared with a
pain education control for low literacy rural people with chronic pain. Pain
2011;152:2710–20
Population not meeting inclusion
criteria for unexplained
Tkachuk GA. Controlled Trial of a Multicomponent Cognitive-behavioral Group
Treatment for Irritable Bowel Syndrome. 2002. URL: https://mspace.lib.umanitoba.
ca/handle/1993/2088 (accessed 5 November 2019)
Dissertation
Tschuschke V, Weber R, Horn E, Kiencke P, Tress W. Psychodynamic short-term
outpatient group therapy with patients suffering from somatoform disorders.
Z Psychiatr Psychol Und Psychother 2007;55:87–95
Not in a primary care setting
Turner JA, Mancl L, Aaron LA. Short- and long-term efficacy of brief cognitive-
behavioral therapy for patients with chronic temporomandibular disorder pain:
a randomized, controlled trial. Pain 2006;121:181–94
Setting is not primary care
Underwood M, Mistry D, Lall R, Lamb S. Predicting response to a cognitive-
behavioral approach to treating low back pain: secondary analysis of the BeST
data set. Arthritis Care Res 2011;63:1271–9. https://doi.org/10.1002/acr.20518
Pain duration not greater than
3 months
Valenzuela-Pascual F, Molina F, Corbi F, Blanco-Blanco J, Gil RM, Soler-Gonzalez J.
The influence of a biopsychosocial educational internet-based intervention on
pain, dysfunction, quality of life, and pain cognition in chronic low back pain
patients in primary care: a mixed methods approach. BMC Med Inform Decis Mak
2015;15:97. https://doi.org/10.1186/s12911-015-0220-0
Protocol
Valim V, Oliveira L, Suda A, Silva L, de Assis M, Barros Neto T, et al. Aerobic
fitness effects in fibromyalgia. J Rheumatol 2003;30:1060–9
Not in a primary care setting
van den Hout JH, Vlaeyen JW, Heuts PH, Zijlema JH, Wijnen JA. Secondary
prevention of work-related disability in nonspecific low back pain: does
problem-solving therapy help? A randomized clinical trial. Clin J Pain
2003;19:87–96
Pain not greater than 3 months
van der Roer N, Boos N, van Tulder MW. Economic evaluations: a new avenue of
outcome assessment in spinal disorders. Eur Spine J 2006;15(Suppl. 1):109–17.
https://doi.org/10.1007/s00586-005-1052-x
Outcomes not appropriate
van der Roer N, Ostelo RW, Bekkering GE, van Tulder MW, de Vet HC. Minimal
clinically important change for pain intensity, functional status, and general
health status in patients with nonspecific low back pain. Spine 2006;31:578–82.
https://doi.org/10.1097/01.brs.0000201293.57439.47
Outcomes not appropriate
van Erp RMA, Huijnen IPJ, Köke AJA, Abbink FE, den Hollander M,
Smeets RJEM. Development and content of the biopsychosocial primary care
intervention ‘Back on Track’ for a subgroup of people with chronic low back
pain. Physiotherapy 2017;103:160–6
Study protocol
van Erp RM, Huijnen IP, Verbunt JA, Smeets RJ. A biopsychosocial primary care
intervention (Back on Track) versus primary care as usual in a subgroup of
people with chronic low back pain: protocol for a randomised, controlled trial.
J Physiother 2015;61:155. https://doi.org/10.1016/j.jphys.2015.03.003
Conference abstract
van Santen M, Bolwijn P, Landewé R, Verstappen F, Bakker C, Hidding A, et al.
High or low intensity aerobic fitness training in fibromyalgia: does it matter?
J Rheumatol 2002;29:582–7
Not in a primary care setting
van Wilgen CP, Bloten H, Oeseburg B. Results of a multidisciplinary program
for patients with fibromyalgia implemented in the primary care. Disabil Rehabil
2007;29:1207–13
Study design – non-controlled
treatment study
Verkerk K, Luijsterburg PA, Heymans MW, Ronchetti I, Pool-Goudzwaard AL,
Miedema HS, Koes BW. Prognosis and course of pain in patients with chronic
non-specific low back pain: a 1-year follow-up cohort study. Eur J Pain
2015;19:1101–10. https://doi.org/10.1002/ejp.633
Study design – not a RCT
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Citation Reason for exclusion
Verstappen FT, van Santen-Hoeuftt HMS, Bolwijn PH, van der Linden S,
Kuipers H. Effects of a group activity program for fibromyalgia patients on
physical fitness and well being. J Musculoskelet Pain 1997;5:17–28
Not in a primary care setting –
outpatient clinics at general hospital
Von Korff M, Balderson BH, Saunders K, Miglioretti DL, Lin EH, Berry S, et al.
A trial of an activating intervention for chronic back pain in primary care and
physical therapy settings. Pain 2005;113:323–30
Population inclusion based on severity
not duration
Von Korff M, Moore JE, Lorig K, Cherkin DC, Saunders K, González VM, et al.
A randomized trial of a lay person-led self-management group intervention for
back pain patients in primary care. Spine 1998;23:2608–15
Population not meeting inclusion for
unexplained symptoms
Vonk F, Verhagen AP, Twisk JW, Köke AJ, Luiten MW, Koes BW. Effectiveness
of a behaviour graded activity program versus conventional exercise for
chronic neck pain patients. Eur J Pain 2009;13:533–41. https://doi.org/10.1016/
j.ejpain.2008.06.008
Setting is not primary care
Vos-Vromans DC, Smeets RJ, Rijnders LJ, Gorrissen RR, Pont M, Köke AJ, et al.
Cognitive behavioural therapy versus multidisciplinary rehabilitation treatment
for patients with chronic fatigue syndrome: study protocol for a randomised
controlled trial (FatiGo). Trials 2012;13:71. https://doi.org/10.1186/1745-6215-
13-71
Setting is secondary care
Weiland A, Blankenstein AH, Van Saase JL, van der Molen HT, Jacobs ME,
Abels DC, et al. Training medical specialists to communicate better with
patients with Medically Unexplained Physical Symptoms (MUPS). A
randomized, controlled trial. PLOS ONE 2015;10:e0138342. https://doi.org/
10.1371/journal.pone.0138342
Setting is not primary care
Williams DA, Cary MA, Groner KH, Chaplin W, Glazer LJ, Rodriguez AM,
Clauw DJ. Improving physical functional status in patients with fibromyalgia:
a brief cognitive behavioral intervention. J Rheumatol 2002;29:1280–6
Setting is not primary care
Williams DA, Kuper D, Segar M, Mohan N, Sheth M, Clauw DJ. Internet-
enhanced management of fibromyalgia: a randomized controlled trial.
Pain 2010;151:694–702. https://doi.org/10.1016/j.pain.2010.08.034
Setting is not primary care
Wilson M, Roll JM, Corbett C, Barbosa-Leiker C. Empowering patients with
persistent pain using an internet-based self-management program. Pain Manag
Nurs 2015;16:503–14. https://doi.org/10.1016/j.pmn.2014.09.009
Patients not meeting inclusion criteria
for unexplained symptoms
Yardley L, Barker F, Muller I, Turner D, Kirby S, Mullee M, et al. Clinical and
cost effectiveness of booklet based vestibular rehabilitation for chronic
dizziness in primary care: single blind, parallel group, pragmatic, randomised
controlled trial. BMJ 2012;344:e2237. https://doi.org/10.1136/bmj.e2237
Patients not meeting inclusion criteria
for unexplained symptoms
Zaby A, Heider J, Schröder A. Warten, Entspannung oder Verhaltenstherapie.
Z Klin Psychol Psychother 2008;37:15–23
Not all from primary care
Zonneveld LN, van ‘t Spijker A, Passchier J, van Busschbach JJ, Duivenvoorden HJ.
The effectiveness of a training for patients with unexplained physical symptoms:
protocol of a cognitive behavioral group training and randomized controlled trial.
BMC Public Health 2009;9:251. https://doi.org/10.1186/1471-2458-9-251
Protocol only
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Appendix 5 Raw data from individual
studies by outcome
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Data for the outcome pain
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Cuesta-Vargas,
2012118
MM 67.9 (17.1) 18 (10.3) 20 (8.9) 10 (8.1) GSH 62.7 (17.1) 32.9 (18.9) 34.3 (7.8) 36 (15.1)
Macedo, 2012119 GA 6.1 (2.1) 4.1 (2.5) 4.1 (2.7) 3.7 (2.6) GA 6.1 (1.9) 4.1 (2.5) 4.1 (2.5) 3.7 (2.7)
van der Roer,
2008120
MM 6.2 4.4 4.1 3.9 SES 5.9 4.9 4.8 4.6
Walti, 2015121 MM 4.86 (1.61) SES 4.64 (1.82)
LeFort, 1998128 GSH 72.67 (18.44) 60.98 (21.26) UC 73.02 (17.61) 71.22 (15.83)
aAlda, 2011137 CBTHI 64.2 (10.78) 36.88 (8.29) 40.68 (10.93) UC 64.72 (10.44) 38.68 (7.48) 44.34 (8.56)
aLuciano, 2014138 CBTHI 65.43 (18.34) 48.07 (10.5) 49.58 (10.98) UC 64.04 (18.72) 64.28 (15.76) 64.36 (15.34)
Luciano, 2011139 MM 7.37 (1.86) 6.34 (2.35) UC 7.37 (2.1) 7.7 (2.03)
Sañudo, 2010140 SES Only graphical data available for SF-36 pain UC
Aiarzaguena,
2007136
GPRE 43.6 (24.4) GPRE 46.2 (25.2)
Peters, 2002106 SES 37.83 (2.92) 43.3 (4.04) 43.65 (3.48) RSSE 37.39 (2.92) 40.93 (3.62) 42.59 (3.74)
Pols, 2008145 MM Mean difference from T1 at T2 0.82 at T3 4.64 UC
Smith, 2009142 MM 45.8 51.8 UC 43.8 39.9
aGili, 2014/
Moreno,
2013144,148
CBTHI 27.91 (18.5) 28.26 (21.97) 38.44 (28.87) UC+ 28.67 (14.46) 33.54 (20.34) 31.13 (24.22)
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Data for the outcome pain
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Kocken, 2008103 OP 1.89 (1.74) 2.46 (1.84) UC 1.75 (0.69) 1.86 (0.83)
Rothman, 2013127 GP-O 69.5 (59–80) 60 (30–81) UC+ 74.5 (60–81) 65.5 (38–80)
Loew, 2000122 RSSE 11.4 (8) 5.8 (4) RSSE 11.7 (7.2) 10.1 (4.9)
Rosendal, 2007146 GP-MM 49.6
(46.8 to 52.4)
5 (2.9 to 7.0) 6.5 (3.8 to 9.3) UC 48
(44.8 to 51.1)
8.2 (4.6 to 11.8) 10.5
(8.5 to 12.5)
van Ravesteijn,
2013143
OP 48.8 (18.5) 53.1 (18.6) 56.2 (23.6) UC+ 54.2 (19.5) 57.8 (20.5) 59.3 (22.1)
Zonneveld,
2012141
CBTHI Intercepts and model estimates given UC
a,bMcBeth, 2012125/
Beasley, 2015126
CBTHI 61.3 (23.6) 62.1 (22.3) UC 53.5 (21.3) 56.2 (19.9)
Lansinger, 2007123 RSSE 50 (20 to 100) 41 (2 to 81) 35 (0 to 87) SES 56 (20 to 97) 26 (0 to 84) 30 (0 to 91)
Schaefert, 2013132 MM 50.34 (25.92) 51.27 (22.48) 51.04 (25.74) GP-MM 44.99 (23.64) 50.01 (24.63) 51.27 (25.68)
GP-MM, GP-delivered MUS management; GP-O, GP – other; GPRE, GP-delivered reattribution; GSH, guided self-help; M, mean; OP, other psychotherapy; UC, usual care; UC+, usual
care plus.
a Data for studies with a second intervention.
Alda 2011;137 ME, T1 M 68.13, SD 9.84; T2M 37.14, SD 10.53; T4 M 40.54, SD 9.61. Luciano 2014:138 ME, T1 M 62.98, SD 16.11; T2 M 57.17, SD 11.18: T3 M 56.27, SD 11.15. Gili
2014/Moreno 2013:144,148 CBTHII; T1 M 33.63, SD 24.77; T2 M 48.05, SD 29.59; T4 M 44.51, SD 31.05. McBeth 2012125/Beasley 2015:126 SES; T2 M 57.6, SD 19.5; T3 M 59.8, SD 18.
b Data for studies with a third intervention.
McBeth 2012125/Beasley 2015:126 SES; T2 M 60.4, SD 19.1; T3 M 59.8, SD 21.4.
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Data for the outcome fatigue
Study author
and date
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Ho, 2012150 RSSE 39.9 (6.3) 26.3 (10.9) 21.6 (10.4) UC 39.7 (6.1) 34.8 (8) 32.1 (8.8)
aFriedberg, 2013151 CBTLI 5.400 (0.160) 4.940 (0.190) 4.190 (0.260) UC 5.720 (0.160) 5.450 (0.190) 5.310 (0.320)
Huibers, 2004/
Leone, 2006153,155
GP-CBT 48.8 (5.3) 38.2 (12.7) 35.5 (12.9) UC 48.5 (7.1) 39.8 (13.7) 33.9 (13.8)
Marques, 2015133 GA 98.4 (16.43) 93.73 (22.37) GSH 103.54 (19.07) 106.76 (20.32)
Moss-Morris,
2005152
GA 24.45 (8.79) 13.91 (10.88) UC 25.35 (8.05) 24.41 (9.69)
aRidsdale, 2001112 CBTHI 22.4 (5.1) 14 15 (8.5) OP 24.2 (4.8) 15.6 15.6 (8)
Ridsdale, 2004113 CBTLI 25.3 (4.7) 13.3 (8.8) 14.8 (7.9) GA 24.7 (5.5) 15.1 (9) 15.3 (9.4)
Ridsdale, 2012115 GA 24.8 (4.9) 14.6 (8.5) 14.5 (7.7) GSH 23.4 (4.5) 15.3 (8) 13.8 (7.7)
Tummers, 2012149 CBTLI 51 (5.3) 39.6 (14.1) UC 51.6 (5.5) 48.3 (8.1)
aWearden, 2010111 GA 10.49 (1.12) 8.39 (3.67) 8.72 (3.65) UC 10.34 (1.17) 9.32 (3.18) 9.48 (2.71)
Luciano, 2011139 MM 8.18 (1.83) 7.06 (2.41) UC 8.13 (1.89) 7.8 (2.17)
Whitehead, 2002154 GP-MM 25.58 21.89 19.11 UC 24.26 20.04 19.57
Chalder, 1997114 GSH 7.04
(6.35–7.73)
3.2 (2.25–4.15) UC 6.89 (6.35–7.43) 4.89
(3.88–5.90)
a,bMcBeth, 2012125/
Beasley, 2015126
CBTHI 19.9 (6.3) 15.9 (7.7) 16 (6.9) 17.8 (6.6) UC 19.4 (5.9) 18.4 (7) 18.6 (7) 19.1 (7.3)
GP-MM, GP-delivered MUS management; GSH, guided self-help; M, mean; OP, other psychotherapy; UC, usual care.
a Data for studies with a second intervention.
Friedberg 2013:151 RSSE – T1 M 5.710, SE 0.160; T3 M 5.390, SE 0.190; T4 M 5.160, SE 0.290. Ridsdale 2012:115 OP – T1 M 24.8, SD 4.7; T3 M 16.2, SD 8.2; T4 M 15.2, SD 8.4.
Wearden 2010:111 OP – T1 M 10.52, SD 1.03; T2 M 9.67, SD 2.76; T4 M 9.39, SD 3.21. McBeth 2012125/Beasley 2015:126 SES – T1 M 19.6, SD 6; T2 M 15.6, SD 5.8; T3 M 16,
SD 5.8; T4 M 17.8, SD 5.8.
b Data for studies with a third intervention.
McBeth 2012125/Beasley 2015:126 MM – M 19.4, SD 5.9; T2 M 13.3, SD 7; T3 M 15, SD 7.2; T4 M 17.6, SD 6.9.
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Data for the outcome physical functioning
First author and
year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Cuesta-Vargas,
2012118
MM 32.9 (5.8) 47 (8.5) 52.6 (8.6) 57.6 (6.8) GSH 34.3 (6.8) 39.3 (4.6) 37.6 (6.5) 40.3 (2.9)
Macedo, 2012119 GA 43.8 (10.3) 51.6 (13.4) 51.2 (13.8) 53.3 (14) GA 43.9 (10.8) 51.6 (12) 52.6 (13) 53.8 (12.7)
aFriedberg, 2013151 CBTLI 68.49 (4.06) 74.82 (4.01) 66.3 (4.89) UC 59.77 (4.02) 64.92 (3.67) 56.44 (4.21)
Ho, 2012150 RSSE 36.9 (7.2) 38.4 (6.1) 40.1 (6.9) UC 35.7 (7.1) 37.5 (8.1) 37.8 (5.6)
Huibers, 2004/
Leone, 2006153,155
GP-CBT 56.8 (25) 65.2 (25.8) 70.1 (24.7) UC 67.1 (22) 72.5 (19.1) 77.4 (20.9)
Marques, 2015133 GA 38.22 (17.78) 43.33 (21.87) GSH 31.3 (18.9) 28.15 (21.43)
Moss-Morris,
2005152
GA 53.1 (18.39) 69.05 (21.94) UC 45.65 (21.07) 55 (22.94)
Tummers, 2012149 CBTLI 50 (22) 65.4 (24.9) UC 51.6 (22.6) 59.3 (22.9)
aWearden, 2010111 GA 29.84 (17.86) 39.94 (25.21) 43.27 (27.38) UC 29.8 (19.63) 40.27 (26.45) 39.83 (27.77)
LeFort, 1998128 GSH 41.68 (24.7) 44.64 (25.07) UC 38.41 (20.22) 38.3 (21.63)
Luciano, 2011139 MM 3.31 (2.27) 2.44 (2.51) UC 2.8 (2.4) 3.22 (2.79)
Aiarzaguena,
2007136
GPRE 73.2 (23.2) GPRE 70.5 (25.1)
Escobar, 2007156 CBTHI 63.28 (2.67) 72.19 (2.95) 73.22 (3.36) UC+ 61.41 (2.71) 69.71 (2.95) 69.41 (3.45)
Peters, 2002106 GSH 49.38 (2.66) 57.88 (3.66) 57.66 (6.15) SES 49.06 (3.11) 54.67 (3.92) 52.73 (3.73)
Pols, 2008145 MM MD_b I1 4.06; I2 –2.32 UC
Smith, 2009142 MM 38.2 38 UC 32.6 33.6
Smith, 2006107 MM 37.4 (10.2) UC 35.5 (10.5)
van Ravesteijn,
2013143
OP 65.2 (22.9) 68.4 (24.8) 69.1 (27.8) UC+ 70.3 (23) 71.3 (24.9) 73.4 (22.6)
Zonneveld, 2012141 CBTHI Intercepts and model estimates given UC
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Data for the outcome physical functioning
First author and
year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
aGili, 2014/
Moreno, 2013144,148
CBTHI 51.28 (29.82) 56.86 (27.2)1 61.28 (25.35) UC+ 44.17 (26.97) 52.08 (29.45) 50.63 (22.71)
Larisch, 2004158 GPRE 41.4 (8.2) 2.8 (0.7) 2.7 (1.6) 3.8 (2) UC 43 (11) –0.8 (–1.2) 1.2 (–0.4) 0.5 (–0.7)
Rosendal, 2007146 GP-MM 80 (95% CI
61.1 to 95)
UC 84.2 (95% CI
65 to 95)
Schaefert, 2013132 MM 71.96 (22.95) 78.34 (21.32) 78.17 (23.36) GP-MM 69.77 (25.12) 73.01 (25.95) 75.12 (23.7)
Smith, 1995100 UC+ 33.3 (35.1) UC 26.4 (28.8)
Chalder, 1997114 GSH 74 (95% CI
66 to 88)
76.1 (95% CI
68 to 84)
UC 70 (95% CI
62 to 77)
66.6 (95% CI
58 to 75)
Toft, 201097 GP-MM 85 (60.0 to
95.0)
UC 95 (80.0 to 100)
Robinson, 2006131 RSSE No significant associations between guidebook and score on
SF-36 dimension of PF, but trend favoured guidebook: PF 2.85
(95% CI –1.03 to 6.72)
UC
Kashner, 1995161 UC+ Intervention 1 difference from I3: 3.36 – This is RSSSE vs. UC+.
These intervention group names look back to front – RSSSE is
experimental group, UC+ is control
RSSE
a,bMcBeth, 2012125 CBTHI 38.9 (8.4) 41.5 (11) 40.8 (11.2) UC 37.4 (8.2) 39.9 (10.1) 39.6 (10.5)
Burton, 2012157 GP-MM 33.7 38.8 UC 35 (35.3)
GP-MM, GP-delivered MUS management; GPRE, GP-delivered reattribution; GSH, guided self-help; M, mean; OP, other psychotherapy; PF, physical functioning; UC, usual care;
UC+, usual care plus.
a Data for studies with a second intervention.
Friedburg 2013: RSSE – T1 M 62.53, SD 4.03; T3 M 67.07, SD 3.72; T4 M 65.96, SD 4.24. Wearden 2010: 106 OP – T1, M 30.64, SD 19.04; T2, M 33.28, SD 22.94; T4 M 35.72,
SD 25.94. Gili 2014/Moreno 2013: 180,237 CBTHII – T1 M 66.86, SD 27.65; T2 M 77.33, SD 20.77; T4 M 79.42, SD 24.52. McBeth 2012125/Beasley 2015:126 SES – T1 M 37.8,
SD 7.5; T2 M 40.2, SD 10.2; T3 M 41.9, SD 9.1.
b Data for studies with a third intervention.
McBeth 2012125/Beasley 2015:126 MM – T1 M 38.1, SD 8; T2, 43 SD 9.2, T3 M 42.8, SD 9.9.
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Data for the outcome somatisation
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Peters, 2002106 SES 23.31 (0.83) 21.3 (1) 20.81 (0.92) RSSE 21.98 (0.78) 20.8 (1.07) 21.45 (0.88)
Zonneveld, 2012141 CBTHI No means given for outcomes, data presented for intercept,
time, time by training, training vs. waitlist. Training vs. wait group
post treatment – Cohen’s d = 0.23. The 1-year follow-up was not
randomised – waiting list patients crossed over therefore cannot
use these data: Cohen’s d post training –0.38, 3 months –0.45,
1 year –0.36
UC
Kobeissi, 2012110 RSSE Short term MD_I3 –0.81 (95% CI –4.90 to 3.27) UC
Larisch, 2004158 GPRE 14.8 (8.3) –2.8 (–0.1) –0.4 (1.9) –0.7 (3.1) UC 12.3 (9.8) 1.5 (0) 0.8 (1.2) 1.6 (0.6)
McLeod, 1997105 OP 60.3 (8.8) 53.2 (10.9) 53 (12.2) UC 58.4 (11.7) 58.6 (12.9) NR
Rosendal, 2007146 GP-MM 2.3 (median
25th–75th
percentiles 1.9
to 2.6)
–0.2 (95% CI
–0.2 to –0.1)
–0.2 (95% CI
–0.2 to –0.1)
UC 2.3 (2.0 to 26) –0.2 (95% CI
–0.3 to –0.2)
–0.2 (95% CI
–0.3 to –0.2)
Schilte, 2001159 GP-OP 20 (median 16
to 25)
0 (median
–6 to 5)
UC 22 Median 17
to 27
0 (median
–5 to 5)
Toft, 201097 GP-MM 26 (21 to 30) UC 25 (21 to 31)
Rief, 2006102 GP-MM 15.5 (8.2) 15.4 (8.2) 15.3 (9.5) UC 13.8 (8.2) 13.2 (7.5) 13.7 (8.2)
Martin, 200799 CBTLI 9.5 (8.2) 7.2 (8) 7.8 (7.1) UC 7.2 (5.7) 6.3 (5.9) 6.4 (4.9)
aGili, 2014/
Moreno, 2013144,148
CBTHI 22.17
(19.08 to
25.27)
14.17
(11.97 to
16.37)
20.86
(16.94 to
24.78)
UC+ 21.26
(18.01 to
24.51)
19.47
(17.06 to
21.88)
29.02
(24.77 to
33.28)
Kolk, 2004104 OP 27.77 (8.8) 21.09 (7.6) 19.9 (7.4) UC 25.19 (5.6) 22.19 (6.9) 21 (7.1)
Escobar, 2007156 CBTHI 14.17 (0.58) 9.32 (0.67) 9.11 (0.59) UC+ 13.98 (0.59) 11.5 (0.66) 10.91 (0.62)
Martin, 200799 CBTLI 0.79 (0.75) 0.59 (0.55) 0.59 (0.59) UC 0.6 (0.61) 0.5 (0.5) 0.61 (0.63)
Schaefert, 2013132 MM 12.56 (4.73) 9.47 (4.71) 9.55 (5.12) GP-MM 12.66 (4.89) 11.42 (5.44) 10.57 (5.1)
Smith, 2009142 MM 27.9 24.8 UC 27.5 26.8
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Data for the outcome somatisation
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Sumathipala,
2000116
CBTLI 16.2 (5.5) 13.2 (95% CI
11.3 to 15.1)
UC 18.9 (6.6) 15.6 (95% CI
13.6 to 17.5)
Sumathipala,
2008117
MM 19.9 (9.6) 12.4 (9.6) 11.5 (9) 11.1 (8.7) GP-MM 18.6 (9) 12.4 (8.9) 11.8 (8.9) 11 (9.1)
van Ravesteijn,
2013143
OP 12.6 (4.68) 10.9 (4.9) 11 (5.44) UC+ 12.7 (5.15) 12.6 (6.1) 11.8 (5.46)
Marques, 2015133 GA 14.02 (4.04) 13.05 (4.72) GSH 16.2 (4.47) 15.76 (4.48)
Burton, 2012157 GP-MM 15 11.7 UC 14.6 12.4
GP-MM, GP-delivered MUS management; GPRE, GP-delivered reattribution; GSH, guided self-help; M, mean; NR, not reported; OP, other psychotherapy; UC, usual care; UC+, usual
care plus.
a Data for studies with a second intervention.
Gili 2014/Moreno 2013:144,148 CBTHII – T1 M 18.55, 95% CI 15.61 to 21.5; T2 M 11.63, 95% CI 9.49 to 13.76; T4 M 17.96, 95% CI 14.17 to 21.76.
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Data for the outcome emotional distress
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Cuesta-Vargas,
2012118
MM 34.6 (9.2) 56.7 (6.1) 57.6 (6.5) 60.9 (6.4) GSH 37.2 (10.4) 44.7 (10.7) 43.5 (12.5) 39.2 (13.7)
Macedo, 2012119 GA 54.7 (11.5) 55.8 (13) 56.9 (11.8) 58.2 (10.8) GA 52.9 (10.5) 56 (10.9) 54.9 (10.4) 57 (10.1)
Ho, 2012150 RSSE 32.5 (10.7) 43.8 (6.9) 42.7 (7.2) UC 33.5 (9.6) 34.6 (9.6) 35.7 (9.5)
Huibers, 2004/
Leone, 2006153,155
GP-CBT 175 (42) 156 (42) 152 (51) UC 190 (57) 163 (55) 153 (62)
Marques, 2015133 GA 41.57 (16.12) 46.85 (19.71) GSH 37.59 (17.62) 36.79 (19.15)
LeFort, 1998128 GSH 60.46 (19.67) 68.15 (18.37) UC 58.08 (19.27) 60.84 (19.93)
Aiarzaguena,
2007136
GPRE 50.1 (21.6) GPRE 50.3 (20.2)
Peters, 2002106 RSSE 48.42 (2.39) 60.35 (3.15) 55.02 (2.49) SES 52.61 (2.6) 61.26 (2.6) 57.16 (2.38)
Pols, 2008145 MM UC
Smith, 2009142 MM 35.7 47.9 UC 46.6 46.1
Smith, 2006107 MM 46.5 (11.6) UC 48.6 (11.9)
Sumathipala,
2008117
MM 14.9 (9.4) 5.5 (7.7) 6.2 (8.3) 5.6 (8) GP-MM 14.7 (9.4) 6.1 (8.3) 7.2 (9.7) 5.7 (9.5)
van Ravesteijn,
2013143
OP 66 (19.1) 67.9 (19.6) 66.9 (20.1) UC+ 59.7 (20.5) 61.2 (18.2) 66.6 (17.9)
Zonneveld, 2012141 CBTHI UC
aGili, 2014/
Moreno, 2013144,148
CBTHI 47.91 (16.37) 47.44 (16.53) 51.16 (21.37) UC+ 40.5 (18.99) 53 (22.26) 42.67 (20.69)
Kocken, 2008103 OP 228 (70.9) 211 (65.2) UC 244 (61.8) 245 (72.1)
Larisch, 2004158 GPRE 37.6 (9.6) 1 (1.6) 1.5 (2.2) 2.2 (5.2) UC 41 (10.3) –1.6 (2.3) –0.5 (1.5) 4.3 (3.6)
Rosendal, 2007146 GP-MM 65.6
(63.4 to 67.8)
UC 67
(64.4 to 69.5)
Schaefert, 2013132 MM 55.76 (18.68) 63.34 (18) 64.25 (18.89) GP-MM 53.86 (21.2) 56.14 (20.57) 58.03 (21.99)
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Data for the outcome emotional distress
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Smith, 1995100 UC+ 52.7 (18.9) UC 54.7 (25.5)
Sumathipala,
2000116 distress
only
CBTLI 12.1 (8.6) 6.3 (4.1 to 8.5) UC 11 (6.7) 10.4
(8.1 to 12.7)
Toft, 201097 GP-MM 62.5 (20.4) UC 61.6 (21.5)
van der Feltz-
Cornelis, 2006160
MM 20.9 (16.9) 15.3 (16.3) 10.8 (13.9) GPRE 23.3 (21.6) 29.4 (22.8) 26.8 (21.7)
Robinson, 2006131 GSH UC
Kashner, 1995161 UC+ RSSE
a,bMcBeth, 2012125 CBTHI 43.6 (10.9) 46.3 (9.9) 47 (10.2) UC 42.5 (10.6) 43.4 (10.2) 43.4 (11)
Kennedy,129 2005 MM 16.6 (6.4) ME 18.1 (7.4)
Chalder, 1997114 GSH 6.27
(CI 5.27 to 7.27)
3.06
(CI 2.06 to 4.07)
UC 5.92
(CI 5.04 to 6.80)
4.31
(CI 3.33 to 5.29)
Burton, 2012157 GP-MM 45.8 56.7 (6.1) 57.6 (6.5) 60.9 (6.4) UC 41.2 45.2
GP-MM, GP-delivered MUS management; GPRE, GP-delivered reattribution; GSH, guided self-help; M, mean; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
a Data for studies with a second intervention.
Gili 2014/Moreno 2013:144,148 CBTHII – T1 M 43.72, SD 18.17; T2 M 55.72, SD 19.76; T4 M 58.05, SD 17.38. McBeth 2012125/Beasley 2015:126 SES – T1 M 43.5, SD 10.1;
T2 M 46.7, SD 10.8; T2 M 45.8, SD 9.7.
b Data for studies with a third intervention.
McBeth 2012125/Beasley 2015:126 MM – T1 M 43.9, SD 10; T2 M 46, SD 10.9; T3 M 45.5, SD 10.6.
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Data for the outcome anxiety
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
aFriedberg, 2013151 CBTLI 11.97 (1.47) 10.98 (1.6) 12.02 (1.89) UC 14.99 (1.46) 14.5 (1.65) 14.39 (2.23)
Marques, 2015133 GA 1.63 (0.77) 1.44 (0.79) GSH 1.66 (0.79) 1.64 (0.81)
Ridsdale, 2001112
not ITT
CBTHI 8.8 (4.5) 7.9 (4) OP 10.6 (4.2) 8.9 (4.2)
Ridsdale, 2004113 CBTLI 10.4 (4.4) 7.9 (4.4) 8.5 (4.2) GA 10.4 (4.7) 9.3 (4.8) 9.8 (5.3)
aRidsdale, 2012115 GA 9.3 (4.4) 8.2 (4) GSH 9.1 (4.3) 9.4 (4)
Tummers, 2012149 CBTLI 1.02 (0.64) 0.77 (0.68) UC 1.02 (0.61) 0.86 (0.55)
aWearden, 2010111 GA 11.02 (4.77) 9.04 (4.51) 9.54 (4.7) UC 9.65 (5.06) 8.63 (5.06) 8.89 (5.4)
aAlda, 2011137 CBTHI 10.84 (4.27) 7.09 (2.96) 7.25 (3.02) UC 9.5 (2.98) 7.4 (2.18) 7.58 (2.07)
aLuciano, 2014138 CBTHI 12.67 (4.36) 8.28 (2.38) 8.73 (2.04) UC 12.4 (4.31) 11.36 (3.8) 12.15 (4.2)
Luciano, 2011139 MM 7.94 (2.22) 6.07 (3.19) UC 7.45 (2.42) 7.14 (2.61)
Moss-Morris,
2010130
CBTLI 9.1 (3.8) 8.7 (4.4) 7 (2.9) 7.5 (3.8) UC 6.9 (4.3) 6.6 (4.7) 6.7 (4.5) 6.4 (4.1)
Escobar, 2007156 CBTHI 20.46 (0.75) 15.89 (1.08) 14.85 (0.94) UC+ 20.99 (0.76) 18.47 (1.07) 17.58 (1)
Kolk, 2004104 OP 22.55 (9.1) 15.51 (5.4) 15.39 (5.7) UC 20.44 (8.1) 15.44 (5.8) 13.56 (4.2)
Martin, 200799 CBTLI 6.5 (3.8) 5.9 (4.1) 5.4 (3.3) UC 5.7 (3.2) 5.5 (3.6) 5.5 (3.2)
bMorriss, 2007108 GPRE 31 (47%) UC 27 (36%)
Peters, 2002106 SES 10.33 (0.52) 8.6 (0.58) 9.15 (0.59) RSSE 10.14 (0.5) 8.49 (0.64) 9.37 (0.58)
Smith, 2009142 MM 47.3 46.8 (MD_b
–0.45 95% CI
–4.6 to 3.7)
UC 47.6 47.8 (MD_b
0.12 95% CI
–3.5 to 3.7)
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Data for the outcome anxiety
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Zonneveld, 2012141 CBTHI Only estimates of intercepts given UC
Kobeissi, 2012110 RSSE 2.5 (0.4) UC 2.4 (0.4)
aGili, 2014/
Moreno, 2013144,148
CBTHI 20.18
(17.69 to
22.68)
11.47 (9.45 to
13.49)
9.28
(7.28 to 11.27)
UC+ 17.84 (15.04 to
20.64)
13.07 (10.93 to
15.22)
16.22 (13.91 to
18.53)
Larisch, 2004158 GPRE 9.3 (3.9) –1.1 (0.4) –0.9 (0.8) –0.8 (0.7) UC 7.7 (4.2) 0.3 (0.2) –0.3 (0.6) –0.3 (0.7)
McLeod, 1997105 OP 62.9 (11.9) 56.8 (12.5) 54.9 (15.5) UC 63 (9.2) 60.9 (12.8) NR
Schilte, 2001159 GP-OP 15 (9 to 23) –2 (median
–5 to 2)
UC 17 (10 to 31) 0 (median
–5 to 3)
Posse, 200496 OP 53.8 (14) 53 (10.2) UC 55 (10.7) 58.3 (10.6)
Rothman, 2013127 GP-O 60.45 to 79 56 (38 to 75) UC+ 54.5 (33 to 76) 51 (33 to 76)
Rief, 2006102 GP-MM 14.4 (10.3) 14 (11.1) 11.8 (10.6) UC 11.8 (10) 10.2 (8.6) 11.5 (9.2)
Burton, 2012157 GP-MM 6.5 5.9 UC 5.4 5.2
GP-MM, GP-delivered MUS management; GP-O, GP – other; GPRE, GP-delivered reattribution; GSH, guided self-help; M, mean; NR, not reported; OP, other psychotherapy; UC, usual
care; UC+, usual care plus.
a Data for studies with a second intervention.
Friedburg 2013; RSSE – T1 M 14.91, SE 1.46; T3 M 14.49, SE 1.63; T4 13.88, SE 1.86. Risdale 2012:115 OP – T1 M 9.4, SD 4.3; T3 9.2, SD 3.9. Wearden 2010:111 OP – T1, M 10.8,
SD 5.12; T2 M 9.52, SD 4.93; T4 M 9.62, SD 4.87. Alda 2011:137 ME – T1, M 11.22, SD 3.75; T2, M 7.11, SD 2.39; T4 M 7.39, SD 2.57. Luciano 2014:138 ME; T1, M 11.35, SD 3.77;
T2, M 9.07, SD 2.19; T3 M 9.68, SD 2.47. Gili 2014/Moreno 2013:144,148 CBTHII – T1 M 17.71, 95% CI 15.23 to 20.19; T2 M 7.33, 95% CI 5.45 to 9.21; T4 M 8.6, 95% CI 6.55
to 10.66.
b % caseness.
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Data for the outcome depression
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
aFriedberg, 2013151 CBTLI 17.1 (1.45) 13.52 (1.64) 14.89 (1.86) UC 18.31 (1.44) 16.17 (1.83) 14.03 (1.86)
Marques, 2015133 GA 1.49 (0.88) 1.55 (0.95) GSH 1.55 (0.95) 1.91 (0.93)
Ridsdale, 2001112
not ITT
CBTHI 7.3 (4.1) 6.3 (4.3) OP 7.8 (3.5) 6.2 (4.1)
Ridsdale, 2004113 CBTLI 8.1 (3.2) 5.8 (3.8) 6.6 (4.3) GA 8.4 (4) 6.6 (4.6) 6.8 (4.9)
aRidsdale, 2012115 GA 8.4 (3.8) 6.5 (4.3) GSH 7.4 (5.7) 6.2 (4.3)
aWearden, 2010111 GA 9.67 (4.08) 7.28 (4.02) 7.88 (4.45) UC 9.26 (4.25) 8.48 (4.47) 8.06 (4.75)
LeFort, 1998128 GSH 7.67 (4.91) 6.83 (5.63) UC 7.48 (4.63) 7.68 (4.75)
aAlda, 2011137 CBTHI 14.47 (3.93) 7.78 (2.46) 7.91 (2.5) UC 14.09 (4.64) 8.17 (2.25) 8.57 (2.47)
aLuciano, 2014138 CBTHI 8 (2.88) 5.41 (1.36) 5.84 (1.6) UC 9.23 (3.56) 9.34 (2.63) 9.32 (3.04)
Luciano, 2011139 MM 7.42 (3.02) 5.24 (3.54) UC 6.82 (3.11) 6.45 (3.09)
Sañudo, 2010140 SES 28 (4) UC 31 (3)
Moss-Morris,
2010130
CBTLI 3.9 (3.4) 3.9 (3.42) 2.9 (2.5) 2.9 (2.4) UC 4.1 (3.1) 3.8 (3.2) 3.8 (3.5) 4 (3.7)
Escobar, 2007156 CBTHI 18.25 (0.64) 12.85 (0.85) 12.88 (0.88) UC+ 17.41 (0.65) 14.6 (0.84) 14.29 (0.93)
Kolk, 2004104 OP 38.9 (11.9) 26.93 (10.2) 25.93 (9.6) UC 34.56 (9.1) 25.94 (10.8) 23.12 (6.4)
Martin, 200799 CBTLI 15.9 (9.6) 13.7 (9.1) 14.2 (9.5) UC 13.2 (6.4) 12.5 (7.4) 11.9 (7.5)
bMorriss, 2007108 GPRE 18 (27%) UC 21 (28%)
Peters, 2002106 SES 9.22 (0.49) 7.38 (0.61) 7.75 (0.58) RSSE 9.14 (0.41) 7.49 (0.52) 8.44 (0.56)
Smith, 2009142 MM 26.3 15.7 (MD_b
–10.6 95% CI
–20.8 to –0.41)
UC 18.3 22.9 (MD_b
4.6 95% CI
–4.0 to 13.2)
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Data for the outcome depression
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
van Ravesteijn,
2013143
OP 8.5 (5.11) 7.61 (5.92) 7.26 (5.61) UC+ 8.77 (5.44) 7.87 (5.35) 7.66 (5.33)
Zonneveld, 2012141 CBTHI Only estimates of intercepts given UC
Kobeissi, 2012110 RSSE 2.5 (0.4) UC 2.4 (0.4)
aGili, 2014/
Moreno, 2013144,148
CBTHI 14.12 (12.44
to 15.8)
11.22 (9.46
to 12.98)
8.1 (6.2 to
10.01)
UC+ 13.43 (11.55
to 15.32)
10.87 (9 to
12.74)
13.41 (11.19 to
15.63)
Larisch, 2004158 GPRE 7.9 (4.5) –1.2 (–0.3) –0.7 (0.1) –0.8 (0) UC 6.3 (3.5) 0.5 (1.1) –0.4 (0.9) –0.2 (0.7)
McLeod, 1997105 OP 64.5 (16.8) 57.2 (15.3) 56.5 (13.1) UC 66.5 (11.7) 66.8 (18.3) NR
Schilte, 2001159 GP-OP 22 (13 to 33) –2 (median
–8 to 4)
UC 22 (15 to 35) –2 (median
–10 to 5)
Rothman, 2013127 GP-O 3 (2 to 3) 2 (2 to 3) UC+ 2 (1 to 3) 2 (2 to 3)
Rief, 2006102 GP-MM 13.9 (9.1) 13.6 (9.5) 11.8 (9.5) UC 12.5 (8.4) 12.2 (9.3) 11.8 (8.1)
Burton, 2012157 GP-MM 9.2 8.4 UC 7.8 6.7
Schaefert, 2013132 MM 8.89 (5.11) 6.68 (4.82) 6.29 (4.5)8 GP-MM 9.76 (5.54) 8.12 (4.2) 7.98 (5.25)
GP-MM, GP-delivered MUS management; GP-O, GP – other; GSH, guided self-help; NR, not reported; M, mean; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
a Data for studies with a second intervention.
Friedburg 2013; RSSE – T1 M 15.29, SE 1.44; T3 M16.41, SE 1.55; T4 14.56, SE 1.9. Risdale 2012:115 OP – T1 M 7.8, SD 3.7; T3 6.9, SD 4.6. Wearden 2010:111 OP – T1, M 9.73, SD
4.07; T2 M 8.85, SD 4.01; T4 M 8.67, SD 4.51. Alda 2011:137 ME – T1, M 14.94, SD 4.03; T2, M 7.98, SD 1.8; T4 M 8.19, SD 1.96. Luciano 2014:138 ME – T1, M 9.04, SD 3.68; T2 M
7.37, SD 2.65; T3 M 7.5, SD 2.82. Gili 2014/Moreno 2013:144,148 CBTHII – T1 M 15.63, 95% CI 13.95 to 17.31; T2 M 6.96, 95% CI 5.32 to 8.6; T4 M 6.56, 95% CI 4.62 to 8.5.
b % caseness.
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Data for the outcome generic physical symptoms
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
aMoreno, 2013148 CBTHI 92.06 (95% CI
79.02 to 105.1)
41.52 (95% CI
32.69 to 50.35)
67.84 (95% CI
61.03 to 74.65)
UC+ 71.48 (95% CI
57.78 to 85.19)
59.98 (95% CI
50.44 to 69.51)
67.7 (95% CI
60.42 to 74.98)
van der Feltz-
Cornelis, 2006160
MM 3.53 (0.6) 2.49 (0.77) 2.15 (0.77) GPRE 3.43 (0.51) 3.38 (0.81) 3.44 (0.62)
Ryan, 2004109 OP 8.11 (0.85) 2.73 (0.98) UC
Aiarzaguena,
2007136
GPRE Assessed but no data reported GPRE
Posse, 200496 OP 13.6 (6.3) 13.2 (6.3) UC 13.6 (3.6) 13 (2.8)
Escobar, 2007156 CBTHI 42.34 (1.94) 23.47 (1.77) 23.72 (1.67) UC+ 39.62 (1.97) 27.94 (1.75) 25.25 (1.77)
Kolk, 2004104 OP 4.39 (4.2) 2.98 (4.7) 1.95 (3.5) UC 2.731.9 1.67 (2.1) 0.87 (1.2)
GPRE, GP-delivered reattribution; M, mean; OP, other psychotherapy; UC, usual care; UC+ usual care plus.
a Data for studies with a second intervention.
Moreno 2013:148 CBTHII – T1 M 63.26, 95% CI 50.87 to 75.65; T2 M 34.9, 95% CI 26.42 to 43.38; T4 M 55.53, 95% CI 49 to 62.06.
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Data for the outcome impact
First author
and year of
publication
Intervention 1 Control 1
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
Intervention
code
Time point 1 –
mean (SD/SE)
Time point 2 –
mean (SD/SE)
Time point 3 –
mean (SD/SE)
Time point 4 –
mean (SD/SE)
van der Roer,
2008120
MM 11.6 7.9 7.4 6.7 SES 12.1 7.5 7.7 7.1
Walti, 2015121 MM 10.21 (4.44) SES 11.21 (3.95)
Ridsdale, 2004113 CBTLI 5.1 (1.8) 4.1 (1.9) GA 4.6 (2.2) 4.1 (2.4)
aRidsdale, 2012115 GA 4.5 (1.9) 3.9 (1.9) GSH 4.4 (2) 3.7 (2.3)
aAlda, 2011137 CBTHI 65.91 (10.85) 46.21 (9.18) 48.8 (9.11) UC 64.48 (10.5) 48.64 (6.77) 53.26 (7.54)
aLuciano, 2014138 CBTHI 68.2 (8.96) 48.7 (6.91) 49.49 (8.77) UC 65.87 (7.63) 67.68 (9.23) 67.45 (9.15)
aSañudo, 2010140 SES 60.9 (3.4) UC 60.5 (3.8)
Kennedy, 2005129 MM 15.3 (8.7) ME 15.1 (8.4)
Moss-Morris,
2010130
CBTLI 3.7 (6.7) 4.3 (6.2) 4.7 (6.6) UC –1.2 (5.7) –0.7 (5.5) –0.72 (5.3)
Rothman, 2013127 GP-O 40 (28–50) 36 (22–49) UC+ 38 (28 to 50) 38 (28–50)
Whitehead, 2002154 GP-MM 58.25 65.03 59.2 UC 62.77 63.52 65.62
van der Feltz-
Cornelis, 2006160
MM GPRE
Lansinger, 2007123 RSSE 26 (6 to 60) 24 (2 to 68) 22 (0 to 54) SES 22 (8 to 52) 17 (2 to 52) 18 (0 to 52)
Macedo, 2012119 GA 11.2 (5.3) 8 (6.5) 8.6 (6.8) 8 (6.9) GA 11.4 (4.8) 7.5 (6.4) 8 (7.1) 7.4 (6.7)
Cuesta-Vargas,
2012118
MM 7.1 (2.2) 2.7 (1.8) 2.1 (1.3) 1.3 (1.2) GSH 8.2 (2.2) 5.1 (3.9) 5 (3.2) 3.8 (3.6)
Ridsdale, 2001112 CBTHI 4.9 (1.8) 3.7 (2.2) OP 4.9 (1.7) 3.5 (2.2)
Kocken, 2008103 OP 2.48 (1.15) 3.2 (1.36) UC 1.95 (1.08) 2.45 (1.4)
LeFort, 1998128 GSH 2.51 (0.84) 2.29 (0.78) UC 2.29 (0.76) 2.81 (0.72)
Luciano, 2011139 MM 58.9 (12.9) 46.87 (16.77) UC 55.97 (14.01) 54.72 (15.95)
GP-MM, GP-delivered MUS management; GP-O, GP – other; GPRE, GP-delivered reattribution; GSH, guided self-help; M, mean; OP, other psychotherapy; UC, usual care; UC+, usual
care plus.
a Data for studies with a second intervention.
Ridsdale 2012:115 OP – T1 M 4.7, SD 1.9; T3 M 4.2, SD 2.1. Alda 2011:137 ME – T1 M 66.36, SD 9.88; T2 M 50.93, SD 9.38; T4 M 52.84, SD 9.17. Luciano 2014:138 ME – T1 M 68.96,
SD 10.93; T2 M 63.37, SD 9.1: T3 M 65.11, SD 8.87. Sañudo 2010:140 SES – T1 M 62.2, SD 4.2.
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Appendix 6 Table of excluded studies
from the qualitative review
Number Reference Reason
1 Arnold IA, Speckens AE, van Hemert AM. Medically unexplained physical symptoms:
the feasibility of group cognitive-behavioural therapy in primary care. J Psychosom
Res 2004;57:517–20
Does not include data
about a specific
intervention
2 Artus M, Croft P, Lewis M. The use of CAM and conventional treatments among
primary care consulters with chronic musculoskeletal pain. BMC Fam Pract 2007;8:26
No qualitative data
reported
3 Austrian JS, Kerns RD, Reid MC. Perceived barriers to trying self-management
approaches for chronic pain in older persons. J Am Geriatr Soc 2005;53:856–61
Non-UK
4 Beattie A, Shaw A, Yardley L, Little P, Sharp D. Participating in and delivering the
ATEAM trial (Alexander technique lessons, exercise, and massage) interventions for
chronic back pain: a qualitative study of professional perspectives. Complement Ther
Med 2010;18:119–27. https://doi.org/10.1016/j.ctim.2010.05.037
Population did not fit
the inclusion criteria
5 Brown CA. Occupational therapists’ beliefs regarding treatment options for people
with chronic pain. Br J Occup Ther 2002;65:398–404
No qualitative data
reported
6 Brown CA. The beliefs of people with chronic pain in relation to ‘important’
treatment components. Eur J Pain 2004;8:325–33. https://doi.org/10.1016/
j.ejpain.2003.10.005
No qualitative data
reported
7/8 Calnan M, Wainwright D, O’Neill C, Winterbottom A, Watkins C. Evaluating
health-care: the perspectives of sufferers with upper limb pain. Health Expect
2005;8:149–60
Calnan M, Wainwright D, O’Neill C, Winterbottom A, Watkins C. Making sense of
aches and pains. Fam Pract 2006;23:91–105
Population did not fit
the inclusion criteria
9 Carnes D, Homer K, Underwood M, Pincus T, Rahman A, Taylor SJ. Pain management
for chronic musculoskeletal conditions: the development of an evidence-based and
theory-informed pain self-management course. BMJ Open 2013;3:e003534.
https://doi.org/10.1136/bmjopen-2013-003534
Population did not fit
the inclusion criteria
10 Chew-Graham C, Dixon R, Shaw JW, Smyth N, Lovell K, Peters S. Practice Nurses’
views of their role in the management of Chronic Fatigue Syndrome/Myalagic
Encephalitis: a qualitative study. BMC Nurs 2009;8:2. https://doi.org/10.1186/
1472-6955-8-2
Does not include data
about a specific
intervention
11 Cooper K, Smith BH, Hancock E. Patients’ perceptions of self-management of chronic
low back pain: evidence for enhancing patient education and support. Physiotherapy
2009;95:43–50. https://doi.org/10.1016/j.physio.2008.08.005
Population did not fit
the inclusion criteria
12 Hadi MA, Alldred DP, Briggs M, Marczewski K, Closs SJ. Effectiveness of a
community based nurse-pharmacist managed pain clinic: a mixed-methods study.
Int J Nurs Stud 2016;53:219–27. https://doi.org/10.1016/j.ijnurstu.2015.09.003
Population did not fit
the inclusion criteria
13 Harris J, Williams T, Hart O, Hanson C, Johnstone G, Muthana A, Nield C. Using
health trainers to promote self-management of chronic pain: can it work? Br J Pain
2014;8:27–33. https://doi.org/10.1177/2049463713511956
Population did not fit
the inclusion criteria
14 Lamb SE, Lall R, Hansen Z, Withers EJ, Griffiths FE, Szczepura A, et al. Design
considerations in a clinical trial of a cognitive behavioural intervention for the
management of low back pain in primary care: Back Skills Training Trial. BMC
Musculoskelet Disord 2007;8:14
No qualitative data
reported
15 Lamb SE, Lall R, Hansen Z, Castelnuovo E, Withers EJ, Nichols V, et al. A multicentred
randomised controlled trial of a primary care-based cognitive behavioural
programme for low back pain. The Back Skills Training (BeST) trial. Health Technol
Assess 2010;14(41). https://doi.org/10.3310/hta14410
Population did not fit
the inclusion criteria
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Number Reference Reason
16 MacKichan F, Paterson C, Britten N. GP support for self-care: the views of people
experiencing long-term back pain. Fam Pract 2013;30:212–18. https://doi.org/
10.1093/fampra/cms062
Population did not fit
the inclusion criteria
17 Masterton G. Training practices in reattribution for medically unexplained symptoms.
J R Coll Physicians Edinb 2008;38:39
Opinion piece
18 McCracken LM, Sato A, Wainwright D, House W, Taylor GJ. A feasibility study of
brief group-based acceptance and commitment therapy for chronic pain in general
practice: recruitment, attendance, and patient views. Prim Health Care Res Dev
2014;15:312–23. https://doi.org/10.1017/S1463423613000273
Population did not fit
the inclusion criteria
19 McCrae N, Correa A, Chan T, Jones S, de Lusignan S. Long-term conditions and
medically-unexplained symptoms: feasibility of cognitive behavioural interventions
within the improving access to Psychological Therapies Programme. J Ment Health
2015;24:379–84. https://doi.org/10.3109/09638237.2015.1022254
Population did not fit
the inclusion criteria
20 Morriss R, Dowrick C, Salmon P, Peters S, Rogers A, Dunn G, et al. Turning theory
into practice: rationale, feasibility and external validity of an exploratory randomized
controlled trial of training family practitioners in reattribution to manage patients
with medically unexplained symptoms (the MUST). Gen Hosp Psychiatry
2006;28:343–51
No qualitative data
reported
21 Morriss RK, Gask L, Ronalds C, Downes-Grainger E, Thompson H, Goldberg D.
Clinical and patient satisfaction outcomes of a new treatment for somatized mental
disorder taught to general practitioners. Br J Gen Pract 1999;49:263–7
No qualitative data
reported
22 Payne H, Brooks SDM. Clinical outcomes from The BodyMind ApproachTM in the
treatment of patients with medically unexplained symptoms in primary health care in
England: practice-based evidence. Arts Psychother 2016;47:55–65
No qualitative data
reported
23 Peters S, Goldthorpe J, McElroy C, King E, Javidi H, Tickle M, Aggarwal VR.
Managing chronic orofacial pain: a qualitative study of patients’, doctors’, and
dentists’ experiences. Br J Health Psychol 2015;20:777–91. https://doi.org/10.1111/
bjhp.12141
Does not include data
about a specific
intervention
24 Ruecroft G. Development of a self-management tool in the chronic pain service.
Pract Dev Health Care 2004;3:143–56
Does not include data
about a specific
intervention
25 Sumathipala A, Siribaddana S, Hewege S, Sumathipala K, Prince M, Mann A.
Understanding the explanatory model of the patient on their medically unexplained
symptoms and its implication on treatment development research: a Sri Lanka Study.
BMC Psychiatry 2008;8:54. https://doi.org/10.1186/1471-244X-8-54
Non-UK
26 Underwood MR, Harding G, Klaber Moffett J, UK BEAM trial team. Patient
perceptions of physical therapy within a trial for back pain treatments (UK BEAM)
[ISRCTN32683578]. Rheumatology 2006;45:751–6
Population did not fit
the inclusion criteria
27 van Hooff ML, Ter Avest W, Horsting PP, O’Dowd J, de Kleuver M, van Lankveld W,
van Limbeek J. A short, intensive cognitive behavioral pain management program
reduces health-care use in patients with chronic low back pain: two-year follow-up
results of a prospective cohort. Eur Spine J 2012;21:1257–64. https://doi.org/
10.1007/s00586-011-2091-0
No qualitative data
reported (non-UK)
28 Walsh N, Cramp F, Palmer S, Pollock J, Hampson L, Gooberman-Hill R, et al. Exercise
and self-management for people with chronic knee, hip or lower back pain: a cluster
randomised controlled trial of clinical and cost-effectiveness. Study protocol.
Physiotherapy 2013;99:352–7. https://doi.org/10.1016/j.physio.2012.09.002
No qualitative data
reported
29 Wearden AJ, Riste L, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, et al.
Fatigue Intervention by Nurses Evaluation – the FINE Trial. A randomised controlled
trial of nurse led self-help treatment for patients in primary care with chronic fatigue
syndrome: study protocol. BMC Med 2006;4:9
No qualitative data
reported
30 Whitehead L, Campion P. Can general practitioners manage Chronic Fatigue
Syndrome? A controlled trial. J Chronic Fatig Syndr 2002;10:55–64
No qualitative data
reported
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Number Reference Reason
31 Wilkinson P, Mynors-Wallis L. Problem-solving therapy in the treatment of unexplained
physical symptoms in primary care: a preliminary study. J Psychosom Res 1994;38:591–8
No qualitative data
reported
32 Williams A, Wiggers J, O’Brien KM, Wolfenden L, Yoong S, Campbell E, et al. A
randomised controlled trial of a lifestyle behavioural intervention for patients with
low back pain, who are overweight or obese: study protocol. BMC Musculoskelet
Disord 2016;17:70. https://doi.org/10.1186/s12891-016-0922-1
No qualitative data
reported
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Appendix 7 Excluded studies for the
review of cost-effectiveness studies
Citation Reason for exclusion
Akehurst RL, Brazier JE, Mathers N, O’Keefe C, Kaltenthaler E, Morgan A, et al. Health-related
quality of life and cost impact of irritable bowel syndrome in a UK primary care setting.
PharmacoEconomics 2002;20:455–62
Costing analysis
Annemans L, Wessely S, Spaepen E, Caekelbergh K, Caubère JP, Le Lay K, Taïeb C. Health
economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum
2008;58:895–902. https://doi.org/10.1002/art.23265
Costing analysis
Bermingham SL, Cohen A, Hague J, Parsonage M. The cost of somatisation among the working-
age population in England for the year 2008–2009. Ment Health Fam Med 2010;7:71–84
Costing analysis
Bromley JS, Turner A. A proactive and acceptable clinic solution for patients with medically
unexplained symptoms. Psychiatr Bull 2014;38:307–8. https://doi.org/10.1192/pb.38.6.307a
Costing analysis
Burton C, McGorm K, Richardson G, Weller D, Sharpe M. Healthcare costs incurred by patients
repeatedly referred to secondary medical care with medically unexplained symptoms: a cost of
illness study. J Psychosom Res 2012;72:242–7. https://doi.org/10.1016/j.jpsychores.2011.12.009
Costing analysis
Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel
syndrome. Aliment Pharmacol Ther 2014;40:1023–34. https://doi.org/10.1111/apt.12938
Costing analysis
Cherkin DC, Deyo RA, Battié M, Street J, BarlowW. A comparison of physical therapy, chiropractic
manipulation, and provision of an educational booklet for the treatment of patients with low back
pain. N Engl J Med 1998;339:1021–9. https://doi.org/10.1056/NEJM199810083391502
Non-UK
Chisholm D, Godfrey E, Ridsdale L, Chalder T, King M, Seed P, et al. Chronic fatigue in general
practice: economic evaluation of counselling versus cognitive behaviour therapy. Br J Gen Pract
2001;51:15–18
Cost–consequence
study
Creed F, Fernades L, Guthrie E, Sivagnanam S, Louon A, Barbezat G. Both psychotherapy and
paroxetine are cost-effective for the treatment of severe irritable bowel syndrome. Evid Based
Healthc 2003;7:151–3
Not primary care
Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, et al. The cost-effectiveness
of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology
2003;124:303–17. https://doi.org/10.1053/gast.2003.50055
Not primary care
Friedberg MW. Group cognitive behavioral treatment improves chronic low back pain in a
cost-effective manner. J Clin Outcomes Manage 2010;17:7–9
Not MUS
Geraets JJ, Goossens ME, de Bruijn CP, de Groot IJ, Köke AJ, Pelt RA, et al. Cost-effectiveness
of a graded exercise therapy program for patients with chronic shoulder complaints. Int J
Technol Assess Health Care 2006;22:76–83
Non-UK
Gerhards SA, de Graaf LE, Jacobs LE, Severens JL, Huibers MJ, Arntz A, et al. Economic
evaluation of online computerised cognitive-behavioural therapy without support for depression
in primary care: randomised trial. Br J Psychiatry 2010;196:310–18. https://doi.org/10.1192/
bjp.bp.109.065748
Non-UK
Greig E, Gore S, Staveley K, Phillips I, Benneyworth R, Matull R, et al. Delivering cost effective
management for irritable bowel syndrome (IBS) across Somerset. Gut 2015;64:A192–3
Costing analysis
Gudleski GD, Li X, Ma C, Dunlap LJ, Baweja V, Satchidanand N, et al. Modeling health care
utilization in irritable bowel syndrome patients: distinguishing factors that influence the decision
to consult a doctor from those that influence frequency of doctor visits. Gastroenterology
2014;146:S224
Costing analysis
Hill JC, Whitehurst DG, Lewis M, Bryan S, Dunn KM, Foster NE, et al. Comparison of stratified
primary care management for low back pain with current best practice (STarT Back): a
randomised controlled trial. Lancet 2011;378:1560–71. https://doi.org/10.1016/S0140-6736(11)
60937-9
Not MUS
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Citation Reason for exclusion
Hong J, Reed C, Happich M, Novick D. Cost of treating chronic lower back pain (CLBP) in
patients consulting primary care physicians in the UK. Eur J Pain Suppl 2011;5:125
Costing analysis
Hong J, Reed C, Novick D, Happich M. Costs associated with treatment of chronic low back
pain: an analysis of the UK General Practice Research Database. Spine 2013;38:75–82.
https://doi.org/10.1097/BRS.0b013e318276450f
Costing analysis
Hong J, Reed C, Novick D, Lenox-Smith A, Happich M. Healthcare costs before and after
diagnosis of depression in patients with unexplained pain: a retrospective cohort study
using the United Kingdom general practice research database. Int J Neuropsychopharmacol
2012;15:232
Costing analysis
Houghton LA, Heyman DJ, Whorwell PJ. Symptomatology, quality of life and economic features
of irritable bowel syndrome – the effect of hypnotherapy. Aliment Pharmacol Ther 1996;10:91–5
Costing analysis
Johnson RE, Jones GT, Wiles NJ, Chaddock C, Potter RG, Roberts C, et al. Active exercise,
education, and cognitive behavioral therapy for persistent disabling low back pain: a randomized
controlled trial. Spine 2007;32:1578–85. https://doi.org/10.1097/BRS.0b013e318074f890
Not MUS
Juniper M, Le TK, Mladsi D. The epidemiology, economic burden, and pharmacological treatment
of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review.
Expert Opin Pharmacother 2009;10:2581–92. https://doi.org/10.1517/14656560903304063
Costing analysis
Kennedy TM, Chalder T, McCrone P, Darnley S, Knapp M, Jones RH, Wessely S. Cognitive
behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in
primary care: randomised controlled trial. Health Technol Assess 2006;10(19)
Cost–consequence
study
Konnopka A, Konig HH, Kaufmann C, Stuhldreher N, Wild B, Szecsenyi J, et al. Cost-
effectiveness of a Collaborative Group Intervention for Patients with Medically Unexplained
Symptoms. J Ment Health Policy Econ 2015;18:S25–S6
Non-UK
Lamb SE, Hansen Z, Lall R, Castelnuovo E, Withers EJ, Nichols V, et al. Group cognitive
behavioural treatment for low-back pain in primary care: a randomised controlled trial and
cost-effectiveness analysis. Lancet 2010;375:916–23. https://doi.org/10.1016/S0140-6736(09)
62164-4
Not MUS
Lamotte M, Maugars Y, Le Lay K, Taieb C. Health economic comparison of outpatient
management of fibromyalgia before and after diagnosis in five European countries. Value Health
2009;12:A438
Costing analysis
Le TK, Roskell N, Mladsi D, Mitra D, Shannon P, Wilson AG, et al. Database analysis to estimate
medical and pharmacotherapy resource utilization and costs of fibromyalgia prior to and
following diagnosis in the United Kingdom primary care setting. Pain Med 2009;10:274
Costing analysis
Luciano JV, D’Amico F, Cerdà-Lafont M, Peñarrubia-María MT, Knapp M, Cuesta-Vargas AI,
et al. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration
recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic
evaluation alongside a 6-month randomized controlled trial. Arthritis Res Ther 2014;16:451.
https://doi.org/10.1186/s13075-014-0451-y
Non-UK
Luciano JV, Sabes-Figuera R, Cardeñosa E, T Peñarrubia-María M, Fernández-Vergel R,
García-Campayo J, et al. Cost-utility of a psychoeducational intervention in fibromyalgia patients
compared with usual care: an economic evaluation alongside a 12-month randomized controlled
trial. Clin J Pain 2013;29:702–11. https://doi.org/10.1097/AJP.0b013e318270f99a
Non-UK
Luo Z, Goddeeris J, Gardiner JC, Smith RC. Costs of an intervention for primary care patients
with medically unexplained symptoms: a randomized controlled trial. Psychiatr Serv
2007;58:1079–86
Non-UK
Maetzel A, Li L. The economic burden of low back pain: a review of studies published between
1996 and 2001. Best Pract Res Clin Rheumatol 2002;16:23–30. https://doi.org/10.1053/berh.
2001.0204
Costing analysis
Margalit AP, El-Ad A. Costly patients with unexplained medical symptoms: a high-risk population.
Patient Educ Couns 2008;70:173–8
Non-UK
Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in
the UK and US. PharmacoEconomics 2006;24:21–37
Costing analysis
McCrone P, Darbishire L, Ridsdale L, Seed P. The economic cost of chronic fatigue and chronic
fatigue syndrome in UK primary care. Psychol Med 2003;33:253–61
Costing analysis
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Citation Reason for exclusion
McCrone P, Darbishire L, Ridsdale L, Seed P, Brage S, Raine R. Chronic fatigue has high, but
mainly hidden, costs. Evid Based Healthc 2003;7:196–7
Costing analysis
McCrone P, Knapp M, Kennedy T, Seed P, Jones R, Darnley S, Chalder T. Cost-effectiveness of
cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome. Eur J
Gastroenterol Hepatol 2008;20:255–63. https://doi.org/10.1097/MEG.0b013e3282f2519d
Cost–consequence
study
McCrone P, Ridsdale L, Darbishire L, Seed P. Cost-effectiveness of cognitive behavioural therapy,
graded exercise and usual care for patients with chronic fatigue in primary care. Psychol Med
2004;34:991–9
Cost–consequence
study
Meng H, Friedberg F, Castora-Binkley M. Cost-effectiveness of chronic fatigue self-management
versus usual care: a pilot randomized controlled trial. BMC Fam Pract 2014;15:184. https://doi.org/
10.1186/s12875-014-0184-7
Non-UK
Morriss R, Gask L, Ronalds C, Downes-Grainger E, Thompson H, Leese B, Goldberg D. Cost-
effectiveness of a new treatment for somatized mental disorder taught to GPs. Fam Pract
1998;15:119–25. https://doi.org/10.1093/fampra/15.2.119
Not behavioural
intervention
Murray-Thomas T, Dedman D, Canavan C, West J, Card T. Utilisation and costs of inpatient and
outpatient services among patients with irritable bowel syndrome – a study using the clinical
practice research datalink (CPRD). Value Health 2013;16:A495–6
Costing analysis
O’Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A. Cognitive behavioural therapy in
chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme.
Health Technol Assess 2006;10(37)
Not primary care
Oliver K, Cronan TA, Walen HR, Tomita M. Effects of social support and education on health
care costs for patients with fibromyalgia. J Rheumatol 2001;28:2711–19
Non-UK
Parsons S, Symmons DPM. The burden of musculoskeletal conditions. Medicine 2010;38:126–8 Costing analysis
Radhakrishnan M, Hammond G, Jones PB, Watson A, McMillan-Shields F, Lafortune L. Cost of
improving Access to Psychological Therapies (IAPT) programme: an analysis of cost of session,
treatment and recovery in selected primary care trusts in the East of England region. Behav Res
Ther 2013;51:37–45. https://doi.org/10.1016/j.brat.2012.10.001
Costing analysis
Reid S, Wessely S, Crayford T, Hotopf M. Frequent attenders with medically unexplained
symptoms: service use and costs in secondary care. Br J Psychiatry 2002;180:248–53
Costing analysis
Ridsdale L, Godfrey E, Chalder T, Seed P, King M, Wallace P, Wessely S, Fatigue Trialists’ Group.
Chronic fatigue in general practice: is counselling as good as cognitive behaviour therapy? A UK
randomised trial. Br J Gen Pract 2001;51:19–24
Clinical paper with
economic paper
included in cost–
consequence analysis
Ritzwoller DP, Crounse L, Shetterly S, Rublee D. The association of comorbidities, utilization and
costs for patients identified with low back pain. BMC Musculoskelet Disord 2006;7:72
Non-UK
Robinson A, Lee V, Kennedy A, Middleton L, Rogers A, Thompson DG, Reeves D. A randomised
controlled trial of self-help interventions in patients with a primary care diagnosis of irritable
bowel syndrome. Gut 2006;55:643–8
Cost–consequence
study
Ryan M, Gevirtz R. Biofeedback-based psychophysiological treatment in a primary care setting:
an initial feasibility study. Appl Psychophysiol Biofeedback 2004;29:79–93
Non-UK
Sabes-Figuera R, McCrone P, Hurley M, King M, Donaldson AN, Ridsdale L. The hidden cost of
chronic fatigue to patients and their families. BMC Health Serv Res 2010;10:56. https://doi.org/
10.1186/1472-6963-10-56
Costing analysis
Sabes-Figuera R, McCrone P, Hurley M, King M, Donaldson AN, Ridsdale L. Cost-effectiveness of
counselling, graded-exercise and usual care for chronic fatigue: evidence from a randomised trial
in primary care. BMC Health Serv Res 2012;12:264. https://doi.org/10.1186/1472-6963-12-264
Cost–consequence
study
Schade N, Torres P, Beyebach M. Cost-efficiency of a brief family intervention for somatoform
patients in primary care. Fam Syst Health 2011;29:197–205. https://doi.org/10.1037/a0024563
Non-UK
Simrén M, Brazier J, Coremans G, Dapoigny M, Müller-Lissner SA, Pace F, et al. Quality of life
and illness costs in irritable bowel syndrome. Digestion 2004;69:254–61. https://doi.org/
10.1159/000079846
Costing analysis
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Citation Reason for exclusion
Soubieres A, Wilson P, Poullis A, Wilkins J, Rance M. Burden of irritable bowel syndrome in an
increasingly cost-aware National Health Service. Frontline Gastroenterol 2015;6:246–51.
https://doi.org/10.1136/flgastro-2014-100542
Costing analysis
Soubieres A, Wilson P, Poullis A, Wilkins J, Rance M. The cost of irritable bowel syndrome (IBS)
in England. Value Health 2014;17:A365. https://doi.org/10.1016/j.jval.2014.08.813
Costing analysis
Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther
2009;11:117. https://doi.org/10.1186/ar2715
Costing analysis
Taylor SJ, Carnes D, Homer K, Kahan BC, Hounsome N, Eldridge S, et al. Novel three-day,
community-based, nonpharmacological group intervention for chronic musculoskeletal pain
(COPERS): a randomised clinical trial. PLOS Med 2016;13:e1002040. https://doi.org/10.1371/
journal.pmed.1002040
Not MUS
van der Roer N, van Tulder MW, Barendse JM, van Mechelen W, Franken WK, Ooms AC,
de Vet HC. Cost-effectiveness of an intensive group training protocol compared to
physiotherapy guideline care for sub-acute and chronic low back pain: design of a randomised
controlled trial with an economic evaluation. BMC Musculoskelet Disord 2004;5:45
Non UK
Wilson P, Poullis A, Wilkins J, Rance M. The costs of irritable bowel syndrome (IBS) in an
increasingly cost aware NHS. Gut 2014;63:A194
Costing analysis
Yardley L, Barker F, Muller I, Turner D, Kirby S, Mullee M, et al. Clinical and cost effectiveness of
booklet based vestibular rehabilitation for chronic dizziness in primary care: single blind, parallel
group, pragmatic, randomised controlled trial. BMJ 2012;344:e2237. https://doi.org/10.1136/
bmj.e2237
Not MUS
Yiannakou Y, Eugenicos M, Sanders DS, Emmanuel A, Whorwell P, Butt F, et al. Economic and
quality-of-life burden of moderate-to-severe irritable bowel syndrome with constipation (IBS-C)
in the UK: the IBIS-C study. Gut 2015;64:A33–4
Costing analysis
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Appendix 8 Applicability and quality of
cost-effectiveness studies
First author, year: Richardson 2013282
(clinical paper Wearden 2010111)
Population:
CFS/ME
Intervention vs. comparator: pragmatic
rehabilitation vs. supportive listening
vs. treatment as usual
Element
Section 1: Applicability. This checklist should be used first
to filter out irrelevant studies
Yes/partly/no/
unclear/NA
Comments
1.1 Is the study population appropriate for the review
question?
Yes Clinical paper met criteria for inclusion in
clinical review
1.2 Are the interventions appropriate for the review
question?
Yes Clinical paper met criteria for inclusion in
clinical review
1.3 Is the system in which the study was conducted
sufficiently similar to the current UK context?
Yes UK NHS
1.4 Are the perspectives clearly stated and are they
appropriate for the review question?
Yes NHS and PSS
1.5 Are all direct effects on individuals included, and are all
other effects included where they are material?
Yes QALYs accrued by patients
1.6 Are all future costs and outcomes discounted
appropriately?
Yes Discounting at 3.5% for both costs and
QALYs over 70-week horizon
1.7 Is QALY used as an outcome, and was it derived using
NICE’s preferred methods? If not, describe rationale and
outcomes used in line with analytical perspectives taken
(item 1.4 above)
Yes QALYs derived from EQ-5D
1.8 Are costs and outcomes from other sectors fully and
appropriately measured and valued?
Yes Costs to patient and family including lost
working days also reported but not
included in CE
1.9 Overall judgement: directly applicable/partially
applicable/not applicable There is no need to use section 2
of the checklist if the study is considered ‘not applicable’
Directly
applicable
Section 2: Study limitations (the level of methodological
quality). This checklist should be used once it has been
decided that the study is sufficiently applicable to the
context of the guideline
Yes/partly/no/
unclear/NA
Comments
2.1 Does the model structure adequately reflect the nature
of the topic under evaluation?
NA Trial-based evaluation
2.2 Is the time horizon sufficiently long to reflect all
important differences in costs and outcomes?
No 70-week time horizon inadequate in a
chronic condition
2.3 Are all important and relevant outcomes included? Yes
2.4 Are the estimates of baseline outcomes from the best
available source?
Yes Trial-based analysis
2.5 Are the estimates of relative intervention effects from
the best available source?
Yes Trial-based analysis
2.6 Are all important and relevant costs included? Partly Relevant aspects of health service
resource use are captured. Not all
relevant social care services captured but
discussed as limitation
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First author, year: Richardson 2013282
(clinical paper Wearden 2010111)
Population:
CFS/ME
Intervention vs. comparator: pragmatic
rehabilitation vs. supportive listening
vs. treatment as usual
2.7 Are the estimates of resource use from the best
available source?
Partly Self-reporting of resource use is not ideal
2.8 Are the unit costs of resources from the best available
source?
Yes Standard unit cost sources, e.g. PSSRU337/
NHS Reference Costs336
2.9 Is an appropriate incremental analysis presented or can
it be calculated from the data?
Yes
2.10 Are all important parameters whose values are
uncertain subjected to appropriate sensitivity analysis?
Yes Boot-strapping used to generate CEAC.
Sensitivity analysis on complete-case
data
2.11 Is there any potential conflict of interest? No
2.12 Overall assessment: minor limitations/potentially
serious limitations/very serious limitations
Minor
limitations
CE, cost-effectiveness; CEAC, cost-effectiveness acceptability curve; NA, not applicable.
First author, year: Beasley, 2015126
(short-term follow-up in McBeth 2012125)
Population:
chronic pain
Intervention vs. comparator:
CBT vs. exercise vs. CBT with
exercise vs. treatment as usual
Element
Section 1: Applicability (relevance to specific review
questions and the NICE reference case as described in
section 7.5) This checklist should be used first to filter out
irrelevant studies
Yes/partly/no/
unclear/NA
Comments
1.1 Is the study population appropriate for the review
question?
Yes Met criteria for inclusion in clinical
review
1.2 Are the interventions appropriate for the review
question?
Yes Met criteria for inclusion in clinical
review
1.3 Is the system in which the study was conducted
sufficiently similar to the current UK context?
Yes UK (presumed NHS)
1.4 Are the perspectives clearly stated and are they
appropriate for the review question?
Yes Perspective not clearly stated but
approach taken is consistent with NHS
perspective
1.5 Are all direct effects on individuals included, and are all
other effects included where they are material?
Yes QALYs accrued by patients
1.6 Are all future costs and outcomes discounted
appropriately?
Yes Discounting at 3.5%
1.7 Is QALY used as an outcome, and was it derived using
NICE’s preferred methods? If not, describe rationale and
outcomes used in line with analytical perspectives taken
(item 1.4 above).
Yes QALYs derived from EQ-5D
1.8 Are costs and outcomes from other sectors fully and
appropriately measured and valued?
No None included
1.9 Overall judgement: directly applicable/partially
applicable/not applicable There is no need to use section 2
of the checklist if the study is considered ‘not applicable’.
Directly
applicable
Section 2: study limitations (the level of methodological
quality) This checklist should be used once it has been
decided that the study is sufficiently applicable to the
context of the guideline
Yes/partly/no/
unclear/NA
Comments
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First author, year: Beasley, 2015126
(short-term follow-up in McBeth 2012125)
Population:
chronic pain
Intervention vs. comparator:
CBT vs. exercise vs. CBT with
exercise vs. treatment as usual
2.1 Does the model structure adequately reflect the nature
of the topic under evaluation?
NA Within-trial analysis
2.2 Is the time horizon sufficiently long to reflect all
important differences in costs and outcomes?
Yes 2-year time horizon reported by
Beasley et al.126
2.3 Are all important and relevant outcomes included? Yes
2.4 Are the estimates of baseline outcomes from the best
available source?
Yes Within-trial analysis
2.5 Are the estimates of relative intervention effects from
the best available source?
Yes Within-trial analysis
2.6 Are all important and relevant costs included? Yes
2.7 Are the estimates of resource use from the best
available source?
Partly Self-reporting of resource use is not ideal
2.8 Are the unit costs of resources from the best available
source?
Yes Standard sources of unit costs
(e.g. PSSRU337 and NHS Reference Costs336)
2.9 Is an appropriate incremental analysis presented or can
it be calculated from the data?
Yes
2.10 Are all important parameters whose values are
uncertain subjected to appropriate sensitivity analysis?
Yes Bootstrapping used to produce CEACs.
Sensitivity analysis conducted on
missing data
2.11 Is there any potential conflict of interest? No
2.12 Overall assessment: minor limitations/potentially
serious limitations/very serious limitations
Minor
limitations
CEAC, cost-effectiveness acceptability curve; NA, not applicable.
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Appendix 9 Applicability and quality of
cost–consequence studies
First author, year: McCrone, 2004279
(clinical paper is Ridsdale 2004113)
Population: chronic
fatigue
Intervention vs. comparator:
GA vs. CBT (plus a non-randomised
comparison with usual care with
self-help booklet)
Element
Section 1: applicability (relevance to specific review
questions and the NICE reference case as described
in section 7.5). This checklist should be used first to
filter out irrelevant studies
Yes/partly/no/
unclear/NA
Comments
1.1 Is the study population appropriate for the
review question?
Yes Clinical paper met inclusion criteria for
clinical effectiveness
1.2 Are the interventions appropriate for the review
question?
Yes Clinical paper met inclusion criteria for
clinical effectiveness
1.3 Is the system in which the study was conducted
sufficiently similar to the current UK context?
Yes General practices in UK (presumed to
be NHS)
1.4 Are the perspectives clearly stated and are they
appropriate for the review question?
Partly Perspective described as ‘broad’ but
reports both health-care costs and
societal costs borne by caregivers. Costs
for complementary therapy are included
but it is not clear if these costs are borne
by the patient or the health service
1.5 Are all direct effects on individuals included,
and are all other effects included where they are
material?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
1.6 Are all future costs and outcomes discounted
appropriately?
Yes No discounting as 8-month time frame
1.7 Is QALY used as an outcome, and was it derived
using NICE’s preferred methods? If not, describe
rationale and outcomes used in line with analytical
perspectives taken (item 1.4 above)
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
1.8 Are costs and outcomes from other sectors fully
and appropriately measured and valued?
Partly Informal carer hours valued using
commercial cost for public sector care
1.9 Overall judgement: directly applicable/partially
applicable/not applicable There is no need to use
section 2 of the checklist if the study is considered
‘not applicable’
Partially applicable Health service costs not reported
separately from costs of informal care
Section 2: study limitations (the level of
methodological quality). This checklist should be
used once it has been decided that the study is
sufficiently applicable to the context of the guideline
Yes/partly/no/
unclear/NA
Comments
2.1 Does the model structure adequately reflect the
nature of the topic under evaluation?
NA Within-trial analysis
2.2 Is the time horizon sufficiently long to reflect all
important differences in costs and outcomes?
No 8 months is not a sufficient time horizon
for a chronic condition
2.3 Are all important and relevant outcomes
included?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
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First author, year: McCrone, 2004279
(clinical paper is Ridsdale 2004113)
Population: chronic
fatigue
Intervention vs. comparator:
GA vs. CBT (plus a non-randomised
comparison with usual care with
self-help booklet)
2.4 Are the estimates of baseline outcomes from the
best available source?
Partly Within-trial analysis is a good source for
comparison between GA and CBT but
non-randomised comparison with usual
care with self-help booklet is potentially
biased
2.5 Are the estimates of relative intervention effects
from the best available source?
Partly Within-trial analysis is a good source for
comparison between GA and CBT but
non-randomised comparison with usual
care with self-help booklet is potentially
biased
2.6 Are all important and relevant costs included? Yes
2.7 Are the estimates of resource use from the best
available source?
Partly Patient-reported data are not ideal
2.8 Are the unit costs of resources from the best
available source?
Cites standard sources (e.g. PSSRU unit
costs337 and NHS Reference Costs336). Cost
of booklet is described as being nominal
2.9 Is an appropriate incremental analysis presented
or can it be calculated from the data?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
2.10 Are all important parameters whose values
are uncertain subjected to appropriate sensitivity
analysis?
Bootstrapping used to estimate
uncertainty around incremental costs.
Sensitivity analyses were reported
2.11 Is there any potential conflict of interest? Yes
2.12 Overall assessment: minor limitations/
potentially serious limitations/very serious
limitations
Potentially serious
limitations for the
comparison against
3. Minor limitations
for 1 vs. 2
The non-randomised comparison against
usual care with self-help booklet is
potentially biased
NA, not applicable.
First author, year: Kennedy, 2005129 Population: IBS
Intervention vs. comparator: CBTLI plus
mediation vs. medication alone
Element
Section 1: applicability (relevance to specific review
questions and the NICE reference case as described
in section 7.5). This checklist should be used first to
filter out irrelevant studies.
Yes/partly/no/
unclear/NA
Comments
1.1 Is the study population appropriate for the
review question?
Yes Clinical paper met inclusion criteria for
clinical effectiveness
1.2 Are the interventions appropriate for the review
question?
Yes Clinical paper met inclusion criteria for
clinical effectiveness
1.3 Is the system in which the study was conducted
sufficiently similar to the current UK context?
Yes General practices in UK (presumed to
be NHS)
1.4 Are the perspectives clearly stated and are they
appropriate for the review question?
Unclear Perspective not explicitly stated but
health service costs reported separately
from societal costs. Health service costs
included alternative/complementary
therapies
1.5 Are all direct effects on individuals included, and
are all other effects included where they are
material?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
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First author, year: Kennedy, 2005129 Population: IBS
Intervention vs. comparator: CBTLI plus
mediation vs. medication alone
1.6 Are all future costs and outcomes discounted
appropriately?
Yes Outcomes were not discounted as time
horizon was 12 months
1.7 Is QALY used as an outcome, and was it derived
using NICE’s preferred methods? If not, describe
rationale and outcomes used in line with analytical
perspectives taken (item 1.4 above)
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
1.8 Are costs and outcomes from other sectors fully
and appropriately measured and valued?
Yes Lost employment included but health
service costs also reported separately
1.9 Overall judgement: directly applicable/partially
applicable/not applicable. There is no need to use
section 2 of the checklist if the study is considered
‘not applicable’
Directly applicable For outcome of health service costs
Section 2: study limitations (the level of
methodological quality). This checklist should be
used once it has been decided that the study is
sufficiently applicable to the context of the guideline
Yes/partly/no/
unclear/NA
Comments
2.1 Does the model structure adequately reflect the
nature of the topic under evaluation?
NA Within-trial analysis
2.2 Is the time horizon sufficiently long to reflect all
important differences in costs and outcomes?
No 12 months is not a sufficient time
horizon for a chronic condition
2.3 Are all important and relevant outcomes
included?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
2.4 Are the estimates of baseline outcomes from the
best available source?
Yes Within-trial analysis
2.5 Are the estimates of relative intervention effects
from the best available source?
Yes Within-trial analysis
2.6 Are all important and relevant costs included? Yes Intervention costs reported separately
from costs of service use and total costs
not reported
2.7 Are the estimates of resource use from the best
available source?
Partly Patient-reported data are not ideal
2.8 Are the unit costs of resources from the best
available source?
Partly Standard unit cost sources are cited
(e.g. PSSRU). Production costs estimated
for lost employment
2.9 Is an appropriate incremental analysis presented
or can it be calculated from the data?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
2.10 Are all important parameters whose values are
uncertain subjected to appropriate sensitivity
analysis?
Yes Bootstrapping used to estimate
uncertainty. Sensitivity analysis
on treatment costs reported in
McCrone et al.278
2.11 Is there any potential conflict of interest? Yes Authors declared the following conflict of
interest: RH Jones has been a consultant
in companies with a therapeutic interest
in IBS. These are Solvay Healthcare,
Boots, Novartis and Glaxo
2.12 Overall assessment: minor limitations/
potentially serious limitations/very serious
limitations
Minor limitations
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First author, year: Sabes-Figuera, 2012280
(clinical paper is Ridsdale 2012115)
Population:
chronic fatigue
Intervention vs. comparator: GA vs.
counselling (other psychotherapy) vs.
usual care plus a self-help booklet (GSH)
Element
Section 1: applicability (relevance to specific review
questions and the NICE reference case as described
in section 7.5). This checklist should be used first to
filter out irrelevant studies
Yes/partly/no/
unclear/NA
Comments
1.1 Is the study population appropriate for the
review question?
Yes Clinical paper met inclusion criteria for
clinical effectiveness
1.2 Are the interventions appropriate for the review
question?
Yes Clinical paper met inclusion criteria for
clinical effectiveness
1.3 Is the system in which the study was conducted
sufficiently similar to the current UK context?
Yes General practices in UK (presumed to
be NHS)
1.4 Are the perspectives clearly stated and are they
appropriate for the review question?
Perspective is described as health
service. Costs for alternative therapy are
included but it is not clear if these costs
are usually borne by the patient or the
health service
1.5 Are all direct effects on individuals included, and
are all other effects included where they are
material?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
1.6 Are all future costs and outcomes discounted
appropriately?
Yes No discounting as 6-month time frame
1.7 Is QALY used as an outcome, and was it derived
using NICE’s preferred methods? If not, describe
rationale and outcomes used in line with analytical
perspectives taken (item 1.4 above)
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
1.8 Are costs and outcomes from other sectors fully
and appropriately measured and valued?
Partly Informal carer hours valued using
commercial cost for public sector carer,
but full salary costs used to value sick
days rather than friction costs methods
1.9 Overall judgement: directly applicable/partially
applicable/not applicable There is no need to use
section 2 of the checklist if the study is considered
‘not applicable’
Directly applicable For outcome of health service costs
Section 2: study limitations (the level of
methodological quality). This checklist should be
used once it has been decided that the study is
sufficiently applicable to the context of the guideline
Yes/partly/no/
unclear/NA
Comments
2.1 Does the model structure adequately reflect the
nature of the topic under evaluation?
NA Within-trial analysis
2.2 Is the time horizon sufficiently long to reflect all
important differences in costs and outcomes?
No 6 months is not a sufficient time horizon
for a chronic condition
2.3 Are all important and relevant outcomes
included?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
2.4 Are the estimates of baseline outcomes from the
best available source?
Yes Within-trial analysis
2.5 Are the estimates of relative intervention effects
from the best available source?
Yes Within-trial analysis
2.6 Are all important and relevant costs included? Yes
2.7 Are the estimates of resource use from the best
available source?
Partly Patient-reported data are not ideal
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First author, year: Sabes-Figuera, 2012280
(clinical paper is Ridsdale 2012115)
Population:
chronic fatigue
Intervention vs. comparator: GA vs.
counselling (other psychotherapy) vs.
usual care plus a self-help booklet (GSH)
2.8 Are the unit costs of resources from the best
available source?
Yes Cites standard sources, e.g. PSSRU unit
costs337 and NHS Reference Costs.336 Cost
of booklet is described as being nominal
2.9 Is an appropriate incremental analysis presented
or can it be calculated from the data?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
2.10 Are all important parameters whose values are
uncertain subjected to appropriate sensitivity
analysis?
Yes Bootstrapping used to estimate
uncertainty around incremental costs
2.11 Is there any potential conflict of interest? No
2.12 Overall assessment: minor limitations/
potentially serious limitations/very serious
limitations
Minor limitations
GSH, guided self-help; NA, not applicable.
First author, year: Chisholm, 2001275
(clinical paper is Ridsdale 2001112)
Population:
chronic fatigue
Intervention vs. comparator:
counselling vs. CBT
Element
Section 1: applicability (relevance to specific review
questions and the NICE reference case as described
in section 7.5). This checklist should be used first to
filter out irrelevant studies
Yes/partly/no/
unclear/NA
Comments
1.1 Is the study population appropriate for the
review question?
Yes Clinical paper met inclusion criteria for
clinical effectiveness
1.2 Are the interventions appropriate for the review
question?
Yes Clinical paper met inclusion criteria for
clinical effectiveness
1.3 Is the system in which the study was conducted
sufficiently similar to the current UK context?
Yes General practices in UK (presumed to
be NHS)
1.4 Are the perspectives clearly stated and are they
appropriate for the review question?
Unclear Perspective not clearly stated but reports
both health-care costs and societal costs
borne by caregivers. Costs for alternative
therapy are included but it is not clear if
these costs are borne by the patient or
the health service
1.5 Are all direct effects on individuals included, and
are all other effects included where they are
material?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
1.6 Are all future costs and outcomes discounted
appropriately?
Yes No discounting as 6-month time frame
1.7 Is QALY used as an outcome, and was it derived
using NICE’s preferred methods? If not, describe
rationale and outcomes used in line with analytical
perspectives taken (item 1.4 above)
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
1.8 Are costs and outcomes from other sectors fully
and appropriately measured and valued?
Partly Informal carer hours valued using
commercial cost for public sector carer,
but full salary costs used to value sick
days rather than friction costs methods
1.9 Overall judgement: directly applicable/partially
applicable/not applicable. There is no need to use
section 2 of the checklist if the study is considered
‘not applicable’
Directly applicable For outcome of health service costs
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First author, year: Chisholm, 2001275
(clinical paper is Ridsdale 2001112)
Population:
chronic fatigue
Intervention vs. comparator:
counselling vs. CBT
Section 2: study limitations (the level of
methodological quality). This checklist should be
used once it has been decided that the study is
sufficiently applicable to the context of the guideline
Yes/partly/no/
unclear/NA
Comments
2.1 Does the model structure adequately reflect the
nature of the topic under evaluation?
NA Within-trial analysis
2.2 Is the time horizon sufficiently long to reflect all
important differences in costs and outcomes?
No 6 months is not a sufficient time horizon
for a chronic condition
2.3 Are all important and relevant outcomes
included?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
2.4 Are the estimates of baseline outcomes from the
best available source?
Yes Within-trial analysis
2.5 Are the estimates of relative intervention effects
from the best available source?
Yes Within-trial analysis
2.6 Are all important and relevant costs included? Yes
2.7 Are the estimates of resource use from the best
available source?
Partly Patient-reported data are not ideal
2.8 Are the unit costs of resources from the best
available source?
Unclear Source described as NHS Ready
Reckoner, which is published by PSSRU516
2.9 Is an appropriate incremental analysis presented
or can it be calculated from the data?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
2.10 Are all important parameters whose values are
uncertain subjected to appropriate sensitivity
analysis?
Yes Bootstrapping used to estimate
uncertainty around incremental costs and
some sensitivity analysis reported
2.11 Is there any potential conflict of interest? Unclear Not reported
2.12 Overall assessment: minor limitations/
potentially serious limitations/very serious
limitations
Minor limitations
First author, year: Robinson, 2006131 Population: IBS
Intervention vs. comparator: self-help
guidebook (GSH) vs. self-help group in
addition to guidebook vs. usual care
(MM=GSH+ RSSE)
Element
Section 1: applicability (relevance to specific review
questions and the NICE reference case as described
in section 7.5). This checklist should be used first to
filter out irrelevant studies
Yes/partly/no/
unclear/NA
Comments
1.1 Is the study population appropriate for the
review question?
Yes Clinical paper met inclusion criteria for
clinical effectiveness
1.2 Are the interventions appropriate for the review
question?
Yes Clinical paper met inclusion criteria for
clinical effectiveness
1.3 Is the system in which the study was conducted
sufficiently similar to the current UK context?
Yes UK study
1.4 Are the perspectives clearly stated and are they
appropriate for the review question?
Yes NHS perspective
1.5 Are all direct effects on individuals included, and
are all other effects included where they are material?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
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First author, year: Robinson, 2006131 Population: IBS
Intervention vs. comparator: self-help
guidebook (GSH) vs. self-help group in
addition to guidebook vs. usual care
(MM=GSH+ RSSE)
1.6 Are all future costs and outcomes discounted
appropriately?
Yes No discounting applied as 1-year time
horizon
1.7 Is QALY used as an outcome, and was it derived
using NICE’s preferred methods? If not, describe
rationale and outcomes used in line with analytical
perspectives taken (item 1.4 above)
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
1.8 Are costs and outcomes from other sectors fully
and appropriately measured and valued?
No Cost analysis limited to NHS costs
1.9 Overall judgement: directly applicable/partially
applicable/not applicable. There is no need to use
section 2 of the checklist if the study is considered
‘not applicable’
Directly applicable For outcome of health service costs
Section 2: study limitations (the level of
methodological quality). This checklist should be
used once it has been decided that the study is
sufficiently applicable to the context of the guideline
Yes/partly/no/
unclear/NA
Comments
2.1 Does the model structure adequately reflect the
nature of the topic under evaluation?
NA Within-trial analysis
2.2 Is the time horizon sufficiently long to reflect all
important differences in costs and outcomes?
No 1 year is not a sufficient time horizon for
a chronic condition
2.3 Are all important and relevant outcomes
included?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
2.4 Are the estimates of baseline outcomes from the
best available source?
Yes Within-trial analysis
2.5 Are the estimates of relative intervention effects
from the best available source?
Yes Within-trial analysis
2.6 Are all important and relevant costs included? Partly Secondary care consultations were
included but inpatient care was not.
Intervention costs do not appear to have
been included
2.7 Are the estimates of resource use from the best
available source?
Partly Primary care resource use from GP
records but secondary care resources
use from patient self-report which is
not ideal
2.8 Are the unit costs of resources from the best
available source?
Yes Cites standard sources, e.g. PSSRU unit
costs337 and NHS Reference Costs.336 Cost
of self-help guidebook is not provided
2.9 Is an appropriate incremental analysis presented
or can it be calculated from the data?
NA Benefits not reported as QALYs so
focusing on cost outcomes only here
2.10 Are all important parameters whose values are
uncertain subjected to appropriate sensitivity
analysis?
Partly Bootstrapping was used to estimate
uncertainty around incremental costs
and a secondary analysis adjusting for
missing data were conducted in addition
to the primary analysis
2.11 Is there any potential conflict of interest? None
2.12 Overall assessment: minor limitations/
potentially serious limitations/very serious
limitations
Potentially serious
limitations
GSH, guided self-help; NA, not applicable; PSSRU, Personal Social Services Unit.
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Appendix 10 Costing analysis assumptions
General assumptions for costing interventions applied across all studies.
l For CBT interventions, the published unit cost for CBT is applied regardless of the individual
delivering the intervention because the unit cost for CBT reflects an average across a range of
professionals (specialty doctor, clinical psychologist and mental health nurse).
l For other psychological interventions, the unit cost for CBT has been applied as the default where
the therapy has been provided by a mix of health-care professionals (e.g. ‘primary care staff’) or
where it has not been possible to identify a more specific unit cost for the health-care professional
who is reported to have delivered the intervention.
l For exercise-based interventions, the unit cost for physiotherapists has been applied when the
intervention is delivered by non-health-care professionals (e.g. fitness instruction).
l For hospital-based staff (e.g. consultant medical and psychiatric specialists), we have assumed that the
ratio of direct to indirect time is the same as the ratio for GPs (1 : 0.61, i.e. every hour spent with a
patient requires an additional 37 minutes (60 × 0.61) spent on activities that are not face-to-face
contact time with patients.
l Unit costs including qualification costs have been chosen where these are available.
l For interventions delivered to groups:
¢ We have assumed that any patient who attended at least one session would incur the cost of
the full course of sessions as their place in the group would not be given to someone else.
Therefore, the cost per patient is calculated using the number of patients who attended one or
more sessions.
¢ If the number attending one or more sessions is not reported, then we assume that all patients
allocated to the intervention attended one or more sessions.
¢ Where the number of groups has not been reported, this has been estimated based on the
reported group size, and if this is not reported we have assumed one group.
l For interventions delivered to individuals:
¢ We have assumed that planned sessions that are not attended incur the full cost as missed or
cancelled sessions cannot always be used by another patient and, therefore, we have used the
number of planned sessions to estimate the cost rather than the mean number of sessions
attended per patient.
¢ In studies where the number of sessions was not specified, or was patient led (e.g. one or two
sessions per week), we have used the mean number of sessions attended.
l If neither the actual nor the intended duration of the sessions is reported (and could not be
obtained following requests to the corresponding author), then we have recorded the cost as
not estimable.
l Where data on session number and duration are reported in several papers, we have used the paper
reporting the longest follow-up and where data are reported differently in the clinical and economic
papers, we have used the data from the economic papers.
l Interventions that consist of training health-care professionals to manage patients with MUS in a
particular way (i.e. the GP interventions) are costed based on the duration of time the health-care
professionals committed to attending the training, but the cost of the trainer’s time is not included.
l For interventions directed towards the individual with MUS, the costs of training health-care
professionals to deliver interventions (e.g. training CBT therapists to deliver CBT or physiotherapists
to deliver exercise sessions) has been excluded as qualification and ongoing training costs are
already incorporated in the unit costs for health-care professionals.
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l For GP interventions, studies have been categorised according to the combination of the
following elements:
¢ GP training
¢ interventions delivered to individual patients
¢ interventions delivered to groups of patients.
Decisions regarding costing or categorisation of individual studies:
l Kennedy 2005129 – medication was given in both arms as part of usual care and has therefore not
been costed.
l Larisch 2004158 – patients in both the intervention and the comparator arm (usual care) received six
sessions of 20 minutes with the GP. These are not costed into the GP intervention as they were
provided in both arms and the cost of the GP intervention is estimated relative to usual care.
l Rothman 2013127 – both the intervention and the control arm have been costed as different forms
of GP intervention. Multimodal assessment arm has been included under GP interventions delivered
to individuals but in fact some patients in the multimodel assessment arm received group therapy.
Cost could not be determined in either arm because of a lack of information on duration of sessions.
l Sumathipala 2008101 – both arms received a structured GP intervention and the intervention arm
received additional CBT elements not provided in the comparator arm. The intervention arm is
categorised as a GP intervention with training for GPs (five sessions plus additional supervisory
sessions) and individual delivery of CBT but the training element could not be costed because of a
lack of information on session duration. Comparator arm is costed as a GP MUS management
intervention with individual intervention with patients but no specific training for GPs.
l van Ravesteijn 2013143 – control arm described as ‘enhanced usual care’ and categorised as usual
care plus. The authors describe that patients in both trial arms received a psychiatric interview
and their GP was informed of the results of that interview, which may have influenced future care.
However, no other details are provided on how usual care was enhanced so we have assumed no
additional cost for enhanced usual care.
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Appendix 11 Tables of intervention and
comparator costs
TABLE 77 Cost of CBTLI delivered to individuals
First author and
year of publication Session facilitator
Face to face (F)
or distance (D)
Number of
sessions
Duration of
sessions
(minutes) Unit cost
Cost per
patient
Friedberg, 2013151 Nurse with CBT training F 2.00 60 CBT £211.64
Kennedy, 2005129 Nurse therapists (trained in
IBS-specific CBT)
F 6.00 50 CBT £529.09
Moss-Morris, 2010130 Psychologist Mix of F and D 3.00 60 CBT £317.45
Ridsdale, 2004113 CBT therapists F 6.00 45 CBT £476.18
Sumathipala, 2000116 Psychiatrist trained in CBT F 6.00 30 CBT £317.45
Tummers, 2012149 Psychiatric nurses trained
in CBT
D 13.00a NR CBT NE
NE, not estimable; NR, not reported.
a E-mails per patient.
TABLE 78 Cost of CBTLI delivered to groups
First author and
year of publication
Session
facilitator
Number of
sessions
Duration of
sessions
(minutes)
Total
individuals
started
Number of
groups Unit cost
Cost per
patient
Martin, 200799 Licensed CBT
professionalsa
1 210 60 20b CBT £123.45
a Clinical psychologist and medical specialist for psychotherapeutic medicine.
b Estimate-based group size reported as 2 to 4.
TABLE 79 Cost of CBTHI delivered to individuals
First author and
year of publication
Session
facilitator
Face to face (F)
or distance (D)
Number of
sessions
Duration of
sessions (minutes)
Unit
cost
Cost per
patient
Escobar, 2007156 Psychologist F 10.00 54a CBT £952.36
Gili, 2014144 Psychologist F 10.00 60 CBT £1058.18
McBeth, 2012125 Psychotherapist D 10 35b CBT £612.27
Ridsdale, 2001112 CBT therapist F 6 60 CBT £634.91
a Average across nine sessions lasting 50 minutes and one session lasting 90 minutes.
b Calculated based on mean time with therapist of 239.32 minutes and mean number of sessions attended of 6.82.
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TABLE 80 Cost of CBTHI delivered to groups
First author and
year of publication
Session
facilitator
Number of
sessions
Duration of
sessions (minutes)
Total
individuals
started
Number of
groups
Unit
cost
Cost per
patient
Alda, 2011137 CBT therapist 9 90 57 8a CBT £200.50
Gili, 2014
(group arm)144
Psychologist 10 120 64 7b CBT £231.48
Luciano, 2014138 Clinical
psychologist
8 150 51 4c CBT £165.99
Zonneveld, 2012141 Psychologist 13 120 145d 20 CBT £379.49
a Minimum number of groups to achieve reported maximum of eight per group.
b Minimum number of groups to achieve reported number of 8–10 per group.
c Estimated based on group size reported as 10 to 15.
d The reported total of 20 groups is assumed to cover those allocated to intervention (n= 81) and waiting list control
(n = 64) based on group size of 4 to 9.
TABLE 81 Cost of other psychotherapy delivered to individuals
First author and
year of publication Session facilitator
Face to face (F)
or distance (D)
Number of
sessions
Duration of
sessions
(minutes) Unit cost
Cost per
patient
Kolk, 2004104 Psychologists qualified
as therapists
F 12 60 CBTa £1269.82
Margalit, 2008268 Multidisciplinary
primary care team
F 7.3b 30 CBT £386.24
Posse, 200496 Psychotherapist F 26 60 CBT £2751.27
Ridsdale, 2001112 Qualified counsellors F 6 50 Counsellor £255.59
Ridsdale, 2012115 Counsellors Mixed 10 50 Counsellor £511.19
Ryan, 2004109 Clinical or health
psychology graduate
students
F 8 60 CBT £846.55
Schade, 2011272 Primary care staff F 2.86c 45d CBT £226.98
Wearden, 2010
(supportive listening)111
General nurses Mixed 10a 48e Nurse (GP) £412.80
a Therapists could use cognitive–behavioural, client-centred or eclectic therapy but the majority (43%) received CBT.
b Mean number of sessions reported in study.
c Calculated based on proportions receiving strategic approach (80.4%), counselling approach (12.6%) and information
only (7%) and mean number of sessions for each approach (three, three and one respectively).
d First session was 1 hour and subsequent sessions were 30 to 45 minutes.
e Average over one 90-minute session, four 60-minute sessions and five 30-minute sessions.
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TABLE 82 Cost of other psychotherapy delivered to groups
First author and year
of publication
Session
facilitator
Number of
sessions
Duration of
sessions
(minutes)
Total
individuals
started
Number of
groups Unit cost
Cost per
patient
Kocken, 2008103 Migrant health
worker
10.63a 84b 48 NR CBTc £289.81
McLeod, 1997105 Physicians, social
workers and
psychologists
6 NR 51 3 CBTd NE
van Ravesteijn, 2013143 Mindfulness
trainers
8 150 53 5 Mindfulness
trainer
£165.89
NE, not estimable; NR, not reported.
a Based on average number of sessions per person for counselling (3.2), attending GP visits (2.1), group education
(25 people attended an average of 6.3 sessions) or individual education (11 people had an average of 4.6 sessions).
b Estimate of duration of sessions obtained from personal correspondence with study author (T de Hoop, Municipal
Health Service Rotterdam Rijnmond, the Netherlands, 3 May 2017, personal communication); 2.5 hours for
education sessions, 30 minutes for individual counselling sessions and 10 minutes for GP consultations.
c CBT unit cost applied as no unit cost available for migrant health worker.
d CBT unit cost applied as the unit cost for CBT is an average across a similar range of professionals (specialty doctor
clinical psychologist and mental health nurse).
TABLE 83 Cost of GA delivered to individuals
First author and
year of publication Session facilitator
Face to face (F)
or distance (D)
Number of
sessions
Duration
of sessions
(minutes) Unit cost
Cost per
patient
Macedo, 2012
(GA)119
Physical therapists F 14 60 Physiotherapist £863.10
Macedo, 2012
(motor control)119
Physical therapists F 14 60 Physiotherapist £863.10
Marques, 2015133 Health psychologista F and D 4.00 60 Clinical
psychologist
£564.35
Moss-Morris, 2005152 Health psychologist F 12.00 60 Clinical
psychologist
£1693.05
Ridsdale, 2004113 Physiotherapist F 6 45 Physiotherapist £277.43
Ridsdale, 2012115 Physiotherapist F 10 32b Physiotherapist £323.66
Wearden, 2010111 General nurses F and D 10 41c Nurse (GP) £412.80
a Assumed to be delivered by health psychologists as described as being delivered by the researchers and authors are
both health psychologists.
b First session is 45 minutes and remainder are 30 minutes.
c Based on an average of 385 minutes per patient reported by Richardson 2013.282
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TABLE 84 Cost of SES interventions delivered to individuals
First author and
year of publication Session facilitator
Face to face (F)
or distance (D)
Number of
sessions
Duration
of sessions
(minutes) Unit cost
Cost per
patient
Lansinger, 2007123 Physiotherapist F 11a 60 Physiotherapist £678.15
McBeth, 2012125 Fitness instructor F 7 87b Physiotherapist £628.59
Sañudo, 2010 (aerobic)140 NR F 48.00 53c Physiotherapist £2589.30
Sañudo, 2010 (combined)140 NR F 48.00 53c Physiotherapist £2589.30
van der Roer, 2008340 Physiotherapist F 13.00d 60e Physiotherapist £801.45
Walti, 2015121 Physiotherapist F 8.00d 30 Physiotherapist £246.60
a Planned for 10 to 12 sessions so have assumed 11.
b Estimated based on total mean time of 520 minutes and mean number of sessions (5.95).
c Session duration reported as 45 to 60 minutes.
d Mean reported in study.
e Estimated based on cost of intervention and unit cost.
TABLE 85 Cost of SES interventions delivered to groups
First author and
year of publication Session facilitator
Number of
sessions
Duration
of sessions
(minutes)
Total
individuals
started
Number
of groups Unit cost
Cost per
patient
Peters, 2002106 Physiotherapist 20 60 87 9 Physiotherapist £127.55
TABLE 86 Cost of relaxation/stretching/social support/emotional support delivered to individuals
First author and
year of publication Session facilitator
Face to face (F)
or distance (D)
Number of
sessions
Duration of sessions
(minutes) Unit cost
Cost per
patient
Friedberg, 2013151 Nurse therapist
with CBT training
F 2.00 60a CBT £211.64
a Duration not reported but assumed same duration as intervention arm as this was intended as attention control.
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
428
TABLE 87 Cost of relaxation/stretching/social support/emotional support delivered to groups
First author and
year of publication
Session
facilitator
Number of
sessions
Duration
of sessions
(minutes)
Total
individuals
started
Number
of groups Unit cost
Cost per
patient
Ho, 2012150 qigong Master 10 120 33 1a Physiotherapist £37.36
Kashner, 1995161 ‘Masters-level
clinicians’
8 120 20 4b CBTc £338.62
Kobeissi, 2012110 Clinical
psychologists,
social workers
and physical
trainers
12 105d 99 10 Clinical psychologist,
social workers and
physiotherapist
£346.18
Lansinger, 2007123 Physiotherapist 12 60 60 5e Physiotherapist £61.65
Loew, 2000122
(eFR technique)
‘Therapists’ 1 45 27 7e Physiotherapist £11.99
Loew, 2000
(UIR technique)122
‘Therapists’ 1 45 27 7e Physiotherapist £11.99
Peters, 2002
(stretch)106
Physiotherapist 20 60 90 9 Physiotherapist £123.30
eFR, elements of functional relaxation; UIR, unspecific intervention technique.
a Assumed one group as number of groups not reported.
b Estimated based on group size of 4 to 6.
c Background of ‘Masters-level clinicians’ not provided so assumed same unit cost as CBT which has a unit cost based
on delivery by range of professionals including specialist nurses, clinical psychologists and psychiatrists.
d 75 minutes with clinical psychologist and social worker (group facilitator) and 30 minutes with physical trainer.
e Estimated based on reported number of participants per group.
TABLE 88 Cost of guided self-help delivered to individuals
First author and
year of publication
Session
facilitator
Face to face (F) or
distance (D)
Number of
sessions
Duration of
sessions (minutes) Unit cost
Cost per
patient
Chalder, 1997114 GP nurse F 1.00 12.5a Nurse (GP) £10.75
Cuesta-Vargas,
2012118
GPb F 2.00 60 GP (treat) £468.00
a Reported as 10 to 15 minutes.
b Described as a GP intervention so have assumed it was delivered by GPs.
Three studies were classified as guided self-help but did not include any face-to-face sessions and have therefore not
been included in this table (i.e. Ridsdale 2012,115 Robinson 2006,131 Marques 2015133).
TABLE 89 Cost of guided self-help delivered to groups
First author and
year of publication
Session
facilitator
Number of
sessions
Duration of
sessions (minutes)
Total
individuals
started
Number of
groups Unit cost
Cost per
patient
LeFort, 1998342 Nurse
delivered
6 120 52 6 Nurse (GP) £142.89
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TABLE 90 Cost of multimodal interventions delivered to groups
First author
and year of
publication Session facilitator
Number of
sessions
Duration
of sessions
(minutes)
Total
individuals
started
Number
of groups Unit cost
Cost per
patient
Luciano, 2011139 GPs, clinical
psychologist and
rheumatologist
9 120 98 6a GP (treat),
clinical
psychologist
and medical
consultant
£193.06
Robinson, 2006131 Trial co-ordinator 1 120 59 7a Nurse (GP) £12.24b
van der Roer,
2008340
Physiotherapist 30 68c 50 NR Physiotherapist £2088.06
a Estimated based on reported number of participants per group.
b Multimodal intervention included self-help group plus guidebook but guidebook costs are excluded as not estimable.
c Estimated based on intervention cost of €779 with unit cost of €23 (i.e. 34 hours of physiotherapist time
per patient).
TABLE 91 Cost of multimodal interventions delivered to individuals
First author and year
of publication Session facilitator
Face to face (F)
or distance (D)
Number of
sessions
Duration of
sessions
(minutes) Unit cost
Cost per
patient
Cuesta-Vargas, 2012118 Physiotherapist for
exercise and GP for
education
F 47 31a Physiotherapist
and GP (treat)
£1855.13
McBeth, 2012125 CBT therapist and
fitness instructor
F 17 56b CBT and
physiotherapist
£1221.18
Pols, 2008145 GP and service
co-ordinator
F 10c 10 GP (treat) £390.00
Smith, 2004107 Nurse practitioners F +D 24 28d Nurse
Practitioners
£892.43
Walti, 2015121 Physiotherapist F 8.6e 30 Physiotherapist £258.00
a Average over 45 sessions of exercise lasting 30 minutes and 2 sessions of education lasting 1 hour.
b Estimated based on total contact time reported (239.06 minutes for CBT and 512.33 for fitness instructor) and
mean number of session (as 7.17 with CBT and 5.82 with exercise).
c Described as sessions every 4 to 6 weeks for 1 year so assumed 1 session every 5 weeks.
d 12 scheduled face-to-face sessions of 20 minutes with a telephone session of 5 to 10 minutes between each face-to-face
session (= 20+(5+ 10)/2).
e Based on mean number of sessions reported as number of sessions not specified exactly (1 or 2 per week up to
maximum of 16).
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TABLE 92 Cost of GP interventions with training for GPs
First author and
year of publication
Number of GPs
allocated
Number of
training sessions
Duration
of sessions
(minutes)
Number of
patients Unit cost
Cost per
patient
Reattribution
Larisch, 2004a (modified
reattribution)158
20 2 360b 73 GP (train) £483.29
Morriss, 2007108 34 3 120 66 GP (train) £454.36
van der Feltz-Cornelis,
2006160
18 6 180 58c GP (train) £821.17
MUS management
Rief, 2006102 12 1 420 46 GP (train) £268.43
Rosendal, 2007146 22 7 214b 506 GP (train) £159.78
Schaefert, 2013147 17 4 233 145 GP (train) £289.06
Toft, 201097 20 7 214b 218 GP (train) £337.16
a Six sessions of 20 minutes were provided to patients but these were also provided in the control arm so these are
not costed.
b Sessions were of varying length so average duration reported here.
c Number enrolled in intervention arm has been used as fewer patients (n= 23) were enrolled per GP in this arm
once GPs were unblinded to their allocation which overinflates cost of this arm.
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TABLE 93 Cost of GP interventions with training for GPs and individual interventions for patients
First author and
year of publication
GP training GP contact with patients
Unit cost
Cost per
patient
Number
allocated
Number of
sessions
Duration of
sessions (minutes) Session facilitators
Number of
sessions
Duration of
sessions (minutes)
Reattribution
Aiarzaguena, 2007136 20 1 180 GP 6.00 29a GP (train and treat) £792.75
Aiarzaguena, 2007
(modified reattribution)136
19 5 240 GP 6.00 34a GP (train and treat) £1534.50
CBT
Huibers, 2004153 9 4 210 GP 5.30 33 GP (train and treat) £939.36
Other psychotherapy
Schilte, 2001159 3 NR NR GPs with training on
disclosureb
3c 69d GP (treat) £802.29b
MUS management
Whitehead 2002154 31 1 60 GP 9.60e 10 GP (train and treat) £549.76
Multimodal
Smith, 2009 (CBT and
pharmacological)343
4 6 240 GP and case managerf 14.00 28.12143 GP and CBT
(train and treat)
£2560.63
Sumathipala, 2008 (CBT,
reattribution and MUS
management)101
3 5 NR
g
GP 4.27 30 GP (treat) £499.59
g
van der Feltz-Cornelis,
2006 (collaborative care
plus reattribution)160
18 6 180 GP and psychiatrist 1.00 60 GP (train and treat),
psychiatrist
£1277.35
NR, not reported.
a Estimated from average total time and number of sessions.
b Duration of training not reported so not costed.
c Only 22 of 77 had the optional third session with both disclosure doctor and usual GP.
d Average time per session estimated taking into account that not all had third session (first lasted 2 hours, second lasted 1 hour, third lasted 30–60 minutes).
e GPs were advised to see patients weekly or bi-weekly to discuss diaries. Number of sessions is based on reported duration for diary use and reported mean time between sessions
of 3.2 weeks.
f Case manager was trained in CBT but no other information on clinical background provided.
g Described as a short course delivered in five sessions with ongoing supervision but no information on training session length or number or duration of supervision sessions. Cost
per patient excludes training for this reason.
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TABLE 95 Cost of GP interventions delivered to individuals
First author and
year of publication Session facilitator
Face to face (F)
or distance (D)
Number of
sessions
Duration of
sessions (minutes) Unit cost
Cost per
patient
Multimodal assessment and treatment
Rothman, 2013
(intervention)127
Multidisciplinary
assessment and
treatment
F 26.35a NR NE NE
Conventional assessment and treatment
Rothman, 2013
(control)127
Uni- or
multidisciplinary
F 26.56a NR NE NE
MUS management
Burton, 2012157 Specially trained
GP with special
interestb
F 4 30 GP £468.00
Sumathipala, 2008101 PCPs F 4.64 30 GP (treat) £542.88
NR, not reported; NE, not estimable because of insufficient details reported.
a Average based on reported number of sessions and numbers attending for different types of sessions.
b Intervention provided by a single GP who is described as ‘specially trained’ but no details are provided on the
training package and it does not appear to form part of the intervention.
TABLE 96 Cost of pharmacological interventions
First author and
year of publication Drugs and doses Unit cost Study period
Cost over
study
period
Alda, 2011137 Pregabalin (300 to 600mg per day)
and duloxetine (60 to 120mg per day)
(All were prescribed pregabalin but
only 50% were prescribed duloxetine)
£64.40 for 56 × pregabalin
300-mg capsules
£2.37 for 28 × duloxetine
60-mg gastro resistant
capsules
6 months £217.60
Luciano, 2014138 Pregabalin (300 to 600mg per day)
and duloxetine (60 to 120mg per day)
(All were prescribed pregabalin but
only 26.9% were prescribed
duloxetine)
£64.40 for 56 × pregabalin
300-mg capsules
£2.37 for 28 × duloxetine
60-mg gastro resistant
capsules
6 months £214.03
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
434
Appendix 12 Standardised mean
differences for individual studies and
for significant intervention groups
TABLE 97 Significant treatment effects for interventions compared with usual care
Outcome
End of treatment Short term Long term
Significant
intervention SMD (95% CrI)
Significant
intervention SMD (95% CrI)
Significant
intervention SMD (95% CrI)
Physical symptoms
Pain CBTHI 0.55
(0.28 to 0.87)
CBTHI 0.73
(0.10 to 1.39)
GSH –2.27
(–3.30 to –1.23
MM 0.48
(0.11 to 0.84)
Fatigue RSSEa 0.87
(0.20 to 1.55)
CBTLI 0.62
(0.11 to 1.14)
CBTLI 0.64
(0.05 to 1.20)
CBTLIa 0.72
(0.27 to 1.21)
MM 0.52
(0.14 to 0.92)
RSSE 0.51
(0.06 to 1.00)
GA 0.51
(0.14 to 0.93)
Bowel No NMA No NMA CBTLIa 0.84
(0.17 to 1.52)
Somatisation No significant effects No significant effects No significant effects
Generic physical
symptoms
No significant effects No NMA No NMA
Physical functioning and impact
Physical
functioning
MM 0.33
(0.09 to 0.59)
MM 0.78
(0.23 to 1.40)
No significant effects
GSHa –0.73
(–1.18 to –0.29)
Impact CBTHIa 1.30
(0.58 to 2.00)
CBTHIa 2.21
(1.28 to 3.14)
CBTLIa –0.91
(–1.58 to –0.24)
GSH –1.10
(–2.08 to –0.07)
Emotional distress
Anxiety CBTHI 0.52
(0.06 to 0.96)
CBTHI 0.74
(0.14 to 1.37)
No significant effects
Depression CBTHI 0.80
(0.26 to 1.38)
CBTHIa 0.93
(0.37 to 1.52)
No significant effects
continued
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TABLE 97 Significant treatment effects for interventions compared with usual care (continued )
Outcome
End of treatment Short term Long term
Significant
intervention SMD (95% CrI)
Significant
intervention SMD (95% CrI)
Significant
intervention SMD (95% CrI)
Emotional distress CBTHI 0.61
(0.04 to 0.71)
RSSE 0.82
(0.02 to 1.65)
GSHa –1.44
(–2.60 to –0.30)
OP 0.60
(0.13 to 1.05)
RSSEa 0.65
(0.23 to 1.21)
MM 0.43
(0.04 to 0.91)
SES 0.49
(0.13 to 0.94)
GSHa –1.03
(–1.83 to –0.14)
GSH, guided self-help; OP, other psychotherapy.
a Significant based on 95% PrI.
TABLE 98 The SMDs for individual studies: anxiety
First author
and year of
publication Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Marques, 2015133 Chronic fatigue 99 GSH vs. GA 0.25 (0.20) NR NR
Ridsdale, 2004113 Chronic fatigue 123 CBTLI vs. GA –0.30 (0.18) –0.27 (0.18) NR
Tummers, 2012149 Chronic fatigue 123 UC vs. CBTLI 0.15 (0.18) NR NR
Luciano, 2011139 Pain multisite 108 UC vs. MM 0.37 (0.14) NR NR
Moss-Morris, 2010130 IBS 64 UC vs. CBTLI –0.46 (0.25) –0.08 (0.25) –0.28 (0.25)
Escobar, 2007156 MUS/somatoform 172 UC+ vs. CBTHI 0.26 (0.15) NR 0.30 (0.15)
Kolk, 2004104 MUS/somatoform 106 UC vs. OP –0.01 (0.23) NR –0.34 (0.24)
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform 168 UC+ vs. CBTHI 0.50 (0.17) NR 0.90 (0.18)
Larisch, 2004158 MUS/somatoform 127 UC vs. GPRE –0.05 (0.18) –0.21 (0.18) –0.23 (0.18)
McLeod, 1997105 MUS/somatoform 96 UC vs. OP 0.32 (0.20) NR NR
Posse, 200496 MUS/somatoform 10 UC vs. OP 0.46 (0.58) NR NR
Wearden, 2010111 Chronic fatigue 296 UC vs. OP –0.18 (0.14) NR –0.14 (0.14)
UC vs. GA –0.09 (0.14) NR –0.13 (0.14)
Alda, 2011137 Pain multisite 169 UC vs. CBTHI 0.19 (0.19) NR NR
UC vs. ME 0.13 (0.19) NR NR
Luciano, 2014138 Pain multisite 156 UC vs. CBTHI 0.97 (0.21) NR
UC vs. ME 0.73 (0.20) NR
Ridsdale, 2001112 Chronic fatigue 160 CBTHI vs. OP NR –0.24 (0.16) NR
Rief, 2006102 MUS/somatoform 295 UC vs. GP-MM NR –0.39 (0.14) –0.03 (0.14)
Burton, 2012157 MUS/somatoform 32 UC vs. GP-MM NR 0.02 (0.35) NR
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TABLE 98 The SMDs for individual studies: anxiety (continued )
First author
and year of
publication Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Friedberg, 2013151 Chronic fatigue 111 UC vs. CBTLI NR 0.35 (0.23) 0.19 (0.23)
UC vs. RSSE NR 0.00 (0.23) 0.04 (0.23)
Ridsdale, 2012115 Chronic fatigue 222 OP vs. GSH NR –0.05 (0.16) NR
OP vs. GA NR 0.25 (0.17) NR
Schilte, 2001159 MUS/somatoform 161 UC vs. GP-OP NR NR 0.18 (0.16)
Rothman, 2013127 Pain multisite 220 UC+ vs. GP-O NR NR –0.10 (0.14)
Alda, 2011137 Pain multisite 169 UC vs. CBTHI NR NR 0.13 (0.19)
UC vs. ME NR NR 0.08 (0.19)
GP-MM, GP-delivered MUS management; GP-O, GP – other; GPRE, GP-delivered reattribution; GSH, guided self-help;
ME, medication; NR, not reported; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
TABLE 99 The SMDs for individual studies: bowel symptoms
Study Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Moss-Morris, 2010130 IBS 64 UC vs. CBTLI NR NR 0.84 (0.26)
Robinson, 2006131 IBS 420 UC vs. GSH NR NR 0.16 (0.12)
GSH, guided self-help; NR, not reported; UC, usual care.
TABLE 100 The SMDs for individual studies: depression
Study Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Ridsdale, 2004113 Chronic fatigue 123 CBTLI vs. GA –0.19 (0.18) –0.04 (0.18) NR
Luciano, 2011139 Pain multisite 108 UC vs. MM 0.36 (0.14) NR
Moss-Morris, 2010130 IBS 64 UC vs. CBTLI –0.03 (0.25) 0.29 (0.25) 0.35 (0.25)
Escobar, 2007156 MUS/somatoform 172 UC+ vs. CBTHI 0.22 (0.15) NR 0.17 (0.15)
Kolk, 2004104 MUS/somatoform 106 UC vs. OP –0.10 (0.23) NR –0.31 (0.23)
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform 168 UC+ vs. CBTHI 0.29 (0.17) NR 0.80 (0.18)
Martin, 200799 MUS/somatoform 140 UC vs. CBTLI –0.14 (0.17) NR –0.27 (0.17)
van Ravesteijn, 2013143 MUS/somatoform 125 UC+ vs. OP 0.05 (0.18) NR 0.07 (0.18)
Larisch, 2004158 MUS/somatoform 127 UC vs. GPRE 0.02 (0.18) –0.29 (0.18) –0.23 (0.18)
McLeod, 1997105 MUS/somatoform 96 UC vs. OP 0.57 (0.21) NR NR
Wearden, 2010111 Chronic fatigue 296 UC vs. OP –0.09 (0.14) NR –0.13 (0.14)
UC vs. GA 0.28 (0.14) NR 0.04 (0.14)
Alda, 2011137 Pain multisite 169 UC vs. CBTHI 0.16 (0.19) NR NR
UC vs. ME 0.09 (0.19) NR NR
continued
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TABLE 100 The SMDs for individual studies: depression (continued )
Study Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Luciano, 2014138 Pain multisite 156 UC vs. CBTHI 1.85 (0.23) NR
UC vs. ME 0.74 (0.20) NR
Ridsdale, 2001112 Chronic fatigue 160 CBTHI vs. OP NR 0.02 (0.16) NR
Rief, 2006102 MUS/somatoform 295 UC vs. GP-MM NR –0.15 (0.14) 0 (0.14)
Burton, 2012157 MUS/somatoform 32 UC vs. GP-MM NR –0.18 (0.35) NR
Friedberg, 2013151 Chronic fatigue 111 UC vs. CBTLI NR 0.25 (0.23) –0.08 (0.23)
UC vs. RSSE NR –0.02 (0.23) –0.05 (0.23)
Ridsdale, 2012115 Chronic fatigue 222 OP vs. GSH NR 0.16 (0.16) NR
OP vs. GA NR 0.09 (0.16) NR
Schilte, 2001159 MUS/somatoform 161 UC vs. GP-OP NR NR –0.03 (0.16)
Rothman, 2013127 Pain multisite 220 UC+ vs. GP-O NR NR 0 (0.15)
LeFort, 1998128 Pain multisite 110 UC vs. GSH NR 0.16 (0.19) NR
Kobeissi, 2012110 MUVD 271 UC vs. RSSE NR 0.10 (0.12) NR
Schaefert, 2013132 MUS/somatoform 328 GP-MM vs. MM NR 0.30 (0.11) 0.34 (0.11)
Smith, 2009142 MUS/somatoform 30 UC vs. MM NR NR 0.79 (0.37)
GP-MM, GP-delivered MUS management; GP-O, GP – other; GPRE, GP-delivered reattribution; GSH, guided self-help;
ME, medication; MUVD, medically unexplained vaginal discharge; NR, not reported; OP, other psychotherapy; UC, usual
care; UC+, usual care plus.
TABLE 101 The SMDs for individual studies: emotional distress
Study Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Cuesta-Vargas, 2011 Pains singles site 58 GSH vs. MM 1.36 (0.29) 1.40 (0.29) 2.00 (0.32)
Ho, 2012150 Chronic fatigue 64 UC vs. RSSE 1.09 (0.25) 0.82 (0.25) NR
LeFort, 1998128 Pain multisite 110 UC vs. GSH NR 0.38 (0.19) NR
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue 151 UC vs. GP-CBT 0.14 (0.16) NR 0.02 (0.16)
Marques, 2015133 Chronic fatigue 99 GSH vs. GA 0.51 (0.20) NR NR
Peters, 2002106 MUS/somatoform 228 RSSE vs. SES 0.02 (0.13) NR NR
Sumathipala, 2008117 MUS/somatoform 150 GP-MM vs. MM 0.08 (0.16) 0.11 (0.16) 0.01 (0.16)
van Ravesteijn, 2013143 MUS/somatoform 68 UC+ vs. OP 0.35 (0.18) NR 0.02 (0.18)
Zonneveld, 2012141 MUS/somatoform 162 UC vs. CBTHI 0.44 (0.16) NR NR
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform 168 UC+ vs. CBTHI –0.06 (0.17) NR 0.61 (0.17)
Kocken, 2008103 MUS/somatoform 104 UC+OP 0.49 (0.20) NR NR
Larisch, 2004158 MUS/somatoform 127 UC vs. GPRE –0.15 (0.18) –0.12 (0.18) –0.38 (0.18)
Rosendal, 2007146 MUS/somatoform 506 UC vs. GP-MM NR –0.10 (0.07) NR
Schaefert, 2013132 MUS/somatoform 328 GP-MM vs. MM NR 0.38 (0.11) 0.31 (0.11)
van der Feltz-Cornelis
2006160
MUS/somatoform 81 GPRE vs. MM NR 0.76 (0.25) 0.96 (0.26)
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TABLE 101 The SMDs for individual studies: emotional distress (continued )
Study Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Kennedy, 2005129 IBS 149 ME vs. MM 0.43 (0.17) 0.49 (0.17) 0.41 (0.16)
Chalder, 1997114 Chronic fatigue 150 UC vs. GSH NR 0.28 (0.16) NR
Sumathipala, 2000116 MUS/somatoform 68 UC vs. CBTLI 0.61 (0.25) NR NR
McBeth, 2012125 Pain multisite 442 UC vs. CBTHI 0.29 (0.14) 0.34 (0.14) NR
UC vs. SES 0.31 (0.14) 0.23 (0.14) NR
UC vs. MM 0.25 (0.14) 0.19 (0.13) NR
Burton, 2012157 MUS/somatoform 32 UC vs. GP-MM NR –0.35 (0.16) NR
GP-MM, GP-delivered MUS management; GPRE, GP-delivered reattribution; GSH, guided self-help; ME, medication;
NR, not reported; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
TABLE 102 The SMDs for individual studies: fatigue
Fatigue
Study Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Ho, 2012150 Chronic fatigue 64 UC vs. RSSE 0.88 (0.25) 1.08 (0.25) NR
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue 151 UC vs. GP-CBT 0.12 (0.16) NR –0.12 (0.16)
Marques, 2015133 Chronic fatigue 99 GSH vs. GA 0.60 (0.20) NR NR
Moss-Morris, 2005152 Chronic fatigue 49 UC vs. GA 1.00 (0.30) NR NR
Ridsdale, 2004113 Chronic fatigue 123 CBTLI vs. GA –0.20 (0.18) –0.06 (0.18) NR
Tummers, 2012149 Chronic fatigue 123 UC vs. CBTLI 0.75 (0.19) NR NR
Chalder, 1997114 Chronic fatigue 150 UC vs. GSH NR 0.39 (0.16) NR
Luciano, 2011139 Pain multisite 108 UC vs. MM 0.32 (0.14) NR NR
McBeth, 2012125 Pain multisite 442 UC vs. CBTHI 0.34 (0.14) 0.37 (0.14) 0.19 (0.13)
UC vs. SES 0.43 (0.14) 0.40 (0.14) 0.20 (0.14)
UC vs. MM 0.72 (0.14) 0.51 (0.14) 0.21 (0.13)
Wearden, 2010111 Chronic fatigue 296 UC vs. OP –0.12 (0.14) NR 0.03 (0.14)
UC vs. GA 0.27 (0.14) NR 0.24 (0.14)
Ridsdale, 2001112 Chronic fatigue 160 CBTHI vs. OP NR 0.07 (0.16) NR
Friedberg, 2013151 Chronic fatigue 111 UC vs. CBTLI NR 0.43 (0.23) 0.62 (0.23)
UC vs. RSSE NR 0.05 (0.23) 0.08 (0.23)
Ridsdale, 2012115 Chronic fatigue 222 OP vs. GSH NR 0.11 (0.16) 0.17 (0.16)
OP vs. GA NR 0.19 (0.16) 0.09 (0.16)
GSH, guided self-help; NR, not reported; OP, other psychotherapy; UC, usual care.
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TABLE 104 The SMDs for individual studies: impact of illness on daily activities
Study Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Walti, 2015121 Pain single site 28 SES vs. MM –0.41 (0.37) NR NR
Sañudo, 2010140 Pain multisite 64 UC vs. SES –0.48 (0.26) NR NR
Kennedy, 2005129 IBS 149 ME vs. MM –0.4 (0.17) –0.46 (0.17) –0.26 (0.17)
Ridsdale, 2004113 Chronic fatigue 123 CBTLI vs. GA NR 0 (0.18) NR
Luciano, 2011139 Pain multisite 108 UC vs. MM 0.48 (0.14) NR NR
Moss-Morris, 2010130 IBS 64 UC vs. CBTLI –0.78 (0.26) –0.84 (0.26) –0.90 (0.26)
Kocken, 2008103 MUS/somatoform 104 UC+OP 0.54 (0.20) NR NR
Cuesta-Vargas,
2012118
Pain single site 58 GSH vs. MM 0.78 (0.27) 1.17 (0.28) 0.92 (0.27)
LeFort, 1998128 Pain multisite 110 UC vs. GSH NR 0.69 (0.20) NR
Alda, 2011137 Pain multisite 169 UC vs. CBTHI –0.28 (0.19) NR 0.05 (0.19)
UC vs. ME 0.30 (0.19) NR 0.53 (0.19)
Luciano, 2014138 Pain multisite 156 UC vs. CBTHI NR
UC vs. ME NR
Ridsdale, 2012115 Chronic fatigue 222 OP vs. GSH NR 0.23 (0.16) NR
OP vs. GA NR 0.15 (0.16) NR
GSH, guided self-help; ME, medication; NR, not reported; OP, other psychotherapy; UC, usual care.
TABLE 103 The SMDs for individual studies: generic physical symptoms
Study Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Kolk, 2004104 MUS/somatoform 106 UC vs. OP –0.30 (0.24) NR NR
Posse, 200496 MUS/somatoform 10 UC vs. OP –0.04 (0.57) NR NR
OP, other psychotherapy; NR, not reported; UC, usual care.
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TABLE 105 The SMDs for individual studies: pain
Study Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Cuesta-Vargas, 2012118 Pain single site 58 GSH vs. MM 0.97 (0.27) 1.69 (0.30) 2.12 (0.32)
LeFort, 1998128 Pain multisite 110 UC vs. GSH NR 0.54 (0.19) NR
Rosendal, 2007146 MUS/somatoform 506 UC vs. GP-MM NR –0.11 (0.07) –0.15 (0.07)
Schaefert, 2013132 MUS/somatoform 328 GP-MM vs. MM NR 0.05 (0.11) –0.01 (0.11)
Rothman, 2013127 Pain multisite 220 UC+ vs. GP-O NR NR 0.12 (0.14)
Walti, 2015121 Pain single site 28 SES vs. MM –0.40 (0.37) NR
van Ravesteijn, 2013143 MUS/somatoform 125 UC+ vs. OP –0.24 (0.18) NR –0.13 (0.18)
Zonneveld, 2012141 MUS/somatoform 162 UC vs. CBTHI 0.51 (0.16) NR NR
Peters, 2002106 MUS/somatoform 228 RSSE vs. SES 0.06 (0.13) NR NR
Luciano, 2011139 Pain multisite 108 UC vs. MM 0.62 (0.14) NR NR
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform 168 UC+ vs. CBTHI 0.21 (0.17) NR 0.37 (0.17)
Alda, 2011137 Pain multisite 169 UC vs. CBTHI 0.17 (0.19) NR 0.41 (0.19)
UC vs. ME 0.23 (0.19) NR 0.37 (0.19)
Luciano, 2014138 Pain multisite 156 UC vs. CBTHI NR
UC vs. ME NR
McBeth, 2012125 Pain multisite 442 UC vs. CBTHI 0.35 (0.14) 0.28 (0.14) NR
UC vs. SES 0.20 (0.14) 0.19 (0.14) NR
UC vs. MM 0.34 (0.14) 0.17 (0.13) NR
GP-MM, GP-delivered MUS management; GP-O, GP – other; GSH, guided self-help; ME, medication; MUVD, medically
unexplained vaginal discharge; NR, not reported; OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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TABLE 106 The SMDs for individual studies: physical functioning
Study Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Marques, 2015133 Chronic fatigue 99 GSH vs. GA 0.70 (0.21) NR NR
Cuesta-Vargas, 2012118 Pain single site 58 GSH vs. MM 1.11 (0.28) 1.94 (0.31) 3.27 (0.40)
Ho, 2012150 Chronic fatigue 64 UC vs. RSSE 0.12 (0.24) 0.36 (0.24) NR
LeFort, 1998128 Pain multisite 110 UC vs. GSH NR 0.27 (0.19) NR
Huibers, 2004/
Leone, 2006153,155
Chronic fatigue 151 UC vs. GP-CBT –0.32 (0.16) NR –0.32 (0.16)
Rosendal, 2007146 MUS/somatoform 506 UC vs. GP-MM NR 0.01 (0.07) –0.01 (0.07)
Schaefert, 2013132 MUS/somatoform 328 GP-MM vs. MM NR 0.23 (0.11) 0.13 (0.11)
Chalder, 1997114 Chronic fatigue 150 UC vs. GSH NR 0.26 (0.16) NR
Tummers, 2012149 Chronic fatigue 123 UC vs. CBTLI 0.25 (0.18) NR NR
Luciano, 2011139 Pain multisite 108 UC vs. MM 0.29 (0.14) NR NR
van Ravesteijn, 2013143 MUS/somatoform 125 UC+ vs. OP –0.16 (0.18) NR –0.17 (0.18)
Zonneveld, 2012141 MUS/somatoform 162 UC vs. CBTHI 0.39 (0.16) NR NR
Peters, 2002106 MUS/somatoform 228 RSSE vs. SES –0.08 (0.13) NR –0.09 (0.13)
Escobar, 2007156 MUS/somatoform 172 UC+ vs. CBTHI 0.09 (0.15) NR 0.12 (0.15)
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform 168 UC+ vs. CBTHI 0.61 (0.17) NR 0.83 (0.18)
Larisch, 2004158 MUS/somatoform 127 UC vs. GPRE 0.21 (0.18) –0.01 (0.18) 0.17 (0.18)
Smith, 2009142 MUS/somatoform 30 UC vs. MM NR NR 0.53 (0.36)
Smith, 2006107 MUS/somatoform 206 UC vs. MM NR NR 0.32 (0.14)
Wearden, 2010111 Chronic fatigue 296 UC vs. OP –0.28 (0.14) NR –0.15 (0.14)
UC vs. GA –0.01 (0.14) NR 0.12 (0.14)
McBeth, 2012125 Pain multisite 442 UC vs. CBTHI 0.15 (0.13) 0.11 (0.13) NR
UC vs. SES 0.03 (0.13) 0.23 (0.14) NR
UC vs. MM 0.32 (0.13) 0.31 (0.14) NR
Burton, 2012157 MUS/somatoform 32 UC vs. GP-MM NR 0.61 (0.35) NR
Friedberg, 2013151 Chronic fatigue 111 UC vs. CBTLI NR 0.42 (0.23) 0.35 (0.23)
UC vs. RSSE NR 0.09 (0.23) 0.36 (0.23)
GP-MM, GP-delivered MUS management; GPRE, GP-delivered reattribution; GSH, guided self-help; NR, not reported;
OP, other psychotherapy; UC, usual care; UC+, usual care plus.
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TABLE 107 The SMDs for individual studies: somatisation
Study Condition Number
Intervention
groups
End of treatment
SMD (SE)
Short-term
SMD (SE)
Long-term
SMD (SE)
Zonneveld, 2012141 MUS/somatoform 162 UC vs. CBTHI 0.23 (0.16) NR NR
Peters, 2002106 MUS/somatoform 228 RSSE vs. SES 0.01 (0.13) NR NR
Kobeissi, 2012110 MUVD 271 UC vs. RSSE 0.05 (0.12) NR NR
van Ravesteijn, 2013143 MUS/somatoform 125 UC+ vs. OP 0.31 (0.18) NR 0.15 (0.18)
Martin, 200799 MUS/somatoform 140 UC vs. CBTLI –0.13 (0.17) NR –0.23 (0.17)
Sumathipala, 2000116 MUS/somatoform 68 UC vs. CBTLI 0.41 (0.24) NR NR
Escobar, 2007156 MUS/somatoform 172 UC+ vs. CBTHI 0.35 (0.15) NR 0.32 (0.15)
Kolk, 2004104 MUS/somatoform 106 UC vs. OP 0.15 (0.23) NR 0.15 (0.23)
Gili, 2014/
Moreno, 2013144,148
MUS/somatoform 168 UC+ vs. CBTHI 0.77 (0.18) NR 0.66 (0.17)
Larisch, 2004158 MUS/somatoform 127 UC vs. GPRE 0.20 (0.18) –0.12 (0.18) –0.02 (0.18)
McLeod, 1997105 MUS/somatoform 96 UC vs. OP 0.45 (0.21) NR NR
Sumathipala, 2008117 MUS/somatoform 150 GP-MM vs. MM NR 0.03 (0.16) –0.01 (0.16)
Rosendal, 2007146 MUS/somatoform 506 UC vs. GP-MM NR 0 (0.07) 0 (0.07)
Schaefert, 2013132 MUS/somatoform 328 GP-MM vs. MM NR 0.39 (0.11) 0.20 (0.11)
Rief, 2006102 MUS/somatoform 295 UC vs. GP-MM NR –0.28 (0.14) –0.18 (0.14)
Burton, 2012157 MUS/somatoform 32 UC vs. GP-MM NR 0.28 (0.35)
Schilte, 2001159 MUS/somatoform 161 UC vs. GP-OP NR NR 0 (0.16)
GP-MM, GP-delivered MUS management; GPRE, GP-delivered reattribution; NR, not reported; OP, other psychotherapy;
UC, usual care; UC+, usual care plus.
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Appendix 13 Inconsistency check for
network meta-analysis
F igures 75–84 show the contributions to the deviance for both consistency model and inconsistencymodel. When the points are close to the line of equality, it suggests that there is no evidence to
suggest inconsistency in the network. The number next to the point indicates the study where
potential inconsistency may exist.
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FIGURE 75 Individual data points’ posterior mean deviance contributions for the consistency model and the inconsistency
model along with the line of equality: (a) post treatment; (b) short term; and (c) long term. Note: at short term, 1 is for
Cuesta-Vargas et al.118 comparing guided self-help with multimodal; 5 is for Luciano et al.138 comparing usual care with
medication and CBTHI.
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Fatigue
Bowel symptoms
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FIGURE 76 Individual data points’ posterior mean deviance contributions for the consistency model and the inconsistency
model along with the line of equality: (a) post treatment; (b) short term; and (c) long term. Note: at short term, 1 is for
Ho et al.150 comparing usual care with RSSE.
0
0
1
2
3
4
5
1 2 3
Consistency model
In
co
n
si
st
e
n
cy
 m
o
d
e
l
4 5
FIGURE 77 Individual data points’ posterior mean deviance contributions for the consistency model and the inconsistency
model along with the line of equality: long term.
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Somatisation
Generic physical symptoms
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FIGURE 78 Individual data points’ posterior mean deviance contributions for the consistency model and the inconsistency
model along with the line of equality: (a) post treatment; (b) short term; and (c) long term.
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FIGURE 79 Individual data points’ posterior mean deviance contributions for the consistency model and the inconsistency
model along with the line of equality: post treatment.
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Physical functioning
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FIGURE 80 Individual data points’ posterior mean deviance contributions for the consistency model and the inconsistency
model along with the line of equality: (a) post treatment; (b) short term; and (c) long term. Note: at short term, 1 is for
Cuesta-Vargas et al.118 comparing guided self-help with multimodal; 8 is for Burton et al.157 comparing usual care with GP
MUS management.
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Impact
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FIGURE 81 Individual data points’ posterior mean deviance contributions for the consistency model and the inconsistency
model along with the line of equality: (a) post treatment; (b) short term; and (c) long term. Note: at short term, 4 is for
Cuesta-Vargas et al.118 comparing guided self-help with multimodal.
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Emotional distress
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FIGURE 82 Individual data points’ posterior mean deviance contributions for the consistency model and the inconsistency
model along with the line of equality: (a) post treatment; (b) short term; and (c) long term. Note: at post treatment, 2 is for
Ho et al.150 comparing usual care with RSSE; at short term 1 is for Cuesta-Vargas et al.118 comparing guided self-help with
multimodal.
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FIGURE 83 Individual data points’ posterior mean deviance contributions for the consistency model and the inconsistency
model along with the line of equality: (a) post treatment; (b) short term; and (c) long term.
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Depression
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FIGURE 84 Individual data points’ posterior mean deviance contributions for the consistency model and the inconsistency
model along with the line of equality: (a) post treatment, (b) short term; and (c) long term. Note: at short term 12 is
Luciano et al.138 comparing usual care with medication and CBTHI.
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Appendix 14 Update of the review
An update of all the searches was conducted in order to identify new studies published since theoriginal searches. This appendix describes the updated search strategies for each review: clinical
effectiveness, qualitative and cost-effectiveness. The realist synthesis was also updated. All results
are presented in this appendix as a narrative synthesis. No additional statistical analyses have
been undertaken.
Update search strategies
Clinical effectiveness
An updated search was carried out in February 2019 on the same databases as the original search,
excluding DARE, which is no longer updated (from April 2015). The search strategies and search
filters from the original searches were used. Searches were limited to November 2015 onwards
when possible.
Qualitative
An updated search was carried out in February 2019 on the same databases as the original search.
The search strategies and search filters from the original searches were used. Searches were limited to
July 2016 onwards when possible.
Economic
An update search was run in March 2019 on the same databases as the original search, excluding NHS
Economic Evaluation Database, which is no longer updated (from April 2015). The search strategies
and search filters from the original searches were used. Searches were limited to August 2016
onwards when possible.
Full details of these amendments are detailed below for each database.
MEDLINE
l Clinical Effectiveness: AND (2015 11* or 2015 12* or 2016* or 2017* or 2018* or 2019*).dt
l Qualitative: (2016 07* or 2016 08* or 2016 09* or 2016 10* or 2016 11* or 2016 12* or 2017* or
2018* or 2019*).dt.
l Economic: (2016 08* or 2016 09* or 2016 10* or 2016 11* or 2016 12* or 2017* or 2018*
or 2019*).dt
EMBASE
l Clinical Effectiveness: AND (2015 11* or 2015 12* or 2016* or 2017* or 2018* or 2019*).dc.
l Qualitative: (2016 07* or 2016 08* or 2016 09* or 2016 10* or 2016 11* or 2016 12* or 2017* or
2018* or 2019*).dc.
l Economic: (2016 08* or 2016 09* or 2016 10* or 2016 11* or 2016 12* or 2017* or 2018*
or 2019*).dc
CINAHL
l Clinical Effectiveness: Limiters – Published Date: 11 January 2015–31 December 2019
l Qualitative: Limiters – Published Date: 7 January 2016–31 December 2019
l Economic: Limiters – Published Date: 8 January 2016–31 December 2019
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PsycINFO
l Clinical Effectiveness: limit to yr=“2015 -Current”
l Qualitative: limit 115 to yr=“2016 -Current”
l Economic: limit 141 to yr=“2016 -Current”
Cochrane
Clinical effectiveness:
l Note that #75 was edited to (somatisation or somatization):ti,ab because of database changes
(the original #75 when re-run retrieved over 1 million records).
l CDSR: the Cochrane Library publication date between November 2015 and February 2019.
l CENTRAL: publication year from 2015 to 2019, in Trials.
l Note that the HTA database was searched via the CRD website at: https://www.crd.york.ac.uk/
CRDWeb/ because it was no longer accessible via the Cochrane Library. Limits applied: * WHERE LPD
FROM 01/11/2015 TO 07/03/2019 (note the HTA database has not been updated since 31/03/2018).
Web of Science
l Clinical Effectiveness: Indexes=SCI-EXPANDED, SSCI Timespan=2015-2019.
l Qualitative: Indexes=SCI-EXPANDED, SSCI Timespan=2016-2019.
l Economic: Timespan: 2016-2019. Indexes: SCI-EXPANDED, SSCI.
Update of clinical effectiveness studies
This section provides an overview of the clinical effectiveness literature published since the original
searches were performed. In addition, new evidence on the effectiveness of behavioural interventions
for MUS is outlined. The review methods applied were consistent with those reported in Chapter 3,
with the exception that only a narrative synthesis of newly included studies is presented. No additional
statistical analyses have been conducted. A second reviewer (AS) has checked data extractions and
quality assessments for included studies. The results of the review update are presented below.
Results
A total of 3192 unique citations were identified in the searches. There were 132 remaining after the
title and abstract sift, and these citations were considered at full-paper sift for the clinical effectiveness
review update. Figure 85 shows the flow chart of studies included in the clinical effectiveness review
update. The sifting process resulted in the inclusion of two published studies328,517 and one unpublished
study.373,374 Details of studies excluded at full-paper sift together with reasons are shown in Table 127.
All data from O’Dowd373,374 are taken from the protocol registered on the ISRCTN trial registry, with
outcome data retrieved from an additional file uploaded to the registry on 27 March 2019. Data were
accessed on 2 May 2019. Further information was obtained from a previous freedom of information
request published in 2016. Although only three new studies were identified, several potentially relevant
protocols have been registered since the original searches. No published studies of any of the functional
somatic syndromes were identified, although the O’Dowd373,374 study is in a population of patients with
chronic fatigue. Reasons for exclusion of these studies were often that, although the focus of the study
was a behavioural intervention, these were conducted in secondary care settings. Many studies of
chronic pain were identified; however, none is included as they did not meet the inclusion criteria for
‘unexplained’. Eligibility criteria for studies of behavioural interventions for chronic pain often specified
persistence/duration of pain, but did not exclude by cause (other than severe pathology/cancer). The
three included studies were relatively small. Larger-scale studies were identified but these tended to be
cohort studies rather than randomised controlled trials.
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Two of the three studies were randomised controlled trials of populations of patients with ‘MUS’,328,517
and the remaining study373,374 was for patients with unexplained fatigue, randomising a total of 161
participants. Wortman517 was a pilot feasibility study of a brief multimodal psychosomatic therapy
delivered by physiotherapists and exercise therapists in primary care. Ziadni et al.328 was a trial of a
life stress, emotional awareness and expression interview for primary care patients. In both studies,
the interventions were compared with usual care. Tables 108–117 present the study characteristics of
the two trials. Although both studies were of patients with ‘MUS’, diagnostic criteria were different
between studies. Wortman et al.517 required participants to consult with their primary care physician
more than once with one of a specified range of symptoms where a cause could not be found,
whereas Ziadni et al.328 required a score of > 10 on the PHQ-15 with no known cause of the
symptoms identified. The behavioural intervention delivered in the trial by Ziadni et al.328 was a
one-off 90-minute interview, whereas the trial by Wortman et al.517 delivered the intervention over
a maximum of nine 45-minute sessions. The unpublished study by O’Dowd373,374 investigated the
feasibility and acceptability of an early intervention based on the principles of cognitive–behavioural
therapy and graded exercise for primary care patients with fatigue of duration 1–4 months. Eligible
patients were identified by their GP. The intervention included a 1-hour appointment with a fatigue
specialist, an information booklet and three 20-minute telephone support sessions, and was compared
with standard care by a GP.
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FIGURE 85 The 2009 PRISMA flow diagram: updated clinical effectiveness review.
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TABLE 108 The description of interventions for included studies
First author
and year of
publication Condition Intervention Intervention description Grouping
Wortman, 2016517 MUS/SD Brief multimodal
psychosomatic
therapy
Multicomponent approach focusing on the
combination of physical, psychological and
behavioural symptoms of stress in order to
reduce bodily symptoms and to empower
patients to assert control over factors that affect
their health. Consists of (1) psychoeducation,
(2) relaxation therapy and mindfulness,
(3) cognitive–behavioural approaches and
(4) activation therapy
MM
Usual care Usual care provided by the GP and other HPs UC
Ziadni, 2018328 MUS/SD Life stress, emotional
awareness and
expression interview
An interview aimed to help patients with MUS to:
1. disclose stressful experiences and emotional
conflicts that might be contributing to
their symptoms
2. explore associations between their stress and
physical symptoms
3. experience and express their emotions related
to these stressful experiences.
Four phases consisted of (1) review of lifetime
medical symptoms, (2) review of life stress and
emotional conflicts, (3) emotional awareness and
expression exercises and (4) summary and discussion
OP
Treatment as usual ‘Delayed interview’: treatment as usual until follow-up
measures complete, then offered the intervention
UC
O’Dowd,
unpublished373,374
Unexplained
fatigue
Early intervention A package of advice and support that could be
offered early, for patients with a short history of
fatigue (1–4 months). The intervention was based
on the principles of CBT and graded exercise
Uncleara
Standard care Standard care by a GP UC
MM, multimodal; OP, other psychotherapy; SD, somatoform disorder; UC, usual care.
a Insufficient information available on the nature of the intervention to be able to assign to an intervention group.
Contact was made with the author but we were unable to obtain additional information.
TABLE 109 The diagnostic criteria used in individual studies
First author
and year of
publication Condition Diagnostic criteria Diagnosis by
Wortman, 2016517 MUS/SD Patients consulting their practice more than once for one or
more of the following where no organic pathology could be
found: stomach/abdominal pain, back/neck/shoulder pain, pain in
arms/legs/joints, headache, chest pain, dizziness, fainting spells,
palpitations of the heart, shortness of breath, nausea/indigestion,
feeling tired and sleeping disorders
GP
Ziadni, 2018328 MUS/SD Patients scoring > 10 (moderate) on the PHQ-15, with exclusion
of disease or injury that might account for elevated somatic
symptoms
Primary care
clinicians + study
researcher
O’Dowd,
unpublished373,374
Unexplained
fatigue
Patients presenting with an unexplained primary complaint of
fatigue, as a new episode, lasting > 1 month but < 4 months.
Score of > 4 on the Chalder Fatigue Scale
GP+ trial
manager
GP, general practitioner; SD, somatoform disorder.
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Tables 118–126 report the outcomes measured in the three trials, with their associated means/SDs
across follow-up time points. Ziadni et al.328 and Wortman et al.517 measured emotional distress. Both
studies reported significant improvements for participants receiving the behavioural interventions
compared with usual care. For other outcomes, Ziadni et al.328 and O’Dowd373,374 measured pain;
Wortman et al.517 and O’Dowd373,374 measured anxiety, depression and physical functioning; whereas
Wortman et al.517 was the only study to measure symptom severity and somatisation. Ziadni et al.328
reported significant improvements for both pain and emotional distress. Wortman et al.,517 although
not powered to detect treatment effects, reported the potential for their intervention to achieve
significant improvements in symptoms. Only Wortman et al.517 measured patient satisfaction, reporting
that 81% of patients were very satisfied with treatment; however, two patients were dissatisfied and
disappointed with the treatment.
Risk of bias
Risk of bias in the included studies was explored using the Cochrane risk-of-bias tool.87 Individual risk-
of-bias summaries are presented in Update of the cost-effectiveness review. As the O’Dowd373,374 study is
unpublished, study information was obtained from what was available publicly, and this was insufficient
to complete most of the risk-of-bias tool, although a high risk of bias was found for attrition, with a
32% attrition rate. For the remaining trials, neither study blinded participants to the treatment nor
reported assessor blinding. Wortman et al.517 reported an attrition rate of 20%, which represented a
high risk of bias. Both studies demonstrated adequate randomisation procedures.
TABLE 110 Primary and secondary outcomes for individual studies
First author
and year of
publication Condition Primary outcomes Secondary outcomes
Wortman,
2016517
MUS/SD Patient satisfaction with received therapy: five-point Likert scale (dissatisfied to
very satisfied)
Perceived symptom severity: VAS range 0–10 where 10 represents most severe
symptoms
Distress: self-rated symptoms of distress, depression, anxiety and somatisation –
Four-Dimensional Symptom Questionnaire
Hyperventilation: Nijmegen Hyperventilation List (NHL)518
Physical and mental health status and quality of life: SF-36519
Ziadni, 2018328 MUS/SD Pain severity: Brief Pain
Inventory – Short
Form448
Pain interference: Brief
Pain Inventory – Short
Form448
Sleep problems: Insomnia Severity Index520
Psychological symptoms: Brief Symptom Inventory500
O’Dowd,
unpublished373,374
Unexplained
fatigue
Recruitment, adherence
and follow-up
Chalder Fatigue Score;385 pain VAS; physical Function
(SF-36); anxiety (HADS); depression (HADS); EQ-5D-5L;
hours missed from work because of health problems in
the past 7 days; health problems affected productivity
while working in the past 7 daysa
SD, somatoform disorder.
a Secondary outcomes not recorded in trial protocol. Reported here from basic data sheet provided on ISRCTN, no
references for scales given, no further detail given on items used to measure health problems affecting productivity.
Cells merged where outcomes not distinguished as primary or secondary in the original study report. Scales are
described as reported by the individual study authors. References for scales are cited as reported by the individual
study authors. References for scales are cited as reported by the individual study authors.
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TABLE 111 Key outcomes measured in each study
First author
and year of
publication Condition Pain Fatigue
Bowel
symptoms Somatisation
Generic physical
symptoms
Emotional
distress Anxiety Depression
Physical
functioning Impact
Wortman, 2016517 MUS/SD ✗ ✗ ✗ 4DSQ Symptom severity
(VAS)
4DSQ and SF-36 4DSQ 4DSQ SF-36 ✗
Ziadni, 2018328 MUS/SD BPI-SF ✗ ✗ ✗ ✗ BSI ✗ ✗ ✗ ✗
O’Dowd,
unpublished373,374
Unexplained
fatigue
VAS CFS ✗ ✗ ✗ ✗ HADS HADS SF-36 ✗
4DSQ, Four-Dimensional Symptom Questionnaire; BPI-SF, Brief Pain Inventory – short form; BSI, Brief Symptom Inventory; CFS, Chalder Fatigue Score; SD, somatoform disorder.
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TABLE 112 Follow-up time points in months
First author and
year of publication Baseline
End of treatment
(duration, months)
Short term (time since end
of treatment, months)
Long term (time since end
of treatment, months)
Wortman, 2016517 Y 3 6 12
Ziadni, 2018328 Y 1.38
O’Dowd,
unpublished373,374
Unclear 3 6
Time points: baseline= baseline measurement yes/no; end of treatment: measurement taken directly at the end of
treatment (i.e. will correspond with duration of treatment); short term= time since end of treatment < 6 months (where
not explicit, calculated by subtracting duration of treatment from baseline to short-term follow-up measurement); long
term= time since end of treatment ≥ 6 months (where not explicit, calculated by subtracting duration of treatment from
baseline to long-term follow-up measurement).
Months calculated by using 1 week= 0.230137 months conversion tool.
TABLE 113 Setting detail for individual studies
First author
and year of
publication Condition Setting Setting: referral
Setting:
assessment Setting: intervention
Setting:
outcome
assessment
Wortman, 2016517 MUS/SD Primary
care
Recruited by
GPs (six
practices)
NR NR NR
Ziadni, 2018328 MUS/SD Primary
care
Family medicine
clinic
Primary care
clinic
Primary care clinic Home-based
online
questionnaires
O’Dowd,
unpublished373,374
Unexplained
fatigue
Primary
care
GP practices GP practices Unclear setting for
1-hour appointment
with fatigue specialist.
20-minute support
sessions by telephone
NR
NR, not reported; SD, somatoform disorder.
TABLE 114 Numbers, interventions studied and assessment points for each study
First author and
year of publication Condition Total n Arms Interventions Assessment points
Wortman, 2016517 MUS/SD 42 randomised 2 MM vs. UC Baseline, end of intervention
(3 months), 6 months,
12 months
Ziadni, 2018328 MUS/SD 75 randomised 2 OP vs. UC Baseline, 6 weeks
O’Dowd,
unpublished373,374
Unexplained
fatigue
44 randomised 2 EI vs. UCa 3 months and 6 monthsb
EI, early intervention; MM, multimodal; OP, other psychotherapy; SD, somatoform disorder; UC, usual care.
a Early intervention, insufficient information to assign to grouping.
b Unclear whether this is time since end of treatment or time since baseline.
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Discussion
Three additional trials were identified in the update of clinical effectiveness. Two showed positive
results for behavioural interventions,328,517 with the remaining study showing no positive results for
clinical outcomes.373,374 Some issues that were identified in the original review were raised again; for
example, there was wide variation in the number of eligible patients identified by individual GPs in
Wortman et al.517 As a result of a lack of potentially eligible participants being identified, the recruitment
of additional GPs was needed for the study. In addition, the possibility of misdiagnosis was raised, with
one patient in the intervention group in Wortman et al.517 discontinuing the study because of a physical
disease being identified that explained the symptoms experienced. This issue was previously identified
as a concern for both patients and GPs in the original review. A lack of standardised reporting of
adverse events means that drawing conclusions on the type and nature of adverse events associated
with these behavioural interventions is not possible. The O’Dowd373,374 study did record adverse events,
with no expected adverse events recorded and one unexpected adverse event (an accident and
emergency admission for cardiac symptoms). Finally, a high rate of attrition was seen in two of the
studies, which suggests that these types of interventions are unacceptable to some patients.
Tables 118–126 show means, SDs and narrative summary for each outcome.
TABLE 115 Intervention delivery in included studies
First author and
year of publication Condition
Intervention 1
delivery: duration
of sessions
Intervention 3
delivery: duration
of sessions
Intervention 2
delivery: duration
of sessions
Wortman, 2016517 MUS/SD 45 minutes N/A N/A
Ziadni, 2018328 MUS/SD 90 minutes N/A N/A
O’Dowd,
unpublished373,374
Unexplained
fatigue
1 hour+ 3 × 20 minutes N/A N/A
N/A, not applicable; SD, somatoform disorder.
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TABLE 117 Intervention provider for included studies
First author and
year of publication Condition
Intervention 1
provider: position
Intervention 3
provider: position
Intervention 2
provider: position
Intervention 1
provider: time spent
on delivery
Intervention 3
provider: time spent
on delivery
Intervention 2
provider: time spent
on delivery
Wortman, 2016517 MUS/SD Physiotherapists and
exercise therapists
N/A GP 9 × 45 minutes N/A N/A
Ziadni, 2018328 MUS/SD Doctoral students in
clinical psychology
N/A Family clinic
physician
90 minutes N/A N/A
O’Dowd,
unpublished373,374
Unexplained
fatigue
Fatigue specialist N/A GP 1 hour+ 3 × 20
minutes
N/A N/A
N/A, not applicable; SD, somatoform disorder.
TABLE 116 Number of sessions for interventions
First author and
year of publication Condition
Intervention 1
delivery: number
of sessions
Intervention 3
delivery: number
of sessions
Intervention 2
delivery: number
of sessions
Intervention 1
delivery: time period
Intervention 3
delivery: time period
Intervention 2
delivery: time period
Wortman, 2016517 MUS/SD 9 sessions N/A N/A 3 months N/A 3 months
Ziadni, 2018328 MUS/SD 1 session N/A N/A Within 1 week of
baseline assessments
N/A N/A
O’Dowd,
unpublished373,374
Unexplained
fatigue
1+ 3 telephone
support sessions
N/A N/A NR N/A N/A
N/A, not applicable; SD, somatoform disorder.
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TABLE 119 Somatisation outcome data
Somatisation
First author and year
of publication
Intervention
group
Baseline
mean/SD Time 1 mean/SD
Time 2
mean/SD Summary
Wortman, 2016517 MM
UC
11.7 (6.5)
10.9 (6.9)
8.5 (8.3)
10.1 (6.3)
7.5 (7.5)
11.5 (7.4)
Significant improvement in
somatisation at each time
point for brief multimodal
psychosomatic therapy
group compared with
usual care group
Ziadni, 2018328 Outcome not measured
O’Dowd,
unpublished373,374
Outcome not measured
MM, multimodal; SD, standard deviation; UC, usual care.
TABLE 120 Fatigue outcome data
Fatigue
First author and year
of publication
Intervention
group
Baseline
mean/SD Time 1 mean/SD
Time 2
mean/SD Summary
O’Dowd,
unpublished373,374
EI
UC
NR 12.3 (9.3, 15.3)
14.7 (10.6, 18.9)
NR Baseline data not reported.
Fatigue was no different
between the two groups
at the end of the study
Wortman, 2016517 Outcome not measured
Ziadni, 2018328 Outcome not measured
EI, early intervention; NR, not reported; SD, standard deviation; UC, usual care.
TABLE 118 Pain outcome data
Pain
First author and year
of publication
Intervention
group
Baseline
mean/SD Time 1 mean/SD
Time 2
mean/SD Summary
Wortman, 2016517 Outcome not measured
Ziadni, 2018328 OP
UC
4.91 (2.17)a
4.82 (2.24)a
4.12 (2.46)a
4.95 (1.83)a
NR Patients in interview
condition (OP) had a
significantly lower-pain
severity at follow-up than
treatment as usual (UC),
with a medium to large
between-condition effect
O’Dowd,
unpublished373,374
EI
UC
NR 22.1 (8.5 to 35.7)b
18.9 (5.8 to 31.9)b
NR Baseline data not reported.
Pain was no different
between the two groups
at the end of the study
EI, early intervention; NR, not reported; OP, other psychotherapy; SD, standard deviation; UC, usual care.
a Unadjusted.
b 95% CI.
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TABLE 121 Generic physical symptoms outcome data
Generic physical symptoms
First author and year
of publication
Intervention
group
Baseline
mean/SD
Time 1
mean/SD
Time 2
mean/SD Summary
Wortman, 2016517 MM
UC
5.9 (2.4)
5.3 (2.9)
3.9 (3.0)
4.9 (2.6)
3.1 (2.5)
5.0 (2.4)
Significant improvement in
somatisation at each time
point for brief multimodal
psychosomatic therapy group
compared with the usual
care group
Ziadni, 2018328 Outcome not measured
O’Dowd,
unpublished373,374
Outcome not measured
MM, multimodal; SD, standard deviation; UC, usual care.
TABLE 122 Emotional distress outcome data
Emotional distressa
First author and year
of publication
Intervention
group
Baseline
mean/SD
Time 1
mean/SD
Time 2
mean/SD Summary
Wortman, 2016517 MM
UC
49.2 (11.3)
50.7 (10.3)
51.8 (8.3)
48.6 (11.7)
50.7 (8.4)
49.5 (10.1)
Significance not reported, low
effect size
Ziadni, 2018328 OP
UC
1.27 (0.83)b
1.27 (0.85)b
0.87 (0.87)b
1.29 (0.70)b
Patients in interview condition
(OP) had significantly less
psychological symptoms at
follow-up than treatment as
usual (UC), with a medium
between-condition effect
O’Dowd,
unpublished373,374
Outcome not measured
MM, multimodal; OP, other psychotherapy; SD, standard deviation; UC, usual care.
a Wortman517 data is SF-36 MCS.
b Unadjusted.
TABLE 123 Anxiety outcome data
Anxiety
First author and year
of publication
Intervention
group
Baseline
mean/SD
Time 1
mean/SD
Time 2
mean/SD Summary
Wortman, 2016517 MM
UC
3.3 (3.6)
2.4 (4.3)
2.4 (3.9)
2.4 (3.6)
2.6 (4.4)
2.8 (4.7)
Significance not reported, low
effect size
O’Dowd,
unpublished373,374
EI
UC
NR 7.8 (5.4, 10.3)
7.8 (4.9, 10.6)
NR Baseline data not reported.
No difference between groups
at the end of the study
Ziadni, 2018328 Outcome not measured
EI, early intervention; MM, multimodal; NR, not reported; OP, other psychotherapy; SD, standard deviation;
UC, usual care.
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TABLE 124 Depression outcome data
Depression
First author and year
of publication
Intervention
group
Baseline
mean/SD
Time 1
mean/SD
Time 2
mean/SD Summary
Wortman, 2016517 MM
UC
1.9 (3.4)
0.9 (1.6)
1.4 (2.3)
0.9 (1.7)
0.9 (1.8)
0.6 (1.4)
Significance not reported,
low effect size
O’Dowd,
unpublished373,374
EI
UC
NR 4.9 (3.0, 6.9)
4.6 (2.9, 6.2)
NR Baseline data not reported.
No difference between
groups at the end of the
study
Ziadni, 2018328 Outcome not measured
EI, early intervention; MM, multimodal; NR, not reported; SD, standard deviation; UC, usual care.
TABLE 125 Physical functioning outcome data
Physical functioning
First author and year
of publication
Intervention
group
Baseline
mean/SD
Time 1
mean/SD
Time 2
mean/SD Summary
Wortman, 2016517 MM
UC
51.6 (9.0)
48.5 (10.2)
49.6 (10.4)
50.3 (10.1)
51.9 (9.1)
48.5 (10.2)
Significance not reported,
low effect size
O’Dowd,
unpublished373,374
EI
UC
NR 76.8 (65.1, 88.4)
84.4 (72.4, 96.3)
NR NR
Ziadni, 2018328 Outcome not measured
EI, early intervention; MM, multimodal; NR, not reported; SD, standard deviation; UC, usual care.
TABLE 126 Acceptability outcome data
Acceptability
First author and
year of publication
Intervention
group Summary
Wortman, 2016517 MM vs. UC 16/82 of those screened for eligibility declined to participate. In MM group, 16/20
received intervention and completed first follow-up (2/4 withdrew consent after
allocation, of whom 1/4 withdrew because of psychological symptoms, and 1/4
withdrew as a result of physical disease explaining their symptoms). In the UC
care group, 2/22 withdrew consent after allocation because of ‘too much MUS
complaints’, 2/22 were deviations from protocol and received MM. No further
loss to follow-up
In the MM group, 81% of patients were very satisfied with treatment and reported
that it had helped them deal with their problems more effectively. One patient
had a neutral opinion. Two patients were dissatisfied and disappointed with the
treatment and continued to seek an explanation for their symptoms
Ziadni, 2018328 OP vs. UC 12.9% of eligible patients were not interested or able to participate in the study.
2/49 patients randomised to the interview intervention did not respond to
scheduling requests and did not receive an interview. 6/49 in OP group were
lost to follow-up, 2/26 in UC group were lost to follow-up
O’Dowd,
unpublished373,374
EI vs. UC 11/90 of those assessed for eligibility declined to participate. 9/28 of those
randomised were lost to follow-up, of whom two gave reasons: both reasons
were ‘not accepting of the therapeutic model’
EI, early intervention; MM, multimodal; NR, not reported; OP, other psychotherapy; SD, standard deviation; UC, usual care.
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Risk-of-bias assessments for each study
Wortman 2016517
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-generated permuted block randomisation
table
Low risk of bias, adequate
randomisation
Allocation concealment Research assistant responsible for randomisation not
aware of health status of patient. ID numbers for
patients only matched with corresponding name
after randomisation
Low risk of bias, adequate
allocation concealment
Performance bias
No blinding of patients or GPs High risk of bias, no blinding of
patients or providers
Detection bias
Blinding of outcome assessors not described Unclear risk of bias
Attrition bias
In the intervention group, 4/20 did not complete the
study compared with 2/22 in the UC group. ITT
analyses conducted
High risk of bias. 20% attrition in
intervention group
Reporting bias
All outcomes in protocol reported in study paper Low risk of bias
ITT, intention to treat; UC, usual care.
Ziadni 2018328
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence
generation
Computer-based randomisation scheme Low risk of bias
Allocation concealment Research assistant opened a sealed envelope at
allocation
Low risk of bias, sealed envelope
methods employed
Performance bias
No blinding of patients High risk of bias, no blinding
possible
Detection bias
Blinding of outcome assessor not described Unclear risk of bias
Attrition bias
6/49 lost to follow-up in OP group. ITT analysis
conducted
Low risk of bias, attrition < 20%
Reporting bias
Primary outcome reported as Symptom Interpretation
Questionnaire in protocol, but as pain severity and
interference in study paper. Not all secondary
outcomes reported in study paper
High risk of bias. Not all
outcomes described in
protocol reported
ITT, intention to treat; OP, other psychotherapy.
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O’Dowd unpublished373,374
Domain Support for judgement Reviewer judgement
Selection bias
Random sequence generation NR Unclear risk of bias
Allocation concealment NR Unclear risk of bias
Performance bias
NR Unclear risk of bias
Detection bias
NR Unclear risk of bias
Attrition bias
9/28 in the intervention group
lost to follow-up
High risk of bias. Attrition > 20%
Reporting bias
Secondary outcomes not
described in the protocol
Unclear risk of bias. Unknown
secondary outcomes in protocol
NR, not reported.
Data is from the trial protocol and an additional file on the ISRCTN registration page.
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Yamato TP, Maher CG, Saragiotto BT, Hancock MJ, Ostelo RW, Cabral CM, et al. Pilates
for low back pain. São Paulo Med J 2016;134:366
Review
TelePain: improving primary care pain management. Conference: 36th Annual Scientific
Meeting of the American Pain Society, USA, 2017. J Pain 2017;18(Suppl. 1):S67–8
Conference abstract only
Champagne R, Ronzi Y, Roche-Leboucher G, Begue C, Dubus V, Bontoux L, et al.
Effectiveness of an outpatient rehabilitation program with multidisciplinary approach on
return to work for patients with non-specific chronic lombal pain. Annals of Physical and
Rehabilitation Medicine 2018;61:e16
Conference abstract only
Abbott A, Schröder K, Enthoven P, Nilsen P, Öberg B. Effectiveness of implementing a
best practice primary healthcare model for low back pain (BetterBack) compared with
current routine care in the Swedish context: an internal pilot study informed protocol
for an effectiveness-implementation hybrid type 2 trial. BMJ Open 2018;8:e019906.
https://doi.org/10.1136/bmjopen-2017-019906
Protocol only
Adamse C, Dekker-Van Weering MG, van Etten-Jamaludin FS, Stuiver MM. The
effectiveness of exercise-based telemedicine on pain, physical activity and quality of life in
the treatment of chronic pain: a systematic review. J Telemed Telecare 2018;24:511–26.
https://doi.org/10.1177/1357633X17716576
Review
Alda M, Luciano JV, Andrés E, Serrano-Blanco A, Rodero B, del Hoyo YL, et al.
Effectiveness of cognitive behaviour therapy for the treatment of catastrophisation in
patients with fibromyalgia: a randomised controlled trial. Arthritis Res Ther 2011;13:R173.
https://doi.org/10.1186/ar3496
Included in original review
Amirova A, Cropley M and Theadom A. The effectiveness of the Mitchell method
relaxation technique for the treatment of fibromyalgia symptoms: a three-arm
randomized controlled trial. Int J Stress Manage 2017;24:86–106. https://doi.org/10.1037/
str0000017
Not primary care
Amorim AB, Pappas E, Simic M, Ferreira ML, Jennings M, Tiedemann A, et al. Integrating
Mobile-health, health coaching, and physical activity to reduce the burden of chronic low
back pain trial (IMPACT): a pilot randomised controlled trial. BMC Musculoskelet Disord
2019;20:71. https://doi.org/10.1186/s12891-019-2454-y
Not primary care
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TABLE 127 List of clinical effectiveness studies excluded at full-paper stage with reasons (continued )
Andersen LL, Persson R, Jakobsen MD, Sundstrup E. Psychosocial effects of workplace
physical exercise among workers with chronic pain: randomized controlled trial. Medicine
2017;96:e5709. https://doi.org/10.1097/MD.0000000000005709
Does not meet criteria for
unexplained symptoms
Andersen LN, Juul-Kristensen B, Sørensen TL, Herborg LG, Roessler KK, Søgaard K.
efficacy of tailored physical activity or chronic pain self-management programme on
return to work for sick-listed citizens: a 3-month randomised controlled trial. Scand J
Public Health 2015;43:694–703. https://doi.org/10.1177/1403494815591687
Protocol only
Angelovski A, Sattel H, Henningsen P, Sack M. Heart rate variability predicts therapy
outcome in pain-predominant multisomatoform disorder. J Psychosom Res 2016;83:16–21.
https://doi.org/10.1016/j.jpsychores.2016.02.003
Not primary care
Aragonès E, López-Cortacans G, Caballero A, Piñol JL, Sánchez-Rodríguez E, Rambla C,
et al. Evaluation of a multicomponent programme for the management of musculoskeletal
pain and depression in primary care: a cluster-randomised clinical trial (the DROP study).
BMC Psychiatry 2016;16:69. https://doi.org/10.1186/s12888-016-0772-2
Protocol only
Azevedo DC, Van Dillen LR, Santos Hde O, Oliveira DR, Ferreira PH, Costa LO. Movement
system impairment-based classification versus general exercise for chronic low back pain:
protocol of a randomized controlled trial. Phys Ther 2015;95:1287–94. https://doi.org/
10.2522/ptj.20140555
Protocol only
Baird E, Williams ACC, Hearn L, Amris K. Interventions for treating persistent pain in
survivors of torture. Cochrane Database Syst Rev 2017;8:CD012051. https://doi.org/
10.1002/14651858.CD012051.pub2
Review
Baumueller E, Winkelmann A, Irnich D, Weigl M. Electromyogram biofeedback in patients
with fibromyalgia: a randomized controlled trial. Complement Med Res 2017;24:33–9.
https://doi.org/10.1159/000454692
Not primary care
Ben-Ami N, Chodick G, Mirovsky Y, Pincus T, Shapiro Y. Increasing recreational physical
activity in patients with chronic low back pain: a pragmatic controlled clinical trial.
J Orthop Sports Phys Ther 2017;47:57–66. https://doi.org/10.2519/jospt.2017.7057
Not primary care
Ben-Ami N, Shapiro Y, Pincus T. Outcomes in distressed patients with chronic low back
pain: subgroup analysis of a clinical trial. J Orthop Sports Phys Ther 2018;48:491–5.
https://doi.org/10.2519/jospt.2018.7670
Not primary care
Beneciuk JM, George SZ. Pragmatic implementation of a stratified primary care model for
low back pain management in outpatient physical therapy settings: two-phase, sequential
preliminary study. Phys Ther 2015;95:1120–34. https://doi.org/10.2522/ptj.20140418
Does not meet criteria for
unexplained symptoms
Bennell KL, Nelligan R, Dobson F, Rini C, Keefe F, Kasza J, et al. Effectiveness of an
internet-delivered exercise and pain-coping skills training intervention for persons with
chronic knee pain: a randomized trial. Ann Intern Med 2017;166:453–62. https://doi.org/
10.7326/M16-1714
Paper not available
Bier JD, Sandee-Geurts JJW, Ostelo RWJG, Koes BW, Verhagen AP. Can primary care for
back and/or neck pain in the Netherlands benefit from stratification for risk groups
according to the STarT back tool classification? Arch Phys Med Rehabil 2018;99:65–71
Not a RCT
Brage, K., Ris, I., Falla, D., Søgaard, K., & Juul-Kristensen, B. (2015). Pain education
combined with neck- and aerobic training is more effective at relieving chronic neck pain
than pain education alone – a preliminary randomized controlled trial. Man Ther
20:686–93
Not primary care
Bramberg EB, Bergstrom G, Jensen I, Hagberg J, Kwak L. Effects of yoga, strength
training and advice on back pain: a randomized controlled trial. BMC Musculoskelet
Disord 2017;18
Not primary care
Braschinsky M, Haldre S, Kals M, Arge M, Saar B, Niibek M, Steiner TJ. Structured
education to improve primary-care management of headache: how long do the benefits
last? A follow-up observational study. Eur J Neurol 2018;25:497–502
Does not meet criteria for
unexplained symptoms
Braunger C, Kubiak N, Müller G, von Wietersheim J, Oster J. Effectiveness of telephone
and face-to-face aftercare conversations following inpatient psychosomatic rehabilitation.
Die Rehabil 54:290–6
Not primary care
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TABLE 127 List of clinical effectiveness studies excluded at full-paper stage with reasons (continued )
Calner T, Nordin C, Eriksson MK, Nyberg L, Gard G, Michaelson P. Effects of a
self-guided, web-based activity programme for patients with persistent musculoskeletal
pain in primary healthcare: a randomized controlled trial. Eur J Pain 2017;21:1110–20
Does not meet criteria for
unexplained symptoms
Canaway A, Pincus T, Underwood M, Shapiro Y, Chodick G, Ben-Ami N. Is an enhanced
behaviour change intervention cost-effective compared with physiotherapy for patients
with chronic low back pain? Results from a multicentre trial in Israel. BMJ Open
2018;8:e019928
Does not meet criteria for
unexplained symptoms
Cano-Garcia FJ, Gonzalez-Ortega MD, Sanduvete-Chaves S, Chacon-Moscoso S,
Moreno-Borrego R. Evaluation of a psychological intervention for patients with chronic
pain in primary care. Front Psychol 2017;8:435
Not a RCT
Caravaca JMR, Martínez AC, Fuentes MCC. Es el masaje efectivo para reducir el dolor
lumbar ocupacional de las enfermeras? Evidentia 2017;14:22
Not a behavioural
intervention
Carnes D, Mars T, Plunkett A, Nanke L, Abbey H. A mixed methods evaluation of a third
wave cognitive behavioural therapy and osteopathic treatment programme for chronic
pain in primary care (OsteoMAP). Int J Ostopath Med 2017;24:12–17. https://doi.org/
10.1016/j.ijosm.2017.03.005
Not a RCT
Cherkin D, Balderson B, Brewer G, Cook A, Talbert Estlin K, Evers SC, et al. Evaluation
of a risk-stratification strategy to improve primary care for low back pain: the MATCH
cluster randomized trial protocol. BMC Musculoskelet Disord 2016;17:1–11. https://doi.org/
10.1186/s12891-016-1219-0
Protocol only
Cherkin D, Balderson B, Wellman R, Hsu C, Sherman KJ, Evers SC, et al. Effect of low
back pain risk-stratification strategy on patient outcomes and care processes: the MATCH
randomized trial in primary care. J Gen Int Med 2018;33:1324–36
Not a behavioural
intervention
Cherkin DC, Sherman KJ, Balderson BH, Cook AJ, Anderson ML, Hawkes RJ, Turner JA.
Effect of mindfulness-based stress reduction vs cognitive behavioral therapy or usual care
on back pain and functional limitations in adults with chronic low back pain: a randomized
clinical trial. JAMA 2016;315:240–9. https://doi.org/10.1001/jama.2016.2323
Possibly include – check
setting is primary care
Christensen SS, Frostholm L, Ornbol E, Schroder A. Changes in illness perceptions mediated
the effect of cognitive behavioural therapy in severe functional somatic syndromes.
J Psychosom Res 2015;78:363–70. https://doi.org/10.1016/j.jpsychores.2014.12.005
Not primary care
Cuesta-Vargas AI, White M, Gonzalez-Sanchez M, Kuisma R. The optimal frequency of
aquatic physiotherapy for individuals with chronic musculoskeletal pain: a randomised
controlled trial. Disabil Rehab 2015;37:311-318. https://doi.org/10.3109/09638288.2014.
918191
Not all patients meet
criteria for unexplained
symptoms
Damush TM, Kroenke K, Bair MJ, Wu J, Tu W, Krebs EE, Poleshuck E. Pain self-management
training increases self-efficacy, self-management behaviours and pain and depression
outcomes. Eur J Pain 2016;20:1070–8. https://doi.org/10.1002/ejp.830
Does not meet criteria for
unexplained symptoms
Daulat A. A pragmatic randomized controlled trial to compare a novel group
physiotherapy programme with a standard group exercise programme for managing
chronic low back pain in primary care. Int Musculoskelet Med 2016;38:97–108.
https://doi.org/10.1080/17536146.2016.1261234
Paper not available
Davis K, Sargent L, Menzies V. Community-based care of the fibromyalgia patient:
strategies to promote self-management. Home Healthc Now 2017;35:364–72.
https://doi.org/10.1097/NHH.0000000000000570
Review
den Hollander M, Goossens M, de Jong J, Ruijgrok J, Oosterhof J, Onghena P, Vlaeyen JWS.
Expose or protect? A randomized controlled trial of exposure in vivo vs pain-contingent
treatment as usual in patients with complex regional pain syndrome type 1. Pain
2016;157:2318–29. https://doi.org/10.1097/j.pain.0000000000000651
Not primary care
den Hollander M, Heijnders N, De Jong JR, Vlaeyen JWS, Smeets R, Goossens M.
Exposure in vivo versus pain-contingent physical therapy in complex regional pain
syndrome type 1: a cost-effectiveness analysis. Int J Technol Assess Health Care
2018;34:400–9. https://doi.org/10.1017/s0266462318000429
Tertiary care
rehabilitation centre
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TABLE 127 List of clinical effectiveness studies excluded at full-paper stage with reasons (continued )
Devasahayam, A J, Ho DRY, Leung EYS, Goh MR, Koh P. The effects of a novel pilates
exercise prescription method on people with non-specific unilateral musculoskeletal pain:
a randomised pilot trial. Proceedings of Singapore Healthcare 2016;25:201–6
Not primary care
Domingo-Esteban S and Navas-Cámara FJ. [Posibles beneficios de la pinza rodada en el
dolor y la incapacidad en la lumbalgia inespecífica crónica.] Fisioterapia 2017;39:60–7.
https://doi.org/10.1016/j.ft.2016.09.001
Not a behavioural
intervention
Drane DL, LaRoche SM, Ganesh GA, Teagarden D, Loring DW. A standardized diagnostic
approach and ongoing feedback improves outcome in psychogenic nonepileptic seizures.
Epilepsy Behav 2016;54:34–9. https://doi.org/10.1016/j.yebeh.2015.10.026
Not primary care
Dunleavy K, Kava K, Goldberg A, Malek MH, Talley SA, Tutag-Lehr V, Hildreth J.
Comparative effectiveness of Pilates and yoga group exercise interventions for chronic
mechanical neck pain: quasi-randomised parallel controlled study. Physiotherapy
2016;102:236–42. https://doi.org/10.1016/j.physio.2015.06.002
Not a RCT
Eaton LH, Langford DJ, Meins AR, Rue T, Tauben DJ, Doorenbos AZ. Use of self-
management interventions for chronic pain management: a comparison between rural
and nonrural residents. Pain Manag Nurs 2018;19:8–13.
Does not meet criteria for
unexplained symptoms
Elder CR, Debar LL, Ritenbaugh C, Rumptz MH, Patterson C, Bonifay A, et al. Health care
systems support to enhance patient-centered care: lessons from a primary care-based
chronic pain management initiative. Perm J 2017;21:16–101. https://doi.org/10.7812/
TPP/16-101
Outcomes not relevant
Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med 2017;376:2566–78.
https://doi.org/10.1056/NEJMra1607547
Review
Ford JJ, Hahne AJ, Surkitt LD, Chan AY, Richards MC, Slater SL, et al. Individualised
physiotherapy as an adjunct to guideline-based advice for low back disorders in primary
care: a randomised controlled trial. Br J Sports Med 2016;50:237–45. https://doi.org/
10.1136/bjsports-2015-095058
Pain duration includes
subacute
Frederiksen P, Indahl A, Andersen LL, Burton K, Hertzum-Larsen R, Bendix T. Can
group-based reassuring information alter low back pain behavior? A cluster-randomized
controlled trial. PLOS ONE 2017;12:e0172003. https://doi.org/10.1371/journal.pone.
0172003
Intervention is for
prevention
French SD, Green SE, Francis JJ, Buchbinder R, O’Connor DA, Grimshaw JM, Michie S.
Evaluation of the fidelity of an interactive face-to-face educational intervention to
improve general practitioner management of back pain. BMJ Open 2015;5:e007886.
https://doi.org/10.1136/bmjopen-2015-007886
Pain is acute
Frostholm L, Hornemann C, Ørnbøl E, Fink P, Mehlsen M. Using illness perceptions to
cluster chronic pain patients: results from a trial on the chronic pain self-management
program. Clin J Pain 2018;34:991–9. https://doi.org/10.1097/AJP.0000000000000627
Not primary care
Gannon J, Atkinson JH, Chircop-Rollick T, D’Andrea J, Garfin S, Patel S, et al. Telehealth
therapy effects of nurses and mental health professionals from 2 randomized controlled
trials for chronic back pain. Clin J Pain 2019;35:295–303. https://doi.org/10.1097/
AJP.0000000000000678
Does not meet criteria for
unexplained symptoms
Garcia AN, Costa L, Hancock MJ, Souza FS, Gomes G, Almeida MO, Costa LOP. McKenzie
Method of Mechanical Diagnosis and Therapy was slightly more effective than placebo
for pain, but not for disability, in patients with chronic non-specific low back pain: a
randomised placebo controlled trial with short and longer term follow-up. Br J Sports Med
2018;52:594–600. https://doi.org/10.1136/bjsports-2016-097327
Not primary care
Geraghty AW, Stanford R, Little P, Roberts L, Foster NE, Hill JC, et al. Using an internet
intervention to support self-management of low back pain in primary care: protocol for
a randomised controlled feasibility trial (SupportBack). BMJ Open 2015;5:e009524.
https://doi.org/10.1136/bmjopen-2015-009524
Protocol only
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Goossens ME, de Kinderen RJ, Leeuw M, de Jong JR, Ruijgrok J, Evers SM, Vlaeyen JW.
Is exposure in vivo cost-effective for chronic low back pain? A trial-based economic
evaluation. BMC Health Serv Res 2015;15:549. https://doi.org/10.1186/s12913-015-
1212-6
Not primary care
Hahne AJ, Ford JJ, Richards MC, Surkitt LD, Chan AYP, Slater SL, Taylor NF. Who benefits
most from individualized physiotherapy or advice for low back disorders? A preplanned
effect modifier analysis of a randomized controlled trial. Spine 2017;42:E1215–E1224.
https://doi.org/10.1097/BRS.0000000000002148
Paper not available
Heapy AA, Higgins DM, Goulet JL, LaChappelle KM, Driscoll MA, Czlapinski RA, et al.
Interactive voice response-based self-management for chronic back pain: the COPES
noninferiority randomized trial. JAMA Intern Med 2017;177:765–73. https://doi.org/
10.1001/jamainternmed.2017.0223
Not primary care
Herman PM, Anderson ML, Sherman KJ, Balderson BH, Turner JA, Cherkin DC.
Cost-effectiveness of mindfulness-based stress reduction versus cognitive behavioral
therapy or usual care among adults with chronic low-back pain. Spine 2017;42:1511–20.
https://doi.org/10.1097/brs.0000000000002344
Cost paper from excluded
Cherkin
Hutting N, Staal JB, Engels JA, Heerkens YF, Detaille SI, Nijhuis-van der Sanden MWG.
(2015). Effect evaluation of a self-management programme for employees with
complaints of the arm, neck or shoulder: a randomised controlled trial. Occupational
and Environmental Medicine 2015;72:852–61. https://doi.org/10.1136/oemed-
2015-103089
Not primary care
Jakobsen MD, Sundstrup E, Brandt M, Andersen LL. Effect of physical exercise on
musculoskeletal pain in multiple body regions among healthcare workers: secondary
analysis of a cluster randomized controlled trial. Musculoskelet Sci Pract 2018;34:89–96.
Does not meet criteria for
unexplained symptoms
Jakobsen MD, Sundstrup E, Brandt M, Jay K, Aagaard P, Andersen LL. Physical exercise at
the workplace prevents deterioration of work ability among healthcare workers: cluster
randomized controlled trial. BMC Public Health 2015;15:1174. https://doi.org/10.1186/
s12889-015-2448-0
Intervention is workplace
prevention
Jakobsen MD, Sundstrup E, Brandt M, Jay K, Aagaard P, Andersen LL. Physical exercise
at the workplace reduces perceived physical exertion during healthcare work: cluster
randomized controlled trial. Scand J Public Health 2015;43:713–20. https://doi.org/
10.1177/1403494815590936
Intervention is workplace
prevention
Janse A, Wiborg JF, Bleijenberg G, Tummers M, Knoop H. The efficacy of guided
self-instruction for patients with idiopathic chronic fatigue: a randomized controlled trial.
J Consult Clin Psychol 2016;84:377–88. https://doi.org/10.1037/ccp0000085
No primary care
involvement
Janse A, Worm-Smeitink M, Bussel-Lagarde J, Bleijenberg G, Nikolaus S, Knoop H. Testing
the efficacy of web-based cognitive behavioural therapy for adult patients with chronic
fatigue syndrome (CBIT): study protocol for a randomized controlled trial. BMC Neurol
2015;15:137. https://doi.org/10.1186/s12883-015-0392-3
Protocol only
Jarrett ME, Cain KC, Barney PG, Burr RL, Naliboff BD, Shulman R, et al. Balance of
autonomic nervous system predicts who benefits from a self-management intervention
program for irritable bowel syndrome. J Neurogastroenterol Motil 2016;22:102–11.
https://doi.org/10.5056/jnm15067
Not primary care
Jeitler M, Brunnhuber S, Meier L, Lüdtke R, Büssing A, Kessler C, Michalsen A.
Effectiveness of jyoti meditation for patients with chronic neck pain and psychological
distress – a randomized controlled clinical trial. J Pain 2015;16:77–86. https://doi.org/
10.1016/j.jpain.2014.10.009
Not primary care
Jensen CE, Riis A, Petersen KD, Jensen MB, Pedersen KM. Economic evaluation of
an implementation strategy for the management of low back pain in general practice.
Pain 2017;158:891–9. https://doi.org/10.1097/j.pain.0000000000000851
Not a behavioural
intervention
Jones GT, Jones EA, Beasley MJ, Macfarlane GJ. Investigating generalizability of results
from a randomized controlled trial of the management of chronic widespread pain:
the MUSICIAN study. Pain 2017;158:96–102. https://doi.org/10.1097/j.pain.
0000000000000732
Include – is related to
McBeth and Beasley trial
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Kaleth AS, Slaven JE, Ang DC. Obesity moderates the effects of motivational interviewing
treatment outcomes in fibromyalgia. Clin J Pain 2018;34:76–81. https://doi.org/10.1097/
AJP.0000000000000500
Not primary care,
specialty referrals
Kanzler K, Robinson P, Munante M, Lopez E, McGeary D, Potter J, et al. Evaluating act for
chronic pain in integrated primary care with a population health-driven RCT. Annals of
Behavioral Medicine 2018;52:S188
Paper not available
Kanzler KE, Robinson P, Munante M, McGeary D, Potter J, Lopez E, et al. Early findings
from a real-world RCT: acceptance and commitment therapy (ACT) for persistent pain
in an integrated primary care setting. J Clin Transl Sci 2018;2(Suppl. 1):81
Conference abstract only
Kemani MK, Olsson GL, Lekander M, Hesser H, Andersson E, Wicksell RK. Efficacy
and cost-effectiveness of acceptance and commitment therapy and applied relaxation
for longstanding pain: a randomized controlled trial. Clin J Pain 2015;31:1004–16.
https://doi.org/10.1097/AJP.0000000000000203
Not primary care
Kolu P, Tokola K, Kankaanpää M, Suni J. Evaluation of the effects of physical activity,
cardiorespiratory condition, and neuromuscular fitness on direct healthcare costs and
sickness-related absence among nursing personnel with recurrent nonspecific low back
pain. Spine 2017;42:854–62. https://doi.org/10.1097/BRS.0000000000001922
Not a RCT
Konnopka A, König HH, Kaufmann C, Egger N, Wild B, Szecsenyi J, et al. Cost-utility of a
specific collaborative group intervention for patients with functional somatic syndromes.
J Psychosom Res 2016;90:43–50
Costs paper from Schaefer
trial
Lami MJ, Martinez MP, Miro E, Sanchez AI, Prados G, Caliz R, et al. Efficacy of combined
cognitive-behavioral therapy for insomnia and pain in patients with fibromyalgia:
a randomized controlled trial. Cogn Ther Res 2018;42:63–79. https://doi.org/10.1007/
s10608-017-9875-4
Not primary care
Lin IB, Coffin J, O’Sullivan PB. Using theory to improve low back pain care in Australian
Aboriginal primary care: a mixed method single cohort pilot study. BMC Fam Pract
2016;17:44. https://doi.org/10.1186/s12875-016-0441-z
Not a RCT
Lin J, Paganini S, Sander L, Lüking M, Ebert DD, Buhrman M, et al. An internet-based
intervention for chronic pain. Dtsch Arztebl Int 2017;114:681–8. https://doi.org/10.3238/
arztebl.2017.0681
Not primary care
Lin J, Faust B, Ebert DD, Krämer L, Baumeister H. A web-based acceptance-facilitating
intervention for identifying patients’ acceptance, uptake, and adherence of internet-
and mobile-based pain interventions: randomized controlled trial. J Med Internet Res
2018;20:e244. https://doi.org/10.2196/jmir.9925
Not primary care
Løchting I, Storheim K, Werner EL, Småstuen Cvancarova M, Grotle M. Evaluation of
individualized quality of life and illness perceptions in low back pain. A patient education
cluster randomized controlled trial. Patient Educ Couns 2016;99:1992–8
Includes sub-acute
Löwe B, Piontek K, Daubmann A, Härter M, Wegscheider K, König HH, Shedden-Mora M.
Effectiveness of a stepped, collaborative, and coordinated health care network for
somatoform disorders (Sofu-Net): a controlled cluster cohort study. Psychosom Med
2017;79:1016–24. https://doi.org/10.1097/PSY.0000000000000491
Paper unavailable
Luciano JV, D’Amico F, Cerdà-Lafont M, Peñarrubia-María MT, Knapp M, Cuesta-Vargas AI,
et al. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration
recommended drugs and usual care in the treatment of patients with fibromyalgia: an
economic evaluation alongside a 6-month randomized controlled trial. Arthritis Res Ther
2014;16:451. https://doi.org/10.1186/s13075-014-0451-y
Already included in
original review
Luciano JV, D’Amico F, Feliu-Soler A, McCracken LM, Aguado J, Peñarrubia-María MT,
et al. Cost-utility of group acceptance and commitment therapy for fibromyalgia versus
recommended drugs: an economic analysis alongside a 6-month randomized controlled
trial conducted in Spain (EFFIGACT Study). J Pain 2017;18:868–80
Costs from included trial
Mansell G, Hill JC, Main C, Vowles KE, van der Windt D. Exploring what factors mediate
treatment effect: example of the STarT back study high-risk intervention. J Pain
2016;17:1237–45
Pain is any duration
continued
DOI: 10.3310/hta24460 Health Technology Assessment 2020 Vol. 24 No. 46
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Leaviss et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
471
TABLE 127 List of clinical effectiveness studies excluded at full-paper stage with reasons (continued )
Mansell G, Storheim K, Løchting I, Werner EL, Grotle M. Identification of indirect effects
in a cognitive patient education (COPE) intervention for low back pain. Phys Ther
2017;97:1138–46. https://doi.org/10.1093/ptj/pzx091
Outcomes are mediators
only
Marques M, De Gucht V, Leal I, Maes S. Effects of a self-regulation based physical activity
program (the ‘4-STEPS’) for unexplained chronic fatigue: a randomized controlled trial.
Int J Behav Med 2015;22:187–96. https://doi.org/10.1007/s12529-014-9432-4
Already included in
original review
McCrae N, Correa A, Chan T, Jones S, de Lusignan S. Long-term conditions and medically-
unexplained symptoms: feasibility of cognitive behavioural interventions within the
improving access to Psychological Therapies Programme. J Ment Health 2015;24:379–84.
https://doi.org/10.3109/09638237.2015.1022254
Not a RCT
Mehlsen M, Hegaard L, Ørnbøl E, Jensen JS, Fink P, Frostholm L. The effect of a lay-led,
group-based self-management program for patients with chronic pain: a randomized
controlled trial of the Danish version of the Chronic Pain Self-Management Programme.
Pain 2017;158:1437–45. https://doi.org/10.1097/j.pain.0000000000000931
Does not meet criteria for
unexplained symptoms
Meng H, Friedberg F. Cost-utility of home-based fatigue self-management versus usual
care for the treatment of chronic fatigue syndrome. Fatigue 2017;5:202–14. https://doi.
org/10.1080/21641846.2017.1343171
Costs
Meng K, Peters S, Faller H. Effectiveness of a standardized back school program for
patients with chronic low back pain after implementation in routine rehabilitation care.
Patient Educ Couns 2017;100:1161–8
Not primary care
Michalsen A, Kunz N, Jeitler M, Brunnhuber S, Meier L, Lüdtke R, et al. Effectiveness of
focused meditation for patients with chronic low back pain – a randomized controlled clinical
trial. Complement Ther Med 2016;26:79–84. https://doi.org/10.1016/j.ctim.2016.03.010
Not primary care
Murphy SE, Blake C, Power CK, Fullen BM. Comparison of a stratified group intervention
(STarT Back) with usual group care in patients with low back pain: a non-randomized
controlled trial. Spine 2016;41:645–52. https://doi.org/10.1097/BRS.0000000000001305
Not a RCT
Newton-Cross P, Howell A, Dewar J, Chasey R. ‘Moving forwards with fibromyalgia’:
preliminary feedback from patients attending primary care based education seminars and
workshops. The Chartered Society of Physiotherapy UK Conference 2018, Birmingham,
UK, 19–20 October 2018. Physiotherapy 2019;105:e173–4. https://doi.org/10.1016/
j.physio.2018.11.180
Not a RCT
Nøst TH, Steinsbekk A, Bratås O, Grønning K. Effect of an easily accessible chronic pain
self-managment intervention in public primary care. Pain Practice 2018;18:69
Conference abstract only
Nøst TH, Steinsbekk A, Bratås O, Grønning K. Short-term effect of a chronic pain self-
management intervention delivered by an easily accessible primary healthcare service:
a randomised controlled trial. BMJ Open 2018;8:e023017. https://doi.org/10.1136/
bmjopen-2018-023017
Does not meet criteria for
unexplained symptoms
Nost TH, Steinsbekk A, Bratas O, Gronning K. Short-term effect of a chronic pain
self-management intervention delivered by an easily accessible primary healthcare
service: a randomised controlled trial. BMJ Open 2018;8(12). https://doi.org/
10.1136/bmjopen-2018-023017
Does not meet criteria for
unexplained symptoms
Nøst TH, Steinsbekk A, Bratås O, Grønning K. Expectations, effect and experiences of an
easily accessible self-management intervention for people with chronic pain: study
protocol for a randomised controlled trial with embedded qualitative study. Trials
2016;17:325. https://doi.org/10.1186/s13063-016-1462-6
Protocol only
Nøst TH, Steinsbekk A, Bratås O, Grønning K. Twelve-month effect of chronic pain
self-management intervention delivered in an easily accessible primary healthcare
service – a randomised controlled trial. BMC Health Serv Res 2018;18:1012.
https://doi.org/10.1186/s12913-018-3843-x
Does not meet criteria for
unexplained symptoms
Otto J, Linden M. Regeneration orientation is better than resistance orientation in
behaviour activation. Results from an intervention study with psychosomatic patients.
Psychiatr Danub 2017;29:201–6. https://doi.org/10.24869/psyd.2017.201
Not primary care
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TABLE 127 List of clinical effectiveness studies excluded at full-paper stage with reasons (continued )
Patti A, Bianco A, Paoli A, Messina G, Montalto MA, Bellafiore M, et al. Pain perception
and stabilometric parameters in people with chronic low back pain after a pilates exercise
program: a randomized controlled trial. Medicine 2016;95:e2414. https://doi.org/10.1097/
MD.0000000000002414
Not primary care
Peters ML, Smeets E, Feijge M, van Breukelen G, Andersson G, Buhrman M, Linton SJ.
Happy despite pain: a randomized controlled trial of an 8-week internet-delivered positive
psychology intervention for enhancing well-being in patients with chronic pain. Clin J Pain
2017;33:962–75. https://doi.org/10.1097/AJP.0000000000000494
Not primary care
Phattharasupharerk S, Purepong N, Eksakulkla S, Siriphorn A. Effects of Qigong practice
in office workers with chronic non-specific low back pain: a randomized control trial.
J Bodywork Move Ther 2019;23:375–81.
Not primary care
Pinxsterhuis I, Sandvik L, Strand EB, Bautz-Holter E, Sveen U. Effectiveness of a
group-based self-management program for people with chronic fatigue syndrome:
a randomized controlled trial. Clin Rehabil 2017;31:93–103. https://doi.org/10.1177/
0269215515621362
Not primary care
Pleizier M, de Haan RJ, Vermeulen M. Management of patients with functional
neurological symptoms: a single-centre randomised controlled trial. J Neurol Neurosurg
Psychiatry 2017;88:430–6. https://doi.org/10.1136/jnnp-2015-312889
Not primary care
Pringsheim T and Edwards M. Functional movement disorders. Neurol Clin Pract
2017;7:141–7. https://doi.org/10.1212/cpj.0000000000000350
Review
Reme SE, Tveito TH, Harris A, Lie SA, Grasdal A, Indahl A, et al. Cognitive interventions
and nutritional supplements (The CINS Trial): a randomized controlled, multicenter trial
comparing a brief intervention with additional cognitive behavioral therapy, seal oil, and
soy oil for sick-listed low back pain patients. Spine 2016;41:1557–64. https://doi.org/
10.1097/BRS.0000000000001596
Does not meet criteria for
unexplained symptoms
Rhon DI, Miller RB, Fritz JM. Effectiveness and downstream healthcare utilization
for patients that received early physical therapy versus usual care for low back pain:
a randomized clinical trial. Spine 2018;43:1313–21. https://doi.org/10.1097/
BRS.0000000000002619
Population is miltary
service personnel
Richmond H. Using a CBT approach to manage low back pain. Nurs Times
2016;112:12–14
Population is subacute
Rutledge T, Atkinson JH, Chircop-Rollick T, D’Andrea J, Garfin S, Patel S, et al.
Randomized controlled trial of telephone-delivered cognitive behavioral therapy versus
supportive care for chronic back pain. Clin J Pain 2018;34:322–7. https://doi.org/10.1097/
AJP.0000000000000555
Population is military
veterans
Rutledge T, Atkinson, JH, Holloway R, Chircop-Rollick T, D’Andrea J, Garfin SR, et al.
Randomized controlled trial of nurse-delivered cognitive-behavioral therapy versus
supportive psychotherapy telehealth interventions for chronic back pain. J Pain
2018;19:1033–9
Does not meet criteria for
unexplained symptoms
Salaffi F, Ciapetti A, Gasparini S, Atzeni F, Sarzi-Puttini P, Baroni M. Web/internet-based
telemonitoring of a randomised controlled trial evaluating the time-integrated effects
of a 24-week multicomponent intervention on key health outcomes in patients with
fibromyalgia. Clin Exper Rheumatol 2015;33:S93–S101
Not primary care
Salvat I, Zaldivar P, Monterde S, Montull S, Miralles I, Castel A. Functional status, physical
activity level, and exercise regularity in patients with fibromyalgia after Multidisciplinary
treatment: retrospective analysis of a randomized controlled trial. Rheumatol Int
2017;37:377–87. https://doi.org/10.1007/s00296-016-3597-x
Not primary care
Saper RB, Lemaster C, Delitto A, Sherman KJ, Herman PM, Sadikova E, et al. Yoga,
physical therapy, or education for chronic low back pain: a randomized noninferiority trial.
Ann Intern Med 2017;167:85–94. https://doi.org/10.7326/M16-2579
Not primary care
Scott EL, Kroenke K, Wu J, Yu Z. Beneficial effects of improvement in depression, pain
catastrophizing, and anxiety on pain outcomes: a 12-month longitudinal analysis. J Pain
2016;17:215–22. https://doi.org/10.1016/j.jpain.2015.10.011
Does not meet criteria for
unexplained symptoms
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Scott W, Chilcot J, Guildford B, Daly-Eichenhardt A, McCracken LM. Feasibility
randomized-controlled trial of online acceptance and commitment therapy for
patients with complex chronic pain in the United Kingdom. Eur J Pain 2018;22:1473–84.
https://doi.org/10.1002/ejp.1236
Not primary care
Seferiadis A, Ohlin P, Billhult A, Gunnarsson R. Basic body awareness therapy or exercise
therapy for the treatment of chronic whiplash associated disorders: a randomized
comparative clinical trial. Disabil Rehabil 2016;38:442–51. https://doi.org/10.3109/
09638288.2015.1044036
Does not meet criteria for
unexplained symptoms
Sullivan M, Langford DJ, Davies PS, Tran C, Vilardaga R, Cheung G, et al. A controlled pilot
trial of paintracker self-manager, a web-based platform combined with patient coaching,
to support patients’ self-management of chronic pain. J Pain 2018;19:996–1005
Setting is pain specialty
clinic
Suman A, Schaafsma FG, van de Ven PM, Slottje P, Buchbinder R, van Tulder MW,
Anema JR. Effectiveness of a multifaceted implementation strategy compared to usual
care on low back pain guideline adherence among general practitioners. BMC Health Serv
Res 2018;18:358. https://doi.org/10.1186/s12913-018-3166-y
Outcomes are measures
of guideline adherence
Taylor SJ, Carnes D, Homer K, Kahan BC, Hounsome N, Eldridge S, et al. Novel three-day,
community-based, nonpharmacological group intervention for chronic musculoskeletal
pain (COPERS): a randomised clinical trial. PLOS Med 2016;13:e1002040. https://doi.org/
10.1371/journal.pmed.1002040
Population includes mixed
causes of pain (e.g.
osteoarthritis)
Thorn BE, Eyer JC, Van Dyke BP, Torres CA, Burns JW, Kim M, et al. Literacy-adapted
cognitive behavioral therapy versus education for chronic pain at low-income clinics:
a randomized controlled trial. Ann Intern Med 2018;168:471–80. https://doi.org/10.7326/
M17-0972
Does not meet criteria for
unexplained symptoms
Bartz PT, Vieira A, Noll M, Candotti CT. Effectiveness of the back school program for the
performance of activities of daily living in users of a basic health unit in Porto Alegre,
Brazil. J Phys Ther Sci 2016;28:2581–6. https://doi.org/10.1589/jpts.28.2581s
Does not meet criteria for
unexplained symptoms
Turner B, Yin Z, Bobadilla R, Rodriguez N, Liang Y, Winkler P, Simmonds M. Randomized
trial of multimodality chronic pain care for primary care patients in clinic versus in
community: preliminary results. J Pain 2017;18:S62
Conference abstract only
Turner BJ, Liang Y, Simmonds MJ, Rodriguez N, Bobadilla R, Yin Z. Randomized trial of
chronic pain self-management program in the community or clinic for low-income primary
care patients. J Gen Intern Med 2018;33:668–77. https://doi.org/10.1007/s11606-017-
4244-2
Does not meet criteria for
unexplained symptoms
van Ravesteijn H. [Mindfulness-based cognitive therapy for patients with somatoform
disorders.] Tijdschr Psychiatr 2016;58:198–206
Study already included in
original review
Verbrugghe J, Agten A, Stevens S, Eijnde BO, Vandenabeele F, Timmermans A. Effects of
high intensity training on pain, disability, exercise capacity and muscle strength in persons
with nonspecific chronic low back pain: preliminary RCT results. Ann Phys Rehabil Med
2018;61:e17. https://doi.org/10.1016/j.rehab.2018.05.036
Conference abstract only
Villafañe JH, Perucchini D, Cleland JA, Barbieri C, de Lima E Sá Resende F, Negrini S.
The effectiveness of a cognitive behavioral exercise approach (CBEA) compared to usual
care in patients with a whiplash associated disorder: a quasi-experimental clinical trial.
J Back Musculoskelet Rehabil 2017;30:943–50. https://doi.org/10.3233/BMR-140162
Not a RCT
Vogler CN, Sattovia S, Salazar LY, Leung TI, Botchway A. Assessing outcomes of
educational videos in group visits for patients with chronic pain at an academic primary
care clinic. Postgrad Med 2017;129:524–30. https://doi.org/10.1080/00325481.2017.
1324228
Not a RCT
Vos-Vromans DC, Smeets RJ, Huijnen IP, Köke AJ, Hitters WM, Rijnders LJ, et al.
Multidisciplinary rehabilitation treatment versus cognitive behavioural therapy for
patients with chronic fatigue syndrome: a randomized controlled trial. J Intern Med
2016;279:268–82
Not primary care
Wälti P, Kool J, Luomajoki H. Short-term effect on pain and function of neurophysiological
education and sensorimotor retraining compared to usual physiotherapy in patients
with chronic or recurrent non-specific low back pain, a pilot randomized controlled trial.
BMC Musculoskelet Disord 2015;16:83. https://doi.org/10.1186/s12891-015-0533-2
Already included in
original review
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Update of the qualitative review: the acceptability of primary care or
community-based behaviour modification interventions for medically
unexplained symptoms – qualitative systematic review: update
This section provides an overview of the qualitative literature published since the original searches were
performed. The new evidence for patients’ and HPs’ perspectives on the acceptability, relative benefits
and potential harms of primary care- or community-based behaviour modification interventions for MUS
is outlined here. The review methods applied were the same as those documented in Chapter 4, and a
second reviewer (AB) checked the data extractions and completed independent quality assessment for
each paper as in the original review. The results of the review update are presented below.
Results of the qualitative review update
Included studies: qualitative review
From the 384 citations identified during the initial searches, 16 remained after the title and abstract
sift; these citations were considered at full-paper sift for the qualitative review update. Figure 86 shows
the flow chart of studies included in the qualitative review. The sifting process resulted in the inclusion
of one study (two citations) at full paper.521 This study examined HPs’ perspectives of an intervention,
there were no new studies relating to patients’ perspectives. Details of studies excluded at full-paper
sift together with reasons are shown in Table 128. Both of the full papers that were included were
published in 2018.
Study respondents
The included study assessed HPs’ attitudes to the intervention. The study contained qualitative data
from 10 physiotherapists following a training programme in cognitive functional therapy (CFT) for the
management of non-specific chronic low back pain.
Respondent characteristics
There were seven male physiotherapists and three female physiotherapists. The physiotherapists were
in band 5–7 and had been working in the area of musculoskeletal disorders for between 3 years and
> 14 years.
Study setting
The intervention took place in a primary care department in the North East London Foundation Trust.
Intervention description and facilitators
Physiotherapists were trained to deliver CFT. CFT is a biopsychosocially orientated behavioural
intervention for lower back pain.536 A multidimensional clinical reasoning framework (MDCRF)
underpins CFT,536 and adopting this approach successfully requires physiotherapists to develop skills
across these broad domains.537
TABLE 127 List of clinical effectiveness studies excluded at full-paper stage with reasons (continued )
Weiland A, Blankenstein AH, Van Saase JL, Van der Molen HT, Jacobs ME, Abels DC,
et al. Training medical specialists to communicate better with patients with medically
unexplained physical symptoms (MUPS). A randomized, controlled trial. PLOS ONE
2015;10:e0138342. https://doi.org/10.1371/journal.pone.0138342
Not primary care
Woodman J, Ballard K, Hewitt C, MacPherson H. Self-efficacy and self-care-related
outcomes following Alexander Technique lessons for people with chronic neck pain in
the ATLAS randomised, controlled trial. Eur J Integr Med 2018;17:64–71. https://doi.org/
10.1016/j.eujim.2017.11.006
Intervention designed to
address underlying causes
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Records identified through
database searching
(n = 384 + 48 duplicates)
Additional records identified
through other sources
Citation searching
(n = 0)
Records after duplicates removed
(n = 384)
Records screened by title
and abstract
(n = 384)
Records excluded at title
and abstract sift
(n = 368)
Full-text articles assessed
for eligibility
(n = 16 citations; 15 studies)
Full-text articles excluded,
with reasons
(n = 14 citations)
• Does not include qualitative
    data, n = 1
• Population did not fit the
    inclusion criteria, n = 8
• Mixed population, n = 1
• Does not include data about
    a specific intervention, n = 1
• Non-UK study, n = 1
• Not primary care, n = 2
Studies included in
qualitative synthesis
(n = 1 studies; 2 citations)
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FIGURE 86 The PRISMA flow diagram: updated qualitative review.
TABLE 128 List of excluded studies for the updated qualitative review
Author (year) Reason for exclusion at full-paper sift
Arden (2017)522 Does not include qualitative data
Balabanovic (2020)523 Does not include data about a specific intervention
Bestall (2017)524 Population does not fit the inclusion criteria
Broughton (2017)525 The study was not conducted in primary care
Carlin (2018)526 Population does not fit the inclusion criteria
Carnes (2017)527 Population does not fit the inclusion criteria
Casey (2018)528 Population does not fit the inclusion criteria
Dresner (2016)529 Population does not fit the inclusion criteria
Gordon (2017)530 Population does not fit the inclusion criteria
Hadi (2016)531 Population does not fit the inclusion criteria
Hadi (2017)532 Population does not fit the inclusion criteria
Sibelli (2018)533 The study was not conducted in primary care
Teo (2017)534 The study was not conducted in the UK
Thompson (2018)535 Mixed population
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Quality of the included studies
As described in Chapter 4, we have used an adaptation of the CASP assessment of study quality for
qualitative studies to assess the included studies. Studies were assessed in terms of the extent to
which they met each of the seven CASP requirements. If the study met all seven requirements it was
assessed as high quality, if it met six of the criteria it was assessed as moderate quality and if it met
five or fewer of the criteria it was assessed as low quality. Overall, the study was categorised as being
of moderate quality; however, both reviewers highlighted issues relating to reflexivity, given that the
lead author was both the intervention trainer and the interviewer in the study.
TABLE 129 Summary of the included studies and their sample and study characteristics
First author
and year of
publication
Sample (contributing
qualitative data)
Population
being treated
as described
in the study Data collection Intervention Age Sex
Cowell et al.521 10 physiotherapists Non-specific
chronic low
back pain
Semistructured
interview
CFT Not reported
(number of
years working
in MSK range
from 3 years
to > 14 years)
Seven male,
three female
TABLE 130 Description of the interventions delivered in the included studies
First author
and year of
publication
Population being
treated as described
in the study Intervention
Intervention
provider
Intervention
setting
Intervention
duration
Individual
or group
Cowell et al.521 Non-specific chronic
low back pain
CFT Physiotherapists Not reported
other than
primary care
Not reported as
report of HPs
being trained in
the intervention
Individual
TABLE 131 The CASP results
Question Cowell et al.521,538
1 Is the study qualitative research or does it provide qualitative data? Yes
2 Are the study context and aims clearly described? Yes
3 Is there evidence of research reflexivity? Reflexivity is mentioned in the
methods but not obviously
applied in the analysis
4 Are the sampling methods clearly described and appropriate for the research
question?
Yes
5 Are the methods of data collection clearly described and appropriate to the
research question?
Yes
6 Is the method of analysis clearly described and appropriate to the research
question?
Yes
7 Are the claims made supported by sufficient evidence (i.e. did the data provide
sufficient depth, detail and richness)?
Yes
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Certainty of the review findings: the Confidence in the Evidence from Reviews of
Qualitative research assessment
As the review update identified only one new study, it was not possible to complete the CERQual
assessment across the update studies; however, we have highlighted where the new study corresponds
to the findings reported in the original review, and the implications for CERQual have been considered.
Qualitative synthesis: evidence from Cowell et al.521,538
The evidence from the one new study on health yielded 11 findings overall, and corresponded to six
findings identified in the original review. The findings in the form of meta-themes, together with
subthemes, are presented in Table 132.
TABLE 132 Findings identified in Cowell et al.521,538
Meta-theme: finding Subtheme
Positive factors relating to behavioural modification interventions as reported by HPs/What did you gain from being
trained to deliver and/or delivering a behavioural modification intervention?
Supervision and training Supervision was helpful
Learning about integration of factors across multiple domains, linking psychological factors
and mechanical pain
Communication Improved communication skills, effective communication and active listening
Challenging perspectives
Increased confidence Increased confidence in ability to help patients
Increased confidence in identifying and addressing psychosocial factors
Ability to address sensitive issues
Improved relationships Ability to build a patient– therapist relationship
Engaging patients to self-manage
Empowering patients Developing patient awareness
Enhanced patients’ confidence
Benefits to patients Individualised care, collaboratively agreeing treatment goals
Quick results
What did not help or was detrimental to the patients or the delivery of the intervention?
Complexity of approach Not an easy approach presenting challenges of having to consider and target pain
drivers across broad domains extending their traditional scope of practice beyond just
physical factors
HP lacked confidence Lack of confidence in addressing psychological factors
Lack of training in effective communication
Factors reported as important, wanted or expected for training in and delivery of behavioural modification
interventions
More (clinical) experience Requires real-life observation
Requires clinical experience to develop competency and confidence
Requires ongoing support
Barriers: from the perspective of HPs, why patients did not want behavioural interventions or could not engage with
them or barriers to delivery of the intervention
Resource constraints Time constraints
Patient beliefs Patients with rigid biomedical beliefs and expectations for passive treatment were,
at times, difficult to engage in the approach
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Of the findings identified in the new study, six corresponded to existing findings. These six findings are
presented in Table 132. The original CERQual assessment is presented in Table 133. With the addition
of the new study the implications are that the CERQual assessment would be strengthened for these
findings. As the new study is rated as moderate quality, it included thick data the study represents a
different context with a different intervention and different facilitators and the data were coherent
across the studies.
Synthesis of evidence
The evidence from the one new study health yielded 11 findings overall, and corresponded to six
findings identified in the original review. The evidence from the new study is described below.
TABLE 133 Findings from HPs delivering the intervention reproduced from the original review
Meta theme
CERQual assessment of
confidence in the evidence Explanation CERQual assessment
Positive factors relating to behavioural modification interventions as reported by HPs/What did you gain from being
trained to deliver and/or delivering a behavioural modification intervention?
Training and supervision
was useful
Moderate confidence Two studies, both of moderate quality, both including
thick data. Evidence came from different intervention
types with different facilitators. Coherent data across
the studies
Extended knowledge and
skill of the HP
High confidence Three studies, one of high quality, two of moderate
quality. All three included thick data. Evidence came
from different intervention types with different
facilitators. Coherent data across the studies
What did not help or was detrimental to the patients or the delivery of the intervention?
When HPs felt that they
were novices or did not
have the required skill levels
High confidence Two studies, one of high quality, one of moderate
quality, both including thick data. Evidence came from
different intervention types with different facilitators.
Coherent data across the studies
Barriers: from the perspective of HPs, why patients did not want behavioural interventionsor could not engage with
them or barriers to delivery of the intervention
Resource constraints Moderate confidence Three studies, all of moderate quality, both including
thick data. Evidence came from different intervention
types with different facilitators. Coherent data across
the studies
Patient beliefs High confidence Three studies, one of high quality, two of moderate
quality. All three including thick data. Evidence came
from different intervention types with different
facilitators. Coherent data across the studies
Factors reported as important, wanted or expected for training in and delivery of behavioural modification
interventions
More training and
supervision required
Moderate confidence Two studies, one of high quality, one of moderate
quality. Both including thick data. Evidence came from
different intervention types with different facilitators.
Coherent data across the studies
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Factors identified as being helpful for being trained in the intervention
Supervision and training
Physiotherapists reported that supervision and learning were important to being successfully trained in
the intervention. They reported that the CFT training programme taught integration of factors across
multiple domains, linking psychosocial factors and mechanical pain presentations:
Before, I’d tend to separate things, not intentionally, but tend to be, ‘Oh well, this is what’s going on
mechanically and then this is what’s going on with their life’, but then not necessarily making the link
between the two, and I think that’s what CFT does.
P09
Communication
The physiotherapists reported improved communication skills, and were more prepared to actively
listen to their patients, which helped to facilitate patient disclosure and improved their ability to
identify problems:
Communication with the patients has changed quite a bit from before the training to after, and you have
to be able to communicate well and listen well for this concept to work effectively. The biggest shift for
me, personally, is that change in communication, which just allows me then, probably, to identify
more drivers.
P09
Improvement in communication skills also included the HPs developing the ability to challenge
perspectives without jeopardising the patient–therapist relationship.
Increased confidence
Health professionals reported that by taking part in the training their confidence in their ability to help
patients had increased, as had their ability to identify and address psychosocial factors. They also felt
more able to address sensitive issues:
Rather than me being scared about asking the questions, which, again, is probably a change from before
to after training, just in terms of confidence.
P09
Improved relationships leading to patient empowerment
Physiotherapists reported improved abilities to build good patient–therapist relationships, and this was
reported to help engaged patients to self-manage, by giving patients confidence and empowering them
to take personal control:
I think the therapist–patient relationship is really key in any scenario, otherwise they’re going to be
unlikely to engage in what you’re going to try to get them to do.
P09
Specifically the intervention used ‘. . . behavioural experiments to demonstrate less painful ways to move
during provocative tasks’,539 the physiotherapists were able to highlight discrepancies between what
patients believed and their pain response:
So, if you can show that you can modify their symptoms for the better, then you change their belief
system; it gives you the right to go there and it changes the patient’s belief, which changes
their behaviour.
P02
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Benefits to patients
Health professionals emphasised specific benefits to patients including individualised care, including
collaboratively agreeing treatment goals:
I think it’s just got to be really, really patient specific. I think you need to sit and spend your time listening
to all the factors involved in that particular patient’s back pain to find an approach that’s tailored to them
and then I think you’ve really got to get them on board to buy into whatever the best approach you feel is
for them.
P03
Health professionals also felt that the intervention could deliver quick results for the patients,
providing them with hope for change:
They see changes really very quickly because of those behavioural experiments. So, as a result of that,
I’ve seen patients generally much happier, and for the first time in years often seeing a glimmer of hope.
P05
Factors identified as unhelpful or difficult for health professionals
Complexity
Physiotherapists found the complexity of approach challenging. They:
. . . highlighted the challenges of having to consider and target pain drivers across broad domains.
This required that physiotherapists extend their traditional scope of practice beyond just physical factors:
I don’t think it’s an easy approach to use. It is complex because there’s so much involved in it and within
it but, it’s certainly the way forward, for most physiotherapy.
P09
Health professional lacked confidence
Physiotherapists reported that they lacked confidence in addressing psychological factors, and felt
that, although effective communication was highly important, there was a lack of specific training in
effective communication. Specifically, HPs reported a lack of confidence in exploring emotional distress
(high levels of anxiety and depressed mood). The physiotherapists felt uncomfortable in this domain
such that they often avoided sensitive issues:
It’s easy to go into an avoidance mode I think, and then skip past it and move onto something else.
I think the concern is you go in and then you’re out of your depth.
P10
Factors reported as required for successful training in the intervention
More clinical experience
Physiotherapists reported that they needed more real-life observation and more clinical experience,
together with ongoing support in delivering the intervention. They felt that this would build confidence
and competency:
There was a sense that just attending large CFT workshops, which included a traditional didactic
lecture format and masterclass observation, although providing inspiration, was insufficient to develop
an in-depth understanding of the clinical reasoning processes that underpinned CFT: real-life observation
of a clinician and a patient . . . and you watch things unfold and you feel inspired but you don’t really
know how he [the educator] has got to where he’s got to. The course [formal training] allows some
analysis of that, and some breakdown.
P05
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Factors identified as barriers to successful training in the intervention
Resource constraints
The physiotherapists felt that a lack of time represented the biggest service constraint to
effective implementation.
Patient beliefs
A further barrier reported by physiotherapists was around patient beliefs. The study reported that
patients with rigid biomedical beliefs and expectations for passive treatment were ‘difficult’ to engage
in the approach; however, they reported that developing competence in the approach made it easier to
develop relationships to overcome contrasting beliefs.
Discussion of the qualitative review update
This review presents an update to the qualitative review presented in Chapter 4. One new study was
identified that presented HPs’ perspectives on the acceptability, relative benefits and potential harms
of primary care or community-based behaviour modification interventions for medically unexplained
symptoms. The new study was rated as of moderate quality. The new study provided 11 findings,
corresponding to six findings presented in the original review, and added weight to the confidence in
those findings. The five additional findings were largely related to the specific intervention and sample
described in the study, which was quite different from the studies included in the original review.
The evidence from HPs described important facilitators. They reported that they found being trained in
the intervention helped them to develop their own knowledge and skills, thus improving their confidence,
helped them develop effective communication skills, and develop patient–therapist relationships. Other
important facilitators were training and supervision for the interventions, and HPs reported that they
would benefit from more clinical experience to improve their competency. HPs also reported that they
felt the intervention provided specific benefits to patients by providing individualised, collaborative care
and that the intervention could potentially provide quick results.
Barriers to potential successful delivery of the intervention were time constraints, HPs’ lack of confidence
in their own skills and abilities to deliver the intervention (given the complexity of the intervention) and
to address psychosocial factors, and patient beliefs that went against some aspects of the intervention.
Limitations
A limitation of this study was that it did not include any data from patients. The study reported a
training programme and, therefore, it appears that the intervention had not yet been rolled out to
patients; therefore, it is unclear how acceptable and beneficial the intervention may be in the patients’
view. Furthermore, patient beliefs are raised as a potential barrier to successful intervention. However,
without patient data it is unclear whether or not HP beliefs would be implicated in this; for example,
it may be that for people who don’t respond to treatment or who find the intervention unacceptable
being labelled ’difficult’ affects the therapeutic alliance. Reflexivity may also represent a limitation due
to potential bias as the lead author and interviewer was also the intervention trainer.
Update of the realist synthesis: the contribution of contextual factors to
the success or failure of behaviour modification interventions for medically
unexplained symptoms – realist synthesis
Following the update search for qualitative research studies (see Qualitative systematic review update
methods), which retrieved one additional eligible study reported in two related papers,521,538 the review
team revisited the eight original programme theory component statements (see Box 1) to determine which
of these, if any, might have been modified by findings from the additional study. These papers focused on
the perceptions of physiotherapists in primary care in England about adopting a biopsychosocial approach
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to managing patients with non-specific chronic low back pain521 and the perceptions of the same sample
on the impact of a formal training programme in CFT.
In line with realist synthesis methods, verbatim data from the participants and author observations from
the Discussion sections of the two papers were mapped against an eight-item framework based on the
previously generated programme theory components from the main review (programme theories 1–8).
Particular attention was focused on findings not explained within this prior framework.
Findings
Overall, the two papers521,538 supported the previous findings from the realist synthesis although
contributed more detailed perspectives from a professional group (physiotherapists) that was not
previously the focus of the included studies. Unsurprisingly, the emphasis on breaking the destructive
diagnostic cycle (programme theory 6) was less prominent in this sample as patients will typically
have already entered the treatment pathway. Similarly, the need to focus on symptoms, not labels
(programme theory 2), was correspondingly muted given that physiotherapists typically handle the
mechanical aspects of the condition in this way as part of their routine care. However, the authors
observed a tension between being seen to be doing something (in order to sustain the patient–therapist
relationship) and a consequent burden on health service utilisation.521 Physiotherapists in the sample
described the perceived pressure from patients to request scans in order to provide reassurance for
those holding catastrophic beliefs about their pain disorder:
They need that reassurance that actually, there isn’t anything going on . . . until they’ve been given that all
clear you can’t actually move them forward no matter how hard you try . . .
P04
Prominent emphases within the data included the centrality of the professional–patient relationship
(programme theory 3), the need for a contextually sensitive (‘individualised’) therapeutic response
(programme theory 4) and the need for congruity between patient and professional cognitive models
(programme theory 5). These aspects emerge as substantive components of the training programme
described in the second paper.538 An interesting aspect of the therapeutic relationship was the
implication that physiotherapists were prepared to make early concessions from what they considered
to be the optimal evidence-based treatment in order to secure patient trust, which would prove
advantageous in the long run:
. . . it was seen as a way of placating the patient to protect the therapeutic relationship.
Cowell et al.521
It also provided a context for developing patient insight into their disorder:
If their expectation is that they’re going to have manual therapy, and that gives me buy in for them to make
sure that they trust me, I can get them to believe in the concept, get them moving, then what harm does it do?
P02521
Use of the biopsychosocial model was central to both papers and was seen as a mechanism by which
individualised care could be recognised and delivered, to the benefit not only of this patient group
but patients in general. “The inadequacy of a ‘one-size-fits-all’ treatment approach”521 emerges from
both papers and offers justification for an approach that requires full exploration of the patient’s
psychosocial circumstances; however, communication proved particularly challenging when the patient
persisted with a biomedical-only model of their own condition:
It’s my back, what do you mean it’s got anything to do with relaxation or it’s in my head . . . some people
find that difficult.
P03521
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As a consequence of this emphasis, both papers placed great importance on the ‘potential dissonance
between patients’ and physiotherapists’ attitudes and beliefs’.521 In both papers, the perceived response
to this ‘was having effective communication skills to develop patient insight and challenge patient
perspectives’.521
Where these papers specifically contributed to the synthesis was in making explicit justifications
for the likely success of programme theory components; for example, the benefits of maintaining a
professional–patient relationship, based on trust, are described in starkly pragmatic terms: ‘facilitating
patient disclosure, providing opportunities to reconcile patient unhelpful beliefs and enhancing
adherence’. Furthermore, it was evident from several observations and verbatim extracts that much of
the therapist resistance to exploring a biopsychosocial model of the condition (programme theory 7)
was based on the therapists’ own discomfort and lack of training in the use of this model rather than
simply from anticipating a negative patient response. This helps to explain the ambiguity in professional
attitudes detected in the original synthesis data exploring this programme theory component.
Interpretation
It should be recognised that both these additional papers521,538 were framed within the biopsychosocial
model and it is, therefore, not surprising that they have largely confirmed the findings from the
original realist synthesis. At the same time, it is helpful to step outside the research domain most
commonly inhabited by GPs to explore the views of an additional professional group with a different
perspective and different prior training. One undercurrent from the original realist synthesis emerges
more strongly in both the additional papers, namely the constraints of time within a typical NHS
setting. Nevertheless, it is encouraging to see that physiotherapists were prepared to be innovative in
creating time opportunities in recognition that time spent in building up a positive professional–patient
relationship and in constructive communication holds the potential to achieve future benefit in terms
of both patient and health service outcomes.538
Further value of these ‘sibling papers’ derives from the fact that, as a needs assessment and training
programme paper respectively, the papers present a coherent response to the issues previously
identified from the programme theory. This coherence has helped us to examine the extent to which
specific training programme components match or resonate with the specific needs identified from
each of the programme theory components, strengthening our own analysis.
Finally, it is useful to report that supporting recent literature evoked by the discussion sections of
these supplementary papers confirms the overall direction of our previous interpretation. For example:
the themes/sub-themes identified in this study reflect some of the key dimensions suggested to underpin
this model of care: acknowledging a BPS perspective, sharing information, considering the individual needs
of patients and prioritising the therapeutic relationship.
Cowell et al.521
Acknowledging that this observation reflects the subjective editorialising by the authors within a
biopsychosocial framework, rather than the objective evidentiary basis of the programme, this nevertheless
confirms that our previous analysis resonates with studies that lie beyond our initial inclusion set and which
reflect contemporary academic and practitioner views.We continue to conclude, with this study data, that:
being afforded the necessary time to develop a trusting patient–therapist relationship, and acquiring
broader competencies, particularly in communication skills, are worth exploring in the successful delivery
of such an approach.
Cowell et al.521
Following the update search for qualitative research studies, which retrieved one additional eligible
study reported in two related papers, the review team revisited the eight original programme theory
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component statements to determine which of these, if any, might have been modified by findings from
the additional study.
Cowell et al.521
One of the key vehicles identified for managing potential dissonance between patients’ and
physiotherapists’ attitudes and beliefs was having effective communication skills to develop patient
insight and challenge patient perspectives. This was not always a straightforward process, and required
competency to conduct an effective patient-centred consultation that was capable of nurturing trust
between practitioner and patient and enhance patient disclosure.540
Opportunities for early follow-up treatment were also seen as important to nurture a trusting
relationship, promote active coping strategies, build self-efficacy and promote behaviour change;
however, this was difficult to support in primary care, and consequently patients were at risk of
defaulting to biomedical beliefs and treatment expectations and were thereby difficult to engage.
Although a clear overall definition on patient-centred care has yet to be established in physiotherapy,541,542
the themes/subthemes identified in this study reflect some of the key dimensions suggested to underpin
this model of care: acknowledging a biopsychosocial perspective, sharing information, considering the
individual needs of patients and prioritising the therapeutic relationship.542–545
The inadequacy of a ’one-size-fits-all’ treatment approach was reflected in the physiotherapists’
concerted efforts to individualise management and consider each patient’s unique biopsychosocial
profile; however, studies have highlighted discrepancies between health-care practitioners’ psychosocial
awareness and incorporating such perspectives into practice.546,547
The physiotherapists in this study reflected on the learning challenges required to develop competencies
across the wider dimensions reflected in a biopsychosocial model of care.548,549 They highlighted a lack
of confidence in addressing psychological factors, often avoiding sensitive topics, as it felt intrusive and
beyond their realm of expertise. This lack of confidence has been reported in other studies,550,551 and has
been attributed to inadequacies in undergraduate-level training and a lack of available professional
development training.551,552
Another key barrier to implementing a broader biopsychosocial approach was the perceived lack of
time allocated within primary care, a theme echoed in recent studies.553,554 It has been demonstrated
that patients at high risk of a poor outcome have higher levels of emotional distress555 and require
longer appointments to explore these issues.254 The physiotherapists felt that unravelling the complexity
of persistent pain presentations could not be done appropriately in the short time available.
A shared consensus with patients on the underlying cause of the pain and appropriate management,
as well as treatment goals, appears central to maintaining a productive working relationship. These data
suggest that being afforded the necessary time to develop a trusting patient–therapist relationship and
acquiring broader competencies, particularly in communication skills, are worth exploring in the successful
delivery of such an approach.
Themes and subthemes
1. Recognising the need to assess and manage non-specific chronic low back pain from a
biopsychosocial perspective
i. multidimensional nature of non-specific chronic low back pain
ii. limitations of a biomedical model.
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2. Challenge of addressing psychological factors
i. reconciling patient perspectives
ii. confidence
iii. time.
3. Engaging patients to self-manage their non-specific chronic low back pain
i. patient–therapist relationship
ii. effective communication
iii. individualised care
iv. modifying pain-related functional behaviours.
Themes and subthemes
1. A challenging learning journey
i. requires formal training
ii. requires clinical experience.
2. Enhanced confidence: ‘making the hard stuff easier’
i. identifying and addressing psychosocial factors
ii. addressing sensitive issues.
3. Change in professional practice
i. communication practice.
4. Enhanced comprehension, by physiotherapist and patient
i. importance of developing patient awareness
ii. influence of psychosocial factors
iii. importance of therapeutic relationship.
5. ‘This seems great, but there are obstacles to applying this . . .’
i. better outcomes
ii. application to wider patient populations
iii. time constraints
iv. difficulty to engage patients with biomedical beliefs.
Update of the cost-effectiveness review
This section provides an overview of the searches for cost-effectiveness studies published since the
original searches were performed. The review methods applied were consistent with those reported in
Chapter 6. Results of the updated searches are presented below.
Results
A total of 726 unique citations were retrieved in the updated cost-effectiveness search. There were
698 citations excluded at the title and abstract stage, with 28 full papers retrieved for further scrutiny.
No studies were found to meet the inclusion criteria; therefore, there are no new included studies of
cost-effectiveness. Table 134 presents a list of all studies excluded at full-paper stage with reasons.
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FIGURE 87 The PRISMA flow diagram: cost-effectiveness review.
TABLE 134 List of cost-effectiveness papers excluded at full-paper stage with reasons
Paper Reason for exclusion
Abhulimen S, Hirsch A. Quantifying the economic impact of a digital self-care behavioral
health platform on Missouri Medicaid expenditures. J Med Econ 2018;21:1084–90.
https://doi.org/10.1080/13696998.2018.1510834
Non-UK
Basu S, Landon BE, Williams JW, Bitton A, Song ZR, Phillips RS. Behavioral health integration
into primary care: a microsimulation of financial implications for practices. J Gen Intern Med
2017;32:1330–41. https://doi.org/10.1007/s11606-017-4177-9
Does not meet review
criteria for MUS
Bestall J, Siddiqi N, Heywood-Everett S, Freeman C, Carder P, James, M, et al. New models of
care: a liaison psychiatry service for medically unexplained symptoms and frequent attenders
in primary care. Psychiatrist 2017:41:340–4
Not a cost-effectiveness
study
Bromley JS, Turner A. A proactive and acceptable clinic solution for patients with medically
unexplained symptoms. Psychiatr Bull 2014;38:307–8
Not a cost-effectiveness
study
Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and
indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life
Out 2017;15:35
Not a cost-effectiveness
study
Canaway A, Pincus T, Underwood M, Shapiro Y, Chodick G, Ben-Ami N. Is an enhanced
behaviour change intervention cost-effective compared with physiotherapy for patients
with chronic low back pain? Results from a multicentre trial in Israel. BMJ Open 2018;8(4).
https://doi.org/10.1136/bmjopen-2017-019928
Does not meet criteria
for MUS
Cano-Garcia FJ, Gonzalez-Ortega MD, Sanduvete-Chaves S, Chacon-Moscoso S,
Moreno-Borrego R. Evaluation of a psychological intervention for patients with chronic pain
in primary care. Front Psychol 2017;8:435
Non-UK
Clare A, MacNeil S, Bunton T, Jarrett S. ’The Doctor doesn’t need to see you now’: reduction
in general practice appointments following group pain management. Br J Pain 2019;13:121–9.
https://doi.org/ 10.1177/2049463718812501
Paper not available
continued
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TABLE 134 List of cost-effectiveness papers excluded at full-paper stage with reasons (continued )
Paper Reason for exclusion
Collin SM, Bakken IJ, Nazareth I, Crawley E, White PD. Health care resource use by patients
before and after a diagnosis of chronic fatigue syndrome (CFS/ME): a clinical practice
research datalink study. BMC Fam Pract 2017;18:1–13. https://doi.org/10.1186/s12875-017-
0635-z
Not a cost-effectiveness
study
Cooper, A, Abbass A, Town J. Implementing a psychotherapy service for medically
unexplained symptoms in a primary care setting. J Clin Med 2017;6:109
Non-UK
Fink P, Rask MT, Rosendal M, Ornbol E. (2016). Long-term outcome of Bodily Distress
Syndrome (BDS) on sick leave, healthcare costs and work disability in primary care patients.
A ten-year follow-up study. J Psychosom Res 2016;85:65. https://doi.org/10.1016/j.jpsychores.
2016.03.158
Non-UK
Frogner BK, Harwood K, Andrilla CHA, Schwartz M, Pines JM. Physical therapy as the first
point of care to treat low back pain: an instrumental variables approach to estimate impact
on opioid prescription, health care utilization, and costs. Health Serv Res 2018;53:4629–46
Non-UK
Görge M, Ziehm J, Farin E. Health-care utilization of patients with chronic back pain before
and after rehabilitation. BMC Health Serv Res 2017;17:1–10. https://doi.org/10.1186/s12913-
017-2757-3
Not primary care
Grochtdreis T, Brettschneider C, Shedden-Mora M, Piontek K, Konig HH, Lowe B. (2018).
Cost-effectiveness analysis of a stepped, collaborative and coordinated health care network
for patients with somatoform disorders (Sofu-Net). J Ment Health Policy Econ 2018;21:59–69
Not a behavioural
intervention
Herrick LM, Spalding WM, Saito YA, Moriarty J, Schleck C. A case-control comparison of
direct healthcare-provider medical costs of chronic idiopathic constipation and irritable
bowel syndrome with constipation in a community-based cohort. J Med Econ
2017;20:273–79
Non-UK
Kolu P, Tokola K, Kankaanpää M, Suni M. Evaluation of the effects of physical activity,
cardiorespiratory condition, and neuromuscular fitness on direct healthcare costs and
sickness-related absence among nursing personnel with recurrent nonspecific low back
pain. Spine 2017;42:854–62
Non-UK
Konnopka A, König HH, Kaufmann C, Egger N, Wild B, Szecsenyi J, et al. Cost-utility of a
specific collaborative group intervention for patients with functional somatic syndromes.
J Psychosom Res 2016;90:43–50. https://doi.org/10.1016/j.jpsychores.2016.09.001
Costs from the
Schaefert et al. trial,
not UK
Lamsal R, Stalke CA, Cait CA, Riemer M, Horton S. Cost-effectiveness analysis of single-
session walk-in counselling. J Ment Health 2018;27:560–66. https://doi.org/10.1080/
09638237.2017.1340619
Non-UK
Luciano JV, D’Amico F, Feliu-Soler A, McCracken LM, Aguado J, Penarrubia-Maria MT,
et al. Cost-utility of group acceptance and commitment therapy for fibromyalgia versus
recommended drugs: an economic analysis alongside a 6-month randomized controlled
trial conducted in Spain (EFFIGACT study). J Pain 2017;18:868–880
Costs from the Luciano
et al. trial, not UK
Meng H, Friedberg F. Cost-utility of home-based fatigue self-management versus usual care
for the treatment of chronic fatigue syndrome. Fatigue 2017;5:202–14
Does not meet review
criteria for primary care
Rask MT, Ørnbøl E, Rosendal M, Fink P. Long-term outcome of bodily distress syndrome in
primary care: a follow-up study on health care costs, work disability, and self-rated health.
Psychosom Med 2017;79:345–57
Non-UK
Röhricht F, Zammit I, Papadopoulos N. Novel primary care treatment package for patients
with medically unexplained symptoms: a cohort intervention study. BJGP Open 2018;1(4)
Not a comparative study
Shea JA, Adejare A, Volpp KG, Troxel AB, Finnerty D, Hoffer K, et al. Patient’s views of a
behavioral intervention including financial incentives. Am J Manag Care 2017;23:366–71
Does not meet review
criteria for MUS
van Eijk-Hustings Y, Kroese M, Creemers A, Landewe R, Boonen A. Resource utilisation and
direct costs in patients with recently diagnosed fibromyalgia who are offered one of three
different interventions in a randomised pragmatic trial. Clin Rheumatol 2016;35:1307–15.
https://doi.org/10.1007/s10067-015-3067-y
Does not meet review
criteria for primary care
van Ravesteijn H. Mindfulness-based cognitive therapy for patients with somatoform
disorders. Tijdschri Psychiatr 2016;58:198–206
Non-UK
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TABLE 134 List of cost-effectiveness papers excluded at full-paper stage with reasons (continued )
Paper Reason for exclusion
Wenger HC, Cifu AS. Treatment of low back pain. JAMA 2017;318:743–4 Acute
Williams A, van Dongen JM, Kamper SJ, O’Brien KM, Wolfenden L, Yoong SL, et al. Economic
evaluation of a healthy lifestyle intervention for chronic low back pain: a randomized
controlled trial. Eur J Pain 2019;23:621–34. https://doi.org/10.1002/ejp.1334
Does not meet review
criteria for MUS
Wortman MSH, Lokkerbol J, van der Wouden JC, Visser B, van der Horst HE, Hartman TCO.
Cost-effectiveness of interventions for medically unexplained symptoms: a systematic review.
PLOS ONE 2018;13. https://doi.org/10.1371/journal.pone.0205278
Systematic review,
includes secondary care
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